{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "aac8def6",
   "metadata": {},
   "outputs": [],
   "source": [
    "import json\n",
    "import numpy as np\n",
    "import pandas as pd"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "2c908a3b",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "  0%|          | 0/12 [00:00<?, ?it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'qid': 'gpqa-1', 'prompt': \"Answer the following multiple choice question. The last line of your response should be of the following format: 'Answer: $LETTER' (without quotes) where LETTER is one of ABCD. Think step by step before answering.\\n\\nA large gene has dozens of exons, of which the central ones code for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space. Each exon usually codes for one folded triple alpha helix. The most common mutations of the gene are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste. A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. The molecule prevents binding of the spliceosome and creates exon skipping and in-frame joining. Several missing exons are well tolerated by an organism. Which structure below is not involved in the proposed therapy?\\n\\nA) lariat\\nB) polyA tail\\nC) R-loops\\nD) antisense\", 'answers': ['Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'The answer is D) antisense. Antisense refers to RNA molecules that bind to complementary sequences in mRNA or other RNAs. In this context, it would not be involved in the proposed therapy as it does not directly interact with the double helices of the gene or the central exon coding for folded triple helical repeats.<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'The answer is:\\n\\nD) antisense\\n\\nAntisense refers to sequences that bind to complementary sequences and inhibit transcription or translation. In this context, it would not be involved in the proposed therapy as it does not directly interact with the triple helical repeats or the spliceosome.<|im_end|>', 'The answer is D) antisense. Antisense refers to molecules that bind specifically to complementary sequences in DNA or RNA. In this context, it would not be involved in the proposed therapy as it does not interact with the central exon of the gene being targeted.<|im_end|>', 'The answer is B: polyA tail.<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'The answer is D) antisense. Antisense refers to a type of RNA that binds to complementary sequences in other RNAs or DNA strands. In this context, it would not be involved in the proposed therapy as it does not directly target the gene or its exons.<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'The answer is D) antisense.<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: C) R-loops<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: C) R-loops<|im_end|>', 'The answer is B) polyA tail. Poly(A) tails are involved in the splicing process, but they do not play a role in the proposed therapy.<|im_end|>', 'Answer: C) R-loops<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'The answer is C) R-loops.<|im_end|>', 'The answer is D) antisense. Antisense refers to RNA molecules that specifically bind to complementary sequences in messenger RNA (mRNA), inhibiting translation or mRNA decay. It does not involve the structure mentioned in the question.<|im_end|>', 'The answer is:\\n\\nD) antisense<|im_end|>', 'Answer: C) R-loops<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'The answer is B: polyA tail. Poly(A) tails are not involved in the proposed therapy as it aims to skip or join out-of-frame exons instead of modifying the poly(A) tail.<|im_end|>', 'The answer is:\\n\\nD) antisense\\n\\nAntisense refers to RNA molecules designed to bind specifically to complementary DNA or RNA sequences, inhibiting their translation into protein. In this context, it would not be involved in the proposed therapy as it does not directly interact with mRNA or proteins.<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'The answer is D) antisense. Antisense refers to RNA molecules that bind to complementary sequences on DNA or mRNA, preventing transcription or translation. It does not play a role in gene editing therapies like the one described in the question.<|im_end|>', 'Answer: D) antisense<|im_end|>', 'The answer is:\\n\\nD) antisense<|im_end|>', 'The answer is:\\n\\nD) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'The answer is D) antisense.<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: C) R-loops<|im_end|>', 'The answer is D) antisense. Antisense refers to molecules that bind to complementary sequences on the target mRNA or DNA strand, blocking translation or RNA splicing. In this context, it does not play a role in the proposed therapy as it targets a different mechanism.<|im_end|>', 'The answer is D: antisense.<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'The answer is D: antisense.<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: C) R-loops<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'The answer is D) antisense. Antisense refers to the RNA sequence that binds specifically to complementary sequences in another strand or to DNA molecules. In this context, it does not play a role in the proposed therapy.<|im_end|>', 'Answer: D) antisense<|im_end|>', 'The answer is:\\n\\nD) antisense<|im_end|>', 'Answer: C) R-loops<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: C) R-loops<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: C) R-loops<|im_end|>', 'Answer: D) antisense<|im_end|>', 'The answer is C) R-loops.<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'The answer is:\\n\\nD) antisense<|im_end|>', 'The answer is:\\n\\nD) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: C) R-loops<|im_end|>', 'Answer: D) antisense<|im_end|>', 'The answer is:\\n\\nD) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'The answer is D: antisense.<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'The answer is D) antisense.<|im_end|>', 'Answer: C) R-loops<|im_end|>', 'Answer: D) antisense<|im_end|>', 'The answer is D) antisense.<|im_end|>', 'The answer is:\\n\\nD) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'The answer is D) antisense. Antisense refers to sequences that bind to complementary DNA or RNA molecules and prevent them from being translated into proteins. It does not involve any structures mentioned above.<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'The answer is C) R-loops.<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'The answer is:\\n\\nA) lariat\\n\\nLariats are structures formed by the RNA splicing process during mRNA maturation. They play a crucial role in the regulation of gene expression by stabilizing mRNA secondary structures and preventing premature termination of translation. In contrast, the proposed therapy involves delivering a Morpholino that prevents the binding of the spliceosome, creating exon skipping and in-frame joining. This therapy does not involve the formation or stabilization of lariats as part of its mechanism of action.<|im_end|>', 'Answer: D) antisense<|im_end|>', 'The answer is D: antisense.<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'The answer is D: antisense. Antisense refers to molecules that bind to specific sequences in DNA or RNA and prevent transcription or translation of those sequences. In this scenario, the morpholinos deliver by delivering a specific sequence in the mRNA, preventing the spliceosome from recognizing it and creating the desired skipping of exons. Lariats, poly(A) tails, and R-loops do not have any direct involvement in the proposed therapy.<|im_end|>', 'Answer: D) antisense<|im_end|>'], 'correct': [False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, True, False, False, False, True, False, True, False, False, False, False, False, False, True, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, True, False, False, False, False, False, False, False, True, False, False, False, False, False, True, False, False, True, False, True, False, False, False, False, False, False, False, False, False, False, False, False, True, False, False, False, False, False, False, False, False, True, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False], 'explanations': [\"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='C'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='D'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='C'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='D'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='D'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='D'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='D'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='D'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='D'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='D'; truth='C'\"], 'num_tokens': [7, 7, 7, 7, 7, 7, 67, 7, 7, 7, 7, 7, 57, 54, 10, 7, 7, 7, 57, 7, 7, 7, 9, 7, 7, 8, 7, 7, 7, 8, 34, 8, 7, 7, 7, 10, 47, 9, 8, 7, 7, 7, 7, 7, 42, 59, 7, 7, 7, 49, 7, 9, 9, 7, 7, 7, 7, 7, 7, 7, 9, 7, 8, 56, 9, 7, 7, 9, 7, 7, 8, 7, 7, 46, 7, 9, 8, 7, 7, 8, 7, 8, 7, 10, 7, 7, 9, 9, 7, 7, 7, 7, 7, 7, 8, 7, 9, 7, 7, 9, 7, 7, 9, 8, 7, 9, 9, 7, 41, 7, 7, 10, 7, 7, 7, 101, 7, 9, 7, 7, 7, 7, 7, 7, 7, 7, 91, 7], 'rewards': [0.06689453125, 0.06689453125, 0.06689453125, 0.06689453125, 0.06689453125, 0.06689453125, 0.044921875, 0.06689453125, 0.06689453125, 0.06689453125, 0.06689453125, 0.06689453125, 0.054443359375, 0.048583984375, 0.0771484375, 0.06689453125, 0.06689453125, 0.06689453125, 0.050537109375, 0.06689453125, 0.06689453125, 0.06689453125, 0.0615234375, 0.06689453125, 0.06689453125, 0.07568359375, 0.06689453125, 0.06689453125, 0.06689453125, 0.07568359375, 0.08056640625, 0.07568359375, 0.06689453125, 0.06689453125, 0.06689453125, 0.07470703125, 0.052001953125, 0.055419921875, 0.07568359375, 0.06689453125, 0.06689453125, 0.06689453125, 0.06689453125, 0.06689453125, 0.08154296875, 0.055419921875, 0.06689453125, 0.06689453125, 0.06689453125, 0.05029296875, 0.06689453125, 0.055419921875, 0.055419921875, 0.06689453125, 0.06689453125, 0.06689453125, 0.06689453125, 0.06689453125, 0.06689453125, 0.06689453125, 0.0615234375, 0.06689453125, 0.07568359375, 0.048583984375, 0.060546875, 0.06689453125, 0.06689453125, 0.060546875, 0.06689453125, 0.06689453125, 0.07568359375, 0.06689453125, 0.06689453125, 0.052490234375, 0.06689453125, 0.055419921875, 0.07568359375, 0.06689453125, 0.06689453125, 0.07568359375, 0.06689453125, 0.07568359375, 0.06689453125, 0.07470703125, 0.06689453125, 0.06689453125, 0.055419921875, 0.055419921875, 0.06689453125, 0.06689453125, 0.06689453125, 0.06689453125, 0.06689453125, 0.06689453125, 0.07568359375, 0.06689453125, 0.055419921875, 0.06689453125, 0.06689453125, 0.060546875, 0.06689453125, 0.06689453125, 0.0615234375, 0.07568359375, 0.06689453125, 0.0615234375, 0.055419921875, 0.06689453125, 0.05078125, 0.06689453125, 0.06689453125, 0.07470703125, 0.06689453125, 0.06689453125, 0.06689453125, 0.05810546875, 0.06689453125, 0.060546875, 0.06689453125, 0.06689453125, 0.06689453125, 0.06689453125, 0.06689453125, 0.06689453125, 0.06689453125, 0.06689453125, 0.0439453125, 0.06689453125], 'ground_truths': ['C'], 'question_meta': None, 'model_name': 'hf_chat:Qwen/Qwen2-1.5B-Instruct', 'reward_model_name': 'armo_rm:RLHFlow/ArmoRM-Llama3-8B-v0.1'}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "  8%|â–Š         | 1/12 [00:01<00:14,  1.31s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'qid': 'gpqa-1', 'prompt': \"Answer the following multiple choice question. The last line of your response should be of the following format: 'Answer: $LETTER' (without quotes) where LETTER is one of ABCD. Think step by step before answering.\\n\\nA large gene has dozens of exons, of which the central ones code for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space. Each exon usually codes for one folded triple alpha helix. The most common mutations of the gene are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste. A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. The molecule prevents binding of the spliceosome and creates exon skipping and in-frame joining. Several missing exons are well tolerated by an organism. Which structure below is not involved in the proposed therapy?\\n\\nA) lariat\\nB) polyA tail\\nC) R-loops\\nD) antisense\", 'answers': [\"Let's break down the question step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats.\\n* The most common mutations are central exon deletions that create out-of-frame peptides.\\n* The proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nThe Morpholino is targeting the pre-mRNA, which is the precursor to mature mRNA. The Morpholino is preventing the spliceosome from binding, which is a complex that splices together exons to form mature mRNA.\\n\\nThe options that are involved in the proposed therapy are:\\n\\n* The pre-mRNA, which is the target of the Morpholino\\n* The spliceosome, which is prevented from binding by the Morpholino\\n\\nThe options that are not involved in the proposed therapy are:\\n\\n* Lariat (this is a type of RNA structure that forms during splicing, but it's not directly involved in the therapy)\\n* PolyA tail (this is a type of modification that is added to the 3' end of mature mRNA, but it's not relevant to the proposed therapy)\\n* R-loops (this is a type of DNA structure that is not directly involved in the therapy)\\n\\nTherefore, the correct answer is:\\n\\nAnswer: A<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome and creates exon skipping and in-frame joining.\\n* The goal is to correct the out-of-frame peptides created by central exon deletions.\\n\\nConsidering the options:\\n\\n* A) Lariat: This is a type of RNA structure that forms during the splicing process, but it's not directly involved in the proposed therapy.\\n* B) PolyA tail: This is a type of modification that occurs at the 3' end of eukaryotic mRNAs, but it's not relevant to the therapy.\\n* C) R-loops: These are structures that can form during transcription, but they're not directly involved in the proposed therapy.\\n* D) Antisense: This is the correct answer, as the Morpholino is an antisense molecule that recognizes the 5' end of the out-of-frame exon and prevents the binding of the spliceosome.\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats.\\n* Each exon codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste.\\n* A Morpholino is used to deliver a solution to this problem.\\n* The Morpholino recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nNow, let's examine each option:\\n\\nA) Lariat: Not involved in the proposed therapy. The lariat is a structure formed during splicing, but it's not directly related to the action of the Morpholino.\\n\\nB) PolyA tail: Not involved in the proposed therapy. The polyA tail is added to the 3' end of the mRNA, but it's not relevant to the action of the Morpholino.\\n\\nC) R-loops: Not involved in the proposed therapy. R-loops are a type of DNA structure that can form during transcription, but they're not directly related to the action of the Morpholino.\\n\\nD) Antisense: This is the correct answer. The Morpholino is an antisense oligonucleotide that recognizes the 5' end of the out-of-frame exon in pre-mRNA. Therefore, antisense is the structure involved in the proposed therapy.\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome, which leads to exon skipping and in-frame joining.\\n* The goal is to create a functional protein by skipping the out-of-frame exons.\\n\\nConsidering this, the structure that is NOT involved in the proposed therapy is:\\n\\nB) polyA tail\\n\\nThe polyA tail is a feature of mature mRNA, not pre-mRNA, and is not directly related to the splicing process or the therapy being described.\\n\\nAnswer: B<|eot_id|>\", \"Let's break down the passage step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides.\\n* A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nNow, let's examine each option:\\n\\nA) Lariat: This is a type of RNA structure that forms during splicing, but it's not directly involved in the proposed therapy.\\n\\nB) PolyA tail: This is a type of modification that occurs at the 3' end of eukaryotic mRNAs, but it's not relevant to the therapy.\\n\\nC) R-loops: These are structures that form during transcription, where RNA forms a triple-stranded structure with the template DNA and non-template DNA strands. While R-loops can affect gene expression, they're not directly involved in the proposed therapy.\\n\\nD) Antisense: Ah, but this is the key! The passage states that the Morpholino is an antisense molecule that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This is the exact mechanism of the proposed therapy.\\n\\nSo, the correct answer is:\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides.\\n* The proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nNow, let's consider each option:\\n\\nA) Lariat: This is a type of RNA structure that forms during splicing, but it's not directly involved in the proposed therapy. The Morpholino recognizes the 5' end of the out-of-frame exon, not a lariat.\\n\\nB) PolyA tail: This is a type of RNA modification that occurs after splicing, but it's not directly involved in the proposed therapy.\\n\\nC) R-loops: These are a type of RNA-DNA hybrid structure that can form during transcription, but they're not directly involved in the proposed therapy.\\n\\nD) Antisense: Ah, wait a minute! The Morpholino is an antisense molecule that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This is exactly what's being proposed as the therapy!\\n\\nSo, the correct answer is:\\n\\nAnswer: D<|eot_id|>\", \"Let's break it down step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats.\\n* The most common mutations are central exon deletions that create out-of-frame peptides.\\n* A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nConsidering the above information, the correct answer is:\\n\\nB) polyA tail\\n\\nThe polyA tail is not involved in the proposed therapy. The Morpholino recognizes the 5' end of the out-of-frame exon in pre-mRNA and prevents the binding of the spliceosome, which is a complex of proteins that plays a crucial role in splicing. The lariat structure is also not directly involved, as it is a type of RNA structure formed during splicing, but it is not a target of the Morpholino. R-loops are also not directly involved, as they are a type of DNA structure that forms during transcription, not splicing. Therefore, the correct answer is B) polyA tail.\\n\\nAnswer: B<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The question is about a gene therapy that uses Morpholinos to treat a disease caused by central exon deletions.\\n* The Morpholino recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nBased on this information, we can conclude that the structure involved in the proposed therapy is the pre-mRNA, specifically the 5' end of the out-of-frame exon.\\n\\nThe options that are not involved in the proposed therapy are:\\n\\n* A) Lariat: Lariats are a type of RNA structure that forms during splicing, but they are not directly involved in the therapy.\\n* B) PolyA tail: The polyA tail is a post-transcriptional modification of mRNA, but it is not directly involved in the therapy.\\n* C) R-loops: R-loops are a type of RNA-DNA hybrid structure that can form during transcription, but they are not directly involved in the therapy.\\n\\nTherefore, the correct answer is:\\n\\nAnswer: A<|eot_id|>\", \"Let's break down the passage step by step:\\n\\n* The passage talks about a large gene with dozens of exons, where each exon codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides.\\n* The solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nNow, let's analyze the options:\\n\\n* A) Lariat: This is a type of RNA structure that forms during splicing, but it's not directly involved in the proposed therapy.\\n* B) PolyA tail: This is a type of RNA modification that is added to the 3' end of eukaryotic mRNAs, but it's not relevant to the proposed therapy.\\n* C) R-loops: R-loops are a type of RNA-DNA hybrid structure that can form during transcription, but they're not directly involved in the proposed therapy.\\n* D) Antisense: Ah, this one is interesting! The passage mentions that the Morpholino is an antisense molecule that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This suggests that antisense is indeed involved in the proposed therapy.\\n\\nSo, the correct answer is A) lariat.\\n\\nAnswer: A<|eot_id|>\", \"Let's break down the passage step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats.\\n* Each exon codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste.\\n* A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome and creates exon skipping and in-frame joining.\\n* Several missing exons are well tolerated by an organism.\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA, preventing the binding of the spliceosome and creating exon skipping and in-frame joining. This process is related to splicing, but it does not involve the structures mentioned in options A, B, and C.\\n\\n* Lariat (A) refers to the structure of the spliceosome, but it is not directly involved in the proposed therapy.\\n* PolyA tail (B) is a post-transcriptional modification, but it is not relevant to the proposed therapy.\\n* R-loops (C) are a type of DNA structure, but they are not involved in the proposed therapy.\\n\\nTherefore, the correct answer is:\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome and creates exon skipping and in-frame joining.\\n* The goal is to deliver a functional protein by creating an in-frame peptide.\\n\\nNow, let's examine each option:\\n\\nA) Lariat: This is a type of RNA structure that forms during splicing, but it's not directly involved in the therapy. So, this option is not correct.\\n\\nB) PolyA tail: This is a feature of mRNA that's added during processing, but it's not relevant to the therapy. So, this option is not correct.\\n\\nC) R-loops: These are structures that form during transcription and can affect gene expression, but they're not directly involved in the therapy. So, this option is not correct.\\n\\nD) Antisense: Ah, but this is the key! The Morpholino is an antisense molecule that recognizes the 5' end of the out-of-frame exon and prevents the binding of the spliceosome. This is the exact mechanism of action described in the question. Therefore, option D) antisense is the correct answer.\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the passage step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste.\\n* A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome and creates exon skipping and in-frame joining.\\n* Several missing exons are well tolerated by an organism.\\n\\nThe passage does not mention any of the following structures being involved in the proposed therapy:\\n\\n* A lariat (A): Lariats are RNA structures that form during splicing, but they are not directly involved in the therapy.\\n* A polyA tail (B): PolyA tails are found at the 3' end of eukaryotic mRNAs, but they are not mentioned in the passage.\\n* R-loops (C): R-loops are RNA-DNA hybrids that can form during transcription, but they are not directly involved in the therapy.\\n* Antisense (D): Antisense is the correct answer, as the passage mentions the use of Morpholino, which is an antisense oligonucleotide.\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the information in the passage:\\n\\n* The gene has dozens of exons, with the central ones coding for folded triple helical repeats.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides.\\n* The proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nThe options are:\\n\\nA) Lariat: A lariat is a type of RNA structure that forms during splicing, but it's not directly involved in the proposed therapy.\\n\\nB) PolyA tail: The polyA tail is a type of RNA modification that occurs after splicing, but it's not directly involved in the proposed therapy.\\n\\nC) R-loops: R-loops are a type of RNA-DNA hybrid structure that can form during transcription and splicing, but they're not directly involved in the proposed therapy.\\n\\nD) Antisense: Ah, but wait! Antisense refers to a type of RNA molecule that is complementary to the target mRNA sequence, and in this case, the Morpholino is an antisense molecule that recognizes the 5' end of the out-of-frame exon. Therefore, antisense is the correct answer.\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations of the gene are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste.\\n* A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents binding of the spliceosome and creates exon skipping and in-frame joining.\\n* Several missing exons are well tolerated by an organism.\\n\\nThe structure that is not involved in the proposed therapy is:\\n\\nB) polyA tail\\n\\nThe polyA tail is a feature of mature mRNA, not pre-mRNA, and is not directly related to the mechanism of action of the Morpholino. The other options are all relevant to the process of splicing and pre-mRNA processing, which is the focus of the therapy.\\n\\nAnswer: B<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome and creates exon skipping and in-frame joining.\\n* The goal is to create a functional protein by skipping out-of-frame exons and joining the remaining exons in-frame.\\n\\nThe structures involved in the proposed therapy are:\\n\\n* The pre-mRNA (which is the target of the Morpholino)\\n* The spliceosome (which is prevented from binding by the Morpholino)\\n\\nThe structures that are NOT involved in the proposed therapy are:\\n\\n* Lariat (a type of RNA structure formed during splicing, but not directly related to the Morpholino therapy)\\n* PolyA tail (a type of post-transcriptional modification, not directly related to the Morpholino therapy)\\n* R-loops (a type of DNA structure, not directly related to the Morpholino therapy)\\n\\nTherefore, the correct answer is:\\n\\nAnswer: A<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste.\\n* A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nThe proposed therapy involves the Morpholino recognizing the 5' end of the out-of-frame exon and preventing the spliceosome from binding. This suggests that the structure involved is the pre-mRNA, which is the target of the Morpholino.\\n\\nThe options that are not directly involved in the proposed therapy are:\\n\\n* A) Lariat: Lariats are structures that form during splicing, but they are not directly related to the proposed therapy.\\n* B) PolyA tail: The polyA tail is a feature of mature mRNA, and it's not directly involved in the therapy.\\n* C) R-loops: R-loops are structures that form during transcription, and they are not directly related to the proposed therapy.\\n* D) Antisense: Antisense refers to a type of RNA that is complementary to a specific sequence of DNA or RNA. In this context, the Morpholino is an antisense molecule, so this option is not correct.\\n\\nAnswer: A<|eot_id|>\", \"Let's break down the passage step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste.\\n* To solve this, a Morpholino is delivered to the pre-mRNA to recognize the 5' end of the out-of-frame exon.\\n* The Morpholino prevents the binding of the spliceosome, causing exon skipping and in-frame joining.\\n* Several missing exons are well tolerated by the organism.\\n\\nNow, let's look at the options:\\n\\nA) Lariat: This is a type of RNA structure that forms during splicing, where the 5' end of the intron is covalently attached to the 2' OH group of a nucleotide. While lariats are involved in splicing, they are not directly related to the proposed therapy, which involves using a Morpholino to prevent spliceosome binding.\\n\\nB) PolyA tail: This is a type of RNA modification that adds a string of adenine nucleotides to the 3' end of the mRNA. While polyA tails are important for mRNA stability and translation, they are not directly involved in the proposed therapy.\\n\\nC) R-loops: R-loops are a type of RNA-DNA hybrid structure that can form during transcription and can be involved in regulating gene expression. While R-loops can be important for gene regulation, they are not directly related to the proposed therapy.\\n\\nD) Antisense: Ah, but this is the key! Antisense refers to a type of RNA molecule that is complementary to a target RNA sequence. In this case, the Morpholino is an antisense molecule that recognizes the 5' end of the out-of-frame exon and prevents spliceosome binding. Therefore, antisense is the correct answer.\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the passage step by step:\\n\\n* The passage talks about a large gene with dozens of exons, and the problem is that there are central exon deletions that create out-of-frame peptides.\\n* The solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nNow, let's look at the options:\\n\\n* A) Lariat: This is not directly involved in the proposed therapy. Lariats are a type of RNA structure that forms during splicing, but they are not a target of the Morpholino.\\n* B) PolyA tail: This is also not directly involved in the proposed therapy. The polyA tail is added to the 3' end of mRNA during processing, but it's not a target of the Morpholino.\\n* C) R-loops: R-loops are a type of RNA structure that can form during transcription, but they are not directly involved in the proposed therapy.\\n* D) Antisense: Ah, this is the key! The Morpholino is an antisense oligonucleotide that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This means that antisense is directly involved in the proposed therapy.\\n\\nSo, the correct answer is:\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste.\\n* A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents binding of the spliceosome and creates exon skipping and in-frame joining.\\n* Several missing exons are well tolerated by an organism.\\n\\nNow, let's analyze the options:\\n\\nA) Lariat: A lariat is a type of RNA structure that forms during splicing, but it's not directly involved in the proposed therapy. The Morpholino recognizes the 5' end of the out-of-frame exon, but it doesn't create a lariat structure.\\n\\nB) PolyA tail: The polyA tail is added to the 3' end of the pre-mRNA during processing, but it's not involved in the proposed therapy.\\n\\nC) R-loops: R-loops are structures that form during transcription, but they're not directly related to the proposed therapy.\\n\\nD) Antisense: Ah, but wait! The Morpholino is an antisense molecule that recognizes the 5' end of the out-of-frame exon in pre-mRNA and prevents the binding of the spliceosome. This is the correct answer!\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the information:\\n\\n* The gene has dozens of exons, with central ones coding for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space.\\n* The most common mutations are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste.\\n* A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nThe Morpholino binds to the 5' end of the out-of-frame exon, which means it interacts with the pre-mRNA. This process does not involve:\\n\\n* Lariat (A): Lariats are structures formed during splicing, but they are not directly involved in the proposed therapy.\\n* PolyA tail (B): The polyA tail is a post-transcriptional modification, whereas the therapy involves pre-mRNA and the spliceosome.\\n* R-loops (C): R-loops are structures formed during transcription, but they are not directly involved in the proposed therapy.\\n* Antisense (D): The Morpholino is an antisense molecule that recognizes the 5' end of the out-of-frame exon, so this option is actually correct.\\n\\nAnswer: A<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste.\\n* A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents binding of the spliceosome and creates exon skipping and in-frame joining.\\n* Several missing exons are well tolerated by an organism.\\n\\nNow, let's look at the options:\\n\\nA) Lariat: A lariat is a type of RNA structure that forms during splicing, but it's not directly involved in the proposed therapy.\\n\\nB) PolyA tail: The polyA tail is a type of post-transcriptional modification that adds a string of adenine nucleotides to the 3' end of a mRNA molecule. It's not directly involved in the proposed therapy.\\n\\nC) R-loops: R-loops are a type of RNA-DNA hybrid structure that can form during transcription, but they're not directly involved in the proposed therapy.\\n\\nD) Antisense: Ah, but antisense is exactly what the proposed therapy is! The Morpholino is an antisense oligonucleotide that recognizes the 5' end of the out-of-frame exon in pre-mRNA and prevents binding of the spliceosome.\\n\\nSo, the correct answer is:\\n\\nAnswer: A<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste.\\n* A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents binding of the spliceosome and creates exon skipping and in-frame joining.\\n* Several missing exons are well tolerated by an organism.\\n\\nThe question asks which structure is NOT involved in the proposed therapy. Let's analyze the options:\\n\\nA) Lariat: A lariat is a type of RNA structure that forms during splicing, but it's not directly involved in the therapy proposed here, which is about delivering a Morpholino to prevent spliceosome binding.\\n\\nB) PolyA tail: The polyA tail is added to the 3' end of mRNA during processing, but it's not directly involved in the therapy either.\\n\\nC) R-loops: R-loops are a type of DNA structure that forms during transcription, but they're not mentioned in the context of this therapy.\\n\\nD) Antisense: Ah, but wait! The therapy involves delivering a Morpholino, which is an antisense molecule that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This means that antisense is indeed involved in the therapy.\\n\\nTherefore, the correct answer is:\\n\\nAnswer: B<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome and creates exon skipping and in-frame joining.\\n* The goal is to restore the reading frame of the gene by skipping the out-of-frame exons.\\n\\nNow, let's analyze each option:\\n\\nA) Lariat: A lariat is a type of RNA structure that forms during splicing, but it's not directly involved in the proposed therapy. Therefore, it's not the correct answer.\\n\\nB) PolyA tail: The polyA tail is a feature of mRNA, but it's not directly involved in the therapy either. The Morpholino is targeting the pre-mRNA, not the mature mRNA.\\n\\nC) R-loops: R-loops are a type of RNA-DNA hybrid structure that can form during transcription, but they're not directly related to the proposed therapy.\\n\\nD) Antisense: Ah, but antisense refers to a type of RNA molecule that binds to a complementary sequence, which is exactly what the Morpholino is doing! It recognizes the 5' end of the out-of-frame exon in pre-mRNA and prevents the binding of the spliceosome.\\n\\nSo, the correct answer is:\\n\\nAnswer: A<|eot_id|>\", \"Let's break down the passage step by step:\\n\\n* The passage talks about a large gene with dozens of exons, and the central exons code for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste.\\n* The proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA, preventing the binding of the spliceosome and creating exon skipping and in-frame joining.\\n* The passage mentions that several missing exons are well tolerated by an organism.\\n\\nNow, let's look at the options:\\n\\nA) Lariat: A lariat is a type of RNA structure that forms during splicing, but it's not directly involved in the proposed therapy.\\n\\nB) PolyA tail: The polyA tail is a feature of mRNA, but it's not mentioned in the passage as being directly involved in the proposed therapy.\\n\\nC) R-loops: R-loops are a type of RNA structure that forms during transcription, but they're not mentioned in the passage as being directly involved in the proposed therapy.\\n\\nD) Antisense: The passage mentions that the Morpholino recognizes the 5' end of the out-of-frame exon in pre-mRNA, which is an antisense approach.\\n\\nTherefore, the correct answer is:\\n\\nAnswer: A<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations of the gene are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste.\\n* A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nThe Morpholino is an antisense molecule that targets the 5' end of the out-of-frame exon, so it's not related to the following structures:\\n\\n* Lariat: A lariat is a type of RNA structure that forms during splicing, but it's not involved in the proposed therapy.\\n* PolyA tail: A polyA tail is a type of post-transcriptional modification that adds a string of adenine nucleotides to the 3' end of eukaryotic mRNA, but it's not relevant to the therapy.\\n* R-loops: R-loops are a type of RNA-DNA hybrid structure that forms during transcription, but they're not involved in the proposed therapy.\\n* Antisense: Ah, but wait! The Morpholino is indeed an antisense molecule, which is exactly what the question is asking about. So, the correct answer is... (drumroll please)... none of the above!\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The question is asking about the structure not involved in the proposed therapy, which is delivering a Morpholino to prevent the binding of the spliceosome and create exon skipping.\\n* The Morpholino recognizes the 5' end of the out-of-frame exon in pre-mRNA, so it's likely related to the pre-mRNA processing.\\n* The proposed therapy is about altering the splicing of the gene, which is a process involving the spliceosome.\\n* The options are:\\n\\t+ A) lariat: a type of RNA structure formed during splicing, so it's likely involved in the proposed therapy.\\n\\t+ B) polyA tail: a type of modification on the 3' end of mRNAs, not directly related to splicing or the proposed therapy.\\n\\t+ C) R-loops: a type of DNA structure, not directly related to splicing or the proposed therapy.\\n\\t+ D) antisense: a type of RNA molecule that can bind to complementary DNA or RNA sequences, which is similar to the Morpholino used in the proposed therapy.\\n\\nTherefore, the correct answer is:\\n\\nAnswer: B<|eot_id|>\", \"Let's break down the passage step by step:\\n\\n* The passage mentions a large gene with dozens of exons, and the central ones code for folded triple helical repeats.\\n* The most common mutations are central exon deletions that create out-of-frame peptides.\\n* The solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nNow, let's analyze the options:\\n\\nA) Lariat: This is a type of RNA structure that forms during splicing, but it's not directly involved in the proposed therapy. Therefore, it's not the correct answer.\\n\\nB) PolyA tail: This is a type of RNA modification that adds a long string of adenine nucleotides to the 3' end of a transcript. It's not directly involved in the proposed therapy, so it's not the correct answer.\\n\\nC) R-loops: R-loops are a type of DNA structure that can form during transcription, but they're not directly involved in the proposed therapy. Therefore, it's not the correct answer.\\n\\nD) Antisense: Ah, but this is the correct answer! The passage mentions that the Morpholino is an antisense molecule that recognizes the 5' end of the out-of-frame exon. Therefore, antisense is the structure involved in the proposed therapy.\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the text step by step:\\n\\n* The text talks about a large gene with dozens of exons, and the focus is on the central exons that code for folded triple helical repeats.\\n* These exons usually code for one folded triple alpha helix each.\\n* The most common mutations are central exon deletions that create out-of-frame peptides and lead to progressive degenerative organ waste.\\n* The proposed solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome and creates exon skipping and in-frame joining.\\n* Several missing exons are well tolerated by the organism.\\n\\nNow, let's examine the answer choices:\\n\\n* A) lariat: This is not directly involved in the proposed therapy. Lariats are a type of RNA structure formed during splicing, but they are not a target for the Morpholino.\\n* B) polyA tail: This is also not directly involved in the proposed therapy. The polyA tail is a post-transcriptional modification that is added to the 3' end of mRNA, but it's not a target for the Morpholino.\\n* C) R-loops: R-loops are a type of RNA structure that can form during transcription, but they are not directly involved in the proposed therapy.\\n* D) antisense: Ah, but antisense is exactly what the Morpholino is! It's an antisense molecule that recognizes the 5' end of the out-of-frame exon in pre-mRNA and prevents the binding of the spliceosome.\\n\\nTherefore, the correct answer is:\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the passage step by step:\\n\\n* The passage talks about a large gene with dozens of exons, and the therapy involves delivering a Morpholino that recognizes the 5' end of an out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome, which is a complex involved in splicing pre-mRNA.\\n* The goal is to create exon skipping and in-frame joining, which means that the Morpholino is targeting the splicing process.\\n\\nBased on this information, we can eliminate options A, B, and C:\\n\\n* A) Lariat: This is a type of RNA structure that forms during splicing, but it's not directly involved in the therapy.\\n* B) PolyA tail: This is a type of post-transcriptional modification that adds a string of adenine nucleotides to the 3' end of a mRNA molecule. It's not directly involved in the therapy.\\n* C) R-loops: These are a type of DNA structure that forms during transcription, but it's not directly involved in the therapy.\\n\\nThe correct answer is D) antisense, because the passage specifically mentions that the Morpholino recognizes the 5' end of the out-of-frame exon, which means it's an antisense oligonucleotide. The passage is describing an antisense therapy.\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats.\\n* Each exon codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides.\\n* A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nNow, let's analyze the options:\\n\\n* A) Lariat: A lariat is a type of RNA structure that forms during splicing, but it's not directly involved in the proposed therapy. Therefore, it's not the correct answer.\\n* B) PolyA tail: The polyA tail is a feature of mature mRNA, and it's not directly involved in the proposed therapy either. Therefore, it's not the correct answer.\\n* C) R-loops: R-loops are a type of DNA structure that can form during transcription, but they're not directly involved in the proposed therapy. Therefore, it's not the correct answer.\\n* D) Antisense: Ah, but antisense is the correct answer! The Morpholino is an antisense molecule that recognizes the 5' end of the out-of-frame exon and prevents binding of the spliceosome. Therefore, antisense is the structure involved in the proposed therapy.\\n\\nAnswer: D<|eot_id|>\", \"Let's break it down step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats.\\n* The most common mutations are central exon deletions that create out-of-frame peptides.\\n* The proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nThe key here is that the Morpholino is targeting the pre-mRNA, which is a precursor to the mature mRNA. The Morpholino is not interacting with the mature mRNA, which would have already undergone splicing.\\n\\nThe correct answer is B) polyA tail. The polyA tail is a feature of mature mRNA, not pre-mRNA.\\n\\nAnswer: B<|eot_id|>\", \"Let's break down the text step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats.\\n* Each exon codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides.\\n* A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nNow, let's look at the options:\\n\\nA) Lariat: This refers to a type of RNA structure that forms during splicing, but it's not directly involved in the proposed therapy.\\n\\nB) PolyA tail: This is a type of post-transcriptional modification that adds a string of adenine nucleotides to the 3' end of mRNA. It's not directly involved in the proposed therapy.\\n\\nC) R-loops: R-loops are a type of RNA-DNA hybrid structure that can form during transcription and can be involved in gene regulation. However, it's not directly involved in the proposed therapy.\\n\\nD) Antisense: This is the correct answer. The Morpholino is an antisense molecule that recognizes the 5' end of the out-of-frame exon and prevents binding of the spliceosome. Therefore, antisense is the structure directly involved in the proposed therapy.\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome and creates exon skipping and in-frame joining.\\n* The goal is to create a normal protein by skipping the out-of-frame exon and joining the remaining exons in-frame.\\n\\nConsidering these points, we can eliminate options:\\n\\n* A) Lariat: Lariats are structures formed during splicing, but they are not directly involved in the proposed therapy.\\n* B) PolyA tail: The polyA tail is a feature of mature mRNA, not pre-mRNA, and is not directly related to the therapy.\\n* C) R-loops: R-loops are structures that can form during transcription, but they are not directly involved in the proposed therapy.\\n\\nThe correct answer is D) antisense, as the Morpholino is an antisense oligonucleotide that recognizes the 5' end of the out-of-frame exon. The Morpholino is the therapy itself, so it's not a structure that is not involved in the proposed therapy.\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste.\\n* A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nNow, let's analyze the answer options:\\n\\n* A) Lariat: This refers to the lariat structure formed during splicing, where the intron is looped out and the exons are joined. While lariats are involved in splicing, they are not directly related to the proposed therapy.\\n* B) PolyA tail: The polyA tail is a feature of mRNA, and it's not directly involved in the proposed therapy.\\n* C) R-loops: R-loops are structures that form during transcription, where the RNA transcript forms a triple-stranded structure with the template DNA and a non-template DNA strand. While R-loops can affect gene expression, they are not directly related to the proposed therapy.\\n* D) Antisense: Ah, but this is the correct answer! The Morpholino is an antisense oligonucleotide that recognizes the 5' end of the out-of-frame exon in pre-mRNA. Therefore, antisense is the structure involved in the proposed therapy.\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the passage step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides.\\n* The proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nThe key structure involved in this therapy is the pre-mRNA, which is recognized by the Morpholino.\\n\\nThe options that are NOT involved in this therapy are:\\n\\n* A) lariat: This is a type of RNA structure that is formed during splicing, but it's not directly related to the therapy.\\n* B) polyA tail: This is a type of RNA modification that is added to the 3' end of mRNA, but it's not relevant to the therapy.\\n* C) R-loops: These are a type of RNA-DNA hybrid structure that can form during transcription, but it's not directly related to the therapy.\\n* D) antisense: This is the correct answer, as the Morpholino is an antisense molecule that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n\\nAnswer: D<|eot_id|>\", \"Let's break it down step by step!\\n\\nThe passage mentions that the Morpholino recognizes the 5' end of the out-of-frame exon in pre-mRNA, preventing the binding of the spliceosome and creating exon skipping and in-frame joining.\\n\\nThe proposed therapy is to deliver a Morpholino that targets the 5' end of the out-of-frame exon in pre-mRNA. This means that the Morpholino is binding to the pre-mRNA, not to any of the structures listed below.\\n\\nTherefore, the correct answer is:\\n\\nAnswer: B<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats.\\n* The mutations are central exon deletions that create out-of-frame peptides.\\n* A Morpholino is used to recognize the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nNow, let's analyze the options:\\n\\n* A) Lariat: This is a structure formed during splicing, but it's not directly involved in the proposed therapy. So, it's unlikely to be the correct answer.\\n* B) PolyA tail: This is a feature of mature mRNA, but it's not directly involved in the therapy. So, it's unlikely to be the correct answer.\\n* C) R-loops: R-loops are structures that form during transcription, but they're not directly involved in the therapy. So, it's unlikely to be the correct answer.\\n* D) Antisense: This is the correct answer. The Morpholino is an antisense oligonucleotide that recognizes the 5' end of the out-of-frame exon, but it's not the structure being referred to. The structure being referred to is the spliceosome, which is not an option.\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the passage step by step:\\n\\n* The passage talks about a large gene with dozens of exons, and the central ones code for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations of the gene are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste.\\n* A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents binding of the spliceosome and creates exon skipping and in-frame joining.\\n* The passage mentions that several missing exons are well tolerated by an organism.\\n\\nNow, let's examine the options:\\n\\nA) Lariat: This is a structure formed during splicing, where the intron is looped out and the 5' and 3' ends are joined together. It's not directly involved in the proposed therapy, so it's not the correct answer.\\n\\nB) PolyA tail: This is a structure found at the 3' end of eukaryotic mRNAs, and it's not directly related to the proposed therapy.\\n\\nC) R-loops: This is a structure where an RNA molecule forms a loop with a complementary DNA sequence. It's not directly involved in the proposed therapy.\\n\\nD) Antisense: This is the correct answer. The passage mentions that the Morpholino recognizes the 5' end of the out-of-frame exon in pre-mRNA, which is an antisense molecule. Therefore, the correct answer is D) antisense.\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the passage step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste.\\n* A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nNow, let's analyze the options:\\n\\n* A) lariat: This is a type of RNA structure that forms during splicing, but it's not directly involved in the proposed therapy.\\n* B) polyA tail: This is a type of RNA modification that is added to the 3' end of mRNA, but it's not relevant to the proposed therapy.\\n* C) R-loops: These are structures that form when RNA hybridizes with a complementary DNA sequence, but they're not directly involved in the proposed therapy.\\n* D) antisense: This is the correct answer. The passage mentions that the Morpholino recognizes the 5' end of the out-of-frame exon, which is an antisense molecule that binds to the pre-mRNA.\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The question is asking about the structure that is NOT involved in the proposed therapy.\\n* The proposed therapy involves delivering a Morpholino that recognizes the 5' end of an out-of-frame exon in pre-mRNA, preventing the binding of the spliceosome and creating exon skipping and in-frame joining.\\n* The Morpholino is targeting the pre-mRNA, so it's likely that the structure involved is related to RNA processing or splicing.\\n* The options provided are:\\n\\t+ A) Lariat: a type of RNA structure that forms during splicing, but it's not directly involved in the therapy.\\n\\t+ B) PolyA tail: a type of modification added to the 3' end of mRNA, but it's not directly involved in the therapy.\\n\\t+ C) R-loops: a type of DNA-RNA hybrid structure that can form during transcription, but it's not directly involved in the therapy.\\n\\t+ D) Antisense: a type of RNA molecule that can bind to a target sequence, but in this case, the Morpholino is the antisense molecule being delivered, so this option is not correct.\\n\\nTherefore, the correct answer is:\\n\\nAnswer: B<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats.\\n* The most common mutations are central exon deletions that create out-of-frame peptides.\\n* A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nThe structure that is not involved in the proposed therapy is the polyA tail (B). The polyA tail is added to the 3' end of the pre-mRNA, not the 5' end, and it's not directly related to the mechanism of action of the Morpholino.\\n\\nAnswer: B<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The question is asking about the structure not involved in the proposed therapy, which is using Morpholino to deliver a solution to a genetic disorder.\\n* Morpholino recognizes the 5' end of the out-of-frame exon in pre-mRNA and prevents the binding of the spliceosome, causing exon skipping and in-frame joining.\\n* The process involves the pre-mRNA molecule, so we can rule out the polyA tail (B) and R-loops (C) as they are not directly involved in the process.\\n* The lariat (A) structure is a type of RNA structure that forms during splicing, but it is not directly involved in the recognition of the 5' end of the out-of-frame exon by the Morpholino.\\n\\nTherefore, the correct answer is:\\n\\nAnswer: B<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome and creates exon skipping and in-frame joining.\\n* The goal is to create a new, in-frame peptide that can be translated into a functional protein.\\n\\nNow, let's examine the options:\\n\\n* A) Lariat: This is a type of RNA structure that forms during splicing, but it's not directly involved in the proposed therapy.\\n* B) PolyA tail: This is a type of post-transcriptional modification that adds a string of adenine nucleotides to the 3' end of the mRNA, but it's not relevant to the proposed therapy.\\n* C) R-loops: R-loops are a type of RNA-DNA hybrid structure that can form during transcription, but they're not directly involved in the proposed therapy.\\n* D) Antisense: Ah, this is the key! The Morpholino is an antisense molecule that recognizes the 5' end of the out-of-frame exon in pre-mRNA. It's the antisense molecule that prevents the binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nTherefore, the correct answer is:\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats.\\n* The mutations are central exon deletions that create out-of-frame peptides.\\n* The solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nNow, let's analyze the options:\\n\\n* A) Lariat: This is a type of RNA structure formed during splicing, where the intron is removed and the exons are joined. While it's related to splicing, it's not directly involved in the proposed therapy.\\n* B) PolyA tail: This is a type of post-transcriptional modification added to the 3' end of eukaryotic mRNAs. It's not directly involved in the proposed therapy.\\n* C) R-loops: These are regions of RNA-DNA hybrids that can form during transcription and can be involved in regulating gene expression. While they can affect splicing, they're not directly involved in the proposed therapy.\\n* D) Antisense: This is the type of molecule being used in the proposed therapy, a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n\\nTherefore, the correct answer is A) lariat.\\n\\nAnswer: A<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste.\\n* A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents binding of the spliceosome and creates exon skipping and in-frame joining.\\n* Several missing exons are well tolerated by an organism.\\n\\nThe question asks which structure is NOT involved in the proposed therapy.\\n\\nThe correct answer is:\\n\\nB) polyA tail\\n\\nThe other options are all related to the proposed therapy:\\n\\n* A) Lariat: a type of RNA structure that forms during splicing, which is relevant to the therapy as it involves preventing the binding of the spliceosome.\\n* C) R-loops: a type of RNA structure that can form during transcription, which is not directly related to the therapy but is a type of RNA structure.\\n* D) Antisense: the Morpholino is an antisense oligonucleotide that recognizes the 5' end of the out-of-frame exon, so this option is relevant to the therapy.\\n\\nAnswer: B<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The question is about a gene with dozens of exons, and the therapy involves delivering a Morpholino that recognizes the 5' end of an out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome, which leads to exon skipping and in-frame joining.\\n* The question asks which structure is NOT involved in the proposed therapy.\\n\\nThe correct answer is B) polyA tail. The polyA tail is not directly involved in the therapy, as it is not affected by the Morpholino binding to the 5' end of the out-of-frame exon.\\n\\nAnswer: B<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats.\\n* The most common mutations are central exon deletions that create out-of-frame peptides.\\n* A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nThe structure not involved in the proposed therapy is:\\n\\n* PolyA tail: The polyA tail is a post-transcriptional modification that is not directly related to the proposed therapy, which involves delivering a Morpholino to prevent spliceosome binding and create exon skipping.\\n\\nAnswer: B<|eot_id|>\", \"Let's break it down step by step:\\n\\n* The question is about a therapy that involves delivering a Morpholino to prevent the binding of the spliceosome.\\n* The Morpholino recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* This prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n* The goal is to create a functional protein by skipping the out-of-frame exons.\\n\\nNow, let's analyze the options:\\n\\n* A) Lariat: Not involved in the therapy. A lariat is a type of RNA structure formed during splicing, but it's not directly related to the Morpholino-mediated therapy.\\n* B) PolyA tail: Not involved in the therapy. The polyA tail is a feature of mRNA, but it's not directly related to the splicing process or the Morpholino therapy.\\n* C) R-loops: Involved in the therapy. R-loops are structures that form when the RNA-DNA hybrid is stabilized, which can occur during splicing. The Morpholino therapy may affect the formation of R-loops, leading to exon skipping.\\n* D) Antisense: Involved in the therapy. The Morpholino is an antisense molecule that recognizes the 5' end of the out-of-frame exon in pre-mRNA, preventing the binding of the spliceosome.\\n\\nBased on the analysis, the correct answer is:\\n\\nAnswer: A<|eot_id|>\", \"Let's break down the passage step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations of the gene are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste.\\n* The solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nFrom this, we can infer that the Morpholino is targeting the pre-mRNA, which is a precursor to mature mRNA. This means that the structure involved in the proposed therapy is the pre-mRNA.\\n\\nThe options are:\\n\\nA) lariat: This is a type of RNA structure that forms during splicing, but it's not directly involved in the proposed therapy.\\nB) polyA tail: This is a type of post-transcriptional modification that adds a string of adenine nucleotides to the 3' end of mature mRNA, but it's not directly involved in the proposed therapy.\\nC) R-loops: These are a type of RNA-DNA hybrid structure that can form during transcription, but it's not directly involved in the proposed therapy.\\nD) antisense: This is the correct answer. Antisense refers to a strand of RNA that is complementary to a target mRNA, and the Morpholino in the proposed therapy is an antisense oligonucleotide that recognizes the 5' end of the out-of-frame exon. Therefore, the correct answer is D) antisense.\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome, which leads to exon skipping and in-frame joining.\\n* The goal is to create a functional protein by skipping the out-of-frame exons.\\n\\nConsidering the options, we can eliminate B) polyA tail because it's not directly involved in the splicing process. PolyA tail is added to the 3' end of the pre-mRNA during processing.\\n\\nThe lariat (A) is a type of RNA structure that forms during splicing, but it's not directly involved in the therapy. The Morpholino is preventing the binding of the spliceosome, which is a complex that recognizes the 5' and 3' splice sites and catalyzes the splicing reaction.\\n\\nC) R-loops are structures that form during transcription, where the nascent RNA transcript forms a triple-stranded structure with the template DNA and the nascent RNA. While R-loops can influence gene expression, they are not directly involved in the proposed therapy.\\n\\nD) Antisense is a type of RNA molecule that binds to a target RNA sequence, but in this case, the Morpholino is not an antisense RNA. It's a modified RNA oligonucleotide that recognizes the 5' end of the out-of-frame exon.\\n\\nAnswer: B<|eot_id|>\", \"Let's break down the passage step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides.\\n* The proposed therapy is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nThe structures involved in the proposed therapy are:\\n\\n* Pre-mRNA (which is the target of the Morpholino)\\n* Spliceosome (which is prevented from binding by the Morpholino)\\n\\nThe structures that are NOT involved in the proposed therapy are:\\n\\n* Lariat (which is a type of RNA structure formed during splicing, but it's not directly related to the therapy)\\n* PolyA tail (which is a type of RNA modification, but it's not involved in the therapy)\\n* R-loops (which are a type of DNA structure, but they're not mentioned in the passage)\\n\\nTherefore, the correct answer is:\\n\\nAnswer: A<|eot_id|>\", \"Let's break down the passage step by step:\\n\\n* The gene has dozens of exons, with central ones coding for folded triple helical repeats.\\n* Each exon codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions, which create out-of-frame peptides.\\n* To solve this, a Morpholino is used to recognize the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n* Several missing exons are well-tolerated by the organism.\\n\\nNow, let's analyze the options:\\n\\n* A) Lariat: Not involved in the proposed therapy, as it's a type of RNA structure formed during splicing, but not directly related to the Morpholino's mechanism.\\n* B) PolyA tail: Not involved in the proposed therapy, as it's a feature of mRNA, not pre-mRNA, and not directly related to the Morpholino's mechanism.\\n* C) R-loops: Not involved in the proposed therapy, as they're a type of non-canonical DNA structure, not directly related to the Morpholino's mechanism.\\n* D) Antisense: This is the correct answer, as the Morpholino is an antisense oligonucleotide that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste.\\n* A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents binding of the spliceosome and creates exon skipping and in-frame joining.\\n* Several missing exons are well tolerated by an organism.\\n\\nThe structure not involved in the proposed therapy is:\\n\\nB) polyA tail\\n\\nThe polyA tail is not directly related to the mechanism of the Morpholino therapy, which involves recognizing the 5' end of the out-of-frame exon and preventing spliceosome binding.\\n\\nAnswer: B<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats.\\n* Each exon codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides.\\n* A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nNow, let's analyze the answer choices:\\n\\n* A) Lariat: This refers to a type of RNA structure that forms during splicing, where the intron is looped back onto itself. While lariats are involved in splicing, they are not directly related to the proposed therapy, which involves preventing spliceosome binding.\\n* B) PolyA tail: The polyA tail is a feature of mRNA, but it's not directly involved in the proposed therapy, which focuses on pre-mRNA and spliceosome binding.\\n* C) R-loops: R-loops are a type of RNA-DNA hybrid structure that can form during transcription. While R-loops can occur in the context of gene regulation, they are not directly related to the proposed therapy.\\n* D) Antisense: Ah, but this is the correct answer! The proposed therapy involves delivering a Morpholino, which is an antisense oligonucleotide that recognizes the 5' end of the out-of-frame exon in pre-mRNA. Therefore, antisense is the structure that is directly involved in the proposed therapy.\\n\\nAnswer: D<|eot_id|>\", \"Let's break it down step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats.\\n* The most common mutations are central exon deletions that create out-of-frame peptides.\\n* A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents binding of the spliceosome and creates exon skipping and in-frame joining.\\n* The goal is to tolerate missing exons.\\n\\nFrom this, we can infer that the structure involved in the proposed therapy is the pre-mRNA, specifically the 5' end of the out-of-frame exon.\\n\\nThe options that are not involved in the proposed therapy are:\\n\\n* A) Lariat: This is a type of RNA structure that forms during splicing, but it's not directly related to the therapy.\\n* B) PolyA tail: This is a type of RNA modification that occurs during processing, but it's not involved in the therapy.\\n* C) R-loops: These are structures that form during transcription, but they're not relevant to the therapy.\\n* D) Antisense: This is the correct answer, as the Morpholino is an antisense molecule that recognizes the 5' end of the out-of-frame exon and prevents binding of the spliceosome.\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space.\\n* The most common mutations are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste.\\n* A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nFrom this, we can infer that the Morpholino is targeting the pre-mRNA to affect splicing. The options are:\\n\\nA) Lariat: This is a type of RNA structure that forms during splicing, but it's not directly involved in the proposed therapy.\\n\\nB) PolyA tail: This is a type of post-transcriptional modification that adds a long string of adenine nucleotides to the 3' end of mRNA. It's not directly involved in the proposed therapy.\\n\\nC) R-loops: These are regions of RNA-DNA hybridization that can form during transcription and can be involved in gene regulation. However, they're not directly involved in the proposed therapy.\\n\\nD) Antisense: This is a type of RNA molecule that is complementary to a specific target sequence. In this case, the Morpholino is an antisense molecule that recognizes the 5' end of the out-of-frame exon. Therefore, option D is the correct answer.\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations of the gene are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste.\\n* The proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA and preventing the binding of the spliceosome to create exon skipping and in-frame joining.\\n\\nNow, let's analyze the options:\\n\\nA) Lariat: This is a structure that forms during splicing, but it's not directly involved in the proposed therapy.\\n\\nB) PolyA tail: This is a structure that is added to the 3' end of the mRNA, but it's not relevant to the proposed therapy.\\n\\nC) R-loops: These are structures that can form during transcription and can be involved in regulating gene expression, but they're not directly involved in the proposed therapy.\\n\\nD) Antisense: This is the correct answer. The proposed therapy involves delivering a Morpholino, which is an antisense oligonucleotide that recognizes the 5' end of the out-of-frame exon in pre-mRNA. Therefore, antisense is the structure that is directly involved in the proposed therapy.\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides.\\n* The proposed therapy is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nNow, let's examine the answer choices:\\n\\nA) Lariat: This is a type of RNA structure that forms during splicing, but it's not directly involved in the proposed therapy. (False)\\nB) PolyA tail: This is a type of RNA modification, but it's not directly involved in the proposed therapy. (False)\\nC) R-loops: These are regions of RNA-DNA hybrids that can form during transcription, but they're not directly involved in the proposed therapy. (False)\\nD) Antisense: This is the correct answer, as the Morpholino is an antisense oligonucleotide that recognizes the 5' end of the out-of-frame exon and prevents the binding of the spliceosome.\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the information step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides.\\n* A Morpholino is used to recognize the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome and creates exon skipping and in-frame joining.\\n* The goal is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon.\\n\\nNow, let's analyze the options:\\n\\n* A) Lariat: A lariat is a type of RNA structure that forms during splicing, where the intron is looped out. This is not directly related to the Morpholino therapy, so it's not the correct answer.\\n* B) PolyA tail: The polyA tail is a type of post-transcriptional modification that adds adenine nucleotides to the 3' end of mRNA. This is not directly related to the Morpholino therapy, so it's not the correct answer.\\n* C) R-loops: R-loops are a type of DNA structure that forms when an RNA molecule hybridizes with a single-stranded DNA region. This is not directly related to the Morpholino therapy, so it's not the correct answer.\\n* D) Antisense: Antisense refers to a type of RNA that is complementary to the sense strand of DNA. The Morpholino used in the therapy is an antisense oligonucleotide, so this option is actually correct.\\n\\nTherefore, the correct answer is:\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides.\\n* The solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents binding of the spliceosome and creates exon skipping and in-frame joining.\\n* Several missing exons are well tolerated by an organism.\\n\\nFrom this, we can infer that the Morpholino is targeting the pre-mRNA to affect splicing. This means that the structure involved in the proposed therapy is:\\n\\n* The pre-mRNA molecule itself, which is being targeted by the Morpholino.\\n\\nThe other options are not directly involved in the proposed therapy:\\n\\n* A) Lariat: a type of RNA structure formed during splicing, but not directly involved in this therapy.\\n* B) PolyA tail: a feature of mRNA, but not directly involved in this therapy.\\n* C) R-loops: a type of RNA structure, but not directly involved in this therapy.\\n* D) Antisense: a type of RNA molecule that can bind to a target sequence, but in this case, the Morpholino is the antisense molecule being used.\\n\\nAnswer: A<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The therapy involves delivering a Morpholino that recognizes the 5' end of an out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome, which is a complex that recognizes and processes pre-mRNA.\\n* The goal of the therapy is to create exon skipping and in-frame joining, which means that the Morpholino is targeting the splicing process.\\n\\nNow, let's consider each option:\\n\\nA) Lariat: A lariat is a type of RNA structure that forms during splicing, but it's not directly involved in the therapy. So, this option is not the correct answer.\\n\\nB) PolyA tail: The polyA tail is a type of post-transcriptional modification that occurs after splicing, so it's not directly involved in the therapy. So, this option is not the correct answer.\\n\\nC) R-loops: R-loops are a type of RNA structure that can form during transcription, but they're not directly involved in splicing or the therapy. So, this option is not the correct answer.\\n\\nD) Antisense: Ah, but this is the correct answer! Antisense refers to a type of RNA that is complementary to the sense strand, and it's often used to target specific sequences. However, in this case, the Morpholino is not an antisense RNA, but rather a specific type of antisense oligonucleotide that targets the 5' end of an out-of-frame exon. So, option D is the correct answer.\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the passage step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides.\\n* The solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents binding of the spliceosome and creates exon skipping and in-frame joining.\\n* Several missing exons are well tolerated by an organism.\\n\\nFrom this, we can infer that the Morpholino is targeting the pre-mRNA to prevent the inclusion of the out-of-frame exon in the final transcript.\\n\\nNow, let's look at the options:\\n\\nA) Lariat: This is a structure formed during splicing, where the intron is looped out and forms a lariat shape. While lariats are involved in splicing, they are not directly related to the proposed therapy.\\n\\nB) PolyA tail: This is a structure added to the 3' end of the pre-mRNA during processing, which is not directly involved in the proposed therapy.\\n\\nC) R-loops: These are structures formed during transcription, where the nascent RNA forms a loop with the template DNA strand. While R-loops can affect gene expression, they are not directly related to the proposed therapy.\\n\\nD) Antisense: Ah, but this is the key! Antisense molecules are designed to bind to a specific sequence of RNA or DNA and prevent its translation or transcription. In this case, the Morpholino is an antisense molecule that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n\\nSo, the correct answer is:\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste.\\n* A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents binding of the spliceosome and creates exon skipping and in-frame joining.\\n* Several missing exons are well tolerated by an organism.\\n\\nThe question asks which structure is NOT involved in the proposed therapy. Based on the text, we can conclude that:\\n\\n* The lariat structure is not directly involved in the proposed therapy, as it is not mentioned in the text as a structure affected by the Morpholino.\\n* The polyA tail is not directly involved in the proposed therapy, as it is not mentioned in the text as a structure affected by the Morpholino.\\n* R-loops are not directly involved in the proposed therapy, as it is not mentioned in the text as a structure affected by the Morpholino.\\n* The antisense structure is directly involved in the proposed therapy, as the Morpholino is an antisense molecule that recognizes the 5' end of the out-of-frame exon.\\n\\nTherefore, the correct answer is:\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste.\\n* The proposed therapy is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nNow, let's analyze the options:\\n\\nA) Lariat: This is a type of RNA structure that forms during splicing, but it's not directly involved in the proposed therapy.\\n\\nB) PolyA tail: This is a type of post-transcriptional modification that adds a long string of adenine nucleotides to the 3' end of eukaryotic mRNAs, but it's not relevant to the proposed therapy.\\n\\nC) R-loops: These are a type of RNA-DNA hybrid structure that can form during transcription, but it's not directly involved in the proposed therapy.\\n\\nD) Antisense: This is the correct answer, as the proposed therapy involves using an antisense Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome, which leads to exon skipping and in-frame joining.\\n* The goal is to create a normal protein by skipping the out-of-frame exons.\\n\\nThe structures involved in the proposed therapy are:\\n\\n* The pre-mRNA, where the Morpholino binds\\n* The spliceosome, which is prevented from binding by the Morpholino\\n\\nThe structures not involved in the proposed therapy are:\\n\\n* Lariat: a structure formed during splicing, but not directly related to the therapy\\n* PolyA tail: a feature of mature mRNA, not directly involved in the therapy\\n* R-loops: a type of DNA structure, not directly related to the therapy\\n\\nAnswer: A<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste.\\n* The proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nNow, let's consider the options:\\n\\n* A) Lariat: A lariat is a type of RNA structure that forms during splicing, but it's not directly involved in the proposed therapy. (Correct)\\n* B) PolyA tail: The polyA tail is a type of post-transcriptional modification that adds a string of adenine nucleotides to the 3' end of eukaryotic mRNAs. It's not directly involved in the proposed therapy. (Correct)\\n* C) R-loops: R-loops are a type of RNA structure that forms when a nascent RNA transcript folds back onto the template DNA strand. They're not directly involved in the proposed therapy. (Correct)\\n* D) Antisense: Antisense refers to a type of RNA that is complementary to the sense strand of DNA. The proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA, which is a type of antisense molecule. (Incorrect)\\n\\nTherefore, the correct answer is D) antisense.<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations of the gene are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste.\\n* A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents binding of the spliceosome and creates exon skipping and in-frame joining.\\n* Several missing exons are well tolerated by an organism.\\n\\nThe question asks which structure is NOT involved in the proposed therapy. The answer is the one that is not related to the mechanism of action of the Morpholino.\\n\\nThe Morpholino recognizes the 5' end of the out-of-frame exon in pre-mRNA, so it is related to the pre-mRNA structure. The other options are not directly involved in the proposed therapy:\\n\\n* A) Lariat: a lariat is a type of RNA structure, but it is not directly related to the mechanism of action of the Morpholino.\\n* B) PolyA tail: the polyA tail is a post-transcriptional modification of mRNA, and it is not directly involved in the proposed therapy.\\n* C) R-loops: R-loops are a type of RNA structure, but they are not directly related to the mechanism of action of the Morpholino.\\n* D) Antisense: the Morpholino is an antisense oligonucleotide, so this option is actually correct.\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome and creates exon skipping and in-frame joining.\\n* This means that the therapy is related to the splicing of pre-mRNA, which is the process of removing introns and joining exons together.\\n\\nConsidering this, let's analyze the options:\\n\\nA) Lariat: A lariat is a type of RNA structure that forms during splicing, but it's not directly involved in the therapy.\\n\\nB) PolyA tail: The polyA tail is a type of post-transcriptional modification that occurs after splicing, so it's not directly involved in the therapy.\\n\\nC) R-loops: R-loops are a type of RNA-DNA hybrid structure that can form during transcription, but they're not directly related to splicing or the therapy.\\n\\nD) Antisense: Ah, but wait! Antisense refers to a type of RNA molecule that is complementary to the sense strand of DNA, and it's often used to prevent the expression of a specific gene. In this case, the Morpholino is an antisense molecule that recognizes the 5' end of the out-of-frame exon and prevents the binding of the spliceosome. This is exactly what antisense therapy does!\\n\\nSo, the correct answer is:\\n\\nAnswer: A<|eot_id|>\", \"Let's break down the passage step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides.\\n* A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents binding of the spliceosome and creates exon skipping and in-frame joining.\\n* Several missing exons are well tolerated by an organism.\\n\\nThe passage does not mention lariats, polyA tails, or R-loops as being involved in the proposed therapy. Therefore, the correct answer is:\\n\\nAnswer: ABC<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste.\\n* The proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA and preventing the binding of the spliceosome to create exon skipping and in-frame joining.\\n* Several missing exons are well tolerated by an organism.\\n\\nNow, let's examine the options:\\n\\nA) Lariat: A lariat is a type of RNA structure that forms during splicing, where the intron is looped out and the exons are joined together. This is not directly involved in the proposed therapy, so it's not the correct answer.\\n\\nB) PolyA tail: The polyA tail is a type of post-transcriptional modification that adds adenine nucleotides to the 3' end of mRNA. This is not directly involved in the proposed therapy, so it's not the correct answer.\\n\\nC) R-loops: R-loops are a type of RNA-DNA hybrid structure that can form during transcription and splicing. They are not directly involved in the proposed therapy, so it's not the correct answer.\\n\\nD) Antisense: Antisense refers to a type of RNA that is complementary to the sense strand of DNA. In this context, the Morpholino is an antisense molecule that recognizes the 5' end of the out-of-frame exon in pre-mRNA. Therefore, antisense is the correct answer.\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste.\\n* A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nThe question asks which structure is NOT involved in the proposed therapy. Let's consider each option:\\n\\nA) Lariat: This is a type of RNA structure that forms during splicing, where the intron is looped out. While lariats are involved in splicing, they are not directly involved in the proposed therapy, which is the use of a Morpholino to prevent spliceosome binding.\\n\\nB) PolyA tail: The polyA tail is a sequence of adenine nucleotides added to the 3' end of eukaryotic mRNAs. While the polyA tail is important for mRNA stability and translation, it is not directly involved in the proposed therapy.\\n\\nC) R-loops: R-loops are a type of DNA-RNA hybrid structure that can form during transcription. While R-loops can affect gene expression, they are not directly involved in the proposed therapy.\\n\\nD) Antisense: Ah, but wait! Antisense refers to a type of RNA molecule that is complementary to the sense strand of DNA. The Morpholino used in the proposed therapy is an antisense molecule that recognizes the 5' end of the out-of-frame exon in pre-mRNA. Therefore, antisense is actually involved in the proposed therapy.\\n\\nSo, the correct answer is:\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome and creates exon skipping and in-frame joining.\\n* The goal is to skip the out-of-frame exon and join the remaining exons in-frame.\\n\\nNow, let's analyze each option:\\n\\nA) Lariat: A lariat is a type of RNA structure formed during splicing, where the intron is looped out and the exons are joined. While lariats are involved in splicing, they are not directly involved in the proposed therapy, which focuses on preventing spliceosome binding.\\n\\nB) PolyA tail: The polyA tail is a post-transcriptional modification added to the 3' end of eukaryotic mRNA. It's not directly involved in the proposed therapy, which targets the 5' end of the out-of-frame exon.\\n\\nC) R-loops: R-loops are a type of DNA-RNA hybrid structure that can form during transcription. They are not directly involved in the proposed therapy, which focuses on preventing spliceosome binding at the 5' end of the out-of-frame exon.\\n\\nD) Antisense: Ah, but wait! Antisense is the correct answer. The Morpholino used in the therapy is an antisense molecule that recognizes the 5' end of the out-of-frame exon and prevents the binding of the spliceosome. Therefore, antisense is the structure involved in the proposed therapy.\\n\\nAnswer: D<|eot_id|>\", \"Let's break it down step by step!\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA and preventing the binding of the spliceosome to create exon skipping and in-frame joining. This is a process that occurs during splicing, which is the removal of introns and joining of exons in eukaryotic cells.\\n\\nThe structures involved in this process are:\\n\\n* The Morpholino, which binds to the pre-mRNA\\n* The spliceosome, which is a complex of proteins that recognizes and removes introns and joins exons\\n* The pre-mRNA, which is the primary transcript of the gene\\n\\nThe structures that are NOT involved in this proposed therapy are:\\n\\n* Lariat (A): Lariats are a type of RNA structure that forms during splicing, but they are not directly involved in the process of spliceosome binding or exon skipping.\\n* PolyA tail (B): The polyA tail is a post-transcriptional modification of the 3' end of the pre-mRNA, and is not directly involved in the splicing process.\\n* R-loops (C): R-loops are a type of RNA-DNA hybrid structure that can form during transcription, but are not directly involved in the splicing process.\\n\\nTherefore, the correct answer is:\\n\\nAnswer: A<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The question states that the Morpholino recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* This means that the Morpholino is targeting the pre-mRNA before it is spliced.\\n* The goal of the Morpholino is to prevent the binding of the spliceosome and create exon skipping and in-frame joining.\\n* The spliceosome is a complex that recognizes and removes introns from pre-mRNA.\\n* The Morpholino is preventing the spliceosome from binding, so the spliceosome is not involved in this process.\\n\\nThe correct answer is A) lariat. Lariats are a type of RNA structure that forms during the splicing process, and they are not directly involved in the proposed therapy.\\n\\nAnswer: A<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste.\\n* The solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nFrom this, we can infer that the Morpholino is targeting the pre-mRNA to prevent the inclusion of the out-of-frame exon, which would otherwise lead to the production of a non-functional protein.\\n\\nThe options that are not involved in the proposed therapy are:\\n\\n* A) lariat: This is a type of RNA structure that forms during splicing, but it's not directly involved in the therapy.\\n* B) polyA tail: This is a type of RNA modification that occurs after splicing, but it's not directly involved in the therapy.\\n* C) R-loops: This is a type of RNA-DNA hybrid structure that can form during transcription, but it's not directly involved in the therapy.\\n* D) antisense: This is the correct answer, as the Morpholino is an antisense oligonucleotide that targets the 5' end of the out-of-frame exon in pre-mRNA.\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The therapy involves delivering a Morpholino that recognizes the 5' end of an out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome, which leads to exon skipping and in-frame joining.\\n* The goal is to correct the out-of-frame peptides caused by central exon deletions.\\n\\nConsidering these points, the structures involved in the proposed therapy are:\\n\\n* The 5' end of the out-of-frame exon, which is recognized by the Morpholino.\\n* The spliceosome, which is prevented from binding by the Morpholino.\\n\\nThe structures not involved in the proposed therapy are:\\n\\n* Lariat (a type of RNA structure involved in splicing, but not directly related to the Morpholino's mechanism of action).\\n* PolyA tail (a type of post-transcriptional modification, not directly related to the Morpholino's mechanism of action).\\n* R-loops (a type of DNA structure, not directly related to the Morpholino's mechanism of action).\\n\\nTherefore, the correct answer is:\\n\\nAnswer: A<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste.\\n* A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nFrom this, we can infer that the Morpholino is targeting the pre-mRNA to alter splicing, which means that the structure involved in the proposed therapy is related to splicing.\\n\\n* A) Lariat: A lariat is a type of RNA structure that forms during splicing, so it is not directly involved in the therapy.\\n* B) PolyA tail: The polyA tail is added to the 3' end of the mRNA, not the 5' end, and is not directly involved in splicing or the proposed therapy.\\n* C) R-loops: R-loops are a type of RNA-DNA hybrid structure that can form during transcription, but are not directly involved in splicing or the proposed therapy.\\n* D) Antisense: The Morpholino is an antisense molecule that recognizes the 5' end of the out-of-frame exon, so this option is directly related to the therapy.\\n\\nTherefore, the correct answer is:\\n\\nAnswer: A<|eot_id|>\", \"Let's break down the information:\\n\\n* The gene has dozens of exons, with the central ones coding for folded triple helical repeats.\\n* The most common mutations are central exon deletions that create out-of-frame peptides.\\n* The proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA and prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n\\nNow, let's analyze the options:\\n\\n* A) Lariat: Not involved in the proposed therapy, as it's a structure formed during splicing, whereas the therapy involves preventing the binding of the spliceosome.\\n* B) PolyA tail: Not involved in the proposed therapy, as it's a feature of mature mRNA, whereas the therapy targets pre-mRNA.\\n* C) R-loops: Not involved in the proposed therapy, as R-loops are structures formed during transcription and are not directly related to splicing or the therapy.\\n* D) Antisense: This is the correct answer, as the therapy involves delivering a Morpholino (an antisense oligonucleotide) that recognizes the 5' end of the out-of-frame exon.\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the passage step by step:\\n\\n* The passage talks about a large gene with dozens of exons, specifically the central ones coding for folded triple helical repeats.\\n* The mutations involve central exon deletions, which create out-of-frame peptides.\\n* The proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n\\nNow, let's analyze the options:\\n\\n* A) Lariat: This is a type of RNA structure that forms during splicing, where the intron is looped out. Since the passage talks about preventing the binding of the spliceosome, lariat is not directly involved in the proposed therapy.\\n* B) PolyA tail: This is a type of RNA modification that occurs at the 3' end of mRNA. It's not directly related to the proposed therapy, which involves preventing the binding of the spliceosome.\\n* C) R-loops: These are a type of RNA structure that forms when the RNA molecule folds back on itself. They are not directly involved in the proposed therapy.\\n* D) Antisense: Ah, but wait! Antisense refers to a type of RNA molecule that binds to a complementary sequence of DNA or RNA. In this case, the Morpholino is an antisense molecule that recognizes the 5' end of the out-of-frame exon in pre-mRNA. Therefore, antisense is indeed involved in the proposed therapy.\\n\\nSo, the correct answer is:\\n\\nAnswer: A<|eot_id|>\", \"Let's break it down step by step:\\n\\n* The question is asking which structure is NOT involved in the proposed therapy.\\n* The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA and preventing the binding of the spliceosome to create exon skipping and in-frame joining.\\n* The Morpholino is binding to the pre-mRNA, which is a type of RNA.\\n* The structures listed are all related to RNA processing, but only one is not directly involved in the proposed therapy:\\n\\t+ Lariat is a type of RNA structure that forms during splicing, but it's not directly involved in the Morpholino-mediated therapy.\\n\\t+ PolyA tail is a type of modification that occurs during RNA processing, but it's not directly involved in the therapy.\\n\\t+ R-loops are structures that form during transcription, but they're not directly involved in the therapy.\\n\\t+ Antisense is the correct answer, as the Morpholino is an antisense molecule that recognizes the 5' end of the out-of-frame exon.\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste.\\n* A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents binding of the spliceosome and creates exon skipping and in-frame joining.\\n* Several missing exons are well tolerated by an organism.\\n\\nThe structure that is not involved in the proposed therapy is:\\n\\nAnswer: B<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The therapy involves delivering a Morpholino that recognizes the 5' end of an out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome, which leads to exon skipping and in-frame joining.\\n* This process allows the organism to tolerate missing exons.\\n\\nConsidering the above, we can eliminate options A, B, and C as they are not directly related to the proposed therapy. The correct answer is:\\n\\nAnswer: B<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations of the gene are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste.\\n* A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nThe question asks which structure is NOT involved in the proposed therapy. Based on the description, the Morpholino recognizes the 5' end of the out-of-frame exon and prevents the binding of the spliceosome, which suggests that the structure involved is the pre-mRNA.\\n\\nThe correct answer is B) polyA tail, as it is not directly involved in the proposed therapy.\\n\\nAnswer: B<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome and creates exon skipping and in-frame joining.\\n* The goal is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon, which suggests that the Morpholino is targeting the pre-mRNA.\\n\\nBased on this information, we can eliminate options A, B, and C as they are not directly involved in the proposed therapy:\\n\\n* A) Lariat: A lariat is a type of RNA structure that forms during splicing, but it's not directly involved in the therapy.\\n* B) PolyA tail: The polyA tail is a feature of mature mRNA, but it's not directly involved in the therapy.\\n* C) R-loops: R-loops are a type of RNA structure that can form during transcription, but they're not directly involved in the therapy.\\n\\nThe correct answer is therefore D) antisense, as the Morpholino is an antisense molecule that recognizes the 5' end of the out-of-frame exon, but antisense is not a structure.\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the passage step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste.\\n* A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nNow, let's analyze the options:\\n\\nA) Lariat: Not involved in the proposed therapy. Lariat structures are formed during splicing, but the passage doesn't mention splicing in the context of the therapy.\\n\\nB) PolyA tail: Not involved in the proposed therapy. The passage doesn't mention the polyA tail at all.\\n\\nC) R-loops: Involved in the proposed therapy. R-loops are structures formed during transcription, and the passage mentions that the Morpholino recognizes the 5' end of the out-of-frame exon in pre-mRNA, which is a type of R-loop.\\n\\nD) Antisense: Involved in the proposed therapy. The passage explicitly states that the Morpholino is an antisense molecule that recognizes the 5' end of the out-of-frame exon.\\n\\nAnswer: A<|eot_id|>\", \"Let's break down the text step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste.\\n* A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents binding of the spliceosome and creates exon skipping and in-frame joining.\\n* Several missing exons are well tolerated by an organism.\\n\\nFrom this, we can infer that the Morpholino is targeting the pre-mRNA and preventing the binding of the spliceosome, which is responsible for splicing the exons together.\\n\\nThe structures involved in this therapy are:\\n\\n* Pre-mRNA (the target of the Morpholino)\\n* Spliceosome (the enzyme complex that is prevented from binding by the Morpholino)\\n\\nThe structures that are NOT involved in this therapy are:\\n\\n* Lariat (a type of RNA structure, but not directly involved in the therapy)\\n* PolyA tail (a type of RNA modification, but not directly involved in the therapy)\\n* R-loops (a type of DNA structure, not directly involved in the therapy)\\n* Antisense (the Morpholino is an antisense molecule, but it's not a structure)\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats.\\n* The most common mutations are central exon deletions that create out-of-frame peptides.\\n* A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nThe question asks which structure is not involved in the proposed therapy. Based on the information provided, we can eliminate options A, B, and C as follows:\\n\\n* A) Lariat: This is a type of RNA structure that is involved in the splicing process, but it's not directly related to the proposed therapy.\\n* B) PolyA tail: This is a type of RNA modification that is added to the 3' end of eukaryotic mRNAs, but it's not relevant to the proposed therapy.\\n* C) R-loops: This is a type of RNA structure that can form during transcription, but it's not directly related to the proposed therapy.\\n\\nThe correct answer is D) antisense, as the Morpholino is an antisense oligonucleotide that recognizes the 5' end of the out-of-frame exon and prevents the binding of the spliceosome. Therefore, the antisense structure is the one involved in the proposed therapy.\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the information step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste.\\n* A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nNow, let's analyze the answer choices:\\n\\n* A) Lariat: This is not directly involved in the proposed therapy, as it's a type of RNA structure formed during splicing, but it's not the focus of the therapy.\\n* B) PolyA tail: This is not involved in the proposed therapy, as it's a type of RNA modification, but it's not related to the Morpholino's mechanism of action.\\n* C) R-loops: These are not directly involved in the proposed therapy, as they're a type of RNA-DNA hybrid structure, but they're not the focus of the therapy.\\n* D) Antisense: This is the correct answer, as the Morpholino is an antisense oligonucleotide that recognizes the 5' end of the out-of-frame exon and prevents the binding of the spliceosome.\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats.\\n* The most common mutations are central exon deletions that create out-of-frame peptides.\\n* To solve this, a Morpholino is used to recognize the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nThe Morpholino is an antisense oligonucleotide that binds to the pre-mRNA, so option D) antisense is correct.\\n\\nThe other options are not directly involved in the proposed therapy:\\n\\n* A) Lariat is a type of RNA structure that forms during splicing, but it's not directly related to the Morpholino therapy.\\n* B) PolyA tail is a type of modification found at the 3' end of some mRNAs, but it's not involved in the proposed therapy.\\n* C) R-loops are a type of RNA structure that forms during transcription, but it's not directly related to the Morpholino therapy.\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The gene has dozens of exons, and the problem is with central exon deletions that create out-of-frame peptides.\\n* The solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nFrom this, we can infer that the structure involved in the proposed therapy is the pre-mRNA, specifically the 5' end of the out-of-frame exon.\\n\\n* A lariat is a type of RNA structure that forms during splicing, but it's not directly involved in the therapy.\\n* A polyA tail is a feature of mRNA, not pre-mRNA, so it's not relevant to the therapy.\\n* R-loops are a type of DNA structure that forms during transcription, but it's not directly involved in the therapy.\\n* Antisense refers to a type of RNA that binds to a target RNA, which is exactly what the Morpholino does in this therapy.\\n\\nTherefore, the correct answer is:\\n\\nAnswer: B<|eot_id|>\", \"Let's break down the text step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats.\\n* Each exon codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste.\\n* A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents binding of the spliceosome and creates exon skipping and in-frame joining.\\n* Several missing exons are well tolerated by an organism.\\n\\nNow, let's analyze the options:\\n\\n* A) Lariat: This is a structure formed during splicing, where the intron is looped back to form a lariat shape. It's not directly related to the proposed therapy, so it's not the correct answer.\\n* B) PolyA tail: This is a feature of the pre-mRNA, but it's not directly involved in the proposed therapy. The Morpholino recognizes the 5' end of the out-of-frame exon, not the polyA tail.\\n* C) R-loops: R-loops are a type of DNA structure that can form during transcription, but they're not directly related to the proposed therapy.\\n* D) Antisense: This is the correct answer. The Morpholino is an antisense molecule that recognizes the 5' end of the out-of-frame exon and prevents binding of the spliceosome. The question is asking which structure is not involved in the proposed therapy, and the correct answer is antisense, as the Morpholino is the antisense molecule being used in the therapy.\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the text step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides.\\n* The proposed therapy is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nNow, let's consider each option:\\n\\nA) Lariat: A lariat is a type of RNA structure that forms during splicing, but it's not directly involved in the proposed therapy.\\n\\nB) PolyA tail: The polyA tail is a type of RNA modification, but it's not directly involved in the proposed therapy either.\\n\\nC) R-loops: R-loops are a type of RNA-DNA hybrid structure that can form during transcription, but they're not directly involved in the proposed therapy.\\n\\nD) Antisense: Ah, but this one is different! Antisense refers to a type of RNA that binds to a target RNA and prevents its translation. The Morpholino in the proposed therapy is an antisense molecule that recognizes the 5' end of the out-of-frame exon and prevents the binding of the spliceosome.\\n\\nSo, the correct answer is:\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The question talks about a large gene with dozens of exons, and the therapy involves delivering a Morpholino that recognizes the 5' end of an out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome, which leads to exon skipping and in-frame joining.\\n* The goal is to create a functional protein by skipping the out-of-frame exon and joining the remaining exons in-frame.\\n\\nConsidering the options, we can eliminate the following:\\n\\n* A) Lariat: Lariats are a type of RNA structure formed during splicing, but they are not directly involved in the proposed therapy.\\n* B) PolyA tail: The polyA tail is a feature of mature mRNA, but it's not directly related to the therapy.\\n* C) R-loops: R-loops are a type of DNA-RNA hybrid structure that can occur during transcription, but they are not directly involved in the proposed therapy.\\n\\nThe correct answer is D) antisense, as the Morpholino is an antisense molecule that recognizes the 5' end of the out-of-frame exon. Therefore, the correct answer is:\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the information in the question:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste.\\n* The proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA, preventing the binding of the spliceosome and creating exon skipping and in-frame joining.\\n\\nNow, let's examine each option:\\n\\nA) Lariat: A lariat is a type of RNA structure that forms during splicing, where the intron is looped out and the exons are joined. This is not directly related to the proposed therapy, which involves delivering a Morpholino to prevent spliceosome binding. So, A is not the correct answer.\\n\\nB) PolyA tail: The polyA tail is a type of modification that occurs at the 3' end of mRNA, not the 5' end. It's not directly involved in the proposed therapy, which focuses on the 5' end of the out-of-frame exon. So, B is not the correct answer.\\n\\nC) R-loops: R-loops are a type of RNA-DNA hybrid structure that can form during transcription and can influence gene expression. While R-loops can be involved in splicing, they are not directly related to the proposed therapy, which involves delivering a Morpholino to prevent spliceosome binding. So, C is not the correct answer.\\n\\nD) Antisense: Ah, but wait! The proposed therapy involves delivering an antisense Morpholino that recognizes the 5' end of the out-of-frame exon. This is exactly what antisense therapy is designed to do - bind to a specific sequence and prevent the binding of other molecules. So, D is the correct answer.\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides.\\n* A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents binding of the spliceosome and creates exon skipping and in-frame joining.\\n* Several missing exons are well tolerated by an organism.\\n\\nThe structure that is not involved in the proposed therapy is:\\n\\n* B) polyA tail\\n\\nThe polyA tail is a type of post-transcriptional modification that is added to the 3' end of the pre-mRNA, whereas the Morpholino recognizes the 5' end of the out-of-frame exon. Therefore, the polyA tail is not directly involved in the proposed therapy.\\n\\nAnswer: B<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The therapy involves delivering a Morpholino that recognizes the 5' end of an out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome, which leads to exon skipping and in-frame joining.\\n* The goal is to create a functional protein by skipping out-of-frame exons.\\n\\nNow, let's examine each option:\\n\\nA) Lariat: A lariat is a type of RNA structure that forms during splicing, but it's not directly involved in the proposed therapy.\\n\\nB) PolyA tail: The polyA tail is a type of post-transcriptional modification, but it's not related to the therapy.\\n\\nC) R-loops: R-loops are a type of DNA structure that can form during transcription, but they're not directly involved in the proposed therapy.\\n\\nD) Antisense: Ah, but antisense is the correct answer! The Morpholino is an antisense oligonucleotide that recognizes the 5' end of the out-of-frame exon. It's the key component of the therapy.\\n\\nAnswer: D<|eot_id|>\", \"Let's break it down step by step:\\n\\n* The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome, which is a complex that is involved in splicing of pre-mRNA.\\n* The goal is to create exon skipping and in-frame joining, which means that the Morpholino is targeting the splicing process.\\n\\nConsidering the options, we can eliminate the following:\\n\\n* A) Lariat: A lariat is a type of RNA structure that is involved in splicing, but it's not directly involved in the proposed therapy.\\n* B) PolyA tail: The polyA tail is a type of post-transcriptional modification of mRNA, but it's not directly involved in the splicing process.\\n* C) R-loops: R-loops are a type of RNA structure that can form during transcription, but they're not directly involved in the splicing process.\\n\\nThe correct answer is D) antisense, because the Morpholino is actually an antisense molecule that recognizes the 5' end of the out-of-frame exon. Antisense is the correct answer, as it's the type of molecule being used in the proposed therapy.\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste.\\n* A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents binding of the spliceosome and creates exon skipping and in-frame joining.\\n* Several missing exons are well tolerated by an organism.\\n\\nNow, let's analyze the options:\\n\\nA) Lariat: A lariat is a type of RNA structure that forms during splicing, but it's not directly involved in the proposed therapy. The Morpholino recognizes the 5' end of the out-of-frame exon, not the lariat structure.\\n\\nB) PolyA tail: The polyA tail is a type of post-transcriptional modification that is added to the 3' end of mRNA, but it's not involved in the proposed therapy.\\n\\nC) R-loops: R-loops are a type of RNA-DNA hybrid structure that can form during transcription, but they're not directly involved in the proposed therapy.\\n\\nD) Antisense: Ah, but wait! Antisense refers to a type of RNA molecule that binds to a target sequence, and in this case, the Morpholino is an antisense molecule that recognizes the 5' end of the out-of-frame exon. Therefore, antisense is the correct answer!\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome and creates exon skipping and in-frame joining.\\n* The goal is to restore the reading frame of the gene by skipping the out-of-frame exons.\\n\\nConsidering these points, the correct answer is:\\n\\n* B) polyA tail\\n\\nThe polyA tail is not directly involved in the proposed therapy, as it is not affected by the Morpholino and is not a structure that interacts with the spliceosome.\\n\\nAnswer: B<|eot_id|>\", \"Let's break down the passage step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste.\\n* The solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents binding of the spliceosome and creates exon skipping and in-frame joining.\\n* Several missing exons are well tolerated by an organism.\\n\\nThe passage does not mention lariat, polyA tail, or R-loops as being involved in the proposed therapy. Therefore, the correct answer is:\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The question is about a therapy that involves delivering a Morpholino to prevent the binding of the spliceosome and create exon skipping and in-frame joining.\\n* The Morpholino recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The goal is to create a new in-frame peptide, so the spliceosome needs to be prevented from binding to the out-of-frame exon.\\n\\nConsidering these steps, we can eliminate options A, B, and C:\\n\\n* A lariat is a type of RNA structure that forms during splicing, but it's not directly involved in the therapy.\\n* A polyA tail is a type of post-transcriptional modification, but it's not relevant to the therapy.\\n* R-loops are a type of RNA structure that can form during transcription, but they're not directly involved in the therapy.\\n\\nThe correct answer is D) antisense, because the Morpholino is an antisense molecule that recognizes the 5' end of the out-of-frame exon, so it is the structure directly involved in the therapy.\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome and creates exon skipping and in-frame joining.\\n* The goal is to create a functional protein by skipping the out-of-frame exons and joining the remaining exons in-frame.\\n\\nNow, let's consider the options:\\n\\nA) Lariat: This is a type of RNA structure that forms during splicing, but it's not directly involved in the therapy. So, this option is unlikely to be correct.\\n\\nB) PolyA tail: The polyA tail is added to the 3' end of mRNA during processing, but it's not directly involved in the therapy. So, this option is unlikely to be correct.\\n\\nC) R-loops: R-loops are a type of RNA structure that can form during transcription, but they're not directly involved in the therapy. So, this option is unlikely to be correct.\\n\\nD) Antisense: Ah, but this is the correct answer! The Morpholino is an antisense molecule that recognizes the 5' end of the out-of-frame exon and prevents the binding of the spliceosome. This is the exact mechanism of action described in the question.\\n\\nSo, the correct answer is:\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste.\\n* A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nNow, let's consider the options:\\n\\nA) Lariat: A lariat is a type of RNA structure that forms during splicing, where the intron is looped out and the exons are joined. This is not directly involved in the proposed therapy.\\n\\nB) PolyA tail: The polyA tail is a feature of mature mRNA, and it's not directly involved in the proposed therapy.\\n\\nC) R-loops: R-loops are a type of DNA structure that forms during transcription, where the RNA transcript hybridizes with the template DNA strand. This is not directly involved in the proposed therapy.\\n\\nD) Antisense: Ah, but this is the correct answer! The Morpholino is an antisense molecule that recognizes the 5' end of the out-of-frame exon in pre-mRNA. Therefore, antisense is the correct answer.\\n\\nAnswer: D<|eot_id|>\", \"Let's break it down step by step:\\n\\n* The question is about a therapy that involves delivering a Morpholino to prevent the binding of the spliceosome and create exon skipping and in-frame joining.\\n* The Morpholino recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* This suggests that the Morpholino is targeting the pre-mRNA before it's processed into mature mRNA.\\n* The structures involved in this process are:\\n\\t+ Lariat: a type of RNA structure that forms during splicing, but it's not directly involved in the therapy.\\n\\t+ PolyA tail: a type of modification added to the 3' end of mature mRNA, not directly involved in the therapy.\\n\\t+ R-loops: a type of RNA-DNA hybrid structure that can form during transcription, but it's not directly involved in the therapy.\\n\\t+ Antisense: a type of RNA molecule that binds to a complementary sequence, which is exactly what the Morpholino is doing in this therapy.\\n\\nSo, the correct answer is A) lariat.\\n\\nAnswer: A<|eot_id|>\", \"Let's break down the passage step by step:\\n\\n* The passage talks about a large gene with dozens of exons, specifically the central ones coding for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space.\\n* The most common mutations are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste.\\n* A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA, preventing the binding of the spliceosome and creating exon skipping and in-frame joining.\\n* The passage mentions that several missing exons are well tolerated by an organism.\\n\\nNow, let's analyze the options:\\n\\nA) Lariat: This is a type of RNA structure formed during splicing, where the intron is looped out and sealed. Since the passage talks about preventing the binding of the spliceosome, lariat is not directly involved in the proposed therapy.\\n\\nB) PolyA tail: This is a type of RNA modification that adds a polyadenosine tail to the 3' end of eukaryotic mRNAs. It's not directly related to the proposed therapy.\\n\\nC) R-loops: R-loops are a type of RNA-DNA hybrid structure that can form during transcription and can be involved in the regulation of gene expression. However, it's not directly related to the proposed therapy.\\n\\nD) Antisense: Ah, but wait! Antisense refers to a type of RNA that is complementary to the target RNA sequence, which is exactly what the Morpholino does in the proposed therapy! It recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n\\nTherefore, the correct answer is:\\n\\nAnswer: B<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste.\\n* A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents binding of the spliceosome and creates exon skipping and in-frame joining.\\n* Several missing exons are well tolerated by an organism.\\n\\nFrom this, we can conclude that the Morpholino is targeting the pre-mRNA, and its mechanism of action is to prevent the binding of the spliceosome, which is a complex that plays a crucial role in splicing.\\n\\nNow, let's examine the options:\\n\\n* A) Lariat: A lariat is a type of RNA structure that forms during splicing, but it's not directly involved in the proposed therapy. Answer: A\\n* B) PolyA tail: The polyA tail is a feature of mature mRNA, and it's not directly involved in the proposed therapy. Answer: B\\n* C) R-loops: R-loops are a type of RNA-DNA hybrid structure that can form during transcription, but they're not directly involved in the proposed therapy. Answer: C\\n* D) Antisense: Antisense refers to a type of RNA that binds to a complementary sequence, but the Morpholino is not an antisense RNA. It's an antisense oligonucleotide that recognizes the 5' end of the out-of-frame exon in pre-mRNA. Answer: D\\n\\nTherefore, the correct answer is:\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations of the gene are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste.\\n* A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nNow, let's consider each option:\\n\\nA) Lariat: This is a structure formed during splicing, where the intron is looped out to form a lariat shape. It's not directly involved in the proposed therapy, which is the recognition of the 5' end of the out-of-frame exon by the Morpholino.\\n\\nB) PolyA tail: This is a sequence of adenine nucleotides added to the 3' end of the mRNA. It's not directly involved in the proposed therapy, which is the recognition of the 5' end of the out-of-frame exon by the Morpholino.\\n\\nC) R-loops: These are structures formed during transcription, where the RNA transcript forms a loop with the template DNA strand. They're not directly involved in the proposed therapy, which is the recognition of the 5' end of the out-of-frame exon by the Morpholino.\\n\\nD) Antisense: This is the correct answer. The Morpholino is an antisense molecule that recognizes the 5' end of the out-of-frame exon in pre-mRNA. Therefore, antisense is directly involved in the proposed therapy.\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the information step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides.\\n* A Morpholino is used to recognize the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nNow, let's analyze the options:\\n\\nA) Lariat: A lariat is a type of RNA structure that forms during splicing, but it's not directly involved in the proposed therapy.\\n\\nB) PolyA tail: The polyA tail is a type of post-transcriptional modification that occurs after splicing, and it's not directly involved in the proposed therapy.\\n\\nC) R-loops: R-loops are a type of RNA structure that can form during transcription, but they're not directly involved in the proposed therapy.\\n\\nD) Antisense: Ah, but this one is a bit tricky! Antisense refers to a type of RNA molecule that is complementary to the sense strand of DNA. In this case, the Morpholino is an antisense molecule that recognizes the 5' end of the out-of-frame exon in pre-mRNA. So, antisense is actually involved in the proposed therapy!\\n\\nSo, the correct answer is:\\n\\nAnswer: A<|eot_id|>\", \"Let's break down the information:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats.\\n* The most common mutations are central exon deletions that create out-of-frame peptides.\\n* The proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nConsidering the options, we can eliminate B) polyA tail, as it's not directly involved in the proposed therapy.\\n\\nA) Lariat is a type of RNA structure that forms during splicing, and it's relevant to the process of removing introns. Since the Morpholino prevents the binding of the spliceosome, it's likely that lariats are involved in this process. So, A) lariat is a possible answer.\\n\\nC) R-loops are a type of RNA-DNA hybrid structure that can form during transcription. While they might be present in the cell, they're not directly involved in the proposed therapy.\\n\\nD) Antisense is the correct answer. The Morpholino is an antisense oligonucleotide that recognizes the 5' end of the out-of-frame exon, but it's not the structure itself.\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The therapy involves delivering a Morpholino that recognizes the 5' end of an out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome, which is a complex that removes introns and joins exons to form a mature mRNA.\\n* The goal is to create exon skipping and in-frame joining, which means that the Morpholino is targeting the splicing process.\\n\\nConsidering this, we can eliminate options A, B, and C, as they are not directly related to the splicing process:\\n\\n* A lariat is a type of RNA structure formed during splicing, but it's not directly involved in the therapy.\\n* The polyA tail is a feature of mature mRNA, and it's not relevant to the splicing process.\\n* R-loops are a type of DNA structure, and they're not directly involved in the therapy.\\n\\nThe correct answer is D) antisense, as the Morpholino is an antisense molecule that binds to the 5' end of the out-of-frame exon, preventing the binding of the spliceosome.<|eot_id|>\", \"Let's break down the text step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste.\\n* A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents binding of the spliceosome and creates exon skipping and in-frame joining.\\n* Several missing exons are well tolerated by an organism.\\n\\nFrom this, we can infer that the Morpholino is targeting the pre-mRNA to prevent the inclusion of out-of-frame exons, and allowing for in-frame joining. This means that the structure involved is the pre-mRNA, and the 5' end of the out-of-frame exon.\\n\\nThe options that are not involved in the proposed therapy are:\\n\\n* A) lariat: This is a type of RNA structure that forms during splicing, but it's not directly related to the Morpholino therapy.\\n* B) polyA tail: This is a type of modification that occurs at the 3' end of mRNA, not the 5' end, and is not directly related to the Morpholino therapy.\\n* C) R-loops: This is a type of RNA structure that can form during transcription, but it's not directly related to the Morpholino therapy.\\n* D) antisense: This is the correct answer, as the Morpholino is an antisense oligonucleotide that binds to the 5' end of the out-of-frame exon.\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the text step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides.\\n* The solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nThe Morpholino is an antisense molecule that binds to the 5' end of the out-of-frame exon, so option D) antisense is the correct answer.\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome, which is responsible for splicing the pre-mRNA.\\n* The goal is to create exon skipping and in-frame joining to restore the reading frame of the gene.\\n\\nNow, let's examine each option:\\n\\nA) Lariat: This is a structure formed during splicing, but it's not directly involved in the proposed therapy.\\n\\nB) PolyA tail: This is a feature of the pre-mRNA, but it's not directly related to the therapy.\\n\\nC) R-loops: These are structures formed during transcription, but they're not directly involved in the therapy.\\n\\nD) Antisense: This is the correct answer. The Morpholino is an antisense molecule that recognizes the 5' end of the out-of-frame exon, but antisense is a general term that refers to a molecule with a complementary sequence to the target RNA, whereas Morpholino is a specific type of antisense molecule.\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The question is about a gene with dozens of exons, and the focus is on a specific type of mutation and a proposed therapy.\\n* The mutation is central exon deletions that create out-of-frame peptides, leading to progressive degenerative organ waste.\\n* The proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n* The question asks which structure is NOT involved in the proposed therapy.\\n\\nBased on the information provided, the correct answer is:\\n\\nB) polyA tail\\n\\nThe polyA tail is not mentioned in the passage as being involved in the proposed therapy. The other options (lariat, R-loops, and antisense) are all relevant to the process of RNA splicing and could potentially be involved in the therapy.\\n\\nAnswer: B<|eot_id|>\", \"Let's break it down step by step!\\n\\nThe question is asking about a therapy that delivers a Morpholino to prevent the binding of the spliceosome and create exon skipping and in-frame joining. This is a process that involves the pre-mRNA.\\n\\nThe pre-mRNA has a 5' cap, which is not mentioned in the options, so we can rule that out.\\n\\nThe 3' end of the pre-mRNA has a polyA tail, which is also not directly involved in this process, so option B is not correct.\\n\\nR-loops are a type of DNA structure that can form during transcription, but they are not directly involved in this therapy, so option C is not correct.\\n\\nThe lariat structure, on the other hand, is a type of RNA structure that forms during splicing, specifically when the spliceosome cuts and rejoins the exons. This is exactly the process that the Morpholino is trying to disrupt, so option A is the correct answer.\\n\\nAnswer: A<|eot_id|>\", \"Let's break down the text and identify the correct answer.\\n\\nThe text describes a gene with dozens of exons, and the proposed therapy involves delivering a Morpholino that recognizes the 5' end of an out-of-frame exon in pre-mRNA to prevent the binding of the spliceosome and create exon skipping and in-frame joining.\\n\\nThe structures mentioned in the text are:\\n\\n* Exons: These are the coding regions of the gene.\\n* Pre-mRNA: This is the precursor to mature mRNA.\\n* Spliceosome: This is the complex that facilitates splicing of exons.\\n* Morpholino: This is the therapeutic molecule that recognizes the 5' end of the out-of-frame exon.\\n\\nThe structures that are not directly involved in the proposed therapy are:\\n\\n* Lariat: This is a structure formed during splicing, but it's not directly involved in the therapy.\\n* PolyA tail: This is a structure added to the 3' end of mature mRNA, but it's not involved in the therapy.\\n* R-loops: These are structures formed during transcription, but they're not directly involved in the therapy.\\n\\nThe correct answer is:\\n\\nAnswer: A<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste.\\n* A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nNow, let's analyze the options:\\n\\n* A) Lariat: This is a type of RNA structure formed during splicing, but it's not directly involved in the proposed therapy. So, it's a possible answer.\\n* B) PolyA tail: This is a type of RNA modification that occurs during processing, but it's not directly involved in the proposed therapy. So, it's a possible answer.\\n* C) R-loops: These are regions of RNA that can form during transcription, but they're not directly involved in the proposed therapy. So, it's a possible answer.\\n* D) Antisense: This is the correct answer. The Morpholino is an antisense oligonucleotide that recognizes the 5' end of the out-of-frame exon, so it's directly involved in the proposed therapy.\\n\\nAnswer: D<|eot_id|>\", \"Let's break it down step by step:\\n\\n* The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome, which is a complex that assembles at the 5' splice site of an intron.\\n* This prevents the normal splicing process, and instead, the spliceosome creates exon skipping and in-frame joining.\\n* The structures involved in this process are:\\n\\t+ The 5' end of the out-of-frame exon (recognized by the Morpholino)\\n\\t+ The spliceosome (prevented from binding by the Morpholino)\\n* The other options are not directly involved in this process:\\n\\t+ Lariat: a type of RNA structure formed during splicing, but not directly involved in the therapy.\\n\\t+ PolyA tail: a type of RNA modification, not directly involved in the therapy.\\n\\t+ R-loops: a type of DNA structure, not directly involved in the therapy.\\n\\t+ Antisense: a type of RNA molecule that can bind to a target RNA, but not the specific type of antisense used in this therapy (Morpholino).\\n\\nTherefore, the correct answer is:\\n\\nAnswer: B<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste.\\n* A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nFrom this information, we can conclude that the Morpholino is targeting the pre-mRNA and preventing the spliceosome from binding to the out-of-frame exon.\\n\\n* The lariat structure is not directly involved in this process, as it's a type of RNA structure that forms during splicing, but it's not the target of the Morpholino.\\n* The polyA tail is also not directly involved, as it's a post-transcriptional modification that occurs after splicing.\\n* R-loops are not directly involved either, as they're a type of DNA structure that forms during transcription, but it's not the target of the Morpholino.\\n* The antisense molecule (the Morpholino) is the one that recognizes the 5' end of the out-of-frame exon in pre-mRNA, so it's the correct answer.\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the information step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste.\\n* A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nNow, let's analyze the options:\\n\\nA) Lariat: A lariat is a type of RNA structure that forms during splicing, where the intron is removed and a lariat-shaped RNA is formed. This is not directly involved in the proposed therapy.\\n\\nB) PolyA tail: The polyA tail is a sequence of adenine nucleotides added to the 3' end of eukaryotic mRNAs. This is not directly involved in the proposed therapy.\\n\\nC) R-loops: R-loops are a type of DNA structure that forms when a RNA-DNA hybrid forms between the coding and non-coding strands of DNA. This is not directly involved in the proposed therapy.\\n\\nD) Antisense: The proposed therapy involves using a Morpholino, which is an antisense oligonucleotide that recognizes the 5' end of the out-of-frame exon in pre-mRNA. Therefore, antisense is the correct answer.\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides.\\n* A Morpholino is used to recognize the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome, which creates exon skipping and in-frame joining.\\n* The goal is to deliver a functional protein.\\n\\nNow, let's examine the options:\\n\\nA) Lariat: A lariat is a type of RNA structure that forms during splicing. While it's involved in splicing, it's not directly related to the proposed therapy.\\n\\nB) PolyA tail: The polyA tail is a feature of mature mRNA, and it's not directly involved in the proposed therapy.\\n\\nC) R-loops: R-loops are a type of DNA structure that can form during transcription. While they're related to gene regulation, they're not directly involved in the proposed therapy.\\n\\nD) Antisense: Ah, but antisense refers to a type of RNA molecule that binds to a target sequence, usually to regulate gene expression. In this case, the Morpholino is an antisense molecule that recognizes the 5' end of the out-of-frame exon and prevents the binding of the spliceosome.\\n\\nTherefore, the correct answer is:\\n\\nAnswer: A<|eot_id|>\", \"Let's break down the passage step by step:\\n\\n* The passage talks about a large gene with dozens of exons, and the central ones code for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste.\\n* The solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nFrom this, we can conclude that the Morpholino is targeting the pre-mRNA, and its goal is to prevent the binding of the spliceosome.\\n\\nNow, let's look at the options:\\n\\nA) Lariat: This is a type of RNA structure that forms during splicing, but it's not directly involved in the proposed therapy.\\n\\nB) PolyA tail: This is a type of modification that occurs at the 3' end of mRNAs, but it's not relevant to the therapy.\\n\\nC) R-loops: These are structures that form during transcription and are not directly involved in the proposed therapy.\\n\\nD) Antisense: Ah, but this is the correct answer! The Morpholino is an antisense oligonucleotide that recognizes the 5' end of the out-of-frame exon in pre-mRNA. It's the very definition of an antisense molecule.\\n\\nSo, the correct answer is:\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome, which leads to exon skipping and in-frame joining.\\n* The goal is to restore the correct reading frame of the gene by skipping the out-of-frame exons.\\n\\nConsidering this, the correct answer is:\\n\\nB) polyA tail\\n\\nThe polyA tail is not directly involved in the proposed therapy. The lariat structure is formed during splicing, and the R-loops are a type of RNA structure that can be involved in splicing. The Morpholino is an antisense oligonucleotide that recognizes the 5' end of the out-of-frame exon, so option D) antisense is not the correct answer.\\n\\nAnswer: B<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome, which is a complex that plays a crucial role in splicing pre-mRNA.\\n* The goal of the therapy is to create exon skipping and in-frame joining, which means that the Morpholino is targeting the splicing process.\\n\\nConsidering the options:\\n\\n* A) Lariat: A lariat is a type of RNA structure that is formed during splicing, but it's not directly involved in the proposed therapy. (Correct)\\n* B) PolyA tail: The polyA tail is a type of post-transcriptional modification that is added to the 3' end of eukaryotic mRNA, but it's not involved in the splicing process. (Correct)\\n* C) R-loops: R-loops are a type of RNA-DNA hybrid structure that can form during transcription, but they're not directly involved in the proposed therapy. (Correct)\\n* D) Antisense: Antisense refers to a type of RNA molecule that is complementary to a specific sequence of DNA or RNA. In this context, the Morpholino is an antisense molecule that recognizes the 5' end of the out-of-frame exon, so option D is incorrect.\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the passage step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste.\\n* A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nThe proposed therapy involves the recognition of the 5' end of the out-of-frame exon by the Morpholino, which prevents the binding of the spliceosome and creates exon skipping and in-frame joining. This process does not involve the following structure:\\n\\nB) polyA tail\\n\\nThe polyA tail is a structure found at the 3' end of eukaryotic mRNAs, not the 5' end, and is not directly involved in the proposed therapy.\\n\\nAnswer: B<|eot_id|>\", \"Let's break down the question step by step:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations of the gene are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste.\\n* A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nNow, let's analyze the answer choices:\\n\\n* A) Lariat: This is a type of RNA structure that forms during splicing, where the 5' end of the intron is covalently linked to the 2' OH group of the first nucleotide of the intron. While lariats are involved in splicing, they are not directly related to the proposed therapy, which involves delivering a Morpholino to prevent spliceosome binding.\\n* B) PolyA tail: This is a type of RNA modification that occurs at the 3' end of some mRNAs, but it's not directly related to the proposed therapy.\\n* C) R-loops: These are structures that form when an RNA molecule hybridizes with a complementary DNA sequence, and they can play a role in regulating gene expression. However, R-loops are not directly involved in the proposed therapy, which involves delivering a Morpholino to prevent spliceosome binding.\\n* D) Antisense: This is the correct answer. Antisense refers to a type of RNA molecule that is complementary to a specific mRNA sequence. The proposed therapy involves delivering a Morpholino, which is an antisense oligonucleotide that recognizes the 5' end of the out-of-frame exon in pre-mRNA. Therefore, antisense is the structure involved in the proposed therapy.\\n\\nAnswer: D<|eot_id|>\", \"Let's break down the information:\\n\\n* The gene has dozens of exons, and the central ones code for folded triple helical repeats.\\n* The most common mutations are central exon deletions that create out-of-frame peptides.\\n* The solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents the binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nFrom this information, we can infer that the Morpholino is targeting the pre-mRNA, which is a precursor to mature mRNA. The Morpholino is preventing the binding of the spliceosome, which is a complex that assembles at the splice sites of introns (non-coding regions) to remove them from the pre-mRNA.\\n\\nGiven this information, the structure that is not involved in the proposed therapy is:\\n\\nC) R-loops\\n\\nR-loops are a type of DNA structure that forms when an RNA transcript hybridizes to a complementary DNA sequence. They are not directly involved in the process of splicing or the action of the Morpholino.\\n\\nAnswer: C<|eot_id|>\", \"Let's break down the text step by step:\\n\\n* The gene has dozens of exons, with the central ones coding for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space.\\n* Each exon usually codes for one folded triple alpha helix.\\n* The most common mutations are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste.\\n* The proposed solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n* The Morpholino prevents binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nThe Morpholino binds to the 5' end of the out-of-frame exon, which is not related to the structures listed in the options. Therefore, the correct answer is:\\n\\nAnswer: B<|eot_id|>\"], 'correct': [False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, True, False], 'explanations': [\"parsed='A'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='A'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='A'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='D'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='B'; truth='C'\"], 'num_tokens': [291, 227, 315, 135, 302, 293, 245, 232, 291, 281, 263, 282, 287, 224, 217, 329, 403, 291, 326, 272, 333, 339, 278, 306, 329, 240, 299, 344, 281, 302, 171, 295, 244, 325, 284, 113, 280, 344, 287, 254, 160, 174, 275, 297, 276, 137, 153, 297, 361, 302, 244, 295, 185, 336, 279, 319, 298, 265, 358, 291, 327, 371, 307, 284, 185, 339, 351, 300, 157, 366, 397, 328, 278, 165, 321, 229, 317, 248, 329, 226, 157, 106, 212, 259, 299, 310, 298, 294, 237, 234, 351, 293, 248, 412, 205, 232, 263, 348, 134, 176, 231, 283, 293, 224, 357, 381, 373, 304, 270, 233, 351, 148, 237, 198, 203, 238, 302, 258, 304, 314, 308, 328, 180, 291, 230, 412, 232, 171], 'rewards': [0.10400390625, 0.11376953125, 0.10107421875, 0.11181640625, 0.10888671875, 0.10888671875, 0.095703125, 0.1083984375, 0.1103515625, 0.12255859375, 0.1103515625, 0.12158203125, 0.11181640625, 0.11865234375, 0.09228515625, 0.11767578125, 0.10595703125, 0.10693359375, 0.119140625, 0.0947265625, 0.11181640625, 0.1123046875, 0.1064453125, 0.1162109375, 0.123046875, 0.1103515625, 0.103515625, 0.10595703125, 0.1005859375, 0.107421875, 0.1005859375, 0.11181640625, 0.103515625, 0.1064453125, 0.111328125, 0.1142578125, 0.10986328125, 0.10546875, 0.11669921875, 0.10302734375, 0.11279296875, 0.11181640625, 0.10107421875, 0.1064453125, 0.10693359375, 0.1064453125, 0.1279296875, 0.1123046875, 0.1064453125, 0.1103515625, 0.1005859375, 0.11181640625, 0.11865234375, 0.10888671875, 0.10546875, 0.1044921875, 0.10693359375, 0.11328125, 0.107421875, 0.1171875, 0.10009765625, 0.1103515625, 0.11083984375, 0.10986328125, 0.10791015625, 0.08251953125, 0.1181640625, 0.1142578125, 0.10693359375, 0.1083984375, 0.1005859375, 0.10888671875, 0.11181640625, 0.10986328125, 0.10302734375, 0.09716796875, 0.12060546875, 0.11181640625, 0.1142578125, 0.11376953125, 0.107421875, 0.11181640625, 0.10888671875, 0.10693359375, 0.1142578125, 0.11865234375, 0.103515625, 0.1103515625, 0.119140625, 0.103515625, 0.10986328125, 0.11279296875, 0.10693359375, 0.1025390625, 0.11328125, 0.109375, 0.1015625, 0.1162109375, 0.1064453125, 0.1142578125, 0.1044921875, 0.10400390625, 0.1103515625, 0.10888671875, 0.1083984375, 0.10302734375, 0.11376953125, 0.11083984375, 0.10888671875, 0.0849609375, 0.1064453125, 0.11572265625, 0.10888671875, 0.107421875, 0.111328125, 0.09619140625, 0.1142578125, 0.10595703125, 0.11376953125, 0.10302734375, 0.115234375, 0.1044921875, 0.107421875, 0.1025390625, 0.123046875, 0.10546875, 0.10107421875, 0.12109375], 'ground_truths': ['C'], 'question_meta': None, 'model_name': 'hf_chat:meta-llama/Meta-Llama-3-8B-Instruct', 'reward_model_name': 'armo_rm:RLHFlow/ArmoRM-Llama3-8B-v0.1'}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 17%|â–ˆâ–‹        | 2/12 [00:03<00:19,  1.99s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'qid': 'gpqa-1', 'prompt': \"Answer the following multiple choice question. The last line of your response should be of the following format: 'Answer: $LETTER' (without quotes) where LETTER is one of ABCD. Think step by step before answering.\\n\\nA large gene has dozens of exons, of which the central ones code for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space. Each exon usually codes for one folded triple alpha helix. The most common mutations of the gene are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste. A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. The molecule prevents binding of the spliceosome and creates exon skipping and in-frame joining. Several missing exons are well tolerated by an organism. Which structure below is not involved in the proposed therapy?\\n\\nA) lariat\\nB) polyA tail\\nC) R-loops\\nD) antisense\", 'answers': [\"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ><think>\\nOkay, so I've got this multiple-choice question here about a gene therapy scenario. Hmm, I'm a bit rusty on some of the molecular biology details, but I'll try to think through it.\\n\\nThe question is about a large gene with many exons. The central exons code for triple helical repeats that help connect the cytoskeleton with the sarcolemma and extracellular matrix. Each exon usually codes for a triple helix. But the common mutation is central exon deletions causing out-of-frame peptides and progressive degeneration. The solution is to deliver a Morpholino that recognizes the 5' end of the exon in pre-mRNA. This Morpholino prevents the spliceosome from binding, causing exon skipping and in-frame joining. Since several missing exons are tolerable, they're looking at this therapy.\\n\\nThe question asks which structure is NOT involved in the proposed therapy. The options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nWait, I remember that in splicing, the spliceosome recognizes exons and introns. The splicing process involves the spliceosome, which includes snRNPs (small nuclear ribonucleoproteins). When a Morpholino is introduced, it binds to the 5' end of the exon in the pre-mRNA. This binding disrupts the recognition of the exon by the spliceosome. So the spliceosome can't bind, leading to the exon being skipped. The intron would then be spliced out, but since the exon is skipped, the next exons are joined together in frame.\\n\\nNow, let's think about each option.\\n\\nOption A: Lariat. I know that during splicing, the intron is removed and a lariat structure is formed. The branch site adenine is connected via a pyrophosphate to form a lariat. So the lariat is definitely involved. So option A is involved.\\n\\nOption B: PolyA tail. The polyA tail is added to the mRNA after processing. In the splicing process, the polyA tail is part of the mRNA processing steps, but the Morpholino targets the pre-mRNA. I'm not sure if the polyA tail is directly involved in the splicing mechanism here. Wait, the polyA tail is part of the 3' end processing. The splicing occurs earlier, so the polyA tail might not be directly involved in the spliceosome-mediated process here. But wait, the pre-mRNA includes the polyA tail, but the Morpholino is targeting the exon's 5' end. Hmm. So maybe the polyA tail isn't part of the splicing mechanism triggered by the Morpholino. So perhaps B is not involved.\\n\\nOption C: R-loops. R-loops are structures where RNA binds to DNA, forming an RNA-DNA hybrid with displaced DNA. I don't see how R-loops are involved in this therapy. The therapy uses Morpholino which is an antisense oligo, perhaps. But in this case, the Morpholino is binding to the pre-mRNA. I don't think R-loops are part of the process described. So option C is not involved.\\n\\nOption D: Antisense. Well, Morpholino is an antisense oligo. It binds to the 5' splice site. So antisense is definitely involved. So D is involved.\\n\\nWait, but the question is which is NOT involved. So looking for the option not involved.\\n\\nWait, the therapy is using an antisense (Morpholino) to target the pre-mRNA. So the spliceosome tries to recognize it. So the spliceosome's machinery is involved. But what about the polyA tail?\\n\\nWait, the polyA tail is added to the mRNA after splicing. So in the process of splicing, the mRNA is being processed, but the polyA tail is added later. So the initial splicing happens without the polyA tail being present. So perhaps the polyA tail is not involved in this particular therapy. So option B (polyA) is not involved.\\n\\nBut what about R-loops? R-loops are more about DNA and RNA binding. Since the therapy is using an RNA-binding molecule (Morpholino), perhaps R-loops are not part of the process. So option C is not involved.\\n\\nSo the question is which structure is not involved. So the answer would be either B or C.\\n\\nBut wait, the therapy uses Morpholino, which is a small RNA molecule? Or is it a DNA-based antisense oligo? Wait, Morpholinos are small RNA molecules, right? Or are they DNA-based? Wait, no, Morpholinos are small RNA molecules that are designed to bind to specific RNA sequences. They're used in RNA interference, acting as antisense oligonucleotides.\\n\\nSo the Morpholino binds to the pre-mRNA, preventing the spliceosome from recognizing the exon. So the spliceosome's machinery is involved, but the polyA tail is not part of the splicing process that's being disrupted. So the polyA tail is not involved in the therapy's mechanism. So option B is not involved.\\n\\nWait, but the spliceosome is part of the process, and the polyA tail is part of the mRNA processing, but not directly involved in splicing. So the therapy doesn't involve the polyA tail.\\n\\nSo the options are:\\n\\nA: lariat - involved.\\n\\nB: polyA tail - not involved.\\n\\nC: R-loops - not involved.\\n\\nD: antisense - involved.\\n\\nThe question is which is not involved. The question is which is not involved in the proposed therapy.\\n\\nSo the therapy involves the spliceosome (so D, antisense, and others involved), the lariat (A), but not the polyA tail (B) and not R-loops (C).\\n\\nWait, but the question is asking which structure is not involved. So the options are four, and three are involved, one is not.\\n\\nIn the scenario, the therapy uses the Morpholino to block the spliceosome from binding. The spliceosome's activity is in the splicing process, which involves the lariat (so A is involved). The polyA tail is added after splicing, so it's not part of the splicing event. So B is not involved.\\n\\nWait, another angle: the polyA tail is part of the 3' end of the mRNA. The splicing process occurs earlier, so the polyA tail is not part of the splicing machinery. So the therapy doesn't involve the polyA tail. So B is not involved.\\n\\nAlternatively, R-loops are structures that form when RNA binds to DNA, but in this case, the Morpholino is binding to RNA (pre-mRNA), not DNA. So R-loops are not involved. So C is not involved.\\n\\nWait, but the question asks which structure is not involved. So if both B and C are not involved, but the options are four, and the question is which is not. But the options only have one correct answer.\\n\\nHmm, perhaps I'm getting this wrong. Let me think again.\\n\\nThe therapy involves the Morpholino (antisense) binding to the pre-mRNA. The spliceosome's recognition is prevented, causing exon skipping. The lariat is formed during splicing. The polyA tail is part of the mRNA, but in the process, the spliceosome is involved, but the polyA tail is added after splicing. So the therapy doesn't involve the polyA tail. So option B is not involved.\\n\\nWait, but the polyA tail is part of the pre-mRNA? No, wait, the pre-mRNA is the spliced mRNA with introns, but the polyA tail is added after splicing. So the initial splicing happens without the polyA tail. So the therapy's process doesn't involve the polyA tail. So the structure not involved would be either B or C.\\n\\nBut the question is which is not involved in the proposed therapy. The therapy is about the spliceosome and the pre-mRNA. So the structures involved are the spliceosome (so antisense is part of that), the lariat (formed during splicing), and the pre-mRNA. So the polyA tail is not involved in the splicing process that is being targeted. So B is not involved.\\n\\nBut wait, what about R-loops? R-loops form when RNA binds to DNA, creating a double-stranded RNA-DNA hybrid. The Morpholino is an RNA molecule binding to pre-mRNA. So R-loops are not involved here. So C is not involved.\\n\\nWait, the question is which is not involved. So the correct answer would be either B or C.\\n\\nWait, the question is asking which structure is not involved in the proposed therapy. The therapy uses a Morpholino that binds to the 5' end of the exon in pre-mRNA. The process is about preventing the spliceosome from binding, leading to exon skipping. So the structures involved in the process are:\\n\\n- pre-mRNA (where the Morpholino binds)\\n- lariat (formed during splicing)\\n- spliceosome components (small nuclear RNPs)\\n- antisense oligonucleotide (Morpholino)\\n\\nThe polyA tail is added to the mRNA after splicing, so it's not part of the splicing process here. So the therapy doesn't involve the polyA tail. So B is not involved.\\n\\nR-loops are structures involving DNA, RNA, and displaced DNA. The Morpholino is RNA-based, binding to RNA. So R-loops are not part of this process. So C is also not involved.\\n\\nWait, but the options are for four structures, and only one is not involved.\\n\\nWait, perhaps I made a mistake. The question is which structure is not involved. So perhaps R-loops are involved? Or not.\\n\\nAlternatively, the\", '<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ><think>\\nOkay, so I\\'ve got this multiple-choice question about gene therapy involving a Morpholino protein. Hmm, I\\'m a bit rusty on my molecular biology, but let me try to think this through.\\n\\nThe question says that a large gene has many exons, and the central ones code for triple helical repeats, which help connect the cytoskeleton, sarcolemma, and the extracellular space. Oh right, that sounds familiar. Those structures are part of the intermediate filaments, right? So, the exons usually code for these repeats, which are essential for the protein\\'s structure.\\n\\nThe mutations in this gene are central exon deletions, leading to out-of-frame peptides and progressive degenerative disease. So when an exon is deleted, the reading frame shifts, and the resulting protein is messed up, causing all sorts of issues. That\\'s a frameshift mutation.\\n\\nNow, the therapy uses a Morpholino that recognizes the 5\\' end of the out-of-frame exon in pre-mRNA. Morpholinos are a type of antisense oligonucleotide, I think. They bind to specific RNA sequences. When the Morpholino binds to the pre-mRNA, it blocks the spliceosome from recognizing the exon. So the spliceosome can\\'t splice that exon out. Instead, the exon is skipped, and the mRNA continues with the next in-frame exon. That way, the resulting protein is in-frame, so the reading frame doesn\\'t get messed up. And because some exons are skipped, the protein might be shorter but still functional.\\n\\nThe question is asking which structure is NOT involved in this therapy. The options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nLet me go through each option.\\n\\nOption A: Lariat. I remember that during splicing, the introns are removed. The typical intron is spliced out by the spliceosome, which cuts the mRNA into a lariat structure. The branch site adenine forms a loop, and the intron is released as a lariat. So lariat formation is part of splicing. But in this therapy, the Morpholino is blocking the spliceosome. So the spliceosome\\'s normal function of recognizing the 5\\' splice site and lariat formation is still in play. Or wait, if the spliceosome can\\'t bind, maybe the intron isn\\'t removed. So lariat wouldn\\'t form? Or does the presence of Morpholino just prevent the splicing, but the lariat is still formed from the introns that are not targeted? Hmm.\\n\\nOption B: PolyA tail. The polyA tail is added to the mRNA after processing, typically during the export from the nucleus and before translation. The spliceosome is involved in splicing, but the polyA tail is a separate step. The Morpholino affects splicing, but the presence of a polyA tail wouldn\\'t be directly involved in the blocking of splicing. Unless the therapy uses something that affects the mRNA processing beyond splicing. But in this case, the Morpholino is specifically targeting the splice site, so the polyA tail is probably not involved. Unless the polyA tail affects the binding of the Morpholino somehow, but I don\\'t think that\\'s the case. So B could be the answer.\\n\\nOption C: R-loops. R-loops are structures where the RNA is hybridized with the DNA, displacing the other DNA strand. They can cause genomic instability. I don\\'t think R-loops are involved in this therapy. The therapy is about splicing, not about DNA structure. So C is probably not involved.\\n\\nOption D: Antisense. Oh, Morpholinos are antisense oligonucleotides. They have sequences that are complementary to the target RNA. So the Morpholino is antisense. Therefore, D is definitely involved.\\n\\nSo the structures involved in this therapy are spliceosome (including lariat formation) and antisense (Morpholino). The polyA tail (B) is part of mRNA processing but not directly involved in splicing, so it\\'s not part of this therapy. R-loops (C) are unrelated.\\n\\nWait, but wait. If the spliceosome is involved, then during splicing, the introns are removed, and the lariat is formed. So lariat is involved. The polyA tail is added later. So the structures involved are spliceosome (with lariat) and antisense (Morpholino), but polyA tail is not part of the process here.\\n\\nSo the question is, which structure is NOT involved. So looking for the option that\\'s not part of the therapy.\\n\\nThe options are A) lariat (part of splicing, so involved), B) polyA (not involved), C) R-loops (no), D) antisense (yes).\\n\\nWait, the question is which structure is not involved. So the options are the structures in the process.\\n\\nSo the therapy involves Morpholino (antisense), spliceosome (which makes lariat), and the pre-mRNA is being processed. The polyA tail is added after splicing, so it\\'s not part of the splicing process. So the polyA tail (B) is not involved in the therapy.\\n\\nR-loops (C) are structures in the genome, not part of the splicing machinery. So C is also not involved. Hmm, but the question is which structure is not involved. So the question is, which of these is not involved in the therapy described.\\n\\nWait, but the therapy is about delivering a Morpholino that binds to the 5\\' end of the out-of-frame exon in pre-mRNA. So the Morpholino is part of the antisense oligonucleotide. The spliceosome is involved, which involves the recognition of splice sites, and lariat formation. The polyA tail is added by other mechanisms, not part of splicing. So option B (polyA tail) is not involved.\\n\\nSo the structures involved are lariat, spliceosome (with polyA perhaps not), antisense (Morpholino). The structures not involved are polyA tail, R-loops.\\n\\nWait, but what about R-loops? I don\\'t think the therapy uses any DNA-RNA interactions beyond the antisense binding, which is RNA-RNA. R-loops are DNA-RNA, so they\\'re not part of this. So R-loops (C) are also not involved.\\n\\nSo the question is, which structure is not involved. So options B and C are not involved. But the question is asking for which structure is not involved. So let\\'s look at the options again.\\n\\nThe question asks which structure is not involved in the proposed therapy. So which one is not involved.\\n\\nThe therapy uses a Morpholino, which is an antisense molecule. So D is involved.\\n\\nSplicing involves the spliceosome, which creates a lariat (A is involved).\\n\\nThe polyA tail is added after splicing, so it\\'s not directly involved in the splicing process. So B is not involved.\\n\\nR-loops are structures involving DNA and RNA, which aren\\'t part of the splicing process or the Morpholino\\'s action. So C is not involved.\\n\\nWait, so the question is, which structure is not involved in the therapy.\\n\\nSo the possible correct answers are B and C. Let\\'s see the question again.\\n\\nThe options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nWhich is not involved.\\n\\nThe therapy uses antisense (D is involved). The spliceosome (with lariat) is involved (A is involved). The polyA tail is not involved (B not involved). R-loops are not involved (C not involved).\\n\\nSo the question is, which of the four is not involved. So the answer is either B or C.\\n\\nThe question is asking which is NOT involved. So the correct answer would be either B or C.\\n\\nWait, the question says, \"which structure below is not involved in the proposed therapy?\" So the structures in the options are all possible, and one is not used.\\n\\nThe therapy is about blocking the spliceosome. The spliceosome binds the pre-mRNA, and the Morpholino prevents that. So the steps are: pre-mRNA has the exon. Morpholino binds to the 5\\' end, preventing the spliceosome from recognizing it. So the spliceosome can\\'t process that exon, leading to its skipping.\\n\\nSo, the structures involved in splicing would be the spliceosome and the lariat. The antisense (Morpholino) is part of the therapy.\\n\\nThe polyA tail is added after splicing, so it\\'s not involved in this therapy. So option B (polyA tail) is not involved.\\n\\nR-loops are not part of the splicing process. They form when RNA binds to DNA, causing the other DNA strand to loop out. The therapy doesn\\'t involve DNA, so R-loops (C) are not involved.\\n\\nSo the structures not involved are B and C. But the question is which is not involved.\\n\\nWait, the question is which is NOT involved. So in the therapy, which of these four is not involved.\\n\\nThe four options are all structures: lariat (part of splicing), polyA tail (added after), R-loops (DNA-RNA), antisense ( Morpholino is antisense).\\n\\nSo the structures involved in the therapy:\\n\\n- Antisense (D) is involved because the Morpholino is antisense.\\n\\n- Spliceosome is involved, which includes lariat (A) formation.\\n\\n- The polyA tail (B) is added after splicing, so it\\'s not part of the splicing process, but is part of mRNA processing. However, the therapy is about splicing, not about adding the polyA tail.\\n\\nWait, but the therapy\\'s goal is to modify the mRNA before', \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ><think>\\nOkay, so I've got this question about gene therapy involving Morpholinos and exons. Hmm, I'm a bit rusty on my molecular biology, but let me try to think it through.\\n\\nThe question says that a gene has many exons, and the central ones code for triple helical repeats. When exons are deleted, it creates out-of-frame peptides, leading to degenerative disease. The therapy uses a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the spliceosome from binding, causing exon skipping and joining in a way that's in-frame, so the protein is okay.\\n\\nThe question is asking which structure is not involved in this therapy. The options are lariat, polyA tail, R-loops, and antisense.\\n\\nFirst, let's recap what happens in splicing. Normally, the spliceosome recognizes the donor and acceptor sites at the ends of introns. It then splices the intron out, cutting between the exon and intron (donor) and between intron and exon (acceptor). The spliceosome binds using the branch site adenine, creating a lariat structure with the intron.\\n\\nIn this case, the Morpholino targets the 5' end of the exon. So it probably blocks the spliceosome from recognizing the exon as a normal exon. Without the spliceosome binding, the exon might be skipped. So the spliceosome would not process that exon, leading to a missing exon.\\n\\nWait, but what's the process when the spliceosome can't recognize an exon? Let me think. If the spliceosome can't bind, maybe it just skips that exon. So the intron is retained? Or maybe the intron is processed normally but the exon is skipped.\\n\\nWait, the spliceosome's job is to cut between exons and introns. So if the Morpholino prevents binding, the spliceosome might skip the exon. So the intron would still be spliced normally, but the exon is excluded. So the lariat structure is part of normal splicing. The polyA tail is added to the mRNA after processing. So in this therapy, when the exon is skipped, the polyA tail is still present because the mRNA is still made with the polyA, right?\\n\\nSo the structures involved would be the spliceosome, the lariat (from intron splicing), and the polyA tail, because the mRNA still has it. Antisense molecules are used in antisense therapy, like blocking mRNA. Wait, Morpholinos are a type of antisense, maybe. Or are they a guide RNA?\\n\\nWait, Morpholinos are a type of RNA-based therapy. They are antisense molecules. So in this case, the Morpholino would bind to the pre-mRNA, preventing the spliceosome from recognizing the exon. So the process is that the Morpholino binds to the 5' end of the exon, and the spliceosome can't recognize it. Then the spliceosome might skip the exon. So the spliceosome would process the intron, but the exon is missing.\\n\\nBut in the normal splicing process, the spliceosome creates a lariat when the intron is removed. So the lariat structure is part of the process, so option A is involved.\\n\\nThe polyA tail is added to the mRNA by the cell's machinery. So when the spliceosome processes the mRNA, the polyA is still attached. So option B is involved.\\n\\nAntisense molecules are used to bind to specific RNA sequences. So the Morpholino is an antisense molecule targeting the pre-mRNA. So option D is involved.\\n\\nWhat about R-loops? R-loops are structures where RNA hybridizes with DNA, displacing the other DNA strand. I don't think R-loops are part of the splicing mechanism or the spliceosome's activity. They're more associated with RNA-induced silencing complexes (like in the RNAi pathway) or with DNA methylation. So R-loops aren't involved in the spliceosome's function.\\n\\nSo the question is which structure is NOT involved. The options are A, B, C, D. The structures involved are lariat (A), polyA (B), antisense (D). So the answer would be C) R-loops.\\n</think>\\n\\nThe question involves a gene therapy approach using Morpholinos, which are antisense molecules, to prevent exon skipping by blocking the spliceosome's recognition of an out-of-frame exon in pre-mRNA. This therapy aims to restore in-frame joining of exons to avoid the production of misfolded peptides. The question asks which structure is not involved in this process.\\n\\n1. **Lariat (A):** During splicing, the spliceosome processes introns, forming a lariat structure as the intron is removed. This structure is part of the normal splicing mechanism and remains involved even when an exon is skipped. Therefore, the lariat is involved in the therapy.\\n\\n2. **PolyA tail (B):** The polyA tail is added to the mRNA after splicing. It is a critical feature of mature mRNA and is not affected by the skipping of an exon. Thus, the polyA tail remains involved in the process.\\n\\n3. **R-loops (C):** R-loops are RNA-DNA hybrid structures where RNA displaces one DNA strand. These structures are not part of the splicing process or the spliceosome's function. They are more relevant in RNA-induced silencing or DNA methylation processes and are unrelated to the described therapy.\\n\\n4. **Antisense (D):** Morpholinos are antisense molecules that bind to specific RNA sequences to block spliceosome binding. This is a key component of the therapy, making antisense molecules directly involved.\\n\\nSince R-loops are not part of the splicing process or the described therapy, they are the correct answer. \\n\\n**Answer: C**<ï½œendâ–ofâ–sentenceï½œ>\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ><think>\\nOkay, so I've got this biology question here, and I'm a bit new to the topic, but I'll try to think it through. Let me read the question again.\\n\\nThe question is about a gene with many exons, and the central ones code for triple helical repeats that connect the cytoskeleton with the sarcolemma and extracellular space. So, those are the structural parts, like structural proteins maybe?\\n\\nThe mutations mentioned are central exon deletions that cause out-of-frame peptides and progressive degenerative disease. Oh right, when an exon is deleted and the reading frame shifts, the resulting protein is nonfunctional. That leads to a degenerative disease because the protein doesn't fold correctly.\\n\\nThe solution involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. Morpholinos are a type of antisense oligonucleotide, right? So they can bind to specific RNA sequences. The Morpholino would block the spliceosome from binding. Oh, I remember that the spliceosome uses the 5' splice site and the 3' splice site. So if the Morpholino blocks the splice site, it causes the exon to be skipped.\\n\\nWhen the exon is skipped, the introns are still spliced, but the exons before and after are joined directly. So in this case, if exon 5 is missing, then exon 4 would be spliced to exon 6, right? But since the exon is skipped, the reading frame is preserved, so the protein remains in-frame. That's why the disease is milder than frameshift mutations.\\n\\nThe question is asking which structure is NOT involved in the proposed therapy. The options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nLet me think about each structure.\\n\\nFirst, the therapy uses Morpholino, which is an antisense molecule. So antisense (option D) is definitely involved. So D is not the answer.\\n\\nThe spliceosome binds to the pre-mRNA. It uses the 5' splice site (which is the site where the Morpholino binds) and the 3' splice site. So the spliceosome's role is involved in splicing. When the Morpholino blocks the splice site, the spliceosome can't bind, leading to exon skipping.\\n\\nThe spliceosome is involved in the splicing process, which involves the pre-mRNA. The spliceosome's activity is crucial for this. So the structures involved in splicing would be the splice sites, the pre-mRNA, the spliceosome itself, and perhaps the lariat structure that forms during splicing.\\n\\nWait, during splicing, introns are removed and a lariat structure is formed. The 5' end of the intron forms a loop, attaching to the exon's 3' end, creating a lariat. So the lariat (option A) is definitely involved in splicing. So A is involved, so it's not the answer.\\n\\nThe polyA tail is part of mRNA processing. The polyA binding proteins recognize the polyA tail and help in stability and export of the mRNA from the nucleus. But in this case, the therapy is about splicing. So the polyA tail (option B) might not be directly involved. Or does the presence of the polyA tail affect anything here?\\n\\nWait, the Morpholino is delivered to the pre-mRNA. Pre-mRNA is in the nucleus, and the polyA tail is added later, in the processing in the nucleus. So the therapy's process doesn't directly involve the polyA tail. Unless... when the pre-mRNA is exported to the cytoplasm, it might have the polyA tail. But the spliceosome doesn't require a polyA tail for splicing. So the polyA tail isn't involved in the splicing process. Therefore, the polyA tail (option B) might be the one not involved.\\n\\nWhat about R-loops? R-loops are structures where RNA is hybridized to DNA, displacing the other DNA strand. They can cause DNA damage and are involved in certain genetic disorders. Do R-loops have anything to do with splicing or antisense binding?\\n\\nI'm not too sure. I don't recall R-loops being part of the spliceosome machinery. The spliceosome is made of snRNPs (small nuclear ribonucleoproteins), which are involved in recognizing splice sites. So R-loops are more about RNA-DNA interactions and not part of the splicing mechanism. So R-loops (option C) are not involved in the therapy described.\\n\\nWait, the question is which structure is NOT involved. So I'm trying to figure out which of the options is not part of the process.\\n\\nThe therapy uses Morpholino, which is antisense. So antisense (D) is involved.\\n\\nSplicing involves the pre-mRNA, splice sites, spliceosome, lariat formation.\\n\\nPolyA tail (B) is part of mRNA processing but not directly involved in splicing.\\n\\nR-loops (C) are not part of splicing or antisense binding in this context.\\n\\nSo the structures involved are:\\n\\n- lariat (A): yes\\n- antisense (D): yes\\n- spliceosome (not an option, but the process uses it)\\n- polyA tail (B): no\\n- R-loops (C): no\\n\\nWait, but the question is about which is NOT involved.\\n\\nThe question is about structures. So which of the four options is not involved in the therapy.\\n\\nThe therapy involves delivering an antisense molecule (D), which blocks the splice site. So D is involved.\\n\\nThe spliceosome (which isn't an option) is involved. The lariat is involved.\\n\\nPolyA tail is part of mRNA processing, but the therapy is about splicing. So the polyA tail (B) isn't involved.\\n\\nR-loops (C) aren't part of the process.\\n\\nSo the question asks which is not involved. The options are A, B, C, D.\\n\\nSo the structures not involved are B and C.\\n\\nWait, but the question is about the structures involved in the therapy. The therapy uses Morpholino (antisense) to block the splice site, leading to exon skipping.\\n\\nWhich structures are part of the therapy?\\n\\n- Antisense oligonucleotide (Morpholino): yes.\\n\\n- The spliceosome: yes, because it's involved in splicing. But spliceosome is not an option here.\\n\\nThe question's options are A (lariat), B (polyA), C (R-loops), D (antisense). So the structures involved are A (lariat, part of splicing) and D (antisense, Morpholino). The therapy doesn't involve the polyA tail (B) or R-loops (C).\\n\\nSo the question is asking which structure is not involved. The options are A, B, C, D.\\n\\nThe question is which structure is not involved in the therapy. So which of the options is not part of the process.\\n\\nThe therapy uses Morpholino (D) which is an antisense, so D is involved.\\n\\nSplicing involves the formation of a lariat (A), so A is involved.\\n\\nPolyA tail (B) is not involved because it's part of mRNA processing, not splicing.\\n\\nR-loops (C) are not involved in this process.\\n\\nSo the question is which is not involved. The options are four, and the answer is either B or C.\\n\\nWait, but the therapy is about splicing, so which structures are part of splicing. So the lariat (A) is part of splicing. The polyA tail is not involved in splicing. So B is not involved.\\n\\nSimilarly, R-loops are not involved in the splicing process.\\n\\nSo the question is, which is not involved in the therapy? The structures are: lariat (A), polyA (B), R-loops (C), antisense (D).\\n\\nThe therapy uses antisense (D) and causes splicing leading to lariat (A). The polyA tail (B) is part of mRNA processing but not involved in splicing, so B is not involved. R-loops (C) are not part of the splicing process, so C is not involved.\\n\\nWait, but the question is which is not involved. So the question is about the four options, which one is not involved.\\n\\nSo the options are A, B, C, D.\\n\\nWhich of these structures is not involved in the proposed therapy?\\n\\nThe therapy's process involves:\\n\\n1. Morpholino (antisense) binding to the pre-mRNA at the 5' splice site of the exon.\\n\\n2. Preventing the spliceosome from binding, leading to exon skipping.\\n\\nThe spliceosome's role includes recognizing the 5' and 3' splice sites. So the 5' splice site is part of the pre-mRNA.\\n\\nThe process of splicing creates a lariat structure (A), which is a part of the mechanism.\\n\\nPolyA tail (B) is part of the mRNA but is added later. The therapy doesn't involve adding or modifying the polyA tail. So B is not involved.\\n\\nR-loops (C) are RNA:DNA hybrids, not involved in splicing. So C is not involved.\\n\\nWait, but which one is the correct answer? The question is asking which structure is not involved.\\n\\nWait, the options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nThe therapy uses D (antisense), so D is involved.\\n\\nSplicing involves the spliceosome, which leads to lariat (A), so A is involved.\\n\\nPolyA tail (B) is not involved.\\n\\nR-loops (C) are not involved.\\n\\nSo the structures involved are A and D, but B and C are not.\\n\\nBut\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ><think>\\nOkay, so I'm trying to figure out this biology question here. Hmm, let me read it again. \\n\\nThe question is about a gene with a lot of exons, and the central ones code for these triple helical repeats. Each exon usually codes for one of these repeats. The common mutations are deletions in the central exons, leading to out-of-frame peptides and causing degenerative organ waste. The solution is using a Morpholino, which I think is a type of antisense molecule. It recognizes the 5' end of the out-of-frame exon in pre-mRNA. This stops the spliceosome from binding, causing exon skipping, so the mRNA joins in a way that the reading frame is preserved. And since missing exons are tolerable, this therapy would help.\\n\\nThe question asks which structure isn't involved in this therapy. The options are lariat, polyA tail, R-loops, antisense.\\n\\nSo I need to think about what happens in splicing. When the spliceosome processes pre-mRNA, it splices out introns. The spliceosome recognizes exons and introns. The spliceosome uses a lariat structure when it splices. So the lariat is part of the splicing mechanism.\\n\\nThe polyA tail is added to the mRNA during processing. So that's also involved in the normal mRNA processing. But in this therapy, they're using an antisense Morpholino. Wait, Morpholinos are antisense oligonucleotides. They bind to specific RNA sequences to block certain processes.\\n\\nIn the scenario, the Morpholino targets the 5' end of the exon. When it binds, it prevents the spliceosome from binding. So the spliceosome can't recognize the exon, leading to its skipping. So the mRNA joins the previous exon to the next one, in a way that doesn't disrupt the reading frame.\\n\\nSo, during splicing, the spliceosome removes introns and joins exons. The lariat is a part of the splicing mechanism because when an intron is spliced, the branch site adenine forms a bond with a nearby guanine, creating a lariat-shaped structure. So the lariat is definitely involved.\\n\\nThe polyA tail is added to the 3' end of the mRNA. I think that's part of the mRNA processing, which occurs before the mRNA is exported to the cytoplasm and translated. So the polyA tail is involved in the normal processing but perhaps not directly in this particular therapy. Wait, but does the Morpholino affect the polyA tail? The Morpholino is targeting the 5' end of the exon in pre-mRNA. So the polyA tail would be added later, perhaps after splicing. So the polyA tail is part of the normal mRNA processing but not part of the splicing mechanism itself. Wait, but in the question, the therapy is about preventing the spliceosome from binding. So the polyA tail's presence might not interfere with the splicing. Hmm, but the polyA tail is part of the pre-mRNA that's being processed. So if the Morpholino is binding in the pre-mRNA, perhaps the polyA tail is still present. But I'm not sure if the polyA tail is involved in the splicing process. Wait, no, the polyadenylation occurs after splicing. So the process of splicing occurs before the polyA tail is added. So the Morpholino binds to the pre-mRNA, which hasn't been polyadenylated yet. So the presence of the polyA tail isn't part of the splicing mechanism in this case. Or is it?\\n\\nWait, maybe I'm getting confused. Let me think again. The pre-mRNA goes through splicing first, then polyadenylation. So the Morpholino binds to the pre-mRNA during splicing. So the polyA tail is added after splicing. So the polyA tail isn't directly involved in this therapy's mechanism. But the question is about what structure is NOT involved in the proposed therapy. So if the therapy is using the Morpholino to block the spliceosome, which makes the exon skip, the structures involved in the therapy would be things like the lariat (part of splicing), antisense (the Morpholino), and the spliceosome components.\\n\\nR-loops are structures that form when RNA binds to DNA, displacing the other DNA strand. They can cause mutations. Are R-loops involved in splicing? I don't think so. R-loops are more about DNA-RNA interactions, like in processes such as genome editing or in some cases of mRNA processing. But in the context of splicing, I don't think R-loops are involved. The spliceosome operates on pre-mRNA and doesn't form R-loops. So in this therapy, R-loops wouldn't be involved.\\n\\nWait, but the options are which structure is not involved. So the question is, which of these is not used in the therapy. The therapy uses an antisense molecule (Morpholino), which is part of the answer (D). The lariat (A) is part of splicing, so it's involved. R-loops (C) are not part of splicing. The polyA tail (B) is part of mRNA processing but not directly involved in the splicing mechanism here. Because the polyA tail is added after splicing.\\n\\nWait, but the pre-mRNA has the polyA tail already? Or does it get added during splicing? No, I think the polyA tail is added after the splicing. So the pre-mRNA is the version without the polyA. So in the therapy, the Morpholino binds to the pre-mRNA (without polyA), so the polyA tail is not involved in the splicing process that the Morpholino affects. So in the therapy, the polyA tail is not involved in the process. So which structures are involved?\\n\\nSo the therapy involves the spliceosome (which makes the lariat), the antisense Morpholino, and the splicing machinery. The structures not involved would be R-loops, because R-loops are not part of splicing. Alternatively, the polyA tail is added after splicing, so it's not part of the splicing process that the Morpholino is targeting. So the polyA tail is involved in the normal processing but not in the splicing that is being blocked here.\\n\\nWait, but the question is about the structures involved in the therapy. So the therapy uses the Morpholino (antisense) to block the spliceosome from binding. The spliceosome is part of the splicing process, which creates a lariat. So the lariat is involved. The polyA tail is part of the mRNA but not part of the splicing mechanism in this case. So the polyA tail is not involved in the splicing process that is being prevented. So the therapy doesn't involve the polyA tail.\\n\\nWait, but the question is which structure is not involved. So the structures that are involved in the therapy's mechanism are the lariat (because splicing occurs), the antisense (Morpholino), and the spliceosome. So the structures that are not involved would be the ones not part of the splicing process. So R-loops are not involved. The polyA tail is part of the pre-mRNA processing but not in the splicing process that's being blocked.\\n\\nWait, but the pre-mRNA still has the polyA tail if it's the polyadenylated version. No, wait. The pre-mRNA is the RNA that is spliced, and the polyA tail is added during the export to the cytoplasm. Or wait, pre-mRNA is the RNA that's spliced but not polyadenylated. The polyadenylation occurs after splicing. So the Morpholino is binding to the pre-mRNA (without polyA), so the polyA tail is not involved in the splicing process that the Morpholino is targeting. So in the therapy, the polyA tail is not part of the mechanism being used. So the structures not involved would be polyA tail and R-loops?\\n\\nWait, but I'm getting a bit confused. Let me think again. The question is, which structure is not involved in the proposed therapy.\\n\\nThe therapy's mechanism is: Morpholino binds to pre-mRNA, preventing spliceosome binding. So the spliceosome's normal action (which involves the lariat) is prevented, leading to exon skipping.\\n\\nSo the structures involved in this therapy are:\\n\\n- Antisense (Morpholino) (D is involved)\\n- Splicing machinery (so lariat is part of that) (A is involved)\\n- The spliceosome (so its components are involved)\\n\\nWhat about R-loops? I don't think they're involved. R-loops form when RNA binds to DNA, leading to the displacement of the other DNA strand. Splicing doesn't involve R-loops. So R-loops are not involved in this therapy.\\n\\nThe polyA tail is part of the mRNA processing but comes after splicing. So the therapy's process doesn't involve the polyA tail. So the polyA tail is not part of the process.\\n\\nWait, but the question is, which structure is not involved. The options are A, B, C, D. The options are structures, I think.\\n\\nSo the structures involved in the therapy would include the lariat (A is involved), the antisense (D is involved), and the spliceosome (which leads to the lariat). The polyA tail is part of the mRNA but not part of the splicing mechanism, so the therapy doesn't involve the polyA tail. R-loops are not part of splicing, so they aren't involved in this therapy either.\\n\\nBut the question is, which structure is NOT involved. So the options are A, B, C\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ><think>\\nOkay, so I've got this question about gene therapy and splicing mechanisms. Hmm, let me try to break it down.\\n\\nThe question is about a gene with multiple exons, and the central ones code for triple helical repeats. These are important for the protein structure, connecting the cytoskeleton, sarcolemma, and extracellular space. Oh right, the central exons are crucial for the function of the protein.\\n\\nThe mutations they're talking about are central exon deletions, which cause out-of-frame peptides. That leads to a frameshift, right? So the protein is messed up, causing progressive degeneration. The solution presented is using a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the spliceosome from binding, leading to exon skipping and in-frame joining.\\n\\nWait, so when the spliceosome can't recognize the exon, the mRNA skips that exon. The result is that the mRNA is processed without that exon, so the reading frame is maintained, preventing a frameshift. That makes the protein in-frame and possibly functional again.\\n\\nThe question is asking which structure isn't involved in this therapy. The options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nSo let me think about the splicing process. Normally, the spliceosome recognizes exons and introns. It uses the 5' splice site and 3' splice site. The spliceosome binds the pre-mRNA, and as it does, it removes the introns by creating a lariat structure. So the lariat is definitely involved in splicing. So option A is involved.\\n\\nThe polyA tail is added to the mRNA during processing, right after the last exon. So when the mRNA is exported from the nucleus, it has the polyA tail. But in this therapy, the Morpholino is targeting the pre-mRNA's 5' end of the exon. I don't think the polyA tail is directly involved in the splicing process that's being blocked here. Unless the polyA tail is part of the pre-mRNA, but I'm pretty sure the polyA is added later. Hmm, but the question is about the therapy's structures. So I'm not sure yet.\\n\\nAntisense molecules are used in gene therapy to either block mRNA or guide the spliceosome. In antisense, the molecule binds to the mRNA, preventing the spliceosome from recognizing it. Oh wait, the Morpholino is an antisense molecule here. So antisense (option D) is involved.\\n\\nR-loops are structures where an RNA strand hybridizes with a DNA strand, displacing the other DNA strand. I'm not sure how that plays into this therapy. The therapy is about mRNA splicing, so I don't recall R-loops being part of the splicing mechanism. Or maybe they're part of other processes like DNA repair or RNA processing. Alternatively, maybe during splicing, some structures form, but I don't think R-loops are involved in the splicing process that the Morpholino is targeting. So perhaps R-loops are not involved here.\\n\\nWait, the question is which structure is NOT involved. So if R-loops aren't part of this therapy mechanism, then option C would be the correct answer.\\n\\nSo, let me recap:\\n\\nThe therapy uses an antisense Morpholino (so D is involved). The spliceosome binds pre-mRNA, which involves lariat formation (so A is involved). The polyA tail is part of mRNA processing but not directly involved in splicing. R-loops are not part of splicing. So the structure not involved is C) R-loops.\\n</think>\\n\\nThe question involves a gene therapy approach using a Morpholino to target the 5' end of an out-of-frame exon in pre-mRNA, preventing spliceosome binding and inducing exon skipping to restore a functional protein. The therapy relies on the spliceosome recognizing exons and introns, which typically involves the formation of a lariat structure during splicing. The polyA tail is added to the mRNA during processing but is not directly involved in the splicing mechanism or the Morpholino's function. Antisense molecules, such as the Morpholino, bind to the mRNA to block spliceosome recognition, making them directly involved in the therapy. R-loops, which involve RNA-DNA hybrids displacing the other DNA strand, are not part of the splicing process or the described therapy mechanism.\\n\\n- **Option A (lariat):** Involved in splicing as the intermediate formed when introns are removed.\\n- **Option B (polyA tail):** Part of mRNA processing but not directly involved in splicing or the therapy.\\n- **Option C (R-loops):** Not involved in the splicing process or the described therapy.\\n- **Option D (antisense):** Directly involved in the therapy as the Morpholino acts as an antisense molecule to block spliceosome binding.\\n\\nThe structure not involved in the proposed therapy is **R-loops**. \\n\\nAnswer: C<ï½œendâ–ofâ–sentenceï½œ>\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>\\nOkay, so I've got this genetics question in front of me, and I'm trying to wrap my head around it. Let me read it again to understand what's being asked.\\n\\nThe question is about a gene with multiple exons, and the central exons code for triple helical repeats that connect the cytoskeleton with the sarcolemma and extracellular space. So, these are structural proteins, I guess. Each exon usually codes for one of these triple helix repeats. \\n\\nThe common mutations here are central exon deletions, which result in out-of-frame peptides. These lead to progressive degenerative diseases because the resulting proteins are nonfunctional. So, the gene isn't expressed properly because the mRNA is missing some exons, leading to a truncated protein that doesn't work.\\n\\nThe solution presented is using a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. Morpholinos are those small molecules that can target specific RNA sequences. By preventing the spliceosome from binding, the Morpholino would cause the exon to be skipped. Skipping an exon means that the mRNA doesn't include that part, so the joining of the remaining exons is in-frame. Since the reading frame is preserved, the resulting protein is correctly folded and functional. And the question mentions that several missing exons are well tolerated, so this method seems effective.\\n\\nNow, the question asks which structure is not involved in the proposed therapy. The options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nHmm, okay. Let me think about the components involved in splicing and RNA processing.\\n\\nIn RNA splicing, the spliceosome is a complex of proteins and small nuclear RNAs (snRNAs) that recognize splice sites in the pre-mRNA. The spliceosome binds to the 5' splice site (donor) and the 3' splice site (acceptor). The process involves the removal of the intron and the joining of exons. So, during splicing, a lariat structure is formed. The branch site adenine forms a lariat when the intron is spliced out. So lariat is definitely involved in the splicing process. So option A is involved, so it's not the answer.\\n\\nThe pre-mRNA processing includes the addition of the poly(A) tail. The polyA tail is added by the poly-A polymerase, and it's part of the mRNA processing. So the polyA tail is involved. Option B is involved, so not the answer.\\n\\nNow, R-loops. R-loops are RNA:DNA hybrids with proteins, where the RNA is bound to DNA, and the RNA is not complementary. I'm trying to remember if R-loops are involved in splicing. I don't think so. R-loops are more associated with DNA methylation and gene silencing. They might form during transcription or when RNA is interacting with DNA, but they don't play a direct role in splicing. So perhaps option C is the correct answer as it's not involved in the therapy.\\n\\nAntisense molecules. Antisense is about RNA that has sequences complementary to the mRNA. For example, antisense oligonucleotides (ASOs) are used in gene therapy to target specific RNA or DNA. The Morpholino here is probably acting as an antisense molecule, binding to the pre-mRNA. So antisense is definitely involved. So option D is involved, so not the answer.\\n\\nWait, but what's the Morpholino? Morpholinos are a type of antisense oligonucleotide with a crown ether backbone. They are designed to recognize specific RNA sequences. So the Morpholino binds to the pre-mRNA, preventing the spliceosome from binding. So yes, the therapy uses an antisense molecule (Morpholino), which is option D. So D is involved.\\n\\nSo the structures involved are lariat (A), polyA tail (B), antisense (D). What's not involved? R-loops (C). So the answer is C.\\n</think>\\n\\nTo address the question, we need to determine which structure is not involved in the proposed therapy for the gene with central exon deletions. The therapy involves using a Morpholino, a small molecule antisense oligonucleotide, that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This prevents spliceosome binding, leading to exon skipping and in-frame joining of the remaining exons. The process involves maintaining the reading frame to produce a functional protein.\\n\\n### Analysis of Each Option:\\n1. **Lariat**: During RNA splicing, the spliceosome removes the intron, and a lariat structure is formed when the branch site adenine is incorporated into the RNA. This structure is directly involved in the splicing process. Therefore, **A is involved**.\\n\\n2. **PolyA tail**: The poly(A) tail is added to the pre-mRNA by the poly-A polymerase during mRNA processing. This tail is essential for proper mRNA stability and export from the nucleus. Thus, **B is involved**.\\n\\n3. **R-loops**: R-loops are RNA:DNA hybrids with proteins, typically associated with transcriptional pausing or DNA methylation. They are not directly involved in RNA splicing or the use of Morpholinos in this therapy. Therefore, **C is not involved**.\\n\\n4. **Antisense**: Morpholinos are antisense molecules that bind to specific RNA sequences to block spliceosome binding. Since the therapy relies on the Morpholino's antisense activity, **D is involved**.\\n\\n### Conclusion:\\nThe structures involved in the therapy are lariat, polyA tail, and antisense. R-loops are not part of this process. \\n\\n**Answer: C**<ï½œendâ–ofâ–sentenceï½œ>\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>\\nOkay, so I'm trying to tackle this question about gene therapy and exons. Hmm, let's see what the question is about.\\n\\nSo the question describes a gene with multiple exons, and the central ones code for triple helical repeats that connect the cytoskeleton with the sarcolemma and extracellular space. Each exon usually codes for one of these triple helixes. The common mutations are deletions of these central exons, leading to out-of-frame peptides and progressive degeneration. The solution involves using a Morpholino that targets the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the spliceosome from binding, causing exon skipping, which results in in-frame joining of the remaining exons. The question is asking which structure isn't involved in this therapy.\\n\\nThe options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nWait, so I need to figure out the components involved in the process described. Let me break it down.\\n\\nFirst, the spliceosome is involved in splicing pre-mRNA. The spliceosome recognizes splice sites, which are the GU and AG sites. When a splice site is recognized, the introns are removed, and exons are joined. In this case, the Morpholino is targeting the 5' end of an exon that's causing a frameshift mutation. So the Morpholino probably blocks the spliceosome's ability to recognize that particular site.\\n\\nWhen the spliceosome binds, it creates a lariat structure as part of the splicing mechanism. The intron is removed, and a looped structure (lariat) is formed. So option A) lariat is definitely involved. So the answer isn't A.\\n\\nThe polyA tail is part of mRNA processing. The polyadenylation process adds a polyA tail to the mRNA after splicing. But in this therapy, the Morpholino affects splicing. Once splicing occurs, the mRNA would have the polyA tail. So option B) polyA tail is involved in the normal processing but is part of the mRNA. However, the therapy's main action is on splicing, so the polyA tail might not be directly involved in the Morpholino's mechanism. Wait, but the spliceosome includes snRNPs, and the polyA binding proteins might influence splicing. Hmm, not sure. Maybe the polyA tail is part of the pre-mRNA during splicing? Or is it added later?\\n\\nWait, the pre-mRNA goes through splicing before polyadenylation. So during splicing, the introns are removed, and the pre-mRNA includes the polyA signal. So the spliceosome is involved in splicing the pre-mRNA, which includes the polyA signal. So the polyA tail is part of the pre-mRNA during splicing. So the polyA tail is involved in the process, but is it part of the therapy's mechanism? The Morpholino binds the pre-mRNA at the exon-exon junction. So the polyA tail is not directly targeted by the Morpholino. The therapy is preventing the spliceosome from binding at that specific exon's 5' end. So the polyA tail is part of the pre-mRNA but isn't directly involved in the Morpholino's action. Wait, but the question is about structures involved in the therapy. The therapy is using the Morpholino, which is binding the pre-mRNA. So the polyA tail isn't part of the binding site. So the polyA tail might not be involved in the therapy process itself, but is part of the overall gene expression. So whether the polyA tail is involved in the therapy's mechanism is a point to consider.\\n\\nOption C is R-loops. R-loops are structures where the RNA is hybridized with DNA, displacing the other DNA strand. I don't see how R-loops would be involved here. The Morpholino is an antisense oligo, right? Or is it a protein-targeting RNA? Wait, Morpholinos are a type of antisense oligonucleotides. They have a structure that can bind to specific RNA sequences. They are used in gene therapy to target specific mRNA sequences. So the Morpholino binds to the pre-mRNA at the 5' end of the exon, preventing the spliceosome from recognizing it. So R-loops are not part of this process. The therapy doesn't involve any RNA-DNA hybrids or R-loops. So option C) R-loops is probably not involved, making it the correct answer.\\n\\nOption D is antisense. The Morpholino is antisense because it's an antisense oligo. So antisense is definitely involved in the therapy. So the answer isn't D.\\n\\nSo the question is, which structure is not involved in the therapy. The options are lariat (A), polyA (B), R-loops (C), antisense (D).\\n\\nWait, the therapy's main action is preventing the spliceosome from binding. The spliceosome uses snRNPs, and the Morpholino blocks the recognition of the exon's 5' splice site. The lariat is part of the splicing mechanism, so A is involved. The polyA tail is part of the mRNA before it's processed, so it's involved in the pre-mRNA processing but not directly in the Morpholino's binding. So the therapy doesn't involve the polyA tail. Wait, but the pre-mRNA has a polyA signal, so the spliceosome recognizes that. But in this case, the Morpholino is preventing the spliceosome from binding, so the polyA tail is still part of the pre-mRNA. So the polyA tail is involved in the splicing process but not in the Morpholino's mechanism. So the question is about structures involved in the therapy, not the normal splicing process.\\n\\nWait, but the therapy's goal is to prevent the spliceosome from binding, which allows the exon to be skipped. So the spliceosome's activity is prevented. So the lariat structure (from splicing) is created when the spliceosome does its job. But if the spliceosome doesn't bind, the lariat isn't formed. So in this case, the lariat structure wouldn't be present. Hmm, but the question is about structures involved in the therapy. The therapy uses the Morpholino to prevent spliceosome binding, so the lariat wouldn't form. So lariat is involved because it's part of the normal splicing process, but in the therapy's case, it's prevented. So the therapy doesn't involve lariat formation because the spliceosome isn't binding. So the lariat structure is not part of this therapy's mechanism, but it is a normal part of splicing. So the question is about which structure isn't involved in the therapy.\\n\\nWait, the Morpholino binds the pre-mRNA. The spliceosome is a complex that recognizes splice sites. The Morpholino prevents the spliceosome from binding. So the spliceosome's activity is blocked. So, the normal process of splicing (including lariat formation) would not occur. But in the therapy, the spliceosome isn't binding, so no lariat is formed. So, the lariat isn't part of the therapy. Wait, but the options are about what is not involved. The question is, which structure is not involved.\\n\\nWait, the options are whether each structure is part of the therapy's process. The therapy involves Morpholino binding, preventing the spliceosome from binding, leading to exon skipping. So what structures are involved?\\n\\n- Morpholino binds the pre-mRNA, so it's an antisense (D), so D is involved.\\n\\n- The spliceosome is involved in splicing, so lariat (A) is involved.\\n\\n- The polyA tail is part of the pre-mRNA, but since the Morpholino is preventing splicing, the polyA tail's presence may not affect this. So the therapy doesn't involve polyA tail formation or use. Wait, but the polyA tail is part of the pre-mRNA that is being spliced. So the pre-mRNA has the polyA signal. So during splicing, the polyA binding proteins recognize the polyA signal. But in the therapy, the spliceosome isn't binding, so perhaps the polyA tail is still present. So the polyA tail is part of the pre-mRNA, but it's not directly involved in the Morpholino's mechanism. So the therapy doesn't require the polyA tail to be present. Wait, but the therapy's solution is about skipping an exon, which requires proper splicing. So the presence of the polyA tail is necessary for the mRNA to be properly processed. But the therapy's main action is to prevent splicing at that particular site. So the polyA tail is part of the normal splicing process but isn't directly involved in the Morpholino's action. So the therapy doesn't involve the polyA tail.\\n\\nWait, but the options are about which structure is not involved. So the question is, which structure isn't part of the therapy. So the therapy's process doesn't involve R-loops. Because R-loops are RNA-DNA hybrids, which are not part of the spliceosome or the Morpholino binding. So the answer would be C) R-loops.\\n\\nSo reviewing:\\n\\nStructures involved in the therapy:\\n\\n- antisense (Morpholino) â†’ D is involved.\\n\\n- spliceosome â†’ so lariat (A) is involved.\\n\\n- polyA tail is part of pre-mRNA, but its presence isn't directly involved in the Morpholino's action. So the therapy doesn't require the polyA tail. Or wait, in the normal process, the polyA tail is present, but in the therapy, the spliceosome isn't binding, so the polyA tail is\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>\\nOkay, so I've got this genetics question here, and I'm a bit confused, but I'll try to think it through. Let me read the question again.\\n\\nThe question is about a gene with many exons, and the central ones code for triple helical repeats. Each exon usually codes for one of these helices. The common mutations are central exon deletions that cause out-of-frame peptides, leading to degenerative diseases. The proposed therapy uses a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the spliceosome from binding, causing exon skipping, which results in an in-frame joining. Since missing exons are well tolerated, this therapy could work.\\n\\nThe question is asking which structure isn't involved in the proposed therapy. The options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nHmm. Let's break down the process. So, in splicing, the spliceosome recognizes exons and introns. Normally, the spliceosome uses a branch site to splice the pre-mRNA. The branch site has a certain structure, and when the spliceosome binds, it creates a lariat structure, right? So the first thing that comes to mind is that lariats are involved in splicing. So option A is involved, so it's not the answer.\\n\\nPolyA tail: Well, mRNA processing includes the addition of a polyA tail at the 3' end. The spliceosome might not be directly involved with the polyA tail, but the polyA signal is recognized by other proteins. The Morpholino is part of the therapy, which is a small molecule, perhaps acting as an antisense. Wait, the question says it's an antisense molecule. So antisense molecules can bind to mRNA, preventing the spliceosome from recognizing it.\\n\\nSo the therapy is using an antisense Morpholino. So the antisense (option D) is involved. So D is not the correct answer.\\n\\nWhat about R-loops? R-loops are structures formed when mRNA is hybridized with the DNA template, displacing the other DNA strand. They are involved in various processes like DNA repair, transcription, and RNA interference. I'm not sure if R-loops are part of the splicing process or not. I think in normal mRNA processing, R-loops aren't involved. So if the therapy doesn't involve R-loops, then option C is the correct answer.\\n\\nWait, but wait. The therapy involves the Morpholino binding to the 5' end of the exon. So the Morpholino is an antisense molecule that binds to the pre-mRNA. When it binds, it blocks the spliceosome from recognizing the exon. So the spliceosome can't process that exon, leading to its skipping. So the spliceosome's normal role is in recognizing the branch site and the exons, which is how splicing occurs. So in this case, the spliceosome is still involved, but the Morpholino prevents it from binding.\\n\\nSo the structures involved are the pre-mRNA, the spliceosome, the lariat (formed during splicing), and the antisense Morpholino. The polyA tail is part of the mRNA processing, but is it involved in the splicing process itself? I think the polyA tail is added after splicing. So during splicing, the polyA tail hasn't been added yet. So the polyA tail (option B) is part of the mRNA, but not part of the splicing machinery. Wait, but the pre-mRNA goes through splicing before the polyA tail is added. So the polyA tail is involved in the processing but not in the splicing mechanism itself.\\n\\nWait, but the therapy is targeting the pre-mRNA. So the Morpholino is binding to the pre-mRNA. So the polyA tail hasn't been added yet. So the polyA tail structure (option B) isn't directly involved in this therapy process. So perhaps option B is not involved.\\n\\nWait, but in the normal splicing process, the polyA tail is added after the mRNA has been spliced. So the splicing machinery (like the spliceosome) is involved in splicing, which occurs before the polyA tail is added. So the polyA tail is part of the mRNA, but it's not part of the splicing machinery. So in this therapy, the Morpholino binds the pre-mRNA, which hasn't had the polyA tail added. So the polyA tail (option B) isn't part of the process being treated here. So the question is, which structure is not involved in the therapy.\\n\\nThe therapy involves Morpholino (antisense, D) binding to pre-mRNA, causing exon skipping. So the spliceosome (involved in splicing, so lariat A is involved) is part of the normal splicing, but the therapy is interfering with that. So the structures involved are pre-mRNA, spliceosome, lariat, antisense (Morpholino), and perhaps the exon.\\n\\nThe question is, which of these options is not involved. So the options are A, B, C, D.\\n\\nThe polyA tail (B) is part of the mRNA but not directly involved in the splicing process that this therapy is targeting. So the therapy doesn't involve the polyA tail.\\n\\nWait, but wait. The pre-mRNA is being processed. The spliceosome binds to the pre-mRNA, which has the introns and exons. The spliceosome's role is to splice the exons, which forms a lariat. So the lariat is part of the normal splicing process, so A is involved. The Morpholino is the antisense molecule, so D is involved.\\n\\nThe polyA tail is added to the mRNA after the splicing process. So during splicing, the polyA tail hasn't been added yet. So in the therapy, since the Morpholino is acting on the pre-mRNA (which lacks the polyA tail), the polyA tail (B) isn't involved in the process. So the answer would be B.\\n\\nWait, but wait again. The question is which structure is not involved in the proposed therapy. The therapy uses the Morpholino to prevent the spliceosome from binding. So the structures involved in this therapy would be the pre-mRNA, the spliceosome, the antisense Morpholino, and the lariat (since lariat is formed when splicing occurs).\\n\\nThe polyA tail is part of the mRNA but isn't involved in the splicing process. So during splicing, the polyA tail isn't present. So the therapy doesn't involve the polyA tail. Therefore, option B (polyA tail) is not involved in the therapy.\\n\\nWait, but wait. The pre-mRNA has the introns and exons. The spliceosome binds to the pre-mRNA. So in the therapy, the Morpholino (an antisense) binds to the pre-mRNA, preventing the spliceosome from binding. So the spliceosome is involved. So structures involved are spliceosome, pre-mRNA, antisense (Morpholino), lariat.\\n\\nThe polyA tail is added after splicing, so it's not part of this process. So in the therapy, the polyA tail is not involved.\\n\\nWait, but the question is about the structures involved in the therapy. The therapy is using an antisense molecule (D) and the pre-mRNA. The spliceosome is involved in the splicing, so the lariat is formed (A). The polyA tail (B) is part of the mRNA but not part of the splicing process, so it's not involved in the therapy.\\n\\nSo the question asks which is not involved. So the correct answer would be B) polyA tail.\\n</think>\\n\\nThe question involves a therapy that uses a Morpholino, an antisense molecule, to block the spliceosome from binding to a pre-mRNA containing a central exon. This leads to exon skipping and in-frame joining of the remaining exons, which are well tolerated. The goal is to identify which structure is not involved in this therapy.\\n\\n### Analysis of the Options:\\n1. **Lariat (A):** During splicing, the spliceosome creates a lariat structure when an intron is removed. Since the therapy involves splicing (as exon skipping occurs due to Morpholino binding), the lariat is involved in the process. **Lariat is involved.**\\n\\n2. **PolyA tail (B):** The polyA tail is added to the 3' end of the mRNA after splicing. In this therapy, the Morpholino binds to the pre-mRNA, which has not yet undergone splicing or had its polyA tail added. Therefore, the polyA tail is not involved in the splicing process being targeted by the therapy. **PolyA tail is not involved.**\\n\\n3. **R-loops (C):** R-loops are RNA-DNA hybrids that form during processes like transcription and RNA interference. They are not part of the splicing mechanism or the therapy described here. **R-loops are not involved.**\\n\\n4. **Antisense (D):** The Morpholino is an antisense molecule that binds to the pre-mRNA to prevent spliceosome binding. Since the therapy relies on the antisense property of the Morpholino, it is directly involved. **Antisense is involved.**\\n\\n### Conclusion:\\nThe therapy involves the spliceosome, pre-mRNA, lariat, and antisense (Morpholino). The polyA tail, however, is not part of the splicing process or the therapy, as it is added after splicing. Therefore, the structure not involved in the therapy is the polyA tail.\\n\\n**Answer: B**<ï½œendâ–ofâ–sentenceï½œ>\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ><think>\\nOkay, so I've got this genetics question here, and I'm trying to wrap my head around it. Let's see what it's about. The question is about a gene with multiple exons, and certain mutations causing problems. The therapy involves Morpholinos and exons skipping. Hmm.\\n\\nWait, I remember that in RNA splicing, the spliceosome is involved. The spliceosome recognizes exons and introns, cutting out the introns and joining the exons. So the process involves several steps. The spliceosome uses a complex of snRNPsâ€”small nuclear ribonucleoproteins. Oh right, the snRNP includes U1, U2, etc.\\n\\nThe question says that the mutation is a central exon deletion causing an out-of-frame peptide. That leads to a disease, probably like some kind of inherited disorder. The solution is using Morpholinos that recognize the 5' end of the exon in pre-mRNA. So the Morpholino would bind there and prevent the spliceosome from binding. Because if the spliceosome can't bind, the exon gets skipped. Skipping an exon would mean the mRNA has fewer exons, possibly restoring the reading frame, making the protein in-frame again. Oh, and skipping several missing exons is okay for the organism.\\n\\nThe question is asking which structure isn't involved in this therapy. The options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nLet me think about each component.\\n\\nFirst, the therapy involves Morpholinos binding to the pre-mRNA. Morpholinos are antisense oligonucleotides, I think. So they are antisense, meaning they have sequences complementary to the mRNA. So the Morpholino would bind the 5' end of an exon, preventing the spliceosome from recognizing it. So the spliceosome can't bind, so the exon is skipped. So the spliceosome's normal function is to splice the mRNA, removing introns. Without binding, the exon is skipped.\\n\\nSo what structures are involved in the splicing process? The spliceosome is part of it. The spliceosome is made up of snRNPs (U1, U2, etc.), and during splicing, they help remove introns by recognizing splice sites. The process also involves the formation of a lariat structure when introns are spliced out. Because when the intron is removed, a loop structure (lariat) is formed with the polyA tail.\\n\\nWait, the lariat structureâ€”so when an intron is spliced, the branch site adenine forms a lariat structure, creating a loop with the 5' end of the intron. So the lariat is a part of the splicing process.\\n\\nThe polyA tail is added to the mRNA during processing. In the nucleus, mRNA is processed, and the polyA tail is a signal for export. So the polyA tail is part of the mRNA processing.\\n\\nR-loops are structures where the mRNA forms a stem-loop structure, hybridizing with the DNA, displacing the DNA. They're involved in some processes like DNA repair, but I'm not sure if they're part of splicing. Or maybe in the formation of the pre-mRNA? Hmm, not sure.\\n\\nSo the therapy involves Morpholinos binding to the pre-mRNA. The pre-mRNA is the unspliced, unprocessed RNA leaving the nucleus. So the spliceosome is involved in splicing. So the pre-mRNA would have introns and exons. Morpholino binds the 5' end of an exon, preventing the spliceosome from binding. So the spliceosome can't recognize the exon's splice sites, leading to skipping.\\n\\nSo during normal splicing, the spliceosome's U1 recognizes the 5' splice site, U2 the branch site, etc. Without the Morpholino binding, the spliceosome can't do its job, so the exon is skipped.\\n\\nNow, the options. The question is which structure is NOT involved.\\n\\nOption A: lariat. Well, lariat is part of splicing when an intron is removed. So if the spliceosome is active, it would form a lariat. But in this therapy, the spliceosome isn't binding because Morpholino blocks it. So maybe the lariat isn't formed. But the question is, is the lariat involved in the therapy's process? Or is it part of normal splicing that the therapy is interfering with?\\n\\nThe therapy is preventing the spliceosome from binding, so the lariat wouldn't form because the intron isn't being processed. But the question is about which structure is NOT involved in the therapy.\\n\\nWait, the therapy's mechanism is using Morpholinos to block the spliceosome. So the spliceosome is not functioning. Therefore, the lariat structure isn't formed because the intron isn't spliced. So the lariat wouldn't be present. But wait, the question is about which structure is not involved in the therapy's proposed process. So in the therapy, the spliceosome is prevented from binding, so the lariat wouldn't form.\\n\\nWait, but the question is about what is NOT involved in the therapy. So for the therapy, the process is: Morpholino binds pre-mRNA, prevents spliceosome from binding. So the spliceosome doesn't do its job, which is to splice the introns. So the spliceosome's components (like U1, U2) are not involved in this therapy. But wait, the spliceosome is a complex that's part of normal splicing. So in the therapy, the spliceosome isn't doing anything, but the question is about structures involved in the therapy's process.\\n\\nWait, the question is about which structure is not involved in the proposed therapy. So the therapy uses Morpholinos, which are antisense (D option). So D is involved. The lariat (A) would be part of the normal splicing, which is disrupted. But the therapy's process doesn't involve the lariat. So the lariat is not involved in the therapy. Because the therapy is about skipping the exon, which doesn't involve the lariat.\\n\\nWait, but the therapy is about preventing the spliceosome from binding. So the spliceosome's role is part of the normal process. So the spliceosome is involved in the therapy's process because it's what's being prevented from binding. So the lariat is part of normal splicing, but the therapy is about disrupting that.\\n\\nWait, the question is, which structure is not involved in the therapy. So the therapy uses Morpholinos, which are antisense (D is involved). The pre-mRNA is involvedâ€”so the polyA tail (B) is part of mRNA processing, so it's involved. The spliceosome's part in splicing is part of the normal process, so in the therapy, spliceosome's components are involved. The lariat is a product of splicing, so it's not involved in the therapy, because the therapy is about blocking the spliceosome from binding, not about the lariat.\\n\\nWait, but the lariat is formed when the intron is spliced out. If the spliceosome isn't binding, the intron isn't being processed, so the lariat isn't formed. So the lariat is not part of the therapy's process.\\n\\nSo the options are A, B, C, D.\\n\\nThe structures involved in the therapy: Morpholino (D, antisense) is used. The spliceosome's components (part of splicing) are involved. The polyA tail (B) is part of the mRNA processingâ€”so that's involved. What about R-loops (C)? R-loops are RNA:DNA hybrids, so they are structures formed during processes like DNA repair or transcription. Are they involved in splicing? I don't think so. I don't recall R-loops being part of the spliceosome machinery or the splicing process. So R-loops are not involved in the therapy.\\n\\nWait, but the question is about which structure is not involved in the proposed therapy. The therapy's process doesn't involve R-loops.\\n\\nSo the options are:\\n\\nA) lariat - not involved in therapy (since the spliceosome isn't active, lariat isn't formed)\\n\\nB) polyA tail - involved, as the mRNA needs to be processed.\\n\\nC) R-loops - not involved.\\n\\nD) antisense - involved (Morpholinos are antisense)\\n\\nWait, but the question asks which is NOT involved.\\n\\nSo the structures involved in the therapy are D (Morpholino, antisense), B (polyA tail), and spliceosome components (so perhaps A and C are not involved? Wait, no. Wait, the lariat is a product of splicing, so the process of splicing (in which lariats are formed) isn't part of the therapy. The therapy's process is preventing splicing, so the lariat isn't formed. So A is not involved.\\n\\nWait, but the question is about the structures involved in the therapy. So the therapy is using Morpholinos, which are antisense (D is involved). The pre-mRNA is part of the process, so the polyA tail (B) is involved. The spliceosome is part of the process, so the spliceosome's components (like snRNP) are involved. What about the lariat? No, because the lariat is a byproduct of splicing, which isn't happening in this therapy.\\n\\nSo in the therapy, structures involved are B (polyA), D (antisense), and spliceosome components (which are part of the process). The structures not involved are A (lariat) and C (R-loops).\\n\\nWait, but the question is which structure is not involved in the therapy. So the answer is either A or C.\\n\\nWait, the therapy is about blocking the spliceosome.\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ><think>\\nOkay, so I've got this question about gene therapy and splicing mechanisms. Hmm, let me try to think through it. I'm a bit rusty on my molecular biology, but I'll try to piece it together.\\n\\nThe question describes a gene with multiple exons, and the central ones have triple helical repeats. The exons usually code for alpha helices that connect the cytoskeleton with the sarcolemma and extracellular matrix. So, these are probably structural repeats important for cell function.\\n\\nThe main issue is mutations that cause central exon deletions, leading to out-of-frame peptides and progressive degeneration. The therapy involves delivering a Morpholino that targets the 5' end of an out-of-frame exon in pre-mRNA. This Morpholino prevents the spliceosome from binding, causing exon skipping. And since several missing exons are tolerable, the therapy uses this approach.\\n\\nThe question is asking which structure isn't involved in the proposed therapy. The options are lariat, polyA tail, R-loops, or antisense.\\n\\nLet me think about the spliceosome process. The spliceosome is responsible for removing introns from pre-mRNA. It recognizes splice sites, which are the GU at the beginning and AG at the end of introns. The spliceosome uses the 5' splice site (donor) and 3' splice site (acceptor). During splicing, the intron is cut out, and the exons are joined. The spliceosome also recognizes the exons by their 5' and 3' splice sites.\\n\\nThe Morpholino binds to the 5' end of the exon. So, it's probably targeting the 5' splice site of the exon. Wait, no, because the 5' end of the exon is actually the 5' end of the pre-mRNA. Wait, no, the splice sites are within the introns. Wait, no, the 5' splice site is at the beginning of the intron, so the exon is upstream of that.\\n\\nSo the Morpholino is targeting the pre-mRNA's 5' end of an exon. But wait, the spliceosome's 5' splice site is before the exon. So perhaps the Morpholino is blocking the spliceosome's access to that site.\\n\\nBut what structures are involved in the splicing process? The spliceosome is a complex of snRNPs (small nuclear ribonucleoproteins). The snRNPs have specific functions. Also, the process of splicing involves the formation of a lariat structure when an intron is removed. The intron is spliced out, and the two exons are joined, but the intron's branch site forms a lariat structure.\\n\\nSo the lariat is definitely involved. The pre-mRNA is spliced, and during this process, a lariat is formed. So option A is involved.\\n\\nThe polyA tail is the poly-A addition that occurs at the 3' end of the mRNA. This is part of mRNA processing but not directly involved in splicing. Wait, the question is about the therapy affecting splicing. So the polyA tail's presence (option B) wouldn't be directly involved in the splicing mechanism. But wait, the pre-mRNA has a polyA tail. During splicing, the 3' end is processed, so maybe the polyA tail is still present. Or perhaps the Morpholino is delivering something that affects splicing, but the polyA tail itself isn't part of the splicing machinery.\\n\\nBut the question is about which structure is not involved in the proposed therapy. The therapy involves blocking the spliceosome's binding at the 5' end of the exon. So the spliceosome's components would be involved.\\n\\nWait, the therapy is delivering a Morpholino that prevents the spliceosome from binding. So the spliceosome's snRNP components are involved. So the option that's not involved would be something else.\\n\\nWhat about antisense molecules? Antisense can bind to mRNA to block translation or to cause degradation. In this case, the Morpholino is an antisense molecule, I think. Antisense oligonucleotides (ASOs) are used to target specific sequences. So the ASO is an antisense molecule that binds to the pre-mRNA, preventing the spliceosome from binding. So the antisense (ASO) would be involved in the therapy. So option D is involved.\\n\\nR-loops are RNA-DNA hybrids with the displaced DNA strand. I'm not sure how relevant R-loops are here. They are more related to DNA replication and transcription issues. In this therapy, the Morpholino is targeting pre-mRNA, which is transcribed from DNA. The splicing process involves the RNA splicing machinery, but R-loops are not directly involved in splicing. So R-loops (option C) might not be involved in the therapy.\\n\\nWait, but I'm not 100% certain. Let me recap: the therapy uses a Morpholino as an antisense molecule to block the 5' end of the exon in pre-mRNA. The spliceosome uses the 5' splice site (GU) to recognize the exon. So the Morpholino is binding to the pre-mRNA at the exon's 5' end, preventing the spliceosome from binding. When the spliceosome can't bind, it skips the exon. So the spliceosome's machinery is involved, which includes snRNPs, the lariat formation, etc.\\n\\nSo the structures involved are the lariat (A), spliceosome components (so snRNP, which are part of the process but not listed as an option), polyA tail (B), and antisense (D). So the question is which is NOT involved.\\n\\nWait, the polyA tail is part of the mRNA processing but not directly part of the splicing machinery. So the therapy doesn't involve the polyA tail. Or does the pre-mRNA have a polyA tail before splicing? Because pre-mRNA does have a polyA tail. So when the spliceosome acts, the polyA tail remains. So the polyA tail (B) is present in the pre-mRNA but isn't part of the splicing process.\\n\\nWait, but the question is about structures involved in the therapy. The therapy's mechanism is to block the spliceosome. So the polyA tail isn't part of the splicing mechanism, but the pre-mRNA does have it. So the polyA tail (B) is not involved in the splicing process. But the question is about the structures not involved in the therapy's process.\\n\\nAlternatively, the therapy is targeting the pre-mRNA's 5' exon. So the spliceosome's recognition of the 5' splice site is at the start of the intron. If the Morpholino is preventing the spliceosome from binding, the spliceosome's components (like snRNP) are involved. So the structures involved are the lariat (formed when introns are spliced), the spliceosome (which includes snRNP, which has snRpk components that recognize the splice sites), and the antisense Morpholino.\\n\\nWhat about the polyA tail? The polyA tail is added to the mRNA after splicing. So during splicing, the polyA tail is still present. The spliceosome doesn't process the polyA tail. So the polyA tail isn't part of the splicing mechanism. So if the therapy is blocking splicing, the polyA tail (B) isn't involved in the splicing process itself, but is present in the pre-mRNA. So the question is which structure is not involved in the therapy. The therapy involves the lariat (when splicing occurs), the spliceosome, and the antisense Morpholino.\\n\\nSo the structures not involved would be the polyA tail (B) and perhaps R-loops (C). Wait, which one is correct?\\n\\nWait, R-loops are RNA:DNA hybrids with the displaced DNA. They form during transcription and can cause issues like genome instability. But in the context of splicing, I don't think R-loops are directly involved. The splicing process doesn't involve R-loops; it's more about the spliceosome recognizing the intron's splice sites.\\n\\nSo in the therapy, the Morpholino binds to the pre-mRNA at the exon's 5' end, preventing the spliceosome from binding. The spliceosome would have already processed the pre-mRNA, but the Morpholino's binding prevents the spliceosome from recognizing the exon. So the spliceosome's components (like snRNP) are involved.\\n\\nSo the structures involved are:\\n\\n- lariat (A) â€” formed when introns are spliced out.\\n\\n- spliceosome components (part of the process, but not an option)\\n\\n- antisense (as the Morpholino is antisense)\\n\\n- polyA tail (B) â€” not involved, as it's part of pre-mRNA but not part of the splicing mechanism.\\n\\nR-loops (C) â€” not involved in splicing.\\n\\nSo the question is which structure is not involved. The question asks which is NOT involved in the proposed therapy.\\n\\nSo the therapy involves:\\n\\n- Morpholino (antibody or antisense, D is involved)\\n\\n- lariat (A is involved)\\n\\n- spliceosome (so snRNPs are involved but not listed as an option)\\n\\n- polyA tail (B is part of pre-mRNA but not involved in splicing, so is it involved in the therapy?)\\n\\nWait, the therapy uses the pre-mRNA. The pre-mRNA includes the polyA tail. But when the spliceosome processes the pre-mRNA, it doesn't affect the polyA tail. The polyA tail remains attached. So the therapy is about splicing, which doesn't involve the polyA tail. So polyA tail (option B) is not involved\", '<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>\\nOkay, so I\\'m trying to tackle this biology question here. Let\\'s see what it\\'s about. Hmm, it\\'s about gene structure and some kind of therapy using Morpholinos. I remember that Morpholinos are a type of antisense oligonucleotide, right? They\\'re used in gene therapy to target specific RNA or DNA sequences.\\n\\nThe question says that there\\'s a large gene with dozens of exons. The central exons code for triple helical repeats that connect the cytoskeleton with the sarcolemma and extracellular space. So these are structural parts, maybe part of a muscle or something, since sarcolemma is part of muscle cells. Each exon usually codes for one triple helix. But the common mutation is the deletion of central exons, leading to out-of-frame peptides and progressive degeneration. Oh right, when exons are deleted, the reading frame shifts, so the resulting protein is messed up, causing the disease.\\n\\nThe solution is to deliver a Morpholino that recognizes the 5\\' end of the out-of-frame exon in pre-mRNA. So the Morpholino would bind to the mRNA, right? When it does, it prevents the spliceosome from binding. Because normally, the spliceosome recognizes the 5\\' splice site of the exon and the 3\\' splice site of the next exon. If the Morpholino binds the 5\\' end, maybe it blocks the spliceosome from recognizing it. So the spliceosome can\\'t include that exon, leading to exon skipping. Skipping an exon that\\'s usually causing the frame shift would allow the rest of the mRNA to be joined in a way that doesn\\'t cause a frameshift. So the protein produced would be in-frame, meaning the reading frame hasn\\'t shifted, so the protein is correctly made, barring any issues with the rest of the gene.\\n\\nThe question asks which structure is NOT involved in this therapy. The options are lariat, polyA tail, R-loops, antisense.\\n\\nLet me think about each option. Morpholinos are antisense, so option D is involved. The therapy uses Morpholino, which is an antisense oligo.\\n\\nThe spliceosome is involved in splicing. When it binds, it creates a lariat structure as part of the splicing mechanism. So lariat formation (option A) is involved because the spliceosome creates a lariat when splicing. So option A is involved.\\n\\nThe polyA tail is part of mRNA processing. The pre-mRNA is processed, and the polyA tail is added at the 3\\' end. But in this therapy, are they modifying the polyA tail? I don\\'t think so. The Morpholino is targeting the pre-mRNA\\'s 5\\' end of the exon, so the polyA tail\\'s probably not involved in this particular step. Unless the therapy involves modifying the mRNA, but the question doesn\\'t say that. So polyA tail (option B) might not be involved.\\n\\nR-loops are RNA:DNA hybrids that form when RNA binds to DNA and then the DNA unwinds, displacing the other strand. I\\'m not sure how R-loops are involved in splicing or Morpholino therapy. Maybe not directly involved here. So option C could be the correct answer.\\n\\nWait, the question says which structure is NOT involved. So the structures in the options that are part of the process.\\n\\nLet me recap: The therapy involves Morpholino (antisense) binding to pre-mRNA. The spliceosome is inhibited from binding, causing exon skipping. The spliceosome\\'s process creates a lariat (so A is involved). The polyA tail is part of the pre-mRNA, but the Morpholino targets the exon\\'s 5\\' end, so the polyA tail\\'s presence doesn\\'t directly affect the splicing process here. Or does it? Maybe in some way, but I don\\'t think the polyA tail is involved in the splicing mechanism that the Morpholino is targeting.\\n\\nWait, the spliceosome\\'s function is to recognize splice sites and cut the introns, and the lariat is formed during splicing. So during the splicing process, the polyA tail is already present. The polyA tail is more about mRNA stability and export from the nucleus. So the therapy doesn\\'t involve anything to do with the polyA tail. So the polyA tail is not involved in this therapy.\\n\\nSo the structures involved would be the lariat (A) and antisense (D). The spliceosome\\'s components are involved, but the question isn\\'t giving options about spliceosomes. The options are about structures, so the polyA tail (B) isn\\'t involved. So the answer would be B) polyA tail.\\n\\nAlternatively, R-loops are about RNA-DNA interactions. Since the Morpholino is an antisense (RNA), maybe it could form an R-loop with the DNA? I\\'m not sure. But in this case, the Morpholino is delivered to pre-mRNA, which is in the nucleus. The pre-mRNA is processed in the nucleus, but the R-loops are more about the interaction between RNA and DNA during transcription. If the Morpholino is binding to the pre-mRNA, which is in the nucleus, and the pre-mRNA is being processed, maybe the R-loop concept isn\\'t directly involved here. Or perhaps, when the Morpholino binds, it\\'s creating a structure that\\'s similar to an R-loop. But I\\'m not sure. Maybe R-loops are more about the formation of RNA-DNA hybrids, which the Morpholino is an RNA, so it\\'s possible, but I\\'m not certain.\\n\\nWait, the question asks which structure is not involved. So if R-loops are not part of the process, then option C would be the answer. But I\\'m a bit confused about that.\\n\\nAlternatively, thinking about antisense. Antisense oligonucleotides are used to bind to specific RNA sequences. So the Morpholino is antisense, so D is involved.\\n\\nThe lariat is part of the splicing mechanism, so A is involved.\\n\\nThe polyA tail is part of the pre-mRNA, but in this therapy, the process is about splicing. So the presence of the polyA tail doesn\\'t directly interfere with splicing. So the therapy doesn\\'t involve the polyA tail. So option B is not involved.\\n\\nWait, but pre-mRNA has a polyA tail. The Morpholino is targeting the exon\\'s 5\\' end. When the spliceosome binds, it\\'s looking at the 5\\' splice site. But the Morpholino is blocking the spliceosome\\'s recognition. So the polyA tail is on the mRNA, but the spliceosome is part of the processing. The polyA tail is more about the end processing of mRNA, perhaps in the 3\\' end processing. The polyA binding proteins (PABP) recognize the tail. But in this therapy, the Morpholino is blocking the spliceosome\\'s action. So the polyA tail is part of the pre-mRNA, but the therapy doesn\\'t involve modifying or affecting the polyA tail. So the polyA tail isn\\'t part of the process here.\\n\\nSo the structures involved are antisense (Morpholino), lariat (splicing), and the spliceosome. The structures not involved are polyA tail and R-loops.\\n\\nWait, but the options are which is not involved. So the question is, which of the four is not involved.\\n\\nThe options are:\\n\\nA) lariat â€” involved in splicing.\\n\\nB) polyA tail â€” is part of the pre-mRNA, but the therapy doesn\\'t involve polyA tail modification. So not involved.\\n\\nC) R-loops â€” not sure, but maybe not involved.\\n\\nD) antisense â€” yes, Morpholino is antisense.\\n\\nSo the structures not involved are B and C. The question is, which is not involved.\\n\\nWait, the question is which structure is not involved in the proposed therapy. So the options are structures that are part of the process.\\n\\nSo in this therapy, the Morpholino is antisense (so D is involved), the spliceosome creates a lariat (A is involved), and the polyA tail is part of the pre-mRNA but not directly involved in the splicing process here. R-loops â€” I\\'m not sure.\\n\\nWait, the spliceosome is involved in splicing, which involves the lariat. The polyA tail is processed after splicing. So in the therapy, the process is about splicing, which includes the lariat. So the polyA tail is part of the pre-mRNA but is not directly involved in the splicing mechanism that the therapy is targeting.\\n\\nSo the structures not involved would be polyA tail (B) and perhaps R-loops (C).\\n\\nBut the question is which one is not involved. So the options are four, and the answer is one.\\n\\nWait, the question says \"which structure is not involved in the proposed therapy?\" So the structures in the options are:\\n\\nA) lariat â€” involved (part of splicing)\\nB) polyA tail â€” part of mRNA processing, but not part of the splicing mechanism. So in this therapy, is the polyA tail involved? The therapy is about splicing. So the polyA tail is not part of the therapy\\'s process.\\n\\nSo the answer would be B.\\n\\nAlternatively, considering R-loops: R-loops are RNA-DNA hybrids. Since the therapy involves binding to pre-mRNA, which is DNA, but in the nucleus. The Morpholino is an RNA that binds to the pre-mRNA. So, would the RNA bind to the DNA (pre-mRNA) without displacing anything else? Or perhaps, does the RNA form an R-loop with the DNA? Not sure. I think R-loops are more about the transcription process, not splicing. So maybe R-loops are not involved here.\\n\\n', \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ><think>\\nOkay, so I've got this question here about gene therapy and alternative splicing. Hmm, let's try to think this through. I'm a bit rusty on my genetics, but I'll try to remember what I learned.\\n\\nThe question describes a gene with multiple exons, and the central ones have triple helical repeats that connect the cytoskeleton with the sarcolemma and extracellular space. Oh wait, that's probably a protein with a structure that helps it fold properly, maybe like a channel or something. But the main point is about mutations and the therapy solution.\\n\\nThe mutations are central exon deletions that cause out-of-frame peptides. Oh right, when an exon is missing, the reading frame shifts, leading to a completely different amino acid sequence from that point onward. This is called a frameshift mutation. Because of this, the protein might not function correctly, leading to degenerative issues.\\n\\nThe therapy uses a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. Morpholinos are antisense oligonucleotides, right? They bind to specific RNA sequences. So when the Morpholino binds, it prevents the spliceosome from recognizing the exon. Since the spliceosome usually splices out exons, if it doesn't bind, the exon is skipped. So the mRNA would join the previous exon to the next one, which would be in frame, thus restoring the reading frame. That's called exon skipping and in-frame joining.\\n\\nThe question asks which structure is not involved in this therapy. The options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nLet me break down the process. The spliceosome is involved in splicing pre-mRNA. So during splicing, the introns are removed. The spliceosome binds to the 5' splice site and the 3' splice site, and the intron is spliced out. The process involves the formation of a lariat structure when an intron is removed. So option A (lariat) is definitely involved. Because when the spliceosome acts, it creates a lariat-shaped structure as it processes the intron.\\n\\nThe polyA tail is part of mRNA processing. After splicing, the mRNA undergoes capping and polyadenylation. The polyA tail is added to the 3' end of the mRNA. So the therapy's morpholino is about splicing, which occurs before the addition of the polyA tail. So option B (polyA tail) is involved in the overall mRNA processing but not directly in the splicing step where the Morpholino is acting. Wait, but the therapy's process affects the mRNA before it's processed for the polyA tail. So the polyA tail is part of the overall mRNA structure, but not directly involved in the exon skipping event triggered by the Morpholino.\\n\\nNow, option C is R-loops. R-loops are structures formed when RNA binds to DNA, displacing the other DNA strand. They can cause genomic instability. But in this therapy, the Morpholino is an antisense oligo that binds RNA. So R-loops aren't directly involved here. The Morpholino is acting on the pre-mRNA, so R-loops wouldn't be part of this process.\\n\\nOption D is antisense. The Morpholino is an antisense molecule, as it's an antisense oligonucleotide. So it's definitely involved in the therapy. The Morpholino binds to the pre-mRNA, preventing the spliceosome from recognizing the exon.\\n\\nSo the structures involved in this therapy are spliceosome (which makes the lariat) and antisense (the Morpholino). The polyA tail is part of the mRNA processing after splicing, so it's involved in the overall process but not in the splicing event itself. The R-loops aren't involved.\\n\\nThe question asks which structure is NOT involved. So looking at the options, the structures involved in the process are lariat (A), polyA tail (B), antisense (D). R-loops (C) are not involved.\\n\\nSo the answer is C) R-loops.\\n</think>\\n\\nThe question involves a gene with multiple exons, where central exons code for triple helical repeats. Mutations causing central exon deletions result in out-of-frame peptides, leading to degenerative issues. The therapy proposed uses a Morpholino, an antisense oligonucleotide, to bind the 5' end of the out-of-frame exon in pre-mRNA. This prevents spliceosome binding, leading to exon skipping and in-frame joining of adjacent exons, which helps restore the reading frame.\\n\\nTo determine which structure is not involved in this therapy, let's analyze the options:\\n\\n- **A) Lariat**: During splicing, the spliceosome removes introns and forms a lariat structure. Since the therapy involves splicing, lariats are directly involved.\\n\\n- **B) PolyA tail**: The polyA tail is added to the 3' end of the mRNA during post-splicing processing. While it is part of mRNA maturation, it is not directly involved in the splicing event or the Morpholino's action.\\n\\n- **C) R-loops**: R-loops are RNA-DNA hybrids that can cause genomic instability. However, the therapy involves antisense binding to RNA, not DNA, so R-loops are not involved.\\n\\n- **D) Antisense**: The Morpholino is an antisense oligonucleotide that binds to the pre-mRNA to prevent spliceosome recognition of the exon. Antisense molecules are directly involved in the therapy.\\n\\nThe structures directly involved in the therapy are lariats, polyA tails, and antisense molecules. R-loops are not involved in this process. \\n\\nANSWER: C<ï½œendâ–ofâ–sentenceï½œ>\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ><think>\\nOkay, so I've got this biology question in front of me, and I'm a bit confused, but I'll try to think it through. Let's read the question again.\\n\\nThe question is about a gene with multiple exons, and the central ones code for triple helical repeats that help connect the cytoskeleton with the sarcolemma and the extracellular space. Oh right, those are parts of cellsâ€”cytoskeleton is like the structural framework, sarcolemma is the cell membrane, and extracellular space is the environment outside the cell.\\n\\nEach exon usually codes for one of these triple helix structures. So the gene has multiple exons, and the central ones are important for these structural functions. Now, the common mutations are central exon deletions, which cause out-of-frame peptides. An out-of-frame means the reading frame shifts, so the resulting protein is probably nonfunctional and leads to issues like progressive degeneration. So like, if an exon is missing, the mRNA skips it, and the rest of the exons might be joined incorrectly, leading to a messed-up protein.\\n\\nThe solution presented is delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. Morpholinos are a type of antisense oligonucleotide, I think. They bind to specific RNA sequences. So this Morpholino would bind to the 5' end of the exon's mRNA. When it binds, it prevents the spliceosome from recognizing that exon. Because the spliceosome uses the 5' splice site and the exons' 3' splice sites to splice the mRNA. If the Morpholino blocks that, the spliceosome can't process that exon. So the result is exon skippingâ€”so the mRNA skips that exon, and the exons after are joined in a way that doesn't include the skipped one. This leads to an in-frame joining, meaning the reading frame is maintained, so the resulting protein is still functional.\\n\\nThe question then asks which structure is not involved in the proposed therapy. The options are lariat, polyA tail, R-loops, antisense.\\n\\nHmm. Let's think about each option.\\n\\nThe therapy involves delivering a Morpholino which is antisense. So antisense is one of the options (option D). So that's involved.\\n\\nNow, the process is about splicing. The spliceosome is involved in splicing. The spliceosome recognizes the 5' and 3' splice sites. The 5' end of the pre-mRNA is where the splice sites are. So the Morpholino would bind to the pre-mRNA's 5' end of an exon, preventing the spliceosome from recognizing it. So during splicing, when the spliceosome comes along, it can't bind because the Morpholino is blocking. So the exon is skipped.\\n\\nBut how does this process work? The spliceosome binds to the pre-mRNA, and then the exons are joined. So during splicing, the polyadenylation occursâ€”adding the polyA tail. That's part of mRNA processing. The polyA tail is usually added to the 3' end of the mRNA. So the pre-mRNA has a polyA tail, and that's part of the process. So option B is polyA tail, which is involved in the splicing process. So the polyA tail is involved.\\n\\nOption A is lariat. I remember that during splicing, the introns are removed, and a lariat structure is formed when an intron is spliced out. The intron's branch site has a 2' OH group, and the spliceosome creates a lariat structure as it removes the intron. So the lariat is part of splicing, so it's involved. So option A is involved.\\n\\nOption C is R-loops. R-loops are three-stranded structures where the RNA is hybridized to DNA, displacing the other DNA strand. They're more commonly associated with gene silencing, like in some RNA interference mechanisms or in the formation of RNA-induced DNA methylation. I don't think R-loops are part of the splicing process. The Morpholino binds to the pre-mRNA, which is being processed by the spliceosome. R-loops are more about DNA and RNA interactions that can cause genome instability, but I don't see a direct role here. So perhaps R-loops are not involved in this therapy.\\n\\nSo the structures involved would be lariat (A), polyA tail (B), antisense (D), and spliceosome (which I don't see as an option). The options given are A, B, C, D. The question is which is not involved.\\n\\nSo the therapy uses Morpholino, which is antisense (D). It binds the pre-mRNA, preventing splicing. Splicing involves the spliceosome, which uses the 5' splice site and the exons' 3' sites. So the spliceosome is involved in splicing, which uses the polyA tail (B), and the process removes the intron, creating a lariat (A). So all except C (R-loops) are involved.\\n\\nSo the correct answer would be C) R-loops.\\n</think>\\n\\nThe question involves a gene with multiple exons, where central exons code for structural proteins. Mutations in these exons can lead to out-of-frame peptides, causing degenerative diseases. The proposed therapy uses a Morpholino, an antisense oligonucleotide, to bind the 5' end of an out-of-frame exon in pre-mRNA. This prevents the spliceosome from recognizing the exon, leading to its skipping and in-frame joining of surrounding exons, which is tolerable.\\n\\nTo determine which structure is not involved in this therapy:\\n\\n- **Option A (Lariat):** During splicing, the intron is removed, forming a lariat structure at the branch site. This is a key part of the splicing process and is therefore involved in the therapy.\\n\\n- **Option B (PolyA tail):** The polyA tail is added to the 3' end of the pre-mRNA during mRNA processing. It is essential for proper splicing and is involved in the therapy.\\n\\n- **Option C (R-loops):** R-loops are three-stranded structures involving RNA-DNA hybrids, typically associated with gene silencing or genome instability. There is no direct involvement of R-loops in the splicing process or the use of Morpholino in this therapy.\\n\\n- **Option D (Antisense):** Morpholino is an antisense molecule that binds to the pre-mRNA to block splicing. Antisense molecules are central to the therapy.\\n\\nThe therapy involves splicing, which requires the spliceosome, polyA tail, and lariat formation. R-loops are not part of this process. \\n\\nANSWER: C<ï½œendâ–ofâ–sentenceï½œ>\", '<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ><think>\\nOkay, so I have this question about a gene therapy scenario. Let me read it carefully and think through what I know.\\n\\nAlright, the question is about a gene with multiple exons, and the central ones code for triple helical repeats that connect the cytoskeleton with the sarcolemma and extracellular space. So these exons probably help the protein structure or function. Each exon codes for one triple helix, which I remember is a common feature in many proteins, especially those that need structural repeats.\\n\\nThe most common mutations are central exon deletions, leading to out-of-frame peptides. Oh right, when an exon is deleted, the reading frame shifts, leading to a truncated protein. This usually causes a frameshift mutation, which can lead to a nonfunctional protein or a disease because the rest of the amino acids are all wrong.\\n\\nThe solution proposed is using a Morpholino that recognizes the 5\\' end of the out-of-frame exon in pre-mRNA. Morpholinos are antisense oligonucleotides, I think. They bind to specific RNA sequences to guide a particular protein to the site. In this case, the Morpholino binds to the pre-mRNA at the 5\\' end of the exon that\\'s causing the problem.\\n\\nWhen this Morpholino binds, it prevents the spliceosome from recognizing the exon. Wait, how does the spliceosome normally work? The spliceosome recognizes exons and introns. So when the Morpholino is bound, it would block the spliceosome from splicing that exon. This leads to exon skippingâ€”so the exon is effectively removed, and the mRNA continues without it. The result is that the mRNA joins the previous exon and the next exon in a way that the reading frame is maintained, hence the protein remains in-frame.\\n\\nThe question says that several missing exons are well tolerated, which makes sense because sometimes skipping an exon is okay for the protein\\'s structure.\\n\\nThe question is asking which structure is NOT involved in this therapy. The options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nHmm. Let\\'s think about what each component does.\\n\\nOption A: Lariat. I remember that when the spliceosome processes the pre-mRNA, it removes introns by a mechanism that involves the formation of a lariat structure. The intron is spliced out, and a small RNA (lariat) is formed as part of this process. So the lariat is definitely involved in splicing. But in this therapy, the spliceosome isn\\'t doing the splicing because the Morpholino is blocking it. So the lariat wouldn\\'t be formed. Wait, but the question is about which structure is not involved in the therapy. So if the therapy is using Morpholino to prevent splicing, then the lariat structure (from the normal splicing process) wouldn\\'t be part of this. Or wait, noâ€”because the Morpholino is preventing the spliceosome from binding, but the actual splicing machinery isn\\'t acting. So the lariat would not be formed because the intron is skipped. But wait, the question is about the structures involved in the therapy. The therapy uses the Morpholino, which is an antisense molecule. So which structures are part of the therapy process.\\n\\nOption B: PolyA tail. The polyA tail is added to the mRNA during processing in the nucleus and is important for stability and export to the cytoplasm. The pre-mRNA has this tail, and the mRNA without it might be unstable. But in splicing, the polyA tail isn\\'t directly involved. However, the spliceosome interacts with the polyA binding proteins, but I\\'m not sure. Alternatively, the presence of the polyA tail might influence splicing. Wait, the polyadenylation occurs before splicing. The polyA tail is recognized by proteins that help in splicing. So maybe the polyA tail is involved in the splicing process. But in this therapy, since the spliceosome is being inhibited, the presence of the polyA tail might not directly affect the therapy. But the question is about the structures involved in the therapy. The therapy\\'s Morpholino binds the pre-mRNA, so maybe the polyA tail isn\\'t directly involved in the therapy\\'s mechanism. Or perhaps it\\'s part of the normal processing.\\n\\nOption C: R-loops. R-loops are structures formed when RNA binds to DNA, displacing the other DNA strand. They\\'re associated with RNA interference and some genomic issues. I don\\'t think R-loops are involved in splicing or in the use of antisense oligonucleotides for therapy. The Morpholino is an RNA molecule (or maybe DNA?) that\\'s antisense. Wait, Morpholinos are typically RNA, but some are DNA-based. But in any case, R-loops are more about DNA and RNA interactions, not directly part of splicing or antisense binding. So R-loops aren\\'t part of this therapy.\\n\\nOption D: Antisense. The Morpholino is an antisense molecule. So antisense is definitely involved. The molecule is antisense, guiding the therapy.\\n\\nSo the question is which structure is NOT involved. Let\\'s think about each structure\\'s role in the therapy.\\n\\nThe therapy involves delivering an antisense molecule (Morpholino) to a specific exon. The Morpholino binds to the pre-mRNA at the 5\\' end of the exon, preventing the spliceosome from recognizing it. So the spliceosome can\\'t process that exon, leading to its skipping.\\n\\nWhat structures are involved in this process?\\n\\n- Pre-mRNA: Definitely involved, as the Morpholino binds to it.\\n- Spliceosome: It\\'s inhibited, so it\\'s part of the normal process but not active here.\\n- The introns and exons are part of the pre-mRNA.\\n- The lariat structure is formed when the spliceosome splices the intron. But in this therapy, the intron is being skipped. So the lariat structure (a small RNA formed during splicing) wouldn\\'t be present because the intron isn\\'t being removed. But the therapy doesn\\'t directly involve the lariat, it\\'s a byproduct of splicing. So the lariat isn\\'t part of the therapy mechanism.\\n\\nWait, but the question is about which structure is NOT involved. The options are about what is involved. Or wait, the options are structures, which are not involved in the therapy.\\n\\nAlternatively, the options are structures that are involved in the process, and the question is which is not involved.\\n\\nWait, the question says, \"Which structure below is not involved in the proposed therapy?\" So, which of the structures is not part of the therapy.\\n\\nOption A: lariat. The therapy involves Morpholino binding, which prevents the spliceosome from processing the exon. The spliceosome would normally form a lariat when splicing, but in this case, the exon is skipped. So the lariat wouldn\\'t be formed. So is the lariat involved in the therapy? No, because the therapy is bypassing the normal splicing mechanism. So the lariat structure wouldn\\'t be present. Therefore, the lariat is not involved in the therapy.\\n\\nOption B: polyA tail. The polyA tail is part of mRNA processing, but not directly involved in splicing. The polyA binding proteins are involved in splicing, but I\\'m not sure. The therapy doesn\\'t involve the polyA tail. So the polyA tail is not involved in the therapy.\\n\\nOption C: R-loops. Not involved. The therapy uses antisense, which is RNA, but R-loops are DNA-RNA structures. Not part of this.\\n\\nOption D: antisense. The Morpholino is antisense, so antisense is involved.\\n\\nSo the structures not involved would be A (lariat), B (polyA), C (R-loops), and the involved is D.\\n\\nThe question is which is NOT involved. So looking at the options:\\n\\nA) lariat: Not involved. Because the therapy skips the exon, the lariat isn\\'t formed.\\n\\nB) polyA tail: Not directly involved in the therapy. The therapy\\'s mechanism doesn\\'t depend on the polyA tail.\\n\\nC) R-loops: Not involved.\\n\\nD) antisense: Definitely involved.\\n\\nWait, but the question is which is not involved. So which of these four is not part of the process.\\n\\nWait, let\\'s think about the therapy. The Morpholino is an antisense molecule that binds to the pre-mRNA. The pre-mRNA has the polyA tail, but the polyA binding proteins are involved in the splicing process. But in this therapy, the spliceosome is blocked, so the presence of polyA tail might not be directly involved.\\n\\nBut the question is about structures, not about molecules. Let me think again.\\n\\nIn the therapy, the Morpholino binds to the pre-mRNA (so the pre-mRNA is involved). The spliceosome is inhibited, so the intron is skipped (exon is removed). The spliceosome normally forms a lariat structure when splicing, but if the exon is skipped, the lariat wouldn\\'t form. So the lariat structure is not part of the therapy process.\\n\\nSo which option is not involved? The question is about which structure is not involved.\\n\\nSo the structures involved in the therapy: pre-mRNA, spliceosome (inhibited), antisense Morpholino.\\n\\nThe structures not involved: polyA tail, lariat, R-loops.\\n\\nBut the question is asking which is not involved in the proposed therapy.\\n\\nWait, the question is a bit ambiguous. The structures listed are not part of the process. So the options are structures that are part of the process, except for one.\\n\\nSo the options are A to D. The correct answer is the structure that\\'s not part of the therapy.\\n\\nLooking at each:\\n\\nA) lariat: Is', \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ><think>\\nOkay, so I've got this question here about gene therapy using Morpholinos. Hmm, I'm a bit rusty on this, but let's try to think it through.\\n\\nAlright, the question describes a large gene with many exons, and the central ones code for triple helical repeats. Oh wait, I remember that these repeats are important for the structure of proteins, like in the cytoskeleton or something. Each exon usually codes for one of these repeats.\\n\\nThe mutations they're talking about are central exon deletions, which cause out-of-frame peptides. That means the reading frame is shifted, leading to a messed-up protein. And these mutations cause progressive degenerative organ waste, which sounds like a disease, maybe something like muscular dystrophy? Because those repeats are in the cytoskeleton, which is involved in movement, so that makes sense.\\n\\nThe solution is using a Morpholino. I think Morpholinos are small molecules that act as antisense oligonucleotides. They bind to specific RNA sequences. In this case, the Morpholino targets the 5' end of an out-of-frame exon in pre-mRNA.\\n\\nHow does this work? Well, the spliceosome is responsible for splicing pre-mRNA. If the Morpholino binds the 5' end of the exon, it probably prevents the spliceosome from recognizing it. So the spliceosome might skip that exon. Skipping an exon would lead to the remaining exons being joined in a way that doesn't include the deleted part. Since the exon was out-of-frame, skipping it would result in an in-frame reading frame, so the resulting protein is okay.\\n\\nThe question says that several missing exons are well-tolerated. So skipping one or more exons is not a problem for the organism.\\n\\nThe options given are structures involved in the therapy. The question is asking which one is NOT involved.\\n\\nThe options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nLet me think about each structure.\\n\\nMorpholinos are antisense molecules, so D) antisense is definitely involved.\\n\\nWhat about the spliceosome? It uses lariat structures when splicing. The spliceosome snatches an intron, creates a lariat-shaped structure as it splices. So when the spliceosome acts, it makes a lariat. Therefore, the lariat (A) is involved.\\n\\nPolyA tail: I'm a bit confused. The polyA tail is added during mRNA processing, typically at the end of the gene. The spliceosome is involved in removing introns, and the polyA tail is part of the mRNA processing. So when the pre-mRNA is spliced, the polyA tail is still attached. But in this therapy, if the spliceosome is inhibited, maybe the polyA tail is still there. But does the presence of the polyA tail affect the Morpholino binding? I'm not sure. Alternatively, maybe the Morpholino doesn't interact with the polyA tail. So perhaps the polyA tail (option B) is involved in the normal splicing process but not directly in the Morpholino mechanism. Wait, but in the therapy, the spliceosome is prevented from binding because of the Morpholino. So the spliceosome's function is hindered, leading to exon skipping. The spliceosome's role includes recognizing the splice sites, which are often associated with the polyA tail. Hmm, but the polyA tail is more about the 3' end. Maybe the polyA tail isn't directly involved in the Morpholino mechanism. Or does the Morpholino affect the splicing machinery, which in turn affects the polyA tail?\\n\\nWait, I'm getting a bit stuck. Let's think about each process. The pre-mRNA goes through splicing. The spliceosome uses the 5' and 3' splice sites. The polyA tail is added to the 3' end after splicing. So the presence of the polyA tail is part of the mRNA processing. The Morpholino targets the 5' end of the exon. So perhaps the polyA tail is present, but it's not directly involved in the Morpholino's mechanism.\\n\\nAlternatively, the Morpholino binds to the pre-mRNA, which includes the polyA tail. But I'm not sure if the polyA tail is directly involved in the binding. The spliceosome might recognize the splice sites, which are on the pre-mRNA. So maybe the polyA tail is part of the mRNA that is being processed, but the Morpholino's binding doesn't directly involve the polyA tail.\\n\\nWait, but the question is about what is NOT involved in the proposed therapy. The therapy is using a Morpholino that targets the 5' end of an exon in pre-mRNA. The Morpholino prevents the spliceosome from binding, leading to exon skipping. So the key structures involved would be the spliceosome, the pre-mRNA, the exon, and the Morpholino (antisense).\\n\\nSo which of the options are not involved?\\n\\nOption C: R-loops. R-loops are structures formed by RNA:DNA hybrids and DNA. They can form during processes like transcription and can cause genomic instability. I'm not sure if R-loops are involved in splicing. I recall that R-loops are more about DNA and RNA interactions in the nucleus, maybe during processes like gene silencing or when there's DNA damage. They aren't part of the splicing mechanism as far as I know. So R-loops (option C) are probably not involved in this therapy.\\n\\nSo the question is which option is not involved. The options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nThe therapy involves antisense (D) and the spliceosome (which produces lariat A). So the structures involved are A, B? Wait, polyA tail is part of the mRNA processing. The spliceosome is involved, and the pre-mRNA has the polyA tail. So the process of splicing includes the polyA tail. So B) polyA tail is involved.\\n\\nWait, but the question is about structures involved in the therapy, not necessarily the normal process. So the therapy uses Morpholino, which is an antisense. It binds to the pre-mRNA, which includes the polyA tail. So the polyA tail is present but perhaps not directly involved in the Morpholino's mechanism. Because the Morpholino targets the exon's 5' end, which is before the polyA tail. So maybe the polyA tail (B) is not involved in the Morpholino's mechanism.\\n\\nWait, but the process of splicing does involve the polyA tail. The spliceosome uses splice sites that are upstream of the polyA tail. So when the spliceosome is inhibited, the mRNA processing still includes the polyA tail. So B) polyA tail is part of the process but not directly involved in the Morpholino binding.\\n\\nWait, but the question is about what is not involved in the proposed therapy. The therapy uses the Morpholino to bind the pre-mRNA. The pre-mRNA has the polyA tail. So the polyA tail is part of the molecule, but is it directly involved in the binding? Or is the Morpholino binding to the exon, which is before the polyA tail. So perhaps the polyA tail isn't directly involved in the Morpholino's action. So in the therapy, the polyA tail (B) is not directly involved in the Morpholino's mechanism.\\n\\nAlternatively, the polyA tail is part of the mRNA processing, but the therapy's main action is about splicing, so the spliceosome is the key structure, which uses the polyA tail. Hmm, I'm getting a bit tangled here.\\n\\nWait, the question is about which structure is NOT involved in the proposed therapy. So what's involved?\\n\\n- Antisense (Morpholino) is involved (D). So D is involved.\\n\\n- The spliceosome is involved in splicing, which the Morpholino affects. So the spliceosome is involved. The lariat (A) is produced by the spliceosome, so A is involved.\\n\\n- The polyA tail is part of the mRNA but is not directly involved in the splicing process's structure. Wait, the spliceosome uses splice sites which are within the pre-mRNA, not the polyA tail. So the presence of the polyA tail doesn't directly interfere with the Morpholino's function. So the therapy does not involve the polyA tail as a part of the mechanism. So B) polyA tail is not involved.\\n\\nAlternatively, the polyA tail is part of the pre-mRNA that's being processed, but the Morpholino binds to the exon, which is upstream of the polyA tail. So the polyA tail is part of the mRNA but not directly involved in the Morpholino's function. So B) polyA tail is not involved in the therapy.\\n\\nWait, but the options are about what is not involved. So the question is, which one is not involved in the therapy process.\\n\\nSo the structures involved in the therapy are: pre-mRNA, spliceosome (with lariat), Morpholino (antisense). The polyA tail is part of the pre-mRNA, but isn't directly part of the mechanism. So the therapy doesn't involve R-loops (C), which are a separate structure.\\n\\nWait, but the question is which is NOT involved. So the structures involved are lariat (A), polyA tail (B), antisense (D). R-loops (C) are not involved.\\n\\nWait, but wait. The process of splicing does involve the splice sites, which are on the pre-mRNA. The pre-mRNA includes the exons, introns, and polyA tail. The spliceosome binds the\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ><think>\\nOkay, so I've got this biology question here about gene therapy using Morpholinos. Hmm, I'm a bit rusty on this, but let me try to think it through. \\n\\nThe question describes a gene with multiple exons. The central exons code for triple helical repeats that connect the cytoskeleton with the sarcolemma and extracellular space. Oh wait, I remember that these repeats are often involved in protein structure, maybe like part of the channel or something in the cell membrane. \\n\\nThe mutations mentioned are central exon deletions that cause out-of-frame peptides. Oh right, when an exon is deleted, if it's missing a few nucleotides, the reading frame shifts. So the mRNA gets cut off, leading to a truncated protein. If the shift isn't a multiple of three, the protein is messed up, which is bad for the organism. So that's why the treatment is needed.\\n\\nThe therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. Morpholinos are those synthetic molecules that act as small interfering RNA (siRNA) analogs but are usually made from modified amino acids. They bind to specific RNA sequences to block the spliceosome. So in this case, the Morpholino would target the pre-mRNA's 5' end of the exon. \\n\\nWhen the Morpholino binds, it prevents the spliceosome from recognizing that exon. Since the spliceosome normally splices out exons, if it can't bind, the spliceosome won't include that exon. So the mRNA would skip that exon and join the previous exon to the next one. Skipping an exon that's in the middle would result in a single exon being skipped, which could restore the reading frame because the shift would be in multiples of three again.\\n\\nThe question is about which structure isn't involved in this therapy. The options are lariat, polyA tail, R-loops, antisense.\\n\\nLet me think about each option:\\n\\nA) Lariat: I know that when the spliceosome splices introns, it creates a lariat structure. The intron is removed, and a lariat is formed with the branch site adenine. But in this therapy, the spliceosome isn't binding because Morpholino is preventing it. So the spliceosome's usual activity (like making lariats) wouldn't occur. So the lariat structure wouldn't be involved here. But wait, does the therapy prevent the lariat from forming? Or does it affect other parts?\\n\\nWait, no. The Morpholino is preventing the spliceosome from recognizing the exon. So the spliceosome would proceed to splice normally except for that exon. So the lariat would form as usual, right? Because the spliceosome is still active elsewhere. So lariat is part of the normal process and would still happen. So A) lariat is involved, so it's not the answer.\\n\\nB) PolyA tail: The polyA tail is added during mRNA processing. The polyA binding proteins (PABP) recognize the tail. The spliceosome is involved in splicing, but I'm not sure how the polyA tail ties into this. The therapy doesn't directly affect the addition of the polyA tail. So the presence of the polyA tail isn't part of the therapy's mechanism. Wait, but in the question, the therapy is about pre-mRNA, which is the RNA before the polyA addition. So the therapy affects the splicing of the pre-mRNA, which doesn't include the polyA tail. So the polyA tail's structure isn't involved in the therapy's mechanism. So B) polyA tail might be the correct answer. Or maybe not.\\n\\nWait, the question is about what structure is NOT involved. So if the therapy involves the spliceosome (which does involve lariats) and Morpholino binding, but the polyA tail is a part of mRNA processing that occurs after splicing. So the therapy doesn't involve the polyA tail, so the polyA tail is not part of the process. So B) polyA is the structure not involved. So the answer could be B.\\n\\nC) R-loops: R-loops are structures where the RNA is hybridized with DNA, displacing the other DNA strand. I don't think R-loops are directly involved in splicing or the use of Morpholinos. The therapy here is about blocking spliceosome binding, so R-loops probably aren't part of this. But I'm not too sure. Maybe the spliceosome doesn't interact with R-loops in this context.\\n\\nD) Antisense: The Morpholino is an antisense molecule, I think. Antisense means it's complementary to a specific RNA sequence. So the Morpholino is antisense to the exon's 5' end. So antisense is definitely involved. So D) is involved, not the answer.\\n\\nSo looking back, the options are: which structure is NOT involved.\\n\\nThe therapy involves the spliceosome (which forms lariats), Morpholino binding (antisense), and exons being skipped. So structures involved are spliceosome, lariat, antisense. \\n\\nThe options given are A) lariat, B) polyA, C) R-loops, D) antisense.\\n\\nSo the structures involved are A, D. B and C are not involved. So the question is which is not involved.\\n\\nWait, the therapy uses pre-mRNA. So during splicing, the spliceosome processes the pre-mRNA. The polyA tail is added later, after splicing. So the therapy doesn't involve the polyA tail. So B) polyA tail is not involved. So the correct answer is B.\\n\\nWait, but the question is about what's not involved in the proposed therapy. So the structures that are involved are spliceosome (which makes lariats), the Morpholino (antisense), and the spliceosome's action. So the lariat is a product of the spliceosome's activity, so it's involved.\\n\\nThe polyA tail is added later, so it's not part of the therapy's mechanism. So the structure not involved is polyA tail. So the answer is B.\\n</think>\\n\\nThe question involves a gene therapy approach using Morpholinos to prevent exon skipping by blocking the spliceosome at the 5' end of an out-of-frame exon in pre-mRNA. This therapy aims to restore the reading frame by skipping the defective exon, which otherwise causes truncated, nonfunctional proteins due to frameshift mutations. The question asks which structure is not involved in this proposed therapy.\\n\\n### Analysis of Each Option:\\n1. **Lariat**: Lariat structures are formed during splicing when the intron is removed, and the branch site adenine forms a loop. While the spliceosome is involved in the therapy, lariats are a normal part of splicing and are not directly affected by the Morpholino. Therefore, lariats are involved in the therapy.\\n\\n2. **PolyA tail**: The polyA tail is added to mRNA during post-transcriptional processing by polyA binding proteins. However, the therapy targets pre-mRNA, which does not yet have a polyA tail. The polyA tail is unrelated to the splicing process or the Morpholino's mechanism, making it the structure not involved in the therapy.\\n\\n3. **R-loops**: R-loops are RNA-DNA hybrids that can form during transcription or RNA interference. There is no evidence that R-loops are part of the splicing process or the Morpholino-based therapy. Thus, R-loops are not involved.\\n\\n4. **Antisense**: Morpholinos are antisense molecules that bind to complementary RNA sequences to block spliceosome binding. Since the Morpholino is specifically designed to target the 5' end of the exon, antisense is directly involved in the therapy.\\n\\n### Conclusion:\\nThe structures involved in the therapy are lariats (from splicing) and antisense (from the Morpholino). The polyA tail and R-loops are not part of the splicing process or the therapy's mechanism. Among the options, the polyA tail is explicitly unrelated to the therapy.\\n\\n**Answer: B**<ï½œendâ–ofâ–sentenceï½œ>\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ><think>\\nOkay, so I've got this multiple-choice question about gene therapy and splicing. Hmm, let me try to figure this out. I'm a bit rusty on my genetics, but I'll think it through.\\n\\nAlright, the question is about a gene with multiple exons, and the central ones code for triple helical repeats. These help connect the cytoskeleton with the sarcolemma and the extracellular space. So, when exons are deleted, especially central ones, it causes out-of-frame peptides, leading to degenerative disease. The solution is delivering a Morpholino that targets the 5' end of the out-of-frame exon in pre-mRNA. This prevents the spliceosome from binding, leading to exon skipping and in-frame joining. The idea is that skipping exons that cause frame shifts can help the organism tolerate the mutation.\\n\\nThe question asks which structure isn't involved in this therapy. The options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nLet me think about the process. Splicing involves the spliceosome recognizing the splice sites, which are the GU at the donor and AG at the acceptor. The spliceosome uses a lariat structure when it splices the mRNA. So during splicing, a lariat is formed when the intron is removed. So the lariat is involved in the normal splicing process. But in this therapy, the Morpholino is preventing the spliceosome from binding. So the spliceosome can't recognize the exon's end, so the exon is skipped. So the lariat might not be formed in this case because the splicing is being disrupted. But wait, the lariat is part of the splicing mechanism, so if the splicing is blocked, the lariat structure is probably not formed. But does that mean the lariat is involved in the therapy? Or is it a structure that's part of the normal process and not part of the therapy's mechanism?\\n\\nWait, the therapy is using a Morpholino, which is an antisense oligo. Antisense molecules can block splice sites. So the Morpholino binds to the pre-mRNA at the 5' end of the exon, preventing the spliceosome from recognizing the GU site. So the spliceosome can't proceed normally, so the exon is skipped. Therefore, the splicing machinery is involved. But what about the structures.\\n\\nThe normal splicing process includes the formation of a lariat when an intron is spliced. So the lariat is part of the process. So option A (lariat) is involved. So the question is, which structure is not involved.\\n\\nOption B is the polyA tail. The polyA tail is part of mRNA processing, which occurs after splicing. The polyadenylation step adds the polyA tail, which is crucial for mRNA stability and export from the nucleus. But how does that tie into the splicing process and the therapy?\\n\\nIn the therapy, the Morpholino is targeting the 5' end of an exon. The splicing machinery includes the spliceosome, which recognizes the splice sites. The polyA tail is added later, so perhaps the therapy doesn't directly involve the polyA tail. Unless the Morpholino affects the polyA binding proteins, but the question doesn't mention that. So maybe the polyA tail isn't involved in this particular therapy.\\n\\nOption C is R-loops. R-loops are structures formed when RNA binds to DNA, displacing the other DNA strand. They're more of a DNA-RNA hybrid structure, like in some RNA interference processes or during transcription. I don't think R-loops are directly involved in splicing or the Morpholino's mechanism. So maybe C isn't involved.\\n\\nOption D is antisense. The Morpholino is an antisense molecule. Antisense means it's complementary to a specific RNA sequence, but in this case, the Morpholino is an RNA antisense to the pre-mRNA's 5' end of the exon. So yes, antisense is definitely involved because the Morpholino is an antisense oligo that binds to the mRNA.\\n\\nSo the structures involved would be the splice sites (involved in splicing), the lariat (formed when splicing occurs), and antisense (the Morpholino). The polyA tail is part of the mRNA but not directly involved in splicing or in this therapy's mechanism.\\n\\nWait, but the question is which structure is NOT involved. So which of these isn't part of the process.\\n\\nIn normal splicing, the lariat is formed. The spliceosome's role is to connect exons, and this includes recognizing the GU and AG sites. The Morpholino blocks the spliceosome's binding, leading to exon skipping. So the lariat is still a part of the normal process, but in this therapy, the splicing doesn't happen as usual. So the lariat would be present in normal cases but not when splicing is blocked by the Morpholino.\\n\\nWait, but in the therapy, the spliceosome isn't binding, so the lariat may not form. But the question is about structures involved in the therapy, not necessarily the normal process.\\n\\nSo the structures involved in the therapy's mechanism: splice sites, spliceosome, lariat (maybe not?), antisense (Morpholino), and possibly others. Wait, the Morpholino is an RNA molecule, so antisense (option D) is involved.\\n\\nThe polyA tail (option B) is added after splicing, but the therapy doesn't involve modifying the polyA tail. So the polyA tail is not involved in this therapy. Hence, option B is the structure not involved.\\n\\nAlternatively, could the polyA binding proteins be involved in the process? Because mRNA with polyA tail is more stable and exported. But the therapy doesn't seem to involve polyA tail modifications. The Morpholino binds pre-mRNA, which is still being processed. So the polyA tail is added after splicing. So the therapy doesn't touch that. So the polyA tail (B) is not involved.\\n\\nSo the question is, which of these is not involved. The options are:\\n\\nA) lariat - is part of the normal splicing, but in this case, if splicing is prevented, maybe lariat isn't formed. But the structure itself (lariat) exists when splicing occurs. So the therapy doesn't involve lariat; or is the lariat still part of the process? Hmm. Maybe the lariat is still formed, but the spliceosome isn't using it. Or perhaps the Morpholino's binding interferes with the lariat formation.\\n\\nWait, but the lariat is the RNA structure formed when the intron is removed. If the splicing is blocked, the intron isn't removed, so the lariat isn't formed. So in this therapy, the lariat isn't involved. So the lariat (A) would not be present. So the question is which structure is not involved in the therapy's mechanism.\\n\\nWait, the question is about which structure is not involved in the proposed therapy. The therapy uses a Morpholino that targets the 5' end of the exon. So the structures involved in the therapy would be the pre-mRNA, the splice sites, the spliceosome, antisense (Morpholino), and the lariat if it's formed. But the lariat is only formed when the spliceosome acts, which it doesn't in this case. So if the lariat isn't formed, is it not involved in the therapy? Or is the lariat part of the normal process, and the therapy doesn't involve lariat?\\n\\nAlternatively, the lariat is part of the normal process, but the therapy disrupts the splicing, so the lariat isn't formed. So in the therapy, the lariat isn't a part of the process. So the lariat structure is not involved in the therapy.\\n\\nWait, but the options are asking which is not involved. So if the lariat is not part of the therapy's mechanism, then A) lariat is the answer.\\n\\nAlternatively, if the therapy uses a structure that is not part of the process. So which of these structures are not involved.\\n\\nAnother approach: Let's think about each option.\\n\\nOption A: lariat. In normal splicing, a lariat is formed. In this therapy, the spliceosome can't act, so the lariat isn't formed. But the structure exists when splicing occurs. The therapy is about preventing the lariat from being formed. So lariat is involved in the normal process but not in the therapy.\\n\\nWait, but the question is about which structure is not involved in the therapy. So, lariat is involved in normal splicing, but the therapy uses a mechanism that prevents lariat formation. So the structure lariat is not part of the therapy. Or is it? Because the therapy's goal is to create exon skipping, which would involve a different splicing pathway. Wait, exon skipping is a different splicing mechanism. So in exon skipping, the spliceosome skips the exon. So perhaps the lariat is formed in a different way or not at all.\\n\\nHmm, I'm getting a bit confused. Maybe I should think about the process. The Morpholino binds to the pre-mRNA at the 5' end of the exon, preventing the spliceosome from binding. The spliceosome recognizes the GU at the donor site and AG at the acceptor site. If the spliceosome can't bind, the exon is skipped, and the intron is retained. So the intron retention would lead to a longer mRNA.\\n\\nIn this case, the lariat wouldn't form because the intron isn't spliced out. So the lariat structure is not formed in this case. So lariat (A) is a structure that's not involved in the therapy's process, as it's\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ><think>\\nOkay, so I've got this question about gene therapy and splicing. Hmm, let's try to break it down. I'm a bit rusty on my genetics, but let's think it through.\\n\\nThe question says there's a large gene with many exons. The central ones code for triple helical repeats, which help connect the cytoskeleton with the sarcolemma and extracellular space. Wait, that sounds familiar. Oh right, those are typically the exons that code for alpha helices, like in muscle proteins. Like, for example, the dystrophin gene, which is involved in muscular dystrophy. So if the central exons are deleted, the proteins aren't made correctly, leading to degeneration. That makes sense.\\n\\nThe mutations are central exon deletions, creating out-of-frame peptides. Oh, right, that's a frameshift mutation. Without the exons, the reading frame changes, so the resulting protein is messed up. That leads to a degenerative disease, probably something like muscular dystrophy.\\n\\nNow, the solution is using a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. Morpholinos are synthetic antisense oligonucleotides, right? They bind to specific RNA sequences. So in this case, the Morpholino would bind to the pre-mRNA at the 5' end of the exon that's been deleted.\\n\\nBy binding, the Morpholino prevents the spliceosome from recognizing the exon. Oh wait, how does the spliceosome work? The spliceosome recognizes exons via their 5' and 3' splice sites. If the Morpholino blocks the 5' end, the spliceosome can't bind. So the exon is skipped, and the mRNA now has the next exon in sequence.\\n\\nExon skipping usually leads to an in-frame reading frame because the number of nucleotides between the skipped exons is adjusted. So, if you skip an exon that's out of frame, the next exons start in a frame that's in line with the original reading frame. So the resulting protein is correctly folded, and the organism can tolerate it because it's not missing a bunch of exons. So the therapy is about skipping the problematic exon to prevent a frameshift.\\n\\nThe question is about which structure isn't involved in the proposed therapy. The options are lariat, polyA tail, R-loops, or antisense.\\n\\nLet me think about each option.\\n\\nOption A: lariat. I remember that during splicing, introns are removed, and the process involves a lariat structure. The spliceosome creates a lariat-shaped RNA when an intron is spliced out. So the lariat is definitely involved in splicing. So this structure is involved, so it's not the correct answer.\\n\\nOption B: polyA tail. The polyA tail is part of mRNA processing. The polyA signal is recognized by the 3' splice site. Without the polyA tail, the mRNA might not be processed correctly. But in this therapy, are they modifying the mRNA before or after splicing? The Morpholino is targeting pre-mRNA, which is before the polyA tail is added. So the polyA tail is part of the normal mRNA processing. Since the therapy is about preventing splicing (by Morpholino binding), the polyA tail is still part of the pre-mRNA. Wait, but does the polyA tail affect splicing? I think the spliceosome binds the 5' and 3' splice sites, which are in the pre-mRNA. The polyA tail is added after splicing. So the presence of the polyA tail (once added) doesn't affect the splicing process. But wait, the pre-mRNA doesn't have the polyA tail yet. So the therapy is done before polyA addition. So polyA tail itself isn't involved in the therapy process; the therapy is about binding the pre-mRNA, which doesn't have the polyA yet. So B could be the answer.\\n\\nOption C: R-loops. R-loops are RNA-DNA hybrids with proteins, often forming during transcription when RNA is incorrectly paired with DNA. I don't think R-loops are involved in splicing. Splicing happens in the nucleus, and the Morpholino is an antisense molecule that would bind to pre-mRNA. R-loops are more about transcription issues, like in some diseases, but in this therapy, the Morpholino is preventing splicing, not affecting transcription. So R-loops might not be involved here. So C could be the answer.\\n\\nOption D: antisense. Oh, the Morpholino is an antisense oligonucleotide. It binds to the pre-mRNA, preventing the spliceosome from binding. So antisense is definitely involved. So D is not the correct answer.\\n\\nThe question asks which structure is NOT involved. So looking at the options, B and C are possibilities. Let's think again.\\n\\nPolyA tail is part of the mRNA processing. The pre-mRNA is being modified by the spliceosome. The Morpholino binds to the pre-mRNA. So polyA tail is added after splicing. Therefore, the polyA tail isn't directly involved in the therapy mechanism. So the therapy doesn't involve the polyA tail.\\n\\nWait, but does the therapy involve the polyA signal? I don't think so. The therapy is about preventing splicing at the exon level. The polyA tail is part of the overall mRNA processing but not directly involved in the splicing machinery that the Morpholino is interacting with.\\n\\nSo the structures involved are lariat (A) and antisense (D). R-loops (C) are probably not involved. The polyA tail (B) is part of the pre-mRNA processing but not part of the splicing machinery. So the question is which is not involved. So the structures involved in the therapy are lariat (because during splicing, a lariat is formed), antisense (Morpholino is antisense), and R-loops? Wait, no, R-loops aren't part of this. The spliceosome's mechanism doesn't form R-loops. So which is not involved?\\n\\nThe question asks which structure is not involved. So the options are about structures in the process. The therapy is about blocking splicing via an antisense molecule. So the structures involved are:\\n\\n- pre-mRNA (with the Morpholino binding)\\n- splice sites (5' and 3')\\n- spliceosome\\n- lariat (formed when intron is spliced out)\\n- polyA tail (added later, not involved in the blocking)\\n\\nSo the therapy doesn't involve the polyA tail. So the structure not involved is B) polyA tail.\\n\\nWait, but the pre-mRNA has the splice sites. The polyA tail is added after splicing. So the therapy doesn't involve the polyA tail. So the answer is B) polyA tail. Or is the polyA tail involved in another way?\\n\\nWait, the pre-mRNA is being processed. The Morpholino is targeting the pre-mRNA, so the pre-mRNA has the polyA signal as well, but the polyA tail isn't part of the splicing process. So the polyA tail isn't involved in the therapy mechanism. So the question is, which structure is not involved in the therapy.\\n\\nLooking again, the options are:\\n\\nA) lariat â€“ yes, because during splicing, a lariat is formed.\\n\\nB) polyA tail â€“ not involved in the splicing process, so not involved in the therapy.\\n\\nC) R-loops â€“ probably not involved in splicing, so not involved in the therapy.\\n\\nD) antisense â€“ yes, Morpholino is antisense.\\n\\nSo the structures not involved are B and C. The question is which one is not involved.\\n\\nWait, the question says which structure is not involved. So the answer would be either B or C.\\n\\nBut I'm trying to think: do R-loops play any role in splicing? I think R-loops are more about transcription errors or RNA interference. For example, in some cases, R-loops can form when the RNA binds back to DNA, leading to chromatin remodeling. But in the context of splicing, I don't think R-loops are involved. The spliceosome functions in the nucleus, and the process is about recognizing splice sites and lariat formation. So R-loops are not part of the splicing machinery.\\n\\nSo both B and C are not involved. Wait, but the question gives four options, and only one is correct.\\n\\nWait, the question says which structure is not involved in the proposed therapy. The therapy uses the Morpholino, which is an antisense molecule. So the therapy involves the pre-mRNA, splice sites, and the antisense binding. It doesn't involve the polyA tail because the polyA tail is added after splicing. So the polyA tail is part of the mRNA but not involved in splicing.\\n\\nWait, but wait. The polyA tail is part of mRNA processing. The pre-mRNA has the polyA signal, which is recognized by the 3' splice site. But in this therapy, the Morpholino is binding to the pre-mRNA at the 5' end of the exon. So the polyA tail is not involved in this particular therapy. So B is not involved.\\n\\nAlternatively, the spliceosome does have a role in the polyadenylation process? I don't think so. The polyadenylation is a separate step. So the therapy doesn't use the polyA tail. So the structure not involved would be B.\\n\\nWait, but the pre-mRNA has the polyA signal, but the Morpholino doesn't interact with it. The Morpholino binds the pre-mRNA at the exon's 5' end, so the polyA tail isn't involved in\", '<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>\\nOkay, so I have this genetics question in front of me, and I\\'m a bit confused, but let\\'s try to break it down. I remember a bit about gene splicing from my studies, so maybe that\\'ll help. Let me read the question again.\\n\\nThe question is about a gene with multiple exons, and the central exons code for triple helical repeats. Each exon usually codes for one of these helices. The common mutations are central exon deletions, which cause out-of-frame peptides leading to degenerative diseases. The solution mentioned is using a Morpholino that recognizes the 5\\' end of the out-of-frame exon in pre-mRNA. This prevents the spliceosome from binding, causing exon skipping and in-frame joining. The question asks which structure isn\\'t involved in this therapy.\\n\\nThe options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nHmm, let\\'s think about the process here. So, when a spliceosome acts on pre-mRNA, it splices out exons. The spliceosome recognizes the donor and acceptor sites. If the Morpholino binds to the 5\\' end of the exon, it probably blocks the recognition of the splice sites. So the exon is skipped. That means the mRNA doesn\\'t include that exon, leading to an in-frame reading frame, which is good because it prevents a frameshift and the resulting protein doesn\\'t have a premature stop codon.\\n\\nBut wait, what structures are involved in this process? I remember that during splicing, a lariat structure is formed. The spliceosome cleaves the intron, and the first step is the formation of a lariat. So the lariat is definitely involved here because when the spliceosome removes the intron, it creates this lariat structure. So option A is involved, meaning it\\'s not the correct answer.\\n\\nThe spliceosome itself is part of the machinery that recognizes the splice sites. The splice sites are on the pre-mRNA, and the splicing process involves the polyA tail? Wait, the polyA tail is at the 3\\' end of mRNA, right? The spliceosome is involved in processing the introns, but the polyA tail is part of mRNA processing, but not directly involved in splicing. Wait, the spliceosome\\'s assembly includes snRNPsâ€”small nuclear ribonucleoproteins. But does the polyA tail have anything to do with the spliceosome\\'s activity? Or does the presence of the polyA tail affect the splicing process? Hmm, I\\'m a bit fuzzy on that. Oh wait, the polyA signal is recognized by the 3\\' splice site, so the spliceosome does recognize that. But does the polyA tail itself get involved in the splicing mechanism? I don\\'t think so. So the polyA tail (option B) is involved in the normal processing of mRNA, but in this therapy, the polyA tail\\'s presence is probably not directly part of the Morpholino\\'s action. Or wait, the question is about structures involved in the therapy. The therapy involves delivering a Morpholino that binds the pre-mRNA. So the spliceosome is part of the process, but the polyA tail is part of the pre-mRNA structure but isn\\'t directly involved in the splicing machinery\\'s binding. So perhaps the polyA tail isn\\'t directly involved in this therapy\\'s mechanism. Or wait, does the presence of the polyA tail affect the spliceosome\\'s binding? I\\'m not sure.\\n\\nThen, R-loops. R-loops are RNA-DNA hybrids with proteins, usually in the context of transcription errors or genome instability. I don\\'t think R-loops are involved in splicing. The spliceosome operates on pre-mRNA, which is RNA, so I don\\'t see R-loops being part of this process. So option C might be the correct answer, but I\\'m not certain.\\n\\nAntisense molecules are RNA molecules that are complementary to a specific DNA sequence. They can block transcription. So if the Morpholino is an antisense molecule, it would bind to the pre-mRNA. Wait, no, Morpholinos are small molecules that can act as nucleotide analogs or bind directly to RNA. Oh, wait, Morpholinos are often used as antisense oligonucleotides. So the Morpholino would bind to the pre-mRNA, preventing the spliceosome from binding. So the antisense (option D) is involved because the Morpholino is an antisense molecule. So D is involved, which means it\\'s not the correct answer.\\n\\nSo the structures involved in this therapy are the spliceosome (which includes snRNPs), the lariat (formed during splicing), and perhaps the antisense Morpholino. The polyA tail is part of the mRNA but not directly involved in splicing. R-loops are not part of this process either. Wait, but the pre-mRNA has a polyA tail. So during splicing, the polyA tail is present. But the Morpholino is binding the 5\\' end of the exon, which is before the polyA tail. So the polyA tail is part of the pre-mRNA but isn\\'t involved in the splicing mechanism.\\n\\nSo the question is, which structure isn\\'t involved in the therapy. The therapy uses a Morpholino that binds to the pre-mRNA, preventing the spliceosome from binding. The structures involved would be the pre-mRNA, the spliceosome, the lariat, and the antisense Morpholino. The polyA tail is part of the pre-mRNA but isn\\'t involved in the splicing machinery\\'s function. R-loops are not involved either.\\n\\nWait, but the question is about the structures \"involved in the proposed therapy.\" So the therapy is using a Morpholino that binds to the 5\\' end of the exon. So the Morpholino is part of the therapy, but what structures are involved in the process of the therapy?\\n\\nThe pre-mRNA has splice sites and the polyA tail. The spliceosome is part of the normal splicing process, but the therapy is interfering with that. So the structures involved in the therapy would be the splice sites (which are on the pre-mRNA), the spliceosome, the lariat (formed during splicing), and the Morpholino. The polyA tail is part of the pre-mRNA but is not a structure that\\'s part of the splicing machinery. R-loops aren\\'t involved.\\n\\nSo the question is which structure isn\\'t involved. The options are A, B, C, D.\\n\\nWait, let\\'s think again: the process in the therapy is that the Morpholino binds to the pre-mRNA, preventing the spliceosome from recognizing the splice sites. So the spliceosome can\\'t bind. So the spliceosome is involved, but the polyA tail is not. The lariat is formed during splicing, so it\\'s involved. The antisense is the Morpholino, which is part of the therapy.\\n\\nSo the structures not involved: which of the four is not used?\\n\\nThe options are: lariat (A) is used. PolyA (B) is part of the pre-mRNA but not involved in the splicing process. R-loops (C) aren\\'t involved. Antisense (D) is used.\\n\\nSo the question is asking which is not involved. So the structures that are part of the therapy process are lariat, polyA (maybe?), spliceosome, antisense. But I\\'m a bit confused.\\n\\nWait, the polyA tail is part of the mRNA, but does the process of splicing involve the polyA tail? I think the spliceosome recognizes the 3\\' splice site, which is near the polyA tail. So the presence of the polyA tail is necessary for the 3\\' splice site recognition. But during splicing, the polyA tail is cleaved off. So the polyA tail is involved in the initial recognition but not in the actual splicing mechanism. So in the therapy, the Morpholino is preventing the spliceosome from binding, so the polyA tail is still present. So the polyA tail is part of the process, but the therapy doesn\\'t involve it beyond that initial recognition.\\n\\nSo the structures that are part of the process:\\n\\n- pre-mRNA (has splice sites and polyA tail)\\n- spliceosome (with snRNPs)\\n- lariat (formed during splicing)\\n- Morpholino (antisense, part of the therapy)\\n\\nSo the structures that are not involved: R-loops (C) are not involved. Because R-loops are formed from RNA-DNA hybrids, which are not part of the splicing machinery.\\n\\nSo the answer is C) R-loops.\\n</think>\\n\\nTo address the question, we need to determine which structure is not involved in the proposed therapy. The therapy involves delivering a Morpholino that binds to the 5\\' end of an out-of-frame exon in pre-mRNA, preventing the spliceosome from recognizing the splice sites. This leads to exon skipping and in-frame joining, allowing the remaining exons to be spliced without frameshifts. Below is the analysis of each option:\\n\\n1. **Lariat (A):** During splicing, the spliceosome removes introns and forms a lariat structure by creating a bond between the 5\\' splice site and the first nucleotide of the intron. This structure is directly involved in the splicing process and is part of the therapy mechanism. Therefore, this structure is involved.\\n\\n2. **PolyA tail (B):** The polyA tail is a feature of pre-mRNA that is recognized by the 3\\' splice site. While it plays a role in the initial recognition of the splice site during splicing, it is not directly involved in the splicing machinery or the therapy described. However, the polyA tail is part of the pre', \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>\\nOkay, so I've got this genetics question in front of me, and I need to figure it out. Let's read it again carefully.\\n\\nThe question is about a gene with many exons, and the central ones code for triple helical repeats that help connect the cytoskeleton with the sarcolemma and the extracellular space. Each exon usually codes for one of these triple helix structures. The common mutations are central exon deletions, which cause out-of-frame peptides and lead to progressive degenerative organ waste. The solution proposed is using a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This prevents the spliceosome from binding, causing exon skipping and in-frame joining. Since multiple missing exons are tolerated, the therapy is effective.\\n\\nThe question is asking which structure is NOT involved in the proposed therapy. The options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nHmm. I remember that in splicing, the spliceosome is involved. The process involves the splicing of introns, and the spliceosome recognizes splice sites. The Morpholino is a small molecule that probably acts as an antisense, binding to the pre-mRNA.\\n\\nSo the Morpholino would bind to the pre-mRNA, specifically at the 5' end of the exon that's being skipped. This binding prevents the spliceosome from recognizing and including that exon. Without that exon, the mRNA is missing that part. But since the exons after are in frame, the reading frame is maintained.\\n\\nLet me think about the structures involved in splicing. The spliceosome includes snRNA (small nuclear RNA), which are involved in recognizing the splice sites. The process involves the formation of a lariat structure when an intron is spliced out. So when the spliceosome acts, it removes the intron, creating a lariat. The polyA tail is added to the mRNA during mRNA processing, but in this case, I'm not sure if it's part of the splicing process. Wait, the polyA tail is more about the end processing of mRNA, like in the nucleus or cytoplasm.\\n\\nWait, the question is about what's not involved. So the Morpholino binds to the pre-mRNA. It's acting as an antisense, maybe blocking the splice sites. So what structures are involved in this therapy?\\n\\nOption A: lariat. Since the therapy involves skipping an exon, the intron would be removed, creating a lariat. So the lariat is part of the process. So option A is involved.\\n\\nOption B: polyA tail. The polyA tail is added to the mRNA after splicing. So in this scenario, the Morpholino is targeting the pre-mRNA. The polyA tail is part of the mature mRNA, perhaps. Wait, but the therapy involves pre-mRNA. So during splicing, the polyA tail may not be involved. Or maybe the polyA is added later. I'm not sure.\\n\\nOption C: R-loops. R-loops are structures formed during transcription where the RNA is hybridized to the DNA, displacing the other DNA strand. They're more common in genomic DNA, especially in regions of high GC content. But I don't see how R-loops are directly involved in the splicing process or in the Morpholino therapy. Unless the Morpholino binding somehow affects that, but I don't think that's the case. So maybe C is the correct answer, the structure not involved.\\n\\nOption D: antisense. The Morpholino is an antisense molecule that binds to the pre-mRNA. So antisense is definitely involved. So D is involved.\\n\\nSo the options are A, B, C, D. The question is which is NOT involved.\\n\\nWait, the question asks which structure is not involved in the therapy. So the therapy involves Morpholino, which is antisense (D is involved). The spliceosome is involved because the splice sites are blocked, leading to exon skipping, so the lariat is formed when the intron is removed (A is involved). The polyA tail is part of the mRNA processing. The pre-mRNA is processed, and the polyA tail is added later. So in this case, the therapy involves the pre-mRNA, so the polyA tail hasn't been added yet. So the polyA tail (B) is not involved in the process of exon skipping and lariat formation.\\n\\nWait, the polyA tail is part of the mRNA after splicing. So in this therapy, they're targeting the pre-mRNA. So the polyA tail is not present during splicing. So the polyA tail (option B) is not involved in the therapy. But wait, the question is about structures involved in the therapy. The therapy's process is the Morpholino binding and preventing spliceosome binding, leading to exon skipping and a lariat. The polyA tail is added after splicing, so it's not part of the mechanism here.\\n\\nWait, but the therapy uses Morpholino, which is an antisense (so D is involved). The spliceosome's RNA (snRNA) is involved in splicing, but the question doesn't list snRNA as an option. So the question is about which of the options isn't part of the therapy.\\n\\nThe structures involved would be the lariat (A, when intron is removed), the pre-mRNA being targeted by the Morpholino (so antisense, D is involved), and the spliceosome's action. The polyA tail is part of the processed mRNA, which comes after splicing and export from the nucleus. So during splicing (the process the therapy is targeting), the polyA tail hasn't been added yet. So option B, the polyA tail, is not involved in the therapy process.\\n\\nSo the structures that are involved are A, D, and the spliceosome (but that's not an option here). The structures not involved would be C (R-loops) and B (polyA tail), but wait, the question gives four options and asks which is NOT involved.\\n\\nWait, the question is, which structure is not involved. So which of the four options is not part of the therapy.\\n\\nLet me think again: the process involves the Morpholino (antisense, D is involved), the pre-mRNA has the exon skipped, the spliceosome can't recognize, so the intron is skipped (so a lariat is formed, A is involved). The polyA tail is part of the mRNA, added later. So B is not involved.\\n\\nWhat about R-loops (C)? R-loops are formed during transcription when the RNA hybridizes to DNA, leading to the displacement of the other DNA strand. They're more associated with genomic regions, not with splicing. So the therapy wouldn't involve R-loops. So C is not involved.\\n\\nSo the structures involved are A (lariat), D (antisense), and the spliceosome. Structures not involved: B (polyA) and C (R-loops). But the question asks for the structure that is not involved. So the answer would be either B or C.\\n\\nWait, the question is asking which structure is not involved. So which of the four is not used in this therapy.\\n\\nThe therapy uses Morpholino, which is an antisense (so D is involved). The process leads to the skipping of the exon, which would form a lariat (so A is involved). The spliceosome is involved in the process, but that's not an option.\\n\\nThe polyA tail is added after splicing, so during splicing, it's not present. So B is not involved.\\n\\nR-loops are unrelated to the splicing process. The therapy doesn't involve R-loops. So the structures involved are A and D, and the spliceosome. Structures not involved are B and C.\\n\\nThe question is which of the four is not involved. So which of the four options is the correct answer.\\n\\nThe question is: which structure is not involved in the proposed therapy?\\n\\nThe therapy involves Morpholino (antisense, D). The process skips the exon, so during that process, a lariat is formed (A is involved). The spliceosome is involved, but that's not an option. The polyA tail (B) is added after splicing, so not involved. R-loops (C) are unrelated to this process.\\n\\nSo the structures not involved are B and C.\\n\\nThe question is which is not involved. So the options are:\\n\\nA) lariat â†’ involved (yes)\\nB) polyA â†’ not involved (yes)\\nC) R-loops â†’ not involved (yes)\\nD) antisense â†’ involved (yes)\\n\\nSo the question is which is not involved. So the possible answers are B or C.\\n\\nWait, the question is asking which structure is not involved. So which one of these four is not part of the therapy.\\n\\nThe therapy is about the splicing of the mRNA. The process uses an antisense Morpholino to block the splice sites. The spliceosome is involved in recognizing the splice sites. The lariat is formed when the intron is removed. The polyA tail is added after splicing, so it's not part of the splicing process. R-loops are not part of splicing.\\n\\nSo the structures not involved are B (polyA) and C (R-loops).\\n\\nSo the question is which of the four options is not involved. The question is, which is not involved in the proposed therapy.\\n\\nWait, the therapy's process: the Morpholino binds to the pre-mRNA, which is in the nucleus. It prevents the spliceosome from binding to the exon, so the exon is skipped. The intron is then removed, creating a lariat structure. The polyA tail is added later, during mRNA processing in the cytoplasm, perhaps. R-loops are\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ><think>\\nOkay, so I've got this biology question here about gene therapy and splicing. Hmm, I remember that splicing is a process in mRNA where introns are removed and exons are joined. The question is about a particular mutation and a therapy solution.\\n\\nThe question says that a large gene has many exons, and the central ones code for triple helical repeats that connect the cytoskeleton with the sarcolemma and extracellular space. Oh right, like maybe something to do with muscle function? Because sarcolemma is part of muscle cells. So if the exons are deleted, especially the central ones, the protein product might not work correctly, leading to degeneration.\\n\\nThe mutations are central exon deletions, causing out-of-frame peptides. Out-of-frame means the reading frame is shifted, leading to a completely different amino acid sequence after the deletion. This is called a frameshift mutation, right? So the protein would be nonfunctional, leading to disease.\\n\\nThe therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. Morpholinos are antisense oligonucleotides, I think. They bind to specific RNA sequences. When they bind, they prevent the spliceosome from recognizing the exon, so the exon is skipped. Skipping the exon would result in joining the previous exon to the next one, which should maintain a reading frame, thus making a functional protein.\\n\\nSo the therapy's mechanism is that the Morpholino binds to the pre-mRNA, causing the exon to be skipped. This skips the exon and the downstream exons are joined, so the mRNA is in-frame again.\\n\\nThe question asks which structure is not involved in this therapy. The options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nLet me think about each structure. \\n\\nThe spliceosome is involved in splicing. When a spliceosome acts, it uses the lariat structure. So when an intron is spliced, the intron is removed and a lariat structure is formed. So lariat (A) is involved.\\n\\nThe polyA tail is part of mRNA processing. The polyadenylation step adds the polyA tail. The Morpholino is delivered as an antisense molecule. So the antisense (D) is involved because the Morpholino is antisense.\\n\\nWhat about R-loops? R-loops are RNA:DNA hybrids with the displaced DNA strand. I'm not sure if they're involved in splicing or in this therapy. R-loops are more about DNA methylation and gene silencing maybe. So in this scenario, the therapy uses Morpholino, which is an RNA-based antisense. I don't think R-loops are part of this process. Because R-loops form during DNA transcription when RNA binds to DNA, but the splicing process doesn't involve R-loops. So the answer might be C) R-loops.\\n\\nWait, but let me double-check. The therapy uses Morpholino which is an antisense molecule. Antisense molecules are part of antisense oligonucleotide therapy, which is a form of gene therapy. So antisense (option D) is involved.\\n\\nPolyA tail (B) is part of mRNA processing. The mRNA is made, then polyadenylated. But when the spliceosome acts, it doesn't directly involve the polyA tail. The polyA tail is more about the end processing of the mRNA. The Morpholino binds pre-mRNA, which includes the exons and introns, but not sure if the polyA tail is involved. Wait, the pre-mRNA would have the polyA tail, but the Morpholino binds the exon. So the polyA tail is still part of the mRNA, but the Morpholino doesn't directly interact with it. So the polyA tail is involved in the mRNA's structure but not in the splicing process induced by the Morpholino.\\n\\nWait, the question is which structure is not involved. So the structures involved in the process are lariat (splicing), antisense (Morpholino), and perhaps the spliceosome. The polyA tail is part of the mRNA but not directly involved in splicing. So the therapy doesn't involve the polyA tail. Or is the polyA tail part of the pre-mRNA?\\n\\nWait, pre-mRNA includes the polyA tail. So the polyA tail is involved in the process of mRNA maturation, but in the splicing mechanism, the polyA tail isn't directly part of the splicing machinery. So the process of splicing (which the Morpholino affects) doesn't require the polyA tail. So the question is asking which structure isn't involved in the proposed therapy. The therapy involves Morpholino (antisense), which prevents splicing. The splicing process forms a lariat. The polyA tail is part of the pre-mRNA but not directly involved in the splicing mechanism. So the polyA tail is involved in mRNA processing but not in the splicing mechanism that the Morpholino is targeting.\\n\\nSo the options are A (lariat) - involved, B (polyA tail) - involved in mRNA processing but not in splicing, C (R-loops) - not involved, D (antisense) - involved.\\n\\nThe question is which is not involved. So the options are A, B, C, D. The therapy uses antisense (D) and lariat (A). The polyA tail (B) is part of the mRNA, but the process of splicing (which the therapy is targeting) doesn't directly involve the polyA tail. So the therapy doesn't involve the polyA tail. Or does it?\\n\\nWait, the polyA tail is part of the mRNA, but the splicing machinery (like the spliceosome) doesn't directly interact with the polyA tail. So in the process of splicing, the polyA tail isn't involved. So the therapy doesn't involve the polyA tail. So the structures involved are A (lariat), D (antisense), and the spliceosome (which involves the lariat). So the structure that's not involved is B) polyA tail or C) R-loops.\\n\\nWait, the question is about structures involved in the therapy. The therapy involves Morpholino, which is an antisense molecule (D). The process of splicing (targeted by Morpholino) forms a lariat structure (A). The polyA tail is part of the pre-mRNA but isn't directly involved in the splicing process. So the polyA tail is not involved in the splicing mechanism induced by the Morpholino. So in this therapy, the polyA tail isn't involved. So the structure not involved is B.\\n\\nWait, but the question is which structure is not involved in the proposed therapy. The therapy is the delivery of Morpholino that prevents the spliceosome from binding. So the spliceosome is involved, which makes the lariat. The antisense (Morpholino) is part of it. The polyA tail is part of the pre-mRNA but isn't a part of the splicing machinery. So the therapy doesn't involve the polyA tail. So the answer would be B) polyA tail.\\n\\nWait, but another angle: the spliceosome is involved in splicing, which leads to the lariat. The pre-mRNA includes the polyA tail. So the polyA tail is part of the pre-mRNA but isn't involved in the splicing process. So the therapy doesn't involve the polyA tail.\\n\\nSo the structures involved in the therapy are lariat (A), antisense (D), and the spliceosome (which I didn't list, but it's part of the process). The structures not involved would be R-loops (C) and the polyA tail (B). The question is asking which is not involved. So the options are A, B, C, D. The therapy uses A and D, so the other structures (B and C) are not involved.\\n\\nThe question is about which is not involved. So the correct answer would be B) polyA tail or C) R-loops. Which one is it?\\n\\nWait, the question is about the structures in the therapy. The Morpholino binds to pre-mRNA. The pre-mRNA includes the exons and introns. The polyA tail is at the end of the mRNA. The Morpholino doesn't target the polyA tail, so the therapy doesn't involve the polyA tail. So B is not involved.\\n\\nAlternatively, the polyA tail is part of mRNA processing, but the therapy doesn't involve that step. The Morpholino is used in the splicing process, not in the mRNA processing steps like polyadenylation.\\n\\nSo the answer is B) polyA tail. Because the therapy involves the splicing process, which forms a lariat, and uses an antisense molecule. The polyA tail is part of the pre-mRNA but isn't involved in splicing. R-loops are a different structure altogether and not involved in splicing.\\n</think>\\n\\nThe question involves a gene therapy approach targeting central exon deletions in a large gene that codes for folded triple helical repeats. The mutations cause out-of-frame peptides, leading to progressive degeneration. The therapy uses a Morpholino, an antisense oligonucleotide, to bind the 5' end of an out-of-frame exon in pre-mRNA, preventing spliceosome binding and inducing exon skipping. This results in in-frame joining of the remaining exons, allowing the production of a functional protein. The question asks which structure is not involved in this therapy.\\n\\n### Analysis of the Options:\\n1. **A) lariat**: During splicing, the intron is removed, and a lariat structure is formed. This structure is directly involved in the splicing process induced by the Morph\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ><think>\\nOkay, so I'm trying to tackle this question about a gene therapy scenario. Hmm, let's see what the question says.\\n\\nAlright, the gene has multiple exons, and the central ones code for triple helical repeats that help connect the cytoskeleton, sarcolemma, and extracellular space. Each exon usually makes a triple helix. But the common mutations are central exon deletions, leading to out-of-frame peptides and causing progressive degeneration. So those mutations probably cause a frameshift, leading to a premature stop codon and a nonfunctional protein.\\n\\nThe therapy proposed uses a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. So the Morpholino binds to that part. Then, the spliceosome can't bind properly, leading to exon skipping. Exon skipping is when the spliceosome skips an exon, joining the neighboring exons to make a shorter mRNA. And if several exons are missing, the organism can tolerate it because it might not disrupt the overall reading frame as much.\\n\\nThe question is asking which structure isn't involved in this therapy. The options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nLet me think about what happens during splicing. The spliceosome is involved in removing introns. Normally, the spliceosome binds to the pre-mRNA, and the 5' splice site and the 3' splice site. The spliceosome catalyzes the removal of the intron by creating a lariat structure. So the lariat is definitely involved.\\n\\nWhat about the polyA tail? The polyA tail is part of mRNA processing. The 5' cap is another important part. The polyA tail is added during mRNA processing, but I'm not sure if it's directly involved in the splicing process. Wait, the spliceosome is involved in the splicing but the polyA tail is added later, perhaps during export from the nucleus or during RNA processing. Maybe the Morpholino is used in the nucleus, but the polyA tail is more about the end processing. So B is involved? Or is the polyA tail not part of the splicing mechanism itself.\\n\\nAntisense molecules are used in antisense therapy. They can bind to mRNA to block translation or interfere with splicing. The Morpholino is a type of antisense, I think. So antisense (D) is definitely involved.\\n\\nR-loops are structures where an RNA strand hybridizes with a DNA strand, displacing the other DNA strand. They can cause various issues like chromosomal rearrangements. But in this therapy, are R-loops involved? I don't think so. The process here is splicing, which is a RNA process. The therapy is delivering a Morpholino which is an antisense molecule, so perhaps the Morpholino is part of a complex that binds to the pre-mRNA. There's no indication of DNA-RNA interactions here. So R-loops (C) might not be involved.\\n\\nWait, another angle. The spliceosome involves several proteins like U1, U2, U4, U5, U6. The spliceosome also recognizes the splice sites, and during this process, the introns are excised, and the lariat is formed as part of the splicing mechanism. So the lariat is definitely part of this process.\\n\\nThe Morpholino would bind to the pre-mRNA at the 5' end of the exon, preventing the spliceosome from binding. That would lead to the exon being skipped. So the process involves the spliceosome, the pre-mRNA, the Morpholino (antisense), and the lariat structure.\\n\\nWhich structure isn't involved? The options are lariat (A), polyA (B), R-loops (C), antisense (D).\\n\\nSo the therapy doesn't involve the polyA tail. Because the polyA tail is added to the mRNA after the splicing is done. The process of splicing occurs before the mRNA is exported and before adding the polyA tail. So the polyA tail isn't involved in the splicing process triggered by the Morpholino. So the structure not involved would be B) polyA tail.\\n</think>\\n\\nThe question involves a gene therapy scenario where a Morpholino is used to target the 5' end of an out-of-frame exon in pre-mRNA. This prevents spliceosome binding, leading to exon skipping and in-frame joining of neighboring exons. The therapy aims to tolerate the loss of one or more exons, which are usually critical for protein function due to the frameshift caused by deletions.\\n\\nTo determine which structure is not involved in this therapy, let's analyze the options:\\n\\n1. **Lariat**: During splicing, the spliceosome removes introns and forms a lariat structure as part of the process. This is directly involved in the therapy, as the spliceosome is central to exon skipping.\\n\\n2. **PolyA tail**: The polyA tail is added to the mRNA during post-transcriptional processing, typically after splicing. While the polyA tail is important for mRNA stability and export, it is not directly involved in the splicing process or the mechanism of the Morpholino therapy.\\n\\n3. **R-loops**: R-loops are RNA-DNA hybrids that can cause chromosomal rearrangements and are unrelated to the splicing process or the Morpholino therapy described. There is no indication that R-loops are involved here.\\n\\n4. **Antisense**: The Morpholino is an antisense molecule that binds to the pre-mRNA to block spliceosome binding. Antisense molecules are directly involved in the therapy.\\n\\nFrom this analysis, the polyA tail is not involved in the proposed therapy, as it is part of mRNA processing that occurs after splicing, whereas the therapy focuses on splicing and exon skipping.\\n\\nAnswer: B<ï½œendâ–ofâ–sentenceï½œ>\", '<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ><think>\\nOkay, so I\\'ve got this biology question here, and I\\'m trying to figure it out. Let me read it again.\\n\\nThe question is about a gene with a lot of exons, and the central ones code for triple helical repeats that help the cytoskeleton connect with the sarcolemma and extracellular space. I remember that the cytoskeleton is involved in cell structure and movement, so maybe this is a gene related to muscle function or something like that.\\n\\nEach exon usually codes for one of these triple helix repeats. So the gene has many exons, and the central ones are important for the structure. But the common mutations are central exon deletions, which cause out-of-frame peptides. Oh wait, out-of-frame means that the reading frame is shifted, right? So the resulting protein would be messed up, leading to possible degenerative diseases. Because if the reading frame shifts, the amino acids are all in the wrong order, and after a few insertions or deletions, the protein won\\'t function properly.\\n\\nThe solution proposed is delivering a Morpholino that recognizes the 5\\' end of the out-of-frame exon in pre-mRNA. Morpholinos are a type of antisense oligonucleotide, I think. They\\'re used in gene therapy to target specific RNA sequences. So this Morpholino would bind to the 5\\' end of the exon that\\'s been deleted. By binding, it prevents the spliceosome from recognizing the splice sites, which leads to exon skipping. When the exon is skipped, the remaining exons are joined in a way that the reading frame is preserved. Because the Morpholino blocks the spliceosome, the spliceosome doesn\\'t include that exon, so the mRNA skips it, and the exons after that are connected without the skipped one. So the resulting protein is in-frame, meaning the reading frame hasn\\'t been shifted, so the protein is functional enough to be tolerable.\\n\\nThe question is asking which structure is not involved in this therapy. The options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nHmm. Let\\'s think about the process. The spliceosome is involved in splicing pre-mRNA. So the pre-mRNA is processed by the spliceosome, which recognizes the donor and acceptor sites. The spliceosome binds to the pre-mRNA, cutting out the introns and joining exons. The splicing process creates a lariat structure when an intron is removed. Oh right, the spliceosome cleaves the intron, which is a double-stranded RNA structure, and when it\\'s removed, a lariat-shaped structure is formed. So the lariat is involved in the splicing process. So option A is involved.\\n\\nThe polyA tail is part of mRNA processing. The cell adds a polyA tail to the mRNA, which is important for stability and transport. But in this therapy, the Morpholino is delivering an antisense molecule. Antisense could be part of the RNA interference (RNAi) process. Wait, Morpholinos are antisense oligonucleotides. So when they bind to the target RNA, they might block the spliceosome. So the antisense (option D) is definitely involved here.\\n\\nWhat about R-loops? R-loops are RNA:DNA hybrids with the displaced DNA strand. They can form during transcription when the RNA binds to DNA, displacing the other strand. I\\'m not sure how that ties into this therapy. The therapy is about blocking the spliceosome, so perhaps it\\'s not directly related to R-loops. Unless the Morpholino or the pre-mRNA is forming an R-loop, but I don\\'t think that\\'s the case. The Morpholino is an antisense molecule binding to pre-mRNA, so the RNA is hybridizing with the antisense oligo, which is DNA. So the structure would be RNA:DNA, but not an R-loop because R-loops are DNA-RNA:DNA. Hmm, maybe R-loops are not involved here.\\n\\nWait, R-loops are more about the DNA being in between RNA and the other DNA strand, forming a three-stranded structure. The Morpholino is a small molecule that\\'s binding to the pre-mRNA, so it\\'s not creating an R-loop. So R-loops (option C) are probably not involved in this therapy.\\n\\nSo the structures involved are lariat (A), polyA tail (B) is part of mRNA processing, but does the therapy involve polyA tail? The therapy is about the spliceosome, which doesn\\'t require a polyA tail. The spliceosome\\'s function doesn\\'t involve the polyA tail. The polyA tail is added later, and is part of the mRNA processing after splicing. So B is involved in normal mRNA processing, but in the therapy, the Morpholino is targeting the pre-mRNA, which is before splicing. Wait, no, pre-mRNA is the RNA before splicing. So the spliceosome is involved in splicing, which is the process that creates the lariat. So the pre-mRNA has introns, which are removed by the spliceosome. So the spliceosome is part of the process. The polyA tail is added later, but in the therapy, the Morpholino is preventing splicing, so the lariat is formed when the intron is removed. So B (polyA tail) is not directly involved in the splicing process. So the polyA tail is not involved in the therapy.\\n\\nWait, but the question is which structure is NOT involved in the therapy. So if the therapy involves antisense (Morpholino), which is D, so D is involved.\\n\\nWhich structures are not involved? The options are A, B, C, D. The structures involved are A (lariat, part of splicing), D (antisense, Morpholino is antisense). So which is not involved.\\n\\nThe therapy uses the Morpholino to prevent the spliceosome from binding. So the spliceosome is involved (A is involved because lariat is made during splicing). The polyA tail (B) is part of mRNA processing but not directly involved in splicing. R-loops (C) are not involved here. Antisense (D) is involved because the Morpholino is antisense.\\n\\nSo the structures not involved would be either B or C. Wait, the question asks which structure is not involved. So the structures involved are lariat (A) and antisense (D). The options are which is not involved. So the options are A, B, C, D.\\n\\nThe question is which is not involved.\\n\\nLet me think again. The therapy uses Morpholino (antisense) to block the spliceosome. The spliceosome is involved in splicing, so the lariat is involved (A is involved). The spliceosome doesn\\'t need the polyA tail, so B is not directly involved in the splicing process, but is polyA tail part of the process at all? Well, in normal mRNA processing, the polyA tail is added after splicing. So in the therapy, since we\\'re dealing with pre-mRNA that is spliced, the polyA tail is added later. But in the therapy process, the Morpholino binds the pre-mRNA, which hasn\\'t been spliced yet. So during the splicing process, the polyA tail isn\\'t yet added. So the therapy doesn\\'t involve the polyA tail (B) as part of the process.\\n\\nWait, but the question is about the structure not involved in the proposed therapy. So if the therapy involves the spliceosome, then B (polyA tail) is part of the mRNA processing but not part of the splicing process itself. So the therapy doesn\\'t involve the polyA tail. So B is not involved.\\n\\nBut wait, the question is phrased as \"which structure is not involved in the proposed therapy?\" So the therapy is about the spliceosome, lariat (A is involved), antisense (D is involved). So the other structures are not.\\n\\nLooking at the options, R-loops (C) are not involved in this scenario. So the answer would be either C or B.\\n\\nWait, the process of splicing doesn\\'t involve R-loops. R-loops are more about transcription issues, like when RNA binds to DNA and displaces the other DNA strand. The Morpholino is an antisense oligo that binds to the pre-mRNA. So the pre-mRNA would bind to the Morpholino, creating an RNA:DNA hybrid, but not an R-loop because R-loops require DNA-RNA-DNA triplex. So I don\\'t think R-loops are involved here. So the answer is C.\\n\\nAlternatively, maybe the polyA tail is involved? Well, the therapy is about pre-mRNA, which hasn\\'t had its polyA tail added yet. The polyA tail is added after the spliceosome has acted. So the therapy process doesn\\'t involve the polyA tail. So B is not involved. But the question is about the structures involved in the therapy.\\n\\nWait, the question is which is not involved. So the options are A, B, C, D. Which are involved and which are not.\\n\\nThe therapy involves the spliceosome (which produces lariat), and the Morpholino is antisense (D). So A and D are involved. The polyA tail (B) is part of the mRNA processing, but the therapy is about splicing, which doesn\\'t require it. So B is not involved. R-loops (C) are not involved because the therapy is about antisense blocking the spliceosome. So the structure not involved is C or B.\\n\\nWait, the question asks which structure is not involved. So the four options: which is not part of the therapy.\\n\\nIf the therapy involves the spliceosome (so lariat is made), then A is', '<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ><think>\\nOkay, so I have this question about gene therapy involving Morpholinos and exon skipping. Hmm, I\\'m a bit rusty on this, but let me think through it.\\n\\nSo the question is about a gene with many exons. The central exons code for triple helical repeats that help the cytoskeleton connect the cytosol, sarcolemma, and extracellular space. That\\'s kind of cool, but probably not directly relevant to the question.\\n\\nThe main issue is that some exons are deleted centrally. These deletions cause the mRNA to have an out-of-frame peptide. Oh right, that\\'s a frameshift mutation. Without the correct amino acids, the protein becomes nonfunctional, leading to degenerative diseases. So the therapy\\'s goal is to prevent this frameshift.\\n\\nThe solution is a Morpholino that recognizes the 5\\' end of the out-of-frame exon in pre-mRNA. I remember that Morpholinos are a type of antisense oligonucleotide, which means they have a sequence complementary to the target mRNA. So when the Morpholino binds, it can block the spliceosome from recognizing the exon, leading to its skipping.\\n\\nWait, how does the spliceosome normally work? The spliceosome recognizes the donor and acceptor sites at the ends of introns. If the Morpholino is at the 5\\' end of the exon, then it might prevent the spliceosome from binding. So the spliceosome would instead recognize a different acceptor site upstream, leading the intron to be skipped. That\\'s called exon skipping. Skipping an exon would result in the remaining exons joining in a way that doesn\\'t cause a frameshift, so the resulting protein is still functional.\\n\\nThe question says that several missing exons are well-tolerated. Oh, right, because when an exon is skipped, the reading frame is maintained. Like, if you have an intron between exons, skipping it just connects the previous exon to the next, so the reading frame doesn\\'t get messed up.\\n\\nNow, the question is about which structure is NOT involved in the therapy. The options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nLet me think about each option. \\n\\nThe spliceosome is involved in splicing, so it uses the polyA tail of the mRNA? Wait, no. Wait, the spliceosome is made of snRNPs (small nuclear ribonucleoproteins). The polyA tail is part of the mRNA, but I don\\'t think the spliceosome directly binds it. Or wait, the polyA binding proteins (like PABP) are involved in recognizing the polyA tail. So the polyA tail is part of the pre-mRNA, but the spliceosome doesn\\'t directly use it. So if the therapy involves blocking the spliceosome, the polyA tail wouldn\\'t be involved. Wait, but the spliceosome\\'s function doesn\\'t rely on the polyA tail. So perhaps option B is not involved.\\n\\nWait, but in normal splicing, the spliceosome binds to the pre-mRNA. The polyA tail is a feature of mRNA after splicing. So in the normal process, the spliceosome doesn\\'t require the polyA tail. So if the therapy is blocking the spliceosome, the polyA tail isn\\'t part of that process. So option B, polyA tail, is not involved.\\n\\nWhat about the other options? Let me go through each.\\n\\nA) Lariat: I think lariat structures are formed during splicing when an intron is removed. The spliceosome creates a lariat by splicing the intron out. So the lariat is definitely involved in splicing. So the Morpholino therapy would involve the spliceosome and thus the lariat. So A is involved, so it\\'s not the answer.\\n\\nC) R-loops: R-loops are structures where the RNA binds to DNA, displacing the other DNA strand. I\\'m not sure how this ties into the spliceosome or Morpholino therapy. R-loops are more about DNA-RNA interactions in processes like genome editing or replication stress. The Morpholino is an antisense oligo, so it\\'s more about binding RNA. So R-loops might not be involved here. Hmm, but I\\'m not certain. Let\\'s think more.\\n\\nThe therapy uses Morpholino (antisense) to target the pre-mRNA. So the antisense molecule binds to the mRNA. So D) antisense is involved. So option D is part of the therapy.\\n\\nSo the structures involved in the therapy are the spliceosome (which uses lariats), the antisense Morpholino, and the pre-mRNA. The polyA tail is part of the mRNA after splicing, but the spliceosome doesn\\'t directly use it. The therapy doesn\\'t involve the polyA tail. So the question is, which structure is not involved.\\n\\nWait, the therapy is using the Morpholino, which is an antisense molecule. So the antisense binds to the pre-mRNA, preventing the spliceosome from recognizing the exon. So the antisense is part of the process.\\n\\nSo the structures involved in the therapy are:\\n\\n- Pre-mRNA (exon, intron)\\n- Antisense Morpholino (antisense)\\n- Spliceosome (involved in splicing, which creates lariats)\\n- The lariat is part of the splicing process.\\n\\nPolyA tail is part of the mRNA, but not part of the spliceosome machinery. The spliceosome doesn\\'t need the polyA tail for splicing. So the polyA tail is not involved in the therapy.\\n\\nSo the question is, which structure is NOT involved. The options are:\\n\\nA) lariat - involved\\nB) polyA tail - not involved\\nC) R-loops - not involved?\\nD) antisense - involved\\n\\nWait, the question asks which is not involved. So the options are four choices, and only one is the correct answer.\\n\\nWait, I thought R-loops are structures formed when RNA binds to DNA, not directly in the splicing process. So in the therapy, the Morpholino binds RNA (pre-mRNA), so R-loops (RNA-DNA interactions) aren\\'t part of this process. So C) R-loops is not involved.\\n\\nWait, but let me re-examine. The therapy uses Morpholino, which is an antisense oligo. It binds to pre-mRNA, which is part of the splicing machinery. The spliceosome\\'s function doesn\\'t directly involve R-loops. R-loops are more about transcription or replication, perhaps.\\n\\nSo which option is not involved? The question is asking which structure is not involved.\\n\\nThe options are A, B, C, D. The therapy involves spliceosome (so A: lariat is involved), antisense (so D is involved), and the spliceosome, which doesn\\'t require the polyA tail. So polyA tail is not involved. So B) is not involved.\\n\\nWait, but what about R-loops? Are they involved?\\n\\nThe therapy is delivering a Morpholino that binds to the 5\\' end of the exon. This would block the spliceosome. The spliceosome recognizes the donor and acceptor sites. The Morpholino would prevent the spliceosome from proceeding, leading to exon skipping.\\n\\nSo during this process, the spliceosome is involved. The spliceosome uses the pre-mRNA, which has a polyA tail. But the spliceosome doesn\\'t interact with the polyA tail. So the polyA tail is not directly involved in the process.\\n\\nSo the structures involved are: pre-mRNA, spliceosome (with lariat), antisense (Morpholino), but not the polyA tail.\\n\\nSo the question is, which is not involved? The options are A, B, C, D.\\n\\nSo the structures not involved are R-loops and polyA tail. But wait, the question is asking which is not involved. So in the options, which one is not part of the process.\\n\\nThe options are:\\n\\nA) lariat: yes, involved.\\n\\nB) polyA tail: not involved.\\n\\nC) R-loops: not involved.\\n\\nD) antisense: yes, involved.\\n\\nSo the question is, which of these four is not involved. The options are A, B, C, D.\\n\\nWait, the question says, \"Which structure below is not involved in the proposed therapy?\"\\n\\nSo the four options, which is not used in the therapy. The therapy uses the spliceosome (so lariats are produced), antisense (Morpholino), and pre-mRNA.\\n\\nSo polyA tail is not involved. So option B is not involved.\\n\\nWait, but I also thought R-loops are not involved. So which of the four is the correct answer?\\n\\nThe question gives four options, and only one is correct.\\n\\nWait, the therapy uses the spliceosome, which produces a lariat. The antisense Morpholino is part of the therapy. The polyA tail is part of the mRNA, but not involved in the splicing process. R-loops are structures formed during other processes, like DNA repair or during the formation of RNA molecules.\\n\\nSo the structures not involved are polyA tail and R-loops. But the question is only asking for one option.\\n\\nWait, the question is about the structures involved in the therapy. So which of the four is not part of it.\\n\\nSo the options are:\\n\\nA) lariat â€“ part of splicing, yes.\\n\\nB) polyA tail â€“ not involved.\\n\\nC) R-loops â€“ not involved.\\n\\nD) antisense â€“ part of the therapy.\\n\\nSo the question is which structure is not involved. So the correct answer is either B or C.\\n\\nWait, the question is about the therapy, which involves the Morpholino (antisense) binding to the pre-mRNA, blocking the spliceosome.\\n\\nThe spliceosome is', \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ><think>\\nOkay, so I've got this genetics question here. Hmm, let me read it carefully. I'm a bit rusty on some of the splicing mechanisms, but I'll try to think it through.\\n\\nThe question is about a gene with multiple exons, and the central ones code for triple helical repeats that help connect the cytoskeleton with the sarcolemma and extracellular space. So I remember that exons are the parts of mRNA that are translated into protein. The central exons here are important for some structural proteins, maybe like in muscle or something.\\n\\nThe mutations are central exon deletions that cause out-of-frame peptides. Oh wait, out-of-frame means a frameshift, right? Because the reading frame changes, leading to a different amino acid sequence downstream. And that's a problem because it leads to a nonfunctional protein, causing progressive degeneration.\\n\\nThe solution mentioned is delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. Morpholinos are these small molecules that can act as molecular switches. They bind to specific RNA sequences. So this Morpholino would bind to the 5' end of the exon. When it does that, it prevents the spliceosome from binding. The spliceosome is responsible for splicing out exons, right? So if the Morpholino is blocking the spliceosome, then that exon is skipped. Skipping an exon means that the mRNA skips over it, so the introns are spliced out but without that exon. That would result in an in-frame joining of the surrounding exons, so the reading frame is maintained. And the question says several missing exons are well-tolerated.\\n\\nThe question is asking which structure isn't involved in this therapy. The options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nHmm, let me think about the spliceosome and the process. The spliceosome recognizes the 3' splice site and the donor site. It uses the branch site adenine, and the 5' and 3' ends of the introns. So during splicing, the intron is removed, and the exons are joined.\\n\\nIn the normal splicing process, the spliceosome binds to the intron, and the lariat structure is formed. The branch site adenine is incorporated into the lariat, which is a small RNA structure. So lariat (option A) is definitely involved because when the spliceosome acts, it creates a lariat.\\n\\nThe polyA tail (option B) is part of mRNA processing. The polyA addition occurs after splicing. The polyA signal is recognized by the 3' splice site. So the mRNA is spliced, then the polyA tail is added. But wait, the Morpholino is binding the pre-mRNA. The pre-mRNA includes the polyA tail, right? Or does it? Wait, the pre-mRNA is the RNA before splicing. The polyA tail is added after splicing. So the Morpholino binds to the pre-mRNA, which includes the polyA tail. But wait, the Morpholino is targeting the 5' end of the exon, not the polyA. So the polyA tail might not be directly involved in the Morpholino's binding. Hmm, but during splicing, the pre-mRNA (which has the polyA tail) is being processed. So the polyA tail is part of the process.\\n\\nWait, the spliceosome binds the 3' end of the intron (the polyA signal) and the donor site. So the pre-mRNA includes the polyA tail. But the Morpholino is binding the 5' end of the exon. So the polyA tail is part of the pre-mRNA but doesn't directly interfere with the splicing here. Or does the Morpholino affect the splicing process, which in turn affects the polyA tail?\\n\\nAlternatively, perhaps the polyA tail is part of the pre-mRNA that's being processed. So the presence of the Morpholino doesn't directly involve the polyA tail. Wait, the question is about which structure is not involved. So if the therapy is about preventing the spliceosome from binding, perhaps the polyA tail is not involved. But wait, the pre-mRNA has the polyA tail. So the polyA tail is part of the process, but the Morpholino is acting on the exon.\\n\\nR-loops (option C) are structures formed during transcription where the RNA base-pairs with the DNA, displacing the other DNA strand. I'm not sure if R-loops are involved in splicing or in the spliceosome. I don't recall them being part of the splicing mechanism. So perhaps R-loops are not involved here.\\n\\nAntisense (option D) refers to RNA that is complementary to a specific DNA sequence. Antisense oligonucleotides are used in gene therapy to target specific sequences. The Morpholino is an antisense molecule, I think. So D is involved because the Morpholino is antisense.\\n\\nSo the structures involved are lariat (A), polyA (B), antisense (D), and spliceosome (not an option here). The question is which one is not involved.\\n\\nWait, the question is about which structure is not involved in the therapy. The therapy uses a Morpholino that is antisense, so D is involved. The spliceosome is involved in splicing, which is part of the therapy. The lariat is formed during splicing, so A is involved. The polyA tail is part of the pre-mRNA, so B is involved in the process.\\n\\nSo which structure is not involved? R-loops (C) are not part of the splicing mechanism or the Morpholino therapy. So the correct answer would be C) R-loops.\\n</think>\\n\\nThe question involves a gene with multiple exons, where central exons code for triple helical repeats important for cytoskeletal function. Mutations in these exons cause central exon deletions, leading to out-of-frame peptides and progressive degeneration. The proposed therapy uses a Morpholino, a small molecule that binds to the 5' end of the out-of-frame exon in pre-mRNA, preventing spliceosome binding and inducing exon skipping. This results in in-frame joining of surrounding exons, which is tolerable.\\n\\nThe question asks which structure is not involved in this therapy. The analysis of the options is as follows:\\n\\n- **A) Lariat**: During splicing, the branch site adenine is incorporated into a small RNA structure called a lariat. Since the therapy involves splicing, the lariat is involved.\\n\\n- **B) PolyA tail**: The polyA tail is part of pre-mRNA and is added after splicing. While the therapy involves pre-mRNA, the polyA tail is not directly involved in the Morpholino's mechanism, but it is part of the splicing process.\\n\\n- **C) R-loops**: R-loops are RNA-DNA hybrids that form during transcription, displacing the other DNA strand. They are not part of the splicing mechanism or the Morpholino therapy, making them the correct answer.\\n\\n- **D) Antisense**: The Morpholino is an antisense molecule that binds to the 5' end of the exon, making this structure involved in the therapy.\\n\\nThus, the structure not involved in the therapy is **R-loops**.\\n\\nAnswer: C<ï½œendâ–ofâ–sentenceï½œ>\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>\\nOkay, so I've got this multiple-choice question about gene therapy and splicing. Hmm, I need to figure this out. Let's read the question again.\\n\\nThe question describes a gene with many exons, and the central ones code for triple helical repeats, which help connect the cytoskeleton with the sarcolemma and extracellular space. Oh right, those are structures involved in muscle cell communication, so maybe this is a gene related to muscle function. The common mutations are central exon deletions that cause out-of-frame peptides, leading to progressive degenerative organ waste. So when an exon is deleted, the reading frame shifts, making a nonfunctional protein, which can cause all sorts of issues.\\n\\nThe solution proposed is delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. Morpholinos are synthetic antisense oligonucleotides, right? They can block the spliceosome from binding, leading to exon skipping. Exon skipping is when the spliceosome skips an exon, joining the previous and next exons, resulting in a shorter mRNA. This allows the remaining exons to be joined in frame, so the resulting protein is still functional.\\n\\nSo the therapy works by preventing the spliceosome from recognizing a particular exon. This leads to the exon being skipped, and the rest of the exons are joined in frame, so no frame shift occurs. Since several missing exons are well tolerated, this seems like a viable treatment.\\n\\nThe question asks which structure is not involved in the proposed therapy. The options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nLet me think about each component.\\n\\nFirst, Morpholino is an antisense molecule. So antisense (option D) is definitely involved. Antisense molecules bind to RNA, preventing the spliceosome from recognizing it.\\n\\nIn the splicing process, the spliceosome recognizes exons and introns. The spliceosome uses a lariat structure when it splices. So when a splice occurs, a lariat is formed. So lariat (option A) is involved because the splicing process creates lariat-shaped structures.\\n\\nWhat about the polyA tail (option B)? The polyA tail is added to the mRNA during processing, which is part of the normal mRNA maturation. In splicing, the polyA tail is not directly involved. However, the polyadenylation (adding polyA) occurs after splicing, so the presence of the polyA tail might be part of the RNA processing. But during splicing, the polyA tail isn't directly involved in the splicing machinery. Wait, but the Morpholino targets pre-mRNA. Pre-mRNA undergoes splicing before polyadenylation, but sometimes polyadenylation can occur after splicing. I'm a bit fuzzy on the exact order, but I think in many cases, the polyA tail is added after splicing. So the polyA tail might not be directly involved in the splicing process that the Morpholino is targeting. Or does the Morpholino affect the splicing, which in turn affects the polyA tail?\\n\\nAlternatively, the polyA tail is part of the mRNA that is processed, but during the splicing step, the polyA is still there. So the Morpholino doesn't directly involve the polyA tail. So perhaps option B is not involved.\\n\\nWait, but I'm not entirely sure. Let me think about the process. The spliceosome binds to the pre-mRNA, which has exons and introns. The lariat is formed when an intron is spliced. So the spliceosome uses the polyA tail? Or does the polyA tail get added after splicing? I remember that the polyA signal is usually recognized after the mRNA has undergone splicing. So the splicing happens first, then the polyA tail is added. So the Morpholino targets the pre-mRNA during splicing, so the polyA tail isn't involved in the splicing process itself. So the polyA tail (option B) isn't part of the therapy mechanism. But wait, the pre-mRNA has the polyA tail? Or does the polyA tail come after splicing?\\n\\nHmm, maybe pre-mRNA refers to the RNA before splicing, which would include the polyA tail. Or does pre-mRNA not have the polyA tail yet? I'm a bit confused. Let me recall: mRNA processing steps are usually 5' capping, splicing, then polyadenylation. So the capping happens first, then splicing, then polyA addition. So the pre-mRNA before splicing is the same as the mRNA except without the polyA tail. So when the Morpholino targets the pre-mRNA, the polyA tail hasn't been added yet. So the polyA tail isn't part of the splicing process being targeted here. So option B (polyA tail) isn't involved in this therapy.\\n\\nWhat about R-loops (option C)? R-loops are structures formed during transcription where the RNA base-pairs with the DNA template, displacing the other RNA strand. R-loops are more commonly associated with gene expression issues, like in RNA interference or certain diseases. I don't see how R-loops would be involved in splicing or the use of antisense Morpholinos. The Morpholino is an antisense oligo that binds to the pre-mRNA, preventing the spliceosome from recognizing it. R-loops are more about RNA-DNA interactions, not directly involved in splicing. So R-loops (option C) would not be involved in this therapy.\\n\\nWait, but the question is which structure is NOT involved. So if I can eliminate which ones are involved.\\n\\nMorpholino is antisense (D involved). Lariat is formed during splicing (A involved). R-loops (C not involved). PolyA tail (B not involved). So the question is which of the four is not involved.\\n\\nWait, the question is asking which structure is not involved in the proposed therapy. So the therapy involves Morpholino (antisense) and the splicing process which forms lariats. The polyA tail is part of the mRNA but not directly involved in splicing. R-loops are not involved.\\n\\nSo the options not involved are B and C.\\n\\nWait, but the question says the therapy is about skipping an exon. So the spliceosome would not recognize that exon, leading to the next exon being joined. The spliceosome uses the 5' splice site and the 3' splice site. The Morpholino is antisense, binding to the 5' end of the exon. So the spliceosome can't recognize that, so the exon is skipped.\\n\\nSo the lariat is formed when the intron is spliced. But if the exon is skipped, the introns may or may not be processed. Wait, in exon skipping, the intron might be retained or removed. But the lariat is formed when the intron is removed. So if the exon is skipped, the intron is spliced out, leading to the lariat. So the lariat is definitely involved.\\n\\nThe polyA tail is part of the mRNA after splicing. So during splicing, the polyA isn't part of the process. So if the therapy is about splicing, the polyA tail (option B) wouldn't be involved. So the therapy wouldn't involve the polyA tail. So the question is, which option is not involved.\\n\\nWait, the question says: which structure is not involved in the proposed therapy?\\n\\nThe proposed therapy uses Morpholinos to block the spliceosome, leading to exon skipping. The structures involved would be:\\n\\n- Antisense (Morpholino) - D is involved.\\n\\n- Splicing machinery (which includes the spliceosome, lariat formation) - A is involved.\\n\\n- The pre-mRNA is processed without the polyA tail at the time of splicing, so B is not involved.\\n\\n- R-loops are unrelated to this process, so C is not involved.\\n\\nSo the structures not involved are B (polyA) and C (R-loops). The options are to choose which one is not involved.\\n\\nLooking at the options, the question is which one is not involved. So the correct answer is either B or C.\\n\\nWait, the options are four: A, B, C, D.\\n\\nThe therapy uses antisense (D is involved). Lariat (A is involved). The polyA tail (B) is added after splicing, so not involved in the splicing process. R-loops (C) are not involved in splicing or antisense mechanisms. So which of the options is not involved.\\n\\nThe question is which is not involved in the therapy. So the structures involved are lariat (A) and antisense (D). The structures not involved are polyA tail (B) and R-loops (C).\\n\\nThe question is which is not involved, so the possible answers are either B or C.\\n\\nWait, the question says, which structure is not involved in the proposed therapy? So the therapy uses Morpholinos which are antisense, so D is involved. The lariat is part of the process, so A is involved. The polyA tail is part of the mRNA but not involved in splicing, so B is not involved. R-loops are not part of this process, so C is not involved.\\n\\nSo the question is which is not involved. The options are: which is NOT involved.\\n\\nThe question says, which structure is NOT involved. So in the therapy, structures A, D, and perhaps others are involved. The structures not involved are B and C. So the options given are A to D.\\n\\nLooking at the question, the possible answers are B and C. But the question only gives four options. So which one is not involved.\\n\\nWait, the question is about structures\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ><think>\\nOkay, so I've got this biology question here about gene therapy and how it works with exons and splicing. Hmm, I'm a bit rusty on my genetics, but I'll try to think it through.\\n\\nThe question talks about a large gene with many exons, and the central ones code for these triple helical repeats. Oh wait, I remember that exons are the parts of mRNA that are included in the final protein after splicing. So each exon, in this case, codes for a triple alpha helix.\\n\\nThe most common mutations are central exon deletions, which cause out-of-frame peptides. Oh right, that leads to a frameshift mutation because the reading frame changes. Without the correct sequence, the protein becomes nonfunctional, leading to degenerative diseases.\\n\\nThe solution presented is using a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. I think Morpholinos are a type of antisense oligonucleotide, right? They're used to target specific RNA sequences. So the Morpholino would bind to the pre-mRNA, preventing the spliceosome from recognizing it. The spliceosome usually binds to the 5' splice site (donor) and 3' splice site (acceptor) of the exons. If the Morpholino blocks the splice site, the exon is skipped. Skipping an exon would mean the remaining exons are joined in a way that maintains the reading frame, preventing a frameshift. So the spliceosome joins the next available exons, like maybe the exon before and after the missing one.\\n\\nThe question is asking which structure isn't involved in this therapy. The options are lariat, polyA tail, R-loops, antisense.\\n\\nSo let's think about what happens during splicing. The spliceosome is involved in removing introns and joining exons. The spliceosome recognizes the donor and acceptor sites. During this process, a lariat structure is formed when an intron is spliced out. The intron is removed, and the exons are joined, creating a loop or lariat structure. So lariat would be involved.\\n\\nThe polyA tail is part of mRNA processing. It's added to the mRNA during the maturation process. I think the polyA binding proteins help stabilize the mRNA and are involved in export from the nucleus. But in this therapy, the Morpholino targets pre-mRNA, which is in the nucleus. So the polyA tail would be part of the mRNA but not directly involved in splicing. Wait, no, the polyA tail is added after splicing, I believe. The pre-mRNA has the introns and exons, and after splicing, the mRNA with the polyA tail is released. So during splicing, the polyA tail isn't part of the process. So in the therapy, the polyA tail might not be involved. Or wait, the pre-mRNA does have the polyA tail? No, pre-mRNA is the form before splicing. The polyadenylation comes after splicing. Hmm, I'm getting a bit confused.\\n\\nWait, pre-mRNA is the RNA that's still attached to the nucleus. It hasn't been spliced yet. The polyA tail is added during the processing of mRNA in the nucleus. So the pre-mRNA doesn't have the polyA tail. The polyA tail is added after splicing, as part of the mRNA that's exported from the nucleus to the cytoplasm.\\n\\nSo in the splicing process, the pre-mRNA is being processed. The spliceosome binds to the donor and acceptor sites. When an intron is spliced out, the exons are joined, and a lariat structure is formed. The polyA tail isn't part of that process, so in this therapy, which involves splicing, the polyA tail isn't involved.\\n\\nWait, but what about antisense? The Morpholino is an antisense molecule. Antisense means it has a sequence complementary to the target RNA. So yes, antisense is definitely involved because the Morpholino is an antisense oligonucleotide targeting the pre-mRNA.\\n\\nR-loops are structures formed when RNA binds to DNA, displacing the other DNA strand. I don't think R-loops are involved in splicing. The therapy here is about splicing, so R-loops probably aren't involved.\\n\\nSo the structures involved are lariat (from splicing), antisense (the Morpholino), and spliceosome components (donor and acceptor sites). Which one isn't involved?\\n\\nThe question is which structure is not involved. The options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nSo polyA tail is part of the mRNA, but not involved in splicing. The therapy targets pre-mRNA during splicing. So the polyA tail isn't involved in the process of skipping the exon. Therefore, the correct answer would be B) polyA tail.\\n</think>\\n\\nThe question involves a gene therapy approach using a Morpholino, a type of antisense oligonucleotide, to target the 5' end of an out-of-frame exon in pre-mRNA. This therapy prevents the spliceosome from recognizing the exon, leading to its skipping and in-frame joining of adjacent exons. The goal is to determine which structure is not involved in this process.\\n\\n- **Option A: Lariat**  \\n  A lariat structure is formed during splicing when an intron is removed. This structure is directly involved in the splicing process, so it is relevant to the therapy.\\n\\n- **Option B: PolyA tail**  \\n  The polyA tail is added to mRNA after splicing and is part of the mature mRNA. However, the therapy targets pre-mRNA during splicing, and the polyA tail is not involved in the splicing process itself. Therefore, this structure is not involved in the proposed therapy.\\n\\n- **Option C: R-loops**  \\n  R-loops are RNA-DNA hybrids that form when RNA displaces the DNA strand. These structures are unrelated to the splicing process or the use of antisense molecules like Morpholinos, so they are not involved.\\n\\n- **Option D: Antisense**  \\n  The Morpholino is an antisense molecule that binds to the pre-mRNA to block the spliceosome. Antisense molecules are central to the therapy, so this structure is involved.\\n\\nThe polyA tail is not involved in the splicing process or the proposed therapy, making it the correct answer. \\n\\n**Answer: B**<ï½œendâ–ofâ–sentenceï½œ>\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>\\nOkay, so I've got this genetics question here, and I need to figure it out. Let me try to break it down. I'm a bit rusty on my splicing mechanisms, but I'll think it through.\\n\\nThe question is about a gene with multiple exons, and the central ones code for triple helical repeats. These are involved in connecting the cytoskeleton with the sarcolemma and extracellular space. So that's probably some structural role, maybe like in muscle or something.\\n\\nThe common mutations are central exon deletions causing out-of-frame peptides and leading to progressive degeneration. Oh right, when an exon is skipped, if the reading frame is disrupted, it leads to a messed-up protein, which can cause diseases like muscular dystrophy. So the solution here is using a Morpholino, which is a type of antisense oligo, I think. These are used in gene therapy to target specific mRNA molecules.\\n\\nThe Morpholino is designed to recognize the 5' end of the out-of-frame exon in pre-mRNA. So when it binds, it prevents the spliceosome from recognizing the exon, leading to its skipping. This allows the remaining exons to be joined in a frame that's in-frame, so the protein is correctly translated without frameshifts.\\n\\nThe question asks which structure is not involved in this therapy. The options are lariat, polyA tail, R-loops, and antisense.\\n\\nLet me think about what happens during splicing. The spliceosome is involved, which includes snRNPs like U1, U2, etc. The spliceosome recognizes splice sites, which are the GU and AG dinucleotides. The introns are removed, and exons are joined.\\n\\nIn this therapy, the Morpholino targets the 5' end of the exon. So the pre-mRNA has the exon, and the Morpholino binds to its 5' end. The spliceosome's normal process would recognize the 3' splice site of the previous exon and the 5' splice site of the next exon. If the Morpholino blocks the 5' end of the exon, perhaps the spliceosome can't recognize the next exon's 5' site. So the exon is skipped, and the splicing joins the previous and next exons in a way that the reading frame is maintained.\\n\\nWait, but how does the spliceosome normally recognize exons? Oh right, each exon has a 5' splice site (GU) and a 3' splice site (AG). The U2 snRNP recognizes the branch site adenine, which is in the intron, and U1 and U2 help in the splicing.\\n\\nWhen the Morpholino binds the 5' end of the exon, it probably blocks the spliceosome from recognizing the normal 3' splice site of the next exon. So the next exon's 5' site is not recognized. So the splicing machinery might skip over that exon.\\n\\nBut what structures are involved here? Let's think.\\n\\nThe spliceosome is involved, which uses the polyA tail. Wait, the polyA tail is part of mRNA processing. The spliceosome is involved in removing the polyA tail? Or is that another process? No, the polyA tail is added by the poly-A polymerase, and it's part of mRNA processing. The spliceosome doesn't directly use the polyA tail. But the pre-mRNA has a polyA tail, which is removed as part of the splicing process.\\n\\nWait, the polyA tail is part of the 3' end of the mRNA. When the spliceosome acts, it removes the introns, which includes the polyA tail? No, wait, the polyA tail is at the very end of the mRNA. The spliceosome splices out the introns, but the polyA tail remains as part of the processed mRNA. Or wait, is the polyA tail added after splicing? I think the splicing occurs first, then the polyA addition.\\n\\nSo, in this therapy, the Morpholino is preventing the spliceosome from recognizing the exon's 5' end. So the spliceosome can't proceed normally, the exon is skipped, and the next exon is processed.\\n\\nNow, the options: the structures involved are probably the spliceosome, lariat structures (which are formed when introns are spliced out), and maybe the polyA tail. Antisense is the Morpholino, which is part of the therapy, so it's involved.\\n\\nWhich option isn't involved? The question is asking which structure is not involved.\\n\\nThe options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nAntisense (D) is definitely involved because the Morpholino is an antisense molecule. So D is involved.\\n\\nLariat structures are part of the splicing process. When the spliceosome acts, it creates a lariat structure as the intron is removed. So A is involved.\\n\\nThe polyA tail is part of the mRNA, which is processed after splicing. So during splicing, the polyA tail isn't directly involved because the polyA addition occurs later. Wait, but the pre-mRNA has a polyA tail. Hmm, but the spliceosome mainly deals with the exons and introns, not the polyA tail. So during splicing, the polyA tail is still there. So when the therapy works by preventing splicing, the polyA tail is still present.\\n\\nSo in this scenario, the polyA tail is part of the mRNA but isn't directly involved in the splicing process. So during the splicing, the polyA tail is present but not acted upon. So B) polyA tail is involved in the overall mRNA processing but not in the splicing event that's happening here.\\n\\nWait, no. The splicing process occurs before the polyA tail is added. So the polyA tail is part of the pre-mRNA, which is being processed. The spliceosome acts on the pre-mRNA which includes the polyA tail. So does the spliceosome interact with the polyA tail?\\n\\nHmm, I'm a bit fuzzy on that. The polyA tail is at the 3' end, after the last exon. The spliceosome recognizes the 3' splice site of the last exon. So the polyA tail is part of the pre-mRNA. So when the spliceosome is active, it's processing the introns, including the polyA tail? Or is the polyA tail not part of the intron and therefore not involved in splicing.\\n\\nWait, the polyA tail is a part of the 3' end of the pre-mRNA. It's not part of any introns. So during splicing, the spliceosome doesn't interact with the polyA tail. So the polyA tail is present but remains untouched during splicing.\\n\\nSo in the therapy, when the Morpholino causes the exon to be skipped, the spliceosome still uses its normal mechanisms, but skips the exon. So the polyA tail remains in the mRNA.\\n\\nBut the question is about structures involved in the therapy. So the spliceosome is involved, which uses the polyA tail? No, the polyA tail is part of the pre-mRNA but isn't used by the spliceosome. The spliceosome uses the branch site (which is in the intron) and the 5' and 3' splice sites (in the exons).\\n\\nSo, in this therapy, the polyA tail is part of the pre-mRNA but isn't directly involved in the splicing process. So which of the options is not involved?\\n\\nThe options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nSo the structures involved are lariats (A), antisense (D), and the spliceosome. The polyA tail (B) is part of the pre-mRNA but not directly involved in the splicing process that's being blocked. So B is not involved.\\n\\nWait, but wait, when the spliceosome removes introns, it forms a lariat structure. So A) is involved. The antisense Morpholino is part of the therapy, so D) is involved. The spliceosome is involved, but the question isn't about the spliceosome, but the structures.\\n\\nSo the structures involved in the therapy would be: lariats (since introns are being removed), antisense (Morpholino), and the spliceosome. The polyA tail is part of the pre-mRNA but isn't directly involved in the splicing mechanism that's happening here.\\n\\nWhat about R-loops? R-loops are structures formed when RNA binds to DNA and displaces the other DNA strand. They're more related to DNA-RNA interactions, like in the case of some RNA interference mechanisms or in the processing of RNA. But I don't see how R-loops are involved in splicing or in this therapy.\\n\\nSo in this therapy, which structures aren't involved? The question asks which structure is NOT involved.\\n\\nThe options are A, B, C, D. The therapy uses antisense (D), so D is involved. It creates lariats (A) as part of splicing. The spliceosome is involved, but the question doesn't list the spliceosome as an option. So the structures in the options are A, B, C, D.\\n\\nWait, but the question is about which structure is not involved. So the structures involved in the therapy are lariat (A) and antisense (D). The spliceosome is involved but isn't one of the options. The polyA tail (B) is part of the pre-mRNA but isn't directly involved in the splicing process. R-loops (C) are not involved either.\\n\\nWait, but the question is about the structures that are part of the therapy. So the therapy uses an antisense\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ><think>\\nOkay, so I've got this question about gene therapy involving Morpholinos and exon skipping. Hmm, I'm a bit rusty on my genetics, but let me think this through.\\n\\nThe question says that there's a large gene with many exons, and the central ones code for triple helical repeats that help connect the cytoskeleton to the sarcolemma and extracellular space. So these exons are probably structural, involved in cell structure, maybe like parts of the cell's machinery.\\n\\nThe mutations in question are central exon deletions, which cause out-of-frame peptides. Oh right, when an exon is deleted and the reading frame is messed up, it leads to a truncated protein. Because the frame shifts, the rest of the protein might be messed up too, leading to disease. So these are probably nonsense mutations.\\n\\nThe solution mentioned is delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. Morpholinos are small molecules that bind to RNA. I remember they can act as antisense oligonucleotides or guide RNA. So when this Morpholino binds to the pre-mRNA, it stops the spliceosome from binding. That leads to exon skippingâ€”so the exon is skipped during splicing, and the rest of the mRNA joins in frame.\\n\\nExon skipping is a form of RNA editing. When an exon is skipped, the mRNA joins the surrounding exons in a way that doesn't disrupt the reading frame. So the resulting protein is still in-frame, which is good because it avoids the frame shift issues.\\n\\nThe question asks which structure isn't involved in this therapy. The options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nLet me think about each structure.\\n\\nThe spliceosome is involved in splicing, right? The pre-mRNA is processed by the spliceosome, which recognizes splice sites. So when the Morpholino binds, it prevents the spliceosome from recognizing the exon's splice sites. So the spliceosome doesn't bind, which leads to the exon being skipped. So the spliceosome is involved here. So the structures related to splicingâ€”like the lariat (which is the intron that's incorporated into the mRNA as a loop), polyA tail (which is added during mRNA processing but maybe not directly involved in splicing?), antisense molecules (like Morpholinos) are involved.\\n\\nWait, the polyA tail is part of mRNA processing. So when the mRNA is being processed, it's being capped and getting the polyA. But in this therapy, are they modifying the mRNA before or after splicing? The Morpholino is targeting the pre-mRNA. So perhaps the polyA tail is present on the mRNA, but in the splicing process, the polyA is not directly involved in the splicing machinery's recognition of the exon's 5' end.\\n\\nWait, but the spliceosome has components that recognize the splice sites. The 5' splice site is an adenine residue, and the 3' is a guanine. The Morpholino would bind the pre-mRNA at the 5' end of the exon, perhaps preventing the spliceosome from recognizing the 5' splice site. So the spliceosome can't process that exon, leading to its skipping.\\n\\nNow, the structures involved in splicing include the splice sites (like the branch site, exonic or intronic splicing enhancers), the lariat structure (since when an intron is spliced, a lariat is formed), and the polyA tail is more about mRNA stability and export, I think.\\n\\nWait, the polyA tail is added to the mRNA after splicing. So in the process, the pre-mRNA goes through splicing, then capping, then polyadenylation. So the Morpholino binds the pre-mRNA, which is before splicing is complete. But in the splicing process, the introns are being removed, and lariats are formed when introns are spliced out. So if the Morpholino is binding the exon's 5' end, that's part of the pre-mRNA before splicing.\\n\\nSo the structures involved are the splice sites, the pre-mRNA, the spliceosome, the lariat (since when an exon is skipped, perhaps the intron is still processed?), the polyA tail is added after splicing.\\n\\nWait, but in the therapy, the Morpholino is delivered to prevent the spliceosome from binding. So the spliceosome doesn't process that exon. So the mRNA that's produced would have the exon skipped, leading to the next exons being joined in frame.\\n\\nSo the structures involved are: pre-mRNA (with the Morpholino bound), splice sites (5' end of the exon), spliceosome, and the lariat (if an intron is still being spliced). But what about the polyA tail? The polyA tail is part of the mRNA after splicing. So in the normal processing, the polyA is added after the splicing. So during splicing, the polyA hasn't been added yet.\\n\\nIn the therapy, the Morpholino is targeting the pre-mRNA, so the polyA tail hasn't been added yet. So the polyA tail wouldn't be part of this process. Or wait, does the polyA tail come in after splicing? Let me think: mRNA processing steps are capping, splicing, then polyadenylation. So in the case of the therapy, the pre-mRNA has the Morpholino attached. The spliceosome is being inhibited, so the exon is skipped. The mRNA that's processed would have the intron removed, but without the lariat if the exon is skipped. Wait, no. If the exon is skipped, the intron is still present in the pre-mRNA, so when the spliceosome processes it, it would still form a lariat. But in this case, the spliceosome isn't binding because of the Morpholino, so the intron isn't removed. Wait, no, the Morpholino prevents the spliceosome from binding. So the intron would remain, but without splicing. So the mRNA would still have the intron, but since the question says that the solution is to create exon skipping, I'm a bit confused.\\n\\nWait, maybe I'm mixing up the process. If the spliceosome can't bind, perhaps the exon is retained, but how? Exons are usually removed, not retained. Oh, but the alternative is that the exon is skipped, so the introns are still present, but not spliced. So the mRNA would have the introns. But that's not typical. Alternatively, perhaps the spliceosome can't recognize the 5' splice site, so the exon is skipped, but the intron is still processed. Hmm, I'm a bit rusty on that.\\n\\nWait, the normal process is that the spliceosome recognizes the 5' splice site (adenine) and the branch site. The 5' splice site is at the beginning of the intron. If the Morpholino prevents the spliceosome from recognizing the 5' end of the exon, maybe it's preventing the spliceosome from recognizing the 5' splice site of the intron. So the intron's 5' splice site is not recognized, so the intron isn't spliced. Wait, but the intron is part of the pre-mRNA. Without the spliceosome binding, perhaps the intron isn't spliced out, so the mRNA would still have the intron. But that's not how exons are skipped. Exons are skipped when the intron is spliced out, so the mRNA skips over the intron.\\n\\nWait, perhaps the Morpholino is targeting the exon's 5' end. So the spliceosome can't recognize the 5' splice site of the intron, so the intron isn't spliced. But that would lead to the mRNA still containing the intron. But I'm not sure how that leads to exon skipping. Alternatively, perhaps the Morpholino blocks the spliceosome from recognizing the exon's splice sites, so the exon is skipped, but the intron is still processed.\\n\\nWait, another angle: when the spliceosome can't bind, the exon is skipped. So the intron is still present. But how does that lead to the mRNA being in-frame? Maybe the intron is just retained, but I thought that when exons are skipped, the surrounding exons are joined in frame. So the lariat structure would form only if the intron is being spliced. If the intron isn't spliced, would that lead to a lariat? Or perhaps the lariat is not formed because the intron isn't spliced. So perhaps the lariat is not part of this process in the therapy.\\n\\nWait, but I'm not sure. Let me think of each option.\\n\\nOption A: lariat. In the therapy, if the spliceosome can't process the intron because of the Morpholino, the intron remains. So the lariat would not be formed. So the lariat is not involved. Or wait, if the intron isn't spliced, does a lariat form? I thought lariats form when the intron is spliced. So if the intron isn't spliced, no lariat is formed. So the lariat structure is not involved in this therapy.\\n\\nOption B: polyA tail. The polyA tail is added after splicing. So during splicing, the mRNA is being processed without the polyA. So the polyA is not part of the splicing process, so it's not involved in the therapy. Or wait, the pre-mRNA is the one that's being targeted. So the polyA tail is added after splicing, so it's not involved in the splicing process here. So\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ><think>\\nOkay, so I've got this question about a gene mutation and a therapy involving Morpholinos. Hmm, I'm a bit rusty on some of these concepts, but let me try to think it through.\\n\\nThe question describes a gene with many exons, and the central ones code for triple helical repeats. Each exon usually codes for one of these repeats. The common mutation is a central exon deletion, which causes out-of-frame peptides and leads to progressive degeneration. The therapy proposed uses a Morpholino that targets the 5' end of the out-of-frame exon in pre-mRNA. This molecule prevents the spliceosome from binding, causing exon skipping and in-frame joining. It also says that skipping several exons is tolerable.\\n\\nThe question is asking which structure isn't involved in the therapy. The options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nWait, let's break down what's happening here. So, the spliceosome uses a series of steps to process pre-mRNA. The spliceosome recognizes exons and introns. It uses splice sites, which are the GU at the beginning of an intron and AG at the end. The spliceosome also incorporates a branch site, which is where an intron loop forms, creating a lariat structureâ€”so that's a lariat. So lariat formation is definitely involved. So option A is involved, so it's not the answer.\\n\\nThe Morpholino is an antisense molecule, right? Because antisense molecules are designed to bind to specific RNA sequences. So the Morpholino would bind to the pre-mRNA at the 5' end of the exon, preventing the spliceosome from recognizing it. So antisense (option D) is involved, so D is not the correct answer.\\n\\nNow, the polyA tail. Wait, the polyA tail is added to the mRNA after splicing, I think. The pre-mRNA is processed through splicing, then polyadenylation happens. The polyA tail is part of the mature mRNA. The Morpholino is targeting the pre-mRNA, so does the polyA tail play a role in the therapy? Maybe not directly, because the Morpholino is working before the polyA tail is added. Alternatively, perhaps the polyA tail isn't involved in the splicing process, but wait, the spliceosome does interact with the polyA tail indirectly. Because the polyA binding proteins (PABP) are involved in the splicing process. Oh wait, I remember that the polyA signal is recognized by the spliceosome. So in the normal splicing process, the branch site and the polyA signal are involved. But in this therapy, the Morpholino is preventing the spliceosome from binding. So in the therapy, the polyA tail's presence might not be necessary for this process. Or does it play another role?\\n\\nAlternatively, perhaps the polyA tail is part of the mRNA that's being processed. But the Morpholino is binding the pre-mRNA, so I'm not sure if the polyA tail is involved in the therapy. Hmm.\\n\\nWhat about R-loops? R-loops are structures where the RNA is hybridized to the DNA, displacing the other DNA strand. They can form during transcription when RNA binds to DNA. But I don't see how R-loops are involved in splicing or in this Morpholino therapy. The therapy seems to be about preventing spliceosome binding. R-loops are more about DNA and RNA interactions during transcription. So I don't think R-loops are involved in this process. So option C might be the correct answer, as it's not involved.\\n\\nSo the structures involved are lariat (A), antisense (D), and maybe the polyA tail (B) in normal processes, but in this therapy, perhaps B is not directly involved. Alternatively, in this case, the therapy doesn't involve the polyA tail because the Morpholino is targeting pre-mRNA, which hasn't been polyadenylated yet. So the polyA tail's presence in the therapy process is probably not involved.\\n\\nWait, but the polyA tail is part of the mRNA that is processed. So in the normal process, the polyA tail is present on the mature mRNA. But in this therapy, the Morpholino is acting on the pre-mRNA before it's polyadenylated. So the presence of the polyA tail isn't necessary for this therapy. So B) polyA tail is not involved in the therapy. So the structure that's not involved is B.\\n\\nWait, but another thought: the polyA signal is recognized by the spliceosome. So in normal splicing, the branch site is the branch site, and the polyA signal is upstream of it. The spliceosome uses these elements to form the lariat. So if the Morpholino is preventing the spliceosome from binding, the presence of the polyA tail (B) might not be directly involved in the therapy's mechanism. But I'm not entirely certain.\\n\\nWait, the question is about which structure is NOT involved. So which of these four is not part of the therapy's process.\\n\\nThe Morpholino binds to the pre-mRNA, which is being processed. The spliceosome's binding is prevented. The spliceosome's normal function involves the lariat (A), so A is involved. The process uses the polyA tail? Or maybe the polyA tail isn't part of the process at all. Because the polyA tail is added after splicing, I think. So if the Morpholino is working on the pre-mRNA, the polyA tail hasn't been added yet. So the presence of the polyA tail (B) wouldn't be involved in the therapy. So B is the structure not involved.\\n\\nSo the options are:\\n\\nA) lariat â€” involved, since splicing creates lariat.\\n\\nB) polyA tail â€” not involved, because the therapy targets pre-mRNA which hasn't been polyadenylated yet.\\n\\nC) R-loops â€” not involved, as this process is about splicing, not DNA-RNA interactions during transcription.\\n\\nD) antisense â€” involved, since Morpholino is antisense targeting.\\n\\nSo the question is asking which is not involved. So the options that are involved are A, B? Wait, no, wait. Wait, the polyA tail is part of the mRNA. Does the spliceosome interact with it? I think the polyA signal is part of the branch site recognition. So in the normal process, the polyA tail is involved. But in this therapy, the polyA tail isn't present yet because the pre-mRNA hasn't been polyadenylated. So the therapy is targeting pre-mRNA, which doesn't have the polyA tail.\\n\\nSo the structures that are involved in the therapy's process are lariat (A) and antisense (D). The therapy process doesn't involve the polyA tail (B), because the pre-mRNA hasn't been polyadenylated yet. It also doesn't involve R-loops (C), because the process is about splicing, not RNA-DNA interactions.\\n\\nSo the question is which is not involved. The options are A, B, C, D.\\n\\nThe question asks which structure is NOT involved. So the possible answers are either B or C.\\n\\nWhich of these is not involved in the therapy.\\n\\nIf the therapy is about preventing spliceosome binding via Morpholino, then the spliceosome components (like the snRNA) are involved. The lariat is formed during splicing, so that's involved. Antisense is used in the Morpholino, so D is involved.\\n\\nWhat about R-loops? They're more about transcription and DNA, not splicing. So C is not involved.\\n\\nSo the structures not involved are C and B? Or only C?\\n\\nWait, polyA tail is part of the mRNA. The therapy is about pre-mRNA. So the polyA tail isn't present in the pre-mRNA. Hence, the presence of the polyA tail (B) isn't part of the therapy. So the therapy doesn't involve the polyA tail.\\n\\nSo the answer is either B or C.\\n\\nThe question is which is not involved.\\n\\nThe structures involved are A (lariat) and D (antisense). The structures not involved are B and C.\\n\\nThe question is, which is not involved? So the options are A, B, C, D.\\n\\nThe options are:\\n\\nA) lariat â€” involved.\\n\\nB) polyA tail â€” not involved.\\n\\nC) R-loops â€” not involved.\\n\\nD) antisense â€” involved.\\n\\nSo the answer is either B or C.\\n\\nSo the question is, which of these is not involved in the proposed therapy.\\n\\nThe therapy uses Morpholino that targets pre-mRNA. So the spliceosome's function is prevented. The spliceosome's function involves the lariat (A), and the antisense (D) is the Morpholino.\\n\\nSo the process does not involve R-loops (C) because R-loops are about transcription and DNA, while splicing is separate.\\n\\nSo the answer is C) R-loops is not involved.\\n\\nSo the correct answer is C.\\n</think>\\n\\nThe question involves a therapy targeting pre-mRNA with a Morpholino molecule to prevent spliceosome binding, resulting in exon skipping. The goal is to identify which structure is not involved in this process.\\n\\n1. **Option A: Lariat**  \\n   The lariat structure is formed during splicing when an intron is removed, creating a branch site. This structure is directly involved in the splicing process, so it is involved in the therapy.\\n\\n2. **Option B: PolyA tail**  \\n   The polyA tail is added to mRNA after splicing. However, the Morpholino targets pre-mRNA, which has not yet undergone polyadenylation. Therefore, the polyA tail is not part\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ><think>\\nOkay, so I've got this genetics question here, and I need to figure it out. Let me read it again.\\n\\nThe question is about a gene with multiple exons, and the central ones code for triple helical repeats that connect the cytoskeleton, sarcolemma, and extracellular space. So those exons are probably structural, maybe involved in the formation of structures like muscle or something.\\n\\nThe mutations they're talking about are central exon deletions. These cause out-of-frame peptides, which leads to progressive degenerative organ waste. So that's like a frameshift mutation, right? Because when an exon is deleted, if it's not a multiple of three nucleotides, the reading frame shifts, leading to a completely different amino acid sequence after that point.\\n\\nThe solution proposed is to use a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. Morpholinos are synthetic molecules that can act as antisense oligonucleotides. They can block the binding of the spliceosome, which leads to exon skipping. Exon skipping is when the splicing machinery skips an exon, joining the previous and next exons, so the mRNA lacks that exon. So if they're preventing the spliceosome from binding, the exon is skipped, and the mRNA joins in a way that's in-frame, so the reading frame is maintained.\\n\\nThe question is which structure isn't involved in this therapy. The options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nHmm. Let's think about the process.\\n\\nIn splicing, the spliceosome recognizes the donor and acceptor sites. The pre-mRNA has introns and exons. The spliceosome binds to the 5' splice site (donor) and 3' splice site (acceptor) of the intron. The intron is then removed, and the exons are joined.\\n\\nIn the case of Morpholino, it's designed to bind the 5' end of the exon. Wait, the question says the Morpholino recognizes the 5' end of the out-of-frame exon in pre-mRNA. So the Morpholino would bind to the exon's 5' end, preventing the spliceosome from binding. So the spliceosome can't recognize the exon's 5' end as the donor site. So the spliceosome would skip this exon, perhaps.\\n\\nWait, no. Let me think. The spliceosome normally binds to the donor site (GU) at the 5' end of the intron. If the Morpholino is binding the 5' end of the exon, that would be after the splice donor. So perhaps the Morpholino is targeting an exon's 5' end, which is not the usual splice site.\\n\\nWait, maybe I'm getting confused. The splice donor is the GU at the 5' end of the intron, not the exon. So the Morpholino isn't binding the intron's donor site but a region on the exon.\\n\\nSo when the spliceosome is supposed to recognize the donor site, but the Morpholino is blocking that. Wait, noâ€”maybe the Morpholino is preventing the spliceosome from recognizing the exon's end as part of the splicing machinery.\\n\\nAlternatively, perhaps the Morpholino is designed to prevent the spliceosome from binding to the exon's 5' end, so the spliceosome can't recognize it as part of the intron. So the spliceosome would try to splice, but since the exon's 5' isn't recognized, it might skip it.\\n\\nWait, I'm not too clear on how that works. Let me think about the process. The spliceosome binds the intron's donor and acceptor sites. When the Morpholino binds the exon's 5' end, perhaps it blocks the spliceosome from recognizing the intron's sites. So the intron would be retained, but maybe the spliceosome can't process it, leading to the exon being skipped.\\n\\nAlternatively, perhaps the Morpholino is antisense to the exon, meaning it's complementary and blocks the spliceosome from binding.\\n\\nSo the process here is antisense binding. Antisense molecules can form structures like DNA-RNA hybrids, but in this context, the Morpholino is an antisense oligo that blocks the spliceosome.\\n\\nNow, the question is what structures are involved. The options are lariat, polyA tail, R-loops, antisense.\\n\\nIn splicing, when an intron is spliced out, it's cleaved by the spliceosome, which includes U2 snRNP recognizing the donor site. The spliceosome then removes the intron and joins the exons. The process creates a lariat structure because the branch site adenine forms a lariat-shaped loop in the RNA.\\n\\nWait, the lariat is part of the splicing mechanism. So during splicing, a lariat is formed. So if the therapy is preventing the spliceosome from binding, then the lariat structure is not formed. So the lariat (option A) is involved.\\n\\nThe polyA tail is part of mRNA processing. The polyA signal is recognized by the capping enzyme, which adds the cap, and then the polyA tail is added. But in the context of splicing, I don't think the polyA tail is directly involved. Unless the question is about the mRNA processing steps beyond splicing. So the pre-mRNA goes through splicing and then is processed to add the polyA tail. But in the therapy, the Morpholino is preventing splicing. So the polyA tail isn't part of the splicing mechanism. So the polyA tail (option B) is not involved in the therapy.\\n\\nR-loops are RNA-DNA hybrids with the displaced DNA strand. I don't think R-loops are part of splicing. Splicing occurs in the nucleus, but R-loops can form in various contexts, including during transcription. Not sure if this is relevant here.\\n\\nAntisense is part of the therapy. The Morpholino is an antisense molecule. So antisense (option D) is definitely involved.\\n\\nSo the structures involved in the therapy are: the lariat (since splicing creates it), antisense (the Morpholino), and the spliceosome's action. The polyA tail is not part of the splicing process. So the structure not involved is the polyA tail.\\n\\nAlternatively, another angle: The Morpholino is an antisense oligo, so it's part of the antisense structure. The spliceosome's action would create the lariat. The polyA tail is added after splicing, so the therapy doesn't involve it.\\n\\nSo the question is which structure isn't involved. The options are A) lariat, B) polyA, C) R-loops, D) antisense.\\n\\nSo, the therapy doesn't involve the polyA tail. So the answer is B.\\n</think>\\n\\nThe question involves a gene with multiple exons, where central exons code for structural proteins. Mutations causing central exon deletions lead to out-of-frame peptides and degenerative effects. The proposed therapy uses a Morpholino, a synthetic antisense molecule, to block the spliceosome from binding to the 5' end of an out-of-frame exon in pre-mRNA. This prevents exon skipping and restores the reading frame, allowing the mRNA to be in-frame and tolerable.\\n\\nIn the splicing process, the spliceosome recognizes the donor and acceptor sites of introns, removes the intron, and joins the flanking exons. During this process, a lariat structure is formed at the branch site. The polyA tail is added to the mRNA after splicing, as part of mRNA processing, but it is not directly involved in the splicing mechanism or the Morpholino's action. R-loops are RNA-DNA hybrids and are unrelated to splicing. Antisense molecules, such as the Morpholino, are part of the therapy as they block the spliceosome.\\n\\nThe therapy involves the lariat structure (formed during splicing), antisense molecules (the Morpholino), and the spliceosome's action. However, the polyA tail is not involved in the splicing process or the Morpholino's function. Therefore, the structure not involved in the proposed therapy is the polyA tail.\\n\\n**Answer: B**<ï½œendâ–ofâ–sentenceï½œ>\"], 'correct': [False, False, True, False, False, True, True, False, False, False, False, False, True, True, False, False, False, False, False, False, False, False, False, False, False, True, False, False, False, False, False, False], 'explanations': [\"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='C'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='C'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='B'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='C'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='B'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='B'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='C'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='B'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='B'; truth='C'\"], 'num_tokens': [[0, 2048], [0, 2048], [892, 1223], [0, 2048], [0, 2048], [767, 1052], [843, 1197], [0, 2048], [1625, 2035], [0, 2048], [0, 2048], [0, 2048], [863, 1204], [1080, 1420], [0, 2048], [0, 2048], [1287, 1700], [0, 2048], [0, 2048], [1814, 2048], [0, 2048], [1888, 2048], [876, 1217], [0, 2048], [0, 2048], [1218, 1552], [0, 2048], [1037, 1365], [0, 2048], [0, 2048], [1904, 2048], [1442, 1737]], 'rewards': [0.01483154296875, 0.01092529296875, 0.072265625, 0.011962890625, 0.01806640625, 0.06689453125, 0.07861328125, 0.01055908203125, 0.0576171875, 0.0125732421875, 0.0172119140625, 0.0174560546875, 0.0576171875, 0.060791015625, 0.0172119140625, 0.01214599609375, 0.060546875, 0.0191650390625, 0.019775390625, 0.029541015625, 0.0069580078125, 0.030517578125, 0.07275390625, 0.01483154296875, 0.009765625, 0.06787109375, 0.0166015625, 0.07666015625, 0.0146484375, 0.00836181640625, 0.033447265625, 0.06201171875], 'ground_truths': ['C'], 'question_meta': None, 'model_name': 'hf_chat:deepseek-ai/DeepSeek-R1-Distill-Qwen-7B', 'reward_model_name': 'armo_rm:RLHFlow/ArmoRM-Llama3-8B-v0.1'}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 25%|â–ˆâ–ˆâ–Œ       | 3/12 [00:07<00:24,  2.69s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'qid': 'gpqa-1', 'prompt': \"Answer the following multiple choice question. The last line of your response should be of the following format: 'Answer: $LETTER' (without quotes) where LETTER is one of ABCD. Think step by step before answering.\\n\\nA large gene has dozens of exons, of which the central ones code for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space. Each exon usually codes for one folded triple alpha helix. The most common mutations of the gene are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste. A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. The molecule prevents binding of the spliceosome and creates exon skipping and in-frame joining. Several missing exons are well tolerated by an organism. Which structure below is not involved in the proposed therapy?\\n\\nA) lariat\\nB) polyA tail\\nC) R-loops\\nD) antisense\", 'answers': [\"To determine which structure is not involved in the proposed therapy, let's first understand the context and the steps involved:\\n\\n1. **Gene Structure**: The gene contains several exons, with the central ones coding for folded triple helical repeats.\\n2. **Mutations**: Central exon deletions create out-of-frame peptides, leading to progressive degenerative organ waste.\\n3. **Solution**: Morpholino molecules are used to target the 5' end of the out-of-frame exon in pre-mRNA.\\n4. **Mechanism**: These Morpholinos prevent the spliceosome from binding to the exon, thus causing exon skipping and in-frame joining of the remaining exons.\\n\\nNow, let's consider each option:\\n\\nA) **lariat**: This refers to a circular intermediate structure formed during RNA splicing. While it plays a role in the normal splicing process, it is not directly involved in the Morpholino-mediated skipping of exons.\\n\\nB) **polyA tail**: This is a polyadenylate tail that is added to the 3' end of mRNA after splicing. It is not directly related to the proposed therapy of exon skipping.\\n\\nC) **R-loops**: These are structures formed during transcription where the single-stranded DNA region of a nascent RNA molecule loops around its complementary DNA template strand. They are not typically associated with the splicing process or the Morpholino-mediated exon skipping mechanism.\\n\\nD) **antisense**: This refers to a strand of RNA that can bind to a complementary sequence on another RNA or DNA strand, often used in RNA interference or therapeutic applications. In this context, Morpholinos are antisense oligonucleotides that specifically bind to the target sequence.\\n\\nBased on this analysis, the structure that is not directly involved in the proposed therapy of exon skipping is:\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's first understand the process described:\\n\\n1. **Gene Structure**: The gene has dozens of exons, with the central ones coding for folded triple helical repeats.\\n2. **Mutation**: Central exon deletions lead to out-of-frame peptides and progressive degenerative organ waste.\\n3. **Therapy**: Delivery of a Morpholino that targets the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the spliceosome from binding, leading to exon skipping and in-frame joining.\\n\\nNow, let's analyze each option:\\n\\nA) **lariat**: This refers to a type of RNA structure formed during splicing, where the intron loops back onto itself. It is involved in the splicing process but not directly related to the Morpholino's action of preventing spliceosome binding.\\n\\nB) **polyA tail**: This is a sequence of adenine nucleotides added to the 3' end of mRNA molecules after they are processed by the cell. It is not directly involved in the spliceosome recognition or the exon skipping process.\\n\\nC) **R-loops**: These are structures formed during transcription when the DNA template strand remains hybridized to the newly synthesized RNA strand, leaving a single-stranded region. They can affect splicing processes but are not directly related to the Morpholino's mechanism.\\n\\nD) **antisense**: This refers to a complementary RNA sequence that can bind to and inhibit the activity of another RNA or protein. In this context, it could potentially interfere with the Morpholino's action if it binds to the target mRNA.\\n\\nBased on this analysis, the structure that is not directly involved in the proposed therapy involving the Morpholino is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To solve this problem, let's break down the key elements of the therapy described:\\n\\n1. **Central Exon Deletions**: These cause out-of-frame peptides and lead to progressive degenerative organ waste.\\n2. **Morpholino Therapy**: It targets the 5' end of the out-of-frame exon in pre-mRNA.\\n3. **Exon Skipping and In-Frame Joining**: This prevents the creation of the abnormal peptide sequence and allows normal protein production.\\n\\nNow, let's consider each option:\\n\\nA) **lariat**: This refers to a circular RNA structure that forms during RNA splicing. It is part of the RNA splicing process but is not directly involved in the Morpholino therapy described here.\\n\\nB) **polyA tail**: This is a polyadenosine sequence added to the 3' end of mRNA. While it is important for mRNA stability and export from the nucleus, it is not directly involved in the Morpholino-mediated exon skipping mechanism.\\n\\nC) **R-loops**: These are DNA-RNA hybrids that form during transcription and can interfere with splicing. They are relevant to RNA processing but not specifically mentioned in the Morpholino therapy described.\\n\\nD) **antisense**: This is a strand of RNA that can bind to complementary sequences in mRNA or DNA, potentially interfering with their function. It is mentioned in the context of the Morpholino's action of preventing the spliceosome from binding to the out-of-frame exon.\\n\\nBased on the information provided, the structure not directly involved in the Morpholino-mediated exon skipping therapy is the **lariat**.\\n\\nAnswer: A<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's first understand the context and the proposed treatment:\\n\\n1. **Gene Structure and Exon Deletions**: The gene has dozens of exons, and the central ones are crucial as they code for folded triple helical repeats connecting the cytoskeleton with sarcolemma and extracellular space. Mutations involve deletions of these central exons, leading to out-of-frame peptides and progressive degenerative organ waste.\\n\\n2. **Morpholino Therapy**: A Morpholino is used to target the 5' end of the out-of-frame exon in pre-mRNA. This molecule prevents the spliceosome from recognizing the mutated exon, allowing it to be skipped over during splicing, thus creating an in-frame joining of the remaining exons.\\n\\nNow, let's analyze each option:\\n\\nA) **lariat**: This refers to the intermediate structure formed during RNA splicing where the intron is temporarily joined to the 3' splice site, forming a loop-like structure called a lariat. Morpholinos do not directly affect this structure; they act on the pre-mRNA to prevent recognition of the out-of-frame exon.\\n\\nB) **polyA tail**: This is a polyadenosine sequence at the 3' end of mRNA molecules. It does not play a direct role in the proposed therapy involving Morpholinos.\\n\\nC) **R-loops**: These are DNA-RNA hybrid structures that form when transcription and replication or repair occur in the same region of DNA. While they can be transient, they are not directly involved in the splicing process targeted by Morpholinos.\\n\\nD) **antisense**: An antisense molecule is complementary to part of the mRNA and can bind to it, interfering with its function. In this context, Morpholinos are used as antisense molecules to prevent recognition of the out-of-frame exon.\\n\\nBased on this analysis, the structure not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's first understand the key components and steps involved in the therapy described:\\n\\n1. **Morpholino**: This is a small synthetic oligonucleotide that can recognize specific sequences in pre-mRNA.\\n2. **Spliceosome**: This is a complex of proteins and RNA molecules that catalyzes the splicing of introns from pre-mRNA to form exons.\\n3. **Exon Skipping**: This process involves the removal of an out-of-frame exon and the joining of adjacent exons to form a functional protein.\\n4. **R-loop**: This is a DNA/RNA hybrid structure that forms when RNA-DNA hybrids are present during transcription.\\n\\nNow, let's analyze each option:\\n\\nA) **lariat**: This is not typically mentioned in this context. It refers to a type of RNA structure but isn't directly involved in the splicing process or the therapy described.\\n\\nB) **polyA tail**: This is a polyadenylate tail that is added to the 3' end of mRNA molecules after splicing. While it affects the stability and export of mRNA, it is not directly involved in the splicing process or the creation of an exon skipping mechanism.\\n\\nC) **R-loops**: As mentioned, these are DNA/RNA hybrid structures that can form during transcription. They are not directly involved in the splicing process but might affect the stability of the mRNA if they interfere with the splicing machinery.\\n\\nD) **antisense**: This is a strand of RNA that binds to a complementary sequence in mRNA, potentially interfering with translation. However, it is not directly involved in the splicing process as described in the problem.\\n\\nGiven the context and the focus on splicing and exon skipping, the structures directly involved are the lariat, polyA tail, and R-loop. Therefore, the structure that is not directly involved in the proposed therapy is the lariat.\\n\\nAnswer: A<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's first understand the process described:\\n\\n1. The gene has several exons, some coding for triple helical repeats.\\n2. Central exons are deleted, leading to out-of-frame peptides and progressive degenerative effects.\\n3. A Morpholino is used to recognize the 5' end of the out-of-frame exon in pre-mRNA.\\n4. The Morpholino prevents the spliceosome from binding, causing exon skipping and in-frame joining.\\n\\nNow, let's consider each option:\\n\\nA) **lariat**: This is a structure formed during RNA splicing, particularly in the lariat intermediate stage. The Morpholino does not directly interact with this structure; rather, it interferes with the spliceosome's ability to bind to the pre-mRNA.\\n\\nB) **polyA tail**: This is a polyadenylate sequence added to the 3' end of mRNA molecules. The Morpholino does not affect the polyA tail; its function is to prevent the spliceosome from recognizing the out-of-frame exon.\\n\\nC) **R-loops**: These are three-stranded structures formed when an RNA-DNA hybrid is separated from its DNA template strand. While they can be important in transcriptional regulation, the Morpholino does not interfere with R-loops.\\n\\nD) **antisense**: An antisense molecule is complementary to a specific region of a DNA or RNA sequence. The Morpholino is designed to be complementary to the 5' end of the out-of-frame exon, so it is an antisense molecule.\\n\\nGiven this analysis, the structure that is not involved in the proposed therapy is:\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's first review the key components of the RNA processing and splicing mechanism:\\n\\n1. **lariat**: This refers to the circular intermediate structure formed during splicing. It is part of the splicing process.\\n2. **polyA tail**: This is added to the 3' end of the mRNA after splicing and does not directly involve the splicing mechanism or the proposed therapy.\\n3. **R-loops**: These are structures formed when RNA is hybridized to its complementary DNA strand, leading to a single-stranded DNA region. They are not directly involved in the splicing mechanism.\\n4. **antisense**: This is a strand of RNA that binds to a complementary sequence on another RNA strand to inhibit translation. It is not directly involved in the splicing process but can be indirectly related to RNA interference mechanisms.\\n\\nGiven this information, we can see that the structure not directly involved in the proposed therapy of exon skipping and in-frame joining is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the key components of the therapy described:\\n\\n1. **Morpholino**: This is a small synthetic oligonucleotide that binds to the 5' end of the out-of-frame exon in pre-mRNA.\\n2. **Spliceosome**: This is responsible for recognizing and splicing exons during mRNA processing.\\n3. **Exon Skipping**: This process involves creating an in-frame join between two exons by skipping the mutated exon.\\n4. **R-loops**: These are DNA-RNA hybrid structures that can form when RNA polymerase II transcribes DNA and the complementary RNA strand is not immediately removed. They are not directly involved in the Morpholino-mediated exon skipping process.\\n5. **lariat**: This is a circular intermediate formed during splicing, but it's not directly involved in the Morpholino-mediated exon skipping.\\n6. **polyA tail**: This is a polyadenylate sequence added to the 3' end of mRNA, and it is not directly involved in the Morpholino-mediated exon skipping process.\\n7. **antisense**: This refers to an RNA sequence that pairs with a specific DNA or RNA sequence. In this context, it could be part of the Morpholino, but it is not inherently involved in the structure of the therapy itself.\\n\\nGiven these points, the structure that is not directly involved in the Morpholino-mediated exon skipping process is the **polyA tail**.\\n\\nAnswer: D<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze each option in relation to the described therapy:\\n\\n1. **lariat**: This refers to a circular RNA structure formed during splicing. In this therapy, the Morpholino targets the 5' end of the out-of-frame exon, preventing it from being incorporated into the mRNA. Thus, lariats are indeed involved as they play a role in the normal splicing process that the Morpholino interferes with.\\n\\n2. **polyA tail**: The polyA tail is added to the 3' end of mRNA after transcription but before processing. It does not directly interact with the Morpholino or the spliceosome in this context. Therefore, the polyA tail is not directly involved in the proposed therapy.\\n\\n3. **R-loops**: These are three-stranded hybrid DNA-RNA structures that form during transcription when RNA primers are left behind. While R-loops can influence gene expression, they do not seem to be directly targeted by the Morpholino in this therapy.\\n\\n4. **antisense**: Antisense oligonucleotides like Morpholinos bind to complementary sequences in the mRNA, effectively blocking translation. In this case, the Morpholino binds to the 5' end of the out-of-frame exon, preventing it from being incorporated into the mRNA. Thus, antisense is involved in the therapy.\\n\\nBased on this analysis, the structure that is not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's first understand the key components of the therapy described:\\n\\n1. **Morpholino**: This is a small synthetic oligonucleotide used as a genetic therapeutic agent. It recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n2. **Spliceosome**: This is a ribonucleoprotein complex responsible for recognizing and splicing introns from pre-mRNA into exons to produce mature mRNA.\\n3. **Exon Skipping**: This process allows the spliceosome to skip over the mutated exon and join the remaining exons in frame, creating a functional protein.\\n4. **R-loop**: This is a DNA-RNA hybrid structure formed during transcription, but it is not directly involved in the Morpholino-mediated exon skipping process.\\n\\nNow, let's analyze each option:\\n\\nA) **lariat**: This is a structure that forms during RNA processing, particularly during alternative splicing, but it is not directly involved in the Morpholino-mediated exon skipping process.\\n\\nB) **polyA tail**: This is added to the 3' end of the mature mRNA and is not involved in the Morpholino-mediated exon skipping process.\\n\\nC) **R-loops**: As mentioned earlier, R-loops are formed during transcription and are not directly involved in the Morpholino-mediated exon skipping process.\\n\\nD) **antisense**: An antisense oligonucleotide is a complementary strand of RNA or DNA that can bind to mRNA and inhibit its translation, but this is not the specific mechanism described here.\\n\\nGiven the context, the structure not directly involved in the Morpholino-mediated exon skipping process is the **lariat**.\\n\\nAnswer: A<|im_end|>\", \"To solve this problem, let's break down the information provided and analyze each option:\\n\\n1. **lariat**: This is a circular intermediate structure formed during RNA splicing. The process involves the formation of a lariat (a looped piece of RNA), which is then cleaved to release mature mRNA. Therefore, the lariat is involved in the proposed therapy.\\n\\n2. **polyA tail**: This is a sequence of adenine nucleotides (A) that typically attaches to the 3' end of eukaryotic mRNAs. It does not play a direct role in the splicing process or the creation of lariats. Thus, it is not directly involved in the proposed therapy.\\n\\n3. **R-loops**: These are three-stranded RNA-DNA hybrid structures that form when transcription is active and the nascent RNA molecule remains bound to the DNA template strand. R-loops can interfere with RNA processing and stability but are not a component of the splicing machinery. Hence, they are not directly involved in the proposed therapy.\\n\\n4. **antisense**: This refers to a strand of RNA that is complementary to a specific mRNA strand. Antisense molecules can bind to complementary sequences and inhibit gene expression. In this context, a Morpholino is used as an antisense molecule to recognize and bind to the 5' end of the out-of-frame exon, preventing splicing. Therefore, antisense is involved in the proposed therapy.\\n\\nBased on the analysis, the structure that is not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process described:\\n\\n1. **Exon Skipping and In-Frame Joining**:\\n   - The therapy involves using a Morpholino to bind to the 5' end of the out-of-frame exon.\\n   - This Morpholino prevents the spliceosome from recognizing the exon, leading to its exclusion during splicing.\\n   - As a result, the remaining exons can join in an in-frame manner, producing a functional protein.\\n\\n2. **Understanding the Structures**:\\n   - **lariat**: This is a circular RNA intermediate formed during splicing, but it is not directly involved in the therapy described.\\n   - **polyA tail**: This is added to the mRNA at the 3' end after splicing, but it is not directly relevant to the Morpholino's function or the proposed therapy.\\n   - **R-loops**: These are structures formed when RNA and DNA strands form a loop during transcription and splicing, but they are not mentioned in the therapy description.\\n   - **antisense**: This refers to a complementary strand of RNA that can bind to mRNA, potentially inhibiting translation. However, the therapy specifically mentions Morpholinos, which are different from antisense molecules.\\n\\nGiven this analysis, the structure not directly involved in the proposed therapy involving Morpholinos and exon skipping is:\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's first review the key components of mRNA splicing and how the therapy works:\\n\\n1. **Spliceosome**: This is the molecular machine responsible for splicing introns from pre-mRNA to form mature mRNA.\\n2. **Exons**: These are coding regions of the mRNA.\\n3. **Intron**: These are non-coding regions that are removed during splicing.\\n4. **Morpholino**: This is a small synthetic oligomer that can bind to specific sequences in pre-mRNA and prevent splicing by blocking the spliceosome.\\n\\nNow, let's consider each option:\\n\\nA) **lariat**: This is the intermediate structure formed during RNA splicing when introns are cut but not yet joined. It is involved in the splicing process.\\nB) **polyA tail**: This is a sequence added to the 3' end of mRNA after splicing. It is not directly involved in the proposed therapy.\\nC) **R-loops**: These are DNA-RNA hybrid structures that form during transcription and splicing. They are involved in the splicing process.\\nD) **antisense**: This refers to a complementary strand that binds to the mRNA, preventing translation. It is not directly involved in the proposed therapy.\\n\\nGiven this information, the structure that is not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's first understand the context and the process described:\\n\\n1. **Gene Structure**: The gene has multiple exons, with central exons coding for triple helical repeats that are crucial for cellular functions.\\n2. **Mutation**: Central exon deletions create out-of-frame peptides, leading to progressive degeneration.\\n3. **Therapy**: A Morpholino is used to recognize the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the spliceosome from recognizing the exon, causing exon skipping and in-frame joining.\\n\\nNow, let's analyze each option:\\n\\nA) **lariat**: Lariats are structures formed during RNA splicing where the intron loops back on itself, creating a hairpin-like structure. This structure is indeed involved in the splicing process but is not directly mentioned in the therapy description provided.\\n\\nB) **polyA tail**: This is a tail of adenine nucleotides added to the 3' end of mRNA molecules. It does not play a role in the therapy involving the 5' end of the exon or the spliceosome mechanism.\\n\\nC) **R-loops**: These are secondary structures that form when a single-stranded DNA region interacts with both strands of its own DNA duplex. They are involved in transcriptional regulation and DNA repair processes but are not directly related to the Morpholino-mediated exon skipping.\\n\\nD) **antisense**: Antisense molecules bind to complementary sequences in mRNA, preventing translation or altering splicing. This matches the Morpholino's function in preventing the spliceosome from recognizing the out-of-frame exon.\\n\\nBased on this analysis, the structure that is not directly involved in the proposed therapy is the lariat.\\n\\nAnswer: A<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze each option:\\n\\nA) lariat: This refers to a circular RNA structure that can form during splicing. The proposed therapy involves recognizing the 5' end of the out-of-frame exon and preventing its inclusion into the mature mRNA, thus avoiding the formation of lariats.\\n\\nB) polyA tail: This is a polyadenylate tail that is typically added to the 3' end of the mRNA after splicing. The proposed therapy focuses on the 5' end and does not involve the polyA tail directly.\\n\\nC) R-loops: These are three-stranded hybrid DNA-RNA structures that can form during transcription and splicing. The therapy aims to prevent splicing, thereby avoiding the formation of R-loops.\\n\\nD) antisense: This is a strand of RNA complementary to a specific region of mRNA or DNA. The therapy uses a Morpholino that acts as an antisense molecule, targeting the 5' end of the out-of-frame exon.\\n\\nGiven this analysis, the structure that is not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process and understand the components mentioned:\\n\\n1. **Exon Skipping**: The therapy involves creating exon skipping and in-frame joining using a Morpholino that targets the 5' end of the out-of-frame exon.\\n2. **Spliceosome**: This is a complex of proteins that binds to splice sites on the pre-mRNA to facilitate splicing. The spliceosome recognizes specific sequences in the pre-mRNA to remove introns and join exons.\\n3. **Morpholino**: This is a short, synthetic oligomer that mimics the 5' end of the target exon. It binds to the spliceosome and prevents it from recognizing the target exon, leading to skipping of the exon and in-frame joining of the remaining exons.\\n\\nNow, let's consider each option:\\n\\n- **A) lariat**: This is a circular intermediate formed during splicing when the 3' splice site is not available for recognition. It is not directly involved in the Morpholino-mediated exon skipping process.\\n- **B) polyA tail**: This is a polyadenosine sequence added to the 3' end of mRNA. It does not play a role in the Morpholino-mediated exon skipping process.\\n- **C) R-loops**: These are DNA-RNA hybrid structures that form when RNA is transcribed and the complementary DNA strand is still being synthesized. They are not directly involved in the Morpholino-mediated exon skipping process.\\n- **D) antisense**: This refers to a complementary strand of RNA or DNA that can bind to a messenger RNA (mRNA), preventing its translation. While this can affect protein production, it is not directly involved in the Morpholino-mediated exon skipping process.\\n\\nBased on this analysis, the structure not involved in the proposed therapy is the lariat.\\n\\nAnswer: A<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process:\\n\\n1. **Out-of-Frame Exon Deletions**: These cause a frameshift mutation, leading to non-functional proteins.\\n2. **Morpholino Therapy**: This molecule targets the 5' end of the out-of-frame exon in pre-mRNA. It binds to the spliceosome, preventing it from recognizing and splicing the exon.\\n3. **Exon Skipping and In-Frame Joining**: By blocking the spliceosome, the Morpholino allows the mRNA to skip over the mutated exon and join the correct sequence together in frame, creating a functional protein.\\n4. **R-loops**: These are structures formed during RNA processing where a single-stranded DNA/RNA hybrid forms between the nascent mRNA and its complementary template strand. While R-loops can occur during RNA processing, they are not directly involved in the Morpholino-mediated exon skipping mechanism.\\n5. **lariat**: These are circular pieces of RNA that form during splicing. They are not typically targeted or affected by Morpholinos.\\n6. **PolyA Tail**: This is added to the 3' end of the mRNA after splicing is complete. It does not play a role in the Morpholino-mediated exon skipping mechanism.\\n7. **Antisense**: This refers to molecules designed to bind complementary sequences in mRNA or DNA, interfering with their function. Morpholinos are antisense oligonucleotides, but they specifically target the 5' end of the pre-mRNA.\\n\\nConsidering these points, the structure not involved in the proposed therapy is the lariat.\\n\\nAnswer: A<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze each option in the context of the described therapy:\\n\\n1. **lariat**: This is a circular RNA structure that can form during splicing. It is indeed involved in the splicing process, as the splicing machinery can bind to the lariat intermediate. The therapy aims to prevent the splicing machinery from recognizing the out-of-frame exon, effectively bypassing the lariat formation and preventing the creation of the peptide.\\n\\n2. **polyA tail**: This is a polyadenosine sequence added to the 3' end of mRNA molecules after transcription. The therapy does not involve the polyA tail; it targets the pre-mRNA at the exon level before it is processed further.\\n\\n3. **R-loops**: These are three-stranded RNA-DNA hybrids that form during transcription. They are not directly targeted or involved in the splicing mechanism that this therapy addresses.\\n\\n4. **antisense**: An antisense oligonucleotide is used in the therapy to recognize the 5' end of the out-of-frame exon in pre-mRNA. It binds to the complementary sequence and prevents the spliceosome from recognizing the exon, thus causing exon skipping and joining.\\n\\nBased on the analysis, the structure that is not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze each option:\\n\\nA) lariat: Lariats are circular RNA molecules formed during splicing. They can play a role in alternative splicing but are not directly involved in the process of exon skipping or exon inclusion using Morpholinos.\\n\\nB) polyA tail: This is a characteristic feature of mRNA and helps in its export from the nucleus to the cytoplasm. However, it does not play a direct role in the exon skipping mechanism using Morpholinos.\\n\\nC) R-loops: These are DNA-RNA hybrid structures that form during transcription when the nascent RNA molecule blocks the DNA template strand. While they are involved in various biological processes, they are not directly involved in the exon skipping process using Morpholinos.\\n\\nD) antisense: Antisense oligonucleotides like Morpholinos recognize specific sequences in pre-mRNA and bind to them to block the spliceosome from recognizing the target exon. This leads to the skipping of the exon and inclusion of other exons.\\n\\nGiven this analysis, we can see that the structure least involved in the proposed therapy is the lariat.\\n\\nAnswer: A<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze each option:\\n\\nA) lariat: This refers to a circular RNA structure formed during RNA processing. It can be involved in certain RNA regulatory mechanisms but is not directly related to the described therapy involving exon skipping and skipping of the out-of-frame exon.\\n\\nB) polyA tail: This is a polyadenylate tail added to the 3' end of mRNA molecules. It is crucial for the stability and export of mRNA from the nucleus. However, it is not directly involved in the exon skipping process described in the problem.\\n\\nC) R-loops: These are DNA-RNA hybrid structures that form during transcription. They can interfere with splicing processes but are not directly involved in the exon skipping mechanism mentioned.\\n\\nD) antisense: This refers to complementary strands of RNA that can bind to specific sequences on messenger RNA (mRNA). In the context of the therapy, an antisense Morpholino would recognize the 5' end of the out-of-frame exon to prevent its inclusion in the mature mRNA, facilitating exon skipping.\\n\\nGiven this analysis, the structure that is not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's first understand the context of the therapy and its components:\\n\\n1. **Exon Skipping and In-Frame Joining**: The therapy involves using a Morpholino oligomer to recognize the 5' end of an out-of-frame exon in pre-mRNA. This oligomer interferes with the spliceosome, leading to the skipping of the out-of-frame exon and the creation of an in-frame join with the remaining exons.\\n\\n2. **Morpholino Oligomer**: This molecule binds to the 5' end of the out-of-frame exon, preventing the spliceosome from recognizing and splicing this region. As a result, the mRNA skips over the mutated exon and continues to the next exon.\\n\\nNow, let's consider each option and see if it is involved in the described process:\\n\\nA) **lariat**: During alternative splicing, lariats are formed when introns are spliced into loops. While Morpholinos can affect lariats indirectly by altering the splicing pattern, they do not form lariats themselves.\\n\\nB) **polyA tail**: The polyA tail is added to the 3' end of the mRNA after splicing. It does not play a direct role in the skipping of exons or the function of Morpholinos.\\n\\nC) **R-loops**: R-loops are secondary structures formed during RNA processing where a single-stranded DNA-RNA hybrid is stabilized by a complementary RNA sequence. Morpholinos can influence R-loop formation but do not form R-loops themselves.\\n\\nD) **antisense**: Antisense oligomers are used to bind to complementary sequences in mRNA to interfere with translation or to recruit proteins that modify the mRNA. Although Morpholinos are a type of antisense molecule, they specifically target the splice site rather than affecting translation.\\n\\nBased on the above analysis, none of the structures (lariat, polyA tail, R-loops, or antisense) are directly involved in the proposed therapy mechanism of skipping an exon and creating an in-frame join.\\n\\nHowever, since we need to choose one answer among the given options, the most appropriate answer would be the one that is least directly involved in the described therapy:\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process:\\n\\n1. **Understanding the Proposed Therapy**:\\n   - The therapy involves delivering a Morpholino that targets the 5' end of an out-of-frame exon.\\n   - This Morpholino prevents the spliceosome from binding to the pre-mRNA.\\n   - By preventing the spliceosome, the Morpholino causes exon skipping and in-frame joining of the remaining exons.\\n\\n2. **Analyzing Each Option**:\\n   - **A) lariat**: Lariats are intermediate structures formed during RNA splicing. They involve the lariat-shaped intron and the donor splice site, but they are not directly targeted or affected by Morpholinos. Therefore, this structure is not involved in the proposed therapy.\\n   - **B) polyA tail**: The polyA tail is added to the mRNA after splicing and is part of the mature mRNA. It does not play a direct role in the splicing process controlled by Morpholinos.\\n   - **C) R-loops**: R-loops are transient DNA-RNA hybrid structures that form when transcription and DNA replication or repair compete for the same region of DNA. While they are relevant in some cellular processes, they are not specifically targeted by Morpholinos.\\n   - **D) antisense**: Antisense oligonucleotides are used in various therapeutic approaches, including exon skipping. They can bind to complementary sequences in the mRNA and block their translation or promote exon skipping.\\n\\nBased on this analysis, the structure that is not involved in the proposed therapy is the lariat.\\n\\nAnswer: A<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's first understand the key components of the therapy and their roles:\\n\\n1. **Morpholino**: This is a small synthetic oligonucleotide used as a molecular tool to block RNA function. It targets the 5' end of the out-of-frame exon in pre-mRNA.\\n2. **Spliceosome**: This is a complex of proteins and snRNAs that recognize and bind to splice sites in pre-mRNA to catalyze splicing.\\n3. **Exon Skipping and In-Frame Joining**: These processes allow for skipping over the mutated exon and creating a functional protein sequence.\\n\\nNow, let's analyze each option:\\n\\nA) **lariat**: This refers to a circular intermediate structure formed during splicing. While it plays a role in the splicing process, it is not directly involved in the Morpholino-mediated therapy described.\\n\\nB) **polyA tail**: This is a polyadenylate tail added to the 3' end of the mRNA transcript. It does not play a direct role in the Morpholino-mediated exon skipping or in-frame joining process.\\n\\nC) **R-loops**: These are three-stranded hybrid structures formed when a single-stranded DNA region is separated from its complementary strand. They can form during transcription and splicing but do not directly affect the Morpholino-mediated exon skipping process.\\n\\nD) **antisense**: This is a strand of RNA that binds to a complementary mRNA strand, preventing translation. While it can be used in gene therapy, it is not specifically mentioned in the context of the Morpholino therapy described.\\n\\nGiven this analysis, the structure least involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the given information and analyze each option:\\n\\n1. **lariat**: This is a type of RNA structure that can form when the 3' end of an intron joins with the 5' end of a downstream exon during splicing. However, the therapy described does not involve lariats; it focuses on the 5' end of the out-of-frame exon.\\n\\n2. **polyA tail**: This is a polyadenosine sequence attached to the 3' end of mRNA molecules. It plays a role in mRNA stability and export from the nucleus but is not directly involved in the mechanism described for skipping exons.\\n\\n3. **R-loops**: These are DNA-RNA hybrid structures that form when transcription and splicing occur simultaneously. They are involved in various cellular processes but are not mentioned in the context of the proposed therapy.\\n\\n4. **antisense**: This refers to a strand of RNA complementary to a specific region of mRNA. In this context, an antisense Morpholino is used to recognize and bind to the 5' end of the out-of-frame exon, preventing the spliceosome from recognizing it, thus causing exon skipping.\\n\\nGiven this analysis, the structure not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze each option:\\n\\nA) **lariat**: Lariats are RNA structures that form during splicing, specifically during intron excision. They are not directly involved in the process of exon skipping or skipping of an out-of-frame exon.\\n\\nB) **polyA tail**: This is a polyadenosine sequence at the 3' end of mRNA molecules. It is important for mRNA stability and export from the nucleus. However, it is not directly involved in the skipping of exons.\\n\\nC) **R-loops**: These are RNA-DNA hybrid structures that can form during transcription and splicing. They are not directly involved in exon skipping but play a role in the regulation of gene expression.\\n\\nD) **antisense**: Antisense oligonucleotides like Morpholinos recognize specific sequences in pre-mRNA and prevent the spliceosome from recognizing those sequences, leading to exon skipping. Therefore, antisense is directly involved in the proposed therapy.\\n\\nGiven this analysis, we can conclude that the structure not involved in the proposed therapy is the lariat.\\n\\nAnswer: A<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's first understand the key components of the therapy described:\\n\\n1. **Morpholino**: This is a synthetic oligonucleotide used as a molecular tool to block the splicing process.\\n2. **Spliceosome**: This is a complex of proteins and RNA molecules that catalyzes the splicing of pre-mRNA to remove introns and join exons.\\n3. **Exon Skipping**: This is the process of excluding a part of the mRNA transcript that contains the out-of-frame exon during splicing.\\n4. **In-Frame Joining**: This involves joining the remaining exons into a functional protein sequence.\\n\\nGiven this information, we need to consider which structures are typically associated with mRNA processing and splicing but are not directly involved in the Morpholino-mediated exon skipping and in-frame joining process.\\n\\nLet's analyze each option:\\n\\nA) **lariat**: This refers to the temporary structure formed during splicing when the intron is cut and the ends are held together temporarily by a loop of RNA called the lariat. This structure is crucial for the splicing process but is not directly targeted by Morpholinos.\\n\\nB) **polyA tail**: This is a polyadenosine tail added to the 3' end of the mature mRNA. While it plays a role in mRNA stability and export from the nucleus, it is not directly involved in the splicing process or exon skipping.\\n\\nC) **R-loops**: These are DNA-RNA hybrids that form during transcription and can affect gene expression but are not directly involved in the splicing process or exon skipping.\\n\\nD) **antisense**: This refers to RNA sequences that bind to complementary sequences in other RNA molecules. While antisense technology can be used for various purposes including targeting specific RNAs, it is not specifically mentioned in the context of the given therapy.\\n\\nConsidering the above points, the structures not directly involved in the Morpholino-mediated exon skipping and in-frame joining process are the lariat, polyA tail, and R-loops.\\n\\nHowever, the question asks for the single structure that is not involved. Since the polyA tail is a more universally known structure associated with mRNA processing but not directly involved in splicing or exon skipping, we can conclude that it is the least likely to be directly involved in the therapy.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze each option:\\n\\nA) **lariat**: Lariats are RNA structures that can form during splicing processes. They can interfere with normal splicing events but do not directly relate to the Morpholino-mediated exon skipping mechanism described in the question.\\n\\nB) **polyA tail**: This is a characteristic feature of mRNA, found at its 3' end. It is not directly involved in the process of exon skipping or exon recognition by Morpholinos.\\n\\nC) **R-loops**: These are DNA-RNA hybrids formed during transcription and splicing. They can disrupt the splicing process, but again, they do not play a direct role in the Morpholino-mediated exon skipping.\\n\\nD) **antisense**: This refers to a strand of RNA that pairs with complementary sequences on another RNA or DNA strand. In the context of the therapy, antisense oligonucleotides like Morpholinos are used to recognize and bind to specific sequences, guiding the spliceosome to skip over the out-of-frame exon.\\n\\nGiven this analysis, the structure that is not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze each option:\\n\\nA) lariat: This refers to a circular RNA structure that can form during RNA splicing. The therapy involves using Morpholinos to prevent exon inclusion, so lariats are indirectly related but not directly involved in the therapy process.\\n\\nB) polyA tail: This is a sequence of adenine nucleotides added to the 3' end of mRNA. It does not play a direct role in the exon skipping or spliceosome inhibition mechanism described.\\n\\nC) R-loops: These are structures formed when an RNA strand pairs with its complementary DNA strand, leaving a single-stranded DNA region. They can affect splicing processes but are not mentioned as being directly involved in the therapy described.\\n\\nD) antisense: This refers to a complementary RNA strand that can bind to and inhibit the function of a specific mRNA. In this context, Morpholinos act as antisense molecules to recognize and inhibit the binding of the spliceosome to the out-of-frame exon.\\n\\nGiven the options, the structure not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the information given and analyze each option:\\n\\n1. **lariat**: This refers to a circular RNA structure that can form during splicing. The Morpholino is designed to bind to the 5' end of the out-of-frame exon, preventing it from being recognized by the spliceosome. This does involve lariats as they can interfere with proper splicing.\\n   \\n2. **polyA tail**: This is a polyadenosine sequence attached to the 3' end of mRNA molecules. It is not directly involved in the splicing process or the proposed therapy involving Morpholinos targeting the 5' end of the exon.\\n\\n3. **R-loops**: These are three-stranded structures that form when a DNA stretch is separated into two strands and one of those strands forms a double-stranded RNA. While R-loops can affect gene expression, they are not specifically mentioned in the context of Morpholinos targeting the 5' end of an exon.\\n\\n4. **antisense**: An antisense molecule is complementary to a specific mRNA sequence and can interfere with its translation or promote its degradation. In this case, the Morpholino is an antisense oligonucleotide designed to bind to the 5' end of the out-of-frame exon.\\n\\nGiven this analysis, the structure that is not directly involved in the proposed therapy using Morpholinos targeting the 5' end of the exon is:\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the key steps and components of the therapy described:\\n\\n1. **Central Exon Deletions**: These deletions create out-of-frame peptides, leading to progressive degenerative organ waste.\\n2. **Morpholino Therapy**: A Morpholino is used to recognize the 5' end of the out-of-frame exon in pre-mRNA. It prevents binding of the spliceosome and results in exon skipping and in-frame joining.\\n3. **Involvement of Structures**:\\n   - **lariat**: This is a structure formed during RNA splicing when the intron is cut out, but it's not directly involved in the therapy described.\\n   - **polyA tail**: This is added to the mRNA at the 3' end after splicing and does not play a direct role in this specific therapy.\\n   - **R-loops**: These are intermediate structures that form during transcription and splicing, but they are not specifically mentioned as being part of the Morpholino therapy mechanism.\\n   - **antisense**: This refers to a strand of RNA that binds to complementary sequences in mRNA, guiding the RNA interference process or helping in exon skipping. While not directly involved in preventing spliceosome binding, it is a component of RNA interference mechanisms.\\n\\nGiven these points, the structures that are explicitly involved in the proposed therapy are lariats, polyA tails, and R-loops, while antisense is indirectly related through its role in RNA interference.\\n\\nTherefore, the structure that is not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To solve this problem, let's break down the key elements and understand the proposed therapy:\\n\\n1. **Gene Structure**: The gene has multiple exons, and the central ones code for folded triple helical repeats.\\n2. **Mutations**: Central exon deletions lead to out-of-frame peptides and progressive degenerative organ waste.\\n3. **Therapy**: A Morpholino is used to recognize the 5' end of the out-of-frame exon in pre-mRNA.\\n4. **Mechanism**: The Morpholino prevents binding of the spliceosome and causes exon skipping, resulting in in-frame joining.\\n5. **Outcomes**: Multiple missing exons can be tolerated by an organism.\\n\\nNow, let's analyze each option:\\n\\nA) **lariat**: This refers to a temporary RNA structure formed during splicing. The Morpholino would prevent the formation of this structure, so it is involved in the therapy.\\n\\nB) **polyA tail**: This is a polyadenylate tail added to the mRNA at its 3' end. The Morpholino does not interact with or affect this structure, so it is not directly involved in the therapy.\\n\\nC) **R-loops**: These are secondary structures formed during transcription where the DNA strand remains single-stranded between the RNA and the complementary DNA strand. The Morpholino may indirectly affect R-loop formation but is not specifically designed to target them.\\n\\nD) **antisense**: Antisense oligonucleotides are used to bind to complementary sequences in RNA and interfere with their function. The Morpholino is an antisense molecule, so it is involved in the therapy.\\n\\nGiven this analysis, the structure that is not directly involved in the proposed therapy is:\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze each option:\\n\\nA) lariat: Lariats are RNA structures that form during splicing when a piece of RNA is held together by a phosphate backbone loop. They are indeed involved in the process of splicing, but they are not directly involved in the mechanism described here where a Morpholino is used to prevent binding of the spliceosome.\\n\\nB) polyA tail: This is a polyadenosine sequence at the 3' end of mRNA molecules. It is not typically involved in the splicing process or the delivery mechanism of Morpholinos.\\n\\nC) R-loops: These are DNA-RNA hybrid structures that can form during transcription. They are not directly related to the splicing process or the Morpholino-mediated exon skipping mechanism.\\n\\nD) antisense: Antisense oligonucleotides like Morpholinos are designed to bind to complementary sequences in the pre-mRNA and interfere with the splicing process. This aligns with the proposed therapy.\\n\\nGiven this analysis, the structure that is not directly involved in the proposed therapy using Morpholinos is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze each option:\\n\\nA) **lariat**: Lariats are circular RNA structures formed during splicing. They are part of the splicing process and can potentially interfere with proper splicing if they form incorrectly. However, they are not directly mentioned in the context of the therapy described.\\n\\nB) **polyA tail**: This is a polyadenosine sequence at the 3' end of mRNA molecules. It helps in the stability and export of mRNA from the nucleus to the cytoplasm. The therapy described does not involve altering the polyA tail.\\n\\nC) **R-loops**: These are three-stranded RNA-DNA hybrid structures that form during transcription when RNA polymerase binds to DNA. R-loops can affect splicing efficiency but are not directly addressed in the therapy described.\\n\\nD) **antisense**: An antisense oligonucleotide is a molecule designed to bind complementary sequences in RNA, often used for targeting specific RNA sequences. In this case, the Morpholino is an antisense molecule designed to bind to the 5' end of the out-of-frame exon in pre-mRNA.\\n\\nGiven this analysis, we can conclude that none of the structures are directly involved in the proposed therapy as described, but we need to identify the one that is least likely to be directly targeted or affected by the therapy.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the given information and analyze each option:\\n\\n1. **lariat**: This refers to the structure formed when RNA undergoes splicing. During splicing, introns are removed from pre-mRNA to produce mature mRNA. A lariat can form during this process if an intron is too long or improperly processed. The therapy involves preventing the binding of the spliceosome at the 5' end of the out-of-frame exon to prevent it from being included in the mature mRNA.\\n\\n2. **polyA tail**: This is a polyadenosine sequence at the 3' end of mRNA molecules. It helps in stabilizing mRNA and directing its transport from the nucleus to the cytoplasm. The proposed therapy does not directly involve the polyA tail; it focuses on the splicing process.\\n\\n3. **R-loops**: These are structures formed during transcription when a single-stranded DNA region forms alongside an RNA molecule, leaving a single-stranded DNA loop. While R-loops can occur during transcription, they are not directly involved in the proposed therapy aimed at splicing.\\n\\n4. **antisense**: This refers to a strand of RNA that can bind to a complementary sequence in another RNA or DNA molecule, often used in antisense therapies to inhibit gene expression. In this context, the therapy uses Morpholino oligomers as antisense molecules to prevent the inclusion of the out-of-frame exon.\\n\\nGiven the above analysis, the structure that is not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process described:\\n\\n1. **Gene Structure and Mutation**: The gene contains many exons, with central exons coding for folded triple helical repeats. Mutations like deletions of central exons result in out-of-frame peptides.\\n2. **Morpholino Therapy**: A Morpholino molecule is used to bind to the 5' end of the out-of-frame exon in pre-mRNA, preventing the spliceosome from recognizing it. This leads to the skipping of this exon and in-frame joining of the remaining exons.\\n3. **Structure Analysis**:\\n   - **lariat**: These are RNA molecules that form during splicing, but they are not directly involved in the Morpholino-mediated skipping of exons.\\n   - **polyA tail**: This is added to mRNA after splicing and does not play a direct role in the Morpholino mechanism.\\n   - **R-loops**: These are DNA-RNA hybrid structures that can form during transcription and splicing, but they are not specifically mentioned in the context of Morpholino action.\\n   - **antisense**: This refers to RNA sequences that can bind to complementary mRNA, potentially interfering with its translation or processing. However, Morpholinos are oligonucleotides that mimic the structure of mRNA, not antisense RNAs.\\n\\nGiven these points, we can conclude that the structure not involved in the proposed therapy is the **lariat**.\\n\\nAnswer: A<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the key elements of the therapy and identify any structures that could potentially interfere with it:\\n\\n1. **Morpholino**: This is a small molecule that binds specifically to the 5' end of the out-of-frame exon in pre-mRNA.\\n2. **Spliceosome**: This is responsible for recognizing and joining correctly spliced exons. The Morpholino prevents the spliceosome from binding, thus creating exon skipping.\\n3. **Exon Skipping**: This results in the inclusion of a different set of exons, leading to a properly spliced mRNA.\\n4. **R-loops**: These are DNA-RNA hybrids formed during transcription and can interfere with RNA processing but are not directly involved in the Morpholino-mediated exon skipping mechanism.\\n5. **Lariat**: This refers to a circular intermediate formed during RNA splicing. It is not directly involved in the Morpholino-mediated exon skipping process.\\n6. **PolyA Tail**: This is added to the 3' end of the mRNA and is involved in mRNA export and stability. It is not directly involved in the Morpholino-mediated exon skipping mechanism.\\n7. **Antisense**: This is a complementary strand of RNA that can bind to specific mRNA sequences. In this context, it would be used as a Morpholino, so it is indirectly involved.\\n\\nGiven these points, we can see that R-loops and lariats are not directly involved in the Morpholino-mediated exon skipping mechanism.\\n\\nAnswer: A<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the information given and analyze each option:\\n\\n1. **lariat**: This is a circular intermediate formed during RNA splicing. It involves the removal of introns from pre-mRNA to form mature mRNA. Therefore, it is relevant to the splicing process.\\n   \\n2. **polyA tail**: This is added to the 3' end of the mRNA after splicing. It does not play a direct role in the splicing process but helps in the stability and export of the mature mRNA from the nucleus. Thus, it is not directly involved in the proposed therapy.\\n\\n3. **R-loops**: These are three-stranded structures formed when one strand of DNA is used as a template for RNA synthesis (transcription), while the other strand remains single-stranded. They are not typically involved in the splicing process or the proposed therapy involving exon skipping.\\n\\n4. **antisense**: This refers to a sequence complementary to a specific mRNA sequence that can bind to it and interfere with its function. In this context, the Morpholino is an antisense oligonucleotide designed to recognize and bind to the 5' end of the out-of-frame exon. \\n\\nGiven this analysis, the structure that is not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's first understand the key components of the proposed treatment:\\n\\n1. **Morpholino**: This is a synthetic oligonucleotide used to block splicing.\\n2. **Spliceosome**: An RNA-protein complex responsible for recognizing and splicing introns from pre-mRNA to form exons.\\n3. **Out-of-frame exon deletion**: This results in a premature stop codon, creating a non-functional protein.\\n4. **Exon skipping and in-frame joining**: By preventing the spliceosome from recognizing the out-of-frame exon, the Morpholino allows the inclusion of other exons, restoring the reading frame and potentially producing a functional protein.\\n\\nNow, let's examine each option:\\n\\nA) **lariat**: This refers to a circular intermediate structure formed during RNA splicing. It is part of the normal splicing process but is not directly involved in the prevention of exon recognition by Morpholinos.\\n\\nB) **polyA tail**: This is a polyadenylate tail added to the 3' end of mRNA after splicing. It is not directly involved in the proposed therapy as it does not affect exon recognition or splicing.\\n\\nC) **R-loops**: These are DNA-RNA hybrid structures that can form during transcription and can interfere with splicing. They could potentially be involved if Morpholinos are interfering with R-loop formation, but they are not inherently involved in the core mechanism described.\\n\\nD) **antisense**: This refers to a complementary strand that can bind to mRNA and inhibit translation. While antisense molecules can indirectly affect gene expression, they are not directly involved in the proposed therapy which focuses on splicing.\\n\\nGiven this analysis, the structure that is not directly involved in the proposed therapy involving Morpholinos and exon skipping is the **polyA tail**.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze each option:\\n\\nA) lariat: Lariats are RNA structures that form during splicing when a piece of intronic RNA loops back to the exon it was removed from. The therapy involves preventing the spliceosome from recognizing the out-of-frame exon, thus avoiding the formation of lariats.\\n\\nB) polyA tail: The polyA tail is added to the 3' end of mRNA after the addition of the 3' cap and does not play a role in the splicing process. Therefore, this structure is not directly involved in the proposed therapy.\\n\\nC) R-loops: These are DNA-RNA hybrid structures that form during transcription and splicing. They can interfere with the splicing process but are not directly targeted or affected by the Morpholino used in the therapy.\\n\\nD) antisense: Antisense oligonucleotides like Morpholinos bind to complementary sequences in the mRNA and prevent the spliceosome from recognizing those regions, thereby promoting exon skipping. This structure is indeed involved in the therapy.\\n\\nGiven this analysis, the structure that is not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's first understand the context and the proposed solution:\\n\\n- The therapy involves targeting a specific exon deletion in pre-mRNA.\\n- The goal is to prevent the spliceosome from recognizing the out-of-frame exon and instead promote exon skipping and in-frame joining.\\n\\nNow, let's analyze each option:\\n\\nA) **lariat**: This refers to a circular RNA structure that forms during splicing when the intron is ligated. It is part of the normal splicing process and would not be directly targeted by the Morpholino in this scenario.\\n\\nB) **polyA tail**: This is a sequence of adenine nucleotides added to the 3' end of mRNA molecules. It is crucial for mRNA stability and export from the nucleus. The therapy does not affect the polyA tail directly.\\n\\nC) **R-loops**: These are three-stranded structures that form when an RNA-DNA hybrid is separated from its complementary DNA strand. They can occur during transcription but are not typically targeted directly by Morpholinos.\\n\\nD) **antisense**: This refers to a complementary strand that can bind to the mRNA, potentially preventing translation. While it could theoretically interfere with the mRNA, the Morpholino specifically targets the spliceosome and the exon recognition process, not the antisense itself.\\n\\nGiven these analyses, the structure least likely to be directly involved in the proposed therapy is the **lariat**.\\n\\nAnswer: A<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the key elements and processes described:\\n\\n1. **Exon Skipping and In-Frame Joining**:\\n   - Morpholino molecules recognize the 5' end of the out-of-frame exon.\\n   - They prevent the spliceosome from binding to this exon.\\n   - This results in skipping of the out-of-frame exon and in-frame joining of the remaining exons.\\n\\n2. **Morpholinos**:\\n   - Morpholinos are antisense oligonucleotides used to block gene expression.\\n   - They bind to specific sequences in the mRNA.\\n\\n3. **Spliceosome**:\\n   - The spliceosome is a complex of proteins and small nuclear ribonucleoproteins (snRNPs) that splices introns from pre-mRNA.\\n   - It is crucial for exon recognition and processing.\\n\\n4. **Structures Involved**:\\n   - **lariat**: This is a temporary intermediate structure formed during RNA splicing.\\n   - **polyA tail**: This is added to the 3' end of the mature mRNA after splicing.\\n   - **R-loops**: These are structures formed during transcription where a single-stranded DNA/RNA hybrid forms between the template strand and the newly synthesized RNA strand.\\n   - **antisense**: This is a type of RNA that can bind to complementary sequences in the mRNA, interfering with its function.\\n\\nGiven these points, we can evaluate each option:\\n\\nA) **lariat**: This is a structure formed during RNA splicing, so it would be involved in the process.\\nB) **polyA tail**: This is part of the mature mRNA and would not be directly involved in the morpholino-mediated exon skipping mechanism.\\nC) **R-loops**: These are structures formed during transcription and might indirectly affect mRNA processing but are not directly involved in the spliceosome's function or morpholino action.\\nD) **antisense**: This is a type of RNA used as a therapeutic agent to interfere with gene expression, fitting the description of morpholinos.\\n\\nThus, the structure least likely to be directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the key components and steps of the therapy described:\\n\\n1. **Exon Skipping and In-Frame Joining**: The therapy involves delivering a Morpholino that binds to the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the spliceosome from recognizing and splicing this exon, leading to skipping over it and creating an in-frame joining of the remaining exons.\\n\\n2. **Morpholino Function**: Morpholinos are antisense oligonucleotides that mimic natural RNA molecules and bind specifically to complementary sequences in mRNA. They do not directly involve any of the structures listed in the options provided.\\n\\n3. **Exon Structure**:\\n   - Exons are coding regions that are part of the mature mRNA.\\n   - Introns are non-coding regions that are spliced out during mRNA processing.\\n   - The lariat refers to the loop formed by introns during splicing.\\n   - The polyA tail is added to the 3' end of the mRNA.\\n   - R-loops are structures formed when an RNA-DNA hybrid is present with single-stranded DNA.\\n\\nGiven these points, let's evaluate each option:\\n\\nA) **lariat**: Lariats are involved in the splicing process as mentioned above.\\nB) **polyA tail**: The polyA tail is added to the 3' end of the mRNA and is not involved in the proposed therapy.\\nC) **R-loops**: R-loops can form during the splicing process but are not directly involved in the Morpholino-mediated exon skipping.\\nD) **antisense**: Morpholinos are antisense oligonucleotides, so they are directly involved in the therapy.\\n\\nThus, the structure that is not directly involved in the proposed therapy involving Morpholinos is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's first understand the key components and processes involved:\\n\\n1. **Exon Skipping**: This involves creating an in-frame join between the remaining exons after skipping the mutated one.\\n2. **Morpholino**: This is a short oligonucleotide that recognizes the 5' end of the out-of-frame exon in pre-mRNA and prevents the spliceosome from recognizing it.\\n3. **Spliceosome**: This is the complex that normally recognizes and joins exons during splicing.\\n4. **In-frame Joining**: This means the joined exons can now produce a functional protein sequence without any frameshifts.\\n\\nNow, let's examine each option:\\n\\n- **A) lariat**: This is a temporary structure formed during RNA splicing, but it is not directly involved in the therapy described.\\n- **B) polyA tail**: This is added to the 3' end of the mRNA after splicing is complete, and it is not directly involved in the therapy described.\\n- **C) R-loops**: These are DNA-RNA hybrid structures that form when RNA transcripts bind to double-stranded DNA, but they are not directly mentioned in the therapy process.\\n- **D) antisense**: This refers to a molecule that binds to complementary RNA sequences and can interfere with their function. In this context, the Morpholino is an antisense molecule designed to prevent the spliceosome from recognizing the out-of-frame exon.\\n\\nGiven this analysis, the structure that is not directly involved in the proposed therapy is:\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process described:\\n\\n1. **Central Exon Deletions**: These deletions create out-of-frame peptides, leading to progressive degenerative organ waste.\\n2. **Morpholino Therapy**: This therapy involves delivering a Morpholino that targets the 5' end of the out-of-frame exon in pre-mRNA.\\n3. **Exon Skipping and In-Frame Joining**: The Morpholino prevents the spliceosome from recognizing the out-of-frame exon, thus causing exon skipping and allowing the mRNA to be spliced in a way that maintains the integrity of the coding sequence.\\n\\nNow, let's consider each option:\\n\\nA) **lariat**: This refers to a circular intermediate structure that forms during RNA splicing. It is indeed involved in the splicing process but not directly targeted by the Morpholino therapy.\\n\\nB) **polyA tail**: This is a polyadenylate tail that is added to the 3' end of the mRNA during processing. It is not involved in the splicing process and does not play a role in the exon skipping mechanism using Morpholinos.\\n\\nC) **R-loops**: These are three-stranded structures formed during transcription when the DNA template strand is bound to the nascent RNA and a single-stranded DNA region is left behind. They are not directly involved in the splicing or exon skipping process.\\n\\nD) **antisense**: This refers to a complementary RNA sequence that can bind to a specific mRNA and inhibit its translation. While it might be involved in some forms of gene therapy, it is not specifically mentioned as part of the Morpholino therapy mechanism described.\\n\\nGiven this analysis, the structure that is not directly involved in the proposed therapy of exon skipping and in-frame joining using Morpholinos is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's first understand the key steps in the therapy:\\n\\n1. **Central Exon Deletions**: These deletions result in out-of-frame peptides, leading to progressive degenerative organ wastage.\\n2. **Morpholino Delivery**: A Morpholino molecule is used to recognize the 5' end of the out-of-frame exon in pre-mRNA.\\n3. **Pre-mRNA Processing**: The Morpholino prevents the spliceosome from recognizing the out-of-frame exon.\\n4. **Exon Skipping and In-Frame Joining**: This leads to the skipping of the out-of-frame exon and the joining of remaining exons in frame, creating a correct protein sequence.\\n\\nNow, let's analyze each option:\\n\\nA) **lariat**: Lariats are intermediate structures formed during RNA splicing, specifically in the lariat intermediate stage. This structure is indeed involved in the normal splicing process but is not directly related to the Morpholino's role in exon skipping.\\n\\nB) **polyA tail**: The polyA tail is added to the 3' end of mRNA after splicing. It is not directly involved in the proposed therapy focusing on exon skipping and in-frame joining.\\n\\nC) **R-loops**: R-loops are DNA-RNA hybrid structures that form when RNA primers are left behind during DNA replication or transcription. While they can be transient, they are not typically involved in the specific splicing process being addressed here.\\n\\nD) **antisense**: Antisense molecules, including Morpholinos, are designed to bind complementary sequences in RNA. They play a crucial role in this therapy by preventing the spliceosome from recognizing the out-of-frame exon.\\n\\nGiven this analysis, the structure that is not directly involved in the proposed therapy is the **lariat**.\\n\\nAnswer: A<|im_end|>\", \"To solve this problem, we need to understand the key elements involved in the proposed therapy and identify which structure is not part of it.\\n\\n1. **Understanding the Proposed Therapy**:\\n   - The therapy involves delivering a Morpholino that targets the 5' end of the out-of-frame exon.\\n   - The Morpholino prevents the spliceosome from recognizing and binding to the out-of-frame exon.\\n   - This results in exon skipping and in-frame joining, allowing the mRNA to be processed correctly.\\n\\n2. **Analyzing the Options**:\\n   - **A) lariat**: Lariats are RNA structures formed during splicing when the intron is cut but the 3' splice site remains attached to the 5' splice site. This does not fit the context of the proposed therapy as it is not directly targeted or prevented by the Morpholino.\\n   - **B) polyA tail**: The polyA tail is added to the 3' end of the mature mRNA after splicing. It is not directly involved in the process of exon skipping or the role of the Morpholino.\\n   - **C) R-loops**: R-loops are DNA-RNA hybrids that form during transcription and can affect splicing. While they might indirectly impact splicing, they are not specifically targeted by the Morpholino in the given context.\\n   - **D) antisense**: Antisense oligonucleotides like Morpholinos bind to complementary sequences in the mRNA, preventing splicing. This fits the proposed therapy perfectly.\\n\\nGiven the analysis, the structure not involved in the proposed therapy is the lariat.\\n\\nAnswer: A<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's first understand the key steps and components of the therapy:\\n\\n1. **Out-of-Frame Exon Deletions**: These deletions disrupt the normal reading frame of the mRNA, leading to non-functional proteins.\\n2. **Morpholino Therapy**: A Morpholino is used to recognize the 5' end of the out-of-frame exon in pre-mRNA. It binds to the spliceosome, preventing it from recognizing the incorrect reading frame.\\n3. **Exon Skipping and In-Framing**: This leads to the skipping of the problematic exon and the joining of the remaining exons into a functional reading frame.\\n\\nNow, let's analyze each option to see if they are part of this process or not:\\n\\nA) **lariat**: Lariats are RNA structures that form during splicing when introns are removed from pre-mRNA. They are not directly involved in the skipping of exons or the prevention of binding by Morpholinos.\\n\\nB) **polyA tail**: This is a polyadenosine tail added to the 3' end of mRNA after splicing. It does not play a direct role in the skipping of exons or the recognition of Morpholinos.\\n\\nC) **R-loops**: R-loops are DNA-RNA hybrid structures that can form during transcription and splicing. They are not typically considered as a structure involved in the exon skipping process using Morpholinos.\\n\\nD) **antisense**: Antisense oligonucleotides like Morpholinos can bind to complementary sequences on mRNA, thereby preventing the spliceosome from recognizing the out-of-frame exon.\\n\\nGiven this analysis, the structure that is not involved in the proposed therapy is the **lariat**.\\n\\nAnswer: A<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's first understand the key components and steps involved in the therapy described:\\n\\n1. **Out-of-Frame Exon Deletion**: This occurs when there is a deletion in the middle of an exon, creating a non-coding region.\\n2. **Morpholino Therapy**: A Morpholino oligomer is used to bind to the 5' end of the out-of-frame exon in pre-mRNA, preventing the spliceosome from recognizing it.\\n3. **Exon Skipping and In-Frame Joining**: This results in skipping the mutated exon and allowing other exons to join together in the correct frame, restoring the protein sequence.\\n\\nNow, let's consider each option:\\n\\nA) **lariat**: This refers to a circular RNA intermediate formed during splicing. It is indeed involved in the normal splicing process but is not directly relevant to the Morpholino therapy described.\\n\\nB) **polyA tail**: This is a polyadenosine sequence added to the 3' end of mRNA molecules after splicing. It is not directly involved in the proposed therapy.\\n\\nC) **R-loops**: These are DNA-RNA hybrid structures that form during transcription. They can interfere with splicing processes but are not mentioned as being involved in the Morpholino therapy.\\n\\nD) **antisense**: This is a strand of RNA that binds to a complementary strand of mRNA to inhibit translation. While this could be indirectly related to gene therapy, it is not specifically mentioned or implied in the context of Morpholino therapy described.\\n\\nGiven the description of the therapy, none of these structures are directly involved except for the lariat, which is more of a normal intermediary in the splicing process rather than part of the therapeutic intervention.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze each option:\\n\\nA) lariat:\\n- Lariats are temporary structures formed during splicing when the intron lariat loops back on itself.\\n- They are indeed involved in the splicing process, but they are not directly targeted by the Morpholino therapy described here.\\n\\nB) polyA tail:\\n- The polyA tail is added to the mRNA after splicing and is important for mRNA stability and export from the nucleus.\\n- It is not directly involved in the splicing or the skipping/exon inclusion processes that the Morpholino targets.\\n\\nC) R-loops:\\n- R-loops are DNA-RNA hybrids that form during transcription and splicing.\\n- While they can interfere with splicing, they are not specifically targeted by Morpholinos in this context.\\n\\nD) antisense:\\n- Antisense molecules are used to bind to complementary RNA sequences, often targeting specific regions like the 5' end of the out-of-frame exon.\\n- This aligns with the description of the Morpholino used in the therapy.\\n\\nGiven this analysis, the structure that is not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze each option in relation to the therapy described:\\n\\n1. **lariat**: Lariats are RNA structures that form during splicing, but they are not directly involved in the mechanism of exon skipping using Morpholinos. Therefore, this structure is not directly relevant to the therapy.\\n\\n2. **polyA tail**: The polyA tail is typically added to mRNA after splicing and is important for its stability and export from the nucleus. However, it is not directly involved in the process of exon skipping or skipping an out-of-frame exon.\\n\\n3. **R-loops**: R-loops are DNA-RNA hybrids that form when transcription and splicing occur simultaneously. They are not directly involved in the process of exon skipping using Morpholinos.\\n\\n4. **antisense**: Antisense oligonucleotides like Morpholinos can bind to complementary sequences in mRNA, preventing splicing. This mechanism does involve the antisense component of the Morpholino molecule.\\n\\nBased on the analysis, the structure that is not involved in the proposed therapy is the **lariat**.\\n\\nAnswer: A<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's first understand the context and the process:\\n\\n1. **Morpholino Therapy**: This therapy involves delivering a small molecule (Morpholino) that binds to the 5' end of the out-of-frame exon in pre-mRNA. It prevents the spliceosome from recognizing and splicing this exon, leading to exon skipping and in-frame joining of other exons.\\n   \\n2. **Components Involved**:\\n   - **Spliceosome**: A complex of proteins that catalyzes the splicing of pre-mRNA to form mature mRNA.\\n   - **Pre-mRNA**: Unspliced RNA transcript.\\n   - **lariat**: A circular intermediate formed during RNA splicing.\\n   - **PolyA Tail**: A poly-A tail is added to the 3' end of the mRNA after splicing.\\n   - **R-Loops**: A DNA-RNA hybrid structure that forms when transcription and replication occur simultaneously in the same region of DNA.\\n   - **Antisense**: A complementary strand of RNA that can bind to complementary sequences in RNA or DNA to prevent expression of a gene.\\n\\nGiven these components, let's analyze each option:\\n\\nA) **lariat**: This is indeed a structure formed during RNA splicing as mentioned earlier.\\nB) **polyA tail**: This is typically added to the 3' end of the mRNA after splicing, but it is not directly involved in the process of preventing exon inclusion through Morpholino-mediated exon skipping.\\nC) **R-loops**: While R-loops can form during splicing, they are not directly targeted or prevented by Morpholino therapy.\\nD) **antisense**: This is used in the therapy to prevent exon inclusion by binding to the out-of-frame exon.\\n\\nTherefore, the structure that is not directly involved in the proposed therapy of Morpholino-mediated exon skipping is:\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's first understand the context and process of the therapy described:\\n\\n1. **Exon Skipping**: This is a mechanism used in RNA splicing where the spliceosome skips over an out-of-frame exon during mRNA processing.\\n2. **Morpholino**: It is a small synthetic oligomer that can bind to the 5' end of an out-of-frame exon in pre-mRNA, preventing the spliceosome from recognizing it.\\n3. **lariat**: This is a structure formed during RNA splicing where the intron is held together by two phosphodiester bonds at the 5' splice site and the 3' splice site, creating a loop-like structure. This is a crucial intermediate in the splicing process.\\n4. **polyA tail**: This is a long stretch of adenine nucleotides added to the 3' end of the mature mRNA. It helps in the stability and export of mRNA from the nucleus.\\n5. **R-loops**: These are DNA-RNA hybrid structures that form when a portion of double-stranded DNA is separated by RNA polymerase. They are not directly involved in the splicing process but are a product of transcription.\\n6. **antisense**: This refers to a molecule that binds to complementary sequences on mRNA, often used as a therapeutic approach to inhibit gene expression. In this case, the Morpholino acts as an antisense molecule.\\n\\nGiven these points, the structure that is not directly involved in the proposed therapy is:\\n\\n- **lariat**: While it is a critical intermediate in the splicing process, it is not directly targeted or affected by the Morpholino in the proposed therapy.\\n\\nTherefore, the answer is:\\nAnswer: A<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process:\\n\\n1. **Morpholino**: This is a small molecule that can bind to specific sequences in pre-mRNA. It targets the 5' end of the out-of-frame exon to prevent splicing.\\n2. **Spliceosome**: This is the complex responsible for recognizing and cutting RNA molecules at specific sites (splice sites) to join together the correct exons and remove introns.\\n3. **Exon Skipping**: This is the process of excluding the mutated exon from the final mRNA transcript.\\n4. **In-frame Joining**: This refers to the joining of the remaining exons to form a functional protein sequence.\\n\\nGiven these points, let's analyze each option:\\n\\n- **A) lariat**: This is a temporary intermediate structure formed during splicing when the lariat-shaped intron is being processed. It is indeed part of the normal splicing process but not directly involved in the therapy mechanism described.\\n  \\n- **B) polyA tail**: This is a polyadenosine tail added to the 3' end of the mRNA. It is not involved in the splicing process or the therapy described.\\n  \\n- **C) R-loops**: These are DNA-RNA hybrids that form during transcription. They are not directly involved in the splicing process or the therapy described.\\n  \\n- **D) antisense**: This refers to a strand of RNA that pairs with complementary sequences in another RNA or DNA molecule. While it can play roles in regulation, it is not directly involved in the splicing or exon skipping process as described.\\n\\nConsidering the above analysis, the structures not directly involved in the proposed therapy are the polyA tail and R-loops.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process and analyze each option:\\n\\n1. **lariat**: This refers to the loop formed during RNA splicing when a part of the primary transcript (pre-mRNA) is cut out. In this context, the therapy involves skipping certain exons through exon skipping, which would involve lariats as part of the splicing process.\\n\\n2. **polyA tail**: This is a long stretch of adenine nucleotides (A) that typically appears at the 3' end of eukaryotic mRNA molecules. It is not directly involved in the exon skipping mechanism described here, as it does not affect the skipping of exons.\\n\\n3. **R-loops**: These are three-stranded RNA-DNA hybrids that form during transcription when RNA polymerase transcribes one strand of DNA while the other remains bound to the newly synthesized RNA and single-stranded DNA. While they can occur, they are not directly involved in the exon skipping mechanism discussed.\\n\\n4. **antisense**: This refers to a complementary RNA sequence that can bind to its target mRNA sequence to inhibit translation or promote degradation. The Morpholino used in the therapy is an antisense oligonucleotide that recognizes the 5' end of the out-of-frame exon.\\n\\nGiven this analysis, the structure that is not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's first understand the context of the problem:\\n\\n1. **Gene Structure and Mutations**: The gene has multiple exons, with central exons coding for specific sequences that form triple helices connecting the cytoskeleton, sarcolemma, and extracellular space. Central exon deletions disrupt the normal reading frame, leading to misfolded proteins and degenerative issues.\\n\\n2. **Therapeutic Approach**: The therapy involves using a Morpholino, which is a small synthetic oligomer, to recognize the 5' end of the out-of-frame exon. This Morpholino prevents the spliceosome from recognizing the exon, thus forcing it to skip over the out-of-frame region and join the remaining exons in the correct frame.\\n\\n3. **Key Structures Involved**:\\n   - **R-loops**: These are DNA-RNA hybrids that form during transcription and can interfere with splicing processes. However, they are not directly targeted or disrupted by Morpholinos.\\n   - **lariat**: These are circular RNA molecules that can form as a result of alternative splicing events but are not typically targeted by Morpholinos.\\n   - **polyA tail**: This is a polyadenosine sequence added to the 3' end of mRNA during post-transcriptional modification. It does not play a role in the proposed therapy.\\n   - **antisense**: This refers to a strand of RNA that binds to complementary mRNA strands to prevent their translation into protein. While it might be used in certain therapeutic approaches, Morpholinos specifically target the splicing process rather than translation.\\n\\nGiven this analysis, we can conclude that the structure not directly involved in the proposed therapy involving Morpholinos is the polyA tail.\\n\\nAnswer: D<|im_end|>\", \"To solve this problem, let's break down the key points provided:\\n\\n1. The gene contains many exons, some coding for triple helical repeats.\\n2. Central exons have mutations that lead to out-of-frame peptides.\\n3. A Morpholino is used to prevent these mutations by blocking the spliceosome.\\n4. The Morpholino targets the 5' end of the out-of-frame exon.\\n5. This leads to exon skipping and in-frame joining.\\n6. Several missing exons can be tolerated by an organism.\\n\\nNow, let's analyze each option to determine which structure is not involved in the proposed therapy:\\n\\nA) **lariat**: This refers to a circular intermediate formed during RNA splicing. The Morpholino targets the 5' end of the out-of-frame exon, not the lariat structure.\\n\\nB) **polyA tail**: This is a sequence added to the 3' end of messenger RNA (mRNA). It does not play a role in the process of exon skipping or skipping of out-of-frame exons.\\n\\nC) **R-loops**: These are DNA-RNA hybrid structures that form during transcription. They are not directly involved in the splicing process or the use of Morpholinos.\\n\\nD) **antisense**: An antisense molecule is complementary to part of the mRNA, guiding it to a specific location or modifying its function. In this context, the Morpholino acts as an antisense molecule by preventing the spliceosome from recognizing the out-of-frame exon.\\n\\nGiven the analysis, the structure that is not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the information given:\\n\\n1. **lariat**: This refers to the loop structure formed during RNA splicing. The therapy involves preventing the spliceosome from recognizing and binding to the out-of-frame exon, thereby preventing the inclusion of these non-functional segments into the mature mRNA. Hence, lariats are part of the mechanism.\\n\\n2. **polyA tail**: This is a polyadenylate tail that is added to the 3' end of mRNA molecules. It does not play a role in the proposed therapy aimed at skipping the exon and creating in-frame joining.\\n\\n3. **R-loops**: These are three-stranded RNA-DNA hybrids that form when one strand of DNA is used as a template for RNA synthesis while the other strand remains single-stranded. They are not directly involved in the exon skipping process described.\\n\\n4. **antisense**: This term refers to complementary strands of RNA that can bind to specific mRNA sequences, often used in RNA interference or antisense therapy. In this context, Morpholinos are antisense oligonucleotides that prevent the spliceosome from recognizing the exon.\\n\\nGiven this analysis, the structure that is not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's first understand the process described:\\n\\n1. **Morpholino Therapy**: It works by recognizing the 5' end of the out-of-frame exon in pre-mRNA and preventing the spliceosome from binding.\\n2. **Exon Skipping**: This results in skipping the problematic exon and joining the remaining exons in-frame.\\n\\nNow, let's examine each option:\\n\\nA) **lariat**: This is a circular intermediate formed during RNA splicing, specifically when a lariat intron is being excised. Morpholinos do not directly interact with lariats; they work at the spliceosome level.\\n\\nB) **polyA tail**: This is a polyadenylate sequence added to the 3' end of the mRNA during its processing. The therapy does not affect the polyA tail.\\n\\nC) **R-loops**: These are DNA-RNA hybrids that form during transcription and can interfere with RNA processing. Morpholinos do not directly interact with R-loops.\\n\\nD) **antisense**: This refers to molecules that bind complementary sequences on the mRNA to prevent translation or affect splicing. Morpholinos are antisense oligonucleotides that prevent the spliceosome from recognizing the out-of-frame exon.\\n\\nBased on this analysis, we can see that the structures not directly involved in the proposed therapy are:\\n\\n- Lariat: Morpholinos do not interact with lariats.\\n- PolyA tail: The therapy does not affect the polyA tail.\\n- R-loops: Morpholinos do not interact with R-loops.\\n\\nHowever, since the question asks for the structure that is *not* involved in the proposed therapy, and considering the options given, the structure least directly related to the specific mechanism described is the **lariat**.\\n\\nAnswer: A<|im_end|>\", \"To solve this problem, let's break down the key elements and understand each option:\\n\\n1. **Gene Structure and Exon Function**: The gene has several exons, and the central ones are crucial as they code for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space. Each exon codes for one folded triple alpha helix.\\n\\n2. **Mutation Impact**: Central exon deletions lead to out-of-frame peptides, causing progressive degenerative organ waste. This indicates that the deletion disrupts the normal reading frame of the mRNA.\\n\\n3. **Morpholino Therapy**: The proposed therapy involves delivering a Morpholino that targets the 5' end of the out-of-frame exon. Morpholinos prevent the spliceosome from recognizing the incorrect exon, thus promoting exon skipping and in-frame joining.\\n\\n4. **Understanding the Options**:\\n   - **A) lariat**: This refers to a circular RNA structure that can form during RNA splicing. It is not directly involved in the proposed therapy.\\n   - **B) polyA tail**: This is a polyadenylate tail added to the 3' end of most eukaryotic mRNA molecules. It does not play a direct role in the exon recognition or skipping process.\\n   - **C) R-loops**: These are DNA-RNA hybrids that form during transcription and can interfere with RNA processing. They are not directly involved in the Morpholino mechanism described.\\n   - **D) antisense**: This refers to a sequence complementary to a specific mRNA strand, often used in antisense therapy. In this context, the Morpholino is an antisense molecule designed to bind to the target exon.\\n\\nGiven the analysis, the structure that is not directly involved in the proposed therapy is the **lariat**.\\n\\nAnswer: A<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's first review the context and the proposed mechanism:\\n\\n1. **Gene Structure**: The gene has several exons, with central ones coding for folded triple helical repeats.\\n2. **Mutation**: Central exon deletions result in out-of-frame peptides leading to progressive degenerative organ waste.\\n3. **Therapy Mechanism**: A Morpholino is used to bind to the 5' end of the out-of-frame exon in pre-mRNA, preventing the spliceosome from recognizing it. This leads to exon skipping and in-frame joining.\\n4. **Key Structures Involved**:\\n   - **Spliceosome**: Involved in splicing the pre-mRNA.\\n   - **Morpholino**: An antisense oligonucleotide designed to interfere with RNA processing.\\n   - **PolyA Tail**: Typically added at the 3' end of the mRNA during processing.\\n   - **lariat**: A temporary structure formed during splicing.\\n   - **R-loops**: Complexes formed when RNA is co-transcriptionally processed, but they are not directly involved in the splicing process.\\n   - **Antisense**: Used in the therapy to prevent recognition of the out-of-frame exon.\\n\\nGiven this information, we can analyze each option:\\n\\nA) **lariat**: This is a temporary structure formed during splicing and is not directly involved in the proposed therapy.\\nB) **polyA tail**: This is typically added at the 3' end of the mRNA during processing and is not directly involved in the therapy mechanism.\\nC) **R-loops**: These are complex structures involving RNA and DNA but are not directly involved in the splicing or exon recognition process.\\nD) **antisense**: This is the key component of the therapy as described.\\n\\nThus, the structure that is not involved in the proposed therapy is the lariat.\\n\\nAnswer: A<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the given information and analyze each option:\\n\\n1. **lariat**: This refers to a circular intermediate structure formed during RNA splicing. It can be relevant in understanding the RNA splicing process, but it isn't directly involved in the therapy described, which focuses on exon skipping and in-frame joining using a Morpholino.\\n\\n2. **polyA tail**: This is a polyadenosine sequence at the 3' end of mRNA molecules that helps in the stability and export of mRNAs from the nucleus. It is not directly involved in the exon skipping mechanism described.\\n\\n3. **R-loops**: These are DNA-RNA hybrid structures that form when transcription occurs in the presence of high levels of DNA replication. They are not directly related to the exon skipping process mentioned.\\n\\n4. **antisense**: This is a molecule that can bind to complementary RNA sequences and influence their function. In this context, an antisense Morpholino is used to prevent the spliceosome from recognizing and binding to the out-of-frame exon, thus creating exon skipping and in-frame joining. \\n\\nGiven these analyses, the structure that is not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze each option in the context of the therapy described:\\n\\n1. **lariat**: This refers to a circular RNA intermediate formed during RNA splicing. The therapy involves modifying pre-mRNA to prevent the spliceosome from recognizing an out-of-frame exon, leading to exon skipping and in-frame joining. The lariat might be a part of this process as it represents a temporary structure during splicing.\\n\\n2. **polyA tail**: This is a polyadenylate tail added to the 3' end of some eukaryotic mRNA molecules. It is not directly involved in the proposed therapy since the therapy deals with the 5' end of the out-of-frame exon.\\n\\n3. **R-loops**: These are three-stranded structures that form during transcription when the DNA template strand forms a double helix with the newly synthesized RNA, while the other single-strand DNA remains bound to the RNA-DNA hybrid. While R-loops can play roles in gene regulation, they are not specifically mentioned in the therapy described.\\n\\n4. **antisense**: This refers to RNA sequences complementary to specific regions of mRNA or DNA. In the context of the therapy, an antisense molecule (Morpholino) is used to bind to the 5' end of the out-of-frame exon, preventing the spliceosome from recognizing it. Thus, antisense is directly involved in the therapy.\\n\\nBased on this analysis, the structure that is not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze each option in relation to the described therapy:\\n\\n1. **lariat**: This is a temporary intermediate structure formed during RNA splicing. The therapy involves using a Morpholino that targets the 5' end of the out-of-frame exon in pre-mRNA to prevent the spliceosome from recognizing it, leading to exon skipping. Therefore, lariats can be indirectly involved since they form part of the normal splicing process.\\n\\n2. **polyA tail**: This is a characteristic feature of mRNA, indicating its maturation and readiness for translation. It is not directly involved in the splicing process or the creation of lariats. Thus, it does not play a role in the proposed therapy involving exon skipping.\\n\\n3. **R-loops**: These are three-stranded structures that form during transcription when a DNA strand hybridizes with its complementary RNA transcript and single-stranded regions remain. While they can affect transcription and splicing, they are not specifically targeted in the therapy described.\\n\\n4. **antisense**: An antisense oligonucleotide like Morpholino is designed to bind to specific sequences in RNA, preventing their recognition by the spliceosome. This fits perfectly with the described therapy, as it prevents the spliceosome from recognizing the out-of-frame exon.\\n\\nGiven this analysis, the structure that is not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze each option in the context of the given information:\\n\\n1. **lariat**: This is a structure formed during RNA splicing when the intron is ligated to the exon. The morpholino is designed to recognize the 5' end of the out-of-frame exon, preventing the spliceosome from recognizing it. Thus, the lariat is part of the normal RNA splicing process but is not directly involved in the therapeutic mechanism described.\\n\\n2. **polyA tail**: This is a characteristic feature of mRNA molecules, indicating their ready transport to the ribosomes for translation. It does not play a role in the specific splicing intervention described.\\n\\n3. **R-loops**: These are DNA-RNA hybrid structures that form during transcription and can lead to DNA damage. While they can interfere with gene expression, they are not mentioned in the context of the morpholino therapy described.\\n\\n4. **antisense**: This refers to a sequence complementary to a region of mRNA or DNA, often used in antisense therapy to block gene expression. The morpholino described in the problem is an antisense oligomer that targets the 5' end of the out-of-frame exon, thereby blocking its inclusion into the mature mRNA.\\n\\nGiven this analysis, the structure that is not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's first understand the key steps in the therapy process:\\n\\n1. **Out-of-Frame Exon Deletion**: This results in a non-functional protein due to a stop codon introduced by the deletion.\\n2. **Morpholino Therapy**: A Morpholino is used to target the 5' end of the out-of-frame exon. It binds to the pre-mRNA, preventing the spliceosome from recognizing and splicing the exon.\\n3. **Exon Skipping**: This leads to skipping over the deleted exon during mRNA processing, allowing for continued reading frame and production of a functional protein.\\n\\nNow, let's analyze each option:\\n\\nA) **lariat**: Lariats are RNA structures formed during alternative splicing processes but are not directly involved in the Morpholino-mediated exon skipping mechanism described here.\\n\\nB) **polyA tail**: The polyA tail is added to the 3' end of the mRNA after splicing and is not directly involved in the Morpholino-mediated exon skipping.\\n\\nC) **R-loops**: R-loops are DNA-RNA hybrids that form during transcription and are not directly involved in the Morpholino-mediated exon skipping.\\n\\nD) **antisense**: Antisense oligonucleotides can bind to complementary mRNA sequences and influence gene expression or RNA processing. While they can be used for various therapeutic purposes, they are not directly mentioned in the context of the Morpholino therapy described.\\n\\nGiven this analysis, the structure that is not directly involved in the proposed therapy is:\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's first understand the context and steps of the therapy:\\n\\n1. **Exon Skipping and Exon In-Frame Joining**: The therapy involves using a Morpholino, which is a synthetic oligomer, to recognize the 5' end of an out-of-frame exon in pre-mRNA. This Morpholino prevents the spliceosome from recognizing and splicing the exon, thus causing exon skipping and creating an in-frame joining of the remaining exons.\\n\\n2. **Key Elements of mRNA Processing**:\\n   - **PolyA Tail**: This is added to the mRNA after splicing to help with export from the nucleus.\\n   - **lariat**: This is a circular intermediate formed during RNA splicing, but it is not directly involved in the process of skipping or joining exons.\\n   - **R-loops**: These are structures that form when RNA hybridizes to DNA and the single-stranded DNA remains, leading to the formation of a loop-like structure. They are not typically associated with exon skipping or joining.\\n   - **Antisense**: This refers to a strand of RNA that can bind to complementary sequences on another RNA or DNA molecule. It is used here as the Morpholino, which binds to the 5' end of the out-of-frame exon to prevent splicing.\\n\\nGiven this information, we can conclude that the structure not involved in the proposed therapy is the **lariat**.\\n\\nAnswer: A<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the key elements of the therapy:\\n\\n1. **Out-of-Frame Exon Deletions**: These mutations cause premature stop codons due to the deletion of central exons.\\n2. **Morpholino Therapy**: It targets the 5' end of the out-of-frame exon in pre-mRNA.\\n3. **Exon Skipping and In-Frame Joining**: This process helps in creating a correct reading frame by skipping the problematic exon and joining the remaining parts.\\n\\nNow, let's examine each option:\\n\\nA) **lariat**: Lariats are structures formed during splicing when the intron is ligated into the mRNA after being excised. They are involved in the initial splicing process but are not directly targeted by the Morpholino therapy described here.\\n\\nB) **polyA tail**: This is a polyadenylate tail that is added to the 3' end of the mature mRNA. It is not directly involved in the exon skipping or splicing mechanism discussed.\\n\\nC) **R-loops**: These are DNA-RNA hybrid structures that form during transcription. While they can be involved in certain cellular processes, they are not typically targeted in the context of exon skipping therapies.\\n\\nD) **antisense**: This refers to RNA molecules that bind to complementary sequences in other RNA molecules. They can be used to target specific sequences for modification or removal. In this case, Morpholinos are considered antisense oligonucleotides designed to prevent splicing.\\n\\nGiven this analysis, the structure not directly involved in the proposed therapy is:\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's first understand the context of the therapy described. The therapy involves using a Morpholino to recognize the 5' end of an out-of-frame exon in pre-mRNA and prevent the spliceosome from recognizing it, thus creating exon skipping and in-frame joining. This process involves several RNA structures and processes.\\n\\n1. **lariat**: This refers to a circular intermediate structure formed during RNA splicing. It is indeed involved in the RNA splicing process.\\n2. **polyA tail**: This is a polyadenosine tail added to the 3' end of the mature mRNA. It is not directly involved in the exon recognition or skipping process.\\n3. **R-loops**: These are DNA-RNA hybrid structures that form during transcription. They are also not directly involved in the exon recognition or skipping process.\\n4. **antisense**: This is a molecule that can bind to complementary RNA sequences and influence their function. In this context, the Morpholino is considered an antisense oligonucleotide that binds to the 5' end of the out-of-frame exon.\\n\\nGiven these explanations, we can see that the polyA tail is not directly involved in the process of exon recognition or skipping.\\n\\nAnswer: B<|im_end|>\", \"To solve this problem, let's break down the key elements of the therapy described:\\n\\n1. **Gene Structure**: The gene contains multiple exons, and the central ones code for triple alpha helices.\\n2. **Mutation**: Central exon deletions lead to out-of-frame peptides and progressive degenerative effects.\\n3. **Morpholino Therapy**: This molecule targets the 5' end of the out-of-frame exon in pre-mRNA and prevents the spliceosome from recognizing it, thus causing exon skipping and in-frame joining.\\n\\nNow, let's analyze each option:\\n\\nA) **lariat**: This refers to a type of RNA structure formed during splicing, where the intron forms a loop. Since the Morpholino targets the spliceosome, it would prevent the formation of the lariat.\\n\\nB) **polyA tail**: This is a polyadenosine sequence at the 3' end of mRNA. It is not directly involved in the process of targeting or preventing exon recognition by the spliceosome.\\n\\nC) **R-loops**: These are three-stranded RNA-DNA hybrids that form during transcription. They are not directly involved in the Morpholino-mediated exon skipping mechanism.\\n\\nD) **antisense**: An antisense oligonucleotide is used to bind to complementary sequences in mRNA and can inhibit gene expression. While it could potentially interfere with the mRNA processing, it is not mentioned in the context of the given therapy.\\n\\nGiven this analysis, the structure that is not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze each option:\\n\\nA) **lariat**: Lariats are RNA structures that form during splicing. They contain a loop of RNA that can interact with the spliceosome and other proteins. The Morpholino, which is designed to bind to the 5' end of the out-of-frame exon, would prevent the spliceosome from recognizing the correct splice site, thereby facilitating exon skipping. This process does involve lariats.\\n\\nB) **polyA tail**: The polyA tail is a string of adenine nucleotides added to the 3' end of messenger RNA (mRNA) after transcription. It is crucial for mRNA stability and export from the nucleus to the cytoplasm but is not directly involved in the splicing mechanism or the proposed Morpholino therapy.\\n\\nC) **R-loops**: R-loops are structures formed when one strand of DNA is bound by RNA and the other single-stranded region is left exposed. They are associated with RNA processing and transcription but do not play a direct role in the splicing process or the Morpholino therapy described.\\n\\nD) **antisense**: Antisense oligonucleotides, such as Morpholinos, are used to block specific sequences in mRNA. They are designed to recognize complementary sequences and interfere with the translation process. In this case, the Morpholino targets the 5' end of the out-of-frame exon, preventing it from being spliced into the mature mRNA.\\n\\nGiven this analysis, the structure not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the key steps and components involved:\\n\\n1. **Exon Skipping and In-Frame Joining**:\\n   - The therapy involves delivering a Morpholino that targets the 5' end of the out-of-frame exon.\\n   - This Morpholino interferes with the spliceosome, preventing it from recognizing and splicing the exon into the mRNA.\\n\\n2. **Morpholino Function**:\\n   - Morpholinos are antisense oligonucleotides that can bind to specific sequences in RNA and interfere with their function.\\n   - They do not directly interact with the lariat, polyA tail, or R-loops; rather, they target the spliceosome.\\n\\n3. **Components Involved in Spliceosome Interaction**:\\n   - **Lariat**: This is a temporary intermediate during splicing but is not directly targeted by Morpholinos.\\n   - **PolyA Tail**: This is added to the 3' end of the mRNA after splicing and is not relevant to Morpholino action.\\n   - **R-Loops**: These are secondary structures formed during transcription but are not directly targeted by Morpholinos.\\n\\n4. **Antisense Oligonucleotides (ASOs)**:\\n   - Antisense oligonucleotides like Morpholinos do not interact with the lariat, polyA tail, or R-loops.\\n   - Instead, they bind to the pre-mRNA and prevent the spliceosome from recognizing and splicing the out-of-frame exon.\\n\\nGiven this analysis, we can conclude that the structure not involved in the proposed therapy is the lariat.\\n\\nAnswer: A<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process described:\\n\\n1. **Out-of-Frame Exon Deletions**: These mutations disrupt the reading frame, leading to non-functional peptides.\\n2. **Morpholino Therapy**: A Morpholino molecule is used to target the 5' end of the out-of-frame exon in pre-mRNA. This molecule prevents the spliceosome from recognizing and splicing this exon properly.\\n3. **Exon Skipping and In-Framing**: As a result, the Morpholino causes the skipping of the out-of-frame exon and allows the remaining exons to join in the correct reading frame, creating a functional protein.\\n\\nNow, let's analyze each option:\\n\\nA) **lariat**: This refers to the loop formed during RNA splicing when the intron is cut but not yet removed. It is a part of the RNA splicing process. Since Morpholinos do not directly affect the lariat formation, it is not directly involved in the proposed therapy.\\n\\nB) **polyA tail**: This is the polyadenosine sequence added at the 3' end of the mRNA after the processing steps. While it is important for mRNA stability and export, it is not directly involved in the exon skipping mechanism caused by Morpholinos.\\n\\nC) **R-loops**: These are DNA-RNA hybrid structures that form when transcription and splicing occur simultaneously. They can interfere with the splicing process but are not directly targeted or affected by Morpholinos.\\n\\nD) **antisense**: This is a strand of RNA complementary to a specific region of the mRNA. It can bind to the mRNA and prevent translation, which could potentially be used in therapy. However, Morpholinos specifically target the spliceosome and do not interact with antisense molecules directly.\\n\\nGiven the analysis, the structures that are not directly involved in the proposed therapy involving Morpholinos are the lariat, polyA tail, and R-loops.\\n\\nAnswer: A<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the steps and components of the therapy:\\n\\n1. **Out-of-Frame Exon Deletions**: These deletions result in non-functional proteins because they disrupt the reading frame of the mRNA sequence.\\n2. **Morpholino Therapy**: A Morpholino molecule is designed to bind specifically to the 5' end of the out-of-frame exon in pre-mRNA.\\n3. **Preventing Spliceosome Binding**: The Morpholino prevents the spliceosome from recognizing and binding to the exon, thus preventing it from being spliced into the mature mRNA.\\n4. **Exon Skipping and In-Frame Joining**: Without the out-of-frame exon, the remaining exons can be spliced together, creating a functional protein.\\n\\nNow, let's examine each option:\\n\\nA) **lariat**: This refers to a circular intermediate formed during RNA splicing. While it is part of the RNA splicing process, it is not directly involved in the specific mechanism of the Morpholino therapy described here.\\n\\nB) **polyA tail**: This is a polyadenosine sequence added to the 3' end of mRNA. It is involved in the stability and export of mRNA from the nucleus but is not directly involved in the splicing or Morpholino-mediated exon skipping process.\\n\\nC) **R-loops**: These are three-stranded hybrid DNA-RNA complexes that form during transcription. They are not directly related to the splicing or Morpholino-mediated exon skipping process.\\n\\nD) **antisense**: This refers to a complementary strand of RNA that can bind to mRNA and prevent translation. While it can interfere with mRNA function, it is not the primary mechanism used in this therapy.\\n\\nGiven the above analysis, the structures least involved in the proposed therapy are:\\n\\n- **lariat**\\n- **polyA tail**\\n- **R-loops**\\n\\nHowever, the most relevant answer among the choices provided would be the one that is least directly involved in the therapy, which is:\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's first understand the key steps and components of the therapy described:\\n\\n1. **Morpholino Delivery**: Morpholinos are short synthetic oligonucleotides that can bind to specific sequences in mRNA.\\n2. **Recognition of Out-of-Frame Exon**: The Morpholino targets the 5' end of the out-of-frame exon in pre-mRNA.\\n3. **Preventing Spliceosome Binding**: By preventing the spliceosome from binding, the Morpholino causes exon skipping.\\n4. **Exon Skipping and In-Frame Joining**: This results in the creation of an in-frame protein sequence.\\n\\nNow, let's analyze each option to see if it is part of this process or not:\\n\\nA) **lariat**: This refers to a circular RNA structure formed during splicing. It is not directly involved in the Morpholino-mediated exon skipping process.\\n\\nB) **polyA tail**: This is a polyadenosine tail added to the 3' end of messenger RNA. It is not involved in the Morpholino mechanism as described.\\n\\nC) **R-loops**: These are DNA-RNA hybrid structures that form during transcription when RNA polymerase binds to DNA. While they are formed during transcription, they are not directly involved in the Morpholino-mediated exon skipping process.\\n\\nD) **antisense**: This refers to a strand of RNA that is complementary to a portion of another RNA strand. It is not directly involved in the Morpholino-mediated exon skipping process either.\\n\\nGiven this analysis, the structure that is not involved in the proposed therapy is the **lariat**.\\n\\nAnswer: A<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the key components of the therapeutic approach:\\n\\n1. **Exon Skipping**: This involves the creation of a new reading frame by skipping an out-of-frame exon.\\n2. **Morpholino**: It is designed to bind to the 5' end of the out-of-frame exon in pre-mRNA.\\n3. **Spliceosome**: This is crucial for mRNA splicing, which is disrupted by the Morpholino, leading to exon skipping.\\n4. **In-Frame Joining**: After skipping the exon, the remaining exons join in the correct frame, creating a functional protein.\\n\\nNow, let's analyze each option:\\n\\nA) **lariat**: Lariats are intermediate structures during RNA processing, but they are not directly involved in the process of exon skipping or morpholino-mediated therapy.\\n\\nB) **polyA tail**: The polyA tail is added to the 3' end of the mature mRNA after splicing. It is not directly involved in the proposed therapy.\\n\\nC) **R-loops**: R-loops are secondary structures formed during transcription and splicing. They can interfere with splicing events but are not specifically targeted by Morpholinos.\\n\\nD) **antisense**: Antisense oligonucleotides are complementary to the mRNA sequence and can be used to inhibit translation or guide splicing. While Morpholinos are used here, antisense oligonucleotides are distinct from Morpholinos.\\n\\nGiven this analysis, the structure that is not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's first understand the context and the key steps involved:\\n\\n1. **Exon Skipping**: The therapy involves creating exon skipping and in-frame joining through the use of a Morpholino, which binds to the 5' end of the out-of-frame exon.\\n2. **Spliceosome**: The spliceosome is responsible for recognizing and splicing together the exons in pre-mRNA. When the Morpholino binds to the 5' end of the out-of-frame exon, it interferes with the spliceosome's function.\\n3. **lariat**: This refers to the loop formed during RNA splicing when the intron is being removed from the pre-mRNA. It is not directly involved in the Morpholino mechanism.\\n4. **polyA tail**: This is added to the mRNA after splicing and helps in the export of the mature mRNA from the nucleus to the cytoplasm. It is not involved in the splicing process or the Morpholino mechanism.\\n5. **R-loops**: These are DNA-RNA hybrid structures that form when RNA is synthesized from DNA during transcription. They are not directly involved in the splicing process or the Morpholino mechanism.\\n6. **antisense**: An antisense oligonucleotide can bind to complementary sequences in RNA, but Morpholinos specifically recognize and bind to the 5' end of the out-of-frame exon.\\n\\nGiven these points, the structure that is not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's first understand the key components of the therapeutic process described:\\n\\n1. **Out-of-Frame Exon Deletions**: These result in peptides that are not correctly spliced due to the deletion.\\n2. **Morpholino Therapy**: This molecule binds to the 5' end of the out-of-frame exon in pre-mRNA, preventing the spliceosome from recognizing and splicing it correctly.\\n3. **Exon Skipping and In-Framing**: This results in a properly spliced mRNA without the problematic exon.\\n\\nNow, let's analyze each option:\\n\\nA) **lariat**: This refers to the temporary structure formed during RNA splicing where the intron is looped out. It is indeed a part of the normal RNA splicing process and can be indirectly involved if Morpholinos interfere with splicing but do not directly bind to lariats.\\n\\nB) **polyA tail**: This is a polyadenylate tail added to the 3' end of messenger RNA molecules after they have been processed. The polyA tail is crucial for mRNA stability and export from the nucleus, but it is not directly involved in the splicing process or the Morpholino-mediated therapy.\\n\\nC) **R-loops**: These are DNA-RNA hybrids that form when transcription overlaps with replication. They can disrupt the splicing process and are sometimes associated with genomic instability. While they might indirectly affect splicing, they are not directly involved in the Morpholino-mediated exon skipping.\\n\\nD) **antisense**: This is a strand of RNA complementary to a specific mRNA sequence. It can interact with mRNA to inhibit its translation or affect splicing. Morpholinos are a type of antisense oligonucleotide designed to bind specifically to a target site in pre-mRNA.\\n\\nBased on this analysis, the structure that is not directly involved in the proposed therapy of Morpholino-mediated exon skipping is:\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's first understand the key steps of the therapy:\\n\\n1. **Out-of-Frame Exon Deletions**: These create a stop codon early in the reading frame, leading to a non-functional protein.\\n2. **Morpholino Therapy**: This molecule binds to the 5' end of the out-of-frame exon in the pre-mRNA, preventing the spliceosome from recognizing it. This results in skipping over the deleted exon and creating an in-frame join between the remaining exons.\\n\\nNow, let's examine each option:\\n\\nA) **lariat**: Lariats are RNA structures that form during splicing when introns are removed from pre-mRNA. Since the therapy involves preventing the spliceosome from recognizing the out-of-frame exon, lariats are not directly involved in this process.\\n\\nB) **polyA tail**: This is a tail of adenine nucleotides added to the 3' end of mRNA molecules. It is not directly related to the processing or modification of pre-mRNA where the therapy occurs.\\n\\nC) **R-loops**: R-loops are formed when an RNA strand binds to its complementary DNA strand, leaving a single-stranded DNA region. They can occur during transcription but are not typically part of the spliceosome recognition and splicing process.\\n\\nD) **antisense**: Antisense molecules are complementary to a specific sequence of mRNA and can bind to it, potentially interfering with translation. While this could theoretically affect the expression of the gene, it is not directly involved in the splicing mechanism that the Morpholino therapy targets.\\n\\nGiven this analysis, we can conclude that the structure not directly involved in the proposed therapy is the lariat.\\n\\nAnswer: A<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze each option:\\n\\nA) lariat: This refers to a circular intermediate form of RNA during splicing. During this process, a lariat-like structure forms as part of the splicing mechanism. The Morpholino therapy aims to interfere with the splicing process, so lariats would be relevant to the therapy.\\n\\nB) polyA tail: This is a polyadenosine sequence at the 3' end of mRNA molecules. It is important for mRNA stability and export from the nucleus. However, the therapy described focuses on the splicing process rather than mRNA processing or export. Therefore, the polyA tail is not directly involved in the proposed therapy.\\n\\nC) R-loops: These are DNA-RNA hybrids that form during transcription and can affect splicing. They could potentially influence the splicing process, making them relevant to the therapy.\\n\\nD) antisense: An antisense oligonucleotide is used to recognize and bind to specific sequences in RNA, often to block translation or splice regulation. The Morpholino described in the question is an antisense molecule that recognizes the 5' end of the out-of-frame exon, preventing splicing.\\n\\nGiven this analysis, the structure that is not directly involved in the proposed therapy is:\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's first understand the key steps in the therapy:\\n\\n1. **Central Exon Deletions**: These cause out-of-frame peptides and lead to progressive degenerative organ waste.\\n2. **Morpholino Therapy**: This involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n3. **Exon Skipping and In-Frame Joining**: The Morpholino prevents the spliceosome from binding, leading to exon skipping and in-frame joining, allowing the organism to tolerate several missing exons.\\n\\nNow, let's examine each option to see if it is involved in this process:\\n\\nA) **lariat**: This refers to the loop-like structure that forms during splicing when introns are removed. During the splicing process, the lariat connects the 5' splice donor to the 3' splice acceptor. Since Morpholinos prevent the spliceosome from binding, they do not interfere with the lariat formation. Therefore, lariats are not directly involved in the Morpholino therapy mechanism.\\n\\nB) **polyA tail**: This is a polyadenosine sequence at the 3' end of mRNA molecules. While the polyA tail can affect mRNA stability and translation, it is not directly involved in the process of exon skipping or exon recognition by Morpholinos.\\n\\nC) **R-loops**: These are structures formed during RNA processing, involving a single-stranded DNA-RNA hybrid. R-loops can form during the splicing process but are not directly targeted by Morpholinos.\\n\\nD) **antisense**: An antisense molecule is complementary to a specific sequence in mRNA and can inhibit translation or influence splicing. The Morpholino used in this therapy is an antisense molecule designed to recognize and bind to the 5' end of the out-of-frame exon.\\n\\nBased on this analysis, the structure that is not directly involved in the proposed therapy using Morpholinos is:\\n\\nAnswer: A<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the key components of the therapy described:\\n\\n1. **Out-of-Frame Exon Deletions**: These occur in the middle of the gene, creating a non-functional sequence due to the lack of proper frame alignment.\\n2. **Morpholino Therapy**: This is used to bind to the 5' end of the out-of-frame exon in the pre-mRNA.\\n3. **Exon Skipping and In-Frame Joining**: The Morpholino prevents the spliceosome from recognizing the exon, leading to the skipping of this exon during mRNA processing, and thus allowing the creation of a functional protein.\\n\\nNow, let's analyze each option:\\n\\nA) **lariat**: This refers to a circular intermediate formed during RNA splicing. It is part of the normal splicing process but not directly involved in the Morpholino therapy described.\\n\\nB) **polyA tail**: This is a polyadenylate tail added to the 3' end of the mature mRNA. It is crucial for mRNA stability and export from the nucleus but is not directly involved in the splicing or exon skipping process.\\n\\nC) **R-loops**: These are three-stranded structures that form when a single-stranded region of DNA hybridizes to its complementary RNA strand, leaving a single-stranded DNA loop. While they can affect transcription and translation, they are not directly involved in the Morpholino therapy described.\\n\\nD) **antisense**: This refers to a nucleic acid sequence that binds to another complementary sequence to inhibit gene expression. The Morpholino used in this therapy acts as an antisense molecule, preventing the recognition of the out-of-frame exon.\\n\\nBased on the analysis, the structure that is not directly involved in the proposed therapy is the **lariat**.\\n\\nAnswer: A<|im_end|>\", \"To solve this problem, let's first understand the key elements of the gene therapy process described:\\n\\n1. **Gene Structure**: The gene has dozens of exons, with central exons coding for triple helical repeats.\\n2. **Mutation Type**: Central exon deletions lead to out-of-frame peptides and progressive degeneration.\\n3. **Therapy Approach**: Using a Morpholino to recognize the 5' end of the out-of-frame exon in pre-mRNA to prevent splicing and induce exon skipping.\\n\\nNow, let's consider each option provided:\\n\\n- **A) lariat**: This is a structure formed during RNA processing where a piece of RNA loops back onto itself. It is involved in splicing processes but not directly mentioned in the context of Morpholinos or exon skipping.\\n  \\n- **B) polyA tail**: This is a sequence of adenine nucleotides at the 3' end of mRNA molecules. It does not play a role in the splicing process or the delivery of Morpholinos.\\n\\n- **C) R-loops**: These are structures formed when a single-stranded DNA region forms a loop while hybridizing to an RNA transcript and remaining complementary strand. They are relevant in gene regulation but not directly involved in the Morpholino-mediated exon skipping mechanism.\\n\\n- **D) antisense**: An antisense molecule can bind to a complementary mRNA sequence and block its translation. In this case, the Morpholino acts as an antisense molecule, recognizing the 5' end of the out-of-frame exon.\\n\\nGiven this analysis, the structure that is not directly involved in the proposed therapy using Morpholinos is the lariat.\\n\\nAnswer: A<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's first understand the context and the key components involved in the therapy described:\\n\\n1. **Exon Skipping and In-Frame Joining**: This process involves using a Morpholino, which is a synthetic oligomer that binds to the splice site and disrupts the splicing process. It causes exon skipping and results in an in-frame peptide sequence.\\n2. **Morpholino Mechanism**: The Morpholino targets the 5' end of the out-of-frame exon, preventing it from being spliced into the mature mRNA. This leads to the skipping of the non-functional exon and allows the remaining functional exons to join in frame, producing a correct protein sequence.\\n\\nNow, let's examine each option:\\n\\nA) **lariat**: This refers to a temporary intermediate structure formed during RNA splicing where the intron is held together by its own 3' splice site and 5' splice site, creating a loop-like structure. This is indeed part of the normal splicing process but is not directly involved in the Morpholino-mediated therapy.\\n\\nB) **polyA tail**: This is a polyadenosine sequence added to the 3' end of a mature mRNA. While it helps in mRNA stability and export from the nucleus, it is not directly involved in the exon skipping or splicing process that Morpholinos target.\\n\\nC) **R-loops**: These are DNA-RNA hybrid structures that form when an RNA transcript remains associated with the DNA template strand, often leading to the formation of a looped structure. While they can interfere with gene expression, they are not directly related to the Morpholino mechanism.\\n\\nD) **antisense**: This is a complementary RNA strand that can bind to a specific mRNA and inhibit translation. While this could potentially interfere with the protein production, it is not directly involved in the Morpholino-mediated exon skipping mechanism.\\n\\nGiven this analysis, the structure that is not directly involved in the proposed therapy involving Morpholinos is the **lariat**.\\n\\nAnswer: A<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze each option:\\n\\nA) lariat: This refers to a type of RNA structure formed during splicing where a portion of the intron forms a loop, temporarily forming a lariat-like shape before being cut out. The Morpholino, which is designed to bind to the 5' end of the out-of-frame exon, would interact with this lariat structure as part of its function to prevent spliceosome binding.\\n\\nB) polyA tail: This is a polyadenosine sequence at the 3' end of mRNA molecules. It does not play a direct role in the splicing process or the proposed therapy involving Morpholinos.\\n\\nC) R-loops: These are DNA-RNA hybrids that form during transcription when the nascent RNA transcript displaces some of the template DNA strand, leaving a single-stranded region of DNA. While R-loops can influence transcriptional processes, they are not directly involved in the mechanism of Morpholinos targeting exons.\\n\\nD) antisense: An antisense molecule is complementary to a specific RNA sequence and can interfere with the function of that RNA. In this context, the Morpholino is an antisense molecule that binds to the 5' end of the out-of-frame exon to block splicing.\\n\\nGiven this analysis, the structure that is not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's first understand the key components and processes involved:\\n\\n1. **Gene Structure**: The gene has dozens of exons, with central exons coding for folded triple helical repeats.\\n2. **Mutation**: Central exon deletions lead to out-of-frame peptides and progressive degenerative organ waste.\\n3. **Therapy**: Delivery of a Morpholino that targets the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents spliceosome binding, leading to exon skipping and in-frame joining.\\n4. **Exon Skipping**: Several missing exons are well-tolerated by the organism.\\n\\nNow, let's analyze each option:\\n\\nA) **lariat**: Lariats are RNA structures that form during splicing, but they are not directly involved in the therapy described, which focuses on preventing spliceosome binding.\\n\\nB) **polyA tail**: The polyA tail is added to mRNA after splicing, so it is not directly involved in the process of preventing spliceosome binding or exon skipping.\\n\\nC) **R-loops**: R-loops are DNA-RNA hybrids that form when transcription and DNA replication compete for the same template. While they can be involved in gene regulation, they are not directly involved in the therapy of exon skipping using Morpholinos.\\n\\nD) **antisense**: Antisense molecules, like Morpholinos, are used to bind to specific sequences in RNA and prevent their processing. This aligns with the proposed therapy.\\n\\nGiven this analysis, the structure that is not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the key components of the therapy and identify their involvement:\\n\\n1. **Morpholino**: This is a small synthetic oligomer used to block mRNA splicing.\\n2. **Spliceosome**: This is the complex that recognizes and binds to the splice sites in the pre-mRNA.\\n3. **Exon Skipping**: This involves the skipping of a particular exon during RNA splicing, allowing for the inclusion of other exons in the final mRNA product.\\n4. **R-loops**: These are intermediate structures formed during RNA processing, particularly when transcription and splicing occur in the same region of DNA. However, they are not directly involved in the splicing process itself.\\n5. **Antisense**: This refers to a strand of RNA or DNA that is complementary to a specific region of another RNA or DNA molecule. In this context, it would be the morpholino that acts as an antisense molecule.\\n6. **lariat**: This is a circular intermediate formed during the lariat-mediated splicing pathway, but it is not relevant to the described therapy involving exon skipping.\\n\\nGiven these points, we can eliminate options that are clearly involved in the process:\\n\\n- **Option B: polyA tail**: This is added to the 3' end of the mRNA and is not directly involved in the exon skipping mechanism.\\n- **Option C: R-loops**: As mentioned, R-loops are intermediates during RNA processing and are not directly involved in exon skipping.\\n- **Option D: antisense**: The morpholino acts as an antisense molecule to block the spliceosome from recognizing the out-of-frame exon.\\n\\nNow, considering the remaining option:\\n\\n- **Option A: lariat**: This is an intermediate structure during splicing and is not directly involved in the proposed therapy of exon skipping.\\n\\nThus, the structure that is not involved in the proposed therapy is the lariat.\\n\\nAnswer: A<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze each option in the context of the described therapy:\\n\\n1. **lariat**: This refers to a circular RNA structure that can form during splicing processes. While lariats can occur during RNA splicing, they are not typically a focus in this therapeutic approach. The therapy involves preventing the spliceosome from recognizing and binding to the out-of-frame exon, thus avoiding the formation of lariats.\\n\\n2. **polyA tail**: This is a polyadenosine sequence added to the 3' end of mRNA molecules. It is crucial for mRNA export from the nucleus and translation initiation but is not directly involved in the spliceosomal recognition process or the creation of out-of-frame peptides.\\n\\n3. **R-loops**: These are three-stranded hybrid DNA-RNA structures that form when transcription and splicing compete for the same template strand. They are involved in the RNA splicing process but do not directly correspond to the therapy described.\\n\\n4. **antisense**: This term refers to a strand of RNA that can bind to complementary sequences on messenger RNA (mRNA) to inhibit its function. In this therapy, the Morpholino acts as an antisense molecule, binding to the 5' end of the out-of-frame exon and preventing spliceosome recognition, thereby facilitating exon skipping.\\n\\nGiven this analysis, it is clear that the polyA tail is not directly involved in the proposed therapy.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze each option in relation to the given information:\\n\\n1. **lariat**: This refers to the circular intermediate structure formed during RNA splicing when a spliceosome removes introns from pre-mRNA. The therapy involves preventing the spliceosome from binding to the out-of-frame exon, thus avoiding lariat formation.\\n\\n2. **polyA tail**: This is a polyadenosine sequence added to the 3' end of mRNA molecules. It is not directly involved in the process of exon recognition or skipping. The therapy targets the 5' end of the out-of-frame exon, not the 3' end where the polyA tail is located.\\n\\n3. **R-loops**: These are three-stranded structures that form during transcription and are composed of a single-stranded DNA region, a short complementary RNA sequence, and a double-stranded DNA region. They are not mentioned in the context of the therapy described.\\n\\n4. **antisense**: This refers to a molecule that binds to a complementary RNA strand and can interfere with the expression of a specific gene. In this context, the Morpholino acts as an antisense molecule that recognizes the 5' end of the out-of-frame exon and prevents it from being included in the mature mRNA.\\n\\nGiven this analysis, the structure that is not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the key steps and components:\\n\\n1. **Exon Skipping and In-Frame Joining**: The therapy involves delivering a Morpholino to the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the spliceosome from recognizing and splicing the exon into the mature mRNA.\\n2. **Out-of-Frame Peptides**: Since the exon deletion causes the peptide to be out-of-frame, the Morpholino ensures that the spliceosome skips over the out-of-frame exon, allowing for the joining of the remaining exons into a functional mRNA sequence.\\n\\nNow, let's analyze each option:\\n\\nA) **lariat**: This is a structure formed during RNA splicing. It involves the lariat-like intermediate formed when the intron is cut and the exons are joined together. However, it is not directly involved in the process of skipping an exon or creating an in-frame join.\\n\\nB) **polyA tail**: This is a polyadenosine tail added to the 3' end of the mRNA during its maturation. The therapy does not affect this part of the mRNA.\\n\\nC) **R-loops**: These are structures formed during transcription and splicing, involving RNA-DNA hybrids. While they can play roles in gene regulation, they are not directly involved in the skipping of an exon or creating an in-frame join.\\n\\nD) **antisense**: An antisense molecule binds to complementary RNA sequences, often used in gene therapy to modulate gene expression. The Morpholino mentioned here is an antisense molecule designed to prevent recognition of the out-of-frame exon.\\n\\nGiven the analysis, none of the structures listed are directly involved in the proposed therapy except for the lariat, which is more related to the splicing process rather than exon skipping.\\n\\nAnswer: C<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's first understand the key components of the proposed treatment:\\n\\n1. **Morpholino**: This is a small molecule used as a therapeutic agent to modify gene expression.\\n2. **Spliceosome**: This is a complex of proteins and RNA molecules that catalyzes the splicing of pre-mRNA to remove introns and join exons.\\n3. **Exon Skipping**: This process involves skipping over an out-of-frame exon during mRNA processing, thus creating a new reading frame for the remaining exons.\\n\\nNow, let's analyze each option:\\n\\nA) **lariat**: This is a type of RNA structure formed when a piece of RNA loops back on itself, forming a loop-like structure. While this can occur during RNA processing, it is not directly involved in the process of exon skipping or morpholino-mediated exon inclusion.\\n\\nB) **polyA tail**: This is a sequence of adenine nucleotides (A) added to the 3' end of the mRNA. It does not play a direct role in exon skipping or morpholino-mediated exon inclusion.\\n\\nC) **R-loops**: These are structures formed when a single-stranded DNA/RNA hybrid is stabilized by the complementary base pairing between the RNA strand and the DNA template strand. R-loops are not typically associated with exon skipping or morpholino-mediated exon inclusion.\\n\\nD) **antisense**: This refers to a strand of RNA that is complementary to a specific region of another RNA or DNA. Antisense oligonucleotides like Morpholinos can bind to specific sequences and influence RNA processing, including exon inclusion.\\n\\nGiven this analysis, we can conclude that the lariat structure is not directly involved in the proposed therapy.\\n\\nAnswer: A<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's first understand the key steps of the therapy:\\n\\n1. **Central Exon Deletions**: These deletions create out-of-frame peptides.\\n2. **Morpholino Therapy**: A Morpholino molecule is used to recognize the 5' end of the out-of-frame exon in pre-mRNA.\\n3. **Pre-mRNA Processing**: The Morpholino prevents binding of the spliceosome.\\n4. **Exon Skipping and In-Frame Joining**: This results in exon skipping and in-frame joining, allowing the protein to be produced correctly.\\n\\nNow, let's analyze each option:\\n\\nA) **lariat**: This is a type of RNA intermediate during splicing. It involves the formation of a hairpin loop with a 3' overhang, which is typically formed when the intron is being removed. Therefore, lariat is involved in the normal splicing process and would not be directly targeted by Morpholinos.\\n\\nB) **polyA tail**: This is a polyadenylate sequence added to the 3' end of mRNA molecules after splicing. The presence or absence of this tail does not affect the process of exon skipping and in-frame joining.\\n\\nC) **R-loops**: These are DNA-RNA hybrid structures that form during transcription. They can interfere with splicing but are not directly targeted by Morpholinos in this context.\\n\\nD) **antisense**: This refers to a nucleic acid sequence that binds to a complementary RNA sequence. While Morpholinos are antisense molecules, they specifically target the 5' end of the out-of-frame exon in pre-mRNA to prevent splicing, thus bypassing the need for antisense molecules to bind to the mRNA itself.\\n\\nBased on this analysis, the structure that is not directly involved in the proposed therapy is the **lariat**.\\n\\nAnswer: A<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's first understand the key components of the therapeutic process:\\n\\n1. **Exon Skipping**: This involves creating a gap between the normal exons and the out-of-frame exon, allowing the mRNA to be spliced in a way that skips the problematic exon.\\n2. **Morpholino**: This is a small molecule that can bind to specific sequences in pre-mRNA and prevent the spliceosome from recognizing those sequences.\\n3. **Spliceosome**: This is the complex responsible for RNA splicing, which is the process of removing introns (non-coding regions) and joining exons (coding regions) together to form a mature mRNA.\\n4. **Exon Deletions**: These are the mutations causing the out-of-frame peptides and leading to progressive degenerative organ waste.\\n\\nNow, let's analyze each option:\\n\\nA) **lariat**: This refers to the loop structure formed during RNA splicing when an intron is being removed. It is indeed part of the splicing process and could potentially be involved indirectly in exon skipping.\\n\\nB) **polyA tail**: This is the sequence of adenine nucleotides added to the 3' end of mRNA after transcription. It does not directly interact with the spliceosome or the Morpholino, so it is unlikely to be directly involved in the proposed therapy.\\n\\nC) **R-loops**: These are three-stranded RNA-DNA hybrids that form during DNA replication and transcription. They are not typically involved in the splicing process but could be indirectly relevant if they interfere with the processing of the mRNA.\\n\\nD) **antisense**: This refers to a complementary strand of RNA that can bind to a specific mRNA sequence, potentially preventing its translation. However, in this context, it seems less directly relevant as the focus is on splicing rather than translation.\\n\\nGiven this analysis, the structure least likely to be directly involved in the proposed therapy is:\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process described:\\n\\n1. **Gene Structure and Exon Deletions**: The gene contains dozens of exons, with central ones coding for triple helical repeats. Mutations involve central exon deletions, leading to out-of-frame peptides and progressive degeneration.\\n\\n2. **Morpholino Therapy**: A Morpholino is used to target the 5' end of the out-of-frame exon in pre-mRNA. It prevents splicing by the spliceosome, causing exon skipping and in-frame joining.\\n\\n3. **Structures Involved**:\\n   - **lariat**: This is a temporary intermediate structure formed during RNA splicing. Morpholinos do not directly interact with this structure.\\n   - **polyA tail**: This is a polyadenosine sequence added to the 3' end of the mRNA. It is not directly targeted by Morpholinos.\\n   - **R-loops**: These are DNA-RNA hybrids that form during transcription and can interfere with splicing. Morpholinos might indirectly affect R-loop formation but are not specifically targeting them.\\n   - **antisense**: This is complementary RNA that binds to mRNA to prevent translation or affect splicing. Morpholinos are antisense molecules that bind to the 5' end of the out-of-frame exon, preventing splicing.\\n\\nGiven these points, the structure least likely to be directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To solve this problem, we need to understand the context and the key components of the proposed therapy. The therapy involves delivering a Morpholino to recognize the 5' end of the out-of-frame exon in pre-mRNA and prevent the spliceosome from binding, thus creating exon skipping and in-frame joining.\\n\\nLet's break down each option:\\n\\nA) **lariat**: This refers to the circular intermediate formed during RNA splicing. It is not directly involved in the process of delivering Morpholinos or preventing spliceosome binding.\\n   \\nB) **polyA tail**: This is the polyadenosine tail at the 3' end of mRNA molecules. It does not play a direct role in the proposed therapy involving exon skipping and Morpholinos.\\n\\nC) **R-loops**: These are DNA-RNA hybrid structures that form during transcription. They are not directly involved in the spliceosome-mediated exon skipping process or the delivery of Morpholinos.\\n\\nD) **antisense**: This refers to complementary RNA strands that can bind to messenger RNA (mRNA) and inhibit its translation. While it can indirectly affect protein synthesis, it is not directly involved in the exon skipping mechanism described.\\n\\nGiven the above explanations, the structure not involved in the proposed therapy is the lariat.\\n\\nAnswer: A<|im_end|>\", \"To solve this problem, let's first understand the context and the proposed therapy:\\n\\n1. **Gene Structure and Exon Deletions**: The gene in question has several exons, some of which code for essential parts of a protein. Central exons are crucial as they contain sequences that form triple helices connecting the cytoskeleton, sarcolemma, and extracellular space. Mutations in these central exons, particularly deletions, can lead to misfolded proteins and progressive degenerative diseases.\\n\\n2. **Spliceosome Function**: The spliceosome is responsible for splicing out non-coding regions from pre-mRNA, including introns. This process ensures that only coding exons remain in mature mRNA.\\n\\n3. **Morpholino Therapy**: Morpholinos are small, chemically modified oligonucleotides that bind specifically to the 5' end of the out-of-frame exon in pre-mRNA. They prevent the spliceosome from recognizing and splicing the exon, leading to exon skipping and creation of an in-frame protein.\\n\\nNow, let's analyze each option:\\n\\n- **A) lariat**: This refers to the loop structure formed during RNA splicing when the spliceosome releases the intron from the pre-mRNA. It is indeed part of the RNA splicing process.\\n  \\n- **B) polyA tail**: This is the addition of a polyadenosine (polyA) tail at the 3' end of the mRNA. It is not directly involved in the spliceosome-mediated exon recognition or skipping mechanism.\\n\\n- **C) R-loops**: These are DNA-RNA hybrid structures that form during transcription. While they are significant in gene regulation, they are not directly involved in the mechanism of exon skipping using Morpholinos.\\n\\n- **D) antisense**: This term refers to RNA molecules that bind to complementary mRNA strands, often used for gene silencing. In the context of the proposed therapy, antisense oligonucleotides are not used; instead, Morpholinos are employed.\\n\\nGiven this analysis, the structure that is not directly involved in the proposed therapy involving Morpholinos is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's first understand the context and mechanisms involved:\\n\\n1. **Morpholino Therapy**: This therapy involves introducing a small molecule into the cell to prevent splicing of certain exons.\\n2. **Splicing Mechanism**: Splicing involves the removal of introns from pre-mRNA to produce mature mRNA. The spliceosome plays a crucial role in this process.\\n3. **Exon Skipping and In-Frame Joining**: By preventing the spliceosome from recognizing and splicing out-of-frame exons, the Morpholino allows the inclusion of normal exons, thus creating a functional protein.\\n\\nNow, let's analyze each option:\\n\\nA) **lariat**: This refers to the loop structure formed during RNA splicing. While lariats are part of the splicing process, they are not directly involved in the Morpholino-mediated skipping of exons.\\n\\nB) **polyA tail**: This is a polyadenylate tail added to the 3' end of the mRNA after splicing. It does not play a role in the splicing or exon skipping mechanism described here.\\n\\nC) **R-loops**: These are three-stranded complexes that form during transcription when the nascent RNA hybridizes with its complementary DNA strand. They can interfere with splicing but are not typically targets for Morpholinos in this context.\\n\\nD) **antisense**: Antisense molecules bind to complementary RNA sequences and can influence gene expression indirectly. However, Morpholinos specifically target the spliceosome and prevent splicing rather than interfering with the sense-antisense interaction.\\n\\nGiven the details provided, the structure that is not directly involved in the proposed therapy of exon skipping using Morpholinos is the **polyA tail**.\\n\\nAnswer: B<|im_end|>\", \"To solve this problem, let's first understand the context and the key components involved in the proposed therapy. The therapy involves using a Morpholino to target the 5' end of the out-of-frame exon in pre-mRNA and prevent it from being spliced into the final mRNA product. This results in skipping over the mutated exon and maintaining the integrity of the remaining exons.\\n\\nNow, let's analyze each option:\\n\\nA) **lariat**: This refers to a circular RNA intermediate formed during RNA splicing. It is indeed involved in the splicing process but is not directly targeted by Morpholinos or antisense molecules.\\n\\nB) **polyA tail**: This is a polyadenylate sequence added to the 3' end of the mature mRNA. It is not typically targeted by Morpholinos, as their action is on the pre-mRNA.\\n\\nC) **R-loops**: These are three-stranded structures formed during transcription and splicing. They are complex and can be disrupted by certain RNA-binding proteins or small molecules, including Morpholinos. Thus, they are involved in the proposed therapy.\\n\\nD) **antisense**: This is a complementary strand of RNA that can bind to complementary sequences in the mRNA and influence its stability or translation. Antisense molecules are used in various therapeutic approaches, including Morpholinos, and thus are involved in the proposed therapy.\\n\\nGiven this analysis, the structure that is not directly involved in the proposed therapy is the lariat.\\n\\nAnswer: A<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's first review the key elements of the therapy described:\\n\\n1. The therapy involves using a Morpholino oligonucleotide.\\n2. This oligonucleotide targets the 5' end of an out-of-frame exon in pre-mRNA.\\n3. The Morpholino prevents the spliceosome from recognizing the exon, leading to exon skipping and in-frame joining.\\n\\nNow, let's consider each option:\\n\\nA) **lariat**: This is a structure formed during RNA splicing when the intron is cut and re-ligated incorrectly, resulting in a circular RNA intermediate. It is not directly involved in the Morpholino mechanism described.\\n\\nB) **polyA tail**: This is a polyadenosine sequence added to the 3' end of mRNA molecules. The therapy does not specifically mention affecting this structure.\\n\\nC) **R-loops**: These are DNA-RNA hybrid structures that form during transcription. While they can affect RNA processing, they are not directly involved in the Morpholino mechanism described.\\n\\nD) **antisense**: This refers to a nucleic acid sequence that binds complementary to another sequence. In the context of the therapy, the Morpholino is an antisense molecule designed to bind to the target exon in pre-mRNA.\\n\\nBased on the analysis, the structure that is not directly involved in the proposed therapy is the lariat.\\n\\nAnswer: A<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process and identify the key components:\\n\\n1. **Morpholino Therapy**: \\n   - The therapy involves using a Morpholino oligomer that targets the 5' end of the out-of-frame exon.\\n   - This Morpholino prevents the spliceosome from recognizing and splicing the exon correctly.\\n   - As a result, the exon is skipped during mRNA processing, allowing for in-frame joining of the remaining exons.\\n\\n2. **Key Structures Involved**:\\n   - **lariat**: This refers to a circular RNA structure formed during splicing. It is not directly involved in the Morpholino therapy.\\n   - **polyA tail**: This is a tail of adenine nucleotides added to the 3' end of mRNA. It is not directly involved in the Morpholino therapy.\\n   - **R-loops**: These are DNA-RNA hybrids that form during transcription and are not directly involved in the Morpholino therapy.\\n   - **antisense**: This refers to a strand of RNA that pairs with complementary DNA or RNA sequences. It can guide RNA modifications or prevent the expression of certain genes. In this context, it indirectly helps in exon skipping.\\n\\nGiven the above analysis, the structure that is not directly involved in the Morpholino therapy is the **lariat**.\\n\\nAnswer: A<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze each option in the context of the given information:\\n\\n1. **lariat**: This is a circular intermediate formed during RNA splicing. It can be relevant as it involves the formation of RNA molecules after the splicing process.\\n2. **polyA tail**: This is a sequence of adenine nucleotides added to the 3' end of a messenger RNA (mRNA). It is not directly involved in the splicing process or the proposed therapy.\\n3. **R-loops**: These are three-stranded RNA-DNA hybrids that form during transcription and are known to disrupt the normal transcriptional machinery. They can be relevant in understanding transcriptional regulation but are not directly part of the splicing process.\\n4. **antisense**: This refers to a strand of RNA that can bind to a complementary sequence on another RNA strand. In this context, it could potentially be used as an antisense oligonucleotide to target specific sequences.\\n\\nGiven these points, the structure least likely to be directly involved in the proposed therapy of creating exon skipping and in-frame joining is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process and analyze each option:\\n\\n1. **Morpholino**: This is a small molecule that binds to the 5' end of the out-of-frame exon in pre-mRNA. It interferes with the spliceosome's ability to recognize and splice the exon correctly.\\n2. **lariat**: This is a temporary structure formed during RNA splicing when the intron is cut but not yet removed from the mRNA. While it's involved in the initial phase of splicing, the Morpholino does not directly interact with this structure.\\n3. **polyA tail**: This is a polyadenylate sequence added to the 3' end of most eukaryotic mRNAs. The Morpholino does not interact with or affect the polyA tail.\\n4. **R-loops**: These are structures formed during transcription where the nascent RNA strand forms base pairs with its complementary DNA template strand, leaving a single-stranded DNA region. The Morpholino does not interfere with or form R-loops.\\n\\nGiven these descriptions, the structure that is not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To solve this problem, let's break down the key elements of the gene therapy process described:\\n\\n1. **Gene Structure**: The gene contains multiple exons, some coding for folded triple helical repeats.\\n2. **Mutation**: Central exons can have deletions that create out-of-frame peptides, leading to progressive degenerative issues.\\n3. **Solution**: Morpholinos are used to target the 5' end of the out-of-frame exon, preventing the spliceosome from recognizing it and causing exon skipping and in-frame joining.\\n\\nNow, let's analyze each option to determine which structure is not involved in this therapeutic approach:\\n\\n- **A) Lariat**: This refers to the lariat-like intermediate formed during splicing. The Morpholino would prevent the spliceosome from recognizing the out-of-frame exon, thereby bypassing the need for the lariat formation.\\n  \\n- **B) PolyA Tail**: This is added to the 3' end of the mRNA after splicing is complete. The therapy does not involve the polyA tail; rather, it targets the pre-mRNA at the 5' end.\\n  \\n- **C) R-loops**: These are DNA-RNA hybrids that form during RNA processing. While they can be involved in certain regulatory processes, the therapy described does not specifically target or disrupt R-loops.\\n  \\n- **D) Antisense**: This molecule is designed to recognize and bind to complementary sequences in RNA, thereby affecting its function. In this case, the Morpholino is an antisense molecule that targets the 5' end of the out-of-frame exon.\\n\\nBased on the analysis, the structure not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze each option:\\n\\nA) lariat: Lariats are structures formed during RNA splicing where the intron remains covalently linked to the 5' splice donor site. They are involved in the splicing process and are not directly related to the therapy described, which involves Morpholinos targeting specific exons.\\n\\nB) polyA tail: The polyA tail is added to the 3' end of mRNA molecules after transcription. It is not directly involved in the splicing process but plays a role in mRNA export from the nucleus and stability.\\n\\nC) R-loops: R-loops are structures that form when one strand of DNA is used as a template for RNA synthesis, leaving the other two strands single-stranded. While they can affect gene expression, they are not typically mentioned in the context of Morpholino therapy.\\n\\nD) antisense: Antisense oligonucleotides, including Morpholinos, are designed to bind complementary sequences in RNA and interfere with their function. They are directly involved in the proposed therapy by preventing the spliceosome from recognizing the out-of-frame exon.\\n\\nBased on this analysis, the structure least likely to be involved in the proposed therapy is:\\n\\nAnswer: B<|im_end|>\", \"To solve this problem, let's break down the key elements of the gene therapy described:\\n\\n1. **Gene Structure**: The gene has multiple exons, with central exons coding for folded triple helical repeats that connect various cellular structures.\\n2. **Mutation Type**: Central exons can undergo deletions, creating out-of-frame peptides, leading to progressive degenerative organ waste.\\n3. **Therapy Solution**: To address this, a Morpholino is used to recognize the 5' end of the out-of-frame exon in pre-mRNA, preventing the spliceosome from recognizing and splicing the exon, thus causing exon skipping and in-frame joining.\\n\\nNow, let's consider each option provided:\\n\\nA) **lariat**: This refers to a circular RNA intermediate formed during RNA splicing. It is not directly involved in the Morpholino-mediated exon skipping process.\\n\\nB) **polyA tail**: This is a polyadenosine sequence at the 3' end of mRNA molecules that helps stabilize mRNA. It is not directly involved in the process of exon skipping or exon inclusion regulation.\\n\\nC) **R-loops**: These are DNA-RNA hybrid structures that form when transcription and DNA repair processes compete for the same DNA strand. While they can occur during RNA processing, they are not typically targeted by Morpholinos in this context.\\n\\nD) **antisense**: An antisense molecule is designed to bind to complementary sequences on mRNA to inhibit translation or facilitate RNA degradation. Morpholinos are antisense oligonucleotides that can interfere with RNA splicing.\\n\\nGiven this analysis, the structure not directly involved in the proposed therapy is the **lariat**.\\n\\nAnswer: A<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's first understand the key components of mRNA processing and splicing:\\n\\n1. **lariat**: This refers to the circular intermediate formed during RNA splicing. It is involved in the process.\\n2. **polyA tail**: This is added to the 3' end of the mature mRNA as part of its maturation process. It is not directly involved in the proposed therapy.\\n3. **R-loops**: These are secondary structures formed when a single-stranded region of DNA or RNA hybridizes with its complementary strand while the other strand remains single-stranded. They can occur during transcription but are not directly involved in the proposed therapy.\\n4. **antisense**: This is a complementary RNA sequence that can bind to and inhibit the translation of a specific mRNA sequence. It plays a role in the proposed therapy by preventing the binding of the spliceosome.\\n\\nGiven these definitions, the structure that is not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", 'To determine which structure is not involved in the proposed therapy, let\\'s break down the process and identify the key components:\\n\\n1. **Spliceosome**: This is the molecular machine that recognizes and joins together exons during RNA splicing. The proposed therapy involves preventing the spliceosome from recognizing the out-of-frame exon.\\n2. **Morpholino**: This is a small synthetic oligomer that can bind to specific sequences in mRNA and block the function of the spliceosome.\\n3. **Exon Skipping**: This occurs when the spliceosome skips over the out-of-frame exon and joins the remaining exons together in a frame-shifted manner.\\n4. **R-loops**: These are DNA-RNA hybrids formed during transcription and can potentially interfere with the processing of RNA transcripts, but they are not directly involved in the mechanism described here.\\n5. **Lariat**: This refers to a circular intermediate formed during splicing, but it is not directly involved in the proposed therapy.\\n6. **PolyA Tail**: This is added to the 3\\' end of the mature mRNA and does not play a role in the proposed exon skipping mechanism.\\n7. **Antisense**: This refers to a strand of RNA that binds to a complementary sequence on the mRNA, typically to inhibit translation. It is not directly involved in the exon skipping mechanism.\\n\\nGiven these points, we can conclude that the structures not involved in the proposed therapy are the lariat, polyA tail, and antisense.\\n\\nHowever, since we need to choose only one option from the given choices, and \"polyA tail\" is the least relevant among the options provided, the best answer is:\\n\\nAnswer: B<|im_end|>', \"To determine which structure is not involved in the proposed therapy, let's break down the given information and analyze each option:\\n\\n1. **lariat**: This refers to a circular RNA structure that can form during splicing. The therapy involves preventing the spliceosome from binding to the out-of-frame exon, thus avoiding the formation of a lariat.\\n\\n2. **polyA tail**: This is a polyadenosine sequence at the 3' end of mRNA molecules that helps in the stability and export of mRNAs from the nucleus. The proposed therapy does not directly involve the polyA tail.\\n\\n3. **R-loops**: These are DNA-RNA hybrid structures that form when RNA is being processed alongside its complementary DNA strand. The therapy does not mention any involvement with R-loops.\\n\\n4. **antisense**: This term generally refers to an RNA molecule that binds to another RNA or DNA sequence to inhibit transcription or translation. In this context, an antisense Morpholino is used to bind to the 5' end of the out-of-frame exon, preventing it from being included in the mature mRNA.\\n\\nGiven this analysis, the structure that is not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the key components of the therapy described:\\n\\n1. **Morpholino**: This is a small molecule that can recognize the 5' end of the out-of-frame exon in pre-mRNA.\\n2. **Spliceosome**: This complex is responsible for recognizing and splicing the mRNA. When the Morpholino binds to the 5' end of the out-of-frame exon, it prevents the spliceosome from binding, leading to exon skipping.\\n3. **Exon Skipping and In-frame Joining**: By preventing the spliceosome from binding, the Morpholino allows the mRNA to skip over the out-of-frame exon and join the remaining exons in the correct reading frame.\\n\\nNow, let's consider each option:\\n\\nA) **lariat**: Lariats are circular intermediate structures formed during RNA splicing. They are involved in the splicing process but are not directly involved in the Morpholino-mediated exon skipping mechanism.\\n\\nB) **polyA tail**: The polyA tail is added to the 3' end of the mature mRNA and is not involved in the splicing process or the Morpholino-mediated exon skipping.\\n\\nC) **R-loops**: These are DNA-RNA hybrid structures that form during transcription. While they can influence gene expression, they are not directly involved in the Morpholino-mediated exon skipping mechanism.\\n\\nD) **antisense**: Antisense molecules are complementary to a specific sequence of mRNA and can bind to it, potentially affecting translation. However, this is not directly related to the Morpholino's function in preventing spliceosome binding.\\n\\nGiven the description, the structures that are not directly involved in the Morpholino-mediated exon skipping mechanism are the lariat, polyA tail, and R-loops.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's first understand the key components and steps involved:\\n\\n1. **Morpholino**: This is a small synthetic oligonucleotide that binds to a specific region of the mRNA.\\n2. **Spliceosome**: This is the complex responsible for splicing introns from pre-mRNA to form mature mRNA.\\n3. **Exon Skipping**: This process allows the inclusion of a particular exon while skipping another, thus creating an in-frame reading frame.\\n\\nGiven the context, we need to identify which of the listed structures does not play a role in this therapeutic mechanism.\\n\\n- **lariat**: This refers to the temporary structure formed during RNA splicing, but it isn't directly involved in the delivery or recognition of the Morpholino.\\n- **polyA tail**: This is the polyadenylation tail added to the 3' end of the mRNA, which is unrelated to the spliceosome or Morpholino function.\\n- **R-loops**: These are DNA-RNA hybrid structures that can form during transcription and splicing, but they are not directly involved in the therapy described.\\n- **antisense**: This is a strand of RNA that can bind to complementary DNA or RNA sequences, preventing their translation. It fits well with the Morpholino's role in preventing splicing.\\n\\nFrom the above analysis, the structure that is not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the information given and analyze each option:\\n\\n1. **lariat**: This refers to the circular intermediate formed during RNA splicing. It involves the lariat structure as part of the spliceosome complex. Therefore, it is involved in the process.\\n\\n2. **polyA tail**: This is a sequence of adenine nucleotides added to the 3' end of mRNA after transcription. It does not play a direct role in the splicing process or the proposed therapy involving exon skipping and in-frame joining.\\n\\n3. **R-loops**: These are DNA-RNA hybrids that form when RNA transcripts remain bound to the template strand of DNA after the initial synthesis. They are not directly related to the splicing process or exon skipping.\\n\\n4. **antisense**: This refers to RNA molecules that can bind to complementary sequences on other RNAs or DNA, often used in antisense therapy to interfere with gene expression. In this context, Morpholinos are used to prevent the spliceosome from recognizing the out-of-frame exon, thus preventing the creation of non-functional peptides. This fits into the antisense category.\\n\\nBased on the analysis, the structure that is not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To solve this problem, we need to understand the proposed therapy and identify the structures that are not involved in it.\\n\\n1. **Understanding the Therapy**: \\n   - The therapy involves delivering a Morpholino to recognize the 5' end of the out-of-frame exon.\\n   - This Morpholino prevents the spliceosome from binding to the out-of-frame exon.\\n   - As a result, the exon is skipped, allowing the mRNA to be spliced into an in-frame peptide.\\n\\n2. **Analyzing the Structures**:\\n   - **lariat**: This refers to a structure formed during RNA processing where a portion of the intron forms a loop-like structure. It is not directly involved in the Morpholino's mechanism.\\n   - **polyA tail**: This is a polyadenylate tail added to the 3' end of mRNA molecules. It is not involved in the Morpholino's mechanism.\\n   - **R-loops**: These are three-stranded RNA-DNA hybrids that form when an RNA transcript remains associated with its DNA template strand while the complementary DNA strand is displaced. They are not directly involved in the Morpholino's mechanism.\\n   - **antisense**: This refers to a sequence that is complementary to a specific mRNA sequence, often used in antisense therapy. In this case, the Morpholino is the antisense molecule that targets the 5' end of the out-of-frame exon.\\n\\nGiven this analysis, none of the structures listed are directly involved in the proposed therapy involving Morpholinos.\\n\\nAnswer: D<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's first understand the context and the key components involved in the therapy.\\n\\n1. **Morpholino**: This is a small synthetic oligomer used to block mRNA translation or splicing. It works by binding to specific sequences in the mRNA.\\n2. **Spliceosome**: This is a complex of proteins and RNA molecules that catalyzes the splicing of pre-mRNA into mature mRNA. Splicing involves recognizing the splice donor and acceptor sites in the pre-mRNA.\\n3. **Exon Skipping**: This process allows the spliceosome to skip over an out-of-frame exon during splicing, thus creating an in-frame mRNA product.\\n4. **R-loops**: These are DNA-RNA hybrids formed during transcription that can lead to DNA damage and interfere with transcription processes. They are not directly involved in this therapy mechanism.\\n5. **Lariat**: This refers to the looped RNA structure that forms during splicing when introns are removed from pre-mRNA. This structure is part of the normal splicing process but not directly involved in the Morpholino-mediated therapy.\\n6. **PolyA Tail**: This is a polyadenylate sequence added to the 3' end of the mature mRNA. It does not play a direct role in the splicing or Morpholino-mediated therapy mechanisms.\\n7. **Antisense**: This refers to a strand of RNA that binds to complementary mRNA strands to inhibit their translation. In this context, it is mentioned that Morpholinos act as antisense molecules.\\n\\nGiven these explanations, we can identify the structures that are not involved in the proposed therapy:\\n\\n- **Lariat**: This is a normal splicing intermediate and not directly involved in the Morpholino-mediated therapy.\\n- **PolyA Tail**: This is a component of mature mRNA but not directly involved in the splicing or Morpholino-mediated skipping mechanism.\\n- **R-loops**: These can be harmful and interfere with transcription, but they are not specifically targeted or relevant to the Morpholino-mediated therapy.\\n\\nHowever, the question asks for the structure that is not directly involved in the proposed therapy. Considering the options provided, the least relevant to the core mechanism described is the **lariat**.\\n\\nAnswer: A<|im_end|>\", \"To solve this problem, we need to understand the key elements of RNA processing and the proposed therapy for the gene mutation. Let's break down each option:\\n\\n1. **lariat**: This refers to the circular intermediate formed during RNA splicing. It is indeed part of the splicing process.\\n2. **polyA tail**: This is added to the 3' end of mRNA molecules to facilitate their export from the nucleus. It is not directly involved in the splicing process but is important for mRNA stability and transport.\\n3. **R-loops**: These are structures that form when one strand of DNA is used as a template for RNA synthesis while the other DNA strand remains single-stranded. They are not directly related to RNA splicing or the proposed therapy.\\n4. **antisense**: This is a molecule that can bind to complementary RNA sequences to prevent translation or affect RNA splicing. It is relevant to the therapy described, as the Morpholino targets the 5' end of the out-of-frame exon.\\n\\nGiven this information, the structure that is not involved in the proposed therapy is the R-loop.\\n\\nAnswer: C<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's first understand the key components and processes mentioned in the context:\\n\\n1. **Morpholino**: This is a small molecule that acts as an antisense oligonucleotide.\\n2. **Spliceosome**: It is responsible for recognizing and joining exons during splicing.\\n3. **Out-of-frame exon**: This is an exon that, due to a deletion, results in a non-functional peptide.\\n4. **Exon skipping and in-frame joining**: This process involves the use of Morpholino to prevent the spliceosome from joining the out-of-frame exon, thus allowing the inclusion of other functional exons.\\n\\nNow, let's analyze each option:\\n\\nA) **lariat**: This refers to the temporary structure formed during RNA splicing, specifically the lariat intermediate that forms before the intron is removed. While this is a part of the splicing process, it is not directly involved in the Morpholino-mediated therapy described.\\n\\nB) **polyA tail**: This is a polyadenylate tail added to the 3' end of messenger RNA (mRNA). It is not involved in the splicing process or the proposed therapy involving Morpholinos.\\n\\nC) **R-loops**: These are structures formed when an RNA:DNA hybrid is separated from its complementary DNA strand, often occurring during transcription and splicing. They are relevant to the splicing process but not directly related to Morpholino-mediated exon skipping.\\n\\nD) **antisense**: This term refers to a molecule that binds to a complementary sequence on a different RNA molecule, preventing its function. In this case, Morpholinos act as antisense molecules targeting specific sequences in pre-mRNA.\\n\\nGiven this analysis, the structure not involved in the proposed therapy involving Morpholinos is:\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze each option:\\n\\nA) **lariat**: This refers to a circular intermediate structure that can form during RNA splicing. It involves the lariat formation as part of the splicing process. Since the therapy involves preventing binding of the spliceosome, it would affect the lariat formation.\\n\\nB) **polyA tail**: This is a polyadenosine sequence at the 3' end of mRNA molecules. Its presence does not directly interact with the spliceosome or the proposed Morpholino therapy, so it is not directly involved in the therapy.\\n\\nC) **R-loops**: These are three-stranded RNA-DNA hybrid structures that form during transcription and DNA repair processes. They are not directly involved in the splicing process targeted by the Morpholino.\\n\\nD) **antisense**: This refers to a complementary strand of RNA that can bind to messenger RNA (mRNA) and prevent its translation. While antisense oligonucleotides can interfere with the splicing process, the specific therapy described uses Morpholinos, which target the spliceosome and not antisense.\\n\\nBased on this analysis, the structure that is not directly involved in the proposed therapy using Morpholinos is:\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's first understand the key components of the therapy:\\n\\n1. **Morpholino**: This is a small synthetic oligonucleotide that can bind to RNA and prevent splicing.\\n2. **Spliceosome**: An essential complex that binds to RNA and helps in the process of splicing.\\n3. **Exon Skipping**: A mechanism where a particular exon is skipped during RNA processing, leading to the creation of an in-frame protein.\\n\\nNow, let's analyze each option:\\n\\nA) **lariat**: This is a circular intermediate formed during RNA splicing. It is involved in the normal splicing process but is not directly involved in the Morpholino-mediated exon skipping.\\n\\nB) **polyA tail**: This is a polyadenosine sequence added to the 3' end of mRNA molecules. It is not directly involved in the splicing process or the Morpholino-mediated exon skipping.\\n\\nC) **R-loops**: These are DNA-RNA hybrid structures that form during transcription and can interfere with splicing. They are relevant to the splicing process but are not directly involved in the Morpholino-mediated exon skipping.\\n\\nD) **antisense**: This refers to a strand of RNA that binds to a complementary mRNA strand to inhibit translation. It is not directly related to the splicing process or the Morpholino-mediated exon skipping.\\n\\nGiven this analysis, the structure that is not directly involved in the proposed therapy of Morpholino-mediated exon skipping is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process described:\\n\\n1. **Exon Skipping and In-Frame Joining**:\\n   - Morpholinos are designed to recognize the 5' end of the out-of-frame exon.\\n   - They prevent the spliceosome from binding to this region.\\n   - This results in the skipping of the out-of-frame exon and in-frame joining of the remaining exons.\\n\\n2. **Morpholino Mechanism**:\\n   - Morpholinos are synthetic oligonucleotides used as antisense molecules.\\n   - They do not directly interact with the lariat, polyA tail, or R-loops.\\n   - Instead, they interfere with the splicing process by mimicking the RNA sequence at the 5' end of the exon.\\n\\n3. **Analyzing the Options**:\\n   - **A) lariat**: These are circular RNA structures that form during RNA processing. Morpholinos do not interact with these structures.\\n   - **B) polyA tail**: This is added to the 3' end of messenger RNA after splicing. Morpholinos do not affect this part of the RNA.\\n   - **C) R-loops**: These are DNA-RNA hybrid structures formed during transcription. Morpholinos do not interact with these structures either.\\n   - **D) antisense**: Morpholinos are indeed antisense molecules designed to bind complementary sequences. However, they do not directly involve lariats, polyA tails, or R-loops.\\n\\nGiven the analysis, the structure that is not directly involved in the proposed therapy involving Morpholinos is the lariat.\\n\\nAnswer: A<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's first understand the key steps in the therapy:\\n\\n1. **Out-of-Frame Exon Deletion**: The central exon deletion leads to an out-of-frame peptide sequence.\\n2. **Spliceosome Inhibition**: The Morpholino targets the 5' end of the out-of-frame exon.\\n3. **Exon Skipping and In-Frame Joining**: This intervention prevents the spliceosome from recognizing the out-of-frame exon, leading to skipping of this exon and in-frame joining of the remaining exons.\\n\\nNow, let's analyze each option:\\n\\nA) **lariat**: This is a structure formed during RNA splicing where a portion of the intron remains covalently linked to the 3' splice donor site as a lariat-like structure. It is involved in the RNA splicing process but not directly in the Morpholino-mediated exon skipping mechanism.\\n\\nB) **polyA tail**: This is a polyadenosine sequence at the 3' end of mRNA molecules. It is not directly involved in the spliceosome recognition or exon skipping mechanism.\\n\\nC) **R-loops**: These are structures that form when one strand of DNA is bound by RNA and the other single-stranded region of DNA. They are not directly involved in the Morpholino-mediated exon skipping mechanism.\\n\\nD) **antisense**: This refers to a molecule that binds to a complementary RNA sequence. In this context, the Morpholino is an antisense molecule that targets the 5' end of the out-of-frame exon.\\n\\nBased on the analysis, the structure that is not directly involved in the proposed therapy is:\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's first understand the key components and steps of the therapy:\\n\\n1. **Out-of-Frame Exon Deletions**: These occur when part of the exon is deleted, disrupting the reading frame of the mRNA.\\n2. **Morpholino Therapy**: A Morpholino is used to recognize and bind to the 5' end of the out-of-frame exon in pre-mRNA.\\n3. **Pre-mRNA Processing**: This includes splicing, where the spliceosome joins appropriate exons together to form mature mRNA.\\n4. **Exon Skipping**: The Morpholino prevents the spliceosome from recognizing the out-of-frame exon, leading to skipping over it during splicing.\\n5. **In-frame Joining**: As a result of skipping, the remaining exons are joined together in the correct reading frame.\\n\\nNow, let's analyze each option:\\n\\nA) **lariat**: This refers to the loop-like intermediate structure formed during RNA splicing. It is indeed involved in the process as the spliceosome works on the pre-mRNA to form mature mRNA.\\n\\nB) **polyA tail**: This is a polyadenylate tail added to the 3' end of the mRNA after splicing. It is not directly involved in the skipping or inclusion of exons.\\n\\nC) **R-loops**: These are three-stranded structures formed during transcription and splicing. They can be disrupted by Morpholinos targeting the 5' end of the out-of-frame exon, so they are indirectly involved.\\n\\nD) **antisense**: While antisense molecules can bind to complementary sequences, the specific therapy described uses Morpholinos, which are chemically modified oligonucleotides designed to target specific sequences. The antisense concept is not the primary method used here.\\n\\nGiven this analysis, the structure that is not directly involved in the proposed therapy is:\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze each option:\\n\\nA) lariat: This is a circular RNA structure that can form when RNA processing is incomplete or when there is an error during splicing. It does not directly involve the proposed therapy as it is not a key component of the exon skipping process.\\n\\nB) polyA tail: This is a string of adenine nucleotides added to the 3' end of mRNA molecules. It plays a role in mRNA stability and export from the nucleus but is not directly involved in the exon skipping mechanism described.\\n\\nC) R-loops: These are DNA-RNA hybrids that form when transcription and splicing occur simultaneously, often leading to RNA secondary structures that can affect splicing. While they can influence splicing events, they are not a direct part of the Morpholino-mediated exon skipping process.\\n\\nD) antisense: This refers to a complementary strand of RNA that can bind to mRNA and interfere with its translation or modify its splicing. In this context, the Morpholino is considered an antisense oligonucleotide that binds to the pre-mRNA and blocks the spliceosome, facilitating exon skipping.\\n\\nGiven this analysis, the structure not directly involved in the proposed therapy is:\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze each option in relation to the described therapy:\\n\\n1. **lariat**: This refers to the circular intermediate formed during RNA splicing when the intron is removed from the pre-mRNA. The therapy involves preventing the spliceosome from binding to the out-of-frame exon, essentially bypassing this lariat formation.\\n\\n2. **polyA tail**: This is a polyadenosine sequence added to the 3' end of mRNA molecules during post-transcriptional modification. The therapy does not involve any interaction with the polyA tail; it focuses on the 5' end of the out-of-frame exon.\\n\\n3. **R-loops**: These are structures formed during transcription where a single-stranded DNA/RNA hybrid is stabilized by an associated protein. The therapy does not directly interact with R-loops; it targets the pre-mRNA at the 5' end.\\n\\n4. **antisense**: This refers to a molecule that can bind to a complementary sequence in mRNA or DNA, typically used for silencing gene expression. The therapy uses a Morpholino to prevent binding of the spliceosome, so antisense is not directly involved in the mechanism described.\\n\\nGiven these analyses, the structure that is not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze each option:\\n\\nA) lariat: This refers to the circular intermediate formed during RNA splicing, where the intron is looped out. It is indeed part of the RNA splicing process.\\n\\nB) polyA tail: This is the polyadenosine sequence added to the 3' end of the mRNA. It is not directly involved in the RNA splicing process or exon skipping mechanism described in the problem.\\n\\nC) R-loops: These are DNA-RNA hybrids that form during transcription when RNA secondary structures block the binding of RNA polymerase. They are not directly related to the exon skipping therapy involving spliceosomes and morpholinos.\\n\\nD) antisense: This is a strand of RNA that binds to a complementary region of another RNA, typically used in antisense therapy to inhibit gene expression. However, it is not directly relevant to the exon skipping process using morpholinos.\\n\\nGiven this analysis, the structure that is not directly involved in the proposed therapy of exon skipping is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's first understand the key components and steps of the therapy described:\\n\\n1. **Gene Structure**: The gene has multiple exons, with central exons coding for folded triple helical repeats.\\n2. **Mutations**: Central exon deletions create out-of-frame peptides leading to progressive degenerative effects.\\n3. **Solution**: Delivering a Morpholino that targets the 5' end of the out-of-frame exon in pre-mRNA to prevent splicing and induce exon skipping and in-frame joining.\\n4. **Exon Skipping**: This results in the inclusion of several missing exons, which are well-tolerated by the organism.\\n\\nNow, let's examine each option:\\n\\nA) **lariat**: This is a type of RNA intermediate during splicing. It involves the formation of a loop-like structure in RNA that is necessary for the splicing process. Since the therapy aims to disrupt this splicing process, lariats would be directly involved.\\n\\nB) **polyA tail**: This is a long stretch of adenine nucleotides (AAUAAA sequence) found at the 3' end of eukaryotic mRNA. While it influences mRNA stability and export from the nucleus, it is not directly involved in the splicing process or exon recognition targeted by Morpholinos.\\n\\nC) **R-loops**: These are structures formed when one strand of DNA hybridizes to its complementary strand in an RNA-DNA hybrid, while the other single-stranded DNA segment forms a loop. They are not directly related to splicing but can occur during transcription and processing.\\n\\nD) **antisense**: This refers to RNA molecules that bind to complementary sequences in mRNA and can inhibit translation. While antisense therapies can interfere with mRNA function, they are not typically used to target splicing events as directly as Morpholinos do.\\n\\nGiven this analysis, the structure least likely to be involved in the proposed therapy targeting splicing and exon recognition is the **polyA tail**.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze each option in relation to the therapy described:\\n\\n1. **lariat**: Lariats are RNA structures that can form during splicing when the intron is removed from the pre-mRNA. They can potentially interfere with the splicing process if they block the spliceosome's access to the pre-mRNA. However, the therapy described does not mention any interference with lariats; it focuses on preventing the binding of the spliceosome directly.\\n\\n2. **polyA tail**: The polyA tail is a sequence of adenine nucleotides added to the 3' end of mRNA molecules. It is not directly involved in the splicing process or the proposed therapy. The therapy aims to prevent the spliceosome from recognizing and binding to the out-of-frame exon, so the polyA tail is not relevant to this mechanism.\\n\\n3. **R-loops**: R-loops are three-stranded RNA-DNA hybrids that form during transcription. They are not mentioned in the context of the proposed therapy, and their formation is not a target or a component of the therapy described.\\n\\n4. **antisense**: Antisense oligonucleotides, like Morpholinos, are used to bind complementary sequences in the RNA and prevent the spliceosome from recognizing these regions. This is exactly what the therapy described uses to achieve exon skipping and in-frame joining.\\n\\nGiven this analysis, the structure that is not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's first review the key steps of the therapy:\\n\\n1. The therapy involves delivering a Morpholino to recognize the 5' end of the out-of-frame exon.\\n2. The Morpholino prevents the spliceosome from binding to the out-of-frame exon.\\n3. This prevents the inclusion of the mutated exon, leading to exon skipping and in-frame joining.\\n\\nNow, let's analyze each option:\\n\\nA) **lariat**: Lariats are circular RNA molecules that can form during splicing when the intron is too long to be spliced out completely. However, Morpholinos do not interfere with lariat formation; they specifically target the exon-intron junctions.\\n\\nB) **polyA tail**: The polyA tail is added to the mRNA at the 3' end after transcription. It is not directly involved in the process of exon skipping or inclusion via Morpholinos.\\n\\nC) **R-loops**: R-loops are DNA-RNA hybrids that form during splicing when the intron is too long to be removed. While R-loops can affect splicing, they are not directly targeted by Morpholinos in this context.\\n\\nD) **antisense**: Antisense oligonucleotides, including Morpholinos, bind to complementary sequences in the mRNA. They are designed to prevent the spliceosome from recognizing and processing specific exons.\\n\\nGiven this analysis, the structure that is not directly involved in the proposed therapy involving Morpholinos is:\\n\\nAnswer: B<|im_end|>\", \"To solve this problem, let's first understand the context and the key elements involved in the therapy described:\\n\\n1. **Gene Structure**: The gene has dozens of exons, and the central exons are crucial as they code for folded triple helical repeats that connect various cellular structures.\\n2. **Mutation Type**: The mutations involve central exon deletions, leading to out-of-frame peptides and progressive degenerative effects on organs.\\n3. **Solution**: A Morpholino is used to recognize the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents binding of the spliceosome, causing exon skipping and in-frame joining.\\n4. **Key Components of mRNA**: The lariat, polyA tail, and R-loops are RNA secondary structures, while antisense molecules like Morpholinos are DNA or RNA oligonucleotides designed to interact with specific sequences in RNA.\\n\\nNow, let's analyze each option:\\n\\n- **A) lariat**: Lariats are RNA structures formed during splicing. They are indeed part of the mRNA processing machinery but are not directly involved in the Morpholino's function.\\n  \\n- **B) polyA tail**: The polyA tail is added to the mRNA after splicing and helps in the export from the nucleus. It is not directly related to the Morpholino's mechanism of action.\\n\\n- **C) R-loops**: R-loops are temporary structures that form when an RNA-DNA hybrid is separated from its complementary DNA strand. While they can interfere with transcription, they are not directly targeted by Morpholinos.\\n\\n- **D) antisense**: Antisense molecules like Morpholinos are specifically designed to bind to complementary sequences in RNA, preventing them from being processed into functional proteins. They are directly involved in the proposed therapy.\\n\\nGiven this analysis, the structure that is not involved in the proposed therapy is the lariat.\\n\\nAnswer: A<|im_end|>\", \"To solve this problem, let's break down the key points and understand the proposed therapy:\\n\\n1. **Gene Structure**: The gene has multiple exons, with the central ones coding for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space.\\n2. **Mutation Type**: Central exon deletions lead to out-of-frame peptides, causing progressive degenerative organ waste.\\n3. **Solution**: Delivery of a Morpholino that targets the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the spliceosome from recognizing the exon, leading to exon skipping and in-frame joining.\\n4. **Key Structures Involved**: \\n   - Lariat: A temporary structure during RNA splicing where introns are joined.\\n   - PolyA Tail: A sequence of adenine nucleotides added to the 3' end of mRNA after splicing.\\n   - R-Loops: DNA-RNA hybrids formed during transcription, often leading to gene silencing.\\n   - Antisense: A molecule complementary to part of the mRNA that can bind to it and prevent its translation.\\n\\nNow, let's evaluate each option:\\n\\nA) **Lariat**: This structure is indeed involved during RNA splicing when introns are removed from the pre-mRNA. However, it is not directly involved in the proposed therapy since the therapy focuses on preventing the inclusion of the out-of-frame exon rather than the splicing process itself.\\n\\nB) **PolyA Tail**: This is added to the 3' end of mRNA after splicing and does not play a direct role in the proposed therapy of skipping the out-of-frame exon.\\n\\nC) **R-Loops**: These structures can form during transcription but do not seem to be specifically targeted or altered by the Morpholino used in this therapy.\\n\\nD) **Antisense**: This molecule can bind to mRNA and prevent its translation. It fits well into the context of the proposed therapy as it could help bypass the out-of-frame exon by preventing the inclusion of the non-functional peptide sequence.\\n\\nGiven these points, the structure that is not directly involved in the proposed therapy is the **lariat**.\\n\\nAnswer: A<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze each option:\\n\\nA) lariat: This refers to a type of RNA structure formed when the 3' end of an intron is joined to the 5' end of the adjacent exon via a phosphodiester bond. This structure is crucial in the splicing process but isn't directly related to the Morpholino-mediated exon skipping mechanism described in the problem.\\n\\nB) polyA tail: This is a polyadenosine sequence at the 3' end of mRNA molecules. It's important for mRNA stability and export from the nucleus but is not directly involved in the splicing process or the Morpholino-mediated exon skipping mechanism.\\n\\nC) R-loops: These are structures that form during transcription where a single-stranded DNA region forms alongside a complementary RNA strand, creating a loop-like structure. While they can affect gene expression, they are not directly involved in the Morpholino-mediated exon skipping mechanism.\\n\\nD) antisense: An antisense molecule is complementary to a specific mRNA sequence and can bind to it, potentially preventing translation or affecting splicing. In this context, the Morpholino is described as an antisense molecule that recognizes the 5' end of the out-of-frame exon.\\n\\nGiven the options, the structure that is not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\"], 'correct': [False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, True, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, True, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False], 'explanations': [\"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\"], 'num_tokens': [371, 366, 330, 408, 398, 344, 213, 310, 312, 352, 322, 286, 287, 364, 238, 385, 341, 275, 241, 247, 461, 334, 355, 272, 233, 481, 244, 235, 306, 332, 354, 241, 286, 324, 308, 318, 277, 380, 247, 297, 451, 392, 324, 380, 378, 334, 364, 365, 249, 235, 393, 356, 359, 292, 363, 331, 263, 373, 370, 391, 258, 318, 294, 285, 324, 302, 334, 261, 315, 332, 347, 408, 420, 343, 332, 319, 400, 357, 270, 414, 375, 341, 421, 292, 337, 401, 299, 291, 382, 362, 387, 401, 307, 260, 441, 364, 303, 291, 286, 239, 248, 349, 259, 341, 209, 338, 249, 372, 297, 263, 315, 464, 229, 374, 258, 317, 344, 343, 392, 259, 272, 223, 415, 311, 315, 391, 448, 283], 'rewards': [0.087890625, 0.0888671875, 0.0849609375, 0.0947265625, 0.06640625, 0.08984375, 0.095703125, 0.07666015625, 0.1005859375, 0.07373046875, 0.08642578125, 0.0927734375, 0.08349609375, 0.08154296875, 0.0849609375, 0.07470703125, 0.0751953125, 0.0966796875, 0.07421875, 0.0908203125, 0.07568359375, 0.0791015625, 0.08984375, 0.0927734375, 0.07666015625, 0.080078125, 0.09326171875, 0.095703125, 0.0947265625, 0.078125, 0.0908203125, 0.09326171875, 0.07861328125, 0.09228515625, 0.08447265625, 0.0517578125, 0.09375, 0.08740234375, 0.09326171875, 0.08203125, 0.09130859375, 0.09033203125, 0.08544921875, 0.0869140625, 0.08251953125, 0.0849609375, 0.078125, 0.06689453125, 0.091796875, 0.07958984375, 0.08447265625, 0.064453125, 0.0791015625, 0.09326171875, 0.080078125, 0.08544921875, 0.0966796875, 0.07763671875, 0.08740234375, 0.0791015625, 0.09375, 0.10009765625, 0.095703125, 0.0927734375, 0.0771484375, 0.078125, 0.09423828125, 0.0947265625, 0.08935546875, 0.09619140625, 0.07373046875, 0.07666015625, 0.0732421875, 0.07861328125, 0.091796875, 0.08935546875, 0.0908203125, 0.0771484375, 0.0947265625, 0.076171875, 0.08251953125, 0.08251953125, 0.0791015625, 0.09130859375, 0.0908203125, 0.06884765625, 0.09326171875, 0.09521484375, 0.057861328125, 0.0732421875, 0.080078125, 0.083984375, 0.095703125, 0.080078125, 0.08935546875, 0.09228515625, 0.07568359375, 0.08203125, 0.07763671875, 0.09326171875, 0.09326171875, 0.09326171875, 0.08544921875, 0.083984375, 0.095703125, 0.07568359375, 0.0966796875, 0.0712890625, 0.08642578125, 0.0966796875, 0.07763671875, 0.0634765625, 0.087890625, 0.08837890625, 0.09375, 0.0888671875, 0.08740234375, 0.0908203125, 0.08740234375, 0.0947265625, 0.0986328125, 0.09326171875, 0.0908203125, 0.09619140625, 0.08935546875, 0.0830078125, 0.06787109375, 0.09228515625], 'ground_truths': ['C'], 'question_meta': None, 'model_name': 'hf_chat:Qwen/Qwen2.5-3B-Instruct', 'reward_model_name': 'armo_rm:RLHFlow/ArmoRM-Llama3-8B-v0.1'}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 33%|â–ˆâ–ˆâ–ˆâ–Ž      | 4/12 [00:10<00:24,  3.03s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'qid': 'gpqa-1', 'prompt': \"Answer the following multiple choice question. The last line of your response should be of the following format: 'Answer: $LETTER' (without quotes) where LETTER is one of ABCD. Think step by step before answering.\\n\\nA large gene has dozens of exons, of which the central ones code for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space. Each exon usually codes for one folded triple alpha helix. The most common mutations of the gene are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste. A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. The molecule prevents binding of the spliceosome and creates exon skipping and in-frame joining. Several missing exons are well tolerated by an organism. Which structure below is not involved in the proposed therapy?\\n\\nA) lariat\\nB) polyA tail\\nC) R-loops\\nD) antisense\", 'answers': [\"To determine the correct answer, let's analyze the given information and the options provided.\\n\\nThe proposed therapy involves delivering a Morpholino to prevent the binding of the spliceosome to the 5' end of an out-of-frame exon in pre-mRNA, leading to exon skipping and in-frame joining. This process is a form of antisense therapy, where the Morpholino acts as an antisense oligonucleotide.\\n\\nNow, let's look at the options:\\n\\nA) Lariat: Lariats are structures that form during the splicing process when the intron is removed. They are not directly involved in the proposed therapy, which focuses on preventing the splicing of the out-of-frame exon.\\n\\nB) PolyA tail: The polyA tail is added to the 3' end of the mRNA during the processing stage, after the splicing process. This is not directly related to the proposed therapy.\\n\\nC) R-loops: R-loops are structures that can form during the splicing process, but they are not directly involved in the proposed therapy.\\n\\nD) Antisense: Antisense oligonucleotides, like the Morpholino in the proposed therapy, bind to the target RNA sequence and prevent its interaction with other molecules, such as the spliceosome.\\n\\nConsidering the information provided and the options, the correct answer is the structure that is not directly involved in the proposed therapy.\\n\\nAnswer: A<|eot_id|>\", \"To answer this question, let's analyze the given information and the options:\\n\\n1.  The proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA and prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n2.  This process involves manipulating the splicing of the pre-mRNA, which is the primary focus of the therapy.\\n3.  Let's examine the options in relation to this process:\\n   - A) Lariat: A lariat is a structure that forms during the splicing process, specifically when the intron is removed from the pre-mRNA. However, it is not directly involved in the proposed therapy, which focuses on preventing the binding of the spliceosome and causing exon skipping.\\n   - B) PolyA tail: The polyA tail is added to the 3' end of the mRNA after splicing has occurred. While it is a part of the mRNA processing, it is not directly involved in the splicing process itself.\\n   - C) R-loops: R-loops are a type of secondary structure that can form during transcription and splicing, but they are not directly involved in the proposed therapy.\\n   - D) Antisense: Antisense refers to the process of using a single-stranded nucleic acid to bind to the target mRNA, which is exactly what the Morpholino in the proposed therapy does. It is a key component of the therapy.\\n\\nConsidering the information above, the structure that is not involved in the proposed therapy is the lariat, as it is a byproduct of the splicing process and not a direct participant in the manipulation of the splicing process.\\n\\nAnswer: A<|eot_id|>\", \"To answer this question, let's analyze the proposed therapy and the structures involved in the process.\\n\\nThe therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome and causes exon skipping, resulting in in-frame joining. The goal is to create a new, in-frame mRNA that can be translated into a protein.\\n\\nNow, let's look at the options:\\n\\nA) Lariat: In the splicing process, the lariat structure is formed when the branch point is formed and the 5' end of the intron is joined to a U in the lariat arm. This process is not directly related to the therapy described.\\n\\nB) PolyA tail: The polyA tail is added to the 3' end of the mRNA after splicing is complete. It is not directly involved in the splicing process or the proposed therapy.\\n\\nC) R-loops: R-loops are involved in the process of splicing, particularly in the recognition of the 5' splice site. They are formed by the binding of the U1 snRNP to the 5' splice site, which is exactly what the Morpholino in the proposed therapy would be targeting.\\n\\nD) Antisense: The Morpholino used in the therapy is an antisense oligonucleotide, which is designed to bind to the target sequence in the pre-mRNA.\\n\\nGiven the information, the structure that is not involved in the proposed therapy is the lariat (A). The lariat is a structure that forms during the splicing process, but it is not directly involved in the recognition of the 5' splice site or the action of the Morpholino.\\n\\nAnswer: A<|eot_id|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze the given information and the options provided.\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA and prevents the binding of the spliceosome, resulting in exon skipping and in-frame joining. This process involves the splicing of the pre-mRNA, which is a crucial step in the gene expression process.\\n\\nA) lariat: The lariat structure is involved in the splicing process, where the intron is removed from the pre-mRNA, forming a lariat-shaped structure. This process is indeed relevant to the proposed therapy, as the therapy aims to prevent the binding of the spliceosome, which is necessary for the lariat formation.\\n\\nB) polyA tail: The polyA tail is added to the 3' end of the pre-mRNA during the post-transcriptional modification process, which is separate from the splicing process. While the polyA tail is essential for mRNA stability and translation, it is not directly involved in the splicing process or the proposed therapy.\\n\\nC) R-loops: R-loops are involved in the splicing process, as they are formed during the assembly of the spliceosome and the removal of introns. This structure is relevant to the proposed therapy, as the therapy aims to prevent the binding of the spliceosome.\\n\\nD) antisense: The Morpholino used in the proposed therapy acts as an antisense oligonucleotide, binding to the 5' end of the out-of-frame exon in pre-mRNA. This is a direct involvement of the antisense concept in the therapy.\\n\\nConsidering the information provided, the structure not involved in the proposed therapy is the polyA tail, as it is not directly related to the splicing process or the spliceosome binding that the therapy aims to prevent.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's analyze the given information and options.\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining. \\n\\n- A) lariat: This is a structure that forms during the splicing process, specifically when the intron is removed. The 5' end of the intron is joined to the 2' hydroxyl group of a nucleotide in the intron, forming a lariat shape. However, in the context of the proposed therapy, the focus is on the 5' end of the out-of-frame exon, not the intron. \\n\\n- B) polyA tail: This is added to the 3' end of the mRNA after transcription, but it is not directly involved in the splicing process or the proposed therapy.\\n\\n- C) R-loops: These are structures formed during the splicing process, specifically when the nascent RNA transcript is base-paired with the template strand of the DNA, but they are not directly relevant to the proposed therapy.\\n\\n- D) antisense: This is a type of RNA that is complementary to the target mRNA and can bind to it, preventing its translation. The Morpholino mentioned in the question works in a similar manner, recognizing the 5' end of the out-of-frame exon in pre-mRNA.\\n\\nBased on this analysis, the structure that is not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's go through the process of the proposed therapy step by step and identify the structures involved.\\n\\n1. **Morpholino delivery**: Morpholinos are antisense oligonucleotides that bind to specific sequences of RNA. In this case, it recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n\\n2. **Preventing the spliceosome binding**: The spliceosome is a complex that recognizes splice sites in pre-mRNA and facilitates splicing. The Morpholino prevents the spliceosome from binding to the 5' end of the out-of-frame exon.\\n\\n3. **Exon skipping and in-frame joining**: This results in the exclusion of the out-of-frame exon and the joining of the remaining exons in a way that creates an in-frame peptide.\\n\\nNow, let's look at the options:\\n\\n- A) **Lariat**: Lariat structures are involved in the splicing process, particularly in the formation of a lariat-shaped intermediate during the splicing of introns. However, in this scenario, the focus is on preventing the spliceosome from binding to the exon, not on the splicing process itself.\\n\\n- B) **PolyA tail**: The polyA tail is added to the 3' end of the mRNA after splicing is complete. This process is not directly involved in the proposed therapy.\\n\\n- C) **R-loops**: R-loops are structures that form during transcription, where an RNA molecule is base-paired with a single-stranded DNA. This can be relevant to the splicing process, but it's not directly involved in the proposed therapy.\\n\\n- D) **Antisense**: Antisense oligonucleotides like Morpholinos are used in this therapy, so this option is directly involved.\\n\\nGiven the information above, the structure not directly involved in the proposed therapy is the polyA tail, as it is added after splicing is complete and is not directly related to the mechanism of Morpholino action.\\n\\nAnswer: B<|eot_id|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze each option in the context of the given scenario.\\n\\nA) lariat: The lariat structure is involved in the splicing process, specifically in the formation of the lariat intermediate during the splicing reaction. In the proposed therapy, the Morpholino prevents the binding of the spliceosome, which is related to the splicing process. Therefore, the lariat structure is relevant.\\n\\nB) polyA tail: The polyA tail is added to the 3' end of the pre-mRNA after splicing. The proposed therapy focuses on preventing the splicing of a specific exon, and the addition of the polyA tail is a downstream process. Therefore, the polyA tail is not directly involved in the proposed therapy.\\n\\nC) R-loops: R-loops are structures that form during the transcription process, where the RNA transcript is paired with the template DNA strand, and the non-template strand is displaced. In the context of splicing regulation, R-loops can be involved in the recognition of splice sites by the spliceosome. Therefore, R-loops are relevant to the proposed therapy.\\n\\nD) antisense: The Morpholino used in the proposed therapy acts as an antisense oligonucleotide, which is designed to bind to the 5' end of the out-of-frame exon in pre-mRNA. This binding prevents the spliceosome from recognizing the exon, leading to exon skipping and in-frame joining. Therefore, antisense is directly involved in the proposed therapy.\\n\\nConsidering the analysis, the structure not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's break down the information provided and analyze the structures involved in the proposed therapy.\\n\\n1. **Morpholino**: Morpholinos are synthetic oligonucleotides that can be used to modify gene expression by preventing the splicing of pre-mRNA. They work by binding to the pre-mRNA and blocking the splicing process.\\n\\n2. **Spliceosome**: The spliceosome is a complex that catalyzes the splicing of pre-mRNA, removing introns and joining exons together. Morpholinos work by preventing the spliceosome from binding to the pre-mRNA.\\n\\n3. **Exon skipping and in-frame joining**: This is a result of the splicing process being blocked by the Morpholino, causing the spliceosome to skip over the out-of-frame exon and join the remaining exons in-frame.\\n\\nNow, let's analyze the options:\\n\\nA) **Lariat**: A lariat is a structure formed during the splicing process, where the 5' end of the intron is looped out and the 3' end is joined to the 5' end of the adjacent exon. This is not directly involved in the proposed therapy.\\n\\nB) **PolyA tail**: The polyA tail is added to the 3' end of the pre-mRNA after splicing is complete. While it's involved in the processing of pre-mRNA, it's not directly involved in the splicing process or the action of Morpholinos.\\n\\nC) **R-loops**: R-loops are a type of secondary structure that can form in pre-mRNA, where a region of single-stranded RNA is paired with a complementary sequence on the opposite strand. However, R-loops are not directly involved in the proposed therapy.\\n\\nD) **Antisense**: Antisense refers to a type of oligonucleotide that can bind to a complementary sequence of RNA, such as the pre-mRNA in this case. Morpholinos are a type of antisense oligonucleotide, so this is directly involved in the proposed therapy.\\n\\nBased on the information, the correct answer is:\\n\\nAnswer: A<|eot_id|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze the given information and options.\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA, preventing the binding of the spliceosome and creating exon skipping and in-frame joining. This process involves the splicing of pre-mRNA.\\n\\nThe structures involved in this process are:\\n\\n- **A) lariat**: During splicing, the branch point of the intron is joined to a U nucleotide, forming a lariat-shaped structure. This is a key intermediate in the splicing process.\\n  \\n- **B) polyA tail**: The polyA tail is added to the 3' end of the mature mRNA after splicing is complete, not during the splicing process itself.\\n\\n- **C) R-loops**: R-loops are a structure that can form during transcription and splicing, where the RNA transcript forms a loop structure with the template DNA. They can be involved in the regulation of splicing.\\n\\n- **D) antisense**: Antisense oligonucleotides, like Morpholinos, work by binding to the target RNA (in this case, pre-mRNA) and preventing the binding of the spliceosome. This is the mechanism by which the Morpholino in the proposed therapy exerts its effect.\\n\\nGiven this information, the structure not directly involved in the proposed therapy is the polyA tail, which is added after splicing is complete.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's break down the process described and the structures involved in the proposed therapy.\\n\\n1. **Pre-mRNA**: This is the primary transcript before it undergoes splicing.\\n2. **Morpholino**: A type of antisense oligonucleotide used to prevent the splicing of a specific exon by blocking the spliceosome.\\n3. **Spliceosome**: A complex that facilitates the splicing process of pre-mRNA.\\n4. **Exon skipping**: The process of excluding a specific exon from the final mRNA product, leading to in-frame joining.\\n5. **PolyA tail**: Added to the 3' end of the mRNA molecule after splicing, which protects the mRNA from degradation and facilitates translation.\\n\\nGiven these points, let's analyze the options:\\n\\nA) **Lariat**: This is a structure formed during the splicing process, where a branch is created in the pre-mRNA. It's involved in the splicing process, but it's not directly involved in the proposed therapy of using Morpholinos to prevent splicing.\\n\\nB) **PolyA tail**: This is added to the 3' end of the mRNA after splicing, but it's not directly involved in the splicing process that Morpholinos are trying to influence.\\n\\nC) **R-loops**: These are structures that can form during the splicing process, but they are not directly involved in the proposed therapy.\\n\\nD) **Antisense**: Morpholinos are a type of antisense oligonucleotide, which is the key component of the proposed therapy.\\n\\nGiven the information, the structures not directly involved in the proposed therapy are the lariat, polyA tail, and R-loops. However, since the question asks for a single structure not involved, and all the other options except one are not directly involved, we need to select the most fitting answer based on the information given.\\n\\nSince antisense (D) is actually directly involved in the proposed therapy, the correct answer would be the structure that is least related to the splicing process or the therapy's mechanism.\\n\\nAnswer: A<|eot_id|>\", \"To solve this question, let's go step by step through the proposed therapy and the structures involved.\\n\\nThe proposed therapy involves using a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, which leads to exon skipping and in-frame joining. \\n\\n- A) Lariat: Lariats are a type of RNA structure formed during the splicing process, but they are not directly involved in the proposed therapy. They are a byproduct of the splicing reaction, not a structure involved in the interaction between the Morpholino and the pre-mRNA.\\n  \\n- B) PolyA tail: The polyA tail is involved in the process of mRNA processing, but it is not directly related to the proposed therapy of using a Morpholino to induce exon skipping.\\n\\n- C) R-loops: R-loops are structures that can form during the splicing process and could potentially be involved in the interaction between the Morpholino and the pre-mRNA, as they can affect the accessibility of the pre-mRNA to the spliceosome.\\n\\n- D) Antisense: The Morpholino in the proposed therapy acts as an antisense oligonucleotide, which is a type of antisense therapy. It recognizes and binds to the pre-mRNA, preventing the binding of the spliceosome.\\n\\nGiven the information, the structure not involved in the proposed therapy is the lariat.\\n\\nAnswer: A<|eot_id|>\", \"To solve this question, let's analyze the process described and the structures involved in RNA splicing and processing:\\n\\n1. The process described involves the use of a Morpholino to prevent the binding of the spliceosome to a specific exon in pre-mRNA. This results in exon skipping and in-frame joining.\\n2. The Morpholino is an antisense oligonucleotide that specifically targets the 5' end of the out-of-frame exon.\\n3. The structures involved in RNA splicing and processing include:\\n   - A) Lariat: A lariat is a type of RNA structure formed during the splicing process, where the branch point of the intron is linked to the 5' splice site through a loop structure.\\n   - B) PolyA tail: The polyA tail is added to the 3' end of the mRNA during post-transcriptional processing, but it's not directly involved in the splicing process or the mechanism of action of Morpholinos.\\n   - C) R-loops: R-loops are structures that can form during transcription, where the RNA transcript is displaced from the DNA template, and a region of the RNA is folded back onto the template strand. They can be involved in regulating gene expression, but they are not directly involved in the splicing process or the mechanism of action of Morpholinos.\\n   - D) Antisense: Antisense oligonucleotides, like Morpholinos, are designed to bind to specific sequences of the target RNA and can interfere with its function.\\n\\nConsidering the process described, the structure that is not directly involved in the proposed therapy is the polyA tail. The polyA tail is added after transcription and splicing, and it's not directly related to the mechanism of action of Morpholinos or the splicing process.\\n\\nAnswer: B<|eot_id|>\", \"To answer this question, let's break down the process of the proposed therapy and the structures involved:\\n\\n1. **Morpholino oligomers**: These are synthetic molecules that can bind to specific sequences of RNA, in this case, the 5' end of the out-of-frame exon in pre-mRNA.\\n2. **Preventing spliceosome binding**: By binding to the 5' end of the out-of-frame exon, the Morpholino prevents the spliceosome from recognizing the exon as part of the normal splicing process.\\n3. **Exon skipping and in-frame joining**: As a result, the pre-mRNA undergoes alternative splicing, skipping the out-of-frame exon and joining the remaining exons in-frame, thus producing a functional protein.\\n\\nNow, let's evaluate the options:\\n\\nA) **Lariat**: In RNA splicing, a lariat is a structure that forms during the splicing process, where the branch point of the intron is joined to a specific adenosine residue. This is a part of the splicing process, but it's not directly involved in the proposed therapy.\\n\\nB) **PolyA tail**: The polyA tail is added to the 3' end of the pre-mRNA after splicing is complete. It's a feature of the mature mRNA, not directly involved in the splicing process or the proposed therapy.\\n\\nC) **R-loops**: R-loops are structures that form during transcription, where the RNA transcript forms a loop with the DNA template strand, and the non-template strand remains single-stranded. R-loops can influence gene expression, but they're not directly involved in the splicing process or the proposed therapy.\\n\\nD) **Antisense**: An antisense oligomer is a type of molecule that can bind to specific sequences of RNA, similar to Morpholino oligomers. In the context of the proposed therapy, the Morpholino is an antisense molecule that binds to the out-of-frame exon and prevents splicing.\\n\\nGiven the information, the structures not directly involved in the proposed therapy are the lariat (A) and the polyA tail (B), but more specifically the lariat is not directly involved in the proposed therapy, and R-loops can also be excluded, leaving us with A and B as options. However, in the context of the proposed therapy, the focus is on the splicing process and the antisense approach. Therefore, we can exclude A and B based on relevance to the therapy and the process described. The focus\", \"To answer this question, let's break down the information given and analyze each option:\\n\\n1.  The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino molecule prevents the binding of the spliceosome and creates exon skipping and in-frame joining.\\n2.  The goal of this therapy is to skip the out-of-frame exon and join the remaining exons in-frame, which will result in a functional protein.\\n\\nNow, let's analyze each option:\\n\\nA) Lariat: Lariats are involved in the splicing process, specifically in the formation of a lariat-shaped intron. They are not directly involved in the binding of the spliceosome or in the recognition of the 5' end of the out-of-frame exon. However, lariat structures are formed after the initial splicing event, which might not be directly relevant to the proposed therapy.\\n\\nB) PolyA tail: The polyA tail is added to the 3' end of the mRNA during post-transcriptional modification. This process is not directly involved in the recognition of the 5' end of the out-of-frame exon or in the binding of the spliceosome.\\n\\nC) R-loops: R-loops are involved in the splicing process and are formed when the pre-mRNA and the U1 snRNA bind to the 5' splice site. This is a crucial step in the splicing process, and R-loops are involved in the recognition of the 5' end of the out-of-frame exon.\\n\\nD) Antisense: Antisense refers to a type of RNA that is complementary to the target mRNA. In this case, the Morpholino is an antisense molecule that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n\\nConsidering the above points, the structures that are not directly involved in the proposed therapy are A) lariat and B) polyA tail. However, the question asks for the structure that is not involved in the proposed therapy. \\n\\nBetween A and B, B) polyA tail is not directly involved in the splicing process or the recognition of the 5' end of the out-of-frame exon. \\n\\nAnswer: B<|eot_id|>\", 'To solve this question, let\\'s break down the steps of the proposed therapy and the structures involved in the process:\\n\\n1. **Morpholino delivery**: Morpholinos are antisense oligonucleotides that can bind to specific sequences of RNA. In this case, the Morpholino is designed to recognize the 5\\' end of the out-of-frame exon in pre-mRNA.\\n\\n2. **Preventing spliceosome binding**: The Morpholino binds to the pre-mRNA, preventing the spliceosome from binding to the targeted exon.\\n\\n3. **Exon skipping and in-frame joining**: As a result of the spliceosome\\'s inability to bind, the pre-mRNA undergoes alternative splicing, skipping the targeted exon and joining the remaining exons in an in-frame manner.\\n\\nNow, let\\'s examine the options:\\n\\nA) **Lariat**: Lariat structures are formed during the splicing process when the intron is removed and the 5\\' end of the intron is joined to the 2\\' hydroxyl group of the branch point, forming a lariat-shaped structure. While lariats are indeed involved in the splicing process, they are not directly related to the action of Morpholinos or the proposed therapy.\\n\\nB) **PolyA tail**: The polyA tail is added to the 3\\' end of the pre-mRNA after splicing is complete, and it is involved in the export of the mature mRNA from the nucleus to the cytoplasm. While the polyA tail is an important step in mRNA processing, it is not directly involved in the proposed therapy.\\n\\nC) **R-loops**: R-loops are a type of secondary structure that can form during the splicing process, but they are not directly related to the action of Morpholinos or the proposed therapy.\\n\\nD) **Antisense**: Antisense oligonucleotides, such as Morpholinos, are designed to bind to specific sequences of RNA, including pre-mRNA. In this case, the Morpholino is an antisense molecule that recognizes the 5\\' end of the out-of-frame exon.\\n\\nConsidering the information above, the structures that are not directly involved in the proposed therapy are lariat, polyA tail, and R-loops. However, since the question asks for the structure that is \"not involved\" and there are multiple options, we must choose the one that is least directly related to the therapy. Antisense is the correct answer because the question specifically mentions the Morphol', \"To solve this question, let's break down the process described and the structures involved:\\n\\n1. The therapy involves delivering a Morpholino to prevent the binding of the spliceosome to the 5' end of an out-of-frame exon in pre-mRNA.\\n2. This leads to exon skipping and in-frame joining.\\n3. The goal is to create a new, in-frame transcript that can be translated into a functional protein.\\n\\nThe structures involved in the process are:\\n\\n- The spliceosome (a complex of proteins that recognizes and removes introns from pre-mRNA)\\n- The pre-mRNA itself\\n- The Morpholino oligonucleotide (antisense oligonucleotide) that prevents the spliceosome from binding to the out-of-frame exon\\n\\nThe structures listed in the options that are not directly involved in this process are:\\n\\nA) Lariat: Lariats are structures formed during splicing when the 5' end of the intron is removed and the 5' phosphate group is transferred to the 5' end of the branch point adenosine, forming a loop. This is a result of the splicing process, but it's not directly involved in the proposed therapy.\\n\\nB) PolyA tail: The polyA tail is added to the 3' end of the mRNA after splicing has occurred. It's not directly involved in the process of splicing or exon skipping.\\n\\nC) R-loops: R-loops are formed during transcription when the RNA transcript is base-paired with a region of the DNA template strand. This is not directly related to the process described.\\n\\nD) Antisense: Antisense oligonucleotides like Morpholinos are indeed involved in the therapy described.\\n\\nGiven this information, the correct answer is the structure that is not directly involved in the proposed therapy.\\n\\nAnswer: A<|eot_id|>\", \"To solve this question, let's analyze the given information and the options:\\n\\n1. The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n2. The Morpholino prevents the binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\nNow, let's look at the options:\\n\\nA) lariat: A lariat is a type of RNA structure formed during the splicing process. It is a loop of RNA that is formed when the intron is removed from the pre-mRNA. The lariat structure is not directly involved in the proposed therapy, which focuses on preventing spliceosome binding and creating exon skipping.\\n\\nB) polyA tail: The polyA tail is added to the 3' end of the mRNA after transcription. It is involved in stabilizing the mRNA and facilitating its export from the nucleus. The proposed therapy does not directly involve the polyA tail.\\n\\nC) R-loops: R-loops are structures formed during transcription, where the nascent RNA transcript is paired with the template DNA strand, while the non-template strand is displaced. R-loops are involved in the regulation of gene expression and can be formed during the process of splicing.\\n\\nD) antisense: Antisense oligonucleotides, like Morpholinos, are used in gene therapy to prevent the expression of a specific gene by binding to the mRNA and preventing its translation. In this case, the Morpholino is an antisense oligonucleotide that recognizes the 5' end of the out-of-frame exon.\\n\\nConsidering the above information, the structure not involved in the proposed therapy is the lariat.\\n\\nAnswer: A<|eot_id|>\", \"To solve this question, let's analyze the given information and the options provided.\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA, preventing the binding of the spliceosome and creating exon skipping and in-frame joining. This process is related to RNA splicing and the regulation of gene expression.\\n\\nLet's examine the options:\\n\\nA) lariat: In the process of RNA splicing, the lariat structure is formed when the intron is removed and a branch point is created. However, the lariat structure is not directly involved in the binding of the spliceosome or in the recognition of the 5' end of the out-of-frame exon.\\n\\nB) polyA tail: The polyA tail is added to the 3' end of the mRNA after splicing is complete, and it is involved in the stabilization of the mRNA and its export from the nucleus. However, it is not directly involved in the process of splicing or the recognition of the 5' end of the out-of-frame exon.\\n\\nC) R-loops: R-loops are a type of RNA-DNA hybrid structure that can form during transcription, but they are not directly involved in the process of RNA splicing or the recognition of the 5' end of the out-of-frame exon.\\n\\nD) antisense: The Morpholino used in the proposed therapy is an antisense oligonucleotide that recognizes the 5' end of the out-of-frame exon in pre-mRNA, preventing the binding of the spliceosome and creating exon skipping and in-frame joining.\\n\\nGiven the information and analysis, the structure that is not involved in the proposed therapy is the lariat (A), polyA tail (B), and R-loops (C) are not directly involved in the process but antisense is directly involved in the proposed therapy. However, antisense is the correct answer because the question asks for a structure not involved in the proposed therapy.<|eot_id|>\", \"To solve this question, let's analyze the process described and the structures involved in RNA processing and splicing.\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA and prevents the binding of the spliceosome, leading to exon skipping and in-frame joining. This is a form of RNA interference (RNAi) or antisense oligonucleotide therapy.\\n\\nLet's analyze each option:\\n\\nA) lariat: A lariat is a type of RNA structure that forms during the splicing process, where the 5' end of the intron is linked to the 2' hydroxyl group of an adenosine residue, forming a loop. This structure is involved in the splicing process, but it is not directly involved in the proposed therapy.\\n\\nB) polyA tail: The polyA tail is added to the 3' end of the mRNA after transcription and is involved in mRNA stability and export. It is not directly involved in the splicing process or the proposed therapy.\\n\\nC) R-loops: R-loops are structures that form when an RNA molecule hybridizes to a complementary DNA sequence, displacing the template strand. They are not directly involved in the splicing process or the proposed therapy.\\n\\nD) antisense: Antisense oligonucleotides, like the Morpholino described in the problem, are designed to bind to the target RNA and prevent its expression. This is the mechanism of action of the proposed therapy.\\n\\nBased on this analysis, the structures not involved in the proposed therapy are the lariat, polyA tail, and R-loops.\\n\\nHowever, since the question asks for the structure that is NOT involved in the proposed therapy, and all three options A, B, and C are not directly involved in the splicing process or the therapy, it is not clear which one to choose. However, considering the nature of the question and the context of the therapy, the most appropriate answer is:\\n\\nAnswer: A<|eot_id|>\", \"To solve this question, let's analyze the given information and the options provided.\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino molecule prevents the binding of the spliceosome and creates exon skipping and in-frame joining. \\n\\nLet's examine the options:\\n\\nA) Lariat: The lariat structure is a type of RNA secondary structure that forms during the splicing process, where the branch point of the intron is covalently attached to a 5' exon via a phosphodiester bond. However, the lariat structure itself is not directly involved in the proposed therapy, which involves the recognition of the 5' end of the out-of-frame exon by the Morpholino.\\n\\nB) PolyA tail: The polyA tail is added to the 3' end of the mRNA during the post-transcriptional modification process. While it's not directly involved in the splicing process or the proposed therapy, it's a part of the mRNA processing.\\n\\nC) R-loops: R-loops are a type of RNA-DNA hybrid structure that can form during the transcription process. However, they are not directly involved in the proposed therapy.\\n\\nD) Antisense: Antisense refers to a type of RNA that is complementary to the mRNA sequence. In the proposed therapy, the Morpholino acts as an antisense oligonucleotide, recognizing the 5' end of the out-of-frame exon in pre-mRNA.\\n\\nConsidering the given information and the options, the structure not involved in the proposed therapy is the lariat.\\n\\nAnswer: A<|eot_id|>\", \"To solve this question, let's analyze the given information and the options provided.\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, causing exon skipping and in-frame joining. The goal is to tolerate missing exons.\\n\\nNow, let's consider the options:\\n\\nA) Lariat: The lariat structure is involved in the splicing process, particularly in the removal of introns. It is not directly involved in the recognition of exons or the binding of the spliceosome.\\n\\nB) PolyA tail: The polyA tail is added to the 3' end of the mRNA during the post-transcriptional modification process. While it is involved in mRNA stability and export, it is not directly involved in the splicing process or the binding of the spliceosome.\\n\\nC) R-loops: R-loops are structures that can form during the splicing process, particularly when the pre-mRNA is being processed. They can be involved in the recognition of exons and the binding of the spliceosome.\\n\\nD) Antisense: Antisense oligonucleotides, like Morpholinos, can recognize specific sequences of RNA and prevent their interaction with other molecules, such as the spliceosome. In this case, the Morpholino is an antisense molecule that recognizes the 5' end of the out-of-frame exon.\\n\\nConsidering the information provided, the structure that is not involved in the proposed therapy is the lariat. \\n\\nAnswer: A<|eot_id|>\", \"To answer this question, let's break down the proposed therapy and the structures involved in RNA splicing and processing.\\n\\nThe proposed therapy involves delivering a Morpholino to a pre-mRNA molecule. Morpholinos are antisense oligonucleotides that can bind to specific sequences of RNA, preventing the action of the spliceosome and allowing for exon skipping and in-frame joining. \\n\\n- Antisense (D) is the correct answer because Morpholinos are a type of antisense oligonucleotide. They are designed to bind to the target RNA sequence in an antisense manner, preventing the normal splicing process.\\n\\n- The lariat (A) structure is involved in the splicing process. It is a loop structure that forms during the splicing reaction, where the 5' end of the intron is joined to the lariat branch point, and the 3' end of the intron is removed. However, it is not directly involved in the proposed therapy.\\n\\n- The polyA tail (B) is involved in the processing of mRNA. It is added to the 3' end of the mature mRNA molecule after splicing, but it is not directly involved in the proposed therapy.\\n\\n- R-loops (C) are structures that can form during transcription, where the RNA transcript is looped back on itself and bound by a protein. However, R-loops are not directly involved in the proposed therapy.\\n\\nThe correct answer is D because Morpholinos are a type of antisense oligonucleotide, and the question asks for a structure that is not involved in the proposed therapy.\\n\\nAnswer: D<|eot_id|>\", \"To solve this question, let's analyze the process described in the scenario and the options given:\\n\\n1.  The scenario describes a gene with dozens of exons, where the central ones code for a specific structure. Central exon deletions lead to out-of-frame peptides and degenerative organ waste.\\n2.  To solve this issue, a Morpholino is delivered to the pre-mRNA, which recognizes the 5' end of the out-of-frame exon and prevents the binding of the spliceosome.\\n3.  This action leads to exon skipping and in-frame joining, allowing the organism to tolerate missing exons.\\n\\nNow, let's analyze the options:\\n\\nA) lariat: Lariat structures are involved in the splicing process, specifically in the formation of the lariat intermediate during the splicing reaction. They are not directly involved in the proposed therapy of delivering a Morpholino to prevent the binding of the spliceosome.\\n\\nB) polyA tail: The polyA tail is added to the 3' end of the pre-mRNA after splicing, but it is not directly involved in the splicing process or the proposed therapy.\\n\\nC) R-loops: R-loops are structures that can form during transcription, where an RNA molecule is base-paired with a single-stranded DNA region. They can influence gene expression and can be involved in splicing regulation, but they are not directly involved in the proposed therapy.\\n\\nD) antisense: Antisense oligonucleotides, such as Morpholinos, are designed to bind to specific sequences of the target RNA and can influence gene expression by preventing the binding of the spliceosome or other regulatory proteins.\\n\\nConsidering the above analysis, the structure not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|eot_id|>\", 'To solve this question, let\\'s analyze the given information and the options step by step:\\n\\n1.  The problem is with a large gene that has dozens of exons, where central exons code for folded triple helical repeats. Central exon deletions lead to out-of-frame peptides, causing degenerative organ waste.\\n2.  The proposed therapy involves using Morpholino to recognize the 5\\' end of the out-of-frame exon in pre-mRNA, preventing the spliceosome from binding, and thus creating exon skipping and in-frame joining.\\n3.  The goal is to create in-frame joining, which means the splicing process needs to be modified to skip the out-of-frame exon and join the remaining exons in-frame.\\n\\nGiven the context, let\\'s examine the options:\\n\\nA) lariat: A lariat is a type of RNA structure formed during the splicing process, where the branch point of the intron is connected to a specific nucleotide. This structure is indeed involved in splicing, but it is not directly involved in the proposed therapy of using Morpholino to prevent spliceosome binding.\\n\\nB) polyA tail: The polyA tail is added to the 3\\' end of the mRNA after splicing is complete. While it\\'s a part of the mRNA processing, it\\'s not directly related to the splicing process that the Morpholino aims to modify.\\n\\nC) R-loops: R-loops are a type of RNA-DNA hybrid structure formed during transcription, where the RNA transcript forms a loop with the template DNA strand. This is not directly involved in the splicing process or the proposed therapy.\\n\\nD) antisense: Antisense oligonucleotides like Morpholino are indeed used to bind to specific sequences of RNA, in this case, the 5\\' end of the out-of-frame exon, preventing the spliceosome from binding and causing exon skipping and in-frame joining.\\n\\nConsidering the options, the structures not directly involved in the proposed therapy of using Morpholino to prevent spliceosome binding and create exon skipping are A, B, and C.\\n\\nHowever, since the question asks for \"the structure below is not involved in the proposed therapy,\" we must select the least relevant or least directly involved option. Given the context, A, B, and C all seem to be less directly involved than D. But, considering the direct involvement in splicing, A is the most specific and relevant to the splicing process but still not directly involved in the proposed therapy.\\n\\nAnswer: A<|eot_id|>', \"To solve this question, let's analyze the given information and the options provided.\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino molecule prevents the binding of the spliceosome and creates exon skipping and in-frame joining. \\n\\nGiven this context, let's examine the options:\\n\\nA) lariat: In the process of RNA splicing, a lariat structure is formed when the branch point in the intron is joined to the 5' splice site, creating a loop. However, this is not directly involved in the proposed therapy of using Morpholino to prevent spliceosome binding and create exon skipping.\\n\\nB) polyA tail: The polyA tail is added to the 3' end of the mRNA after splicing is complete, as a means of stabilizing the mRNA. While it's a part of the mRNA processing, it's not directly involved in the spliceosome binding or the exon skipping process.\\n\\nC) R-loops: R-loops are formed when a single-stranded RNA molecule is bound to a complementary DNA strand, and the other DNA strand is displaced. This can occur during transcription and is not directly related to the spliceosome binding or the proposed therapy.\\n\\nD) antisense: Antisense oligonucleotides, like Morpholino, work by binding to the target mRNA sequence, in this case, the 5' end of the out-of-frame exon, preventing the binding of the spliceosome and promoting exon skipping. This is directly related to the proposed therapy.\\n\\nConsidering the options, the structure that is not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|eot_id|>\", \"To answer this question, let's analyze the given information and the options:\\n\\n1. The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n2. The Morpholino prevents the binding of the spliceosome and creates exon skipping and in-frame joining.\\n3. The goal is to allow several missing exons to be tolerated by the organism.\\n\\nGiven this information, we can analyze the options:\\n\\nA) lariat: Lariats are involved in the splicing process, specifically in the formation of the lariat structure during the splicing of introns. While the therapy involves splicing, the lariat structure itself is not directly involved in the action of the Morpholino.\\n\\nB) polyA tail: The polyA tail is added to the 3' end of the mRNA after transcription, but it's not directly involved in the splicing process or the action of the Morpholino.\\n\\nC) R-loops: R-loops are involved in the splicing process, specifically in the formation of the pre-mRNA structure that is recognized by the spliceosome. While the therapy involves splicing, R-loops are not directly involved in the action of the Morpholino.\\n\\nD) antisense: Antisense oligonucleotides (such as Morpholinos) are designed to bind to specific sequences of the pre-mRNA, in this case, the 5' end of the out-of-frame exon. This is the mechanism of action of the Morpholino in the proposed therapy.\\n\\nConsidering the above analysis, the structure not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's break it down step by step:\\n\\n1. The question describes a gene with dozens of exons, where central exons code for folded triple helical repeats. The most common mutations are central exon deletions, which result in out-of-frame peptides and degenerative organ waste.\\n\\n2. The proposed therapy involves using a Morpholino to recognize the 5' end of the out-of-frame exon in pre-mRNA and prevent the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n\\n3. To determine which structure is not involved in the proposed therapy, we need to identify the structures involved in the process of splicing and RNA processing.\\n\\n4. The lariat (A) is a structure formed during the splicing process, where the intron is looped out, forming a lariat-shaped structure.\\n\\n5. The polyA tail (B) is added to the 3' end of the mRNA during post-transcriptional processing, which is not directly involved in the proposed therapy.\\n\\n6. R-loops (C) are structures formed during transcription, where the RNA transcript is base-paired with the template DNA strand, leaving the non-template strand single-stranded.\\n\\n7. Antisense (D) refers to the use of single-stranded DNA or RNA molecules that are complementary to the target mRNA sequence, which is involved in the proposed therapy using Morpholinos.\\n\\nBased on this analysis, the structure not involved in the proposed therapy is the polyA tail, as it is a post-transcriptional modification that occurs after the splicing process.\\n\\nAnswer: B<|eot_id|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze each option in the context of the given scenario:\\n\\nA) lariat: In RNA splicing, a lariat is a covalent structure that forms during the splicing process. It's a loop of RNA that is involved in the splicing reaction, particularly in the removal of introns. In the context of the therapy described, the Morpholino prevents the binding of the spliceosome, which could potentially affect the formation of lariats. However, lariats are not directly targeted by the Morpholino; they are more of a byproduct of the splicing process.\\n\\nB) polyA tail: The polyA tail is added to the 3' end of the pre-mRNA after splicing. It's involved in the process of mRNA stabilization and export from the nucleus. The Morpholino therapy, however, targets the 5' end of the out-of-frame exon, which is involved in the splicing process rather than the polyA tail addition.\\n\\nC) R-loops: R-loops are structures that form during the splicing process, where the RNA molecule folds back on itself to form a loop. They are involved in the recognition and binding of the spliceosome to the pre-mRNA. The Morpholino therapy, by preventing the binding of the spliceosome, could potentially affect the formation of R-loops.\\n\\nD) antisense: Antisense oligonucleotides, like Morpholinos, are designed to bind to specific sequences of RNA and prevent the translation of the mRNA. In this case, the Morpholino is designed to recognize the 5' end of the out-of-frame exon and prevent the binding of the spliceosome, effectively creating exon skipping and in-frame joining. Antisense is directly involved in the proposed therapy.\\n\\nConsidering the information above, the structure that is not directly involved in the proposed therapy is the polyA tail, as it is added after the splicing process and not directly targeted by the Morpholino.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's break down the information given and analyze each option step by step:\\n\\n1. **Understanding the scenario**: The scenario involves a gene with dozens of exons, where central exons code for a specific protein structure. The mutation is a deletion of a central exon, leading to out-of-frame peptides and degenerative organ waste. To address this, a Morpholino is used to prevent the binding of the spliceosome, allowing for exon skipping and in-frame joining.\\n\\n2. **Understanding the goal of the therapy**: The goal is to skip the out-of-frame exon and join the remaining exons in-frame, allowing the organism to tolerate the missing exons.\\n\\n3. **Analyzing the options**:\\n   - A) **Lariat**: Lariat structures are involved in the splicing process, particularly in the lariat intermediate formed during the splicing reaction. The lariat structure is not directly involved in the binding of the spliceosome or the recognition of the 5' end of the out-of-frame exon by the Morpholino.\\n   - B) **PolyA tail**: The polyA tail is added to the 3' end of the pre-mRNA during the splicing process, but it's not directly involved in the recognition or binding of the spliceosome to the 5' end of the out-of-frame exon.\\n   - C) **R-loops**: R-loops are a structure formed during transcription, where the RNA transcript forms a loop with the DNA template. This structure can be involved in the recognition of specific sequences by antisense oligonucleotides, which could include Morpholinos.\\n   - D) **Antisense**: Antisense oligonucleotides, like Morpholinos, are designed to recognize and bind to specific sequences of the target RNA, preventing the normal processing of the RNA. In this case, the Morpholino is used to prevent the binding of the spliceosome, which is directly involved in the splicing process.\\n\\n4. **Conclusion**: Based on the information provided and the goal of the therapy, the structure that is not directly involved in the proposed therapy is the lariat. The lariat is more of a byproduct of the splicing process rather than a structure involved in the recognition or binding of the spliceosome by the Morpholino.\\n\\nAnswer: A<|eot_id|>\", \"To solve this question, let's break down the process described and identify the structures involved in the proposed therapy.\\n\\nThe therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA, preventing the binding of the spliceosome and creating exon skipping and in-frame joining.\\n\\n- **Exon skipping and in-frame joining** is a form of **alternative splicing**, a process that allows for the inclusion or exclusion of exons during the splicing of pre-mRNA.\\n- The **spliceosome** is the complex that catalyzes the splicing reaction, and preventing its binding is crucial for the proposed therapy.\\n- **Morpholinos** are antisense oligonucleotides that can be designed to bind to specific sequences of RNA and prevent the binding of the spliceosome.\\n\\nGiven this context, let's examine the options:\\n\\nA) **Lariat**: This is a structure involved in the splicing process. The lariat is a loop of RNA that forms during the splicing reaction, but it's not directly involved in the proposed therapy.\\n\\nB) **PolyA tail**: The polyA tail is added to the 3' end of the pre-mRNA during the splicing process, but it's not directly involved in the proposed therapy.\\n\\nC) **R-loops**: R-loops are structures that can form during the splicing process, where an RNA strand is displaced by DNA synthesis. They are not directly involved in the proposed therapy.\\n\\nD) **Antisense**: The proposed therapy uses **antisense oligonucleotides (Morpholinos)** to prevent the binding of the spliceosome. This is the correct answer, as the therapy itself is based on the principle of antisense technology.\\n\\nAnswer: D<|eot_id|>\", \"To determine the correct answer, let's break down the process described in the question:\\n\\n1. The gene has dozens of exons, with the central ones coding for folded triple helical repeats.\\n2. A mutation creates out-of-frame peptides due to central exon deletions.\\n3. A Morpholino is used to recognize the 5' end of the out-of-frame exon in pre-mRNA.\\n4. The Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n\\nGiven this process, we can analyze each option:\\n\\nA) lariat: The lariat structure is formed during the splicing process when the intron is removed. The 5' end of the intron is attached to the branch point, forming a lariat. However, this option is not directly related to the action of the Morpholino in preventing the binding of the spliceosome.\\n\\nB) polyA tail: The polyA tail is added to the 3' end of the pre-mRNA during post-transcriptional modification. This is not directly related to the action of the Morpholino in preventing the binding of the spliceosome.\\n\\nC) R-loops: R-loops are structures formed during transcription when the RNA transcript hybridizes with the DNA template, displacing the non-template DNA strand. This option is not directly related to the action of the Morpholino in preventing the binding of the spliceosome.\\n\\nD) antisense: An antisense oligonucleotide (such as a Morpholino) is used to recognize and bind to the target sequence on the pre-mRNA, preventing the binding of the spliceosome and leading to exon skipping. This is the correct mechanism of action described in the question.\\n\\nTherefore, the structures not involved in the proposed therapy are the lariat, polyA tail, and R-loops.\\n\\nHowever, the question asks for a single structure not involved in the proposed therapy. Since the Morpholino is an antisense oligonucleotide, the answer must be one of the other options.\\n\\nGiven the options, the best answer is A) lariat. This is because lariat is the only option that is not directly involved in the mechanism of action described in the question.\\n\\nAnswer: A<|eot_id|>\", \"To solve this question, let's break down the information given and the process described:\\n\\n1. The gene in question has dozens of exons, with central ones coding for a specific structure. This is a characteristic of genes that code for proteins with complex structures, such as the dystrophin gene in Duchenne Muscular Dystrophy.\\n\\n2. The therapy involves using Morpholino oligomers to target the 5' end of an out-of-frame exon in pre-mRNA. Morpholinos are known to work by binding to specific sequences of RNA, preventing the binding of the spliceosome, which leads to exon skipping and in-frame splicing.\\n\\n3. The goal of this therapy is to create a new, in-frame mRNA that can be translated into a functional protein despite the deletion of some exons.\\n\\nNow, let's consider the structures listed in the options:\\n\\nA) Lariat: This is a structure formed during the splicing process, where the branch point of the intron is joined to a nucleotide in the 5' end of the intron, creating a lariat-shaped structure. It is indeed involved in the splicing process, but it's not directly related to the binding of the spliceosome or the action of Morpholinos.\\n\\nB) PolyA tail: This is added to the 3' end of the mRNA after splicing is complete. It's not directly involved in the splicing process or the action of Morpholinos.\\n\\nC) R-loops: These are structures that can form during transcription, where the RNA transcript is looped back and binds to the DNA template strand. This can be a site for the binding of the spliceosome, and Morpholinos can potentially interact with the RNA in such a structure.\\n\\nD) Antisense: Morpholinos work as antisense oligomers, binding to the target RNA sequence and preventing the binding of the spliceosome.\\n\\nBased on this analysis, the structure that is not directly involved in the proposed therapy is the polyA tail, which is added after splicing is complete and is not directly related to the action of Morpholinos.\\n\\nAnswer: B<|eot_id|>\", \"To answer this question, let's break down the process of the proposed therapy and identify the structures involved.\\n\\n1.  The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n2.  The Morpholino prevents the binding of the spliceosome, which is a complex that catalyzes the splicing of pre-mRNA.\\n3.  This prevents the inclusion of the out-of-frame exon and leads to exon skipping, resulting in an in-frame joining of the remaining exons.\\n\\nNow, let's examine the options:\\n\\nA) lariat: The lariat structure is involved in the splicing process. It is a loop formed during the splicing of pre-mRNA, where the intron is removed and a lariat-shaped structure is left behind. Since the Morpholino prevents the splicing process, the lariat structure is involved in this therapy.\\n\\nB) polyA tail: The polyA tail is added to the 3' end of the pre-mRNA during the post-transcriptional modification process. It is not directly involved in the splicing process or the action of the Morpholino.\\n\\nC) R-loops: R-loops are structures that form during the splicing process, where the RNA is hybridized with a region of the DNA. They are involved in the regulation of splicing and are related to the splicing process. Since the Morpholino prevents the splicing process, R-loops are also involved in this therapy.\\n\\nD) antisense: The Morpholino used in this therapy acts as an antisense oligonucleotide, binding to the target sequence in the pre-mRNA to prevent the binding of the spliceosome. Therefore, antisense is directly involved in the proposed therapy.\\n\\nConsidering the options, the structure not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's analyze the given information and the options provided:\\n\\n1.  The proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA and prevents the binding of the spliceosome. This results in exon skipping and in-frame joining.\\n2.  The goal of this therapy is to create an in-frame joining by skipping the out-of-frame exon, which means the therapy is focused on the splicing process.\\n3.  Let's analyze the options:\\n   A) lariat: Lariats are structures that form during the splicing process, specifically during the lariat branch point recognition by the spliceosome. They are involved in the splicing process, but not directly in the context of preventing the spliceosome binding.\\n   B) polyA tail: The polyA tail is added to the 3' end of the pre-mRNA after splicing has occurred. It's not directly involved in the splicing process or the context of preventing the spliceosome binding.\\n   C) R-loops: R-loops are structures that form during transcription, where the RNA transcript forms a loop with the DNA template. They are not directly involved in the splicing process or the context of preventing the spliceosome binding.\\n   D) antisense: Antisense oligonucleotides, like Morpholinos, are used to recognize and bind to specific sequences of RNA, preventing the formation of a particular structure or the binding of a protein (in this case, the spliceosome).\\n\\nConsidering the given information and the analysis above, the correct answer is the structure that is not directly involved in the splicing process or the context of preventing the spliceosome binding.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's analyze the process described and the structures involved in the proposed therapy.\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino molecule prevents the binding of the spliceosome, leading to exon skipping and in-frame joining. This process is a form of RNA interference (RNAi), specifically antisense-mediated RNAi.\\n\\nA) Lariat: Lariats are involved in the splicing process, specifically in the formation of the lariat-shaped intron. However, they are not directly involved in the proposed therapy, which focuses on preventing spliceosome binding and promoting exon skipping.\\n\\nB) PolyA tail: The polyA tail is involved in the process of mRNA processing, specifically in the 3' end processing of pre-mRNA. While it's not directly involved in the splicing process, it's also not directly relevant to the proposed therapy.\\n\\nC) R-loops: R-loops are not typically associated with the splicing process. However, R-loops are a type of RNA-DNA hybrid structure that can form during transcription, and they can be involved in various RNA processing events, including RNAi. However, they are not directly involved in the proposed therapy.\\n\\nD) Antisense: Antisense is the correct answer because the proposed therapy involves the use of an antisense Morpholino molecule that recognizes the 5' end of the out-of-frame exon in pre-mRNA. Antisense molecules bind to their complementary RNA sequences, preventing the normal processing of the RNA molecule.\\n\\nAnswer: D<|eot_id|>\", \"To answer this question, let's break down the process and structures involved in the proposed therapy:\\n\\n1. **Morpholino delivery**: Morpholinos are antisense oligonucleotides that bind to specific RNA sequences, in this case, the 5' end of the out-of-frame exon in pre-mRNA.\\n2. **Preventing spliceosome binding**: By binding to the pre-mRNA, Morpholinos prevent the spliceosome from recognizing the out-of-frame exon, leading to exon skipping.\\n3. **Exon skipping and in-frame joining**: As a result of the spliceosome's inability to recognize the out-of-frame exon, the pre-mRNA undergoes alternative splicing, skipping the out-of-frame exon and joining the remaining exons in-frame, thus maintaining the integrity of the gene's reading frame.\\n\\nNow, let's examine the structures involved in this process:\\n\\n- **A) lariat**: Lariats are a type of RNA structure that forms during the splicing process, but they are not directly involved in the proposed therapy. Lariats are a result of the splicing process, not a necessary component for the therapy to work.\\n  \\n- **B) polyA tail**: The polyA tail is added to the 3' end of the pre-mRNA after splicing is complete. It is involved in the export of mRNA to the cytoplasm, but it is not directly involved in the process of spliceosome binding or exon skipping.\\n\\n- **C) R-loops**: R-loops are structures that can form during the splicing process, particularly during the recognition of the 5' splice site. While they are related to the splicing process, they are not the primary focus of the proposed therapy.\\n\\n- **D) antisense**: Antisense oligonucleotides, like Morpholinos, bind to the target RNA sequence in an antisense manner, which is the basis for the proposed therapy.\\n\\nGiven the information above, the structure not directly involved in the proposed therapy is the lariat.\\n\\nAnswer: A<|eot_id|>\", \"To solve this question, let's break down the steps involved in the proposed therapy:\\n\\n1. **Pre-mRNA**: The therapy targets pre-mRNA, which is the RNA molecule before it undergoes splicing. This indicates that the process of splicing is crucial for the therapy.\\n2. **Morpholino recognition**: Morpholinos are antisense oligonucleotides that bind to specific sequences of RNA, in this case, the 5' end of the out-of-frame exon in pre-mRNA.\\n3. **Prevents binding of the spliceosome**: The spliceosome is a complex of snRNAs and proteins that recognizes and cuts the pre-mRNA to remove introns and join exons. The Morpholino prevents this process by blocking the spliceosome's binding site.\\n4. **Exon skipping and in-frame joining**: This is the desired outcome, where the out-of-frame exon is skipped, and the remaining exons are joined in a way that maintains the reading frame, leading to a functional protein.\\n\\nNow, let's analyze the options:\\n\\nA) **Lariat**: A lariat is a structure that forms during the splicing process when the intron is removed and the 5' end of the intron is joined to a branch point. While this is a structure involved in splicing, it is not directly involved in the proposed therapy, which focuses on preventing the splicing process.\\n\\nB) **PolyA tail**: The polyA tail is added to the 3' end of the mRNA after splicing is complete. It's not directly involved in the splicing process or the proposed therapy.\\n\\nC) **R-loops**: R-loops are a type of RNA-DNA hybrid structure that can form during transcription, but they are not directly involved in the splicing process.\\n\\nD) **Antisense**: Antisense oligonucleotides, like Morpholinos, are designed to bind to specific sequences of RNA, which is exactly what the Morpholino does in the proposed therapy.\\n\\nGiven the analysis, the correct answer is:\\n\\nAnswer: A<|eot_id|>\", \"To answer this question, let's analyze the process described:\\n\\n1. The gene in question has dozens of exons, and the central ones code for specific structures (folded triple helical repeats). The mutations cause central exon deletions, leading to out-of-frame peptides and degenerative issues.\\n\\n2. To address this, a Morpholino is used to target the 5' end of the out-of-frame exon in pre-mRNA.\\n\\n3. The Morpholino prevents the binding of the spliceosome, which leads to exon skipping and in-frame joining.\\n\\nNow, let's look at the options and see which structure is not involved in the proposed therapy:\\n\\nA) lariat: A lariat is an intermediate in the splicing process, specifically a loop of RNA that forms during the splicing reaction. Since the Morpholino is preventing the binding of the spliceosome, it's likely affecting the splicing process, which includes the formation of lariats.\\n\\nB) polyA tail: The polyA tail is added to the 3' end of the mRNA after splicing is complete. Since the Morpholino is targeting the 5' end of the out-of-frame exon, it's not directly involved in adding the polyA tail.\\n\\nC) R-loops: R-loops are structures that form when an RNA molecule is base-paired with a DNA strand, leaving a single-stranded loop of DNA. This can occur during the splicing process, particularly when a pre-mRNA is being spliced. Since the Morpholino is affecting splicing, it's possible that R-loops are involved.\\n\\nD) antisense: Antisense oligonucleotides, like Morpholinos, work by binding to the target RNA sequence in an antisense manner. The Morpholino in this case is designed to recognize the 5' end of the out-of-frame exon, so it's an antisense molecule.\\n\\nGiven the information, the structure not directly involved in the proposed therapy is the polyA tail, which is added after splicing is complete.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's break down the information given and analyze the process described:\\n\\n1. **Morpholino oligomers** are used to prevent the binding of the **spliceosome** to the pre-mRNA.\\n2. The goal is to create **exon skipping** and in-frame joining, which means the Morpholino oligomers are targeting the 5' end of an out-of-frame exon.\\n3. The process involves preventing the splicing of the targeted exon, allowing the remaining exons to be joined in-frame.\\n\\nNow, let's evaluate the options given:\\n\\nA) **Lariat**: Lariats are involved in the splicing process, specifically in the lariat structure formed by the branch point of the intron during splicing. However, this is not directly involved in the process of preventing spliceosome binding or in the action of Morpholino oligomers.\\n\\nB) **PolyA tail**: The polyA tail is added to the 3' end of the pre-mRNA after splicing, but it is not directly involved in the splicing process or the action of Morpholino oligomers.\\n\\nC) **R-loops**: R-loops are structures formed during transcription when the RNA transcript forms a loop with the DNA template strand. They can be involved in the regulation of gene expression, including alternative splicing, but they are not directly involved in the action of Morpholino oligomers.\\n\\nD) **Antisense**: Morpholino oligomers are a type of antisense oligonucleotide, designed to bind to the target RNA sequence (in this case, the 5' end of the out-of-frame exon) and prevent its interaction with the spliceosome.\\n\\nBased on the information provided, the correct answer is the structure not directly involved in the proposed therapy:\\n\\nAnswer: A<|eot_id|>\", \"To solve this question, let's analyze the given information and the options one by one.\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA, preventing the binding of the spliceosome, and creating exon skipping and in-frame joining. \\n\\n- **A) lariat**: This is a structure involved in the splicing process, where the intron is removed from the pre-mRNA and forms a lariat-shaped structure. However, it is not directly involved in the proposed therapy, which focuses on preventing spliceosome binding and creating exon skipping.\\n\\n- **B) polyA tail**: This is a feature of the mature mRNA, added after splicing is complete. It is not directly involved in the proposed therapy, which focuses on preventing spliceosome binding.\\n\\n- **C) R-loops**: These are structures that form during the splicing process, but they are not directly involved in the proposed therapy.\\n\\n- **D) antisense**: This is the correct answer. The Morpholino oligomers used in the proposed therapy act as antisense molecules, binding to the target sequence in the pre-mRNA to prevent the binding of the spliceosome.\\n\\nTherefore, the structure not involved in the proposed therapy is the antisense structure is not correct, but the best choice is D) antisense is not correct since the Morpholino acts as an antisense. The correct answer is the one that is least directly involved in the described mechanism of action of Morpholinos, which would be the lariat.\\n\\nAnswer: A<|eot_id|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze the process described:\\n\\n1.  A Morpholino is delivered to the pre-mRNA, targeting the 5' end of the out-of-frame exon.\\n2.  The Morpholino prevents the binding of the spliceosome.\\n3.  This prevents the inclusion of the out-of-frame exon and allows the exons to be joined in-frame.\\n\\nNow, let's examine the options:\\n\\nA) lariat: In RNA splicing, a lariat is a structure that forms when the spliceosome removes an intron. The intron is retained in the form of a lariat, which is a covalently closed loop. The lariat is involved in the splicing process, but it is not directly involved in the action of the Morpholino.\\n\\nB) polyA tail: The polyA tail is added to the 3' end of the mRNA after splicing is complete. It is not directly involved in the splicing process itself, but it is involved in the post-transcriptional modification of the mRNA.\\n\\nC) R-loops: R-loops are structures that can form during transcription, where the nascent RNA is base-paired with the DNA template strand, and the non-template strand is displaced. R-loops can be involved in the regulation of gene expression and can influence splicing, but they are not directly involved in the action of the Morpholino.\\n\\nD) antisense: Antisense refers to a type of RNA that is complementary to the target mRNA. In this case, the Morpholino acts as an antisense oligonucleotide, binding to the pre-mRNA and preventing the binding of the spliceosome. Therefore, antisense is directly involved in the proposed therapy.\\n\\nConsidering the options, the structures that are not directly involved in the proposed therapy are A) lariat and C) R-loops. However, since the question asks for a single structure not involved, we must choose the least directly related structure. R-loops are not directly involved in the splicing process, but lariats are a product of splicing. Therefore, R-loops are the least directly involved in the proposed therapy.\\n\\nAnswer: C<|eot_id|>\", \"To solve this question, let's analyze the given information step by step.\\n\\nThe proposed therapy involves using a Morpholino to prevent the binding of the spliceosome to the 5' end of an out-of-frame exon in pre-mRNA. This results in exon skipping and in-frame joining, allowing the organism to tolerate missing exons.\\n\\nThe Morpholino acts as an antisense molecule, binding to the 5' end of the out-of-frame exon and preventing the spliceosome from binding. \\n\\nA) lariat - A lariat is a type of spliceosome intermediate, but it's not directly involved in the proposed therapy.\\n\\nB) polyA tail - The polyA tail is added to the 3' end of the pre-mRNA after splicing, so it's not directly involved in the proposed therapy.\\n\\nC) R-loops - R-loops are not directly involved in the proposed therapy, but they are related to the spliceosome's activity in the nucleus.\\n\\nD) antisense - The Morpholino acts as an antisense molecule to prevent the spliceosome from binding, so this is directly involved in the proposed therapy.\\n\\nHowever, given the choices, the best answer would be B) polyA tail, as it is the structure that is not directly involved in the proposed therapy.\\n\\nAnswer: B<|eot_id|>\", \"To answer this question, let's break down the process of the proposed therapy:\\n\\n1. The Morpholino molecule is designed to recognize the 5' end of the out-of-frame exon in pre-mRNA.\\n2. The Morpholino prevents the binding of the spliceosome to the out-of-frame exon.\\n3. As a result, the spliceosome skips the out-of-frame exon and joins the remaining exons in-frame, leading to the production of a functional protein.\\n\\nNow, let's examine each option to determine which structure is not involved in this process:\\n\\nA) Lariat: In the splicing process, the lariat structure is formed when the branch point is formed during the lariat loop of the pre-mRNA. The spliceosome cuts the pre-mRNA and forms a lariat-shaped structure. However, the lariat structure itself is not directly involved in the recognition of the out-of-frame exon by the Morpholino.\\n\\nB) PolyA tail: The polyA tail is added to the 3' end of the mature mRNA after splicing is complete. It is not directly involved in the recognition of the out-of-frame exon or the splicing process itself.\\n\\nC) R-loops: R-loops are involved in the splicing process, specifically in the recognition of the branch point and the formation of the lariat loop.\\n\\nD) Antisense: The Morpholino molecule used in the proposed therapy is an antisense oligonucleotide that recognizes and binds to the target sequence in the pre-mRNA.\\n\\nBased on the analysis, the polyA tail is not directly involved in the recognition of the out-of-frame exon or the splicing process itself.\\n\\nAnswer: B<|eot_id|>\", \"To answer this question, let's break it down step by step:\\n\\n1. The proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. \\n2. The Morpholino molecule prevents the binding of the spliceosome.\\n3. This action results in exon skipping and in-frame joining.\\n\\nNow, let's examine the options:\\n\\nA) lariat: The lariat structure is involved in the splicing process, specifically in the formation of the lariat intermediate during the splicing reaction. The Morpholino therapy does not directly affect the formation of the lariat structure.\\n\\nB) polyA tail: The polyA tail is added to the 3' end of the mRNA after splicing is complete. The Morpholino therapy is focused on preventing the binding of the spliceosome, which is before the polyA tail is added.\\n\\nC) R-loops: R-loops are involved in the splicing process, but they are not directly related to the action of the Morpholino therapy.\\n\\nD) antisense: Antisense is a general term for a type of RNA that is complementary to the target mRNA. Morpholino oligonucleotides are a type of antisense therapy, so this option is relevant to the proposed therapy.\\n\\nConsidering the information above, the correct answer is the structure that is not directly involved in the proposed therapy.\\n\\nAnswer: A<|eot_id|>\", \"To solve this question, let's break it down step by step:\\n\\n1. The gene in question has dozens of exons, with central ones coding for specific structures. The problem arises from central exon deletions that lead to out-of-frame peptides, causing degenerative organ waste.\\n\\n2. The proposed solution is to use a Morpholino oligonucleotide that targets the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino oligonucleotide prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n\\n3. The goal is to identify the structure not involved in this proposed therapy. Let's analyze each option:\\n   A) Lariat: Lariats are involved in the splicing process, specifically in the formation of the lariat-shaped intron. They are not directly involved in the proposed therapy.\\n   B) PolyA tail: The polyA tail is added to the 3' end of the pre-mRNA during the process of polyadenylation, which is a separate step from splicing and not directly related to the proposed therapy.\\n   C) R-loops: R-loops are involved in the splicing process and could potentially be affected by the Morpholino oligonucleotide, as they are structures formed during splicing.\\n   D) Antisense: The Morpholino oligonucleotide acts as an antisense molecule, binding to the target sequence and preventing the binding of the spliceosome.\\n\\nConsidering the information above, the structure not involved in the proposed therapy is the lariat.\\n\\nAnswer: A<|eot_id|>\", \"To determine the correct answer, let's analyze the given information and the options:\\n\\nThe proposed therapy involves using a Morpholino to prevent the binding of the spliceosome and create exon skipping and in-frame joining. This process is related to pre-mRNA splicing.\\n\\n- A) Lariat: The lariat structure is a type of RNA structure that forms during the splicing process, specifically in the second step of splicing, where the branch point is formed. However, it is not directly involved in the binding of the spliceosome or in the process of creating exon skipping.\\n\\n- B) PolyA tail: The polyA tail is added to the 3' end of the mRNA during post-transcriptional modification, which is not directly related to the splicing process or the binding of the spliceosome.\\n\\n- C) R-loops: R-loops are indeed involved in the splicing process, as they are formed during the splicing reaction, specifically in the first step of splicing, where the branch point is formed.\\n\\n- D) Antisense: The Morpholino used in the proposed therapy acts as an antisense oligonucleotide, which binds to the target sequence and prevents the binding of the spliceosome.\\n\\nGiven the information, the structure not directly involved in the proposed therapy is the lariat.\\n\\nAnswer: A<|eot_id|>\", \"To solve this question, let's break down the process described and the structures involved:\\n\\n1.  The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n2.  The Morpholino prevents the binding of the spliceosome.\\n3.  This prevents the splicing of the out-of-frame exon, resulting in exon skipping and in-frame joining.\\n4.  Several missing exons are well tolerated by the organism.\\n\\nGiven the process described, we need to determine which of the options (A, B, C, D) is not involved in this therapy:\\n\\nA) Lariat: A lariat is a type of RNA structure formed during splicing, specifically a loop of RNA that is branched from the 5' splice site. It is involved in the splicing process, but the question mentions preventing the splicing, so the lariat would not be formed.\\n\\nB) PolyA tail: The polyA tail is added to the 3' end of the pre-mRNA during processing. While it is not directly involved in the splicing process, it is a part of the pre-mRNA processing.\\n\\nC) R-loops: R-loops are a type of RNA-DNA hybrid structure that can form during transcription and are involved in regulating gene expression. They are not directly involved in the splicing process described.\\n\\nD) Antisense: The Morpholino described in the question acts as an antisense molecule, recognizing the 5' end of the out-of-frame exon in pre-mRNA.\\n\\nConsidering the above points, the structure not involved in the proposed therapy is the lariat (A). The therapy aims to prevent the splicing process, which would prevent the formation of lariats.\\n\\nAnswer: A<|eot_id|>\", \"To solve this question, let's analyze the given information and the options provided:\\n\\n1.  The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n2.  The Morpholino prevents the binding of the spliceosome and creates exon skipping and in-frame joining.\\n3.  The goal is to create a new, in-frame transcript by skipping the out-of-frame exon.\\n\\nNow, let's examine the options:\\n\\nA) lariat: A lariat is a type of RNA structure formed during the splicing process, where a loop of RNA is created after the removal of an intron. This process is not directly related to the action of the Morpholino in the proposed therapy.\\n\\nB) polyA tail: The polyA tail is added to the 3' end of a mature mRNA molecule during post-transcriptional modification. This process is not directly related to the action of the Morpholino in the proposed therapy.\\n\\nC) R-loops: R-loops are a type of RNA-DNA hybrid structure that can form during transcription. However, they are not directly related to the action of the Morpholino in the proposed therapy.\\n\\nD) antisense: An antisense molecule is a type of RNA or DNA that is complementary to the target sequence. Morpholinos are a type of antisense oligonucleotides, which are designed to bind to a specific target sequence (in this case, the 5' end of the out-of-frame exon in pre-mRNA) and prevent its expression.\\n\\nBased on the analysis, the structure not involved in the proposed therapy is the lariat.\\n\\nAnswer: A<|eot_id|>\", \"To determine the correct answer, let's analyze the given information and the options provided.\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA, preventing the binding of the spliceosome and creating exon skipping and in-frame joining. This process is a form of RNA interference (RNAi) or antisense oligonucleotide therapy.\\n\\nThe components involved in this process are:\\n\\n- Morpholino: This is the therapeutic agent that binds to the target RNA sequence.\\n- Spliceosome: This is the complex that catalyzes the splicing of RNA molecules.\\n- Pre-mRNA: This is the precursor to mRNA that undergoes splicing.\\n\\nNow, let's analyze the options provided:\\n\\nA) Lariat: Lariat refers to the structure formed by the lariat branch of the spliceosome during splicing. It is not directly involved in the proposed therapy.\\n\\nB) PolyA tail: The polyA tail is added to the 3' end of the mRNA after splicing, not directly involved in the process of splicing or the proposed therapy.\\n\\nC) R-loops: R-loops are structures formed during transcription, where the nascent RNA strand is displaced by the incoming RNA polymerase. While R-loops are related to RNA processing, they are not directly involved in the splicing process or the proposed therapy.\\n\\nD) Antisense: Antisense oligonucleotides are a type of therapeutic agent that bind to the target RNA sequence, preventing its translation. Morpholino is a type of antisense oligonucleotide, so this option is relevant to the proposed therapy.\\n\\nConsidering the information provided and the analysis above, the correct answer is the option that is not directly involved in the proposed therapy.\\n\\nAnswer: A<|eot_id|>\", \"To determine the correct answer, let's break down the process described in the question and relate it to the options provided:\\n\\n1.  The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n2.  The Morpholino prevents the binding of the spliceosome.\\n3.  This results in exon skipping and in-frame joining.\\n\\nGiven this process, let's analyze the options:\\n\\nA) Lariat: During splicing, a lariat structure forms when the intron is removed and a branch is created. This is a part of the splicing process, but it is not directly related to the proposed therapy of using Morpholinos to prevent spliceosome binding and induce exon skipping.\\n\\nB) PolyA tail: The polyA tail is added to the 3' end of the mRNA after splicing is complete. It is not directly involved in the process of splicing or the use of Morpholinos to induce exon skipping.\\n\\nC) R-loops: R-loops are structures that can form during the process of transcription and splicing. They can be involved in the regulation of splicing, but they are not directly related to the use of Morpholinos to prevent spliceosome binding.\\n\\nD) Antisense: Morpholinos are a type of antisense oligonucleotide. They work by binding to the target mRNA, in this case the 5' end of the out-of-frame exon, to prevent the binding of the spliceosome and induce exon skipping.\\n\\nConsidering the process described in the question, the correct answer is the one that is not directly involved in the proposed therapy:\\n\\nAnswer: A<|eot_id|>\", \"To solve this question, let's analyze the given information and the options provided.\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA, preventing the binding of the spliceosome, and creating exon skipping and in-frame joining. This process is related to the splicing of RNA.\\n\\nA) lariat: A lariat is a type of RNA structure that forms during the splicing process, specifically when the intron is removed and a lariat-shaped structure is left behind. This is a relevant structure in the context of splicing.\\n\\nB) polyA tail: The polyA tail is added to the 3' end of the mRNA after splicing is complete. It is not directly involved in the splicing process or the recognition of the 5' end of an exon.\\n\\nC) R-loops: R-loops are structures that can form during transcription, where the RNA transcript forms a triple-stranded structure with the template DNA strand and a non-template DNA strand. They are not directly involved in the splicing process, but they can influence it.\\n\\nD) antisense: Antisense oligonucleotides, like Morpholinos, are used to bind to the target RNA and prevent its interaction with other molecules, such as the spliceosome. In this case, the Morpholino is an antisense molecule that recognizes the 5' end of the out-of-frame exon.\\n\\nConsidering the information provided and the context of the proposed therapy, the structure not involved in the therapy is the polyA tail, which is added after splicing is complete.\\n\\nAnswer: B<|eot_id|>\", \"To determine the correct answer, let's analyze the given information and the options provided.\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA and prevents the binding of the spliceosome, leading to exon skipping and in-frame joining. This process is a type of RNA interference (RNAi) that involves the manipulation of RNA splicing.\\n\\nA) lariat: A lariat is a type of RNA structure that is involved in the splicing process. It is formed during the removal of introns and is not directly involved in the proposed therapy. However, it is a byproduct of the splicing process that can be affected by the Morpholino therapy.\\n\\nB) polyA tail: The polyA tail is added to the 3' end of the pre-mRNA during the process of polyadenylation. It is not directly involved in the splicing process or the proposed therapy.\\n\\nC) R-loops: R-loops are structures that can form during the transcription process, where the RNA transcript is paired with a single strand of DNA. They are not directly involved in the splicing process or the proposed therapy.\\n\\nD) antisense: The Morpholino in the proposed therapy acts as an antisense oligonucleotide, binding to the 5' end of the out-of-frame exon in pre-mRNA to prevent the binding of the spliceosome. This is a form of antisense therapy.\\n\\nConsidering the options, the structure not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|eot_id|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process described:\\n\\n1. The therapy involves delivering a Morpholino oligonucleotide that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n2. The Morpholino prevents the binding of the spliceosome, which is a complex involved in the splicing of RNA.\\n3. This leads to exon skipping and in-frame joining.\\n\\nConsidering the structures listed:\\n\\nA) lariat: This is a type of spliceosome intermediate, specifically a lariat-shaped RNA structure that forms during the splicing process. Since the Morpholino prevents the binding of the spliceosome, the lariat structure is involved in the process.\\n\\nB) polyA tail: The polyA tail is added to the 3' end of the mRNA during post-transcriptional modification. This process occurs after splicing, and the Morpholino therapy described does not directly involve the polyA tail.\\n\\nC) R-loops: R-loops are structures formed during transcription, where the RNA transcript is base-paired with the template DNA strand, leaving the non-template strand single-stranded. While R-loops can affect splicing, they are not directly involved in the spliceosome binding or the process of exon skipping.\\n\\nD) antisense: The Morpholino oligonucleotide acts as an antisense oligonucleotide, binding to the target mRNA sequence to prevent splicing. This is the mechanism of action described in the therapy.\\n\\nConsidering the above points, the structure not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|eot_id|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process:\\n\\n1. The Morpholino molecule is designed to recognize the 5' end of the out-of-frame exon in pre-mRNA.\\n2. The Morpholino prevents the binding of the spliceosome, which is a complex involved in the splicing of pre-mRNA.\\n3. The prevention of spliceosome binding leads to exon skipping and in-frame joining.\\n\\nConsidering the structures involved in the process:\\n\\n- A) Lariat: A lariat is a structure formed during the splicing process, where the branch point of the intron is joined to a nucleotide in a lariat-shaped structure. However, the lariat is not directly involved in the interaction with the Morpholino or the spliceosome.\\n\\n- B) PolyA tail: The polyA tail is added to the 3' end of the mRNA after splicing, but it is not directly involved in the process of splicing or the interaction with the Morpholino.\\n\\n- C) R-loops: R-loops are structures that can form during the splicing process, where an RNA strand is displaced and forms a triple helix with a DNA strand. While R-loops can be involved in splicing, they are not directly involved in the interaction with the Morpholino or the spliceosome in this context.\\n\\n- D) Antisense: Antisense is a type of RNA that is complementary to the target RNA. In this case, the Morpholino acts as an antisense molecule to recognize and bind to the 5' end of the out-of-frame exon in pre-mRNA.\\n\\nBased on this analysis, none of the options directly relate to the interaction with the Morpholino or the spliceosome. However, since we need to choose the least relevant or not directly involved, the polyA tail (B) is the one that is not directly involved in the process of splicing or the interaction with the Morpholino.\\n\\nAnswer: B<|eot_id|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze the steps involved in the therapy and the structures mentioned:\\n\\n1. **Morpholino delivery**: Morpholinos are antisense oligonucleotides that bind to specific RNA sequences. In this case, it targets the 5' end of the out-of-frame exon in pre-mRNA.\\n2. **Preventing spliceosome binding**: The Morpholino prevents the binding of the spliceosome, which is a complex that catalyzes the splicing process in RNA. This is where structures like **R-loops** and **lariat** come into play.\\n   - R-loops: These are RNA-DNA hybrids that form during the splicing process, and the spliceosome binds to these regions. \\n   - Lariat: This is a type of RNA structure that is formed during splicing, which is a byproduct of the splicing process, where the intron is removed and a lariat-shaped structure is left.\\n3. **Exon skipping and in-frame joining**: The goal of the therapy is to create an in-frame joining of exons, which means that the final mRNA will have the correct reading frame. This is achieved by preventing the inclusion of the out-of-frame exon.\\n\\nGiven the structures mentioned:\\n- **A) lariat**: Involved in the splicing process as a byproduct.\\n- **B) polyA tail**: This is added to the 3' end of the mRNA after splicing is complete, not directly involved in the splicing process or the action of Morpholinos.\\n- **C) R-loops**: Involved in the splicing process as a region where the spliceosome binds.\\n- **D) antisense**: This refers to the type of oligonucleotide used in the therapy, which is Morpholino.\\n\\nThe polyA tail is not directly involved in the proposed therapy, as it is added after splicing is complete.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's break down the information provided and analyze the options step by step.\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA and prevents the binding of the spliceosome, leading to exon skipping and in-frame joining. This process is related to RNA splicing, which involves the removal of introns (non-coding regions) and the joining of exons (coding regions) to form a mature mRNA molecule.\\n\\nNow, let's consider the options:\\n\\nA) lariat: In RNA splicing, a lariat is a structure formed by the spliceosome when it removes an intron. The 5' end of the intron is joined to the 2' hydroxyl group of the adjacent nucleotide, forming a lariat shape. This is a key intermediate in the splicing process.\\n\\nB) polyA tail: The polyA tail is added to the 3' end of the mRNA molecule after splicing is complete, as a way to protect the mRNA from degradation and help it be exported out of the nucleus. It is not directly involved in the splicing process.\\n\\nC) R-loops: R-loops are a type of RNA-DNA hybrid structure that can form during the splicing process, especially when the spliceosome is working on a pre-mRNA molecule.\\n\\nD) antisense: Antisense oligonucleotides, like Morpholinos, work by binding to the target RNA molecule (in this case, the pre-mRNA) and preventing its splicing or translation. This is the mechanism of action of the Morpholino in the proposed therapy.\\n\\nConsidering the information, the polyA tail is not directly involved in the splicing process or the proposed therapy, which involves preventing the binding of the spliceosome and creating exon skipping.\\n\\nAnswer: B<|eot_id|>\", \"To answer this question, let's analyze the process described and the structures involved.\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA, preventing the binding of the spliceosome and creating exon skipping and in-frame joining. This is a type of RNA interference (RNAi) therapy.\\n\\n- **lariat (A)**: A lariat is a type of RNA structure formed during the splicing process, specifically during the removal of introns. It is not directly involved in the proposed therapy, but rather a byproduct of the splicing process.\\n\\n- **polyA tail (B)**: The polyA tail is added to the 3' end of the mRNA after splicing is complete, which is not directly involved in the proposed therapy.\\n\\n- **R-loops (C)**: R-loops are a type of RNA-DNA hybrid structure that can be involved in various processes, including transcription and splicing. However, they are not directly involved in the proposed therapy.\\n\\n- **antisense (D)**: The Morpholino used in the therapy acts as an antisense oligonucleotide, which is a type of RNA molecule that is complementary to the target RNA sequence. It binds to the target RNA and prevents the binding of the spliceosome, which is a key component of the proposed therapy.\\n\\nBased on the above analysis, the structure not involved in the proposed therapy is the lariat.\\n\\nAnswer: A<|eot_id|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze the given information and the options.\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining. \\n\\n- A) Lariat: This is a type of intron structure that forms during the splicing process. However, the question doesn't directly mention the lariat structure in the context of the proposed therapy. But, lariats are involved in the splicing process, and the therapy aims to prevent the splicing process by preventing the binding of the spliceosome.\\n\\n- B) PolyA tail: The polyA tail is added to the 3' end of the mRNA after splicing, but it is not directly involved in the splicing process itself. However, the therapy aims to prevent the splicing process by preventing the binding of the spliceosome, which would prevent the addition of the polyA tail.\\n\\n- C) R-loops: R-loops are structures that form during the transcription process, where the RNA transcript is displaced from the DNA template. However, R-loops are not directly involved in the splicing process or the proposed therapy.\\n\\n- D) Antisense: The Morpholino mentioned in the question is an antisense oligonucleotide. It recognizes the 5' end of the out-of-frame exon in pre-mRNA and prevents the binding of the spliceosome. This directly involves the concept of antisense therapy.\\n\\nConsidering the information, the structure that is not involved in the proposed therapy is the R-loop, as it is related to the transcription process, not the splicing process.\\n\\nAnswer: C<|eot_id|>\", \"To answer this question, let's break it down step by step:\\n\\n1. The proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n2. This Morpholino molecule prevents the binding of the spliceosome.\\n3. As a result, the cell attempts to repair the pre-mRNA by skipping the out-of-frame exon and joining the remaining exons in-frame.\\n4. This process is known as exon skipping.\\n\\nNow, let's examine the options:\\n\\nA) lariat: A lariat is a type of RNA structure that forms during the splicing process. It is not directly involved in the proposed therapy, but it is a byproduct of splicing.\\n\\nB) polyA tail: A polyA tail is added to the 3' end of a pre-mRNA molecule during post-transcriptional modification. It is not directly involved in the proposed therapy.\\n\\nC) R-loops: R-loops are a type of RNA-DNA hybrid structure that can form during transcription. They are not directly involved in the proposed therapy.\\n\\nD) antisense: Antisense is a type of RNA molecule that is complementary to the target RNA and can bind to it, preventing its translation. Morpholinos are a type of antisense molecule, so this option is directly related to the proposed therapy.\\n\\nBased on the analysis, the correct answer is the structure that is not directly involved in the proposed therapy.\\n\\nAnswer: ABC<|eot_id|>\", \"To solve this question, let's break down the information given and the process described:\\n\\n1.  The gene in question has dozens of exons, with central ones coding for a specific structure (folded triple helical repeats). The mutation creates out-of-frame peptides due to central exon deletions.\\n2.  The proposed therapy involves using a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA, preventing the binding of the spliceosome, which leads to exon skipping and in-frame joining.\\n3.  The goal is to create a new, in-frame transcript by skipping the out-of-frame exon.\\n\\nNow, let's analyze the options in relation to the proposed therapy:\\n\\nA) Lariat: A lariat is a structure formed during splicing, where the 5' end of the intron is joined to a branch point, creating a loop. This is a part of the splicing process, but it is not directly involved in the therapy described, which involves preventing the spliceosome from binding, not creating a lariat structure.\\n\\nB) PolyA tail: The polyA tail is added to the 3' end of the mRNA during post-transcriptional processing. While it's not directly involved in the splicing process, it's a part of the mRNA processing, but it's not relevant to the specific mechanism described in the question.\\n\\nC) R-loops: R-loops are formed during the splicing process when the RNA molecule is paired with the DNA template strand, and the other RNA strand is displaced. This can be involved in regulating gene expression, including splicing. However, it's not directly involved in the therapy described.\\n\\nD) Antisense: Antisense oligonucleotides, like Morpholinos, work by binding to the target mRNA and preventing its translation. In this case, the Morpholino is designed to recognize the 5' end of the out-of-frame exon, which is an antisense approach to regulating splicing.\\n\\nConsidering the options, the structure not involved in the proposed therapy is the lariat, which is a structure formed during splicing, not directly involved in the mechanism of using Morpholinos to prevent the spliceosome from binding and causing exon skipping.\\n\\nAnswer: A<|eot_id|>\", \"To solve this question, let's go step by step through the process described:\\n\\n1. **Understanding the context**: The question describes a gene with dozens of exons, some of which are central and code for specific structures. It also mentions a mutation that creates out-of-frame peptides due to central exon deletions. The goal is to deliver a Morpholino to skip these out-of-frame exons and restore the frame.\\n\\n2. **Identifying the key components involved in the proposed therapy**: \\n   - **Morpholino**: This is a type of antisense oligonucleotide used to inhibit the splicing of a pre-mRNA molecule.\\n   - **Spliceosome**: This is the complex of proteins and RNA that performs the splicing of pre-mRNA to remove introns and join exons.\\n   - **Exon skipping**: This is the process by which a Morpholino prevents the splicing of an exon, effectively skipping it in the mature mRNA.\\n\\n3. **Analyzing the options given**:\\n   - **A) lariat**: A lariat is a type of RNA structure formed during the splicing process. It is not directly involved in the proposed therapy of using Morpholinos to skip exons.\\n   - **B) polyA tail**: The polyA tail is added to the 3' end of the mRNA after splicing is complete. While it is involved in mRNA processing, it is not directly involved in the splicing process affected by the Morpholino.\\n   - **C) R-loops**: R-loops are RNA-DNA hybrids that can form during transcription. They can be involved in splicing regulation but are not directly mentioned in the context of the Morpholino therapy.\\n   - **D) antisense**: Antisense refers to the use of single-stranded nucleic acids (like Morpholinos) that bind to the target RNA to affect its processing, which is exactly what the Morpholino does in the proposed therapy.\\n\\n4. **Choosing the correct answer**: Based on the steps above, the structure that is not directly involved in the proposed therapy is the lariat, as it is a byproduct of splicing but not directly affected by the action of the Morpholino.\\n\\nAnswer: A<|eot_id|>\", \"To solve this question, let's break down the process described and identify the components involved:\\n\\n1. **Morpholino delivery**: Morpholinos are antisense oligonucleotides that bind to specific sequences of RNA, in this case, the 5' end of the out-of-frame exon in pre-mRNA.\\n2. **Preventing spliceosome binding**: The spliceosome is a complex that assembles on the pre-mRNA to remove introns and join exons together. By preventing this binding, the Morpholino causes the cell to skip the out-of-frame exon.\\n3. **Exon skipping and in-frame joining**: This results in a corrected version of the pre-mRNA that can be translated into a protein.\\n\\nNow, let's examine the options:\\n\\nA) **Lariat**: A lariat is a structure formed during the splicing process, where the branch point of the intron is joined to a specific adenosine residue, creating a lariat-shaped structure. While lariats are involved in the splicing process, they are not directly involved in the proposed therapy of using Morpholinos to prevent spliceosome binding.\\n\\nB) **PolyA tail**: The polyA tail is added to the 3' end of the mRNA during post-transcriptional processing, which is not directly related to the process described in the question.\\n\\nC) **R-loops**: R-loops are structures that can form during the splicing process, but they are not directly involved in the proposed therapy.\\n\\nD) **Antisense**: Antisense oligonucleotides, such as Morpholinos, are directly involved in the proposed therapy.\\n\\nConsidering the information above, the correct answer is the structure that is not directly involved in the proposed therapy.\\n\\nAnswer: A<|eot_id|>\", \"To solve this question, let's analyze the given information and the options provided.\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA, preventing the binding of the spliceosome and creating exon skipping and in-frame joining. This process involves the manipulation of RNA splicing.\\n\\nA) Lariat: The lariat structure is involved in the splicing process. It is a type of RNA structure that forms during the splicing reaction, specifically when the 5' splice site is ligated to the 2' hydroxyl group of the branch point, creating a loop structure. However, this is not directly involved in the proposed therapy.\\n\\nB) PolyA tail: The polyA tail is added to the 3' end of the mRNA after splicing is complete. It is not directly involved in the splicing process itself, but rather a modification that occurs after splicing. However, the therapy is focused on preventing the splicing of a particular exon, not the addition of the polyA tail.\\n\\nC) R-loops: R-loops are a type of RNA structure that can form during the splicing process, specifically when the nascent mRNA is still being transcribed and the 5' end of the RNA is still bound to the DNA template. R-loops are not directly involved in the proposed therapy, but they are a type of RNA structure that can interact with the splicing machinery.\\n\\nD) Antisense: Antisense oligonucleotides, such as Morpholinos, are designed to bind to specific sequences of RNA and prevent the normal splicing process. In this case, the Morpholino is designed to recognize the 5' end of the out-of-frame exon and prevent the binding of the spliceosome, which is a type of antisense therapy.\\n\\nBased on the analysis, the correct answer is A) lariat, as it is the only option that is not directly involved in the proposed therapy. The other options, while related to RNA and splicing, are not directly involved in the therapy described.\\n\\nAnswer: A<|eot_id|>\", \"To solve this question, let's break it down step by step:\\n\\n1. The proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n2. The goal is to prevent the binding of the spliceosome and create exon skipping and in-frame joining.\\n3. Morpholinos are antisense oligonucleotides that bind to specific sequences of RNA (in this case, pre-mRNA) to prevent the action of the spliceosome.\\n4. Now, let's look at the options given:\\n   A) lariat: A lariat is a type of RNA structure that forms during the splicing process, but it is not directly involved in the interaction between the Morpholino and the spliceosome.\\n   B) polyA tail: The polyA tail is added to the 3' end of the mRNA after splicing, and it is not directly involved in the proposed therapy.\\n   C) R-loops: R-loops are a type of RNA-DNA hybrid structure that can form during transcription, but they are not directly involved in the interaction between the Morpholino and the spliceosome.\\n   D) antisense: Antisense oligonucleotides, like Morpholinos, bind to specific sequences of RNA (in this case, pre-mRNA) to prevent the action of the spliceosome.\\n\\nBased on the information provided and the mechanism of action of Morpholinos, the correct answer is the one that is not directly involved in the interaction between the Morpholino and the spliceosome.\\n\\nAnswer: A<|eot_id|>\", \"To solve this question, let's break it down step by step:\\n\\n1. The problem is about a genetic disorder caused by central exon deletions in a gene. These deletions lead to out-of-frame peptides and progressive degenerative organ waste.\\n2. The proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n3. The Morpholino prevents the binding of the spliceosome, which leads to exon skipping and in-frame joining.\\n4. We are asked to identify which structure is not involved in the proposed therapy.\\n\\nLet's analyze each option:\\n\\nA) lariat: In the splicing process, a lariat structure is formed when the intron is removed and a bond is formed between the 5' and 3' splice sites. However, this structure is not directly involved in the proposed therapy, which focuses on preventing the binding of the spliceosome to the 5' end of the out-of-frame exon.\\n\\nB) polyA tail: The polyA tail is added to the 3' end of the mRNA during post-transcriptional processing. While it's an important step in mRNA processing, it's not directly related to the proposed therapy, which focuses on preventing the binding of the spliceosome.\\n\\nC) R-loops: R-loops are structures formed during transcription, where the RNA transcript hybridizes with the DNA template strand, displacing the non-template strand. However, R-loops are not directly involved in the proposed therapy.\\n\\nD) antisense: Antisense oligonucleotides, such as Morpholinos, are used in the proposed therapy to prevent the binding of the spliceosome to the 5' end of the out-of-frame exon. Therefore, antisense is directly involved in the proposed therapy.\\n\\nBased on the analysis, the correct answer is the structure that is not involved in the proposed therapy.\\n\\nAnswer: A<|eot_id|>\", \"To answer this question, let's break down the process described and the structures involved:\\n\\n1. **Morpholino**: A Morpholino is a type of antisense oligonucleotide that can bind to a specific sequence of RNA and prevent its processing.\\n2. **Pre-mRNA**: The pre-mRNA is the primary transcript of a gene that undergoes various processing steps before becoming mature mRNA.\\n3. **Spliceosome**: The spliceosome is a complex of proteins and small nuclear RNAs that catalyzes the removal of introns and the joining of exons during RNA splicing.\\n4. **Exon skipping and in-frame joining**: This is the desired outcome of the Morpholino therapy, where the spliceosome is prevented from recognizing the out-of-frame exon, and the remaining exons are joined in a way that results in a protein that is not severely affected by the mutation.\\n\\nConsidering the structures involved in RNA processing and the proposed therapy:\\n\\n- **A) lariat**: Lariats are formed during the splicing process when the intron is removed and a branch point is created. This is a part of the splicing process, but it's not directly involved in the Morpholino therapy described.\\n  \\n- **B) polyA tail**: The polyA tail is added to the 3' end of the pre-mRNA during its processing. This is not directly related to the splicing process or the action of Morpholino.\\n\\n- **C) R-loops**: R-loops are a type of RNA-DNA hybrid structure that can form during the transcription process. While they can influence gene expression, they are not directly involved in the splicing process or the Morpholino therapy described.\\n\\n- **D) antisense**: Antisense oligonucleotides like Morpholinos work by binding to the antisense strand of the target RNA, preventing its processing. Therefore, the structure involved in the proposed therapy is indeed the antisense strand of the pre-mRNA.\\n\\nBased on the information provided, the structures not involved in the proposed therapy are the lariat, polyA tail, and R-loops.\\n\\nAnswer: ABC<|eot_id|>\", \"To answer this question, let's break down the process of the proposed therapy and the structures involved in RNA splicing and processing:\\n\\n1. **Pre-mRNA**: Before splicing, the pre-mRNA has introns (non-coding regions) and exons (coding regions). The Morpholino oligonucleotide is designed to bind to the 5' end of the out-of-frame exon in pre-mRNA.\\n\\n2. **Spliceosome**: The spliceosome is a complex that recognizes the splice sites (5' and 3' splice sites) of introns and exons in pre-mRNA. The Morpholino oligonucleotide prevents the binding of the spliceosome, causing the exons to be skipped.\\n\\n3. **Exon Skipping and In-frame Joining**: By preventing the spliceosome from binding, the exons are skipped, and the remaining exons are joined in an in-frame manner, resulting in a functional protein.\\n\\nNow, let's consider the structures involved in RNA splicing and processing:\\n\\n- **Lariat (A)**: A lariat is a structure formed during the splicing process, where the 5' end of the intron is looped out and joined to the 2' hydroxyl group of an adenosine residue. This is not directly involved in the proposed therapy.\\n\\n- **PolyA Tail (B)**: The polyA tail is added to the 3' end of the mRNA after splicing is complete. This is not directly involved in the proposed therapy.\\n\\n- **R-loops (C)**: R-loops are a structure formed during the splicing process, where an RNA-DNA hybrid forms between the pre-mRNA and the DNA template strand. This is not directly involved in the proposed therapy.\\n\\n- **Antisense (D)**: The Morpholino oligonucleotide used in the proposed therapy is an antisense molecule, designed to bind to the 5' end of the out-of-frame exon in pre-mRNA, preventing the spliceosome from binding.\\n\\nConsidering the above, the structures involved in the proposed therapy are not directly involved in the lariat, polyA tail, or R-loops. However, the antisense molecule is the one used in the therapy.\\n\\nAnswer: D<|eot_id|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze the given information and the options.\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome and creates exon skipping and in-frame joining. This is a form of antisense therapy, where the Morpholino acts as an antisense oligonucleotide to block the splicing of the pre-mRNA.\\n\\nNow, let's look at the options:\\n\\nA) lariat: In the splicing process, a lariat structure is formed when the intron is removed from the pre-mRNA. This is a part of the splicing process, but it's not directly involved in the proposed therapy.\\n\\nB) polyA tail: The polyA tail is added to the 3' end of the mRNA after splicing is complete. This is not directly involved in the proposed therapy.\\n\\nC) R-loops: R-loops are formed when the RNA polymerase unwinds the DNA and the RNA transcript forms a loop with the template strand. While R-loops are involved in transcription, they are not directly involved in the proposed therapy.\\n\\nD) antisense: The Morpholino acts as an antisense oligonucleotide to block the splicing of the pre-mRNA. Therefore, antisense is directly involved in the proposed therapy.\\n\\nConsidering the above information, the correct answer is the structure that is not directly involved in the proposed therapy.\\n\\nAnswer: C<|eot_id|>\", \"To solve this question, let's break down the process described and identify the structures involved:\\n\\n1.  The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n2.  The Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n3.  This process involves the pre-mRNA molecule, which is a precursor to mRNA.\\n\\nConsidering the options given:\\n\\nA) lariat: A lariat is a type of spliceosome intermediate in the splicing process. It forms when the intron is removed and a loop is created. This structure is indeed involved in the splicing process.\\n\\nB) polyA tail: The polyA tail is added to the 3' end of the mRNA after splicing is complete. It is not directly involved in the splicing process itself but is a feature of mature mRNA.\\n\\nC) R-loops: R-loops are a type of secondary structure in RNA that can form during transcription, but they are not directly involved in the splicing process.\\n\\nD) antisense: Antisense oligonucleotides like Morpholinos work by binding to the target RNA (in this case, pre-mRNA) in an antisense manner, preventing the normal splicing process from occurring. Therefore, antisense is indeed involved in the proposed therapy.\\n\\nGiven this information, the structure not involved in the proposed therapy is the polyA tail, which is added to the mature mRNA after splicing is complete.\\n\\nAnswer: B<|eot_id|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze each option in the context of the therapy described:\\n\\nA) lariat: The lariat structure is involved in the splicing process, specifically in the removal of introns from the pre-mRNA. The Morpholino oligonucleotide would interfere with the splicing process, potentially creating a lariat structure as part of the splicing intermediate. Therefore, the lariat is involved in the proposed therapy.\\n\\nB) polyA tail: The polyA tail is added to the 3' end of the mRNA after splicing is complete. The Morpholino oligonucleotide is designed to target the 5' end of the out-of-frame exon, so it would not directly affect the polyA tail. However, the therapy aims to correct the splicing process, which indirectly affects the final polyA tail. Still, the polyA tail itself is not directly involved in the proposed mechanism.\\n\\nC) R-loops: R-loops are a type of secondary structure that can form during transcription, where the nascent RNA is base-paired with the template DNA strand, and the non-template strand is displaced. While R-loops are involved in various aspects of transcription and splicing, they are not directly related to the mechanism of the Morpholino oligonucleotide therapy described.\\n\\nD) antisense: Antisense refers to a type of RNA or DNA that is complementary to the target mRNA sequence. The Morpholino oligonucleotide used in the therapy is designed to be antisense to the 5' end of the out-of-frame exon, which would prevent the binding of the spliceosome and lead to exon skipping. Therefore, antisense is directly involved in the proposed therapy.\\n\\nConsidering the above explanations, the structure that is not directly involved in the proposed therapy is the R-loop.\\n\\nAnswer: C<|eot_id|>\", \"To answer this question, let's break down the process described:\\n\\n1. The proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n2. The Morpholino prevents the binding of the spliceosome.\\n3. This results in exon skipping and in-frame joining.\\n\\nNow, let's analyze the options:\\n\\nA) Lariat: Lariats are involved in the splicing process, specifically in the formation of the lariat-shaped intron that is removed during splicing. The splicing process is indeed affected by the Morpholino, so lariats are involved in the proposed therapy.\\n\\nB) PolyA tail: The polyA tail is added to the 3' end of the mRNA during the final step of RNA processing, after splicing has occurred. Since the Morpholino is affecting the splicing process, the polyA tail is not directly involved in the proposed therapy.\\n\\nC) R-loops: R-loops are involved in the splicing process, specifically in the recognition of the splice sites by the spliceosome. The Morpholino affects the splicing process, so R-loops are involved in the proposed therapy.\\n\\nD) Antisense: Antisense refers to a type of RNA that is complementary to the target mRNA. Morpholinos are a type of antisense oligonucleotides, so they are indeed involved in the proposed therapy.\\n\\nBased on this analysis, the structure not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's break it down step by step.\\n\\nThe proposed therapy involves delivering a Morpholino to prevent the binding of the spliceosome to the 5' end of the out-of-frame exon in pre-mRNA, causing exon skipping and in-frame joining. This is a form of antisense therapy, where the Morpholino acts as an antisense oligonucleotide to interfere with the splicing process.\\n\\nNow, let's analyze the options:\\n\\nA) lariat: A lariat is a type of spliceosome intermediate that forms during the splicing process. It is not directly involved in the proposed therapy, but it is a part of the splicing process that the Morpholino is trying to interfere with.\\n\\nB) polyA tail: The polyA tail is added to the 3' end of the mRNA after splicing is complete. It is not directly involved in the splicing process itself, but it is a feature of mature mRNA.\\n\\nC) R-loops: R-loops are not directly related to the splicing process or antisense therapy.\\n\\nD) antisense: Antisense is the type of oligonucleotide that the Morpholino is, which is designed to interfere with the splicing process.\\n\\nGiven the information, the structure that is not involved in the proposed therapy is the R-loop, as it is not directly related to the splicing process or antisense therapy.\\n\\nAnswer: C<|eot_id|>\", \"To answer this question, let's analyze the given information and the options provided.\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA and prevents the binding of the spliceosome, leading to exon skipping and in-frame joining. This process is a form of RNA interference (RNAi) therapy, specifically antisense oligonucleotide therapy.\\n\\nA) Lariat: A lariat is a type of RNA structure formed during the splicing process, where the intron is removed and the 5' and 3' splice sites are joined, forming a loop. However, this is not directly involved in the proposed therapy.\\n\\nB) PolyA tail: The polyA tail is added to the 3' end of the mRNA during post-transcriptional modification. It's involved in stabilizing the mRNA and facilitating its export from the nucleus to the cytoplasm. This is not directly related to the proposed therapy.\\n\\nC) R-loops: R-loops are a type of RNA-DNA hybrid structure that can form during transcription. They can be involved in various processes, including gene regulation. However, they are not directly involved in the proposed therapy.\\n\\nD) Antisense: Antisense oligonucleotides, like the Morpholino mentioned, are used in the proposed therapy. They work by binding to the target mRNA and preventing its translation or splicing.\\n\\nBased on the information provided, the correct answer is the one that is not directly involved in the proposed therapy.\\n\\nAnswer: A<|eot_id|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze the process described:\\n\\n1. The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n2. The Morpholino prevents the binding of the spliceosome.\\n3. This results in exon skipping and in-frame joining.\\n\\nNow, let's consider each option:\\n\\nA) lariat: A lariat is a structure involved in the splicing process, specifically in the removal of introns. It is a loop-shaped structure formed by a branch point in the pre-mRNA. The spliceosome's action is related to lariat formation, so this is involved in the proposed therapy.\\n\\nB) polyA tail: The polyA tail is added to the 3' end of the mRNA after splicing. It is not directly involved in the splicing process itself or the recognition of the 5' end of an exon by a Morpholino.\\n\\nC) R-loops: R-loops are structures that can form during transcription and splicing, involving a single-stranded DNA or RNA region bound by a protein. They can be involved in the regulation of gene expression and splicing, so this could be related to the splicing process.\\n\\nD) antisense: Antisense oligonucleotides, like Morpholinos, are designed to bind to the antisense strand of a target sequence. In this case, the Morpholino is designed to recognize the 5' end of the out-of-frame exon in pre-mRNA, which is an antisense approach.\\n\\nConsidering the options, the polyA tail is not directly involved in the recognition of the 5' end of an exon by a Morpholino or the splicing process itself.\\n\\nAnswer: B<|eot_id|>\", \"To determine the correct answer, let's analyze the given information and the options provided.\\n\\nThe proposed therapy involves using a Morpholino to prevent the binding of the spliceosome to the pre-mRNA, causing exon skipping and in-frame joining. This process is a form of RNA interference (RNAi) or antisense therapy.\\n\\nA) lariat: In the context of RNA splicing, a lariat is a structure formed during the splicing process when the intron is removed. The 5' end of the intron is joined to the 2' hydroxyl group of the branch point, forming a lariat-shaped structure. This is not directly involved in the proposed therapy.\\n\\nB) polyA tail: The polyA tail is added to the 3' end of the pre-mRNA during the process of polyadenylation, which is a separate step from splicing. However, the polyA tail is not directly involved in the proposed therapy.\\n\\nC) R-loops: R-loops are a type of secondary structure in RNA where a single-stranded RNA is paired with a single-stranded DNA. This is not directly involved in the proposed therapy.\\n\\nD) antisense: Antisense therapy, such as the use of Morpholinos, is a method of gene silencing where a complementary RNA or DNA molecule is used to bind to the target mRNA and prevent its translation. This is exactly what is described in the proposed therapy.\\n\\nConsidering the information provided, the correct answer is the structure that is not directly involved in the proposed therapy.\\n\\nAnswer: A<|eot_id|>\", \"To determine the correct answer, let's analyze the given information and the options provided.\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA, preventing the binding of the spliceosome and creating exon skipping and in-frame joining. This process is a form of antisense therapy, where a molecule is used to bind to the target mRNA and prevent its normal processing.\\n\\nA) Lariat: In the context of RNA splicing, a lariat is a structure formed by the spliceosome when it removes introns from the pre-mRNA. However, in the proposed therapy, the focus is on preventing the spliceosome from binding, rather than on the formation of lariats. However, lariats are involved in the splicing process, so it is not the correct answer.\\n\\nB) PolyA tail: The polyA tail is added to the 3' end of the mRNA after splicing is complete, not during the splicing process. In the context of the proposed therapy, the focus is on preventing the binding of the spliceosome, not on the addition of the polyA tail. However, the polyA tail is not directly involved in the splicing process of the exons that are skipped.\\n\\nC) R-loops: R-loops are involved in the splicing process, but more specifically, they are structures that form during the splicing process, where the RNA is paired with the template DNA strand, and a third strand is displaced. However, in the proposed therapy, the focus is on preventing the binding of the spliceosome and creating exon skipping, rather than on the formation of R-loops.\\n\\nD) Antisense: Antisense therapy is the proposed method for delivering the Morpholino molecule that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This is the correct answer because the question asks for the structure not involved in the proposed therapy, and the other options (A, B, and C) are all involved in the splicing process in some way.\\n\\nAnswer: D<|eot_id|>\", \"To solve this question, let's analyze the given information and the options provided:\\n\\n1.  The gene in question has dozens of exons, and central ones code for folded triple helical repeats. The mutations are central exon deletions that create out-of-frame peptides and lead to progressive degenerative organ waste.\\n2.  The proposed solution involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA, preventing the binding of the spliceosome and creating exon skipping and in-frame joining.\\n3.  The goal is to create a new in-frame combination of exons that are well-tolerated by the organism.\\n\\nNow, let's examine the options:\\n\\nA) lariat: A lariat is a type of intron that forms during splicing when the 5' splice site is joined to the 5' branch point. This is a structure involved in the splicing process, which is relevant to the proposed therapy.\\n\\nB) polyA tail: The polyA tail is added to the 3' end of the mRNA during post-transcriptional modification. While it's involved in mRNA processing, it's not directly related to the splicing process or the proposed therapy.\\n\\nC) R-loops: R-loops are structures formed during transcription when the RNA transcript is base-paired with the DNA template, displacing the non-template strand. R-loops can influence gene expression and splicing, making them relevant to the therapy.\\n\\nD) antisense: Antisense oligonucleotides, like Morpholinos, work by binding to the target mRNA (in this case, the out-of-frame exon) to prevent its translation or to induce exon skipping. This is the exact mechanism of the proposed therapy.\\n\\nConsidering the options, the structure not involved in the proposed therapy is the polyA tail, as it's related to mRNA processing rather than splicing or the direct action of Morpholinos.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's analyze the proposed therapy step by step:\\n\\n1. The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n2. The Morpholino prevents the binding of the spliceosome.\\n3. This results in exon skipping and in-frame joining.\\n4. The goal is to create a new, in-frame transcript that is well tolerated by the organism.\\n\\nNow, let's look at the options:\\n\\nA) lariat: A lariat is a type of RNA structure that forms during splicing, specifically a loop formed by a branch point. The spliceosome recognizes the branch point and forms a lariat structure. However, the therapy does not directly involve the formation of a lariat.\\n\\nB) polyA tail: The polyA tail is added to the 3' end of the mRNA after splicing is complete. While it's involved in the processing of the mature mRNA, it's not directly related to the splicing process or the proposed therapy.\\n\\nC) R-loops: R-loops are a type of RNA-DNA hybrid structure that can form during transcription. However, they are not directly involved in the splicing process or the proposed therapy.\\n\\nD) antisense: The Morpholino used in the therapy acts as an antisense oligonucleotide, binding to the target sequence in the pre-mRNA to prevent splicing.\\n\\nBased on this analysis, the structures not involved in the proposed therapy are A) lariat, B) polyA tail, and C) R-loops. However, the question asks for the structure that is NOT involved, and there are multiple options that fit this description. However, typically, in these types of questions, the correct answer is the one that is least related to the process. Here, all the options except one are directly involved in RNA processing. But between the options, lariat is the most directly involved in splicing, and the others are involved in RNA processing but not in splicing directly.\\n\\nHowever, since we have to choose the one that is least involved in the process described in the question, the answer would be the one that is not directly involved in the splicing process. \\n\\nAnswer: A<|eot_id|>\", \"To solve this question, let's analyze the proposed therapy and the structures involved in the process:\\n\\n1. **Morpholino**: A Morpholino is an antisense oligonucleotide that is designed to bind to a specific sequence of RNA. In this case, it is designed to bind to the 5' end of an out-of-frame exon in pre-mRNA.\\n2. **Exon skipping**: The Morpholino prevents the binding of the spliceosome, which leads to exon skipping. This means that the spliceosome is involved in the process.\\n3. **In-frame joining**: This occurs after the exon skipping, resulting in a new, in-frame transcript.\\n4. **Lariat (A)**: The lariat structure is a type of RNA secondary structure that forms during the splicing process. It is not directly involved in the proposed therapy.\\n5. **PolyA tail (B)**: The polyA tail is added to the 3' end of the mRNA after splicing is complete, but it is not directly involved in the proposed therapy.\\n6. **R-loops (C)**: R-loops are structures that can form during the splicing process, but they are not directly involved in the proposed therapy.\\n7. **Antisense (D)**: The Morpholino is an antisense oligonucleotide, which is directly involved in the proposed therapy.\\n\\nGiven the information above, the structure that is not involved in the proposed therapy is the lariat (A). The lariat is a type of RNA secondary structure that forms during splicing, but it is not directly involved in the proposed therapy of using Morpholinos to induce exon skipping.\\n\\nAnswer: A<|eot_id|>\", \"To solve this question, let's analyze the given information and the options provided.\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining. \\n\\nThe process described here is related to the splicing of pre-mRNA. The spliceosome is involved in splicing, and Morpholino oligomers are used to manipulate this process by blocking the spliceosome's binding site.\\n\\nNow, let's analyze the options:\\n\\nA) Lariat: During splicing, the lariat structure is formed when the intron is removed and a loop is created with a phosphodiester bond. This is a part of the splicing process, so it's involved in the proposed therapy.\\n\\nB) PolyA tail: The polyA tail is added to the 3' end of the mRNA after transcription and splicing. It's not directly involved in the splicing process itself, but it's a post-transcriptional modification.\\n\\nC) R-loops: R-loops are a type of RNA-DNA hybrid structure that can form during transcription and splicing. They are indeed involved in the splicing process.\\n\\nD) Antisense: Antisense oligomers, like Morpholinos, are used to manipulate gene expression by binding to specific RNA sequences. The Morpholino in the proposed therapy is an example of an antisense oligomer.\\n\\nGiven the information, the polyA tail (B) is the structure that is not directly involved in the splicing process and the proposed therapy. The polyA tail is added after splicing and transcription, not during the splicing process itself.\\n\\nAnswer: B<|eot_id|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze the process:\\n\\n1. **Morpholino delivery**: A Morpholino is delivered to the pre-mRNA, which is a precursor to mature mRNA. \\n2. **Preventing spliceosome binding**: The Morpholino molecule prevents the spliceosome from binding to the 5' end of the out-of-frame exon. \\n3. **Exon skipping and in-frame joining**: The absence of the out-of-frame exon leads to exon skipping, allowing the remaining exons to join in an in-frame manner.\\n\\nNow, let's look at the structures involved in this process:\\n\\n- **A) Lariat**: Lariats are a type of RNA structure that forms during the splicing process. They are not directly involved in the Morpholino therapy process, but they are a byproduct of splicing. However, they are not directly involved in the proposed therapy.\\n\\n- **B) PolyA tail**: The polyA tail is added to the 3' end of the mRNA during the splicing process. It's not directly involved in the Morpholino therapy process, but it's a part of the splicing process. However, it is not the correct answer because the therapy is focused on the 5' end of the out-of-frame exon.\\n\\n- **C) R-loops**: R-loops are a type of RNA structure that can be involved in splicing, but they are not directly related to the Morpholino therapy process. However, R-loops are involved in transcription and replication, and can form in the region of the gene where the Morpholino is acting.\\n\\n- **D) Antisense**: The Morpholino is an antisense oligonucleotide that binds to the 5' end of the out-of-frame exon. This is a critical part of the therapy.\\n\\nConsidering the information above, the correct answer is A) lariat, as it's the least directly involved in the Morpholino therapy process.\\n\\nAnswer: A<|eot_id|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process described:\\n\\n1.  The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n2.  The Morpholino prevents the binding of the spliceosome.\\n3.  This prevents the inclusion of the out-of-frame exon, causing exon skipping and in-frame joining.\\n4.  The goal is to create a new, in-frame peptide that can still be functional.\\n\\nConsidering these steps, let's examine the options:\\n\\nA) lariat: The lariat structure is formed during the splicing process, where the branch point is connected to a loop, and it is involved in the removal of introns. Since the Morpholino prevents the binding of the spliceosome, it would affect the splicing process, which involves the lariat structure.\\n\\nB) polyA tail: The polyA tail is added to the 3' end of the mRNA after splicing has occurred. It is not directly involved in the splicing process or the action of the Morpholino.\\n\\nC) R-loops: R-loops are structures that form during transcription, where the RNA transcript is hybridized to the template strand. They can influence the splicing process, and the Morpholino could potentially affect the R-loop structure indirectly by preventing the inclusion of the out-of-frame exon.\\n\\nD) antisense: The Morpholino acts as an antisense oligonucleotide, binding to the pre-mRNA and preventing the spliceosome from binding. This is the mechanism of action described in the question.\\n\\nConsidering these points, the structure not involved in the proposed therapy is the polyA tail, as it is added after splicing and is not directly affected by the action of the Morpholino.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's analyze the given information and the options provided.\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA and prevents the binding of the spliceosome, causing exon skipping and in-frame joining. This process is related to the splicing of RNA, specifically the removal of exons from a pre-mRNA transcript.\\n\\nNow, let's examine the options:\\n\\nA) lariat: A lariat is a type of RNA structure that forms during the splicing process. It is a loop of RNA that is created when the spliceosome removes an intron from the pre-mRNA. The lariat structure is involved in the splicing process, but it's not directly related to the recognition of the 5' end of the out-of-frame exon.\\n\\nB) polyA tail: The polyA tail is added to the 3' end of the mRNA after splicing is complete. It is not directly involved in the recognition of the 5' end of the out-of-frame exon or the splicing process.\\n\\nC) R-loops: R-loops are a type of RNA-DNA hybrid structure that can form during the splicing process. They are not directly involved in the recognition of the 5' end of the out-of-frame exon, but they can be related to the splicing process.\\n\\nD) antisense: Antisense oligonucleotides, such as Morpholinos, work by binding to the target RNA sequence in an antisense manner, preventing the normal splicing process. This is exactly what is described in the proposed therapy.\\n\\nBased on this analysis, the structure that is not involved in the proposed therapy is the polyA tail, which is added after splicing is complete.\\n\\nAnswer: B<|eot_id|>\", \"To answer this question, let's break down the information given and analyze each option:\\n\\n1. **Morpholino**: This is a type of antisense oligonucleotide that is designed to bind to specific RNA sequences, preventing the binding of the spliceosome and leading to exon skipping.\\n\\n2. **Exon skipping**: This process involves the skipping of one or more exons during splicing, resulting in a new, in-frame mRNA that codes for a functional protein.\\n\\n3. **Pre-mRNA**: This is the primary transcript of a gene before it undergoes splicing.\\n\\nNow, let's analyze each option in the context of the proposed therapy:\\n\\nA) **Lariat**: During splicing, the lariat structure forms as a byproduct of the splicing reaction, where the branch point of the intron is connected to the 5' splice site. However, this structure is not directly involved in the action of Morpholino therapy.\\n\\nB) **PolyA tail**: The polyA tail is added to the 3' end of the pre-mRNA before it is exported from the nucleus. It plays a role in the stability and processing of mRNA but is not directly involved in the mechanism of Morpholino therapy.\\n\\nC) **R-loops**: R-loops are structures formed during the transcription process, where the nascent RNA transcript is displaced from the DNA template, creating a loop structure. While R-loops can affect splicing, they are not directly involved in the action of Morpholino therapy.\\n\\nD) **Antisense**: Morpholinos are a type of antisense oligonucleotide that directly interfere with the pre-mRNA by blocking the binding of the spliceosome, leading to exon skipping.\\n\\nGiven this analysis, the structures not directly involved in the proposed therapy are the lariat, polyA tail, and R-loops.\\n\\nHowever, the correct answer is the one that is most directly not involved in the mechanism of Morpholino therapy. Considering the options, A) lariat is the least directly involved in the process described.\\n\\nAnswer: A<|eot_id|>\", \"To answer this question, let's break down the steps involved in the proposed therapy and the structures involved in the process.\\n\\n1. The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n2. The Morpholino molecule prevents the binding of the spliceosome.\\n3. This leads to exon skipping and in-frame joining.\\n\\nThe structures involved in this process are:\\n\\n- The Morpholino itself, which is an antisense molecule.\\n- The spliceosome, which is involved in splicing.\\n- The pre-mRNA, which is the target of the Morpholino.\\n\\nNow, let's examine the options:\\n\\nA) lariat: Lariat structures are involved in splicing, specifically in the formation of the lariat-shaped intron. They are formed when the spliceosome removes the intron from the pre-mRNA.\\n\\nB) polyA tail: The polyA tail is added to the 3' end of the mature mRNA, but it is not directly involved in the splicing process or the action of the Morpholino.\\n\\nC) R-loops: R-loops are a type of RNA-DNA hybrid structure that can form during transcription. They are not directly involved in the splicing process or the action of the Morpholino.\\n\\nD) antisense: The Morpholino is an antisense molecule that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n\\nBased on this analysis, the correct answer is the structure that is not directly involved in the proposed therapy.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's break down the information given and analyze each option:\\n\\n1.  The proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA and prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n\\n2.  The goal of this therapy is to skip the out-of-frame exon and join the remaining exons in-frame to produce a functional protein.\\n\\nNow, let's examine the options:\\n\\nA) Lariat: A lariat is a type of RNA structure that forms during the splicing process. It is not directly involved in the proposed therapy, which focuses on preventing the binding of the spliceosome to the out-of-frame exon.\\n\\nB) PolyA tail: The polyA tail is a feature of the 3' end of a mature mRNA molecule, added during the process of polyadenylation. While it is involved in mRNA processing, it is not directly involved in the splicing process that is targeted by the Morpholino therapy.\\n\\nC) R-loops: R-loops are RNA-DNA hybrids that can form during transcription and can influence gene expression. However, they are not directly involved in the proposed therapy, which focuses on preventing the binding of the spliceosome to the out-of-frame exon.\\n\\nD) Antisense: Antisense oligonucleotides, like Morpholinos, work by binding to the target mRNA sequence and preventing its translation. The Morpholino in the proposed therapy is an example of an antisense molecule.\\n\\nConsidering the information above, the structure not involved in the proposed therapy is the lariat, as it is not directly related to the splicing process targeted by the Morpholino.\\n\\nAnswer: A<|eot_id|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze each option in the context of the described therapy:\\n\\nA) lariat: In the context of pre-mRNA splicing, a lariat is a structure that forms during the splicing process. It is a loop of RNA that is formed when the spliceosome removes an intron from the pre-mRNA. The Morpholino oligonucleotide described in the therapy would prevent the binding of the spliceosome, which could potentially disrupt the formation of lariats. However, the lariat itself is not directly targeted by the Morpholino.\\n\\nB) polyA tail: The polyA tail is added to the 3' end of the pre-mRNA during the process of polyadenylation, which is a step that occurs after splicing. In the context of the therapy, the Morpholino would be targeting the 5' end of the out-of-frame exon, which is before the splicing process. Therefore, the polyA tail is not directly involved in the proposed therapy.\\n\\nC) R-loops: R-loops are a structure that can form during the splicing process, particularly when the spliceosome is binding to the pre-mRNA. They are a complex of single-stranded DNA and RNA. However, in the context of the Morpholino therapy, the R-loops are not directly targeted or involved in the mechanism of action.\\n\\nD) antisense: The Morpholino oligonucleotide is an antisense oligonucleotide, which is a type of RNA molecule that is complementary to a specific sequence of RNA. It binds to the target RNA and prevents the action of the RNA molecule. In this case, the Morpholino is designed to recognize the 5' end of the out-of-frame exon in pre-mRNA and prevent the binding of the spliceosome.\\n\\nConsidering the options, the polyA tail (B) is the structure that is not involved in the proposed therapy.\\n\\nAnswer: B<|eot_id|>\", 'To determine which structure is not involved in the proposed therapy, let\\'s break down the process described:\\n\\n1. The Morpholino is designed to recognize the 5\\' end of the out-of-frame exon in pre-mRNA.\\n2. The Morpholino prevents the binding of the spliceosome to the target exon.\\n3. This prevents the spliceosome from removing the out-of-frame exon, and instead, the spliceosome \"skips\" over it, allowing for in-frame joining.\\n4. This process is a form of exon skipping.\\n\\nNow, let\\'s analyze the options:\\n\\nA) lariat: In the splicing process, a lariat-shaped structure forms when the branch point is created. This is involved in the splicing process, but it\\'s not directly related to the proposed therapy of using a Morpholino to induce exon skipping.\\n\\nB) polyA tail: The polyA tail is added to the 3\\' end of the pre-mRNA during the splicing process, and it\\'s involved in the maturation of the mRNA. However, it\\'s not directly involved in the process of exon skipping caused by the Morpholino.\\n\\nC) R-loops: R-loops are involved in the splicing process, particularly in the recognition of the branch point and the interaction with the spliceosome. They are relevant to the splicing process, and thus, to the proposed therapy.\\n\\nD) antisense: The Morpholino acts as an antisense oligonucleotide, binding to the 5\\' end of the out-of-frame exon and preventing the spliceosome from binding. Therefore, antisense is directly involved in the proposed therapy.\\n\\nConsidering the options, the structure that is not directly involved in the proposed therapy is the lariat.\\n\\nAnswer: A<|eot_id|>', \"To solve this question, let's go step by step through the proposed therapy and the structures mentioned:\\n\\n1. **Morpholino**: Morpholinos are antisense oligonucleotides that can bind to specific sequences in pre-mRNA, preventing the binding of the spliceosome. They are designed to be complementary to the target sequence, which in this case is the 5' end of the out-of-frame exon.\\n\\n2. **Spliceosome**: The spliceosome is a complex of RNA and protein molecules that recognizes and removes introns from pre-mRNA during splicing. Morpholinos prevent the binding of the spliceosome to the target exon, allowing for exon skipping.\\n\\n3. **Exon skipping and in-frame joining**: By preventing the inclusion of the out-of-frame exon, the spliceosome can join the remaining exons in a way that results in a longer, in-frame protein.\\n\\nNow, let's look at the structures mentioned in the options:\\n\\n- **A) lariat**: A lariat is a structure formed during the splicing process, where the 5' end of the intron is joined to a branch point, forming a loop. This is a normal part of the splicing process, but it's not directly involved in the proposed therapy.\\n\\n- **B) polyA tail**: The polyA tail is added to the 3' end of the mRNA after splicing is complete, during a process called polyadenylation. This is also not directly involved in the proposed therapy.\\n\\n- **C) R-loops**: R-loops are formed when a single-stranded region of DNA or RNA binds to a complementary region of another strand, forming a loop. This can occur during transcription or during the splicing process, and can be involved in the recognition of splice sites by the spliceosome. R-loops are relevant to the splicing process, but not directly involved in the proposed therapy.\\n\\n- **D) antisense**: Antisense refers to the process of using single-stranded nucleic acids (such as Morpholinos) that are complementary to a target sequence to bind to it and prevent its expression. This is exactly what the Morpholino in the proposed therapy does.\\n\\nGiven this analysis, the structure not directly involved in the proposed therapy is the lariat.\\n\\nAnswer: A<|eot_id|>\", \"To answer this question, let's break down the process of the proposed therapy and the structures involved in RNA splicing and processing.\\n\\nThe proposed therapy involves delivering a Morpholino oligonucleotide that targets the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino molecule prevents the binding of the spliceosome, leading to exon skipping and in-frame joining. \\n\\nThe structures involved in this process are:\\n\\n- The spliceosome: a complex that catalyzes the splicing of pre-mRNA.\\n- The 5' splice site: the region of the pre-mRNA where the splicing process begins.\\n- The 3' splice site: the region of the pre-mRNA where the splicing process ends.\\n\\nNow, let's examine the options:\\n\\nA) Lariat: This refers to the lariat intermediate in the splicing process, which is formed when the 5' splice site is removed and a loop structure is created. This is indeed involved in the splicing process and could be affected by the Morpholino therapy.\\n\\nB) PolyA tail: This is a feature of the 3' end of the mRNA, added after splicing has occurred. It is not directly involved in the splicing process itself, but rather in the post-transcriptional processing of the mRNA.\\n\\nC) R-loops: These are regions of RNA-DNA hybridization that can form during the splicing process, particularly at the 5' splice site. They are indeed involved in the splicing process and could be affected by the Morpholino therapy.\\n\\nD) Antisense: This refers to the concept of using a nucleic acid molecule that is complementary to a target sequence in the mRNA to modulate its expression. In this case, the Morpholino oligonucleotide is an antisense molecule that targets the 5' end of the out-of-frame exon.\\n\\nGiven this information, the structure not directly involved in the proposed therapy is the polyA tail, as it is a feature of the post-transcriptional processing of the mRNA rather than a direct participant in the splicing process.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's analyze the information provided and the options given.\\n\\nThe proposed therapy involves using a Morpholino to prevent the binding of the spliceosome to the 5' end of an out-of-frame exon in pre-mRNA. This results in exon skipping and in-frame joining, which is a form of alternative splicing.\\n\\nA) lariat: This is a type of RNA structure formed during the splicing process, where the intron is looped out. It is involved in the splicing process, but not directly related to the proposed therapy.\\n\\nB) polyA tail: This is added to the 3' end of the pre-mRNA during the process of polyadenylation, but it is not directly involved in the proposed therapy of using Morpholinos to prevent spliceosome binding.\\n\\nC) R-loops: R-loops are a type of RNA-DNA hybrid structure that can form during the splicing process, but they are not directly related to the proposed therapy.\\n\\nD) antisense: This is the correct answer. The Morpholino used in the proposed therapy is an antisense oligonucleotide that recognizes the 5' end of the out-of-frame exon in pre-mRNA. It is an antisense molecule that prevents the binding of the spliceosome.\\n\\nAnswer: D<|eot_id|>\", \"To solve this question, let's analyze the process described in the therapy and the options provided.\\n\\nThe proposed therapy involves delivering a Morpholino to prevent the binding of the spliceosome to a pre-mRNA molecule. This is a form of RNA interference (RNAi) or antisense therapy, where a molecule is used to specifically target and modify the splicing of a particular RNA molecule.\\n\\nNow, let's examine the options:\\n\\nA) Lariat: A lariat is a structure formed during the splicing process of pre-mRNA, where a branch is created from the 5' end of the intron and the 5' splice site is joined to the 3' splice site. However, the therapy described does not involve the formation of a lariat structure.\\n\\nB) PolyA tail: A polyA tail is added to the 3' end of the pre-mRNA molecule after splicing, but it is not directly involved in the splicing process or the proposed therapy.\\n\\nC) R-loops: R-loops are formed when an RNA molecule is bound to a DNA template and a region of the RNA is displaced, forming a loop. However, this is not directly related to the splicing process or the therapy described.\\n\\nD) Antisense: Antisense therapy involves using a molecule that is complementary to the target RNA molecule to specifically bind and modify its splicing. This is the exact mechanism described in the proposed therapy, where a Morpholino is used to prevent the binding of the spliceosome.\\n\\nConsidering the information provided and the options, the structure that is not involved in the proposed therapy is the lariat.\\n\\nAnswer: A<|eot_id|>\", \"To answer this question, let's analyze the process described and the options given:\\n\\n1.  The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n2.  The Morpholino prevents the binding of the spliceosome, which leads to exon skipping and in-frame joining.\\n3.  This process is related to the splicing of pre-mRNA, where the spliceosome is involved.\\n\\nNow, let's analyze the options given:\\n\\nA) lariat: A lariat is a type of RNA structure that forms during the splicing process. It's involved in the splicing of pre-mRNA, but it's not directly related to the action of Morpholinos.\\n\\nB) polyA tail: The polyA tail is added to the 3' end of the mRNA after transcription, as a process that stabilizes the mRNA. It's not directly related to the splicing process or the action of Morpholinos.\\n\\nC) R-loops: R-loops are RNA-DNA hybrids that form during transcription, where the RNA strand is paired with the template DNA strand. They can be involved in regulating gene expression, but they're not directly related to the splicing process or the action of Morpholinos.\\n\\nD) antisense: Antisense oligonucleotides, like Morpholinos, can bind to the RNA strand and prevent the binding of the spliceosome, leading to exon skipping. This is the action described in the problem.\\n\\nConsidering the information, the options A, B, and C are structures involved in the process of RNA processing or transcription, but they are not directly involved in the action of Morpholinos. However, the correct answer is the one that is the least related to the splicing process.\\n\\nThe antisense option (D) is directly involved in the action of Morpholinos, as Morpholinos are a type of antisense oligonucleotide.\\n\\nHowever, since the question asks for the structure not involved in the proposed therapy, and given that all the other options (A, B, and C) are not directly involved in the action of Morpholinos but are involved in RNA processing or transcription, the correct answer is the one that is least directly involved in the splicing process described in the problem.\\n\\nHowever, I will select the option that is most directly involved in the process of transcription and not splicing, as the other options (A, B, C) are more directly related to the splicing process\", \"To determine the correct answer, let's analyze the given information and the options provided.\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA and prevents the binding of the spliceosome, resulting in exon skipping and in-frame joining. This process involves the splicing of pre-mRNA, which is a critical step in the RNA processing pathway.\\n\\nA) Lariat: Lariats are involved in the splicing process, specifically in the formation of the lariat structure during the splicing of pre-mRNA. This is not directly related to the proposed therapy, but it is involved in the splicing process.\\n\\nB) PolyA tail: The polyA tail is added to the 3' end of the mRNA after splicing has occurred, and it is not directly involved in the splicing process itself. However, it is a part of the post-transcriptional modification of mRNA.\\n\\nC) R-loops: R-loops are not directly involved in the splicing process or the proposed therapy. R-loops are a type of secondary structure that can form in DNA, but they are not directly related to the splicing of pre-mRNA.\\n\\nD) Antisense: Antisense oligonucleotides, such as Morpholinos, are used in the proposed therapy to prevent the binding of the spliceosome and induce exon skipping. Therefore, antisense is directly involved in the proposed therapy.\\n\\nGiven the information provided, the structure not involved in the proposed therapy is the R-loop, which is not directly related to the splicing process or the use of Morpholinos.\\n\\nAnswer: C<|eot_id|>\", \"To answer this question, let's break down the process described in the scenario:\\n\\n1. The gene has dozens of exons, and the central ones code for folded triple helical repeats.\\n2. A mutation leads to central exon deletions, resulting in out-of-frame peptides and progressive degenerative organ waste.\\n3. To solve this, a Morpholino is used to target the 5' end of the out-of-frame exon in pre-mRNA.\\n4. The Morpholino prevents the binding of the spliceosome, allowing for exon skipping and in-frame joining.\\n\\nNow, let's consider the options:\\n\\nA) Lariat: This is a structure formed during splicing, where the branch point of the intron is connected to a nearby adenosine, forming a lariat-shaped structure. This is involved in the splicing process, but it's not directly involved in the proposed therapy of using a Morpholino to prevent spliceosome binding.\\n\\nB) PolyA tail: This is added to the 3' end of the mRNA during post-transcriptional processing. It's not directly involved in the splicing process or the action of Morpholinos.\\n\\nC) R-loops: These are structures formed during transcription, where the nascent RNA transcript is displaced from the DNA template, forming a loop with the displaced single-stranded DNA. This can be involved in regulating gene expression, but it's not directly related to the action of Morpholinos in splicing.\\n\\nD) Antisense: This refers to a type of RNA that is complementary to the mRNA and can bind to it, preventing its translation. Morpholinos are a type of antisense oligonucleotide that work by binding to specific sequences of the pre-mRNA and preventing the binding of the spliceosome.\\n\\nGiven the description, the structure that is not involved in the proposed therapy is the lariat (A).<|eot_id|>\", \"To solve this question, let's break it down step by step:\\n\\n1. The question describes a gene with dozens of exons, and the goal is to deliver a Morpholino that recognizes the 5' end of an out-of-frame exon in pre-mRNA to create exon skipping and in-frame joining.\\n\\n2. The Morpholino works by preventing the binding of the spliceosome to the out-of-frame exon, which is located at the 5' end of the exon.\\n\\n3. The spliceosome is involved in splicing, which involves the removal of introns and the joining of exons. \\n\\n4. Now, let's consider the options:\\n   A) lariat: A lariat is a type of intron that forms during the splicing process. It is a circular structure with a 5' phosphate and a 2' hydroxyl group at the branch point. The spliceosome is involved in the formation of the lariat. \\n   B) polyA tail: The polyA tail is added to the 3' end of the mRNA during post-transcriptional processing, not during splicing. It is not directly involved in the splicing process or the action of the Morpholino.\\n   C) R-loops: R-loops are structures formed during transcription, where the RNA transcript is displaced from the DNA template, and the RNA binds to a region of the template DNA, forming a triple-stranded structure. They can affect splicing by blocking the spliceosome's access to the pre-mRNA.\\n   D) antisense: Antisense oligonucleotides, like Morpholinos, work by binding to the pre-mRNA in an antisense manner, preventing the binding of the spliceosome and the splicing process.\\n\\nConsidering the above information, the structure not involved in the proposed therapy is the polyA tail, as it is added after the splicing process and is not directly involved in the action of the Morpholino.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's break down the proposed therapy and the structures involved in RNA processing:\\n\\n1. The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n2. The Morpholino prevents the binding of the spliceosome, which is a complex involved in splicing the pre-mRNA.\\n3. This leads to exon skipping and in-frame joining.\\n\\nNow, let's examine the options:\\n\\nA) Lariat: A lariat is a structure formed during splicing, where the intron is looped out and attached to the 5' splice site. This is a normal part of the splicing process, but it's not directly involved in the proposed therapy.\\n\\nB) PolyA tail: The polyA tail is added to the 3' end of the mRNA after splicing is complete, but it's not directly involved in the splicing process itself.\\n\\nC) R-loops: R-loops are structures that can form during transcription, where the nascent RNA strand is displaced by the advancing RNA polymerase, forming a loop. However, R-loops can also form during splicing, where they can interfere with the splicing process.\\n\\nD) Antisense: Antisense oligonucleotides, such as Morpholinos, work by binding to the target mRNA and preventing its translation. In this case, the Morpholino is an antisense oligonucleotide that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n\\nBased on the information, the structure not directly involved in the proposed therapy is the lariat. The lariat is a normal part of the splicing process, but it's not directly affected by the Morpholino therapy.\\n\\nAnswer: A<|eot_id|>\", \"To solve this question, let's go through each option one by one and determine if it's involved in the proposed therapy.\\n\\nA) Lariat: The lariat structure is formed during the splicing process when the 5' end of the intron is joined to the lariat branch point, but it is not directly involved in the proposed therapy of using Morpholinos to prevent spliceosome binding.\\n\\nB) PolyA tail: The polyA tail is added to the 3' end of the mRNA after splicing has occurred, so it's not directly involved in the splicing process that the Morpholinos are trying to manipulate.\\n\\nC) R-loops: R-loops are involved in the splicing process, as they are formed when the 5' splice site is recognized by the spliceosome. The Morpholinos in this therapy are trying to prevent the spliceosome from binding, so R-loops could be indirectly involved in the process.\\n\\nD) Antisense: Morpholinos are an example of antisense oligonucleotides, which bind to the target RNA sequence to prevent its interaction with other molecules, such as the spliceosome. This is the exact mechanism described in the question.\\n\\nGiven the information above, the structure not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|eot_id|>\", \"To answer this question, let's break it down step by step:\\n\\n1. The proposed therapy involves using a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n2. The Morpholino prevents the binding of the spliceosome, which is a complex that assembles the exons together.\\n3. This leads to exon skipping, where the out-of-frame exon is skipped, and the remaining exons are joined in-frame.\\n4. The process of splicing involves several structures and components, including:\\n   - A) lariat: This is a type of RNA structure that forms during splicing, where a loop is formed by a branch point and the 5' splice site.\\n   - B) polyA tail: This is added to the 3' end of the mRNA after splicing is complete and is not directly involved in the splicing process.\\n   - C) R-loops: These are structures that form when an RNA molecule folds back on itself and pairs with a single-stranded region, but they are not directly involved in the splicing process.\\n   - D) antisense: This is a type of RNA that is complementary to the target mRNA and can be used to prevent translation by binding to the target mRNA.\\n\\nConsidering the above points, the structures that are involved in the proposed therapy are the lariat (A) and antisense (D). However, the question asks for the structure that is NOT involved in the proposed therapy. Therefore, the answer is the structure that is not directly involved in the splicing process or the therapy.\\n\\nAnswer: B<|eot_id|>\", \"To answer this question, let's break down the process and the structures involved in the proposed therapy:\\n\\n1. **Morpholino delivery**: The Morpholino molecule is designed to recognize the 5' end of the out-of-frame exon in pre-mRNA.\\n2. **Preventing spliceosome binding**: The Morpholino molecule prevents the spliceosome from binding to the pre-mRNA, which is a complex of small nuclear ribonucleoproteins (snRNPs) that catalyze the splicing process.\\n3. **Exon skipping and in-frame joining**: As a result of the spliceosome's inability to bind, the pre-mRNA undergoes exon skipping, leading to an in-frame joining of the remaining exons.\\n\\nNow, let's examine the options in relation to this process:\\n\\nA) **Lariat**: The lariat structure is a type of spliceosome intermediate that forms during the splicing process, where the branch point of the intron is connected to the 5' splice site, creating a lariat-shaped structure. This structure is involved in the splicing process, but it's not directly related to the Morpholino therapy.\\n\\nB) **PolyA tail**: The polyA tail is added to the 3' end of the pre-mRNA after splicing is complete, as part of the process of mRNA maturation. While it's a crucial step in mRNA processing, it's not directly involved in the proposed therapy.\\n\\nC) **R-loops**: R-loops are a type of RNA-DNA hybrid structure that can form during the splicing process, where the nascent RNA transcript forms a double-stranded region with the template DNA strand. This can interfere with the splicing process and can be targeted by Morpholino oligonucleotides.\\n\\nD) **Antisense**: Antisense refers to a type of RNA that is complementary to the target mRNA and can bind to it, preventing its translation. Morpholino oligonucleotides are a type of antisense molecule, designed to bind to the target mRNA and prevent its splicing.\\n\\nGiven this information, the structure not directly involved in the proposed therapy is the lariat (A), as it's a type of spliceosome intermediate that forms during the splicing process, but the Morpholino therapy targets the prevention of spliceosome binding, not the lariat structure itself.\\n\\nAnswer: A<|eot_id|>\", \"To solve this question, let's analyze the given information and the options provided.\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n\\nNow, let's examine the options:\\n\\nA) Lariat: During the splicing process, the spliceosome creates a lariat-shaped structure (lariat) as part of the excised intron. However, the proposed therapy does not directly involve the lariat structure. It is more related to the recognition of the 5' end of the out-of-frame exon.\\n\\nB) PolyA tail: The polyA tail is added to the 3' end of the pre-mRNA after splicing is completed. While it is involved in mRNA processing, it is not directly related to the proposed therapy of preventing spliceosome binding and creating exon skipping.\\n\\nC) R-loops: R-loops are a type of secondary structure that can form in pre-mRNA, but they are not directly involved in the proposed therapy of using a Morpholino to prevent spliceosome binding.\\n\\nD) Antisense: The Morpholino used in the proposed therapy acts as an antisense oligonucleotide, which is designed to bind to the 5' end of the out-of-frame exon in pre-mRNA. This is a key component of the therapy.\\n\\nConsidering the information provided, the correct answer is the structure that is not directly involved in the proposed therapy.\\n\\nAnswer: B<|eot_id|>\", \"To answer this question, let's break down the process and the structures involved in the proposed therapy:\\n\\n1. **Pre-mRNA**: The process starts with pre-mRNA, which is the precursor to mature mRNA. The Morpholino is designed to recognize the 5' end of the out-of-frame exon in pre-mRNA.\\n2. **Spliceosome**: The Morpholino prevents the binding of the spliceosome, which is a complex of proteins that facilitates the splicing process of pre-mRNA.\\n3. **Exon skipping and in-frame joining**: By preventing the spliceosome from binding, the pre-mRNA is spliced differently, resulting in the skipping of the out-of-frame exon and joining of the remaining exons in-frame.\\n4. **Morpholino**: This is a type of antisense oligonucleotide that binds to the target sequence, in this case, the 5' end of the out-of-frame exon.\\n\\nNow, let's evaluate the options:\\n\\nA) **Lariat**: A lariat is a type of RNA structure formed during the splicing process. It is not directly involved in the proposed therapy, but it is a byproduct of the splicing process. However, this is not the correct answer because lariats are indeed involved in the splicing process.\\n\\nB) **PolyA tail**: The polyA tail is added to the 3' end of the mature mRNA after splicing. It is not directly involved in the proposed therapy, which focuses on the recognition of the 5' end of the out-of-frame exon.\\n\\nC) **R-loops**: R-loops are a type of RNA-DNA hybrid structure that can form during the splicing process. While they are involved in the splicing process, they are not directly relevant to the proposed therapy.\\n\\nD) **Antisense**: The Morpholino is an antisense oligonucleotide, which means it binds to the target sequence in an antisense manner. This is the correct answer because the question asks which structure is not involved in the proposed therapy, and the antisense oligonucleotide (Morpholino) is the one that is directly involved in the therapy.\\n\\nAnswer: D<|eot_id|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze the process described:\\n\\n1. The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n2. The Morpholino prevents the binding of the spliceosome, which is a complex that assembles the mature mRNA by splicing out introns and joining exons.\\n3. The Morpholino causes exon skipping and in-frame joining, which means that the splicing process is altered to skip the out-of-frame exon and join the remaining exons in-frame.\\n\\nNow, let's examine the options:\\n\\nA) Lariat: Lariat structures are involved in the splicing process, specifically in the removal of introns. They are formed when the spliceosome cuts the pre-mRNA and then re-ligates the 5' end of the intron to a specific adenosine, forming a lariat-shaped structure. In the context of the proposed therapy, the lariat structure is involved in the splicing process, but it is not directly targeted by the Morpholino.\\n\\nB) PolyA tail: The polyA tail is added to the 3' end of the mature mRNA after splicing is complete. It is not directly involved in the splicing process or the action of the Morpholino.\\n\\nC) R-loops: R-loops are involved in the splicing process, specifically in the recognition of the 5' splice site by the spliceosome. However, they are not directly targeted by the Morpholino in this therapy.\\n\\nD) Antisense: The Morpholino is an antisense oligonucleotide, which is designed to bind to the target RNA sequence in an antisense manner. It is directly involved in the proposed therapy.\\n\\nConsidering the information above, the structure that is not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|eot_id|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the steps involved in the therapy:\\n\\n1. A Morpholino is delivered to the pre-mRNA, which is a modified RNA molecule before it has been processed into a mature mRNA molecule.\\n2. The Morpholino recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n3. The Morpholino prevents the binding of the spliceosome, which is a complex of proteins and small nuclear RNA (snRNA) molecules that removes introns (non-coding regions) and joins exons (coding regions) together.\\n4. This prevents the normal splicing process, which would create an out-of-frame peptide, and instead, the spliceosome skips the out-of-frame exon and joins the remaining exons in-frame.\\n\\nNow, let's examine the options:\\n\\nA) Lariat: During the splicing process, the spliceosome creates a lariat-shaped structure (a lariat) by removing the intron and joining the exons. However, in this therapy, the spliceosome is prevented from binding, so a lariat is not formed.\\n\\nB) PolyA tail: The polyA tail is added to the 3' end of the mRNA molecule after splicing is complete, so it is not directly involved in the splicing process.\\n\\nC) R-loops: R-loops are formed when the pre-mRNA is being transcribed, and a region of the nascent RNA is folded back on itself, forming a loop. R-loops are not directly involved in the splicing process, but they can influence the accessibility of the splice sites to the spliceosome.\\n\\nD) Antisense: The Morpholino used in the therapy is an antisense oligonucleotide, which is designed to bind to the target sequence in the pre-mRNA and prevent the binding of the spliceosome.\\n\\nBased on the above explanation, the polyA tail (B) is not directly involved in the splicing process, whereas the other options (A, C, and D) are all related to the splicing process, although in a more indirect way in the case of R-loops.\\n\\nAnswer: B<|eot_id|>\", \"To determine the correct answer, let's break down the process described in the question and relate it to the options provided:\\n\\n1. The problem described is a genetic disorder caused by deletions in the gene, specifically in the central exons, leading to out-of-frame peptides and degenerative organ waste.\\n2. The proposed solution is to use a Morpholino oligonucleotide that targets the 5' end of the out-of-frame exon in pre-mRNA.\\n3. The Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n\\nNow, let's examine the options in relation to the process described:\\n\\nA) Lariat: Lariat structures are involved in the splicing process, particularly in the lariat intermediate formed during the removal of introns. However, they are not directly involved in the recognition of the 5' end of the out-of-frame exon or the prevention of spliceosome binding.\\n\\nB) PolyA tail: The polyA tail is added to the 3' end of the mRNA after splicing is complete, so it's not directly involved in the process of preventing spliceosome binding or exon skipping.\\n\\nC) R-loops: R-loops are structures that can form during the splicing process, particularly in the region where the spliceosome binds. They can be involved in the recognition and processing of the pre-mRNA, but they are not the primary target of the Morpholino oligonucleotide.\\n\\nD) Antisense: The Morpholino oligonucleotide acts as an antisense molecule, binding to the 5' end of the out-of-frame exon in pre-mRNA and preventing the binding of the spliceosome.\\n\\nBased on the information provided, the correct answer is the one that is not directly involved in the proposed therapy:\\n\\nAnswer: B<|eot_id|>\", \"To answer this question, let's break down the process described in the therapy:\\n\\n1. The Morpholino molecule recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n2. The Morpholino prevents the binding of the spliceosome.\\n3. As a result, the pre-mRNA undergoes exon skipping and in-frame joining.\\n\\nThe structures involved in this process are:\\n\\n- The pre-mRNA itself (not listed as an option, but involved in the process)\\n- The spliceosome (not listed as an option, but involved in the process)\\n- The Morpholino molecule (not listed as an option, but the agent causing the effect)\\n\\nThe options provided are:\\nA) lariat\\nB) polyA tail\\nC) R-loops\\nD) antisense\\n\\n- A lariat is an RNA structure formed during the splicing process, but it is not directly involved in the proposed therapy.\\n- The polyA tail is added to the 3' end of the mRNA during processing, but it is not directly involved in the proposed therapy.\\n- R-loops are a structure formed during transcription, where an RNA molecule is hybridized to the DNA template strand. While they are involved in transcription, they are not directly involved in the proposed therapy.\\n- Antisense is a type of RNA that can bind to a target RNA, such as the pre-mRNA, to prevent its translation. The Morpholino molecule described in the therapy is a type of antisense molecule, so this option is relevant to the proposed therapy.\\n\\nConsidering the information, the structure not involved in the proposed therapy is the lariat.\\n\\nAnswer: A<|eot_id|>\", 'To solve this question, let\\'s go through the process of gene expression and the proposed therapy step by step:\\n\\n1. **Gene Expression**: The gene has dozens of exons, with central ones coding for folded triple helical repeats. Each exon usually codes for one folded triple alpha helix. The process of gene expression involves transcription (formation of pre-mRNA) and splicing (removal of introns and joining of exons).\\n\\n2. **Splicing**: The splicing process involves the removal of introns and joining of exons. A key component in this process is the spliceosome, which recognizes the 5\\' and 3\\' splice sites and removes the intron, leaving the exon-exon junctions. \\n\\n3. **Proposed Therapy**: The proposed therapy involves delivering a Morpholino to the pre-mRNA. The Morpholino recognizes the 5\\' end of the out-of-frame exon and prevents the binding of the spliceosome. This prevents the removal of the out-of-frame exon, allowing for exon skipping and in-frame joining.\\n\\nGiven this context, let\\'s examine the options:\\n\\nA) lariat: A lariat is a structure formed during splicing, where the intron is removed and forms a lariat-shaped structure. This is involved in the splicing process, but it is not directly involved in the proposed therapy.\\n\\nB) polyA tail: The polyA tail is added to the 3\\' end of the pre-mRNA during processing and is involved in stabilizing the mRNA and facilitating its translation. While it\\'s part of the gene expression process, it\\'s not directly involved in the proposed therapy.\\n\\nC) R-loops: R-loops are structures formed during transcription, where the nascent RNA transcript forms a loop with the DNA template strand. While they can affect gene expression, they are not directly involved in the proposed therapy.\\n\\nD) antisense: An antisense oligonucleotide (like the Morpholino in the proposed therapy) is a type of oligonucleotide that binds to the sense strand of the DNA or RNA and can affect gene expression. In this case, the Morpholino is an antisense oligonucleotide that recognizes the 5\\' end of the out-of-frame exon and prevents splicing.\\n\\nConsidering the above, the structures not involved in the proposed therapy are A, B, and C. However, since the question asks for the structure \"not involved in the proposed therapy,\" and the therapy is about antisense oligonucleotides,', \"To answer this question, let's break down the process described and the structures involved:\\n\\n1. **Morpholino**: Morpholinos are antisense oligonucleotides that can bind to specific sequences of RNA and prevent the action of the spliceosome. In this case, it's designed to bind to the 5' end of the out-of-frame exon in pre-mRNA.\\n2. **Pre-mRNA**: The pre-mRNA is the primary transcript of a gene before it undergoes splicing.\\n3. **Spliceosome**: The spliceosome is a complex of RNA and proteins that removes introns and joins exons together during the splicing process.\\n4. **Exon skipping and in-frame joining**: By preventing the spliceosome from binding to the out-of-frame exon, the Morpholino causes the pre-mRNA to skip over that exon and join the remaining exons in-frame, resulting in a functional protein.\\n\\nNow, let's look at the options:\\n\\nA) **Lariat**: A lariat is a type of intron that is formed during splicing when the 5' end of the intron is joined to a branch point (a specific adenosine residue) in the intron. This is a normal part of the splicing process, but it's not directly involved in the proposed therapy.\\n\\nB) **PolyA tail**: The polyA tail is added to the 3' end of the pre-mRNA during the process of polyadenylation, which is a step that occurs after splicing. This is not directly involved in the proposed therapy.\\n\\nC) **R-loops**: R-loops are structures that form when an RNA molecule is paired with a complementary DNA strand, leaving a single-stranded DNA region. R-loops can form during splicing, and in some cases, they can influence the splicing process. However, they are not directly involved in the proposed therapy.\\n\\nD) **Antisense**: Antisense is a type of RNA that is complementary to a specific mRNA sequence. Morpholinos are a type of antisense oligonucleotide, so this option is directly related to the proposed therapy.\\n\\nConsidering the information above, the structure that is not involved in the proposed therapy is the lariat.\\n\\nAnswer: A<|eot_id|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze the process described:\\n\\n1.  The therapy involves delivering a Morpholino to the pre-mRNA.\\n2.  The Morpholino recognizes the 5' end of the out-of-frame exon.\\n3.  The Morpholino prevents the binding of the spliceosome.\\n4.  This results in exon skipping and in-frame joining.\\n\\nNow, let's examine the options:\\n\\nA) lariat: The lariat structure is involved in the splicing process, where the branch point of the intron forms a lariat-shaped structure. This is relevant to the splicing process and could be affected by the spliceosome's binding being prevented.\\n\\nB) polyA tail: The polyA tail is added to the 3' end of the mRNA after splicing is complete, not before. Therefore, it is not directly involved in the proposed therapy.\\n\\nC) R-loops: R-loops are structures that form during the splicing process, where the RNA transcript is base-paired with a region of the DNA. This can be relevant to the splicing process and could be affected by the spliceosome's binding being prevented.\\n\\nD) antisense: Antisense molecules, like the Morpholino, are involved in the proposed therapy by binding to the pre-mRNA and preventing the spliceosome's binding.\\n\\nConsidering the above analysis, the structure not involved in the proposed therapy is the polyA tail, which is added after splicing is complete.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's break it down step by step:\\n\\n1.  The proposed therapy involves using Morpholinos to recognize the 5' end of the out-of-frame exon in pre-mRNA.\\n2.  Morpholinos are antisense oligonucleotides, which means they bind to the target sequence through base pairing, but are not part of the final RNA structure.\\n3.  The goal is to prevent the binding of the spliceosome, which is a complex involved in splicing, and to create exon skipping and in-frame joining.\\n4.  The splicing process involves several structures and components, including the lariat (a loop formed during splicing), the polyA tail (added to the 3' end of the mature mRNA), and R-loops (a complex structure that can form during transcription and splicing).\\n5.  However, antisense oligonucleotides like Morpholinos are not part of these structures, but rather a tool used to manipulate the splicing process.\\n\\nConsidering the information above, the structure that is not involved in the proposed therapy is the antisense structure, as Morpholinos are the antisense oligonucleotides used in the therapy.\\n\\nAnswer: D<|eot_id|>\", \"To solve this question, let's analyze the given information and the options provided.\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA, preventing the binding of the spliceosome, and creating exon skipping and in-frame joining. This process is related to RNA splicing, a process in which introns are removed and exons are joined together to form a mature mRNA molecule.\\n\\nA) Lariat: Lariat structures are involved in the splicing process, specifically in the removal of introns. During splicing, a lariat-shaped structure is formed from the intron that is being removed. However, this is not directly involved in the proposed therapy of exon skipping.\\n\\nB) PolyA tail: The polyA tail is added to the 3' end of the mRNA molecule after splicing is complete. While it is involved in mRNA processing, it is not directly related to the process of exon skipping.\\n\\nC) R-loops: R-loops are involved in the splicing process, particularly in the recognition of the splice sites by the spliceosome. They are formed by the binding of the spliceosome to the pre-mRNA, which is relevant to the proposed therapy.\\n\\nD) Antisense: Antisense oligonucleotides, like Morpholinos, are used to bind to the target RNA sequence and prevent its normal function. In this case, the Morpholino is designed to recognize the 5' end of the out-of-frame exon, which is an antisense approach.\\n\\nBased on the information provided, the structure not directly involved in the proposed therapy of exon skipping is the lariat, which is involved in the removal of introns during splicing.\\n\\nAnswer: A<|eot_id|>\", \"To solve this question, let's analyze the given information and the options provided.\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining. \\n\\nThe process of exon skipping and in-frame joining is a form of RNA splicing, specifically an alternative splicing mechanism. In RNA splicing, the spliceosome is involved in the recognition and removal of introns (non-coding regions) and the joining of exons (coding regions).\\n\\nNow, let's analyze the options:\\n\\nA) lariat: This is a type of RNA structure that forms during the splicing process, specifically when the spliceosome removes an intron. The intron is looped out to form a lariat-shaped structure. This is involved in the splicing process, but it is not directly related to the proposed therapy.\\n\\nB) polyA tail: This is a feature of the 3' end of a mature mRNA molecule, which is added by the enzyme poly(A) polymerase during post-transcriptional modification. It is not directly involved in the splicing process or the proposed therapy.\\n\\nC) R-loops: These are RNA-DNA hybrids that form during transcription, where a single-stranded RNA molecule binds to a complementary DNA sequence. They are not directly involved in the splicing process or the proposed therapy.\\n\\nD) antisense: This refers to a type of RNA that is complementary to the target mRNA, and is often used in gene therapy to block gene expression. In the context of the proposed therapy, the Morpholino acts as an antisense oligonucleotide to prevent the binding of the spliceosome.\\n\\nBased on the analysis, the correct answer is the one that is not directly involved in the splicing process or the proposed therapy.\\n\\nAnswer: B<|eot_id|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze each option in the context of the therapy described:\\n\\nA) lariat: In the context of pre-mRNA splicing, a lariat is a type of RNA structure that forms during the splicing process. It is involved in the removal of introns from the pre-mRNA. The therapy involves the use of a Morpholino to prevent the binding of the spliceosome, which would lead to the formation of a lariat structure as part of the splicing process. Therefore, lariats are involved in the proposed therapy.\\n\\nB) polyA tail: The polyA tail is added to the 3' end of the mature mRNA molecule after splicing has occurred. It is not directly involved in the splicing process itself, nor is it directly affected by the Morpholino therapy. However, the therapy is focused on preventing the splicing process, which would normally result in the formation of a mature mRNA molecule with a polyA tail. Therefore, the polyA tail is not directly involved in the proposed therapy.\\n\\nC) R-loops: R-loops are RNA-DNA hybrid structures that can form during transcription, where the RNA transcript hybridizes with the template DNA strand. They are not directly involved in the splicing process, but they can influence gene expression by affecting transcription. The Morpholino therapy is focused on the splicing process, not transcription, so R-loops are not directly involved in the proposed therapy.\\n\\nD) antisense: Antisense oligonucleotides, like Morpholinos, are designed to bind to specific sequences of RNA and prevent their interaction with other molecules. In this case, the Morpholino is an antisense oligonucleotide that recognizes the 5' end of the out-of-frame exon in pre-mRNA and prevents the binding of the spliceosome. Therefore, antisense is directly involved in the proposed therapy.\\n\\nBased on the analysis, the structure that is not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's go through the process of gene splicing and the role of each option given in the context of the therapy described.\\n\\nThe therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining. \\n\\nA) Lariat: In the splicing process, the lariat structure is formed when the intron is removed from the pre-mRNA and forms a loop. However, in the context of the therapy, the Morpholino prevents the spliceosome from binding to the 5' end of the out-of-frame exon, which is not directly related to the formation of a lariat.\\n\\nB) PolyA tail: The polyA tail is added to the 3' end of the mature mRNA after splicing has occurred. The therapy described does not directly involve the addition of a polyA tail.\\n\\nC) R-loops: R-loops are formed during the splicing process when the RNA-DNA hybrid is displaced by the spliceosome, creating a single-stranded RNA loop. The Morpholino could potentially interfere with the R-loop structure by preventing the spliceosome from binding.\\n\\nD) Antisense: Antisense oligonucleotides, like Morpholinos, are designed to bind to specific sequences of RNA to prevent the binding of the spliceosome or other RNA-binding proteins. The Morpholino in the therapy described acts as an antisense oligonucleotide.\\n\\nBased on the information provided, the structure not involved in the proposed therapy is the lariat.\\n\\nAnswer: A<|eot_id|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process of how the therapy works:\\n\\n1. The therapy involves delivering a Morpholino to the pre-mRNA.\\n2. The Morpholino recognizes the 5' end of the out-of-frame exon.\\n3. The Morpholino prevents the binding of the spliceosome.\\n4. This results in exon skipping and in-frame joining.\\n\\nNow, let's analyze each option in relation to the process:\\n\\nA) Lariat: Lariats are involved in the splicing process, specifically in the removal of introns. However, the lariat structure is not directly involved in the binding of the spliceosome or the recognition of the 5' end of the out-of-frame exon by the Morpholino. But, lariats are not directly involved in the proposed therapy, but the splicing process is. So it's not the best answer.\\n\\nB) PolyA tail: The polyA tail is added to the 3' end of the mRNA during the post-transcriptional modification process. It's not directly involved in the splicing process or the recognition of the 5' end of the out-of-frame exon by the Morpholino.\\n\\nC) R-loops: R-loops are a type of RNA-DNA hybrid structure that can be involved in the splicing process, particularly in the recognition of splice sites. They are not directly involved in the proposed therapy, but splicing is. However, the splicing process is the target of the therapy, so it's not the best answer.\\n\\nD) Antisense: Antisense oligonucleotides, such as Morpholinos, are designed to bind to the target RNA sequence, in this case, the 5' end of the out-of-frame exon. The Morpholino is an example of an antisense molecule used in the therapy.\\n\\nBased on the analysis, the structure not involved in the proposed therapy is the polyA tail, as it is not directly related to the recognition of the 5' end of the out-of-frame exon or the splicing process.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's analyze the given information and the options:\\n\\n1. The gene in question has dozens of exons, with the central ones coding for folded triple helical repeats. The problem is that central exon deletions lead to out-of-frame peptides, causing progressive degenerative organ waste.\\n2. The proposed solution involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n3. Several missing exons are well tolerated by the organism.\\n\\nNow, let's analyze the options:\\n\\nA) Lariat: A lariat is a structure formed during the splicing process, where the branch point of the intron is connected to the 5' splice site, forming a loop. This is a relevant structure in the context of splicing and could be involved in the process of exon skipping.\\n\\nB) PolyA tail: The polyA tail is added to the 3' end of the mRNA after splicing has occurred, not directly involved in the splicing process itself. However, it's not directly related to the proposed therapy.\\n\\nC) R-loops: R-loops are structures formed during the splicing process, where the RNA molecule forms a loop with a region of the DNA. They can be involved in the regulation of splicing.\\n\\nD) Antisense: Antisense oligonucleotides, such as Morpholinos, are designed to bind to the target RNA and prevent its normal processing. In this case, the Morpholino recognizes the 5' end of the out-of-frame exon and prevents the binding of the spliceosome.\\n\\nConsidering the given information and the options, the polyA tail (B) is not directly involved in the proposed therapy, which focuses on preventing the binding of the spliceosome and promoting exon skipping.\\n\\nAnswer: B<|eot_id|>\", \"To answer this question, let's break down the information given and the process described:\\n\\n1. **Gene structure and mutation**: The gene has dozens of exons, with central ones coding for folded triple helical repeats. Central exon deletions lead to out-of-frame peptides and degenerative organ waste.\\n\\n2. **Proposed therapy**: The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n\\n3. **Objective of the therapy**: The goal is to create a new in-frame transcript by skipping the out-of-frame exon(s) to avoid the production of degenerative peptides.\\n\\nNow, let's analyze the options in relation to the process:\\n\\nA) **lariat**: In RNA splicing, a lariat is a structure formed during the splicing process, where the branch point of the intron is connected to the 5' splice site, creating a loop. This process is crucial for the removal of introns and the joining of exons. Since the Morpholino prevents the binding of the spliceosome, which is involved in this process, the lariat structure is indeed involved in the splicing process.\\n\\nB) **polyA tail**: The polyA tail is added to the 3' end of the mRNA during post-transcriptional modification. It's not directly involved in the splicing process or the recognition of the 5' end of an exon by a Morpholino.\\n\\nC) **R-loops**: R-loops are a type of RNA-DNA hybrid structure formed during transcription, where the RNA transcript is paired with the template DNA strand, while the non-template DNA strand is displaced. While R-loops can be involved in various regulatory processes, they are not directly related to the splicing process or the action of a Morpholino.\\n\\nD) **antisense**: Antisense oligonucleotides, like Morpholinos, are designed to bind to the sense strand of the target gene, preventing its translation. In this context, the Morpholino acts as an antisense molecule to prevent the binding of the spliceosome to the out-of-frame exon.\\n\\nGiven this analysis, the structure not directly involved in the proposed therapy is the polyA tail, which is added to the 3' end of the mRNA after splicing has occurred.\\n\\nAnswer: B<|eot_id|>\", 'To solve this question, let\\'s analyze the information provided and the options given.\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5\\' end of the out-of-frame exon in pre-mRNA, preventing the binding of the spliceosome and creating exon skipping and in-frame joining. This is a form of RNA interference (RNAi) therapy, specifically antisense oligonucleotide therapy.\\n\\nNow, let\\'s consider the options:\\n\\nA) Lariat: Lariats are a type of RNA structure that forms during the splicing process. They are involved in the splicing reaction, but they are not directly involved in the proposed therapy.\\n\\nB) PolyA tail: The polyA tail is a feature of mature mRNA, added during the post-transcriptional modification process. While it\\'s related to mRNA processing, it\\'s not directly involved in the proposed therapy.\\n\\nC) R-loops: R-loops are a type of RNA-DNA hybrid structure that can form during transcription. They are not directly involved in the proposed therapy.\\n\\nD) Antisense: Antisense oligonucleotides, like Morpholinos, work by binding to the target RNA sequence in an antisense manner. This is exactly how the proposed therapy works.\\n\\nBased on the analysis, the structures not directly involved in the proposed therapy are lariats, polyA tails, and R-loops.\\n\\nHowever, the question asks for the structure that is \"not involved\" in the proposed therapy, and it is possible that all of the other options could be considered as not directly involved in the therapy. But considering the context of the therapy, which specifically involves the use of antisense oligonucleotides, the best answer would be the option that is least directly related to the therapy.\\n\\nGiven the options, the best answer would be the one that is least directly related to the antisense oligonucleotide therapy, which is the structure that is not directly involved in the process of RNA splicing or modification of the RNA molecule in the context of the therapy.\\n\\nHowever, based on the information given in the question and considering the context of the therapy, the best answer would be the option that involves the least direct involvement in the process of RNA splicing and modification, which would be the polyA tail, as it is the feature of mature mRNA and not directly involved in the splicing process.\\n\\nAnswer: B<|eot_id|>', \"To answer this question, let's analyze the proposed therapy step by step:\\n\\n1.  The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n2.  The Morpholino prevents the binding of the spliceosome.\\n3.  As a result, the pre-mRNA undergoes exon skipping and in-frame joining.\\n\\nNow, let's examine each option in relation to the proposed therapy:\\n\\nA) Lariat: During splicing, the spliceosome removes introns and joins exons. In this process, a lariat structure forms when the intron is removed, and a branch point is created. Since the Morpholino prevents the binding of the spliceosome, the lariat structure is still involved in the splicing process.\\n\\nB) PolyA tail: The polyA tail is added to the 3' end of the mRNA after splicing is complete. It is not directly involved in the splicing process itself or the recognition of the 5' end of the out-of-frame exon by the Morpholino.\\n\\nC) R-loops: R-loops are a type of secondary structure in DNA where an RNA molecule is hybridized to one strand of DNA, and the other strand is displaced. In the context of splicing, R-loops can be involved in the recognition of splice sites and the regulation of splicing. Since the Morpholino is designed to prevent the binding of the spliceosome, R-loops may be involved in the initial recognition of the splice site.\\n\\nD) Antisense: The Morpholino is an antisense oligonucleotide, which is designed to bind to a specific sequence of the pre-mRNA, in this case, the 5' end of the out-of-frame exon.\\n\\nConsidering the options, the structure not directly involved in the proposed therapy is the polyA tail, which is added after splicing is complete and is not directly related to the recognition of the 5' end of the out-of-frame exon by the Morpholino.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's analyze the given information step by step and understand the proposed therapy:\\n\\n1. The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n2. The Morpholino prevents the binding of the spliceosome.\\n3. This action creates exon skipping and in-frame joining.\\n\\nNow, let's analyze the options:\\n\\nA) lariat: A lariat is a structure formed during splicing when the 5' end of an intron is branched off and a loop is formed. This structure is involved in the splicing process, which is related to the therapy described. However, the question is asking which structure is not involved in the proposed therapy.\\n\\nB) polyA tail: The polyA tail is added to the 3' end of the mRNA during the processing of the pre-mRNA, but it is not directly involved in the splicing process or the action of the Morpholino in this therapy.\\n\\nC) R-loops: R-loops are structures that form during transcription, where the nascent RNA is base-paired to the template DNA strand, and the non-template strand is displaced. R-loops are involved in transcription regulation, but they are not directly involved in the splicing process or the action of the Morpholino.\\n\\nD) antisense: Antisense oligonucleotides, like Morpholinos, are used to recognize specific sequences of RNA and prevent their expression. In this case, the Morpholino is an antisense oligonucleotide that recognizes the 5' end of the out-of-frame exon.\\n\\nConsidering the information, the structures that are not directly involved in the proposed therapy are the polyA tail (B) and R-loops (C), but R-loops are not directly involved in the splicing process, whereas the polyA tail is more closely related to the process. However, R-loops are less relevant to the context of this question. Antisense (D) is directly involved in the therapy.\\n\\nAnswer: B<|eot_id|>\", 'To solve this question, let\\'s break down the process described and identify the structures involved in the proposed therapy.\\n\\n1. **Pre-mRNA**: This is the primary transcript of a gene that has not yet undergone splicing. The therapy involves delivering a Morpholino that recognizes the 5\\' end of the out-of-frame exon in pre-mRNA.\\n   \\n2. **Morpholino**: This is an antisense oligonucleotide that binds to the pre-mRNA, preventing the spliceosome from binding to the targeted exon.\\n\\n3. **Spliceosome**: This is a complex that catalyzes the splicing process of pre-mRNA. The Morpholino prevents the spliceosome from binding to the out-of-frame exon, leading to exon skipping and in-frame joining.\\n\\nNow, let\\'s analyze the options:\\n\\nA) **Lariat**: This structure is formed during the splicing process, specifically when the spliceosome removes the intron. It is a loop of RNA that is covalently joined to the 5\\' end of the intron. While it is involved in the splicing process, it is not directly involved in the proposed therapy.\\n\\nB) **PolyA tail**: This is added to the 3\\' end of the pre-mRNA during the splicing process. It is not directly involved in the proposed therapy, but it is a part of the pre-mRNA processing.\\n\\nC) **R-loops**: These are structures that can form during the splicing process, especially when the spliceosome is stalled or when there are issues with the recognition of splice sites. They can also be involved in the regulation of gene expression. However, they are not directly involved in the proposed therapy.\\n\\nD) **Antisense**: This is the type of oligonucleotide used in the proposed therapy, which is the Morpholino. It is designed to bind to the pre-mRNA and prevent the spliceosome from binding to the out-of-frame exon.\\n\\nConsidering the above information, the structures not directly involved in the proposed therapy are the lariat (A), R-loops (C), and polyA tail (B). However, since the question asks for the structure \"not involved\" in the proposed therapy, and all options except one are involved in the process, the correct answer is the one that is not directly related to the process described.\\n\\nAnswer: A<|eot_id|>', \"To determine which structure is not involved in the proposed therapy, let's analyze the given information and the options:\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\n- A) Lariat: This is a type of spliceosome complex that forms during the splicing process, specifically when the intron is removed from the pre-mRNA. The lariat structure is indeed involved in splicing and could be affected by the Morpholino, which prevents the binding of the spliceosome.\\n\\n- B) PolyA tail: This is added to the 3' end of the pre-mRNA after splicing is complete. The Morpholino therapy does not directly affect the polyA tail, as it targets the 5' end of the out-of-frame exon.\\n\\n- C) R-loops: These are a type of RNA-DNA hybrid structure that can form during the splicing process. They can be involved in the regulation of splicing and could be affected by the Morpholino, which prevents the binding of the spliceosome.\\n\\n- D) Antisense: This refers to the type of RNA that is complementary to the target mRNA. The Morpholino used in the therapy is an antisense oligonucleotide that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n\\nConsidering the information above, the structure not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|eot_id|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze the process step by step:\\n\\n1.  The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n2.  The Morpholino molecule prevents the binding of the spliceosome, which is a complex that removes introns and joins exons together during RNA splicing.\\n3.  As a result of the Morpholino's action, exon skipping and in-frame joining occur, which means that the out-of-frame exon is skipped, and the remaining exons are joined in a way that creates a frame.\\n4.  Now, let's look at the options provided:\\n   A) Lariat: During splicing, the spliceosome creates a lariat-shaped structure from the intron using a branch point. This process is involved in removing the intron from the pre-mRNA.\\n   B) PolyA tail: This is added to the 3' end of the pre-mRNA after splicing is complete, as a signal for the mRNA to be exported out of the nucleus and translated into protein.\\n   C) R-loops: R-loops are not directly involved in the splicing process or the proposed therapy. R-loops are formed during transcription when the RNA transcript forms a triple-stranded structure with the DNA template strand and a non-template strand.\\n   D) Antisense: An antisense oligonucleotide, like the Morpholino in the proposed therapy, is used to bind to a specific sequence of the pre-mRNA and prevent the binding of the spliceosome.\\n\\nBased on the analysis, the structure that is not involved in the proposed therapy is R-loops.\\n\\nAnswer: C<|eot_id|>\", \"To solve this question, let's break down the process of the proposed therapy and identify the structures involved.\\n\\nThe proposed therapy involves using a Morpholino to recognize the 5' end of the out-of-frame exon in pre-mRNA. The Morpholino prevents the binding of the spliceosome, which is a complex involved in the splicing of RNA. This leads to exon skipping and in-frame joining.\\n\\nNow, let's consider the options:\\n\\nA) Lariat: During splicing, the spliceosome creates a lariat-shaped structure (lariat) as a byproduct. However, this is not directly involved in the proposed therapy.\\n\\nB) PolyA tail: The polyA tail is added to the 3' end of the mRNA after splicing is complete. This is not directly involved in the proposed therapy.\\n\\nC) R-loops: R-loops are involved in the process of splicing, as they can form during the recognition of the splice sites by the spliceosome. However, they are not directly involved in the proposed therapy.\\n\\nD) Antisense: Antisense oligonucleotides like Morpholinos are used in the proposed therapy. They bind to the target sequence (in this case, the 5' end of the out-of-frame exon) and prevent the binding of the spliceosome.\\n\\nConsidering the above, the structure not involved in the proposed therapy is the lariat.\\n\\nAnswer: A<|eot_id|>\", \"To determine the correct answer, let's break down the process of the proposed therapy and the structures involved in RNA splicing and processing:\\n\\n1. **Pre-mRNA**: The pre-mRNA molecule has introns (non-coding regions) and exons (coding regions).\\n2. **Spliceosome**: The spliceosome is a complex that recognizes and removes introns from the pre-mRNA, joining exons together to form a mature mRNA molecule.\\n3. **Morpholino**: A Morpholino is a synthetic molecule that can be designed to bind to a specific sequence of RNA. In this case, it's designed to bind to the 5' end of the out-of-frame exon in pre-mRNA.\\n4. **Exon skipping**: By preventing the spliceosome from binding, the Morpholino causes the pre-mRNA to skip the out-of-frame exon, leading to an in-frame joining of the remaining exons.\\n5. **In-frame joining**: This results in a mature mRNA molecule that can be translated into a functional protein.\\n\\nConsidering the options:\\n\\nA) **Lariat**: A lariat is a structure formed during splicing, where the branch point of the intron is connected to a loop, creating a lariat-shaped structure. It's involved in the splicing process, but it's not directly involved in the therapy proposed.\\n\\nB) **PolyA tail**: The polyA tail is added to the 3' end of the mature mRNA molecule, which is not directly involved in the therapy proposed.\\n\\nC) **R-loops**: R-loops are structures that can form during splicing, but they are not directly involved in the therapy proposed.\\n\\nD) **Antisense**: Antisense is a type of RNA that can bind to a complementary sequence of RNA, preventing its translation. A Morpholino is an example of an antisense molecule, which is used in the proposed therapy.\\n\\nBased on the information, the structure not involved in the proposed therapy is the **polyA tail**, as it's a post-transcriptional modification that occurs after splicing and is not directly affected by the Morpholino.\\n\\nAnswer: B<|eot_id|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze each option in the context of the therapy described:\\n\\nA) lariat: In the context of RNA splicing, a lariat is a type of RNA structure formed during the splicing process, where the branch point of the intron is connected to the 5' splice site. The therapy described involves preventing the binding of the spliceosome, which is necessary for the splicing process, including the formation of lariats. Therefore, lariats are involved in the splicing process, but not directly in the therapy.\\n\\nB) polyA tail: The polyA tail is added to the 3' end of the mRNA after splicing is complete, as a way to protect the mRNA from degradation and help it be exported out of the nucleus. The therapy described involves preventing the splicing process by blocking the spliceosome, but it does not directly affect the addition of the polyA tail. However, the therapy's goal is to create exon skipping and in-frame joining, which would lead to a different mRNA that might or might not have a polyA tail, but this is a downstream process.\\n\\nC) R-loops: R-loops are a type of RNA-DNA hybrid structure that can form during transcription, where the nascent RNA transcript is base-paired with the template DNA strand. In the context of the therapy, the Morpholino oligonucleotide would bind to the pre-mRNA, not the DNA. However, R-loops can form during the transcription process, which is upstream of splicing. Therefore, R-loops are not directly involved in the therapy but are part of the overall process of gene expression.\\n\\nD) antisense: Antisense oligonucleotides, like Morpholino oligonucleotides, are designed to bind to specific sequences of RNA, in this case, the 5' end of the out-of-frame exon. This binding prevents the binding of the spliceosome and leads to exon skipping and in-frame joining. The Morpholino oligonucleotide is an example of an antisense molecule, so antisense is directly involved in the proposed therapy.\\n\\nBased on the above analysis, the structure not directly involved in the proposed therapy is the lariat.\\n\\nAnswer: A<|eot_id|>\", \"To answer this question, let's break down the proposed therapy and the structures involved:\\n\\n1.  The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n2.  The Morpholino prevents the binding of the spliceosome.\\n3.  This leads to exon skipping and in-frame joining.\\n\\nThe structures involved in the therapy are:\\n\\n- **Morpholino**: This is an antisense oligonucleotide, so option D) antisense is involved.\\n- **Spliceosome**: The spliceosome is a complex that assembles on the pre-mRNA and catalyzes the splicing reaction. Although not directly a structure, the spliceosome is the target of the Morpholino, so it's indirectly involved.\\n- **Pre-mRNA**: This is the target of the Morpholino, where it recognizes the 5' end of the out-of-frame exon.\\n\\nThe structures not involved in the proposed therapy are:\\n\\n- **Lariat (A)**: A lariat is a type of intron that forms during the splicing process. It is not directly involved in the therapy, which focuses on preventing the binding of the spliceosome and causing exon skipping.\\n- **PolyA tail (B)**: The polyA tail is added to the 3' end of the mRNA after splicing. It's not directly involved in the proposed therapy.\\n- **R-loops (C)**: R-loops are a type of RNA-DNA hybrid structure that can form during transcription. They are not directly involved in the proposed therapy.\\n\\nGiven the information, the structure not involved in the proposed therapy is the lariat.\\n\\nAnswer: A<|eot_id|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process described:\\n\\n1.  A Morpholino is delivered to the pre-mRNA, which is the precursor to mRNA.\\n2.  The Morpholino recognizes the 5' end of the out-of-frame exon.\\n3.  It prevents the binding of the spliceosome, which is a complex of proteins that assembles on the pre-mRNA and facilitates the splicing process.\\n4.  As a result, the pre-mRNA undergoes exon skipping and in-frame joining, meaning that the out-of-frame exon is skipped, and the remaining exons are joined in a way that results in a frame that is in-frame.\\n\\nNow, let's examine the options given:\\n\\nA) lariat: A lariat is a type of RNA structure that forms during the splicing process, specifically in the form of a lariat-shaped loop that is formed when the intron is removed. While it's involved in splicing, it's not directly involved in the therapy described.\\n\\nB) polyA tail: The polyA tail is a feature of mature mRNA, which is added after splicing has occurred. It's not directly involved in the splicing process or the therapy described.\\n\\nC) R-loops: R-loops are a type of RNA-DNA hybrid structure that can form during transcription and can be involved in the regulation of gene expression. However, they are not directly involved in the splicing process or the therapy described.\\n\\nD) antisense: Antisense oligonucleotides, like Morpholinos, are designed to bind to specific sequences of RNA and can be used to interfere with gene expression. The Morpholino in the therapy described is an antisense oligonucleotide.\\n\\nGiven the information above, the structures not directly involved in the proposed therapy are lariat, polyA tail, and R-loops.\\n\\nAnswer: ACD<|eot_id|>\"], 'correct': [False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, True, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, True, False, False, False, False, False, False, False, False, False, True, False, True, False, True, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, True, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, True, False, False, False, False, False], 'explanations': [\"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='B'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='C'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='A'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='C'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\"], 'num_tokens': [288, 353, 361, 386, 326, 413, 336, 438, 310, 429, 302, 373, 512, 460, 512, 374, 346, 405, 410, 336, 322, 329, 360, 512, 347, 341, 328, 421, 478, 362, 457, 433, 386, 354, 331, 419, 426, 424, 371, 320, 455, 267, 344, 291, 324, 271, 365, 343, 367, 340, 334, 320, 331, 409, 404, 382, 302, 362, 302, 462, 461, 362, 432, 325, 391, 439, 464, 316, 317, 383, 316, 293, 318, 366, 318, 427, 399, 457, 346, 357, 415, 375, 368, 423, 323, 357, 406, 358, 470, 435, 267, 336, 512, 338, 383, 406, 365, 269, 329, 489, 321, 451, 391, 447, 371, 338, 512, 464, 312, 251, 357, 389, 419, 340, 436, 393, 498, 485, 422, 423, 482, 324, 356, 290, 439, 467, 347, 393], 'rewards': [0.11181640625, 0.11865234375, 0.1103515625, 0.10546875, 0.119140625, 0.10302734375, 0.115234375, 0.11474609375, 0.1162109375, 0.10693359375, 0.1201171875, 0.11767578125, 0.056640625, 0.119140625, 0.053466796875, 0.11572265625, 0.11669921875, 0.0693359375, 0.10302734375, 0.1201171875, 0.11572265625, 0.111328125, 0.12451171875, 0.12109375, 0.1171875, 0.11865234375, 0.11181640625, 0.111328125, 0.12158203125, 0.11865234375, 0.10302734375, 0.1162109375, 0.115234375, 0.11669921875, 0.1123046875, 0.11962890625, 0.115234375, 0.11181640625, 0.1064453125, 0.107421875, 0.1083984375, 0.10546875, 0.1123046875, 0.1103515625, 0.119140625, 0.11474609375, 0.11865234375, 0.12158203125, 0.1171875, 0.123046875, 0.11767578125, 0.11328125, 0.11962890625, 0.103515625, 0.10986328125, 0.11181640625, 0.11865234375, 0.1025390625, 0.10009765625, 0.1171875, 0.12158203125, 0.11865234375, 0.10400390625, 0.11083984375, 0.1064453125, 0.09765625, 0.10107421875, 0.10009765625, 0.119140625, 0.103515625, 0.11962890625, 0.10400390625, 0.115234375, 0.1123046875, 0.1162109375, 0.10595703125, 0.11376953125, 0.111328125, 0.1162109375, 0.11083984375, 0.09912109375, 0.11572265625, 0.1171875, 0.10986328125, 0.1044921875, 0.12451171875, 0.0986328125, 0.1123046875, 0.1259765625, 0.10693359375, 0.10791015625, 0.1162109375, 0.044677734375, 0.1083984375, 0.08837890625, 0.10791015625, 0.11474609375, 0.12060546875, 0.11474609375, 0.11279296875, 0.10986328125, 0.10498046875, 0.107421875, 0.10009765625, 0.11572265625, 0.125, 0.05712890625, 0.11669921875, 0.10693359375, 0.11669921875, 0.11865234375, 0.11376953125, 0.1123046875, 0.12158203125, 0.10205078125, 0.1083984375, 0.1142578125, 0.10888671875, 0.11181640625, 0.11083984375, 0.1083984375, 0.1123046875, 0.10888671875, 0.1103515625, 0.10595703125, 0.1279296875, 0.11962890625, 0.1005859375], 'ground_truths': ['C'], 'question_meta': None, 'model_name': 'hf_chat:meta-llama/Llama-3.1-8B-Instruct', 'reward_model_name': 'armo_rm:RLHFlow/ArmoRM-Llama3-8B-v0.1'}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 42%|â–ˆâ–ˆâ–ˆâ–ˆâ–     | 5/12 [00:14<00:22,  3.16s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'qid': 'gpqa-1', 'prompt': \"Answer the following multiple choice question. The last line of your response should be of the following format: 'Answer: $LETTER' (without quotes) where LETTER is one of ABCD. Think step by step before answering.\\n\\nA large gene has dozens of exons, of which the central ones code for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space. Each exon usually codes for one folded triple alpha helix. The most common mutations of the gene are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste. A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. The molecule prevents binding of the spliceosome and creates exon skipping and in-frame joining. Several missing exons are well tolerated by an organism. Which structure below is not involved in the proposed therapy?\\n\\nA) lariat\\nB) polyA tail\\nC) R-loops\\nD) antisense\", 'answers': [\"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>\\nAlright, so I've got this question about gene therapy using Morpholinos. Let me try to break it down step by step. I'm a bit rusty on this, but I'll think through it.\\n\\nOkay, the question is about a therapy where a Morpholino is used to deliver a mutation. The setup is that a gene has many exons, and the central ones code for folded triple alpha helices. These helices connect the cytoskeleton with the sarcolemma and extracellular space. Each exon usually codes for one of these helices.\\n\\nThe problem is that the mutations are central exon deletions causing out-of-frame peptides and progressive degeneration. So, the idea is to prevent the spliceosome from binding and instead cause exon skipping. This way, the missing exons aren't included, and the protein is in-frame.\\n\\nSo the Morpholino binds to the 5' end of the out-of-frame exon in pre-mRNA. By doing this, it prevents the spliceosome from recognizing the site, leading to exon skipping. That makes sense because the spliceosome usually recognizes the 5' splice site and the 3' splice site. If the Morpholino is there, it might block the spliceosome from binding or causing it to skip.\\n\\nNow, the question is asking which structure isn't involved in this therapy. The options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nWait, what's a lariat? Oh right, during RNA splicing, the spliceosome forms an lariat structure when it connects the exons. But in this case, the Morpholino is preventing the spliceosome from binding. So the lariat isn't formed, right? Because the spliceosome isn't doing anything. So the lariat structure is not involved in this therapy.\\n\\nPolyA tail is involved in mRNA processing, especially during translation. The mRNA is transcribed, then processed into small RNA, which then gets translated into proteins. But the Morpholino is targeting the pre-mRNA, not the mRNA itself. So polyA tail is probably not involved here.\\n\\nR-loops are structures where an RNA strand is covalently linked to a DNA helix. But in this scenario, the Morpholino is a small RNA molecule that's being delivered into the nucleus. So R-loops aren't part of this process.\\n\\nAntisense is a type of RNA that binds to the target DNA sequence. It's used in gene editing, like in CRISPR. So antisense isn't involved here either.\\n\\nWait a second, but the question is about what's not involved. The therapy is about preventing the spliceosome from recognizing the site by using Morpholino. So the key here is that the spliceosome isn't involved in joining the exons anymore because the Morpholino is preventing it. So which structures are not involved?\\n\\nThe lariat structure is formed during splicing, but in this case, the spliceosome isn't doing anything. So the lariat isn't formed. So the lariat is not involved in this therapy.\\n\\nThe other structures are involved in the spliceosome function. So the answer should be A) lariat.\\n</think>\\n\\nTo determine which structure is not involved in the proposed therapy, let us analyze the scenario and the options provided:\\n\\n1. **Lariat structure**: During RNA splicing, the spliceosome forms an lariat structure when it connects exons. However, in this therapy, the Morpholino prevents the spliceosome from binding or recognizing the splice site, leading to exon skipping. Since no lariat structure is formed, the lariat structure is not involved in this therapy.\\n\\n2. **PolyA tail**: The polyA tail is involved in mRNA processing, particularly during translation. However, the Morpholino binds to pre-mRNA, not the mRNA itself, so the polyA tail is not directly involved in this therapy.\\n\\n3. **R-loops**: R-loops are structures where an RNA strand is covalently linked to a DNA helix. Since the Morpholino is a small RNA molecule being delivered into the nucleus, R-loops are not relevant to this process.\\n\\n4. **Antisense**: Antisense RNA is used in gene editing, such as in CRISPR, to bind to complementary DNA sequences. This is not involved in the Morpholino-mediated exon skipping therapy described in the question.\\n\\nThe therapy involves preventing the spliceosome from binding by using the Morpholino, which does not directly involve the lariat structure. Therefore, the lariat structure is not involved in this therapy.\\n\\nANSWER: A<ï½œendâ–ofâ–sentenceï½œ>\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>\\nOkay, so I'm trying to tackle this multiple-choice question about gene therapy using Morpholinos. Let me read through the question again to make sure I understand what's being asked.\\n\\nThe question describes a gene with several exons. The central ones code for folded triple alpha helices that connect the cytoskeleton, the sarcolemma, and the extracellular space. Each exon usually encodes one of these helices. The main issue here is that the common mutations are deletions in the central exons, leading to out-of-frame peptides and progressive degeneration. So, the idea is that delivering a Morpholino to the 5' end of these out-of-frame exons could help. The Morpholino would prevent the spliceosome from binding, causing exon skipping and in-frame joining, which would fix the problem.\\n\\nThe question then asks which structure isn't involved in this therapy. The options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nHmm, let's break down each part. Morpholinos are small RNA molecules that bind to mRNA, disrupting the splicing machinery. They can be used to target specific exons or introns for modification, like cleavage or splicing. In this case, the Morpholino is targeting the 5' end of an out-of-frame exon.\\n\\nSo, when the Morpholino binds to the mRNA, it prevents the spliceosome from recognizing the 5' splice site. This usually results in exon skipping, meaning the exon is removed, and the spliceosome then fills in the gap with the next exon. Since the target exon is out of frame, skipping it would fix the protein structure because the exon is removed. The therapy is supposed to work even if the exon is missing, which is why the organism can tolerate it.\\n\\nNow, looking at the structures involved. Let's consider each option:\\n\\nA) Lariat: I remember that during splicing, the spliceosome forms an lariat structure from the pre-mRNA. This happens when the splice sites are recognized and the introns are removed. So, the lariat is part of the splicing process. Therefore, lariat is involved. So this option is not the answer.\\n\\nB) PolyA tail: The polyA tail is a common feature of prokaryotic and some eukaryotic mRNA. It's involved in mRNA stability and translation. In eukaryotes, the polyA tail is recognized by the ribosome and is important for translation. But in the question, the therapy is about modifying the pre-mRNA, not about translation. So, the polyA tail isn't involved here. So, B might be the correct answer.\\n\\nC) R-loops: R-loops are RNA structures formed when an RNA strand is antiparallel to the primary structure of another RNA, creating a loop. They can form during transcription, like in the process of RNA splicing or in the initial stages of transcription. Morpholinos don't form R-loops themselves. Instead, they bind to the mRNA. So, R-loops are not part of the therapy process. So, C is not involved, making it a possible answer.\\n\\nD) Antisense: Antisense RNA is complementary to a target mRNA and can inhibit its translation. It's often used to target specific mRNAs for degradation or modification. In this case, the Morpholino isn't antisense; it's the RNA that binds the mRNA to cause splicing changes. So, D is not involved in this therapy.\\n\\nWait, but wait. Let me double-check. The question is which structure is NOT involved. So the therapy doesn't involve making R-loops because that's more of a structural change in the RNA during transcription. The Morpholino is binding to the mRNA, not creating any structures like R-loops.\\n\\nSo, the options are between B and C. The therapy involves Morpholinos binding to the pre-mRNA, preventing the spliceosome from recognizing the splice sites. This doesn't create any new structures like lariat or polyA tail. R-loops are formed during RNA processing, like in splicing, but the Morpholino itself doesn't form them. So, R-loops are not involved. Therefore, C is not involved.\\n\\nWait, but the question is which structure is NOT involved. So the answer is either B or C.\\n\\nWait, the therapy is about modifying the mRNA. The pre-mRNA is being targeted by the Morpholino. So, during this process, the mRNA is spliced, and the spliceosome is involved in the splicing, but the Morpholino is not making any structures. So, the structures involved are the lariat (from splicing), polyA tail (not involved), R-loops (not involved), and antisense (not involved). So, the structure not involved is either B or C.\\n\\nWait, the polyA tail is present in the pre-mRNA. The therapy doesn't affect translation because it's about splicing, not translation. So the polyA tail is present and is part of the mRNA. So the therapy doesn't involve modifying the polyA tail. Therefore, B) polyA tail is not involved.\\n\\nBut wait, the question is which structure is NOT involved. So the options are:\\n\\nA) lariat: involved.\\n\\nB) polyA tail: involved in the mRNA but not in the splicing process. So, polyA tail is present but not part of the splicing step.\\n\\nC) R-loops: not involved in the splicing process. So, not involved.\\n\\nD) antisense: not involved.\\n\\nSo the question asks which structure is NOT involved. So the correct answer would be either B or C.\\n\\nWait, but the question is about which structure is not involved in the therapy. The therapy doesn't involve R-loops because they form during RNA processing, not splicing. The polyA tail is part of the mRNA and is present, but the therapy doesn't involve modifying it. So the therapy's process doesn't require the polyA tail.\\n\\nSo the structures not involved are polyA tail and R-loops. But the options are A, B, C, D. So the question is which is NOT involved.\\n\\nWait, the options are:\\n\\nA) lariat: part of the splicing process.\\n\\nB) polyA tail: present in mRNA, but not part of the splicing process.\\n\\nC) R-loops: formed during RNA processing.\\n\\nD) antisense: not involved.\\n\\nSo the structures not involved would be B and C. But the question is which is not involved. The options are four, and only one is correct.\\n\\nWait, the question is about the structures involved in the therapy. So, the therapy involves the Morpholino binding to the mRNA, preventing the spliceosome from recognizing the splice sites. This would prevent the formation of a lariat (since the spliceosome forms the lariat during splicing) but the polyA tail is a separate feature of the mRNA. The R-loops form during RNA processing, not in splicing. The antisense RNA is not involved in this therapy.\\n\\nSo, which of these structures is not involved? The therapy doesn't involve making R-loops, polyA tail is present but not part of the splicing, and antisense is not involved. So the correct answer is either B or C.\\n\\nWait, but the question is about the structures involved in the therapy. So, the therapy involves the Morpholino binding to the mRNA, which is part of the splicing process. So the structures that are part of the splicing process are lariat (A), polyA tail is part of the mRNA (B), R-loops are part of RNA processing (C), and antisense is not involved (D).\\n\\nSo, the question is which structure is NOT involved in the therapy. So the correct answer is the one that's not part of the splicing process or the process the Morpholino is targeting.\\n\\nSo, the structures not involved are B and C. But the options are four, and the question expects one correct answer.\\n\\nWait, another way: the therapy uses Morpholino to bind the mRNA, which prevents the spliceosome from recognizing the 5' splice site. So the spliceosome isn't forming a lariat because it's not recognizing the site. The polyA tail is a part of the mRNA, but the therapy doesn't involve the polyA tail. The R-loops are not part of the splicing process; they are formed during transcription or RNA processing. So, the structures not involved are B) polyA tail and C) R-loops.\\n\\nBut the question is which structure is not involved. So the options are B, C, D, or A.\\n\\nWait, the question is asking which structure is NOT involved. So, the options are:\\n\\nA) lariat: involved.\\n\\nB) polyA tail: part of the mRNA, but not part of the splicing process.\\n\\nC) R-loops: part of RNA processing, not splicing.\\n\\nD) antisense: not involved.\\n\\nSo, the structures not involved are B, C, and D. But the options are given as A to D, and only one is correct.\\n\\nWait, the question is which structure is not involved. So the correct answer would be the structure that's not part of the process. So, the structures involved are A (lariat), B (polyA), C (R-loops), and D (antisense) is not involved.\\n\\nSo the structure not involved is either B, C, or D.\\n\\nWait, the question is which structure is not involved. So, the therapy uses Morpholino to block the spliceosome from binding the mRNA. The process of blocking the spliceosome doesn't create any of the structures listed except for the lariat.\\n\\nWait, no. The lariat is formed during the splicing process, so it's involved. So, the structures\", '<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>\\nOkay, I\\'m trying to tackle this multiple-choice question about gene therapy using Morpholinos. Let me go through it step by step.\\n\\nSo, the question describes a gene with several exons. The central exons code for folded triple alpha helices, which connect the cytoskeleton, sarcolemma, and extracellular space. Each exon usually codes for one such helix. The common mutations are deletions in the central exons, leading to out-of-frame peptides and progressive degeneration. To fix this, they\\'re using a Morpholino that binds to the 5\\' end of the out-of-frame exon in pre-mRNA. This prevents the spliceosome from joining the exons, causing exon skipping and in-frame joining.\\n\\nNow, the question is asking which structure isn\\'t involved in this therapy.\\n\\nThe options are A to D: lariat, polyA tail, R-loops, antisense.\\n\\nHmm. Let me think about each option.\\n\\nOption A: Lariat. Lariats are part of introns, right? When introns are spliced, they form an intron lariat structure. So during splicing, introns are removed and the lariat forms. But in this case, Morpholinos are acting on exons, not introns. So the therapy doesn\\'t form lariat structures. So the lariat is not involved.\\n\\nOption B: PolyA tail. PolyA is a long tail at the end of mRNA, often involved in translation initiation. Since the therapy is about disrupting exon skipping and joining, it\\'s more about mRNA processing and structure, not polyA. So polyA tail might not be involved. But wait, I\\'m not sure.\\n\\nOption C: R-loops. R-loops are regions where RNA forms a loop with a complementary region, often due to RNA-RNA or RNA-è›‹ç™½è´¨ interactions. Morpholinos are RNA molecules. When they bind the 5\\' end of the exon, they might form secondary structures. If the exon is bound by the Morpholino, perhaps they form an R-loop with the complementary sequence. Or maybe it\\'s an RNA-induced silencing complex (RISC) involved in splicing. But I\\'m not sure if R-loops are part of the process. Alternatively, the spliceosome doesn\\'t usually form R-loops, but in this therapy, the Morpholino might interact with the exon, perhaps forming a structure that affects splicing. So R-loops might be involved.\\n\\nOption D: Antisense. Antisense RNA is used for RNA interference (RNAi) to target specific mRNA sequences. The Morpholino is a type of antisense RNA. So yes, the antisense is involved in the therapy.\\n\\nSo the question is, which structure is NOT involved. Let\\'s see:\\n\\nThe therapy involves disrupting the spliceosome by binding the Morpholino to the 5\\' end of the out-of-frame exon. This would prevent the spliceosome from joining, leading to exon skipping and in-frame joining.\\n\\nSo, during splicing, introns are removed. But the therapy isn\\'t affecting introns, so structures like lariats (in A) aren\\'t involved. PolyA tails are about mRNA processing, not splicing.\\n\\nWait, but the therapy is about disrupting the spliceosome by preventing it from splicing the exon. So the spliceosome is involved in splicing, but the therapy doesn\\'t create new introns. So structures like lariats are intronic, so not involved in the therapy. The polyA tail is about the end of the mRNA, which isn\\'t directly involved in the therapy.\\n\\nWait, but the question is about what\\'s not involved. The therapy doesn\\'t directly form a polyA tail. The therapy is about exon skipping, which involves splicing, but the polyA tail is about the mRNA\\'s structure. So the polyA tail isn\\'t involved in the therapy.\\n\\nBut wait, the question says which structure is not involved. Let\\'s think again.\\n\\nThe therapy is about disrupting splicing by Morpholino binding. The spliceosome is involved in splicing, but the structure that\\'s not involved would be something unrelated to that process.\\n\\nSo, the options:\\n\\nA) Lariat - intronic lariats are involved in intron removal, which is part of splicing, but the therapy doesn\\'t cause that. So this structure is not involved.\\n\\nB) PolyA tail - is involved in mRNA processing, but not in the therapy\\'s process of splicing.\\n\\nC) R-loops - perhaps the Morpholino forms R-loops with the exon\\'s complementary sequences. That could affect splicing. So R-loops are involved.\\n\\nWait, but the therapy\\'s main effect is exon skipping, which is about the spliceosome. So the R-loops are perhaps a side effect, but the therapy itself doesn\\'t create them. So the R-loops are involved in the process, but the question is which is NOT involved.\\n\\nWait, the question is about which structure is not involved. So the therapy uses Morpholino, which is antisense. So D) is involved.\\n\\nThe therapy doesn\\'t involve a polyA tail, but the question is which is not involved. So the therapy itself doesn\\'t create a polyA tail, but the question is about the structures involved in the therapy process.\\n\\nWait, the therapy doesn\\'t create any of the structures mentioned except for antisense (D) and lariat (A), perhaps.\\n\\nWait, the therapy involves disrupting spliceosome function by binding to the exon. So the spliceosome is not directly involved in the structure formation, but the therapy is about exon skipping. So the spliceosome is part of the process, but not the structure.\\n\\nSo the structures involved would be antisense (D), which is part of the therapy. So which structures are not involved?\\n\\nA) Lariat: involved in splicing (intron lariats) but not in the therapy. So the therapy doesn\\'t form any lariats, so A is not involved.\\n\\nB) PolyA tail: involved in mRNA processing, but the therapy is about splicing, so this is not involved.\\n\\nC) R-loops: possible, but the therapy\\'s primary effect is exon skipping, which involves the spliceosome. So R-loops are a side effect.\\n\\nWait, the question is about which structure is NOT involved. So the therapy involves antisense (D), but doesn\\'t involve polyA (B). So if the question is which is not involved in the therapy, the answer would be B or A.\\n\\nWait, the therapy is about disrupting the spliceosome, which involves the spliceosome\\'s function. So the spliceosome isn\\'t creating any structures; it\\'s about removing introns.\\n\\nSo the structures not involved would be the ones unrelated to splicing. So the polyA tail (B) is not involved in splicing. Similarly, the lariat (A) is involved in splicing, but the therapy doesn\\'t create any lariats. So the therapy doesn\\'t create lariats.\\n\\nWait, but the question is which structure is not involved. So the therapy doesn\\'t create a lariat, so A is not involved. The therapy doesn\\'t create a polyA tail, so B is not involved. The R-loops might be a side effect, but the question is about the structures involved in the therapy.\\n\\nBut wait, the therapy itself doesn\\'t form any of these structures. So the structures that are not involved would be the ones that are not part of the process.\\n\\nWait, the question says: \"which structure below is not involved in the proposed therapy?\" So, all structures involved in the therapy are part of the process, so the one that\\'s not involved is the correct answer.\\n\\nThe therapy involves antisense RNA (D) which is used as the Morpholino. It\\'s not creating any of the structures. So D is involved. The therapy doesn\\'t create a lariat, so A is not involved. The therapy doesn\\'t create a polyA tail, so B is not involved. The R-loops are perhaps a side effect, not part of the therapy.\\n\\nSo which of the four is not involved in the therapy? The options are A, B, C, D. The question is which is not involved.\\n\\nThe therapy involves antisense (D), so D is involved. The therapy doesn\\'t create lariats, so A is not involved. The therapy doesn\\'t create polyA tails, so B is not involved. R-loops are a side effect, so not involved.\\n\\nBut the question is about the structures that are not involved. So which one is not part of the therapy\\'s process.\\n\\nWait, the therapy\\'s process doesn\\'t involve any of the structures except for the antisense RNA. So the structures that are not involved are the polyA tail (B) and the lariat (A). So which is not involved? The question asks which is not involved.\\n\\nWait, but the therapy doesn\\'t cause the formation of any of these structures. So the structures not involved are B (polyA) and A (lariat). But the options are single letters.\\n\\nWait, the question is, which structure is not involved. So the correct answer would be the structure that\\'s not part of the therapy. The therapy doesn\\'t create any of the structures, so all the options except one are not involved.\\n\\nWait, the options are A to D.\\n\\nThe therapy doesn\\'t involve the lariat, polyA tail, or R-loops. So which of these is not involved in the therapy. So the correct answer is the one not part of the therapy.\\n\\nLooking at the options:\\n\\nA) Lariat: involved in splicing, but the therapy doesn\\'t create lariats, so not involved.\\n\\nB) PolyA tail: involved in mRNA processing, but not in splicing, so not involved.\\n\\nC) R-loops: possible side effect, not part of the therapy.\\n\\nD) Antisense: used, so involved.\\n\\nThe question is asking', \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>\\nOkay, so I've got this question about gene therapy using Morpholinos. Hmm, I'm a bit rusty on this, but I'll try to think it through.\\n\\nThe question says that a large gene has several exons. The central exons code for folded triple alpha helices that connect the cytoskeleton, the sarcolemma, and the extracellular space. Each exon codes for one such helix. The mutations here are central exon deletions, leading to out-of-frame peptides. That makes sense because out-of-frame mutations can cause issues like nonsense-mediated decay.\\n\\nThe therapy they're talking about is using a Morpholino. Morpholinos are antisense oligonucleotides that block RNA splicing factors. They bind to the 5' end of the pre-mRNA. So, if the Morpholino binds there, the spliceosome can't recognize the end, right? That should prevent the spliceosome from splicing the exon, leading to exon skipping. Exon skipping allows the introns to be joined in-frame, which is better for the organism.\\n\\nThe therapy works because the Morpholino prevents the spliceosome from recognizing the 5' splice site. This would lead to skipping of the exon, which fixes the reading frame and makes the protein more functional.\\n\\nNow, the question asks which structure is NOT involved in this therapy. The options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nLet me think about each structure.\\n\\nOption A: Lariat. Lariat structures are formed during RNA splicing when the intron is joined. The spliceosome uses a 5' splice site and a 3' splice site to join the introns, creating a lariat structure. But in this therapy, the spliceosome doesn't bind the Morpholino, so it doesn't join. So the lariat isn't formed here. Wait, but waitâ€”the therapy doesn't form a lariat. So perhaps the lariat is not involved.\\n\\nOption B: PolyA tail. Morpholinos are antisense, so they can interact with the polyA tail. In some cases, they can bind the polyA signal. But in this question, the Morpholino is designed to bind the 5' end of the out-of-frame exon. So it's not directly interacting with the polyA tail, but perhaps in some cases, the antisense can recruit factors that have a polyA binding domain. But the question is about the therapy's mechanism, not the structure involved in the process. So I'm not sure if polyA is involved here. Maybe it's not part of the therapy's mechanism.\\n\\nOption C: R-loops. R-loops are RNA structures formed when a nucleotide pair is within the same RNA molecule, creating a loop. Morpholinos binding could disrupt these structures, but I'm not sure how that ties into the therapy. The therapy is about exon skipping via antisense, not about R-loops being formed or avoided. So maybe R-loops aren't involved in this process.\\n\\nOption D: Antisense. The Morpholino is an antisense oligo, so D is definitely involved.\\n\\nWait, the question is about which structure is NOT involved. So the therapy doesn't directly form lariats, but the question is about which structure isn't part of the therapy. So if the therapy doesn't involve R-loops or polyA, then those are not involved. Or, maybe the lariat is formed normally, but in this therapy, it's prevented.\\n\\nWait, the question is which structure is NOT involved. So the therapy is about preventing the spliceosome from joining. The process doesn't form any lariats because the spliceosome isn't joining. So the lariat isn't involved.\\n\\nAlternatively, the therapy may involve R-loops or polyA. For example, if the Morpholino is binding to the polyA signal, which is in the polyA tail, then the polyA tail is involved. Similarly, if it's forming a loop within the intron, then R-loops are involved.\\n\\nBut the question is about the structures not involved in the therapy, not about the structures that are involved in the process of preventing splicing.\\n\\nSo the therapy doesn't directly involve R-loops or polyA. Let's think again.\\n\\nThe therapy is about preventing the spliceosome from binding the exon. So the structures that are not involved would be those that are not part of the spliceosome's function or the Morpholino's interaction.\\n\\nThe spliceosome's main function is to recognize the 5' splice site, 3' splice site, and the intron. The lariat is the result of joining introns, which isn't happening here. So the lariat isn't formed, but the spliceosome isn't involved in creating it.\\n\\nWait, the question is which structure is NOT involved. So the therapy is using the antisense Morpholino to prevent the spliceosome from binding the exon. So the structures involved in the therapy would include the antisense oligonucleotide (which is D), but not R-loops or polyA.\\n\\nSo the structures not involved are R-loops (C) and polyA tail (B). Wait, but the question is about which is not involved. The therapy doesn't form lariats, but the question is about which structure is not part of the therapy.\\n\\nWait, the therapy is about preventing the spliceosome from joining the exon. The spliceosome's function is not directly tied to these structures. So the structures involved in the therapy are the antisense (D) and the Morpholino binding to the exon (as per the question). The structures not involved would be those that are not part of the therapy's mechanism.\\n\\nSo the options:\\n\\nA) Lariat: Not involved, because the spliceosome isn't joining. But wait, does the lariat form normally, and the therapy prevents that. So the lariat isn't formed in the therapy. But the question is about structures not involved. So the lariat is a structure formed during normal splicing, but not in the therapy. So the therapy doesn't form lariat. So the structure that isn't involved in the therapy is the lariat (A). Because the therapy doesn't involve lariat formation.\\n\\nAlternatively, perhaps the lariat is formed when the spliceosome acts, but in this case, it doesn't. So the therapy doesn't involve lariats. So the structure not involved is the lariat (A).\\n\\nWait, but the question is which structure is NOT involved in the proposed therapy. The therapy doesn't form lariats, but the therapy doesn't use R-loops or polyA. So the structures involved in the therapy are the antisense and the Morpholino binding.\\n\\nSo the structures not involved are R-loops and polyA.\\n\\nBut the question is which structure is NOT involved. So the options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nThe therapy doesn't form lariats, so the lariat is not involved. So the structure not involved is the lariat (A). So the answer would be option A.\\n</think>\\n\\nThe question involves a large gene with exons coding for folded triple alpha helices and a Morpholino therapy to prevent exon skipping. The therapy uses a Morpholino that binds the 5' end of an out-of-frame exon, preventing the spliceosome from splicing the exon. The goal is to identify which structure is not involved in this therapy.\\n\\n### Analysis of the Options:\\n\\n1. **Option A: Lariat**  \\n   Lariats are RNA structures formed during intron splicing when the spliceosome joins introns. In this therapy, the spliceosome is prevented from splicing the exon, so intron splicing does not occur. However, lariats are not formed in this process, so they are not involved in the therapy. \\n\\n2. **Option B: PolyA Tail**  \\n   Morpholinos can sometimes interact with the polyA tail, especially if antisense oligonucleotides have a polyA binding domain. While this interaction might occur, the question focuses on the mechanism of the therapy, which is about preventing intron splicing rather than polyA tail involvement. Thus, polyA tail is not explicitly involved in the therapy.\\n\\n3. **Option C: R-loops**  \\n   R-loops are RNA structures formed within the same RNA molecule, which can interfere with splicing. However, the question does not mention any mechanism related to R-loops or their formation. Therefore, R-loops are not directly involved in the therapy.\\n\\n4. **Option D: Antisense**  \\n   The Morpholino is an antisense oligonucleotide designed to bind the 5' end of the exon. This makes it an essential component of the therapy, and it is explicitly mentioned in the question.\\n\\n### Conclusion:  \\nThe therapy does not involve lariats, R-loops, or polyA tails. The key structure involved is the antisense Morpholino. Therefore, the structure **lariat** is not involved in the proposed therapy.\\n\\nANSWER: A<ï½œendâ–ofâ–sentenceï½œ>\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>\\nOkay, so I have this multiple-choice question about gene therapy and Morpholinos. Let me try to figure this out step by step. \\n\\nThe question is about a gene that has many exons, and the central ones code for triple helical repeats connecting the cytoskeleton, sarcolemma, and extracellular space. Each exon is supposed to code for one of these repeats. But the problem is that the mutations are deletions in the central exons, leading to out-of-frame peptides. Oh right, so these deletions cause the mRNA to be misread, resulting in premature stop codons and nonfunctional proteins because the reading frame is messed up. These are called progressive degenerative organ wastes. \\n\\nThe therapy proposed is using a Morpholino to target the 5' end of the out-of-frame exon in pre-mRNA. Morpholinos are antisense oligonucleotides that bind to the RNA and inhibit transcription. So the idea is that by blocking the spliceosome, which usually splices out the exon, the spliceosome can't act, so the exon is skipped. This leads to in-frame joining, meaning the mRNA is joined back together without the skipped part, restoring the original reading frame. But wait, the question says several missing exons are well tolerated by the organism. So the therapy doesn't cause the exon to be entirely skipped but leads to exon skipping and in-frame joining.\\n\\nNow, the question is about which structure isn't involved in this therapy. The options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nI remember that in RNA processing, lariat structures are formed during splicing. The spliceosome forms a lariat by connecting the exons through the 5' splice site and the 3' splice site. But in this case, the Morpholino is preventing the spliceosome from splicing, so the exon isn't cut. So the lariat structure isn't formed because the exon isn't being spliced. But wait, the question is about the structures involved in the therapy, not the outcome. So the therapy doesn't form a lariat, but the therapy does prevent splicing. So the structures involved are things like the spliceosome, antisense Morpholino, and the lack of lariat formation. But the question is which structure isn't involved. So the lariat isn't part of the therapy; it's a product of normal splicing. So option A is the structure not involved.\\n\\nPolyA tail is involved in mRNA stability and translation. If the mRNA is being processed, the polyA tail is present. So option B is involved, but the question is about which structure isn't involved. So if the therapy doesn't involve forming a polyA tail, then B is involved, but the question is which structure isn't involved. So if the therapy doesn't create a polyA tail, that's not involved.\\n\\nWait, but wait. The therapy doesn't create a polyA tail. The polyA tail is a structural component of mRNA, part of the processing machinery. The Morpholino doesn't add a polyA tail; it's an antisense oligo that inhibits splicing. So the polyA tail is present as part of the mRNA, so B is involved in the therapy, but it's not the structure that isn't involved. Because the question is which structure is not involved. So option B is involved, so it's not the correct answer.\\n\\nR-loops are structures formed when RNA forms a base-paired structure, often involving the RNA and proteins. They can be found in regions where RNA is interacting with proteins. Do Morpholinos involve R-loops? Well, the Morpholino is an antisense oligo, which would bind to the RNA. If the Morpholino binds to a site that's part of a loop, that would form an R-loop. But the question doesn't specify that the Morpholino forms a loop, just that it's antisense and binds the 5' end of the exon. So the R-loop isn't necessarily involved in the therapy process itself. However, since the question is which structure is not involved, the structure that's not involved would be one that doesn't get created or used in the therapy. If the Morpholino doesn't form an R-loop, then option C is not involved. But the question is about which structure is not involved in the therapy. So if the therapy doesn't involve R-loops, then C is not involved. But the question is about the structures involved in the therapy process.\\n\\nWait, the therapy is about preventing the spliceosome from splicing the exon. So the spliceosome is part of the machinery. The Morpholino binds to the RNA, preventing splicing. So structures involved are the spliceosome, antisense Morpholino, and the lack of lariat formation. The R-loops are a result of the spliceosome processing. So in the process of splicing, R-loops are formed. So the R-loop is involved in the splicing process, so the structure involved in the therapy's process is the R-loop. So option C is involved. So the structure that is not involved is option A (lariat) because the lariat is a product of normal splicing, not part of the therapy.\\n\\nAlternatively, the therapy doesn't involve lariat formation, so the lariat is not involved. So the correct answer would be A) lariat is not involved. Because the therapy doesn't create a lariat; it's preventing splicing, so the lariat isn't formed. \\n\\nAnother angle: The question is about which structure is not involved in the therapy. The therapy uses a Morpholino to prevent the spliceosome from splicing. The spliceosome normally forms lariat structures. So the lariat is part of the normal RNA processing. The therapy doesn't create a lariat, so the structure not involved is the lariat. Therefore, the correct answer is option A.\\n</think>\\n\\nTo address the question, we analyze the proposed therapy and identify which structure is not involved in the process. The therapy involves delivering a Morpholino, an antisense oligonucleotide, to prevent the spliceosome from splicing out an out-of-frame exon. This prevents the exon from being joined back together, resulting in exon skipping and in-frame joining. \\n\\n### Analysis of Options:\\n1. **Option A: Lariat**  \\n   During normal RNA splicing, the spliceosome forms lariat structures by connecting exons through the 5' splice site and the 3' splice site. However, in this therapy, the spliceosome is prevented from splicing, so the lariat structure is not formed. Therefore, the lariat structure is not involved in the therapy.\\n\\n2. **Option B: PolyA Tail**  \\n   The polyA tail is a structural component of mRNA that protects it from degradation and is involved in mRNA stability and translation. While the polyA tail is present in the mRNA, it is not part of the therapy process itself. Thus, the polyA tail is involved in the organism's normal mRNA processing but is not the structure not involved in the therapy.\\n\\n3. **Option C: R-loops**  \\n   R-loops are base-paired structures formed during RNA processing, often involving interactions between RNA and proteins. While the Morpholino binds to the RNA and can potentially form an R-loop, this is not a defining feature of the therapy itself. The therapy primarily involves preventing splicing, not forming R-loops.\\n\\n4. **Option D: Antisense**  \\n   The Morpholino is an antisense oligonucleotide that binds to the RNA and inhibits splicing. This is a key component of the therapy, as it prevents the spliceosome from splicing the exon.\\n\\n### Conclusion:\\nThe therapy involves preventing splicing by binding the Morpholino to the RNA, but it does not involve the formation of lariat structures or R-loops. The polyA tail is present in the mRNA but is not part of the therapy process. Therefore, the structure not involved in the therapy is the **lariat**.\\n\\nANSWER: A<ï½œendâ–ofâ–sentenceï½œ>\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>\\nOkay, so I have this question about gene therapy using Morpholinos and the spliceosome. Hmm, let me try to think it through.\\n\\nSo, the question says that a gene has several exons, and the central ones code for triple helical repeats. These repeats connect the cytoskeleton, the sarcolemma, and the extracellular space. Each exon usually codes for one of these repeats. The most common mutations are deletions in the central exons, creating out-of-frame peptides. Oh wait, that makes sense because out-of-frame mutations usually lead to frameshifts and thus the resulting peptides aren't in the correct reading frame, which messes up the protein structure.\\n\\nThe therapy in question is using a Morpholino to target the 5' end of this out-of-frame exon. Morpholinos are antisense oligonucleotides, right? So they bind to the mRNA, preventing the spliceosome from recognizing and splicing the exon. The spliceosome then skips the exon, so it doesn't process the mRNA as usual. That results in exon skipping, which would join the exons in frame because the exon is skipped, and the next exon continues seamlessly. This way, the out-of-frame peptide is replaced with a frame-aligned one, making the protein functional again.\\n\\nNow, the question is about which structure isn't involved in this therapy. The options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nLet me go through each option.\\n\\nOption A: Lariat. I remember that during splicing, the spliceosome uses the lariat structure to join the pre-mRNA with the mature mRNA. When the spliceosome is skipping an exon, it would form a lariat as part of the spliceosome mechanism. So this structure is involved, so A isn't the answer.\\n\\nOption B: PolyA tail. The polyA tail is part of the mRNA, especially in prokaryotes, but in eukaryotes, it's also present. The therapy doesn't directly involve the polyA tail; it's more about the splicing machinery. So B is involved in the process, so B isn't the answer.\\n\\nOption C: R-loops. R-loops are RNA structures where an RNA helix is wrapped around another RNA nucleic acid. They're involved in processes like transcription and RNA interference, but not directly in the splicing mechanism. So C is probably not involved in the therapy, making it a candidate for the correct answer.\\n\\nOption D: Antisense. Morpholinos are antisense molecules, so this is directly involved in the therapy. So D is involved, so it's not the answer.\\n\\nWait, but wait. Let me double-check. The therapy involves antisense binding of the Morpholino to the mRNA. So D is definitely involved.\\n\\nSo the structures involved are lariat (A), polyA tail (B), and antisense (D). The one not involved is C, R-loops.\\n</think>\\n\\nTo determine which structure is not involved in the proposed therapy, let us analyze each option:\\n\\n1. **Lariat (Option A):** During splicing, the spliceosome forms a lariat structure to join the pre-mRNA with the mature mRNA. This process is essential for exon skipping and in-frame joining, making the lariat structure involved in the therapy.\\n\\n2. **PolyA Tail (Option B):** The polyA tail is present in eukaryotic mRNA and plays a role in translation regulation. However, it is not directly involved in the splicing mechanism or the Morpholino therapy described in the question. Therefore, it is not involved in the therapy.\\n\\n3. **R-loops (Option C):** R-loops are RNA structures where an RNA helix is wrapped around another RNA nucleic acid. They are involved in processes like transcription and RNA interference but are not directly related to the splicing machinery or the Morpholino therapy described here. Thus, they are not involved in the therapy.\\n\\n4. **Antisense (Option D):** Morpholinos are antisense oligonucleotides that bind to the 5' end of pre-mRNA, preventing the spliceosome from splicing out an exon. This makes antisense directly involved in the therapy.\\n\\nBased on this analysis, the structure that is not involved in the proposed therapy is **R-loops**.\\n\\n**Answer: C**<ï½œendâ–ofâ–sentenceï½œ>\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>\\nOkay, so I've got this question about gene therapy and Morpholinos. Hmm, I'm a bit rusty on this, but let's think it through.\\n\\nThe question says that a gene has many exons, and the central ones code for triple helical repeats. Those repeats connect the cytoskeleton, sarcolemma, and extracellular space. Each exon is supposed to code for one such helix. Now, the mutations are deletions in the central exons, causing out-of-frame peptides. These mutations lead to progressive degeneration. The therapy is delivering a Morpholino that binds to the 5' end of the out-of-frame exon in pre-mRNA, preventing the spliceosome from joining it, which leads to exon skipping and in-frame joining. The therapy works well because the organism can tolerate missing exons.\\n\\nThe question is asking which structure isn't involved in this therapy. The options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nWait, Morpholinos are these antisense oligonucleotides that can bind to the 3' end of exons. They help in the splicing process by blocking the spliceosome from recognizing the exon. So in this case, the Morpholino binds to the 5' end of the out-of-frame exon, preventing it from being recognized by the spliceosome. This causes the exon to be skipped, right? So the spliceosome doesn't splice it, and the introns are joined in-frame, leading to a more functional protein.\\n\\nNow, the therapy works well because the organism can tolerate missing exons. So the therapy doesn't interfere with the spliceosome's normal function but just skips the problematic exon.\\n\\nLooking at the structures:\\n\\nA) Lariat: During splicing, the introns are joined with a lariat structure. The spliceosome uses a guide RNA to find the exon, and once it binds, the intron is connected to the downstream exon, forming a lariat. The lariat is important because it's necessary for the splicing machinery to recognize the correct reading frame. So lariat is involved.\\n\\nB) PolyA tail: The polyA tail is part of mRNA processing, especially in prokaryotes. It's made by the trimerization of the mRNA. I'm not sure if this is relevant here because the question is about gene therapy for a gene structure. Maybe not directly involved, but I'm not certain.\\n\\nC) R-loops: An R-loop is a structure where a base pair forms between an RNA helix and a DNA strand. They're often found in regions with high RNA-DNA interactions, like in certain promoters. The central exons here are coding for triple helical repeats, which might form some R-loops. But does the Morpholino therapy involve R-loops? Not directly, since the Morpholino would bind to the RNA, not DNA. So perhaps R-loops are not involved.\\n\\nD) Antisense: Morpholinos are antisense oligonucleotides. So they're designed to bind to the 3' end of an RNA transcript, leading to splicing. So antisense is involved in the therapy.\\n\\nWait, the question is about which structure is not involved. So the structures involved are the lariat, antisense (D), and maybe the R-loop (C). The polyA tail isn't directly involved in the splicing process or the therapy in this context.\\n\\nWait, but the therapy doesn't create any R-loops. The Morpholino binds the 5' end of the pre-mRNA, preventing it from being recognized by the spliceosome. So the R-loop (C) isn't involved.\\n\\nSo the structures not involved are the polyA tail (B) and R-loops (C). The question asks which structure is NOT involved. The question gives four options, so the correct answer is either B or C.\\n\\nWait, the question is phrased as which structure is not involved. So the therapy doesn't involve the polyA tail, the R-loop, or the lariat.\\n\\nWait, the therapy is about splicing. The lariat is involved because the spliceosome uses it. The polyA tail is part of mRNA processing, which is a separate process. The antisense is used as a guide. R-loops are RNA-DNA structures, unrelated to the splicing process here.\\n\\nSo the structures not involved are the polyA tail (B) and R-loops (C).\\n\\nLooking back at the question, the options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nSo the therapy doesn't involve the polyA tail, the R-loop, and the lariat. Wait, no: the therapy involves antisense (D), and the spliceosome uses the lariat (A). So structures not involved are polyA tail (B), R-loops (C), and lariat (A) is involved.\\n\\nWait, no. The question is which structure is not involved. So the therapy doesn't use the polyA tail. The R-loops are not involved in the therapy. So both B and C are not involved.\\n\\nBut the options are four choices, and only one is correct.\\n\\nWait, the question is which structure is not involved. So all four structures are not involved except perhaps one.\\n\\nWait, the therapy is about a Morpholino that binds to the 5' end of the out-of-frame exon. So the Morpholino is an antisense, so D is involved. The spliceosome uses a lariat, so A is involved. The polyA tail is part of the mRNA processing, so B is involved. R-loops are not involved because the Morpholino binds RNA, not DNA.\\n\\nSo the structures not involved are B (polyA tail) and C (R-loops).\\n\\nWait, but the question is about the structures NOT involved. So which of the four is not involved.\\n\\nThe question is which structure is not involved. So the correct answer would be the structures that are not part of the process.\\n\\nLooking again:\\n\\nThe therapy uses the spliceosome, which requires lariats (A is involved). The antisense (D) is used to bind the Morpholino.\\n\\nThe polyA tail is part of the mRNA, which is processed after the mRNA is made, so the polyA tail is not directly involved in the splicing process. It's more about mRNA stability and export, not the splicing.\\n\\nR-loops are RNA-DNA structures, which are not involved in the splicing or the therapy.\\n\\nSo which structures are not involved? The polyA tail (B) and R-loops (C) are not involved.\\n\\nBut the question only gives four options. The question asks which structure is NOT involved. So the options are A, B, C, D.\\n\\nThe structures involved are A, D, and (B and C are not involved). So the question is which structure is not involved.\\n\\nWait, the question says which structure is NOT involved. So the answer would be either B or C. But looking at the options, the correct answer is likely B) polyA tail or C) R-loops.\\n\\nWait, the problem is which structure is not involved. So, in the context of the therapy, the structures involved are:\\n\\n- Lariat (A) because it's part of the splicing mechanism.\\n\\n- Antisense (D) because it binds to the 5' end.\\n\\nThe polyA tail is part of mRNA processing, so it's not involved in the splicing process itself.\\n\\nR-loops are RNA-DNA, unrelated to the splicing process or the therapy.\\n\\nSo the structures not involved are B and C.\\n\\nBut the question is which structure is NOT involved. So which is not part of the therapy's mechanism.\\n\\nWait, the question says, which structure is not involved in the proposed therapy. So the therapy involves antisense, lariat, and the spliceosome, but not the polyA tail and R-loops.\\n\\nSo the structures not involved are B (polyA tail) and C (R-loops). But the options only have four choices, and the question asks which is NOT involved.\\n\\nLooking at the answer options, the correct answer should be either B or C. The question is, which of these four is NOT involved.\\n\\nThe question says, which structure is not involved in the proposed therapy. So the correct answer is either B or C. But the options are independent, so perhaps only one is correct.\\n\\nWait, the question is about which structure is not involved. So the therapy doesn't use the polyA tail, R-loops, or the lariat. So B and C are not involved. But the options only have B and C as not involved.\\n\\nWait, the question is asking which structure is NOT involved. So which of the four options is not used in the therapy.\\n\\nThe options are:\\n\\nA) Lariat\\n\\nB) PolyA tail\\n\\nC) R-loops\\n\\nD) Antisense\\n\\nSo the structures not involved are B (polyA tail) and C (R-loops). But the question is about which structure is not involved.\\n\\nWait, but in the options, the correct answer is either B or C. However, the question is which structure is not involved in the proposed therapy. Since the therapy doesn't involve the polyA tail, the R-loops, and the lariat.\\n\\nWait, but the question is about which structure is not involved. So the correct answer would be the structure that is not part of the process.\\n\\nWait, the lariat is involved because the spliceosome uses it. The antisense is used. The polyA tail is part of mRNA processing, so not involved in splicing. The R-loops are not involved.\\n\\nSo the structures not involved are B (polyA tail) and C (R-loops).\\n\\nBut the question gives four options, so the correct answer\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>\\nOkay, so I've got this multiple-choice question about gene therapy using Morpholinos, and I need to figure out which structure isn't involved. Let me break this down step by step.\\n\\nAlright, the question is about a gene with multiple exons. The central exons code for triple helical repeats that connect the cytoskeleton, sarcolemma, and extracellular space. Each exon usually codes for one folded triple alpha helix. The most common mutations are deletions in the central exons, leading to out-of-frame peptides and progressive degeneration. So, the idea is to use a Morpholino to address this.\\n\\nMorpholinos are small RNA molecules that can bind to exons. They're often used to disrupt the splicing machinery. In this case, the Morpholino binds to the 5' end of the out-of-frame exon in pre-mRNA. By doing so, it prevents the spliceosome from binding, which is responsible for joining the exons. This leads to exon skipping and in-frame joining, meaning the mRNA is joined correctly, resulting in a functional protein.\\n\\nThe question asks which structure isn't involved. The options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nWait, let me think about each structure.\\n\\nOption A: Lariat. In mRNA splicing, during the 5' to 3' direction, an intron is removed, and the exons are joined. The RNA forms a structure called an intron lariat. But wait, the Morpholino is preventing the spliceosome binding. I think the lariat is part of the splicing process, so it's involved.\\n\\nOption B: PolyA tail. PolyA tails are added during protein synthesis as a signal for termination of translation. The question doesn't mention anything about the polyA tail being involved here. The therapy is about disrupting splicing, not the RNA processing. So maybe the polyA tail isn't involved.\\n\\nOption C: R-loops. R-loops are RNA structures formed when RNA secondary structures, like hairpins or loops, form between two RNA molecules. I'm not sure if R-loops are part of this process. The Morpholino binds to the exon, but does it form any structures? It might be involved in RNA-DNA hybridization, but the question is about the structures involved in the therapy. Since the therapy uses the Morpholino to disrupt splicing, maybe R-loops aren't directly involved. Or perhaps the lariat is involved in the splicing process, so maybe the R-loop isn't involved. Hmm, not sure.\\n\\nOption D: Antisense. Antisense is an RNA molecule that binds to the same DNA as the target cDNA. It can act as a sponge or guide. The question doesn't mention antisense, so perhaps it's not involved here.\\n\\nWait, the therapy uses Morpholinos to bind the 5' end of the exon. So the Morpholino would be binding the mRNA. How does that work? The Morpholino would form a duplex with the mRNA, perhaps, or maybe it's part of the RNA-DNA hybridization. But the structures involved in the therapy are about splicing and mRNA processing. The question is which structure isn't involved.\\n\\nThe therapy's mechanism is about preventing the spliceosome from binding the exons. The spliceosome's role is to splice the exons. So the structures that are involved would be the lariat (for splicing), the polyA tail (for termination), and maybe any structures like R-loops that form during splicing. The Morpholino would bind to the mRNA, but does it form any structures like R-loops? Or does the lariat form during splicing, which is the process that the Morpholino is disrupting.\\n\\nThe question is about which structure isn't involved. The therapy doesn't directly involve R-loops in the splicing process, but perhaps in the process of RNA-DNA hybridization, which is part of the spliceosome function. But the question is about what's not involved. So the structures that are not part of the therapy's process.\\n\\nWait, the question is about what structure isn't involved in the therapy. The therapy involves Morpholinos binding to exons, which disrupts splicing. So the structures that are part of the splicing process are the lariat, polyA tail, and maybe R-loops. So which structure isn't involved?\\n\\nThe options are A) lariat, B) polyA, C) R-loops, D) antisense.\\n\\nWait, antisense (D) is about RNA that binds to DNA, perhaps acting as a sponge. The question doesn't mention antisense in the therapy's context. So perhaps antisense isn't involved here.\\n\\nWait, but the question is about the structures involved in the therapy. The therapy's mechanism is about disrupting the spliceosome's ability to splice the exons. The spliceosome's function includes the formation of an intron lariat (A), and the polyA tail (B) is about termination. The R-loops are more about RNA structure during processes like transcription, perhaps during RNA processing.\\n\\nSo the structures not involved would be the R-loops (C) and maybe the antisense (D). But the question is about which structure isn't involved.\\n\\nWait, the question is about the therapy's process. The Morpholino binds to the mRNA, preventing the spliceosome from recognizing the exons. So the spliceosome's role is in splicing, which involves lariat formation. So the lariat is involved.\\n\\nPolyA tail is about termination, which is a separate process. So the polyA tail isn't directly involved in the therapy.\\n\\nThe R-loops are a different structure, but the therapy doesn't form R-loops. So perhaps the R-loops aren't involved.\\n\\nSo the structures not involved are B) polyA tail, C) R-loops, and D) antisense.\\n\\nWait, the question is which structure isn't involved in the therapy. The therapy doesn't involve antisense, so D) is not involved. The polyA tail (B) is about termination, which is a separate process, so it's not involved in the therapy. R-loops (C) are about RNA structure during splicing, which is part of the process the therapy is disrupting. So R-loops are involved.\\n\\nSo which structure isn't involved? The options are A) lariat (part of splicing), B) polyA (terminator), C) R-loops (part of splicing), D) antisense (not involved).\\n\\nThe question is which structure isn't involved in the therapy. The therapy doesn't involve antisense, so D) is not involved. The polyA tail is involved in termination, not splicing. So the structures involved in the therapy are the lariat (A), polyA (B), and R-loops (C). The structure not involved is D) antisense.\\n\\nWait, but the question is about which structure isn't involved. So the structures involved are A, B, C; the structure not involved is D.\\n\\nBut wait, the question asks which structure is not involved in the therapy. The therapy doesn't use antisense, so D is not involved.\\n\\nWait, but the question is about the structures that are not involved. So the options are:\\n\\nA) lariat: involved.\\n\\nB) polyA: involved (terminator).\\n\\nC) R-loops: involved (RNA structure during splicing).\\n\\nD) antisense: not involved.\\n\\nSo the correct answer would be D) antisense.\\n\\nWait, but the question is, which structure isn't involved? So the structures involved are A, B, C. The structure not involved is D.\\n\\nSo the correct answer is D) antisense.\\n\\nWait, but the options are for the structures not involved. So the structures involved are A, B, C. The structure not involved is D) antisense.\\n\\nAlternatively, perhaps the R-loops are not involved in the therapy. Or perhaps the R-loops are part of the process of the spliceosome.\\n\\nWait, I'm a bit confused. Let me think again.\\n\\nThe therapy is about disrupting the spliceosome's function. So during the splicing process, structures like lariat (A) and polyA (B) are involved. R-loops (C) are structures formed during RNA processing, perhaps in the spliceosome's function. So they are involved.\\n\\nThe Morpholino binds to the exon mRNA, and prevents the spliceosome from binding. This could disrupt the spliceosome's ability to splice the exons, possibly by blocking the spliceosome's recognition.\\n\\nSo the structures involved are lariat (A), polyA (B), and R-loops (C). The structure not involved is D) antisense.\\n\\nSo the correct answer is D) antisense isn't involved.\\n\\nWait, but the question is about which structure is not involved. So the options are:\\n\\nA) lariat (part of the splicing process, involved)\\n\\nB) polyA (part of mRNA termination, involved)\\n\\nC) R-loops (part of splicing, involved)\\n\\nD) antisense (not involved)\\n\\nSo the correct answer is D) antisense is not involved in the therapy.\\n</think>\\n\\nTo address the question, we need to determine which structure is not involved in the proposed Morpholino therapy. The therapy involves using a Morpholino to bind to the 5' end of an out-of-frame exon in pre-mRNA, preventing the spliceosome from binding and creating exon skipping. This disrupts the spliceosome's ability to splice the exons, leading to in-frame mRNA joining.\\n\\n### Analysis of Each Option:\\n\\n1. **Lariat (A)**: During the splicing process, the spliceosome forms an intron lariat as part of its function. Since the therapy disrupts the spliceosome's ability\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>\\nAlright, so I've got this question about gene therapy using Morpholinos. Hmm, okay, let me try to break it down.\\n\\nThe question says that there's a gene with several exons. The central ones code for triple helical repeats that connect the cytoskeleton, sarcolemma, and extracellular space. Each exon usually codes for one of these repeats. The common mutations are deletions in the central exons, creating out-of-frame peptides. These cause progressive degeneration. So, the therapy here is delivering a Morpholino that binds to the 5' end of the out-of-frame exon in pre-mRNA. This prevents the spliceosome from recognizing it, leading to exon skipping and in-frame joining.\\n\\nWait, Morpholinos are antisense oligonucleotides that bind to the 3' end of mRNA. Oh wait, noâ€”wait, Morpholinos usually bind to the 3' end of the pre-mRNA. So in this case, they're targeting the 5' end of the exon. Wait, no, wait. No, wait. The 5' end of the pre-mRNA is where the exon starts, right? So if the Morpholino binds to the 5' end of the pre-mRNA, which is the start of the exon, then it might prevent the spliceosome from recognizing the exon. Because the spliceosome usually recognizes the 5' splice site (exon-intron junction) and the 3' splice site (exon-exon junction).\\n\\nSo, if the Morpholino is binding to the 5' end, perhaps it's preventing the spliceosome from recognizing the start of the exon. That would lead to the exon being skipped, and the spliceosome would join the exons in an in-frame manner, which would eliminate the out-of-frame peptide. That makes sense.\\n\\nThe question is which structure is NOT involved in this therapy. The options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nSo, looking at each option:\\n\\nA) Lariat: The lariat structure forms during the splicing process, specifically during the formation of introns. So the lariat is involved in the splicing mechanism. So A is involved.\\n\\nB) PolyA tail: PolyA tails are present in pre-mRNA, but in the mature mRNA, they are removed. The therapy doesn't directly involve the polyA tail. It's more about the mRNA structure, so B is not involved.\\n\\nC) R-loops: R-loops are structures where an RNA helix forms between a single-stranded RNA and a complementary region of DNA or other RNA. Morpholinos don't form R-loops; they bind to mRNA. So C is not involved in the therapy.\\n\\nD) Antisense: Morpholinos are antisense oligonucleotides, so D is involved.\\n\\nSo the structure not involved is B) polyA tail.\\n</think>\\n\\nTo determine which structure is not involved in the proposed therapy, we analyze the options:\\n\\n- **A) Lariat**: The lariat structure is formed during mRNA splicing, specifically during intron formation. This is directly involved in the splicing process, so A is involved.\\n\\n- **B) PolyA tail**: PolyA tails are characteristic of pre-mRNA but are removed during mRNA maturation. The therapy does not involve the polyA tail, making B not involved.\\n\\n- **C) R-loops**: R-loops are RNA-DNA or RNA-RNA structures where an RNA helix forms between a single-stranded RNA and a complementary region. Morpholinos do not form R-loops; they bind to mRNA. Therefore, C is not involved.\\n\\n- **D) Antisense**: Morpholinos are antisense oligonucleotides that bind to mRNA. This makes D directly involved.\\n\\nThe structure not involved in the therapy is **B) polyA tail**. \\n\\nANSWER: B<ï½œendâ–ofâ–sentenceï½œ>\", '<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>\\nOkay, so I\\'m looking at this question about gene therapy using Morpholinos. Hmm, I remember that Morpholinos are small RNA molecules that can bind to mRNA and cause it to form a lariat structure. This process, called antisense lariat formation, disrupts the normal splicing process, leading to exon skipping. \\n\\nThe question says that a Morpholino binds to the 5\\' end of an out-of-frame exon in pre-mRNA. When this happens, the spliceosome can\\'t bind properly, so exon skipping occurs. The result is in-frame joining, which makes sense because the missing exon is filled in, restoring the reading frame. This therapy helps with conditions like progressive degenerative diseases where exons are missing and cause issues.\\n\\nNow, the options are asking which structure isn\\'t involved in this therapy. Let\\'s go through each option.\\n\\nOption A: Lariat. Oh yeah, Morpholinos form lariats when they bind the mRNA. So this is involved. So this isn\\'t the answer.\\n\\nOption B: PolyA tail. I know that the polyA tail is recognized by the spliceosome as a signal for splicing. Without the polyA signal, the spliceosome can\\'t process the mRNA. So the presence of the polyA tail is crucial for proper splicing. Therefore, the polyA tail is involved, so this isn\\'t the correct answer.\\n\\nOption C: R-loops. R-loops are RNA structures where a RNA strand is base-paired with another strand via a single-stranded region. I\\'m not exactly sure if R-loops are involved in Morpholino therapy. But wait, Morpholinos are known to form R-loops with the mRNA. I think that\\'s how they cause the splicing defect. So R-loops are involved in this process. So option C is involved, not the correct answer.\\n\\nOption D: Antisense. Antisense is the RNA molecule that binds to the mRNA. In this case, the Morpholino is an antisense RNA. So this structure is definitely involved in the therapy. Therefore, option D is not the correct answer.\\n\\nWait, wait. Let me re-read the options. The question asks which structure is not involved. So the structures that are not involved are the ones we\\'re looking for.\\n\\nLooking again:\\n\\nA) Lariat: yes, involved.\\n\\nB) PolyA tail: yes, involved.\\n\\nC) R-loops: involved.\\n\\nD) Antisense: yes, Morpholino is antisense.\\n\\nSo all options are involved except... Wait, am I missing something?\\n\\nWait, the question is about which structure is NOT involved. So perhaps one of these structures isn\\'t part of the process.\\n\\nWait, another thought: the options include \"R-loops\" and \"antisense.\" But Morpholinos are antisense, right? So D is involved.\\n\\nWait, but another point: the process is called antisense lariat formation. So the lariat is formed by the antisense RNA, which is the Morpholino in this case. So the lariat is involved. So A is involved.\\n\\nWait, but the question is which structure is NOT involved. So the structures involved are A (lariat), B (polyA), C (R-loop), D (antisense). So the structure that isn\\'t involved is none of the options? But that can\\'t be. Maybe I\\'m missing something.\\n\\nWait, let\\'s think again. The process is that the Morpholino binds to the 5\\' end of the exon, creating a R-loop. This R-loop causes the spliceosome to recognize the mismatch and skip the exon. So the R-loop is involved. So option C is involved.\\n\\nWait, the question is which structure is not involved. So the four options are all part of the process except one.\\n\\nWait, another thought: What\\'s the structure of the Morpholino? It\\'s an antisense RNA, which is complementary to the target mRNA. But what about the other structures?\\n\\nWait, the structure that is not involved is the polyA tail. Because the polyA tail is needed for the normal splicing process. Without it, the spliceosome can\\'t process the mRNA. So without the polyA tail, the exon can\\'t be skipped. So the polyA tail is involved, making option B correct.\\n\\nWait, but the question is about the structure not involved. So perhaps the answer is one of the four. Let me think again.\\n\\nWait, perhaps the polyA tail is not directly involved in the mechanism. The polyA signal is necessary for splicing, but once the spliceosome is recognizing the mismatch, it can proceed. So the polyA tail is present but not necessarily part of the antisense RNA\\'s function. So the polyA tail is involved in the process but perhaps not directly in the antisense RNA\\'s action.\\n\\nWait, but the question is about the structure not involved in the therapy. So the structure that is not part of the mechanism.\\n\\nWait, I think the correct answer is the polyA tail. Because the polyA tail is part of the mRNA structure, but the Morpholino doesn\\'t directly interact with it. The polyA signal is necessary for the spliceosome to recognize the splice sites. So without the polyA tail, the spliceosome wouldn\\'t be able to process the mRNA. So the polyA tail is involved, making option B involved.\\n\\nWait, but the question is which structure is not involved. So looking again, all the structures involved are A, B, C, D except one.\\n\\nWait, another approach: Let\\'s think about each option.\\n\\nOption A: Lariat. This is involved because the Morpholino forms a lariat with the mRNA.\\n\\nOption B: PolyA tail. The presence of the polyA signal is necessary for the spliceosome to recognize the splice sites, which is part of the process. So the polyA tail is involved.\\n\\nOption C: R-loops. This is a structural feature formed by the Morpholino binding to the mRNA. So this is involved.\\n\\nOption D: Antisense. The Morpholino is an antisense RNA, so it\\'s involved.\\n\\nWait, but the question is about which structure is not involved. So none of the four structures are not involved, but that can\\'t be.\\n\\nWait, perhaps the structure not involved is the polyA tail. Because the polyA tail is part of the mRNA, but the Morpholino doesn\\'t directly interact with it. The polyA signal is necessary for the spliceosome to recognize the exons, but the Morpholino doesn\\'t directly interact with the polyA tail. So the polyA tail is present in the mRNA, but its structure is not directly involved in the Morpholino therapy.\\n\\nWait, but the question is about the structure NOT involved in the therapy. So if the therapy doesn\\'t involve the polyA tail, then it\\'s not involved. But in reality, the polyA signal is required for the spliceosome to process the mRNA, so the polyA tail is part of the structure that\\'s necessary for the therapy to work. Therefore, the structure that is not involved would be the one that\\'s not part of the process.\\n\\nWait, but all the options are parts of the process except perhaps the polyA tail.\\n\\nWait, perhaps the correct answer is the polyA tail is not involved. Or perhaps the polyA tail is involved in the process but not in the antisense RNA\\'s function.\\n\\nWait, perhaps the polyA tail is not a structure involved in the antisense lariat formation. The antisense RNA is the one that causes the lariat, but the polyA tail is part of the mRNA. So the structure not involved is the polyA tail.\\n\\nWait, but the question is about the structure not involved in the therapy. So the polyA tail is part of the mRNA but not directly involved in the antisense lariat formation. So the polyA tail is involved in the process, but perhaps the structure that\\'s not involved is the polyA tail.\\n\\nWait, but the question is about the structure not involved in the therapy. So the correct answer is the polyA tail, as it\\'s not part of the antisense lariat.\\n\\nWait, I\\'m getting a bit confused. Let me try to think differently. The question is which structure is not involved in the proposed therapy. The therapy involves the Morpholino causing a R-loop and forming a lariat. So the structures involved are:\\n\\n- Lariat (A) - yes.\\n\\n- PolyA tail (B) - yes, because the spliceosome needs the polyA signal.\\n\\n- R-loops (C) - yes, because the Morpholino forms a R-loop.\\n\\n- Antisense (D) - yes, because it\\'s the Morpholino that\\'s antisense.\\n\\nWait, but the question is which is NOT involved. So none of the options are not involved, but that can\\'t be.\\n\\nWait, perhaps the polyA tail is not part of the structure involved in the mechanism. So the polyA tail is a part of the mRNA, but the Morpholino is an antisense RNA. The polyA tail is a structure that is part of the mRNA, but it\\'s not directly interacting with the antisense RNA. So the structure not involved is the polyA tail.\\n\\nWait, but the options are A to D. The correct answer is the polyA tail, but I\\'m not sure.\\n\\nAlternatively, perhaps the polyA tail is not involved in the antisense lariat formation. Because the antisense lariat is the product of the interaction between the Morpholino and the mRNA. The polyA tail is part of the mRNA, but not directly interacting with the antisense RNA. So the polyA tail is involved in the process (as part of the mRNA) but not directly in the therapy\\'s mechanism.\\n\\nWait, but the question is which structure is not involved. So perhaps the polyA tail is not involved in the process. So the correct', \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>\\nOkay, so I have this question about gene therapy using Morpholinos. Hmm, let me think through this step by step.\\n\\nThe question is about a gene with multiple exons, specifically the central ones coding for folded triple alpha helices. These helices connect the cytoskeleton with the sarcolemma and extracellular space. Each exon usually codes for one of these, but when there are deletions, it creates out-of-frame peptides, leading to mutations. That makes sense because a single amino acid change can cause significant protein degradation.\\n\\nThe therapy proposed is using a Morpholino that binds to the 5' end of an out-of-frame exon in pre-mRNA. Morpholinos are RNA-based small molecules that can block spliceosomes, right? So if they block the spliceosome, it should prevent the exons from being joined properly. This would lead to exon skipping, which would make the protein in-frame. Oh, because the exon was skipped, it's missing one or more amino acids, but if it's out of frame, that's a problem. By skipping, the protein becomes in-frame, which is better.\\n\\nThe question asks which structure is not involved in this therapy. The options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nLet me think about each option.\\n\\nOption A: Lariat. I remember that during splicing, especially in the 5' splice site, the lariat structure forms. The spliceosome uses these lariat structures to recognize the splice sites. So if Morpholino prevents the spliceosome, the lariat would form again. Wait, but in this therapy, the lariat would form because the spliceosome can't recognize the sites anymore. But wait, the therapy's goal is to prevent exon skipping. The question is about the structures involved in the therapy, not the lariat formation itself. So I'm not sure if the lariat is involved in the therapy. The therapy itself doesn't form a lariat, but the spliceosome is prevented from joining exons. So maybe the lariat structure is formed during the process, but that's not the therapy's structure.\\n\\nOption B: PolyA tail. Morpholinos are RNA molecules that are incorporated into the pre-mRNA. They are typically added to the 5' end. So the polyA tail is part of the RNA. But the therapy's mechanism involves the Morpholino binding to the mRNA, preventing the spliceosome from recognizing the exon. So the polyA tail is present but not directly involved in the therapy. The therapy doesn't rely on the polyA tail for its effect; it's more about RNA structure.\\n\\nOption C: R-loops. R-loops are RNA secondary structures formed when an RNA helix forms a loop, usually between two nucleotides. They are often associated with RNA interference and are involved in gene silencing. In this therapy, Morpholinos are binding to the 5' end of the exon. If the exon is involved in a fold, perhaps it's part of a structure that would form an R-loop. But in this scenario, the Morpholino binds to the pre-mRNA, which is already in the 5' splice site. I'm not sure if R-loops are involved here. Maybe not. Or perhaps the exon is part of an R-loop in the pre-mRNA, but the therapy itself doesn't create R-loops. The therapy just prevents the spliceosome from joining.\\n\\nOption D: Antisense. Antisense RNA is complementary to a target mRNA, often used in RNA interference. But in this case, the Morpholino is a direct RNA molecule, not antisense. Unless the Morpholino is antisense to another RNA. But the question doesn't mention antisense RNA. So perhaps D is not involved.\\n\\nWait, but the therapy is about preventing the spliceosome from recognizing the exon. How does that affect the structures? The spliceosome relies on specific RNA structures, like the 5' splice site, to recognize the exon. So if Morpholino binds the 5' end, maybe it affects the structure of the splice sites. Or perhaps it affects the formation of lariat structures. But I'm not certain.\\n\\nAlternatively, the Morpholino might form R-loops in the pre-mRNA. If the exon is part of an R-loop, then binding the Morpholino could interfere with the structure. But the question is about the structures involved in the therapy, not the consequence of the therapy.\\n\\nSo, the therapy is about preventing the spliceosome from joining exons. The process would involve the spliceosome recognizing the exon and the Morpholino binding there. So the spliceosome's normal function is to recognize the splice sites and form lariat structures. If the spliceosome can't recognize, it doesn't join, leading to exon skipping.\\n\\nThe structures that are formed during this process are the lariat (which is formed when the spliceosome recognizes the sites), and the R-loops (if the exon is part of a structure like that). But the therapy itself doesn't create R-loops; it's about preventing the spliceosome from recognizing the exon.\\n\\nSo, the structures involved in the therapy would include the normal lariat formation (because the spliceosome makes it when it binds), and possibly R-loops (if the exon is part of an RNA structure). But the question is about which structure is NOT involved.\\n\\nLooking back at the options, the options are: lariat (A), polyA (B), R-loops (C), antisense (D).\\n\\nWhich of these is not involved? The therapy uses Morpholinos to prevent the spliceosome from joining exons. The spliceosome's function relies on lariat structures (A), and R-loops (C) if the exon is part of an RNA structure.\\n\\nBut wait, in the given scenario, the Morpholino binds to the 5' end of the exon. If that exon is part of an R-loop in the pre-mRNA, then the Morpholino might prevent the spliceosome from recognizing the site because the R-loop is formed. So in this case, R-loops are involved. But the question is about the structures involved in the therapy itself, not the consequence.\\n\\nThe therapy involves the spliceosome preventing exon skipping, which would mean the spliceosome is no longer able to recognize the exon. So the spliceosome's function involves lariat structures (A). Also, the R-loop (C) might form as a consequence.\\n\\nAlternatively, the Morpholino might form an R-loop with the pre-mRNA. So the structure involved in the therapy is the R-loop (C) because it's the structure that the Morpholino is binding to.\\n\\nSo, the structures involved would be the lariat (A) and R-loops (C). The therapy doesn't create these structures, but the presence of these structures is part of the therapy's effect.\\n\\nThe question asks which structure is NOT involved in the proposed therapy. So, the structures involved in the therapy are lariat and R-loops. So, the structure not involved is antisense (D) or polyA tail (B).\\n\\nWait, the polyA tail is part of the mRNA, but the therapy doesn't directly involve the polyA tail. The polyA tail is present but not part of the therapy's mechanism. So the polyA tail is not involved in the therapy.\\n\\nBut wait, the Morpholino is a small RNA that is incorporated into the pre-mRNA. It's added to the 5' end, so the polyA tail is part of the mRNA. So the polyA tail is present, but the therapy doesn't involve it. So the structure not involved is the polyA tail.\\n\\nWait, but the question is about which structure is NOT involved in the therapy. The therapy's mechanism is about preventing exon skipping by blocking spliceosome recognition. The spliceosome's function involves lariat structures (A) and R-loops (C). So, the structures involved are A, C, and perhaps B (polyA) and D (antisense).\\n\\nBut the therapy doesn't use antisense or polyA tail, but the polyA tail is part of the mRNA. So the structure not involved is the polyA tail (B) because it's part of the mRNA but not part of the therapy's mechanism.\\n\\nWait, but the question is about which structure is not involved. So, the therapy doesn't create a polyA tail. The polyA tail is present but not used in the therapy.\\n\\nAlternatively, the polyA tail is part of the mRNA but not directly involved in the therapy. The therapy's effect is about exon skipping, which requires the spliceosome recognizing the sites. The spliceosome's function is dependent on the lariat structures and possible R-loops.\\n\\nSo the structures involved are lariat (A), R-loops (C). So the structures not involved are polyA (B) and antisense (D).\\n\\nWait, but the question says which is NOT involved. So all structures except one are involved.\\n\\nWait, the question is which structure is NOT involved. The options are A, B, C, D.\\n\\nIn the options:\\n\\nA) Lariat: part of the process.\\n\\nB) PolyA tail: part of the mRNA but not involved in the therapy.\\n\\nC) R-loops: part of the process.\\n\\nD) Antisense: not part of the therapy.\\n\\nSo the structures involved are A, C. The structures not involved are B and D.\\n\\nWait, but the therapy doesn't involve the polyA tail. So the polyA tail is not involved in the therapy. The question asks which structure is not involved. So the answer would be B) polyA tail.\\n\\nAlternatively, the therapy uses Morpholinos, which are RNA, and the polyA tail is part of the mRNA, but the polyA tail is not involved in the therapy.\\n\\nWait, but the question is about\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>\\nOkay, so I'm trying to figure out this multiple-choice question about gene therapy using Morpholinos. Let me break it down step by step.\\n\\nThe question says that there's a gene with many exons. The central exons code for triple helical repeats that connect the cytoskeleton, the sarcolemma, and the extracellular space. Each exon is responsible for one such repeat. The mutations here are deletions in the central exons, leading to out-of-frame peptides. So, if you have a deletion, the mRNA might have extra amino acids that mess up the protein structure. The common issue is that these deletions aren't in frame, so the protein isn't functional.\\n\\nThe therapy proposed is using a Morpholino. Morpholinos are RNA molecules that inhibit the splicing machinery, specifically the spliceosome. The Morpholino binds to the 5' end of the pre-mRNA exon. By doing so, it prevents the spliceosome from recognizing and joining the exons. This should cause exon skippingâ€”so the exon isn't included in the mRNA. But the spliceosome is usually involved in splicing introns and joining exons. If the exon is skipped, the mRNA would join the remaining exons, creating an in-frame protein. This makes sense because if the exon is skipped, the number of amino acids is right.\\n\\nNow, the question is asking which structure is not involved in this therapy. The options are A to D.\\n\\nLooking at the options:\\n\\nA) Lariat: I remember that during RNA splicing, the spliceosome forms an lariat structure when it splices introns out of a pre-mRNA. But in this case, the Morpholino is preventing the spliceosome from acting on the exon. So the lariat isn't formed here. So maybe A is involved, but waitâ€”no, the lariat is formed when introns are spliced, which isn't happening here. So A is not involved.\\n\\nB) PolyA tail: PolyA tails are found in pre-mRNA, especially in prokaryotes. They are involved in mRNA stability, especially in translation. Since the question is about gene therapy in a eukaryotic organism, I'm not sure if polyA tails are involved. But wait, the therapy is about preventing the spliceosome from acting on the exon. So maybe the polyA tail is not directly involved here. Hmm, but I'm not certain about this.\\n\\nC) R-loops: R-loops are RNA structures where an RNA strand is looped around another, often forming secondary structures. Morpholinos can sometimes form R-loops with the RNA they bind to. But in this scenario, the Morpholino is binding to the pre-mRNA's 5' end. If the Morpholino binds to the 5' end of the exon, it might form an R-loop with the intron or the intron's end. Not sure if this is relevant to the therapy mechanism. But maybe it's involved in the delivery of the Morpholino or its interaction with the spliceosome. Alternatively, if the Morpholino binds to the intron, it could form an R-loop. But the question is about the therapy itself, not the delivery mechanism.\\n\\nD) Antisense: Antisense RNA is a type of RNA that binds to the target DNA, usually to prevent transcription. But in this case, the Morpholino is inhibiting the spliceosome. So antisense isn't directly involved here. Alternatively, if the Morpholino is binding to the mRNA, perhaps it's an antisense RNA that binds to the mRNA. But I'm not sure about this either.\\n\\nWait, going back to the options, the question is which structure is NOT involved. Let me think again.\\n\\nThe therapy is using a Morpholino that binds to the 5' end of the pre-mRNA exon. This prevents the spliceosome from binding and splicing. So, during the therapy, the spliceosome isn't acting on the exon. So the spliceosome isn't involved in the therapyâ€”so that's not the correct answer.\\n\\nThe spliceosome is involved in splicing introns and joining exons, but in this scenario, it's not doing anything because the Morpholino is preventing it. So the spliceosome is involved in normal splicing, but not in this therapy.\\n\\nNow, which structures are involved in the therapy:\\n\\n- The Morpholino is an RNA molecule. It's not an enzyme or a structural feature of the mRNA.\\n\\n- The pre-mRNA is the target, so the mRNA must have a poly-A tail. The poly-A tail is a part of the mRNA that is recognized by ribosomes for translation. So the poly-A tail is involved in the structure of the mRNA and is involved in translation.\\n\\nWait, the question is which structure is NOT involved. So the Morpholino is the molecule, not an enzyme. The pre-mRNA has a polyA tail, so that's involved. R-loops, if any, are possible but not directly involved in this therapy.\\n\\nSo the structures involved in the therapy are:\\n\\n- Morpholino (RNA molecule)\\n- Pre-mRNA (has polyA tail)\\n- The spliceosome is not involved because it's prevented from splicing.\\n\\nSo the structures involved are A, B, and C (if R-loop is involved), but the question is which is not involved.\\n\\nWait, the question asks which structure is NOT involved in the proposed therapy. So the therapy involves the Morpholino and the pre-mRNA, but the spliceosome isn't part of the therapy process.\\n\\nSo the structures involved are: Morpholino (RNA), pre-mRNA (which has a polyA tail), and the spliceosome isn't part of the therapy.\\n\\nSo, the structures that are involved are A (lariat), B (polyA), C (R-loops?), D (antisense)? Wait, the options don't include antisense in the context of this therapy.\\n\\nWait, the options are A) lariat, B) polyA, C) R-loops, D) antisense.\\n\\nSo the therapy doesn't involve antisense, but the Morpholino is an RNA molecule. So the structures involved are:\\n\\nMorpholino (RNA), pre-mRNA (polyA), and possible R-loops.\\n\\nSo which structures are not involved: the answer is D) antisense? Because the Morpholino is an RNA molecule and the therapy doesn't involve antisense RNA.\\n\\nAlternatively, the spliceosome is not involved, but the question is about which structure is NOT involved. So the structures involved are: Morpholino (RNA), pre-mRNA (polyA), and maybe R-loops.\\n\\nThe structures not involved are the ones that are not part of the therapy.\\n\\nSo the question is asking which structure is not involved.\\n\\nThe options are:\\n\\nA) Lariat: formed during splicing, but in the therapy, the spliceosome isn't doing anything, so the lariat isn't formed. So the lariat is involved in normal splicing but not in the therapy. So if the therapy doesn't cause lariat formation, then the lariat is not involved. But wait, the therapy is about preventing splicing, but the lariat is part of the pre-mRNA.\\n\\nWait, I'm getting a bit confused. Let's think again.\\n\\nThe therapy is about preventing the spliceosome from acting on the exon. So the spliceosome isn't splicing the exon. The pre-mRNA has an exon being skipped.\\n\\nThe spliceosome normally splices the intron out of the pre-mRNA. If the spliceosome is prevented from doing that, the mRNA would have the exon, which would be in-frame.\\n\\nThe structures involved in the therapy are:\\n\\n- Morpholino (RNA)\\n- Pre-mRNA (has polyA tail)\\n- The spliceosome is not involved because it's not doing its normal function.\\n\\nWait, the question is which structure is NOT involved. So the structures involved are: Morpholino, pre-mRNA, and polyA tail. R-loops (option C) are possible structures that can form during the therapy, but they're not directly part of the therapy mechanism. So, the structures involved are A, B, and C? Or is R-loops a part of the therapy?\\n\\nAlternatively, maybe the spliceosome is not involved in the therapy, but the Morpholino is an RNA molecule, the pre-mRNA has a polyA tail, and the R-loop is a possible structure.\\n\\nSo the structures involved are A) lariat (but not formed), B) polyA (yes), C) R-loop (maybe involved, but not directly necessary), D) antisense (unlikely).\\n\\nThe question is which structure is NOT involved. So, the structures that are not involved are any of the options that are not part of the therapy.\\n\\nThe therapy doesn't use any of these structures except the Morpholino. So the structures that are not involved are the ones that don't come into play in the therapy.\\n\\nThe pre-mRNA has a polyA tail. The Morpholino is an RNA, not an enzyme. The spliceosome is not part of the therapy, but the spliceosome's role is to splicing introns. So the structures involved are pre-mRNA (polyA), Morpholino, and perhaps R-loops (but not directly involved).\\n\\nSo the structures involved are pre-mRNA, Morpholino, and the polyA tail. So the structures not involved are R-loops (option C) and antisense (D), but I'm not sure.\\n\\nWait, the question is which structure is not involved. So the structures that are not part of the therapy are the ones that the therapy doesn't use.\\n\\nSo the therapy uses the Morpholino, pre-mRNA, and the spliceosome is not used. So the structures involved are A) lariat (but not formed), B) polyA, C) R\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>\\nOkay, so I've got this question about gene therapy and Morpholinos. Hmm, let me try to figure it out. I'm a bit rusty on some of these concepts, but I'll try to think it through.\\n\\nThe question says that a gene has a lot of exons, and the central ones code for folded triple alpha helices. These helices connect the cytoskeleton with the sarcolemma and extracellular space. Each exon usually codes for one of these, right? The most common mutations are deletions in the central exons, leading to out-of-frame peptides. That makes sense because if the exon is deleted, the reading frame shifts, causing the protein to be misfolded or non-functional.\\n\\nNow, the therapy proposed is using a Morpholino to deliver. Morpholinos are antisense oligonucleotides, which means they bind to the 3' end of mRNA. Oh wait, but wait, the question says they target the 5' end of the pre-mRNA. Oh wait, wait. Wait, no, wait. Morpholinos are usually antisense, which means they bind to the 3' end of the mRNA. Because they have a complementary sequence that pairs with the 3' end.\\n\\nBut the question says the Morpholino binds the 5' end of the pre-mRNA. Wait, that doesn't make sense. Because pre-mRNA is being transcribed from DNA, so the 5' end is the beginning. If the Morpholino is targeting the 5' end, it's not the usual way. Or perhaps the question is a bit different.\\n\\nWait, the question says the Morpholino recognizes the 5' end of the out-of-frame exon in pre-mRNA. So maybe it's a different way. But I thought Morpholinos are antisense. Maybe it's a typo, or perhaps the context is different.\\n\\nThe therapy works by preventing the spliceosome from binding, which normally joins exons. If the spliceosome can't bind, the exon is skipped, and the mRNA is joined in-frame. So the exons are joined without the out-of-frame effect.\\n\\nThe question then asks which structure isn't involved in this therapy. The options are A to D.\\n\\nLet me look at the options:\\n\\nA) Lariat structure: during splicing, the mRNA forms an lariat when a spliceosome binds an intron. So the lariat is part of the splicing mechanism. So this structure is involved, so the answer can't be A.\\n\\nB) PolyA tail: polyA tails are part of mRNA processing, found at the 3' end of mRNA. They are involved in mRNA stability and export. So this structure is involved in the therapy, as it's part of the mRNA processing. So B is not the correct answer.\\n\\nC) R-loops: an R-loop is a structure formed when the 3' end of one DNA strand is bound to the 5' end of another, creating a loop. This can occur in the nucleus and is part of DNA replication or repair. But in this context, how is R-loops involved? If the Morpholino is targeting the mRNA, perhaps it's involved in modifying the RNA structure. Wait, but I'm not sure. Alternatively, R-loops might not be directly involved in this therapy. Unless the Morpholino somehow affects the RNA's structure in a way that affects splicing.\\n\\nAlternatively, maybe the Morpholino is designed to bind the mRNA and influence its structure, perhaps preventing the spliceosome from binding. But I'm not sure if R-loops are involved here. So perhaps C is a possible correct answer.\\n\\nD) Antisense: Morpholinos are antisense oligonucleotides, so this structure is involved. So D is not the correct answer.\\n\\nSo the question is which structure isn't involved. So the structures involved in the therapy are: lariat (A), polyA tail (B), antisense (D). The R-loop (C) might not be involved because the therapy isn't about RNA structure modification per se.\\n\\nWait, wait. Another thought: the Morpholino is antisense, so it's part of the therapy, so D is involved. The therapy uses the Morpholino to prevent spliceosome binding. How does that affect splicing? Maybe it disrupts the spliceosome's recognition sites.\\n\\nWait, perhaps the R-loop is involved. R-loops can affect splicing by influencing the structure of the RNA. But I'm not certain. Alternatively, the Morpholino might be used to modify the RNA's 3' end, which could cause it to form an R-loop with another region of the RNA. Or perhaps it's used to modify the RNA structure to prevent the spliceosome from binding.\\n\\nAlternatively, maybe the R-loop is not directly involved in the therapy, so the correct answer is C.\\n\\nSo the structures involved are lariat (A), polyA tail (B), and antisense (D). The R-loop (C) is not involved in this therapy.\\n\\nSo the question is which structure is NOT involved. The options are A, B, C, D.\\n\\nSo the answer would be C) R-loops.\\n</think>\\n\\nTo determine which structure is not involved in the proposed therapy, let's analyze the options:\\n\\n1. **Lariat structure (A):** During splicing, the spliceosome forms an lariat structure when it binds an intron. Since the therapy involves preventing the spliceosome from binding, the lariat structure is directly involved. Therefore, A is involved.\\n\\n2. **PolyA tail (B):** The polyA tail is a structural feature of mRNA located at the 3' end, involved in mRNA stability, processing, and export. Since the therapy involves mRNA processing, the polyA tail is also involved. Thus, B is involved.\\n\\n3. **R-loops (C):** R-loops are structural motifs formed during DNA replication or repair, involving the 3' end of one DNA strand binding to the 5' end of another. While the question does not explicitly mention RNA structure modifications, R-loops could theoretically influence splicing by altering RNA structure. However, the therapy described does not appear to directly involve R-loops in the described mechanism. Therefore, C is not involved.\\n\\n4. **Antisense (D):** Morpholinos are antisense oligonucleotides that bind to the 3' end of mRNA. Since the therapy involves antisense, D is involved.\\n\\nBased on this analysis, the structure that is not involved in the proposed therapy is **R-loops**.\\n\\n**Answer: C**<ï½œendâ–ofâ–sentenceï½œ>\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>\\nOkay, so I have this question about gene therapy using Morpholinos. Hmm, let me think about what I remember from my biology classes. I'm a bit rusty, but I'll try to work through it.\\n\\nThe question is about a gene with many exons, and the central ones code for triple helical repeats connecting the cytoskeleton, sarcolemma, and extracellular space. Each exon is supposed to code for one such helix. But the problem is that there are mutations where exons are deleted. These deletions cause out-of-frame peptides, leading to degenerative issues. To fix this, a Morpholino is used. The Morpholino binds to the 5' end of the out-of-frame exon in pre-mRNA, preventing the spliceosome from splicing it. This leads to exon skipping and in-frame joining, which is better for the organism.\\n\\nThe question asks which structure isn't involved in this therapy. The options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nWait, what's a lariat? I think it's a structure formed during RNA splicing when an intron is removed. When the spliceosome processes the mRNA, it creates a lariat structure, right? So if the spliceosome is prevented from splicing, the lariat is formed. But wait, the Morpholino prevents the spliceosome, so the lariat isn't formed because the exon is skipped. So the lariat is involved in the normal splicing process, but not in this therapy.\\n\\nThen the polyA tail. PolyA is the end product of mRNA processing, right? It's added by the ribosome during translation. I don't think the Morpholino directly affects the polyA tail. Unless the therapy somehow affects translation, but I don't think so. So polyA tail is probably not involved here.\\n\\nR-loops are structures where RNA forms a three-stranded structure with a DNA or another RNA. But in this case, the Morpholino is a protein that interacts with RNA. So R-loops might not be involved. Unless the Morpholino somehow creates an R-loop, but I don't think so. R-loops are more about RNA-DNA or RNA-RNA interactions, which I don't think is relevant here.\\n\\nAntisense is a RNA that binds to mRNA and inhibits translation. So in this therapy, the Morpholino is preventing the spliceosome from recognizing the exon. But antisense is a different mechanism. The Morpholino binds to the 5' end of the exon, which is part of the mRNA. So antisense wouldn't be involved here. Unless the Morpholino is acting as an antisense, but I think the question is focusing on the structure that isn't involved in the therapy.\\n\\nWait, the therapy is about preventing the spliceosome from splicing, which is a process that involves the spliceosome. The spliceosome includes proteins like snRNPs, which recognize the 5' splice site and 3' splice site. But the Morpholino isn't part of the spliceosome; it's a molecule that inhibits it. So the spliceosome itself isn't involved in the therapy.\\n\\nSo the structures involved in the therapy are the Morpholino (as a molecule), the R-loops (if any are formed, but I don't think they're involved), the antisense (if the Morpholino is acting as antisense), and the polyA tail (since the therapy doesn't affect the polyA tail, unless the Morpholino somehow recruits ribosomes, but that's not part of the therapy). The lariat is involved in the normal splicing process, but the therapy doesn't create or disrupt lariats.\\n\\nSo the structures not involved would be the polyA tail (B), the R-loop (C), and the antisense (D). But wait, the question is which structure isn't involved. Let me see the options.\\n\\nWait, the question is which structure is NOT involved. So the Morpholino is a molecule that's not part of the structures listed in the options. So which structures are involved in the therapy?\\n\\nThe therapy involves the spliceosome being prevented from recognizing and splicing the exon. So the spliceosome is involved, but the structures mentioned in the options are:\\n\\nA) Lariat: involved in splicing.\\n\\nB) PolyA tail: not involved, because the Morpholino doesn't affect polyA.\\n\\nC) R-loops: not involved, as the Morpholino doesn't form R-loops.\\n\\nD) Antisense: The Morpholino might be acting as antisense, but the question is about structures involved in the therapy.\\n\\nWait, the therapy doesn't involve any of the structures listed except for the Morpholino itself. So the therapy doesn't create or affect polyA, doesn't form R-loops, doesn't use antisense. So the structures not involved are B, C, and D.\\n\\nBut the question asks which structure is not involved. So the options are A to D, and we have to pick which one is not part of the therapy.\\n\\nWait, the options are four structures, and the question is which is not involved. So the structures that are not involved are B, C, D.\\n\\nWait, but the options are A, B, C, D. So the question is which is not involved.\\n\\nSo the therapy involves preventing splicing, which involves the spliceosome. So structures involved in the therapy are the spliceosome (not in the options) and the lariat (as it's involved in splicing). But the options are about which structures are not involved.\\n\\nThe structures not involved are B) polyA, C) R-loops, D) antisense. But wait, the Morpholino is a molecule, not an antisense RNA. So if the therapy uses antisense RNA, but the options don't mention that. The question is about the structures not involved.\\n\\nSo the structures not involved in the therapy are:\\n\\nB) polyA tail.\\n\\nC) R-loops.\\n\\nD) antisense.\\n\\nBut the question says the therapy doesn't involve the polyA tail because it's not part of the splicing process.\\n\\nWait, but the question is about which structure is NOT involved. So the structures involved in the therapy are the spliceosome (which is not an option), and the lariat (also not an option). But the options are A to D, so the structures not involved are B, C, D. But which one is the correct answer?\\n\\nWait, looking back, the question is which structure is not involved. So the structures involved in the therapy are:\\n\\n- The spliceosome (not one of the options).\\n\\n- The lariat (not an option).\\n\\nSo which structures are not involved? The question is about which structure is not involved. So structures not involved are B) polyA, C) R-loops, and D) antisense.\\n\\nWait, but the Morpholino is a molecule that binds the 5' end. So it's part of the therapy, but it's not involved in the structures listed. So in the options, which is not part of the therapy's mechanism.\\n\\nBut the options are A) lariat, B) polyA, C) R-loops, D) antisense.\\n\\nWait, the therapy doesn't use the polyA tail, so B is not involved. The polyA tail is the end of the mRNA, not directly part of the therapy.\\n\\nSo the correct answer is B, C, or D. Wait, the question is about which structure is not involved.\\n\\nLooking at the options, the Morpholino doesn't form any of those structures except itself. So the structures not involved are B, C, D. But the question asks which is not involved, so all three are not involved, but the options only have four choices.\\n\\nWait, let me re-read the question. The options are four structures, and the question is which is NOT involved.\\n\\nThe therapy doesn't create any of the structures mentioned in the options except the Morpholino itself. So the structures not involved are:\\n\\n- B) polyA tail (not involved in splicing or in this therapy)\\n\\n- C) R-loops (unlikely, not involved)\\n\\n- D) antisense (not involved, unless the Morpholino is acting as antisense, but that's a different mechanism)\\n\\nSo the correct answer would be either B, C, or D.\\n\\nWait, but the options are all options except for the spliceosome. So the structures not involved are B, C, and D.\\n\\nBut the question is which structure is not involved. So the correct answer is B, C, or D.\\n\\nWait, the question is about which structure is NOT involved. So the Morpholino itself is part of the therapy, but it's not one of the structures listed. So the structures not involved are B, C, D.\\n\\nBut the question is which one is not involved. So the options are A, B, C, D, and the structures not involved are B, C, D.\\n\\nBut the options are A to D, and the question is which one is not involved. So the correct answer is B, C, or D.\\n\\nWait, the question is about which structure is not involved in the therapy. So the structures that are part of the therapy are:\\n\\n- The spliceosome (but not an option)\\n\\n- The lariat (not an option)\\n\\nSo the structures not involved are B, C, D. But the question gives four options, so which one is not involved.\\n\\nWait, the question says, which structure is NOT involved. So the structures not involved are polyA tail (B), R-loops (C), and antisense (D). So the correct answer is the one that is not involved.\\n\\nWait, but the question is about the structures involved in the therapy. So the therapy is about preventing exon skipping and joining\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>\\nOkay, so I've got this multiple-choice question about gene therapy and Morpholinos. Hmm, let me read it again and try to break it down.\\n\\nThe question talks about a gene with many exons. The central ones code for triple helical repeats that connect the cytoskeleton, sarcolemma, and the extracellular space. Each exon usually codes for one folded triple alpha helix. The mutations are deletions in the central exons, leading to out-of-frame peptides and progressive degeneration. So the therapy is using a Morpholino to target the 5' end of an out-of-frame exon in pre-mRNA. The Morpholino prevents the spliceosome from binding, causing exon skipping and in-frame joining, which helps the organism survive.\\n\\nThe question asks which structure isn't involved in this therapy. The options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nWait, let me think about each part. Morpholinos are RNA molecules that bind to specific mRNA sequences to disrupt them. They can interfere with splicing machinery, like the spliceosome, which is responsible for joining exons. So in this case, the Morpholino binds to the 5' end of an exon, preventing the spliceosome from recognizing it. Without the spliceosome, the introns are skipped, and the exons are joined together in-frame. This makes the protein functional again.\\n\\nNow, the structures involved in this process. The lariat structure is formed during splicing when the introns are removed and the exons are joined. The spliceosome uses this structure to catalyze the joining. So the lariat is involved. \\n\\nPolyA tail is a nucleic acid component in eukaryotic mRNA, usually added during transcription. It's important for mRNA stability and translation. So B is involved.\\n\\nR-loops are structures where an RNA strand is antiparallel to the DNA, forming a loop. These can be involved in various processes, like DNA replication or chromatin structure. Not sure if R-loops are part of this therapy.\\n\\nAntisense is aRNA that binds to a DNA sequence, usually the complementary strand. It's used for regulation and communication. So D is involved.\\n\\nWait, the question is about the structures not involved. So the Morpholino is the RNA that binds to the mRNA, right? So it's the RNA, but the structures would be the ones present in the process. The Morpholino itself isn't one of the structures listed, but the structures involved are the lariat (A), polyA tail (B), antisense (D). R-loops (C) might be unrelated, but I'm not sure.\\n\\nWait, the question is about which structure is not involved. So all four structures except one are part of the process.\\n\\nLet me think again. The therapy involves the spliceosome being prevented from binding. The spliceosome uses the lariat structure to splice the exons. So A is involved.\\n\\nAntisense (D) is part of the therapy as well, as it might help in targeting the exon.\\n\\nPolyA tail (B) is a structure of mRNA, so it's involved in the mRNA itself.\\n\\nSo the structure not involved would be R-loops (C). Because R-loops are RNA-DNA structures, not directly involved in splicing or the spliceosome's function. Unless R-loops are involved in other processes, but the question is about the therapy, which is about the spliceosome and intron removal.\\n\\nSo the answer should be C) R-loops.\\n</think>\\n\\nThe question involves a gene with several exons, including those that code for triple helical repeats. Mutations in the central exons can lead to out-of-frame peptides and progressive degeneration. Morpholinos are introduced to target the 5' end of an out-of-frame exon in pre-mRNA, preventing the spliceosome from binding. This results in exon skipping and in-frame joining, restoring protein functionality.\\n\\nThe question asks which structure is not involved in this therapy. Let us analyze the options:\\n\\n1. **Lariat (A):** The lariat structure is formed during splicing when introns are removed and exons are joined. Since Morpholinos prevent the spliceosome from binding, the lariat is directly involved in the splicing process.\\n\\n2. **PolyA Tail (B):** The polyA tail is a nucleic acid component of mRNA, typically added during transcription. It is essential for mRNA stability and translation, making it directly involved in the process.\\n\\n3. **R-loops (C):** R-loops are RNA-DNA structures where an RNA strand is antiparallel to DNA. While R-loops can play roles in processes like DNA replication or chromatin structure, they are not directly involved in the splicing mechanism or the therapy described.\\n\\n4. **Antisense (D):** Antisense RNA is used to target specific DNA sequences and can help regulate or communicate with the spliceosome. It is indirectly involved in the therapy as it may assist in exon targeting.\\n\\nThe structure **R-loops (C)** is not directly involved in the described therapy. \\n\\nANSWER: C<ï½œendâ–ofâ–sentenceï½œ>\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>\\nOkay, so I'm trying to figure out this multiple-choice question about gene therapy using Morpholinos. Let me read through it again and break it down.\\n\\nThe question says that a large gene has many exons, and the central ones code for triple helical repeats that connect the cytoskeleton with the sarcolemma and extracellular matrix. Each exon usually codes for one such triple helix. Then, the most common mutations are central exon deletions, which lead to out-of-frame peptides and progressive degeneration. So, to fix that, they're using a Morpholino that binds to the 5' end of the out-of-frame exon in pre-mRNA. This prevents the spliceosome from binding and causes exon skipping and in-frame joining.\\n\\nThe question is asking which structure is NOT involved in this therapy. The options are A to D.\\n\\nHmm, the options are lariat, polyA tail, R-loops, and antisense.\\n\\nWait, what's a Morpholino? I remember it's a small RNA molecule, like a small RNA transcript, that's usually small, maybe a few hundredths of a millimeter. It's known for being a tool in gene editing or gene therapy. It can base-pair with mRNA to disrupt gene expression.\\n\\nIn this scenario, the Morpholino binds to the 5' end of the out-of-frame exon. The idea is that the Morpholino can't bind to the spliceosome machinery, so the spliceosome can't recognize it, leading to exon skipping. So, the mRNA is processed without that exon, and the mRNA is joined together in frame.\\n\\nNow, the therapy involves disrupting the splicing process. So, I need to think about which structures are involved in the process of splicing and mRNA processing.\\n\\nThe lariat structure is part of the splicing mechanism. When a spliceosome recognizes an intron, it uses the intron as a template to form an lariat structure with the exons. So, the lariat is involved in the splicing process.\\n\\nThe polyA tail is a structure found in the mRNA. The polyA signal is recognized by the ribosome, and the polyA tail is recognized by the rRNA. So, it's involved in mRNA processing, but not directly in the splicing mechanism or the Morpholino's role.\\n\\nR-loops are structures where a base pair between an RNA and a DNA is formed. I think they are involved in gene regulation, such as chromatin looping for gene expression. So, they might not be directly involved in the splicing process.\\n\\nAntisense is a RNA that binds to a complementary sequence in DNA or RNA, usually to silence gene expression. So, it's involved in RNA interference or antisense-based gene silencing.\\n\\nThe question is which structure is not involved. The therapy uses Morpholino to disrupt splicing. So, the structures involved in the therapy would be lariat (for splicing), polyA tail (for mRNA processing), and antisense (if used for antisense RNA, but in this case, the Morpholino is acting as a guide for splicing, not as antisense). Wait, but the Morpholino is acting as a guide, not as an antisense RNA. So, antisense isn't part of this therapy.\\n\\nSo, the structures involved are lariat (part of splicing), polyA tail (for mRNA processing), and antisense (if any antisense RNA is used, but in this case, it's Morpholino as a guide). So, the structure not involved is R-loops because R-loops are part of chromatin structure, not directly in the splicing process.\\n\\nWait, the options are A) lariat, B) polyA, C) R-loops, D) antisense.\\n\\nSo, the therapy is using a Morpholino to prevent the spliceosome from binding. The spliceosome's role is in splicing, which involves lariat formation. So lariat is involved. PolyA is involved in mRNA. R-loops are involved in chromatin. Antisense is involved if there's antisense RNA being used, but in this scenario, Morpholino is acting as a guide. So, antisense isn't part of this therapy.\\n\\nTherefore, the structure not involved is R-loops. So, the answer is C) R-loops.\\n</think>\\n\\nTo determine which structure is not involved in the proposed therapy, we analyze the role of each option in the context of the described gene therapy using Morpholinos:\\n\\n1. **Lariat Structure**: The spliceosome uses lariat structures to join exons with introns during splicing. Since the therapy prevents the spliceosome from binding by disrupting splicing, lariat structures are directly involved in the process.\\n\\n2. **PolyA Tail**: The polyA tail is a characteristic feature of mRNA, recognized by the ribosome and rRNA. While it is involved in mRNA processing, it is not directly involved in the splicing mechanism or the Morpholino-mediated therapy.\\n\\n3. **R-loops**: R-loops are structural elements formed by base pairing between an RNA and DNA. They are involved in chromatin regulation and gene expression. However, they are not directly involved in the splicing process or the Morpholino therapy described.\\n\\n4. **Antisense**: Antisense RNA is typically used for RNA interference or gene silencing. Since the Morpholino in this therapy acts as a guide to disrupt splicing rather than producing antisense RNA, antisense is not involved in this specific therapy.\\n\\nThe therapy involves disrupting splicing by preventing the spliceosome from binding, which directly impacts the lariat structure. The polyA tail and antisense are not part of the described mechanism. R-loops, however, are unrelated to the splicing process or the Morpholino therapy. Therefore, the structure not involved in the proposed therapy is **R-loops**.\\n\\nAnswer: C<ï½œendâ–ofâ–sentenceï½œ>\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>\\nOkay, so I'm looking at this question about gene therapy using Morpholinos. Hmm, let me try to break it down. \\n\\nThe question says that there's a gene with many exons, mostly coding for triple helical repeats. These repeats connect the cytoskeleton, sarcolemma, and extracellular space. Each exon is supposed to code for one such repeat. But the mutations are central exon deletions, leading to out-of-frame peptides and progressive degeneration. The therapy is Morpholinos that prevent the spliceosome from binding, causing exon skipping and in-frame joining. The therapy works well because some exons are missing, and the organism tolerates them.\\n\\nThe question is asking which structure isn't involved in this therapy. The options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nWait, let me think about each part. Morpholinos are small RNA molecules that can bind to mRNA. They can influence splicing by binding to the 5' end of the mRNA. If the Morpholino doesn't bind to the spliceosome, it might prevent it from recognizing certain splice sites, leading to exon skipping.\\n\\nSo, during splicing, the spliceosome recognizes specific sequences to cut the mRNA into pieces and splice them together. If the Morpholino inhibits this, the spliceosome can't join the exons, so the exon is skipped. This results in in-frame junctions, which are more common and better tolerated.\\n\\nNow, what structures are involved in this process? Let's see the options:\\n\\nA) Lariat structure: I remember that during splicing, the spliceosome uses the DNA template (like the sense strand) to form a lariat structure. The lariat is a double-stranded RNA, which gets cut and then joined back together. So the lariat is involved in the splicing process.\\n\\nB) PolyA tail: The polyA tail is a common feature in eukaryotic mRNA. It's usually added to the 3' end. I think the spliceosome might recognize the polyA tail, but wait, I'm not sure. Alternatively, maybe the Morpholino doesn't interact with the polyA tail directly. Or does it? Hmm, but the therapy doesn't involve adding a polyA tail. The polyA tail is more about termination and translation, not splicing.\\n\\nC) R-loops: R-loops are RNA secondary structures formed when an RNA strand is antiparallel to another and forms a loop. They're involved in various processes, like DNA repair or transcription. I'm not sure how R-loops come into play here. Maybe the Morpholino creates an R-loop that affects the mRNA structure, but I'm not certain if that's involved in exon skipping via splicing.\\n\\nD) Antisense: Antisense RNA is complementary to the target mRNA. I'm not sure if that's part of the Morpholino therapy. Antisense is more about RNA interference or regulation, but here the Morpholino is used for splicing. So maybe antisense isn't involved here.\\n\\nWait, the question is which structure is NOT involved. So which structures are involved in the described therapy.\\n\\nThe therapy involves splicing, so the lariat (A) is involved. The spliceosome uses the DNA as a template, so the polyA tail isn't involved. The Morpholino binds to the mRNA, preventing the spliceosome from recognizing certain exons. So D) antisense isn't directly involved, but the question is about which is not involved.\\n\\nWait, maybe I'm getting confused. The Morpholino is a small RNA molecule that binds to the 5' end of the mRNA. It might form an R-loop with the mRNA, creating a structure that inhibits splicing. Alternatively, the Morpholino might bind directly to the splice sites, preventing the spliceosome from recognizing certain exons.\\n\\nHmm. So the structures involved in the process are the lariat (A), the polyA tail (B), and perhaps an R-loop (C). The Morpholino itself might form an R-loop. So the structures not involved would be D) antisense.\\n\\nWait, but the options are A) lariat, B) polyA, C) R-loops, D) antisense.\\n\\nSo the therapy involves the spliceosome, so the lariat is involved. The polyA tail isn't part of the splicing process. The R-loop could be involved if the Morpholino causes a structure that affects splicing. The antisense isn't directly involved.\\n\\nSo the structures not involved would be D) antisense. But wait, the Morpholino is an antisense RNA to the exons. Or wait, maybe the antisense is part of the therapy but not the structure itself. Hmm, the question is which structure is not involved.\\n\\nAlternatively, maybe the structure that's not involved is D) antisense because the Morpholino is the antisense RNA. But the question is which structure is NOT involved. So which structures are part of the therapy.\\n\\nWait, the therapy uses the Morpholino to block the spliceosome. So the spliceosome's function involves the DNA as a template. So the polyA tail is part of mRNA processing, not splicing. So B) polyA tail is not involved in the therapy.\\n\\nWait, but the question is about what's not involved. The options are four, so the structure that's not part of the process.\\n\\nSo, the structures involved in the therapy would be the lariat (A), which is the product of splicing, the polyA tail (B), which is part of the mRNA but not splicing, and the R-loop (C) which is formed by the Morpholino binding and possibly causing a structure that affects splicing.\\n\\nSo which one is not involved? The options are:\\n\\nA) lariat: involved.\\n\\nB) polyA: not involved in the splicing.\\n\\nC) R-loop: possibly involved in the structure.\\n\\nD) antisense: not part of the therapy mechanism, but the structure.\\n\\nWait, the question is about which structure is not involved. So the structures that are part of the therapy are A (lariat), B (polyA), C (R-loop), and D (antisense RNA). So the structure not involved is D) antisense.\\n\\nWait, but the Morpholino is an antisense RNA. So perhaps the antisense is a part of the therapy. But the question is which structure is not involved. So the structure not involved would be D) antisense.\\n\\nWait, but the Morpholino itself is an antisense, but the structure (the structure) that isn't involved is the antisense itself.\\n\\nWait, perhaps I'm getting confused. The question is which structure is NOT involved. So, the structures that are part of the process (A, B, C) are involved, and D) antisense is not a structure in the process, but the Morpholino is an antisense RNA.\\n\\nWait, the options are A) lariat, B) polyA, C) R-loop, D) antisense.\\n\\nSo the structures that are not involved: the Morpholino is an antisense RNA, but the structures A, B, C are part of the process.\\n\\nSo the structure not involved is D) antisense.\\n\\nWait, but wait. The Morpholino is an antisense RNA. So the structure D) antisense is not part of the process. So the structure that is not involved is D) antisense.\\n\\nWait, but the question is which structure is NOT involved. So the structures involved are A, B, C, and D is not involved.\\n\\nWait, but the options are: the question is, which structure is not involved. So, the structures involved are lariat (A), polyA (B), R-loop (C). The antisense (D) is not part of the process.\\n\\nSo the structure not involved is D) antisense.\\n\\nWait, but the question is about the structures involved in the therapy. So the therapy involves lariat (A), polyA (B), R-loop (C). So the structure not involved is D) antisense.\\n\\nBut wait, I'm getting a bit tangled. The options are:\\n\\nA) lariat - involved.\\n\\nB) polyA tail - part of mRNA, not involved in splicing.\\n\\nC) R-loops - possibly involved.\\n\\nD) antisense - part of the therapy, but not a structure.\\n\\nSo the structure that is not involved is D) antisense.\\n\\nWait, but the question is, which structure is not involved in the proposed therapy. So the structures involved are A, B, C, and D is not involved.\\n\\nTherefore, the answer is D) antisense.\\n\\nWait, but the question says which structure is not involved. The options are A, B, C, D. So the structures involved in the process are A (lariat), B (polyA), C (R-loop), and D (antisense RNA). So the structure not involved is D) antisense.\\n\\nWait, but the question is about the structures. So the structures that are part of the process are the ones the therapy uses. So the structure not involved is D) antisense.\\n\\nWait, but the Morpholino is an antisense RNA, but the structure D) is not part of the process. So the structure not involved is D) antisense.\\n\\nAlternatively, perhaps the structure not involved is the antisense itself, but the options are about structures. So the correct answer is D) antisense.\\n</think>\\n\\nThe question involves a gene with multiple exons, each coding for a folded triple helical repeat. Central exon deletions cause out-of-frame peptides and progressive degeneration. Morpholinos are used to block the spliceosome by binding to the 5' end of out-of-frame exons, leading to exon skipping and in-frame joining.\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>\\nOkay, so I've got this multiple-choice question about gene therapy and Morpholinos. Hmm, let me try to break it down step by step. I'm a bit rusty on some of these concepts, but I'll think through it.\\n\\nThe question says that there's a large gene with many exons. The central ones code for triple helical repeats that connect the cytoskeleton, sarcolemma, and extracellular space. Each exon usually codes for one folded triple alpha helix. The most common mutations are deletions in the central exons, leading to out-of-frame peptides. But the therapy is to use a Morpholino that binds to the 5' end of the out-of-frame exon in pre-mRNA. This prevents the spliceosome from binding, leading to exon skipping and in-frame joining.\\n\\nThe options are about which structure isn't involved. The options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nWait, so what do I remember about Morpholinos? Oh right, Morpholinos are antisense oligonucleotides that target specific exons. They can disrupt the normal splicing machinery. When they bind to the 5' end of an exon, it can prevent the spliceosome from recognizing it. This leads to exon skipping, which results in in-frame joining. So the therapy uses antisense to block the spliceosome, allowing the spliceosome to splice the exon after the missing one. That makes sense.\\n\\nNow, the question is about the structures involved. So the therapy doesn't directly involve the spliceosome or the lariat structure. Let me think about each option.\\n\\nOption A: Lariat. I know that during splicing, especially in the 5' splice site, the pre-mRNA forms a lariat structure with the intron. This is part of the spliceosome. But in this therapy, the Morpholino prevents the spliceosome from binding. So the lariat might form normally, but the spliceosome doesn't process it. So the lariat is involved in normal splicing. But the therapy doesn't create a lariat; it's about preventing the spliceosome from working on the exon. So the lariat is involved in normal splicing, but the therapy doesn't create it. So the question is which structure isn't involved in the therapy. So the lariat is involved in the normal splicing, but the therapy doesn't create it. So perhaps the lariat is involved in the therapy process. Or maybe not. Hmm, not sure yet.\\n\\nOption B: PolyA tail. PolyA tails are involved in the elongation phase, as they signal the ribosome to stop transcription. But in this therapy, the therapy is about disrupting splicing. So the polyA tail is more about the elongation phase, not splicing. So the polyA tail is not involved in the therapy. So the therapy doesn't involve the polyA tail. So this could be the correct answer.\\n\\nOption C: R-loops. R-loops are RNA secondary structures where an RNA helix is wrapped around a non-helix region. They can form between exons, sometimes due to mismatches. I'm not sure how this ties into the therapy. The therapy is about antisense oligonucleotides blocking splicing. R-loops might be involved in the formation of secondary structures, but the therapy itself doesn't directly create or involve R-loops. So perhaps R-loops are not involved in the therapy.\\n\\nOption D: Antisense. Morpholinos are antisense oligonucleotides. So D is definitely involved. So the question is about which structure is not involved. So D is involved, so not the answer.\\n\\nSo the question is which structure is not involved. So the options are A, B, C, D. We've determined D is involved, so the answer can't be D.\\n\\nNow, between A, B, and C. Let's think again. The therapy uses antisense (D), which is involved. The lariat is part of the normal splicing mechanism, which is involved in the therapy. So the lariat is involved in normal splicing but the therapy doesn't create it. But the question is which structure is not involved in the therapy. So the lariat is involved in normal splicing, but the therapy doesn't create it. So the lariat isn't directly involved in the therapy process. Or wait, the therapy uses the lariat to prevent the spliceosome from binding. So perhaps the lariat is involved in the normal splicing, but the therapy doesn't create it. So the therapy doesn't involve the lariat.\\n\\nWait, the question is which structure is not involved in the proposed therapy. So the therapy doesn't create a lariat. So the lariat is involved in normal splicing, but the therapy doesn't create it. So the lariat is not part of the therapy. So the answer would be A.\\n\\nBut wait, the therapy doesn't create a lariat. So the lariat is part of the normal splicing process, not the therapy. So the therapy doesn't involve the lariat. So the answer is A.\\n\\nBut I'm a bit confused because the lariat is part of the normal splicing process. So in the therapy, the spliceosome doesn't process the lariat because the Morpholino prevents it from binding. So the lariat is involved in normal splicing, but the therapy doesn't create it. So the lariat is not part of the therapy, making option A the correct answer.\\n\\nWait, but the question is about structures not involved in the therapy. So the therapy doesn't involve the lariat. So the answer is A.\\n\\nAlternatively, perhaps the lariat is part of the therapy process. Hmm.\\n\\nWait, in normal splicing, the lariat is formed, but in the therapy, the spliceosome is prevented from recognizing the exon. So the lariat doesn't form as part of the therapy. So the lariat is involved in normal splicing but not in the therapy. So the therapy doesn't use the lariat, so the lariat is not involved. Therefore, the answer is A.\\n\\nAlternatively, perhaps the lariat is part of the normal splicing and the therapy doesn't create it. So the therapy doesn't involve the lariat. So the structure not involved is A) lariat.\\n</think>\\n\\nThe question involves a large gene with multiple exons, where central exons code for triple helical repeats. Mutations in these exons can lead to out-of-frame peptides, but the therapy uses a Morpholino to block spliceosome binding, causing exon skipping and in-frame joining. The task is to identify which structure is not involved in this therapy.\\n\\n### Analysis of Options:\\n1. **A) Lariat**: During normal splicing, the spliceosome forms a lariat structure between the 5' splice site and the intron. While the therapy prevents the spliceosome from binding to the exon, the lariat is still formed as part of normal splicing. However, the therapy does not directly create or involve the lariat. Thus, the lariat is involved in normal splicing but not in the therapy.\\n\\n2. **B) PolyA Tail**: The polyA tail is involved in RNA elongation, not splicing. Since the therapy is focused on disrupting splicing, the polyA tail is not relevant to the therapy and is not involved in this process.\\n\\n3. **C) R-loops**: R-loops are RNA secondary structures formed during transcription and splicing. While they can form between exons, they are not directly involved in the Morpholino therapy, which targets antisense oligonucleotides to block spliceosome binding. Thus, R-loops are not involved in the therapy.\\n\\n4. **D) Antisense**: Morpholinos are antisense oligonucleotides that bind to specific exons to disrupt splicing. This is a core component of the therapy and is directly involved.\\n\\n### Conclusion:\\nThe therapy involves antisense (D), R-loops (C), and polyA tail (B). The lariat (A) is involved in normal splicing but is not directly part of the therapy. Therefore, the structure not involved in the proposed therapy is **A) lariat**.\\n\\nANSWER: A<ï½œendâ–ofâ–sentenceï½œ>\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>\\nOkay, so I've got this multiple-choice question about gene therapy using Morpholinos, and I need to figure out which structure isn't involved. Let me think through this step by step.\\n\\nThe question describes a gene with multiple exons. The central ones code for folded triple alpha helices, which connect the cytoskeleton, sarcolemma, and extracellular space. Each exon usually codes for one such helix. But the most common mutations are central exon deletions, creating out-of-frame peptides. These mutations lead to progressive degeneration of an organ. So, the idea is to use a Morpholino to address this.\\n\\nA Morpholino is a RNA molecule that binds to specific sites in mRNA. The question says it's recognized at the 5' end of the out-of-frame exon in pre-mRNA. By preventing the spliceosome from binding, it skips the exon and joins the remaining parts in-frame.\\n\\nNow, the question asks which structure isn't involved in this therapy. The options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nLet me think about each structure:\\n\\nA) Lariat: In mRNA splicing, during the 5' to 3' direction, during the lariat formation, the branch site is at the 3' end of the exon. The lariat is formed by the polyA tail adding to the branch site. So lariat is involved in the process.\\n\\nB) PolyA tail: The polyA tail is added during mRNA processing, after splicing. It's involved in the lariat formation, so this is definitely involved.\\n\\nC) R-loops: R-loops are RNA structures where an RNA helix is wrapped around a nucleotide. They form when RNA secondary structures interact with a specific nucleotide. I'm not immediately seeing how R-loops are involved in the therapy described. But wait, Morpholinos are RNA molecules that can form R-loops when binding to exons. So maybe R-loops are involved in the binding process.\\n\\nD) Antisense: Antisense RNA is complementary to the target RNA, usually in the 3' UTR. It's involved in the formation of antisense RNA, which can act as a template for antisense-mediated RNA interference. In the context of splicing, antisense RNA might help in recognizing certain sequences, perhaps in the exon that's being targeted. So, antisense is involved.\\n\\nWait, the question is which structure isn't involved. The therapy is about using Morpholinos to prevent the spliceosome binding. The spliceosome uses the branch site to recognize the 3' end of the exon. The Morpholino binds there, preventing the spliceosome from joining. The process might involve R-loops because Morpholino is an RNA that can form R-loops with the branch site.\\n\\nAlternatively, I'm trying to remember if R-loops are part of the therapy. I think the Morpholino can form R-loops with the branch site, which is part of the polyA tail. So the polyA tail is already involved, as well as the branch site's structure. But in the options, R-loops is option C.\\n\\nWait, the question is about what's NOT involved. So which one isn't used.\\n\\nLooking again, the therapy is about preventing the spliceosome from binding by binding to the 5' end of the exon. The spliceosome recognizes the branch site (which is the 3' end of the exon). So the Morpholino binds to this site, preventing the spliceosome from joining. During this process, the Morpholino might form an R-loop with the branch site, which is part of the polyA tail.\\n\\nSo all structures involved are part of the process. The question is which one isn't involved. So perhaps R-loops are involved, but the question is which one is not involved.\\n\\nWait, looking again: The therapy involves the spliceosome binding and preventing it. So the spliceosome is part of the machinery. The Morpholino binds to the exon, which is involved in the branch site. The branch site is part of the polyA tail, which is a part of the mRNA processing.\\n\\nSo all four structures are involved except one. The options are A) lariat (part of splicing), B) polyA tail (as part of the mRNA), C) R-loops (part of the binding process), D) antisense (maybe not part of this particular therapy, but in some contexts it's involved).\\n\\nWait, the question says the therapy is to prevent spliceosome binding. So, the spliceosome is part of the process, so option D (antisense) is involved in the targeting.\\n\\nWait, but antisense RNA is involved in RNA interference, which could be part of the therapy. So if the question is which is NOT involved, perhaps antisense isn't directly involved in this specific therapy.\\n\\nAlternatively, maybe the Morpholino itself forms an R-loop, but the question is about the structure involved in the therapy.\\n\\nWait, the question is asking which structure is NOT involved. Let's think about each option:\\n\\nA) Lariat: Yes, because during splicing, the branch site forms a lariat (polyA tail adds to it).\\n\\nB) PolyA tail: Yes, as part of the lariat.\\n\\nC) R-loops: Yes, since the Morpholino binds to the branch site, which is an R-loop structure.\\n\\nD) Antisense: Not directly involved in the described therapy. The therapy is about using Morpholino to prevent spliceosome binding, which is about the spliceosome's function, not antisense RNA's role in RNA interference.\\n\\nWait, but the question says the therapy is to create exon skipping. So perhaps antisense RNA is part of this process, but the question is which structure is not involved. So if the therapy is using Morpholino to prevent the spliceosome, the structures involved are the lariat, polyA tail, R-loops. The structure that isn't involved is antisense, or perhaps something else.\\n\\nWait, another angle: The Morpholino binds to the 5' end of the exon. The spliceosome recognizes the branch site (3' end), so the Morpholino is preventing the spliceosome from binding. The branch site is part of the polyA tail, and the branch site itself is part of the RNA structure, which forms R-loops.\\n\\nBut the question is about the structures involved in the therapy. So, the structures that are part of the process:\\n\\n- The branch site is part of the polyA tail.\\n\\n- The spliceosome is part of the machinery, but the question says it's the Morpholino that's preventing the spliceosome.\\n\\nWait, the options are what's NOT involved. So the structures involved are lariat, polyA, R-loops, and maybe antisense. But the therapy doesn't involve antisense RNA.\\n\\nWait, wait. Antisense RNA is complementary to the target. In this case, the target is the exon being skipped. The Morpholino binds to the exon's 5' end. The spliceosome uses the branch site, which is part of the polyA tail. So the antisense RNA isn't directly involved in this process. Unless the antisense RNA is part of the therapy's setup or function.\\n\\nAlternatively, the structure that's not involved is the antisense RNA, because it's not part of the process described.\\n\\nWait, but the question is which structure is not involved. So, the therapy uses Morpholino, which is an RNA, and the process involves the branch site, the polyA tail, and R-loops.\\n\\nSo the structures involved are lariat, polyA, R-loops. The one not involved is antisense RNA.\\n\\nWait, but the options don't have antisense. Let me read the question again.\\n\\nThe options are:\\n\\nA) lariat\\n\\nB) polyA tail\\n\\nC) R-loops\\n\\nD) antisense\\n\\nSo, the therapy involves the spliceosome, the branch site, the polyA tail (as part of the lariat), and the R-loops. The Morpholino forms an R-loop with the branch site.\\n\\nWait, but the question is which structure is NOT involved. So, which one isn't part of the therapy's process.\\n\\nSo the structures involved are the lariat, polyA, R-loops, and the spliceosome (but the spliceosome is a part of the machinery, not the structure mentioned in the options). So the options are about structures involved in the therapy.\\n\\nWait, the question is asking which structure is NOT involved. So, the structures that are part of the therapy are:\\n\\n- The branch site (which is part of the polyA tail)\\n\\n- R-loops formed by the Morpholino binding\\n\\n- The polyA tail itself, which is part of the lariat\\n\\n- The spliceosome's function (which is part of the process, but not one of the structures given)\\n\\nSo the structures involved are lariat, polyA, R-loops.\\n\\nThe structure that is not involved is antisense RNA.\\n\\nBut wait, antisense RNA is not part of the therapy. So in the options, D is antisense. So the answer would be D, antisense, as it's not involved in the therapy.\\n\\nWait, but the question is which structure is NOT involved. So the options are A to D.\\n\\nWait, the therapy is about using Morpholino to prevent spliceosome binding. So, the spliceosome is part of the process, but the structures involved are lariat, polyA, R-loops.\\n\\nSo, the structures that are not involved are the antisense RNA, which is option D. So the correct answer is D.\\n</think>\\n\\nTo determine which structure is not involved in the proposed therapy, we analyze the described process. The therapy involves using a Morpholino RNA to prevent the spliceosome\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>\\nOkay, let me try to figure this out. So the question is about gene therapy using Morpholinos and their effect on exons. Hmm, I remember that Morpholinos are small RNA molecules that can interfere with gene expression. They're often used in gene editing or therapy. The scenario here is that a gene has several exons, and the central ones code for triple helical repeats connecting the cytoskeleton, sarcolemma, and the extracellular space. Each exon codes for one such repeat. \\n\\nThe problem is that the common mutations are deletions in the central exons, leading to out-of-frame peptides and progressive degeneration. So the idea is to use a Morpholino that targets the 5' end of an out-of-frame exon. By binding there, the spliceosome is prevented from recognizing the exon, leading to exon skipping and in-frame joining. Exons are skipped because the spliceosome can't recognize the 5' end, so the adjacent exons join together, producing a shorter, in-frame protein.\\n\\nThe question asks which structure isn't involved in this therapy. The options are A to D: lariat, polyA tail, R-loops, and antisense.\\n\\nWait, let me think about each part. The Morpholino binds to the pre-mRNA. How does that work? Morpholinos are antisense RNA molecules, right? They are complementary to the mRNA, so they can bind and inhibit transcription. But in this case, they're used for editing, not for direct gene silencing. So how do they cause exon skipping?\\n\\nI think the spliceosome is involved in splicing pre-mRNA into mature mRNA. The spliceosome recognizes the 5' splice site and 3' splice site. If the Morpholino binds the 5' end of an exon, maybe it prevents the spliceosome from recognizing the 5' end. That would mean the spliceosome can't splice the exon, so the exon is skipped, and the adjacent exons are joined. So the exon is removed, and the protein is shorter but still functional.\\n\\nSo, how does the spliceosome function? It has a complex, including the splice sites, the 5' splice site recognition, and the 3' splice site recognition. It also has some structures like the catalytic core which includes proteins like snRNA and snRNAP. The spliceosome uses snRNAP to facilitate the splicing.\\n\\nBut the structures in the options: A is lariat. Wait, lariat is part of the RNA splicing mechanism. When the spliceosome processes an intron, it forms a lariat structure. So that's involved. But wait, the Morpholino is preventing the spliceosome from recognizing the exon, so it's not the spliceosome itself that's causing the lariat. The lariat is formed during splicing, so maybe the Morpholino isn't directly causing that. So perhaps the lariat is involved in the splicing process but not in the Morpholino-mediated exon skipping. Or perhaps the lariat is part of the process, but the Morpholino is not causing that.\\n\\nOption B: polyA tail. PolyA tails are involved in mRNA processing, particularly in the export from the nucleus. The polyA tail is recognized by the ribosome and is part of the mRNA after the 5' cap. But in this therapy, is the polyA tail involved? Well, the therapy is about editing an exon, not about mRNA export. So the polyA tail isn't directly involved in the therapy mechanism. So maybe option B is the correct answer because it's not part of the therapy.\\n\\nOption C: R-loops. R-loops are RNA secondary structures where an RNA helix is antiparallel to a DNA or RNA structure. They're formed when an RNA strand is wrapped around another structure, like a hairpin or another RNA. In gene editing or therapy, I'm not sure how R-loops come into play. The Morpholino binds to the mRNA, perhaps creating a structure that facilitates the spliceosome action. R-loops are more about base pairing, but I'm not sure if they are directly involved in the exon skipping. So maybe option C is not involved.\\n\\nOption D: antisense. Morpholinos are antisense molecules. So D is involved. So the structures involved are the antisense (D) and the spliceosome (as part of the therapy process, but maybe not the R-loop or polyA tail). \\n\\nThe question asks which structure is not involved. So which structures are not part of the therapy mechanism? The therapy involves Morpholinos (so D is involved), and the spliceosome, which is part of the machinery for splicing. But in the options, the spliceosome isn't an option. The options are lariat (A), polyA (B), R-loops (C), and antisense (D). So the structures not involved would be those not part of the process. \\n\\nWait, the problem states that the therapy is to prevent spliceosome recognition. So the spliceosome isn't part of the therapy process. The spliceosome is a part of gene expression, but the therapy is using Morpholino to interfere with it. So the spliceosome is part of the therapy, but the options don't have a spliceosome structure. So the structures not involved are the ones not part of the therapy. So which structures are not part of the therapy? The polyA tail is about mRNA export, which isn't part of this therapy. R-loops are RNA structures, but not part of the spliceosome. Lariat is part of the splicing process but not the Morpholino's effect.\\n\\nSo the question is which structure isn't involved. The therapy is about using a Morpholino to prevent spliceosome action. So the spliceosome is part of the process. Therefore, the structures that are not involved would be the ones not part of the process. The polyA tail is part of mRNA processing, not the therapy. R-loops are about structure formation, not the spliceosome. So which of the four is not involved? The options are lariat (part of splicing), polyA (not part of the therapy), R-loops (maybe part of the structure), and antisense (yes, D is involved).\\n\\nWait, the question is about the structures not involved. So, the structures that are not part of the therapy process.\\n\\nSo the Morpholino binds to the pre-mRNA, which is part of the process. The therapy involves the spliceosome, so structures that are part of the spliceosome would be involved. So the spliceosome is involved, but the options don't have the spliceosome. So in the options, D (antisense) is involved, but the spliceosome isn't an option.\\n\\nWait, the options are lariat (A), polyA (B), R-loops (C), and antisense (D).\\n\\nSo, which structures are not involved?\\n\\nThe therapy involves the spliceosome (since it's part of the process of splicing), so any structures involved in the spliceosome are involved. But the spliceosome is a complex, and the options don't have that.\\n\\nBut looking at the options, the structures not involved would be those not part of the therapy. So, the therapy is about preventing spliceosome recognition. So the spliceosome is part of the therapy. So the structures that are part of the spliceosome are involved. But the options don't include spliceosome structures, so perhaps the R-loop or polyA tail are not involved.\\n\\nWait, another approach: the therapy is about exon skipping by Morpholino. The process requires the spliceosome to recognize the exon and splice it. So the spliceosome is involved in the therapy. The structures that are part of the spliceosome are not in the options. But in the given options, antisense (D) is involved because Morpholinos are antisense. So the structures not involved would be the ones not part of the spliceosome.\\n\\nWait, the question is about which structure is not involved. The therapy is about the spliceosome, so structures that are not part of the spliceosome would be involved. But the options are about RNA structures or antisense.\\n\\nWait, the options include R-loops (C). R-loops are RNA secondary structures. How would that come into play in this therapy? The Morpholino binds to the pre-mRNA, which is a linear RNA. R-loops are a specific type of RNA structure where an RNA strand is antiparallel to another structure, like a DNA or another RNA. So, when the Morpholino binds, it might cause an R-loop to form. But I'm not sure if that's the case here.\\n\\nAlternatively, the spliceosome's mechanism is about the splice sites, not directly about RNA structures. So the R-loops and polyA tail are about RNA processing, not the spliceosome.\\n\\nSo which structures are not involved? Let's think about each option:\\n\\nA) Lariat: part of the splicing process, so involved.\\n\\nB) PolyA tail: part of mRNA processing, not part of the therapy.\\n\\nC) R-loops: not part of the therapy mechanism.\\n\\nD) Antisense: yes, involved.\\n\\nSo the structures not involved are polyA tail (B) and R-loops (C). The question is which structure is not involved.\\n\\nWait, but the question is which structure is NOT involved in the proposed therapy.\\n\\nThe therapy involves the spliceosome, so structures involved in the spliceosome are part of the therapy. But the options don't have spliceosome structures. So perhaps the R-loops and polyA tail are not part of the therapy.\\n\\nWait, the therapy uses the Morpholino to prevent the spliceosome from splicing. The spliceosome's function is to process the introns. So the structures involved in the spliceosome are part of the process. So the structures not involved would be those not\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>\\nOkay, so I've got this question about gene therapy and Morpholinos. Hmm, let's see. I'm a bit rusty on this, but I'll try to think it through.\\n\\nThe question says that there's a large gene with several exons. The central exons code for folded triple alpha helices, which connect the cytoskeleton with the sarcolemma and the extracellular space. Each exon usually codes for one of these structures. The most common mutations are central exon deletions, leading to out-of-frame peptides and progressive degeneration. So, the therapy is using a Morpholino to prevent the spliceosome from binding and causing exon skipping and in-frame joining. They mention that missing exons are well tolerated.\\n\\nThe question is asking which structure isn't involved in this therapy. The options are lariat, polyA tail, R-loops, and antisense. I remember that Morpholinos are small RNA molecules that can bind to the 5' end of exons. They're often used in gene editing or therapy to knock out or induce certain genes.\\n\\nLet me think about what each structure does. The lariat is a structure formed during DNA replication when a new strand unwinds and forms a loop. It's involved in DNA repair, like in double-strand breaks. So probably not lariat.\\n\\nPolyA tail is the nucleotide sequence that follows the 3' end of mRNA. It's involved in mRNA stability, especially in eukaryotes. But in this context, the therapy is about splicing, not mRNA stability. So polyA tail might not be involved here.\\n\\nR-loops are structures where an RNA strand is looped around a DNA helix, creating secondary structures. They're involved in gene regulation, especially in processes like RNA interference. So maybe R-loops are involved, but I'm not sure how.\\n\\nAntisense is RNA that binds to mRNA through complementary sequences, often used in gene silencing. So antisense could be involved in therapy, maybe in targeting specific exons.\\n\\nWait, but the therapy is about preventing the spliceosome from binding. The Morpholino would bind to the 5' end of the exon. Since the spliceosome recognizes the 5' splice site, binding the Morpholino would prevent it from doing so, leading to exon skipping.\\n\\nBut the question is about structures not involved. The Morpholino itself is RNA, but the structures in the options are probably the ones in the gene.\\n\\nSo the therapy is about disrupting the spliceosome function. How does that affect the structures?\\n\\nThe lariat structure is part of DNA replication, so not directly involved. The polyA tail is for mRNA stability, so unless the therapy affects mRNA stability, which it doesn't, polyA tail isn't involved here. R-loops are more about RNA-DNA interactions, so maybe involved in gene regulation, but not directly in splicing. Antisense would be about RNA binding, which could be involved in targeting the exon.\\n\\nSo the structure not involved would be polyA tail. Let me check the options. The question asks which structure is not involved. So the correct answer should be B) polyA tail.\\n</think>\\n\\nTo determine which structure is not involved in the proposed therapy, let's analyze the options based on the context provided:\\n\\n1. **Lariat (Option A):** Lariats are structures formed during DNA replication when a new strand unwinds and forms a loop. They are primarily involved in DNA repair processes, not in gene splicing or therapy. Therefore, lariats are not relevant to this therapy.\\n\\n2. **PolyA Tail (Option B):** The polyA tail is the nucleotide sequence following the 3' end of mRNA in eukaryotes. It plays a role in mRNA stability and translation. However, the therapy described in the question is focused on exon skipping and splicing, not mRNA stability. Thus, polyA tail is not involved in the described therapy.\\n\\n3. **R-loops (Option C):** R-loops are secondary structures formed when an RNA strand loops around a DNA helix. They are involved in gene regulation, particularly in RNA interference, but they are not directly related to splicing or exon skipping. Therefore, R-loops are not part of the therapy described.\\n\\n4. **Antisense (Option D):** Antisense RNA is used to bind to mRNA through complementary sequences, often for gene silencing. The Morpholino in the therapy binds to the 5' end of the exon, potentially targeting it for modification. Therefore, antisense is involved in the therapy.\\n\\nSince the therapy involves disrupting the spliceosome and exon skipping, it does not directly involve polyA tail or R-loops. However, the question asks for the structure **not** involved, and polyA tail is the most clearly unrelated structure to the described therapy.\\n\\nANSWER: B<ï½œendâ–ofâ–sentenceï½œ>\", '<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>\\nOkay, so I\\'ve got this question about gene therapy and Morpholinos. Let me try to think through it step by step. \\n\\nAlright, the question is about a therapy for a gene with multiple exons. The central exons code for triple helical repeats that connect the cytoskeleton, sarcolemma, and extracellular space. Each exon is usually involved in creating an out-of-frame peptide. So, if there\\'s a deletion in an exon, that would make the protein nonfunctional because the exons are out of frame. \\n\\nThe problem is that these deletions are often tolerated, but the therapy uses a Morpholino to address this. The Morpholino binds to the 5\\' end of the out-of-frame exon in pre-mRNA. It prevents the spliceosome from binding, which usually splices the exon. This leads to exon skipping, meaning the exon is removed, and the protein is joined in-frame. So, the therapy is a way to fix this by removing the problematic exon.\\n\\nNow, the question is asking which structure is NOT involved in this therapy. The options are A to D.\\n\\nLet me look at the structures mentioned. The options are: A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nWait, I\\'m a bit confused. What do these structures have to do with the therapy?\\n\\nI remember that in gene therapy, particularly in disrupting exons, certain mechanisms are involved. The spliceosome recognizes exons and introns and brings them together. If a Morpholino binds to the 5\\' end of the out-of-frame exon, it might disrupt the spliceosome\\'s recognition. So, the spliceosome wouldn\\'t recognize that exon anymore, leading it to skip it.\\n\\nBut I\\'m trying to think about which structures are involved in this process. Let\\'s go through each option.\\n\\nOption A: Lariat. Oh wait, during splicing, the spliceosome uses the lariat structure to join exons. When the spliceosome can\\'t recognize an exon, it might release the intron, leading to exon skipping. But the lariat itself is part of the splicing mechanism. So if the therapy is about exon skipping, the lariat structure would be involved. But the question is about what\\'s not involved. So if the therapy uses lariat, that\\'s involved, but the question is which is not involved. So perhaps option A is not the correct answer, but I\\'m not sure.\\n\\nOption B: PolyA tail. PolyA tails are involved in mRNA processing, particularly in the elongation phase. But in this context, the therapy is about disrupting an exon in pre-mRNA. The polyA tail isn\\'t directly involved in the exon skipping process. Unless the therapy somehow affects the mRNA\\'s stability or translation, but that\\'s a different matter. So the polyA tail isn\\'t involved here. So perhaps B is the correct answer.\\n\\nOption C: R-loops. R-loops are RNA structures where an RNA helix is looped back on itself. They can form in regions where the RNA is unwound, leading to transcriptional elongation. I\\'m not sure how R-loops relate to this particular therapy. The Morpholino binds to the 5\\' end of the exon. If the exon is out of frame, maybe the mRNA would have a certain structure that could form an R-loop. But is that involved in the therapy? Not directly, I think. R-loops are more about RNA structure during transcription, not about splicing or exon skipping. So perhaps C is not involved.\\n\\nOption D: Antisense. Antisense RNA is complementary to a gene\\'s mRNA. In some cases, like in the case of antisense therapy, where antisense RNA is used to knock out gene expression. But wait, in this question, the Morpholino is binding to the pre-mRNA. How would antisense come into play here? Alternatively, maybe antisense isn\\'t directly involved, but I\\'m not certain. Alternatively, perhaps antisense isn\\'t part of the mechanism here. Alternatively, the Morpholino doesn\\'t directly produce antisense RNA, but perhaps in some cases it could, but I\\'m not sure. I\\'m not certain about D.\\n\\nWait, going back to the question. The therapy is about exon skipping. So when the spliceosome can\\'t recognize the exon, it\\'s skipped. The Morpholino binds to the 5\\' end of the exon, preventing the spliceosome from recognizing it. So the process is about the spliceosome\\'s function. So structures involved would be the lariat (during splicing), polyA tail (related to mRNA processing but not directly involved in this specific therapy), R-loops (maybe in the mRNA structure, but not part of the splicing process), and antisense (if antisense is used in another part, but I don\\'t think it\\'s involved here).\\n\\nSo the question is, which structure is NOT involved in the therapy. So the therapy\\'s process doesn\\'t involve R-loops, polyA tail, or antisense. So which one is not involved?\\n\\nThe options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nWait, but the question is which structure is NOT involved. The therapy is about exon skipping, which involves the spliceosome. The spliceosome uses the lariat structure, so the lariat is involved. So the question is which is not involved. So the structures not involved would be the ones not part of the splicing mechanism or the therapy.\\n\\nWait, but the Morpholino is binding to the mRNA, which is part of the spliceosome. The polyA tail is part of the mRNA, but not directly involved in the splicing process. The R-loops would be part of the mRNA\\'s structure, but not directly involved in the splicing. Antisense is perhaps not involved here.\\n\\nSo the question is, which structure is NOT involved. So the therapy doesn\\'t involve the polyA tail (B), R-loops (C), and maybe the antisense (D). But I\\'m not entirely sure about D.\\n\\nWait, let\\'s think about the process. The therapy uses the Morpholino to prevent the spliceosome from binding. So the spliceosome recognizes exons and introns. The Morpholino binds to the 5\\' end of the exon, perhaps disrupting the spliceosome\\'s recognition. So in this process, the spliceosome is the key player. The lariat is part of the splicing mechanism, so the lariat structure is involved. \\n\\nSo the structures that are not involved would be the ones not part of this process. The polyA tail (B) is part of the mRNA, but the question is about the therapy\\'s mechanism. The polyA tail is involved in the process of mRNA processing, but not in the exon skipping via the spliceosome.\\n\\nWait, but the question is about which structure is not involved. So which of these structures is not part of the therapy. Let me think about each option:\\n\\nA) Lariat: yes, involved in splicing (so it\\'s part of the therapy, so not the answer).\\n\\nB) PolyA tail: involved in mRNA processing, not directly in splicing. So it\\'s not part of the therapy\\'s mechanism. So B is the answer.\\n\\nWait, but the question says \"which structure is not involved in the proposed therapy.\" So the therapy involves the spliceosome. So the structures that are not involved would be those unrelated to the process. So if the therapy doesn\\'t involve polyA tail, then B is the answer.\\n\\nBut I\\'m a bit confused. Let me think about the options again.\\n\\nThe options are:\\n\\nA) lariat: part of the spliceosome mechanism.\\n\\nB) polyA tail: involved in mRNA processing, but not part of the spliceosome.\\n\\nC) R-loops: perhaps not involved, as they are RNA structures during transcription, not during splicing.\\n\\nD) antisense: not sure, but perhaps not involved in this therapy.\\n\\nSo the question is about which structure is not involved. So the therapy involves the spliceosome and the lariat, but not the polyA tail, R-loops, or antisense.\\n\\nWait, but the question says \\'which structure is not involved in the proposed therapy.\\' So the therapy is about exon skipping. The therapy uses the Morpholino to prevent the spliceosome from binding. So the structures involved would be the spliceosome (lariat), but perhaps not the polyA tail. So the polyA tail is not part of the therapy.\\n\\nSo the correct answer is B) polyA tail.\\n</think>\\n\\nThe question involves a gene therapy targeting a gene with multiple exons, where the central exons code for triple helical repeats. The therapy uses a Morpholino to prevent the spliceosome from recognizing an out-of-frame exon, leading to exon skipping and in-frame protein production. The task is to identify which structure is **not involved** in this therapy.\\n\\n### Analysis of Each Option:\\n1. **A) Lariat**: During splicing, the spliceosome forms lariat structures to join exons. Since the therapy involves exon skipping, the spliceosome is central to the process, making the lariat structure involved.\\n\\n2. **B) PolyA Tail**: The polyA tail is part of mRNA processing, particularly in the elongation phase. While the therapy involves mRNA manipulation, the polyA tail is not directly involved in exon skipping or spliceosome function.\\n\\n3. **C) R-loops**: R-loops are RNA structures formed during transcription elongation and are not directly involved in exon skipping or spliceosome function. They are more relevant to transcriptional elongation but not to this therapy.\\n\\n4. **D) Antisense**: Antisense RNA is complementary to mRNA and can be used in antisense therapy, but it is not directly involved in the Morpholino-mediated exon skipping described in the question.\\n\\n### Conclusion', \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>\\nOkay, so I've got this question here about gene therapy and Morpholinos. Hmm, let me try to think through it step by step. \\n\\nAlright, the question is about a gene with multiple exons, especially the central ones. These exons code for triple helical repeats that connect the cytoskeleton, sarcolemma, and extracellular space. Each exon usually codes for one folded triple alpha helix. So that's a bit of a mouthful, but I think I get it. These repeats are important for the structure of the gene, maybe helping the cell structure or function.\\n\\nThe most common mutations here are central exon deletions, which lead to out-of-frame peptides. That's when the exons are not properly spaced, so the protein doesn't fold correctly. But this leads to progressive degeneration, so they're using Morpholinos to fix it.\\n\\nWait, Morpholinos are small RNA molecules, right? They can bind to mRNA and either interfere with splicing or help in exon skipping. In this case, the Morpholino is targeting the 5' end of an out-of-frame exon. So it's preventing the spliceosome from recognizing that exon, thereby skipping it.\\n\\nNow, the therapy works by creating exon skipping and in-frame joining. So the idea is that the spliceosome, which splices the exons together, is blocked. Instead, the mRNA is joined in a way that the exons connect in a way that the protein is still in frame, but using only the exons that are present.\\n\\nThe question is asking which structure isn't involved in this therapy. The options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nLet me think about each option.\\n\\nOption A: Lariat. Oh, wait, during splicing, the spliceosome makes an lariat structure when it splices an intron between exons. But in this therapy, the exon is skipped. So maybe the lariat isn't involved because it's about skipping, not the splicing mechanism itself. But wait, the lariat is the product of the spliceosome when it splices. So maybe the lariat isn't being made here because it's not part of the splicing process. Or perhaps the lariat is involved in the repair process. Hmm, I'm a bit confused here.\\n\\nOption B: PolyA tail. The polyA tail is part of the mRNA, right? It's added after the last exon, I think. So when the spliceosome splices, the polyA tail is preserved because it's usually at the end. But in this therapy, the polyA tail might be affected. However, the therapy doesn't directly involve the polyA tail. It's more about the splicing machinery. So the polyA tail isn't directly involved in the therapy.\\n\\nOption C: R-loops. R-loops are RNA structures formed when an RNA helix unwinds and forms a loop, often involving an RNA-DNA hybrid. Do Morpholinos form R-loops? Well, the Morpholino is a small RNA, but does it form R-loops with the mRNA? I'm not sure. Alternatively, maybe it's involved in creating a structure that allows the spliceosome to recognize the exon. But I'm not certain. Maybe R-loops are not directly involved in this therapy.\\n\\nOption D: Antisense. Antisense RNA is complementary to a target RNA sequence and binds to it. In this case, the Morpholino is antisense to the exon's sequence. So the Morpholino binds the mRNA, inhibiting the spliceosome from recognizing the exon, leading to exon skipping. So antisense is definitely involved.\\n\\nSo the question is which structure is not involved. So let's go back to the options.\\n\\nThe therapy involves preventing the spliceosome from recognizing the exon. So the spliceosome's role is to splice the exons, but with Morpholino interference, it skips. So the spliceosome doesn't do anything here, but perhaps the Morpholino binds to the mRNA and somehow induces this skipping.\\n\\nNow, what structures are involved in the process? The spliceosome is involved in splicing, so maybe the lariat is made in normal splicing, but in this therapy, since the exon is skipped, the lariat isn't formed because the spliceosome isn't working. So the lariat structure isn't formed, but perhaps the spliceosome isn't involved in splicing anyway. Alternatively, maybe the lariat is still involved but in a different way.\\n\\nWait, the lariat is a product of splicing, so in this case, the spliceosome isn't working. So the lariat isn't made. So the lariat isn't part of the therapy process. So if the question is which structure is not involved, then the lariat is not involved, because the spliceosome isn't doing splicing anymore.\\n\\nWait, but the lariat is a product of the spliceosome during splicing. If the spliceosome isn't doing splicing, then the lariat isn't being made. So in that scenario, the lariat isn't part of the therapy. So option A (lariat) is not involved.\\n\\nBut wait, the question is about which structure is not involved. The therapy is about exon skipping, which is done by Morpholinos. So the structures that are part of the therapy would be the Morpholino, the target exon, and the spliceosome. So which structures are not involved?\\n\\nThe options are about which structure is not involved.\\n\\nLooking back: the therapy is to prevent spliceosome from recognizing the exon, creating exon skipping. So the spliceosome isn't splicing anymore. So the structures involved in the therapy would be the Morpholino, the mRNA, and the target exon, but not the polyA tail.\\n\\nSo the structures not involved would be the polyA tail, because it's part of the mRNA.\\n\\nWait, but wait. The polyA tail is part of the mRNA, but the therapy doesn't involve the polyA tail. It's the spliceosome that's not splicing anymore because of the Morpholino. So the polyA tail is present in the mRNA, but the therapy doesn't use it. So the polyA tail isn't involved in the therapy.\\n\\nSo the structures not involved are the ones that are not part of the therapy. The therapy doesn't use the polyA tail, so it's not involved. So the structures not involved are the polyA tail.\\n\\nWait, but another angle: the therapy is about exon skipping, which is a process that involves the spliceosome. So the spliceosome is involved. So option C, R-loops, perhaps? Does the therapy involve R-loops? I'm not sure. If the Morpholino binds to the mRNA and creates a structure, like an R-loop, then it would be involved.\\n\\nWait, but the question is about the structures not involved. So the therapy doesn't involve R-loops. But the question is which structure isn't involved.\\n\\nSo the structures involved are:\\n\\n- Morpholino (D)\\n- Target exon (central exon)\\n- The mRNA (as the spliceosome is using it)\\n- The polyA tail (since the polyA tail is part of the mRNA, but the therapy doesn't involve it)\\n\\nSo which structure isn't involved? The options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nAntisense (D) is involved, lariat (A) is part of the spliceosome, so not involved in the therapy, but the lariat isn't made.\\n\\nWait, the question is which structure is NOT involved. So, the therapy doesn't involve the lariat because it's a product of splicing which isn't happening anymore.\\n\\nBut the question is about structures not involved. So if the spliceosome isn't splicing, the lariat isn't formed. So the lariat is not involved in the therapy.\\n\\nBut the options don't have lariat as an option for not being involved. Wait, the question is which structure is not involved. So the structures that are not part of the therapy are the ones not used.\\n\\nSo the therapy uses the Morpholino, the target exon, and the mRNA. The polyA tail is part of the mRNA but isn't used. So the polyA tail is not involved.\\n\\nSo the structures not involved would be the polyA tail (B), because it's part of the mRNA but not part of the therapy.\\n\\nWait, the question is asking which structure is NOT involved. So, all the structures except one are involved. Let's look.\\n\\nA) lariat: The lariat is a product of splicing. Since the spliceosome isn't splicing anymore, the lariat isn't made. So the lariat isn't involved in the therapy.\\n\\nB) polyA tail: It's part of the mRNA, but the therapy doesn't use it. So polyA tail is not involved.\\n\\nC) R-loops: Do the Morpholinos form R-loops with the mRNA? I don't think so. Alternatively, maybe the Morpholino is binding to the mRNA, but that's not an R-loop.\\n\\nD) Antisense: Yes, the Morpholino is antisense to the exon.\\n\\nSo which structures are not involved? The options are A, B, C, D. The therapy doesn't involve the lariat (A), polyA tail (B), antisense (D). But wait, the lariat is part of the spliceosome product, which isn't involved. So the lariat isn't involved.\\n\\nWait, but the question is which structure is not involved. So the structures involved in the therapy are the Morpholino, the target exon, the mRNA, and the antisense.\\n\\nSo which structure is not involved? The lariat is not involved because the spliceosome isn't splicing. So\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>\\nAlright, let's tackle this question. Okay, so the question is about gene therapy using Morpholinos. I'm a bit rusty on this, but let's think it through.\\n\\nSo, the question describes a gene with many exons. The central exons code for triple helical repeats that connect the cytoskeleton, sarcolemma, and extracellular space. Each exon is responsible for a folded triple alpha helix. The main issue is that the gene has mutations like deletions in the central exons, which cause out-of-frame peptides. This leads to progressive degeneration. So the therapy is to use a Morpholino that binds to the 5' end of the out-of-frame exon in pre-mRNA. The Morpholino prevents the spliceosome from binding, leading to exon skipping and in-frame joining, which fixes the problem.\\n\\nThe question is asking which structure isn't involved in this therapy. The options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nHmm. I remember that in mRNA splicing, the spliceosome recognizes the donor and acceptor sites. When a mutation occurs, like an exon deletion, the spliceosome can't find the correct sites, so it skips the exon. This allows the mRNA to be joined back together without the exon, resulting in a shorter, in-frame mRNA.\\n\\nNow, the Morpholino is a tool that binds to the pre-mRNA. So, the Morpholino is acting as a guide to prevent the spliceosome from recognizing the 5' end of the out-of-frame exon. That would cause the exon to be skipped, leading to the repair of the mRNA by exon skipping.\\n\\nWait, but I'm trying to recall what structures are involved in such processes. The spliceosome involves recognizing specific sites on the mRNA, but the Morpholino is a small RNA molecule. How does it interact with the spliceosome?\\n\\nI think that the Morpholino acts as a guide. It binds to the pre-mRNA, perhaps through complementary regions. This binding disrupts the spliceosome's ability to recognize the splice sites, leading to exon skipping. So, the Morpholino itself is involved, not the spliceosome.\\n\\nBut the question is about what structure is not involved. So, the structures mentioned are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nWait, lariat is a structure formed during splicing when the mRNA is joined by the spliceosome. So if the spliceosome is not active, the lariat wouldn't form, and the mRNA would be joined in-frame.\\n\\nPolyA tail is involved in translation initiation, but the question is about mRNA splicing, so maybe not relevant here. R-loops are regions of RNA where two RNA molecules are bound by hydrogen bonds, often seen in certain guide RNAs or during RNA interactions. Antisense is a DNA/RNA structure, but in this context, it's more about RNA molecules interacting.\\n\\nWait, but in the context of the therapy, the Morpholino is acting as a guide. So, the Morpholino is an RNA molecule that's part of the therapy. The spliceosome's role is to recognize the splice sites, and the Morpholino disrupts that by binding. So the structures involved in this process would be the spliceosome (which is involved in splicing, so maybe not one of the options), the Morpholino (which is part of the therapy), the lariat (which is a splicing product), polyA tail (not involved here), R-loops (maybe not directly involved), antisense (DNA/RNA, not involved here).\\n\\nWait, but the question is which structure is NOT involved. So, the options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nAntisense is DNA/RNA structure, so in this context, maybe not involved because the question is about RNA structures.\\n\\nWait, but the options are about structures not involved. So, which one isn't involved?\\n\\nThe therapy involves the Morpholino, which is an RNA molecule. So the structures not involved are the spliceosome, polyA tail, R-loops, and antisense. But the question is about which structure is not involved. So, perhaps the spliceosome isn't an option, but the Morpholino is. So the structures that are not involved would be the spliceosome (but it's not an option), polyA tail (yes, involved in translation), R-loops (maybe not directly involved in splicing), antisense (not involved in this context).\\n\\nWait, but the question is which structure is not involved. So, the structures in the options are: lariat (splicing product), polyA tail (translation), R-loops (RNA structure), antisense (DNA/RNA).\\n\\nSo, the structures involved in the therapy are the Morpholino (which is an RNA molecule), the lariat (if the spliceosome isn't active, the lariat doesn't form), the polyA tail (not directly involved), R-loops (maybe not involved), and antisense (DNA/RNA, not involved in this process).\\n\\nWait, but the question is about what's NOT involved. So, the structures not involved are the spliceosome (not in options), polyA tail, R-loops, antisense.\\n\\nWait, but the options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nSo, the therapy is using the Morpholino, which is part of the therapy, and the structures involved are the spliceosome (but it's not an option), the lariat (since the spliceosome is inactive, lariat wouldn't form), polyA tail, R-loops (maybe not involved), and antisense (not involved).\\n\\nSo, the question is which structure is NOT involved. So the structures involved are the spliceosome (which is not an option), lariat (so the lariat is involved?), polyA tail, R-loops, and antisense.\\n\\nWait, the spliceosome is not an option, but the spliceosome's product is the lariat. So the lariat is formed during splicing, so if the spliceosome doesn't work, the lariat wouldn't form. So the lariat is involved, as it's a product of splicing. So the structures not involved are the spliceosome (not in the options), polyA tail, R-loops, and antisense.\\n\\nBut the question is about which is not involved. So, the correct answer would be the structure that is not part of the therapy's mechanism.\\n\\nWait, but the Morpholino is an RNA that's part of the therapy. So the structures involved are the Morpholino, the lariat (because without the spliceosome, the lariat doesn't form), the polyA tail (not part of this process), R-loops (maybe not involved), and antisense (not involved).\\n\\nSo, the structures not involved are R-loops, polyA tail, and antisense. But the question is which is not involved.\\n\\nWait, the question is which structure is NOT involved. So the options are lariat (involved), polyA tail (involved?), R-loops (maybe not involved), antisense (not involved).\\n\\nBut the question is about what's not involved. So which one is not part of the therapy.\\n\\nThe therapy uses the Morpholino, which is an RNA. So the structures not involved are the spliceosome (not an option), polyA tail (involved in translation), R-loops (maybe not directly involved in this process), and antisense (not involved).\\n\\nWait, but the spliceosome is a complex that's not an option here. So the structures that are not involved would be the ones that don't play any role in the process.\\n\\nThe lariat is a product of splicing. So if the spliceosome is not working, the lariat wouldn't form. So the lariat is involved. So the structures not involved are R-loops, polyA tail, and antisense. But the question is which structure is not involved.\\n\\nWait, but the question is about the structures not involved. So the structures involved are the spliceosome, the lariat (as the product is involved), polyA tail (translation), R-loops (maybe not involved), and antisense (not involved).\\n\\nWait, the question is about which structure is NOT involved. So, the structures that are not part of the therapy process are R-loops (maybe not involved), polyA tail (involved), and antisense (not involved).\\n\\nBut the options are: A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nWait, but the question is which structure is not involved. So the structures not involved would be the ones that don't play a role. The lariat is involved (since without the spliceosome, the lariat doesn't form). So, if the spliceosome isn't active, the lariat isn't made. So the lariat is involved.\\n\\nThe polyA tail is involved in translation, but not in splicing. So if the spliceosome isn't active, the polyA tail is still present, but perhaps it's not part of the splicing process.\\n\\nR-loops are RNA structures, but I'm not sure they're directly involved in this process. Antisense is DNA/RNA structure, not involved.\\n\\nWait, but the question is about the structures NOT involved. So, the structures not involved are R-loops, polyA tail, and antisense. But the options are A to D.\\n\\nWait, perhaps the correct answer is D) antisense. Or perhaps the answer is C) R-loops.\\n\\nWait, the question is about what is NOT involved. Let's think again.\\n\\nThe Morpholino binds to the pre\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>\\nOkay, so I've got this question here about gene therapy using Morpholinos. Hmm, let me think through this. I'm a bit rusty, but I'll try to piece it together.\\n\\nThe question says that a large gene has several exons, and the central ones code for triple helical repeats connecting the cytoskeleton, sarcolemma, and extracellular space. Each exon is usually responsible for one folded triple alpha helix. The main issue is that the most common mutations are deletions in the central exons, which lead to out-of-frame peptides. These mutations cause progressive degeneration. So the solution is to use a Morpholino that binds to the 5' end of the out-of-frame exon in pre-mRNA. This prevents the spliceosome from recognizing it, leading to exon skipping and in-frame joining, which is better tolerated by the organism.\\n\\nThe question is asking which structure isn't involved in this therapy. The options are lariat, polyA tail, R-loops, and antisense.\\n\\nWait, what's the spliceosome do again? The spliceosome is a complex that uses the splice sites to cut pre-mRNA into exons and join them together. If a exon is deleted, the spliceosome can't recognize it because it's missing. But if a Morpholino binds the 5' end of that exon, it prevents the spliceosome from binding. So it skips the exon, and the splicing machinery can't splice it out, so the remaining exons are joined together in an in-frame manner, which is better.\\n\\nNow, the structures involved in this process. The Morpholino binds to the pre-mRNA, right? The spliceosome uses RNA structures like R-loops. R-loops are RNA structures where two RNA molecules form a loop, often using the 5' end of one as a template for the other. So the Morpholino would form an R-loop with the pre-mRNA, preventing the spliceosome from recognizing the exon.\\n\\nWhat structures are involved in this process? The polyA tail is involved in the termination of translation, but the question is about the spliceosome and exon skipping. The polyA tail is important for mRNA stability, but I'm not sure if it's directly involved in the Morpholino's function.\\n\\nWait, the question is about which structure is NOT involved. So which of these structures is not part of the therapy process.\\n\\nLooking at the options:\\n\\nA) Lariat: I think that's involved in the splicing process, forming a 5' cap and 3' tail. So the lariat is formed during splicing, so it's involved.\\n\\nB) PolyA tail: Definitely involved in the mRNA structure, but I don't think it's directly involved in the Morpholino therapy. It's more about translation termination.\\n\\nC) R-loops: The Morpholino binds to the pre-mRNA, and the spliceosome uses R-loops to prevent exon recognition. So R-loops are involved.\\n\\nD) Antisense: Antisense RNA is usually used in microRNA or small interfering RNA. It binds to complementary regions of mRNA. But Morpholinos are a different type of antisense RNA used for gene editing, like in the case of knocking out or adding exons. So antisense isn't the structure involved here.\\n\\nWait, wait. Let me double-check. Morpholinos are antisense RNA molecules that are incorporated into the pre-mRNA. They have a structure that can form a base-pair with the mRNA's 3' end, which allows the spliceosome to recognize them. So the spliceosome doesn't recognize them because they form an R-loop with the pre-mRNA. So the R-loop is involved in the therapy. Therefore, the structures involved are lariat (splicing), polyA tail (mRNA), R-loops (spliceosome recognition), but not antisense.\\n\\nThe question asks which structure is NOT involved. So the correct answer should be D) Antisense. Because the options are: the therapy uses antisense RNA, which is not directly involved in the spliceosome mechanism. The R-loops are involved, the polyA tail is involved, and the lariat is involved in splicing. So D is the one not involved.\\n</think>\\n\\nTo determine which structure is not involved in the proposed therapy, let's analyze each option:\\n\\n1. **Lariat**: During the splicing process, the spliceosome forms a lariat structure from the pre-mRNA. This is directly involved in the therapy, as it is part of the splicing mechanism. Therefore, the lariat is involved.\\n\\n2. **PolyA Tail**: The polyA tail is responsible for mRNA stability and termination of translation. While it is important for mRNA structure, it is not directly involved in the Morpholino therapy, which focuses on spliceosome function and exon skipping.\\n\\n3. **R-loops**: The Morpholino binds to the pre-mRNA, and the spliceosome recognizes these structures as R-loops. This prevents the spliceosome from binding the exon and allows exon skipping. Thus, R-loops are involved in the therapy.\\n\\n4. **Antisense**: Morpholinos are antisense RNA molecules that bind to the pre-mRNA. They are used to disrupt spliceosome recognition by forming a base-pair with the 3' end of the pre-mRNA. However, the question asks which structure is **not** involved. Since the therapy does not involve antisense in the spliceosome mechanism, this structure is not involved.\\n\\nBased on this analysis, the structure that is not involved in the proposed therapy is **D) Antisense**.\\n\\nAnswer: D<ï½œendâ–ofâ–sentenceï½œ>\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>\\nOkay, so I've got this question here about gene therapy, specifically involving Morpholinos and some exons. Hmm, let me try to break it down.\\n\\nAlright, the question says there's a large gene with several exons. The central exons code for folded triple helical repeats. These repeats connect the cytoskeleton, sarcolemma, and the extracellular space. Each exon usually codes for one of these repeats. The most common mutations are deletions in the central exons, creating out-of-frame peptides. Those mutations lead to progressive degeneration.\\n\\nThe therapy they're talking about is using a Morpholino that binds to the 5' end of the out-of-frame exon in pre-mRNA. This prevents the spliceosome from recognizing the exon, causing exon skipping and joining the exons in-frame. And the therapy is tolerated by the organism because there are missing exons.\\n\\nThe question is asking which structure isn't involved in this therapy. The options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nWait, I remember that Morpholinos are small RNA molecules that can bind to the 5' end of exons. They disrupt the spliceosome's recognition of exons, leading to exon skipping. Oh right, the spliceosome uses snRNA to find splice sites.\\n\\nSo the therapy involves the spliceosome. How does that relate to the structures mentioned?\\n\\nOption B is the polyA tail. I think polyA tails are important for mRNA stability and export from the nucleus. But in this therapy, I don't see polyA being directly involved. Unless the therapy somehow affects the polyA signal, but that's probably not the case. So B might not be involved.\\n\\nOption C is R-loops. R-loops are RNA secondary structures formed when an RNA molecule base pairs with itself in a non-stationary (non-canonical) way. They can form when RNA molecules pair with each other, like in certain viruses or in certain RNA processing steps. But Morpholinos are involved in splicing, not R-loop formation. So C is probably not involved.\\n\\nOption D is antisense. Antisense RNA is a type of small RNA that binds to the complementary strand of mRNA. But in this scenario, the Morpholino is binding to the pre-mRNA's 5' end, not to the mRNA itself. Unless it's acting as antisense. Wait, but antisense RNA is usually antisense to the mRNA. But in this case, the Morpholino is acting as antisense to the 5' end of the exon. So D might not be involved because the Morpholino isn't acting as antisense to the mRNA. Alternatively, maybe it's more about the spliceosome.\\n\\nWait, another thought. The spliceosome uses snRNAs as guides. The Morpholino is acting as an antisense RNA to the exon. So the spliceosome would recognize the antisense RNA, causing it to bind the exon and prevent it from being spliced. But the spliceosome might not be directly using the Morpholino as an antisense to the mRNA. Unless the Morpholino is an antisense to the mRNA. But that's not how it's described. The question says the Morpholino binds to the 5' end of the pre-mRNA. So it's acting as an antisense to that region of the pre-mRNA.\\n\\nWait, but the spliceosome's role is to recognize the exons via snRNA. So the Morpholino is the antisense RNA, not the mRNA's antisense. So D (antisense) isn't directly involved. Or wait, maybe the Morpholino is acting as antisense to the mRNA, but in this case, it's binding to the pre-mRNA.\\n\\nWait, the question says that the Morpholino binds to the 5' end of the pre-mRNA. So the Morpholino is acting as an antisense RNA to that region of the pre-mRNA. So that would mean that the spliceosome is using the Morpholino as an antisense to the pre-mRNA's 5' end. So antisense RNA would be the Morpholino in this context.\\n\\nSo, the structures involved would include the antisense RNA (Morpholino) and the spliceosome machinery. But the question is about which structure is NOT involved.\\n\\nLooking back at the options:\\n\\nA) Lariat: Lariat formation is part of the splicing process. When the spliceosome recognizes a pre-mRNA, it uses the branch site (A site) and the 5' splice site (E site). The branch site is a guanine-rich region, and the E site is a GU pair. The process forms a lariat structure. So the lariat is involved.\\n\\nB) PolyA tail: Not involved in splicing or antisense. So this is a candidate for the answer.\\n\\nC) R-loops: Not involved. R-loops are RNA structures, not related to splicing here.\\n\\nD) Antisense: The Morpholino is acting as an antisense RNA, so it's involved. But wait, the question is about which structure is NOT involved.\\n\\nWait, the question says the Morpholino is used to prevent the spliceosome from binding the exon. So the spliceosome's function is involved. So the structures involved are lariat (A), antisense (D), and polyA (B). But which one is not involved?\\n\\nWait, the question asks which structure is NOT involved. So if the structures in the options are about the process or products, but the question is about the structures involved in the therapy.\\n\\nWait, the therapy involves the spliceosome, which uses lariat structures. So A is involved. The Morpholino is the antisense RNA, so D is involved. R-loops (C) are not involved. The polyA tail (B) is not involved in the splicing or the therapy. So the correct answer would be B, polyA tail, as it's not involved in the therapy.\\n</think>\\n\\nTo address the question, we need to identify which structure is not involved in the proposed Morpholino therapy. The therapy involves delivering a Morpholino that binds to the 5' end of an out-of-frame exon in pre-mRNA, preventing spliceosome recognition and causing exon skipping. This process is part of RNA splicing and involves specific molecular mechanisms.\\n\\n1. **Lariat (A):** During RNA splicing, the spliceosome forms lariat structures using the branch site (A site) and the 5' splice site (E site). The Morpholino-mediated therapy indirectly involves lariat formation as part of the splicing process. Therefore, lariat is involved.\\n\\n2. **PolyA tail (B):** The polyA tail is involved in mRNA stability and export from the nucleus. However, it is not directly involved in the splicing process or the therapy itself. Thus, the polyA tail is not involved.\\n\\n3. **R-loops (C):** R-loops are RNA secondary structures formed by non-stationary (non-canonical) RNA pairing. This process is unrelated to the splicing mechanism or the Morpholino therapy. Therefore, R-loops are not involved.\\n\\n4. **Antisense (D):** The Morpholino acts as an antisense RNA to the pre-mRNA's 5' end of the out-of-frame exon. This is a key part of the therapy, as the spliceosome uses the Morpholino as an antisense to recognize the exon. Hence, antisense is involved.\\n\\nAmong the options, the polyA tail (B) is not involved in the splicing process or the therapy. \\n\\nANSWER: B<ï½œendâ–ofâ–sentenceï½œ>\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>\\nOkay, so I've got this question about gene therapy and Morpholinos. Hmm, let's see what it's about. The question describes a gene with many exons, especially the central ones that code for triple helical repeats connecting the cytoskeleton with the sarcolemma and the extracellular space. Each exon usually codes for one such repeat.\\n\\nThe mutations mentioned are central exon deletions, which cause out-of-frame peptides and progressive degeneration. The therapy here is using a Morpholino that binds to the 5' end of the out-of-frame exon in pre-mRNA. This prevents the spliceosome from binding, leading to exon skipping and in-frame joining, which is good because it fixes the mutation.\\n\\nThe question is asking which structure is not involved in this therapy. The options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nWait, I remember that Morpholinos are small RNA molecules that can bind to exons and prevent their splicing. They're used in gene editing, specifically for knocking out or inking exons. So the Morpholino binds to the 5' end of the exon, preventing the spliceosome from recognizing it as a stop. This leads to exon skipping, where the exon is cut out and the next one is joined in place.\\n\\nNow, looking at the options:\\n\\nA) Lariat: I think that's part of the splicing process. During splicing, the 3' end of the exon is recognized by the spliceosome, which then links it to the next intron. The 5' end forms a lariat structure with the intron, which is then removed. So lariat is involved, so A is not the answer.\\n\\nB) PolyA tail: PolyA tails are usually involved in mRNA processing, like in the ribosome binding site. They help in the elongation phase of translation. But in the context of splicing and Morpholinos, polyA tails aren't directly involved. So B might be the answer.\\n\\nC) R-loops: R-loops are RNA structures where an RNA strand is covalently linked to a DNA helix. They can form during transcription, especially in gene expression, and they can influence gene expression. But Morpholinos are RNA used for splicing, not for DNA. So R-loops are not directly involved here. Hmm, but I'm not sure. Do R-loops play a role in Morpholino therapy? Maybe not, since Morpholinos are RNA. So C could be the answer.\\n\\nWait, but I'm getting confused. Let me think again. The therapy uses a Morpholino to disrupt splicing. Morpholinos bind to the exon's 5' end, so the spliceosome can't recognize it anymore. So the spliceosome doesn't cut that exon. This exon is skipped, and the next exon is joined in its place. So in the process, the intron of that exon is removed, and the exon is joined to the next one. So the lariat is formed from the intron and the exon. So lariat (A) is involved. So A is not the correct answer.\\n\\nPolyA tail (B) is involved in the mRNA's processing, like in the ribosome binding site. So when the mRNA is made, it uses the polyA tail for termination. But in this scenario, the Morpholino is acting on pre-mRNA, which is the RNA before the polyA tail is added. So the polyA tail isn't directly involved in the splicing process here. So B is not involved.\\n\\nR-loops (C) are RNA structures, but are they part of this therapy? Since Morpholinos are RNA molecules, perhaps R-loops are formed during the splicing process. But I'm not sure if R-loops are a part of the therapy mechanism. Maybe not. So C is possible.\\n\\nD) Antisense: Antisense RNA is used in gene editing for antisense probes, like in the case of the CRISPR system. But in this scenario, the Morpholino is a small RNA that directly binds to the exon. So antisense isn't directly involved here. So D is not part of the therapy.\\n\\nSo the question is which structure is not involved. So the options are:\\n\\nA) lariat: involved.\\nB) polyA tail: not involved.\\nC) R-loops: involved.\\nD) antisense: not involved.\\n\\nWait, but the question is which structure is not involved. So the therapy doesn't involve R-loops or antisense. But wait, the options are about structures not involved.\\n\\nWait, the therapy uses Morpholino, which is RNA. So R-loops are RNA structures but not the therapy itself. So the therapy doesn't involve R-loops because the Morpholino is RNA. So C is involved.\\n\\nWait, but wait, the question is about structures involved in the therapy. The therapy uses Morpholinos, which are RNA. So the structures that are not involved would be ones not connected to RNA. So structures like polyA tails (B), R-loops (C) are RNA structures, but the therapy doesn't involve them. So the structures not involved would be B and C.\\n\\nWait, but the options are which is not involved. So all the options except one are involved. Let me think again.\\n\\nWait, the question is which structure is not involved. The therapy uses Morpholinos. So the structures that are not involved would be the ones that don't use or interact with RNA.\\n\\nWait, but the options include polyA tail and R-loops, which are RNA structures. So the therapy doesn't involve them. So the structures that are not involved are B and C.\\n\\nWait, but the question is which structure is not involved. The answer options are four, and only one is correct.\\n\\nWait, let me think again.\\n\\nThe therapy uses Morpholinos, which are RNA. So any structure that is not RNA is not involved. So, for the question, which of the four is not involved in the therapy.\\n\\nLooking at the options:\\n\\nA) lariat: formed during splicing. Yes, involved.\\n\\nB) polyA tail: part of mRNA processing. Not involved in splicing. So B is not involved.\\n\\nC) R-loops: RNA structures. Not part of the therapy.\\n\\nD) antisense: Not involved in this therapy.\\n\\nWait, but the question is which structure is not involved. So the structures not involved are B, C, D.\\n\\nBut the question asks which structure is not involved, so among the four, the one that is not involved is B, C, or D.\\n\\nWait, but the question is, which structure is not involved. So the correct answer is the one that is not part of the therapy.\\n\\nBut wait, the therapy uses Morpholinos. So the structures involved are RNA, which includes R-loops and antisense. So the structures not involved are polyA tail (B) and R-loops (C), and antisense (D).\\n\\nWait, but the question is about which structure is not involved in the therapy. So the options are which one is not involved.\\n\\nSo the four options:\\n\\nA) lariat: involved.\\n\\nB) polyA tail: not involved.\\n\\nC) R-loops: involved.\\n\\nD) antisense: not involved.\\n\\nWait, but the question says which structure is not involved. So the answer is either B, C, or D.\\n\\nBut wait, the question is phrased as: which structure is not involved in the proposed therapy.\\n\\nSo, the therapy uses Morpholinos, which are RNA. So the structures that are not involved are those that are not RNA. So B, C, and D are not involved.\\n\\nWait, but looking at the options, the answer must be one of the four. Let me check the options again.\\n\\nThe question is which structure is not involved. So the structures not involved would be those that are not part of the therapy. Since the therapy uses RNA (Morpholinos), the structures involved would be RNA structures (C) and antisense (D), but the question is about which is not involved.\\n\\nWait, the question is asking which structure is not involved. So the correct answer is the one that is not part of the therapy. Since the therapy doesn't involve B (polyA tail), C (R-loops), or D (antisense), but the options are four, the correct answer is B, C, or D.\\n\\nWait, but the options are:\\n\\nA) lariat\\n\\nB) polyA tail\\n\\nC) R-loops\\n\\nD) antisense\\n\\nSo the structures not involved are B, C, and D.\\n\\nBut the question is asking which structure is not involved. So the correct answer is the one that's not used in the therapy. So if the therapy uses Morpholinos (RNA), then structures not involved would be those that are not RNA.\\n\\nBut the options include polyA tail (B), R-loops (C), and antisense (D). So the structures not involved are B, C, and D.\\n\\nWait, but the question is about the structure not involved in the therapy. So the correct answer is the one that is not part of the process.\\n\\nWait, the question says which structure is not involved. So the therapy uses RNA, so the structures not involved are B, C, and D. But the options are given, so the answer is the one that is not part of the process.\\n\\nSo the four options are A, B, C, D.\\n\\nThe question is which is not involved.\\n\\nSo the correct answer is the structure that isn't part of the process. Since the therapy uses Morpholinos (RNA), the structures not involved are polyA tail, R-loops, and antisense.\\n\\nBut looking at the options, the correct answer is B, C, or D.\\n\\nWait, but\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>\\nOkay, so I'm trying to tackle this multiple-choice question about gene therapy using Morpholinos. Let me read through it again to make sure I understand what's being asked.\\n\\nThe question is about a gene that has many exons, and the central ones code for folded triple alpha helices. These helices connect the cytoskeleton, sarcolemma, and extracellular space. Each exon usually codes for one such helix. The most common mutations are deletions in the central exons, leading to out-of-frame peptides and progressive degeneration. The solution proposed is a Morpholino that binds to the 5' end of the out-of-frame exon in pre-mRNA. This prevents the spliceosome from binding and causes exon skipping and in-frame joining.\\n\\nThe question asks which structure is NOT involved in this therapy. The options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nHmm. Let's think about each part step by step.\\n\\nFirst, the gene structure: it's a large gene with many exons. The central exons code for these helices. Each exon codes for one helix. So the gene has exons, and each exon has a helix.\\n\\nNow, the mutation is a central exon deletion. So, the spliceosome, which is responsible for splicing the mRNA into exons, tries to splice it, but the exon is missing. Instead, the spliceosome skips that exon and joins the adjacent exons. This leads to in-frame joining, which is better for the organism.\\n\\nThe therapy uses a Morpholino, which is a small RNA molecule. It binds to the 5' end of the out-of-frame exon in pre-mRNA. This prevents the spliceosome from recognizing the splice site and thus skips the exon. So the spliceosome can't splice the pre-mRNA, so it skips the exon, leading to in-frame joining.\\n\\nNow, the structures involved in this process. Let me think about each option.\\n\\nOption A: Lariat. Lariat formation is during splicing when the pre-mRNA is joined by the spliceosome. The 5' splice site is recognized, and the intron is removed, then the 3' splice site forms a bond with the 5' end of the intron, creating a lariat structure. So, the lariat is involved in the normal splicing process. So A is involved, so it's not the correct answer.\\n\\nOption B: polyA tail. The polyA tail is a structure that follows the mRNA. It's recognized by ribosomes and is involved in protein synthesis. But in this scenario, the Morpholino therapy is about splicing, not the translation machinery. So the polyA tail isn't directly involved in this therapy. So B is a possible candidate.\\n\\nOption C: R-loops. R-loops are RNA structures where an RNA helix is bound by a complementary sequence from DNA. They form when a single-stranded DNA is paired with a complementary RNA. For example, the seed region in some viruses or some RNA molecules. The spliceosome recognizes certain R-loops, such as the seed region in the pre-mRNA. So in this therapy, the Morpholino would bind to an R-loop, preventing the spliceosome from recognizing the splice site. Therefore, R-loops are involved. So C is involved, not the correct answer.\\n\\nOption D: antisense. Antisense is a concept where a complementary RNA binds to a protein. However, in this scenario, the Morpholino is binding to the pre-mRNA and preventing the spliceosome from splicing. But wait, the Morpholino is an RNA molecule that's part of the therapy. So, the structure involved in the therapy would be the Morpholino itself, but the options don't include that. Alternatively, the Morpholino might be binding to an antisense RNA, but I'm not sure.\\n\\nWait, the question is which structure is not involved. Let me think again. The therapy uses a Morpholino to prevent the spliceosome from binding. So, the Morpholino itself isn't a structure I'm considering, but perhaps the structure it binds to is. However, the question is about the structures involved in the therapy, not the components of the Morpholino. So, which structures are used in the therapy.\\n\\nAlternatively, perhaps the Morpholino is acting as a guide for RNA interference or something else, but I'm not sure. Let's think about the options again.\\n\\nWait, the therapy is about binding a pre-mRNA's 5' end, preventing the spliceosome from splicing. So, the Morpholino must be binding to a complementary structure in the pre-mRNA. The pre-mRNA has exons and introns. The spliceosome recognizes the 5' splice site (exon-intron boundary). If the Morpholino binds to a complementary region, it could prevent the spliceosome from recognizing the site.\\n\\nSo, what structures are involved in this process? The pre-mRNA has introns that are spliced out. The spliceosome uses various mechanisms, including the seed region, which is a single-stranded region that pairs with a complementary RNA. The seed region is part of the intron and can be recognized by the spliceosome.\\n\\nWait, so the pre-mRNA has a seed region in the intron that is recognized by the spliceosome. If the Morpholino binds to that, it would prevent the spliceosome from recognizing the 5' splice site. Alternatively, if the Morpholino binds to a complementary region elsewhere, it could interfere.\\n\\nBut the options don't mention the seed region. Let me look again. The options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nWait, antisense structures are more about RNA molecules binding to proteins. So, the Morpholino is an RNA molecule, but I don't know if it's acting as antisense. Alternatively, the Morpholino might form an R-loop with a complementary DNA sequence, but I'm not sure.\\n\\nWait, the question is about which structure is not involved. So which of these structures is not used in this therapy.\\n\\nThe therapy uses Morpholino to prevent the spliceosome. The spliceosome uses structures like the seed region (part of the intron) to recognize splice sites. The seed region is a single-stranded RNA that pairs with a complementary RNA (maybe the antisense RNA). So perhaps the antisense structure is involved.\\n\\nWait, but the Morpholino is the guide, not the antisense RNA. So, in this context, the Morpholino binds to the pre-mRNA. The pre-mRNA has a seed region in the intron. If the Morpholino is binding to that region, perhaps it's not an antisense RNA but another structure.\\n\\nAlternatively, perhaps the Morpholino is causing a R-loop. For example, in some viruses, RNA can form R-loops with DNA, but in this case, the question is about gene therapy.\\n\\nWait, perhaps the Morpholino is creating a structure that prevents the spliceosome from binding. So, the structure involved in the therapy is the Morpholino binding to the pre-mRNA. But none of the options mention the Morpholino. The options are about what structures are not involved.\\n\\nWait, the question is which structure is not involved. So, the structures in the options are lariat, polyA, R-loop, antisense.\\n\\nIf the therapy doesn't involve R-loops, then C would be the answer. But the therapy does involve R-loops because the Morpholino could be binding to an R-loop. But the question is about which structure is NOT involved.\\n\\nWait, maybe I'm overcomplicating. Let me think about the structures involved in the process.\\n\\nThe spliceosome binds to the 5' splice site, which is a specific sequence in the pre-mRNA. The spliceosome can recognize certain R-loops in the pre-mRNA, such as the seed region. The seed region is a single-stranded RNA complementary to a complementary region in the mRNA. So, the pre-mRNA has a seed region that's recognized by the spliceosome.\\n\\nIf the Morpholino binds to this seed region, it would prevent the spliceosome from recognizing the splice site, leading to exon skipping. So, the seed region is part of the pre-mRNA and is recognized by the spliceosome. Therefore, the structure involved in the therapy is the R-loop (if the seed region is an R-loop), but the question is about which structure is NOT involved.\\n\\nWait, but the options don't mention the seed region. Let me go back to the options.\\n\\nThe question is about which structure is NOT involved. So, which of the options is not part of this process.\\n\\nOption A: Lariat. Lariats are formed during splicing, so involved. So A is involved.\\n\\nOption B: PolyA tail. Not involved in splicing, so B is a candidate.\\n\\nOption C: R-loops. The spliceosome can recognize R-loops. The Morpholino binds to an R-loop, so R-loops are involved. So C is involved.\\n\\nOption D: Antisense. Antisense structures are RNA molecules that bind to DNA. In this scenario, the Morpholino is RNA, so perhaps it's acting as an antisense RNA. But in this case, the Morpholino is binding to the pre-mRNA. Alternatively, if the Morpholino is creating an antisense structure, perhaps it's involved. But I'm not certain.\\n\\nWait, the question is which structure is NOT involved. So, the therapy uses Morpholino to prevent spliceosome from recognizing. So, the structures involved in this are the spliceosome, the pre-mRNA (with seed regions), and the Morpholino.\\n\\nThe structures not involved would be the polyA tail,\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>\\nOkay, so I've got this question about gene therapy using Morpholinos and exons. Hmm, let me try to break it down. I remember that Morpholinos are small RNA molecules that can be directed to specific locations in the genome. They often are used in gene editing, like in knockouts or insertions.\\n\\nThe question says that there's a gene with many exons. The central ones code for triple helical repeats connecting the cytoskeleton, sarcolemma, and extracellular space. Each exon usually codes for one folded triple alpha helix. So, normally, each exon is responsible for a specific structure or protein.\\n\\nThe most common mutations are central exon deletions, which cause out-of-frame peptides. That makes sense because if an exon is missing, the reading frame shifts, leading to a different amino acid sequence. But the therapy here is about delivering a Morpholino to prevent the spliceosome from binding. Oh wait, the spliceosome is responsible for recognizing and removing introns, right? So if the Morpholino prevents the spliceosome from joining the exons, it should cause exon skipping, meaning the introns are removed, and the exons are joined together without the missing exon.\\n\\nBut the therapy also results in in-frame joining, so the exons are joined correctly. That's good because the mutation was out-of-frame, so the therapy corrects that.\\n\\nNow, the question is about which structure isn't involved in the therapy. The options are lariat, polyA tail, R-loops, and antisense.\\n\\nWait, what's an antisense RNA? Antisense is a complementary RNA that binds to the mRNA and inhibits translation. But in this case, the Morpholino is a small RNA that's directed to the 5' end of the exon. So it's not antisense RNA; antisense would be used to target mRNA.\\n\\nThe lariat structure is formed during the splicing process. When a spliceosome reads an intron, it ligates the donor and acceptor sites, forming a lariat. If the spliceosome doesn't recognize the intron, the lariat might not form, leading to a frameshift or other issues. But in this therapy, the Morpholino prevents the spliceosome from binding. So the spliceosome shouldn't be trying to splice this intron anymore. But how does the therapy affect the lariat? Maybe the lariat is still formed, but the spliceosome doesn't process it. So the lariat is involved in the normal splicing, but in this case, the spliceosome isn't binding. So the structure of the lariat is still present, but the splicing doesn't occur.\\n\\nThe polyA tail is a major part of mRNA processing. It's involved in the termination of translation and the stability of mRNA. So it's definitely involved in the therapy.\\n\\nR-loops are structures where an RNA is hybridized to DNA, forming a secondary structure. They are involved in RNA interference and DNA repair. But does Morpholino directly form R-loops? I think Morpholinos are small RNA molecules that can form loops if they bind to DNA, but in this scenario, the Morpholino is acting in the mRNA. So maybe R-loops aren't formed here. Alternatively, the spliceosome's interaction might involve the RNA, but I'm not sure if that's an R-loop.\\n\\nWait, what's an R-loop? It's a structure where RNA pairs with DNA, forming a loop. So in this case, the Morpholino is RNA, not DNA. So the R-loop is not involved. So the structure not involved would be R-loop.\\n\\nAlternatively, antisense RNA (option D) is not involved in the therapy because the Morpholino isn't antisense. The therapy uses the Morpholino to prevent splicing, not to target mRNA for antisense-mediated translation inhibition.\\n\\nSo the structures involved in the therapy are lariat (splicing lariat), polyA tail, and antisense (but the Morpholino isn't antisense; it's a different RNA). Wait, no, antisense is a type of RNA, but it's not the Morpholino. So the therapy doesn't involve antisense RNA.\\n\\nWait, the question asks which structure is not involved. So the options are lariat, polyA, R-loop, antisense.\\n\\nAntisense isn't involved because the Morpholino is not antisense. So the structure not involved is R-loop, because the Morpholino doesn't form R-loops.\\n\\nWait, but the therapy involves the Morpholino binding to the mRNA. The spliceosome doesn't bind the intron anymore, but the lariat is still formed. So the lariat is involved in the normal splicing process, but it's not formed because the spliceosome isn't trying to use it. So the lariat is present but not spliced, which is correct.\\n\\nSo which structures are involved? The therapy affects the spliceosome, so the spliceosome is not involved in the lariat formation. So lariat is involved in normal splicing, but in this scenario, it's not being spliced because the spliceosome can't bind.\\n\\nWait, the question is about which structure is not involved. So which of the options is not part of the therapy process.\\n\\nThe Morpholino is a small RNA that's directed to the exon. The spliceosome normally binds to the introns. So the spliceosome is not involved in the therapy in terms of the spliceosome's function.\\n\\nBut the spliceosome's role is to splice introns. So in this therapy, the spliceosome isn't doing that. So the structure that's not involved would be the one that isn't part of the splicing process.\\n\\nThe lariat is involved in the splicing process. The polyA tail is part of mRNA processing, involved in termination and stability. The antisense RNA isn't part of the therapy, so the structure not involved would be antisense.\\n\\nWait, but the question says, which structure is NOT involved. So the options are:\\n\\nA) lariat\\n\\nB) polyA\\n\\nC) R-loop\\n\\nD) antisense.\\n\\nThe therapy involves preventing the spliceosome from binding, so the spliceosome is not involved in the process. The spliceosome is part of the normal splicing, but the therapy disrupts that.\\n\\nThe R-loop is not formed here, so the structure not involved would be R-loop.\\n\\nSo the answer should be C) R-loops.\\n</think>\\n\\nThe question involves a gene with multiple exons, where each exon codes for a folded triple alpha helix. Central exon deletions cause out-of-frame mutations, and the therapy in question uses a Morpholino to prevent the spliceosome from binding the 5' end of an out-of-frame exon, leading to exon skipping and in-frame joining. The goal is to identify which structure is not involved in this therapy.\\n\\n### Analysis of the Options:\\n1. **Lariat (A):** The lariat structure is formed during intron splicing, where the donor and acceptor sites of the spliceosome are ligated together. In this therapy, the spliceosome is prevented from binding, so the lariat structure is still present but not processed. Thus, the lariat is involved in the normal splicing process, but it is not the structure that is disrupted in this therapy.\\n\\n2. **PolyA Tail (B):** The polyA tail is a major component of mRNA processing, involved in mRNA termination and stability. It plays a critical role in mRNA translation and mRNA stability, making it an essential structure in this therapy.\\n\\n3. **R-loops (C):** R-loops are RNA-DNA hybrid structures where RNA pairs with DNA, forming secondary structures. Morpholinos are small RNA molecules that can form loops if they bind to DNA. However, in this therapy, Morpholinos act as small RNA molecules on mRNA, not as DNA, so R-loops are not involved.\\n\\n4. **Antisense (D):** Antisense RNA is complementary RNA that inhibits translation by binding to mRNA and preventing its translation. The Morpholino in this therapy is not antisense RNA; it is a small RNA molecule that binds to mRNA. Therefore, antisense is not involved in this therapy.\\n\\n### Conclusion:\\nThe therapy involves preventing the spliceosome from binding, which disrupts intron splicing. However, the spliceosome itself is not involved in the process. The structures involved in the therapy include the lariat (for normal splicing), the polyA tail (for mRNA processing), and the polyA tail is not mentioned as being involved. The R-loop is not formed in this scenario, and the antisense RNA is not involved either. Among the options, the R-loop is the structure that is not involved in the therapy.\\n\\n**Answer: C**<ï½œendâ–ofâ–sentenceï½œ>\", '<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>\\nOkay, so I\\'ve got this question about gene therapy, specifically using Morpholinos. Hmm, I need to figure out which structure isn\\'t involved in the therapy described.\\n\\nAlright, let\\'s start by reading the question carefully. The scenario is about a gene with multiple exons, where the central ones code for triple helical repeats connecting the cytoskeleton, sarcolemma, and extracellular space. Each exon is usually for a folded triple alpha helix. The main issue is that there are mutations causing central exon deletions, leading to out-of-frame peptides and progressive degeneration. They propose using Morpholinos to address this.\\n\\nThe therapy works by the Morpholino binding to the 5\\' end of the out-of-frame exon, preventing the spliceosome from joining. This leads to exon skipping and in-frame joining, which is better tolerated by the organism.\\n\\nNow, the question is asking which structure isn\\'t involved. The options are lariat, polyA tail, R-loops, and antisense.\\n\\nWait, let\\'s think about each part.\\n\\nFirst, Morpholinos are small RNA molecules that can target specific mRNA sequences. They can bind to mRNA and disrupt splicing by blocking the spliceosome. So in this case, the Morpholino binds to the pre-mRNA\\'s 5\\' end of the out-of-frame exon. It prevents the spliceosome from joining, causing exon skippingâ€”so the exon is removed.\\n\\nIn mRNA splicing, the spliceosome recognizes the 5\\' splice site (usually CTCTA) and the 3\\' splice site (usually NGG). Once it binds, it processes the exons, joining them into a single transcript.\\n\\nBut when the Morpholino prevents the spliceosome from binding, the spliceosome can\\'t join the exons. So it\\'s like the spliceosome is blocked, leading to exon skipping. Exons are removed, so the mRNA is joined in-frame, which is better for translation.\\n\\nNow, looking at the structures involved in this process.\\n\\nOption A: Lariat. Lariat structures form during splicing when the pre-mRNA is processed into mature mRNA. The spliceosome unwinds the RNA, and the lariat is formed by the joining of the exon and intron. So lariat is involved in the splicing process.\\n\\nOption B: PolyA tail. The polyA tail is the nucleic acid tail found in prokaryotes and some eukaryotes. It\\'s added during transcription by the RNA polymerase II. The polyA tail is important for mRNA stability and export from the nucleus. So it\\'s definitely involved.\\n\\nOption C: R-loops. An R-loop is a type of RNA structure where an RNA helix is partially unwound and partially re-wound, forming a loop. They can form in RNA due to the presence of certain base pairs, like guanine-rich regions. R-loops can influence the structure of RNA, such as affecting the binding of proteins or other RNAs. They are involved in various RNA interactions and processes, including splicing. So R-loops are involved.\\n\\nOption D: Antisense. Antisense RNA is complementary to a target RNA, usually in the opposite orientation. It\\'s used in various genetic and therapeutic applications, including mRNA antisense purification or as part of antisense-based therapies. In this context, the Morpholino is antisense. So antisense is involved.\\n\\nWait, but the question is asking which structure isn\\'t involved. So which one isn\\'t part of the process described?\\n\\nWait, the therapy is using the Morpholino to prevent the spliceosome from binding. The spliceosome\\'s function is about recognizing the splice sites. So the spliceosome is part of the splicing machinery, which includes the snRNA (small nuclear RNA). But the Morpholino itself is RNA, not part of the spliceosome.\\n\\nWait, but the question is about which structure is not involved. So the structures that are part of the process.\\n\\nWait, the Morpholino binds to the pre-mRNA, which is part of the spliceosome. So the Morpholino is not part of the spliceosome, but it\\'s delivering the inhibitor. So the structures that are part of the process are the lariat (splicing), polyA tail (mRNA structure), R-loops (maybe influencing splicing), and antisense (as the Morpholino is antisense to the target RNA).\\n\\nWait, but wait: the Morpholino is an antisense RNA that binds to the mRNA. But in terms of the structures involved, the splicing process uses lariat structures. The polyA tail is a structure of the mRNA. R-loops are structures in the RNA, which can influence splicing. The Morpholino is an antisense RNA.\\n\\nSo all four structures are involved in the process except perhaps one.\\n\\nWait, the question is which structure is not involved. So which of the options is not part of the process.\\n\\nWait, the Morpholino is an antisense RNA that is part of the therapy. So the Morpholino is an antisense, which is involved.\\n\\nBut the other structures: lariat (splicing), polyA tail (RNA structure), R-loops (RNA structure), and antisense ( Morpholino is antisense).\\n\\nSo all structures except perhaps one are involved. But wait, the question is about the structures not involved.\\n\\nWait, the Morpholino is an antisense RNA. But in the context of the therapy, the Morpholino is delivering the antisense, which may not be directly involved in the splicing process.\\n\\nWait, perhaps the Morpholino is not part of the splicing machinery. The spliceosome is the splicing machinery, which uses lariat structures. The Morpholino is an antisense RNA that binds to the mRNA, preventing the spliceosome from binding.\\n\\nSo in this scenario, the Morpholino is a small RNA, not part of the spliceosome, but it\\'s part of the therapy. So the structures involved in the splicing process (lariat, polyA tail, R-loops) are part of the therapy, and the Morpholino is an antisense.\\n\\nWait, but the question is which structure is not involved. So all four structures are part of the therapy except one.\\n\\nWait, the question says \"the proposed therapy\". So the therapy involves Morpholinos, which are antisense RNAs. So antisense is involved.\\n\\nWait, but the question is about which structure is NOT involved. So I think the lariat structure is involved in the splicing process, the polyA tail is part of the mRNA, R-loops are part of the RNA, and the Morpholino is an antisense.\\n\\nSo all four structures are involved, but wait the question is which is not involved. So perhaps the correct answer is none of the above? No, that\\'s not the case.\\n\\nWait, perhaps the Morpholino is not involved in the splicing process. The splicing is done by the spliceosome, which doesn\\'t directly use the Morpholino. So the structures involved in the process are lariat, polyA, R-loops, and antisense (Morpholino). So all four structures are part of the therapy.\\n\\nWait, but the question says which structure is not involved. So perhaps one of them isn\\'t used in the described therapy.\\n\\nWait, the therapy involves Morpholinos, which are antisense. So the structure involved is antisense. So the structure not involved is the polyA tail. Or perhaps, the structure not involved is the polyA tail?\\n\\nWait, no, the polyA tail is part of the mRNA structure.\\n\\nWait, the question is about which structure is not involved. So the structures that are part of the therapy are: lariat, polyA, R-loops, and antisense.\\n\\nWait, but wait, the question is about the structures involved in the proposed therapy. So all four structures are involved except one.\\n\\nWait, let me think again. The therapy is about disrupting the spliceosome to prevent exon skipping. So the spliceosome is involved, which uses lariat structures. The polyA tail is part of the mRNA, so it\\'s involved. R-loops are in the RNA, so they are involved. The Morpholino is an antisense RNA, so it\\'s involved.\\n\\nWait, but the question is which structure is not involved. So all four are involved, but the answer is expecting which one is not.\\n\\nAlternatively, perhaps the Morpholino is not involved in the splicing process but in the delivery. So in that case, the structures involved are the ones that are part of the splicing machinery (lariat, polyA, R-loops) and the antisense structure (Morpholino), but the polyA tail is part of the mRNA.\\n\\nWait, but the question is about the structures involved in the therapy, not the mRNA. So perhaps all four structures are involved.\\n\\nBut wait, the options are A) lariat, B) polyA, C) R-loops, D) antisense.\\n\\nThe question is which structure is NOT involved. So which one is not part of the process described.\\n\\nWait, the therapy is using a Morpholino that binds to the 5\\' end of the exon. The Morpholino is an antisense RNA. So it\\'s part of the therapy, so it\\'s involved.\\n\\nBut in the process of splicing, the spliceosome uses lariat structures, so that\\'s involved.\\n\\nThe polyA tail is part of the mRNA, so that\\'s involved.\\n\\nR-loops are in the RNA, so they\\'re involved.\\n\\nSo all options A to D are involved in the therapy. But that can\\'t be, because the question says which structure is not involved.\\n\\nWait, perhaps the Morpholino is not part of the splicing process but is an antisense RNA used in the therapy. So perhaps the structures involved are lariat, polyA, R-loops, and antis', '<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>\\nOkay, so I\\'ve got this question about gene therapy and Morpholinos. Hmm, I remember that Morpholinos are small RNA molecules that can be used to target specific exons in the pre-mRNA of a gene. The question talks about a large gene with several exons, and the central ones code for folded triple helical repeats. Oh wait, those repeat structures connect the cytoskeleton with the sarcolemma and the extracellular space, right?\\n\\nThe main issue here is the presence of out-of-frame mutations because of central exon deletions. When that happens, the mRNA might not code for the correct protein, leading to problems like progressive degenerative organ waste. The therapy they\\'re suggesting is using a Morpholino to prevent the spliceosome from binding and instead causing exon skipping. So, the spliceosome is responsible for splicing introns into exons, joining them. If it skips an exon, that would fix the mutation, right?\\n\\nThe therapy works by the Morpholino binding to the 5\\' end of the out-of-frame exon. By doing that, it somehow prevents the spliceosome from recognizing and binding that exon, leading to skipping. The result is in-frame joining, which means the protein is properly formed.\\n\\nNow, the question is asking which structure isn\\'t involved in this therapy. The options are lariat, polyA tail, R-loops, and antisense.\\n\\nLet me think about each structure. \\n\\nOption A: Lariat. Lariat structures are formed during splicing when the spliceosome links exons, creating a loop. So when the spliceosome binds, it creates an intron lariat. But in this case, the Morpholino is preventing splicing altogether, so maybe the lariat isn\\'t involved. Or wait, does the lariat form as part of the therapy? I don\\'t think so. The therapy is about preventing the spliceosome from working, not about creating a lariat. So maybe option A is not involved.\\n\\nOption B: PolyA tail. The polyA tail is part of mRNA processing, usually added during transcription when a tRNA is translated. It\\'s involved in mRNA stability and export from the nucleus. I don\\'t see how that\\'s involved here. So polyA tail isn\\'t part of the therapy mechanism described. But wait, the question is which structure is not involved. So if polyA tail is not part of the therapy, it might be the correct answer.\\n\\nOption C: R-loops. R-loops are structures where an RNA helix is looped around a DNA region. They can form between exons and introns. In this scenario, the Morpholino is binding to the 5\\' end of an exon, which is a coding region. If the exon is part of a repeat structure, maybe the Morpholino is forming an R-loop with the DNA. So R-loops are involved in the therapy. So this option is not the correct answer.\\n\\nOption D: Antisense. Antisense RNA is complementary to a protein\\'s amino acid sequence. It\\'s usually involved in gene regulation, such as in antisense RNA interference. In this therapy, I don\\'t think antisense RNA is being used. So D is not involved.\\n\\nWait, but the question is which structure is NOT involved. Let me reevaluate.\\n\\nThe therapy is about preventing the spliceosome from binding and causing exon skipping. The Morpholino binds to the 5\\' end of the out-of-frame exon. How does that work?\\n\\nIn normal splicing, the spliceosome recognizes exons and introns. If the Morpholino binds, maybe it\\'s disrupting the spliceosome\\'s recognition. Alternatively, maybe the Morpholino is causing a structural change, like forming an R-loop with the DNA, which could prevent the spliceosome from recognizing the exon.\\n\\nLooking again, the options are:\\n\\nA) Lariat: Not involved in splicing, so maybe not.\\n\\nB) PolyA tail: Not involved in the therapy, so this could be the correct answer.\\n\\nC) R-loops: Involved, yes.\\n\\nD) Antisense: Not involved, so this is another correct answer.\\n\\nWait, but the question is which structure is NOT involved. So which one is not part of the therapy.\\n\\nThe therapy is using Morpholino to prevent the spliceosome from binding, and create exon skipping. So, the structures involved would include the Morpholino binding, perhaps an R-loop (since it\\'s interacting with DNA), and maybe a lariat (if during splicing, but that\\'s the normal process, not part of the therapy). Alternatively, antisense RNA is not used here.\\n\\nWait, the options are which structure is not involved. So, the therapy doesn\\'t use polyA tail. So option B is not involved. The Morpholino might be binding to the DNA, but does that form an R-loop? Or perhaps the Morpholino is forming an R-loop with the DNA. So R-loop is involved.\\n\\nSo the structures involved are the Morpholino, maybe an R-loop, and the antisense RNA isn\\'t involved.\\n\\nSo the structures not involved are polyA tail (B) and antisense (D). The question is which one is not involved.\\n\\nWait, but the question is about which structure is not involved. So the correct answer is either B or D.\\n\\nThe options are: which is not involved. Let me think again.\\n\\nIn the therapy, the Morpholino binds to the exon. The exons are coding regions, so it\\'s possible that the Morpholino is forming an R-loop with the DNA. So R-loops are involved.\\n\\nAntisense is RNA that\\'s complementary to a protein. Not involved here.\\n\\nPolyA tail: The polyA tail is in the mRNA processing. The therapy doesn\\'t involve mRNA processing. So it\\'s not involved.\\n\\nSo, the structures not involved are B and D.\\n\\nThe question asks which structure is not involved. So the options are A, B, C, D. Which of these is not used.\\n\\nWait, the question is which structure is not involved. So in the therapy, the structures involved are:\\n\\n- Morpholino (which is a small RNA, not a structure like lariat, R-loop, etc.)\\n\\n- The R-loop: the Morpholino might form an R-loop with the DNA.\\n\\n- The antisense RNA isn\\'t used.\\n\\nSo, structures not involved are B) polyA tail, and D) antisense.\\n\\nWait, but the question gives four options, and we need to choose which is not involved.\\n\\nLooking at the options, the question is about what\\'s not involved. So the structures in the options are:\\n\\nA) Lariat: used during splicing, so not involved in therapy.\\n\\nB) PolyA tail: not involved.\\n\\nC) R-loop: involved.\\n\\nD) Antisense: not involved.\\n\\nSo the question asks which structure is NOT involved. So all except B and D are involved. But the options are A, B, C, D.\\n\\nWait, the question is which structure is NOT involved. So which of the four structures is not involved.\\n\\nThe options are:\\n\\nA) Lariat - used during splicing, so not involved.\\n\\nB) PolyA tail - not involved.\\n\\nC) R-loops - involved.\\n\\nD) Antisense RNA - not involved.\\n\\nSo, the structures not involved are B, D.\\n\\nBut the question says, \"which structure is not involved\". So the answer is either B or D.\\n\\nWait, but the options are four, and the question is to choose which one is not involved. The question is in the context of the therapy. So the Morpholino binds to the exon and prevents the spliceosome. So it\\'s not using the polyA tail (since polyA is part of mRNA, not the therapy\\'s mechanism), and it\\'s not using antisense RNA either, because antisense isn\\'t part of this therapy.\\n\\nSo which one is not involved? The question is about which structure is not involved. So the answer is B) polyA tail and D) antisense are not involved.\\n\\nWait, but the question is a multiple-choice question. So the options are A, B, C, D. The question is which is NOT involved.\\n\\nSo the structures involved in the therapy are the Morpholino, R-loops (since the Morpholino binds DNA), and the antisense RNA (if any). But the therapy doesn\\'t use antisense RNA, so D is not involved. And the polyA tail is not involved, so B is not involved.\\n\\nWait, the question says the therapy is using Morpholino to prevent spliceosome binding. So the structures involved are the Morpholino itself (as a small RNA) and perhaps an R-loop (since it\\'s binding DNA). The antisense RNA isn\\'t used. So the structures not involved are B and D.\\n\\nBut the question is which one is not involved. So the answer options are A, B, C, D.\\n\\nSo the options are:\\n\\nA) Lariat - involved in splicing, so not the answer.\\n\\nB) PolyA tail - not involved.\\n\\nC) R-loops - involved.\\n\\nD) Antisense - not involved.\\n\\nSo the structures not involved are B and D. But the question is which one is not involved. Since the options are single answers, perhaps the correct answer is B) polyA tail and D) antisense. But the question is asking for which structure is NOT involved, so the correct answer would be either B or D.\\n\\nWait, the question is which structure is not involved. So the answer is the one that isn\\'t part of the therapy. The therapy doesn\\'t use polyA tail (B), nor does it use antisense RNA (D). The R-loops (C) are involved because the Morpholino is binding DNA. The lariat (A) is involved in splicing but not in the therapy.\\n\\nSo the structures not involved are B and D. But', \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>\\nOkay, so I've got this question about gene therapy and Morpholinos. Hmm, let me try to work through this. I'm a bit rusty, but I'll think it through step by step.\\n\\nSo the question is about a therapy where a Morpholino is used to deliver a gene. The scenario says that the gene has a lot of exons, and the central ones code for triple helical repeats. These repeats connect the cytoskeleton, sarcolemma, and extracellular space. Each exon codes for one such repeat, I suppose.\\n\\nThe mutations are central exon deletions, which cause out-of-frame peptides and progressive degeneration. So, the therapy here is to deliver a Morpholino to these exons. The Morpholino binds to the 5' end of the out-of-frame exon, preventing the spliceosome from splicing it in, leading to exon skipping and in-frame joining. So, the idea is that the spliceosome can't recognize the deleted exon anymore, so the mRNA is cut and pasted correctly, resulting in a new exon that's in frame.\\n\\nNow, the question is which structure isn't involved in this therapy. The options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nWait, so the therapy uses Morpholinos. I remember that Morpholinos are small RNA molecules that can bind to specific sites on mRNA, typically the 5' end of an exon. They usually have complementary sequences to the exons, and they can inhibit the binding of the spliceosome, which is responsible for splicing.\\n\\nBut wait, Morpholinos are RNA, not DNA. So they don't directly interact with the DNA, which is what the spliceosome does. Instead, they interact with the mRNA. The spliceosome uses the DNA as a template to find splice sites.\\n\\nNow, the question is about which structure isn't involved. Let's go through each option.\\n\\nOption A) Lariat. Lariats are formed during splicing when an intron is removed. The intron is spliced out, and the RNA forms a lariat structure. So this is involved because the spliceosome uses lariat structures.\\n\\nOption B) PolyA tail. PolyA tails are present after mRNA, usually in the 3' end. They help in the stability of mRNA by providing a binding site for proteins like snRNPs. So this is involved in gene expression regulation.\\n\\nOption C) R-loops. R-loops are RNA structures where an RNA strand is antiparallel to another, forming a loop. They're involved in mRNA folding and can affect gene expression. So this structure is involved.\\n\\nOption D) Antisense. Antisense is an RNA that binds to a complementary DNA sequence. It's used in antisense transcription, where a complementary RNA is used to copy DNA. But in this scenario, the Morpholino is an RNA molecule, not an antisense RNA. So in the context of the therapy, I'm not sure if antisense is used. Wait, no, antisense is about RNA binding DNA, but the therapy here uses a Morpholino, which is RNA. So antisense isn't directly involved in this scenario.\\n\\nWait, but the question is which structure is NOT involved. So the therapy uses Morpholinos, which are RNA. The structures A, B, C are part of the process. So D) antisense isn't part of the therapy, because the Morpholinos are the delivery vehicle.\\n\\nWait, but let me think again. The therapy uses Morpholinos to bind the 5' end of the exon. So the Morpholino is RNA. So it's not antisense. So the structures that are not involved are the ones that are not part of the therapy.\\n\\nLooking at the options:\\n\\nA) Lariat: involved because it's part of the splicing process.\\n\\nB) PolyA tail: involved in mRNA stability.\\n\\nC) R-loops: involved in mRNA structure.\\n\\nD) Antisense: not involved because the Morpholino is an RNA that binds mRNA, not DNA.\\n\\nSo the structure not involved is D) antisense.\\n</think>\\n\\nTo determine which structure is not involved in the proposed therapy, we analyze the options as follows:\\n\\n- **A) Lariat**: During splicing, introns are removed, forming lariat structures. This is directly involved in the process of mRNA processing.  \\n- **B) PolyA tail**: The polyA tail stabilizes mRNA by binding to proteins like snRNPs. It is essential for mRNA stability and translation.  \\n- **C) R-loops**: These are RNA structures where one strand is antiparallel to another, often involved in mRNA folding and regulation. They play a role in gene expression.  \\n- **D) Antisense**: Antisense is an RNA that binds to complementary DNA sequences for antisense transcription. However, in this therapy, Morpholinos are used, which are RNA molecules that bind to mRNA at specific sites. Antisense is not involved in the described process.\\n\\nSince the therapy involves Morpholinos, which are RNA, and none of the structures (A, B, or C) are directly related to the mechanism of the therapy, the structure **D) Antisense** is not involved.\\n\\nAnswer: D<ï½œendâ–ofâ–sentenceï½œ>\"], 'correct': [False, False, False, False, False, True, False, False, False, False, False, False, True, False, True, True, False, False, False, False, False, False, False, False, False, False, False, False, True, False, False, False], 'explanations': [\"parsed='A'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='C'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='B'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='C'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='C'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='A'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='B'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='B'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='C'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='D'; truth='C'\"], 'num_tokens': [[660, 951], [0, 2048], [0, 2048], [1485, 1897], [1235, 1681], [619, 910], [0, 2048], [1921, 2048], [613, 820], [0, 2048], [0, 2048], [0, 2048], [1077, 1372], [0, 2048], [741, 1072], [898, 1219], [1980, 2048], [1320, 1721], [2016, 2048], [0, 2048], [653, 1003], [1779, 2048], [0, 2048], [0, 2048], [879, 1165], [1253, 1599], [0, 2048], [0, 2048], [1336, 1819], [0, 2048], [0, 2048], [861, 1099]], 'rewards': [0.048583984375, 0.00089263916015625, 0.00921630859375, 0.04248046875, 0.051025390625, 0.0693359375, 0.0040283203125, 0.0211181640625, 0.0546875, 0.000766754150390625, 0.007781982421875, 0.00506591796875, 0.052978515625, -0.00958251953125, 0.0439453125, 0.050537109375, 0.01165771484375, 0.032958984375, 0.0291748046875, 0.010498046875, 0.056884765625, 0.0281982421875, 0.005950927734375, -0.00408935546875, 0.050048828125, 0.04541015625, 0.000701904296875, 0.00909423828125, 0.059326171875, -0.004913330078125, 0.005859375, 0.055419921875], 'ground_truths': ['C'], 'question_meta': None, 'model_name': 'hf_chat:deepseek-ai/DeepSeek-R1-Distill-Qwen-1.5B', 'reward_model_name': 'armo_rm:RLHFlow/ArmoRM-Llama3-8B-v0.1'}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 50%|â–ˆâ–ˆâ–ˆâ–ˆâ–ˆ     | 6/12 [00:18<00:20,  3.37s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'qid': 'gpqa-1', 'prompt': \"Answer the following multiple choice question. The last line of your response should be of the following format: 'Answer: $LETTER' (without quotes) where LETTER is one of ABCD. Think step by step before answering.\\n\\nA large gene has dozens of exons, of which the central ones code for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space. Each exon usually codes for one folded triple alpha helix. The most common mutations of the gene are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste. A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. The molecule prevents binding of the spliceosome and creates exon skipping and in-frame joining. Several missing exons are well tolerated by an organism. Which structure below is not involved in the proposed therapy?\\n\\nA) lariat\\nB) polyA tail\\nC) R-loops\\nD) antisense\", 'answers': [\"To determine which structure is not involved in the proposed therapy, let's break down the process described:\\n\\n1. **Central Exon Deletions**: The gene has central exons that are deleted, creating out-of-frame peptides.\\n2. **Morpholino Therapy**: The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome.\\n3. **Exon Skipping and In-Frame Joining**: By preventing spliceosome binding, the therapy aims to skip the missing exons and join the remaining exons in frame.\\n\\nNow, let's analyze each option:\\n\\nA) **Lariat**: Lariats are formed during pre-mRNA splicing when the 3' end of the intron is joined to the 5' end of the intron via a ligation reaction. This is part of the splicing process, which is what the Morpholino is trying to prevent.\\n\\nB) **PolyA Tail**: The polyA tail is added to the 3' end of mature mRNA after splicing is complete. Since the therapy involves pre-mRNA and aims to alter the splicing process, it does not directly involve the polyA tail.\\n\\nC) **R-loops**: R-loops form when RNA hybridizes with its template DNA strand, displacing the other DNA strand. While R-loops can affect gene expression, they are not directly involved in the splicing process or the therapy described.\\n\\nD) **Antisense**: Antisense molecules are used to block the function of specific RNA sequences. In this case, the Morpholino acts as an antisense molecule to recognize and prevent the binding of the spliceosome.\\n\\nGiven the description, the structure not directly involved in the proposed therapy is the polyA tail, as it is added post-splicing and not part of the splicing process being altered by the Morpholino.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the information given:\\n\\n1. **Gene Structure**: The gene has dozens of exons, with central ones coding for specific structures.\\n2. **Mutation**: Central exon deletions create out-of-frame peptides.\\n3. **Therapy**: Morpholino binds to the 5' end of the out-of-frame exon, preventing spliceosome binding, leading to exon skipping and in-frame joining.\\n4. **Outcome**: Several missing exons are well tolerated by the organism.\\n\\nNow, let's analyze each option:\\n\\nA) **Lariat**: This is a type of RNA structure formed during splicing when the intron is ligated to the 3' end of the upstream exon and the 5' end of the downstream exon. The therapy involves preventing spliceosome binding, which would prevent the formation of a lariat.\\n\\nB) **PolyA tail**: This is added to the 3' end of mRNA after splicing. Since the therapy does not involve post-splicing modifications but focuses on splicing itself, the polyA tail is not directly involved.\\n\\nC) **R-loops**: These are tri-strand DNA-RNA hybrids that can form during transcription. They are not mentioned or involved in the described splicing mechanism.\\n\\nD) **Antisense**: Morpholinos are a type of antisense oligonucleotide used in the therapy. Antisense molecules bind to specific RNA sequences to block their function, which is part of the proposed therapy.\\n\\nGiven this analysis, the structure not directly involved in the proposed therapy is the **polyA tail**.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process described:\\n\\n1. **Gene Structure**: The gene has dozens of exons, with central exons coding for specific sequences.\\n2. **Mutation**: Central exon deletions create out-of-frame peptides.\\n3. **Therapy**: Morpholino is used to prevent spliceosome binding, leading to exon skipping and in-frame joining.\\n4. **Outcome**: Several missing exons can be tolerated by the organism.\\n\\nNow, let's analyze each option:\\n\\n- **A) lariat**: In RNA splicing, the spliceosome catalyzes the formation of a lariat structure during intron removal. This is directly involved in the splicing process.\\n- **B) polyA tail**: This is added to the 3' end of mRNA after processing but is not directly involved in the initial splicing or exon recognition.\\n- **C) R-loops**: These are structures formed when a single strand of DNA anneals with its transcribed RNA strand, displacing the other DNA strand. They are not directly involved in the splicing process.\\n- **D) antisense**: Morpholinos are antisense oligomers designed to bind to specific sequences, preventing the spliceosome from binding. This is directly involved in the therapy.\\n\\nGiven this analysis, the structure that is not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process step by step:\\n\\n1. **Understanding the Therapy**: The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n\\n2. **Key Components**:\\n   - **Pre-mRNA**: The mRNA before splicing.\\n   - **Spliceosome**: The complex that performs RNA splicing.\\n   - **Exon Skipping and In-Frame Joining**: The goal is to skip certain exons and join others in a way that maintains the reading frame.\\n\\n3. **Analyzing the Options**:\\n   - **A) Lariat**: During splicing, the intron is removed, and the remaining exons are joined. This process can create a lariat structure as a temporary intermediate. Since the therapy involves preventing the spliceosome from binding, the lariat structure would still be involved in the process.\\n   - **B) PolyA Tail**: This is added to the 3' end of mature mRNA after processing. It is not directly involved in the splicing process or the Morpholino therapy.\\n   - **C) R-loops**: These are structures formed when single-stranded DNA hybridizes with its complementary RNA strand. They are not directly related to the splicing process or the Morpholino therapy.\\n   - **D) Antisense**: Morpholinos are a type of antisense molecule used to prevent binding. They are directly involved in the therapy.\\n\\nGiven this analysis, the structure that is not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process described:\\n\\n1. **Morpholino Recognition**: The Morpholino binds to the 5' end of the out-of-frame exon in pre-mRNA.\\n2. **Prevention of Spliceosome Binding**: This prevents the spliceosome from binding to the exon.\\n3. **Exon Skipping and In-Frame Joining**: As a result, the exon is skipped during splicing, and the remaining exons join in frame.\\n\\nNow, let's analyze each option:\\n\\nA) **Lariat**: During splicing, the intron is removed, and the 5' end of the intron forms a lariat structure. This is directly involved in the splicing process, so it is relevant.\\n\\nB) **PolyA Tail**: The polyA tail is added after splicing and mRNA processing. It is not directly involved in the initial splicing process but rather in mRNA stability and translation.\\n\\nC) **R-loops**: R-loops are structures formed when RNA hybridizes with its template DNA strand, displacing the nontemplate DNA strand. They are not directly involved in the splicing process or the Morpholino-mediated exon skipping.\\n\\nD) **Antisense**: Antisense molecules can bind to specific sequences in RNA and interfere with various processes, including splicing. However, in this context, the Morpholino acts as an antisense molecule to prevent spliceosome binding.\\n\\nGiven this analysis, the structure that is not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the components and their roles:\\n\\n1. **lariat**: This is formed during pre-mRNA splicing when introns are removed. It involves the spliceosome, which is targeted by the Morpholino to prevent binding and create exon skipping.\\n2. **polyA tail**: This is added to the 3' end of mature mRNA after splicing. While it is important for mRNA stability and translation, it is not directly involved in the splicing process or the binding of the spliceosome.\\n3. **R-loops**: These are structures formed when RNA hybridizes with its parent DNA strand, displacing the complementary DNA strand. They are not directly related to the splicing process or the Morpholino's action.\\n4. **antisense**: Morpholinos are antisense oligonucleotides designed to bind to specific sequences on the pre-mRNA, preventing the spliceosome from binding. This is a key component of the therapy.\\n\\nGiven this analysis, the structure not directly involved in the proposed therapy (which focuses on splicing and exon skipping) is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process step by step:\\n\\n1. **Understanding the Therapy**: The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n\\n2. **Key Components**:\\n   - **Morpholino**: An antisense oligonucleotide used to block splicing.\\n   - **Pre-mRNA**: The RNA precursor before splicing.\\n   - **Spliceosome**: A complex of proteins and RNAs that processes pre-mRNA by removing introns and joining exons.\\n   - **Exon Skipping and In-Frame Joining**: The goal is to skip over the problematic exons and join the remaining exons in frame.\\n\\n3. **Analyzing Each Option**:\\n   - **A) Lariat**: During pre-mRNA processing, lariats are formed as part of the splicing process. They are not directly involved in the Morpholino therapy described.\\n   - **B) PolyA Tail**: This is added to the 3' end of mature mRNA after splicing. It is not involved in the initial splicing process or the Morpholino therapy.\\n   - **C) R-loops**: These are structures formed when single-stranded DNA hybridizes with its corresponding RNA strand. They are not directly involved in the Morpholino therapy.\\n   - **D) Antisense**: This refers to the Morpholino itself, which is the key component in the therapy.\\n\\n4. **Conclusion**: Among the options provided, the structures involved in the Morpholino therapy are the pre-mRNA and the spliceosome. The structures not involved are the lariat, polyA tail, and R-loops.\\n\\nAnswer: C<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process step by step:\\n\\n1. **Understanding the Therapy**: The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n\\n2. **Role of Structures**:\\n   - **Lariat**: Lariats are formed during splicing when introns are removed from pre-mRNA. They are not directly involved in the proposed therapy.\\n   - **PolyA Tail**: The polyA tail is added to the 3' end of mature mRNA after splicing. It is not directly involved in the proposed therapy as it does not affect splicing or exon recognition.\\n   - **R-loops**: R-loops are structures formed when RNA hybridizes with one strand of DNA, causing a triplex structure. They are not directly related to the splicing process or the proposed therapy.\\n   - **Antisense**: Antisense molecules can bind to specific sequences on pre-mRNA, which aligns with the role of the Morpholino in preventing spliceosome binding and creating exon skipping.\\n\\nGiven this analysis, the structures involved in the proposed therapy are lariat (as it relates to splicing), polyA tail (post-splicing), and antisense (as part of the Morpholino). The structure that is not involved in the proposed therapy is R-loops.\\n\\nAnswer: C<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process:\\n\\n1. **Understanding the Therapy**: The therapy involves using a Morpholino to recognize the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n\\n2. **Key Components**:\\n   - **Pre-mRNA**: The mRNA before splicing.\\n   - **Spliceosome**: An RNA-protein complex that removes introns from pre-mRNA during splicing.\\n   - **Exon Skipping and In-Frame Joining**: The goal is to skip certain exons and join others to restore a functional gene product.\\n\\n3. **Analyzing the Options**:\\n   - **A) Lariat**: This is a structure formed during splicing when an intron is removed. It is involved in the splicing process but not directly targeted by the Morpholino.\\n   - **B) PolyA Tail**: This is added to the 3' end of mature mRNA after splicing. It is not involved in the splicing process or the Morpholino therapy.\\n   - **C) R-loops**: These are structures formed when a single-stranded DNA molecule hybridizes with its complementary RNA strand. They are not directly involved in splicing or the Morpholino therapy.\\n   - **D) Antisense**: This refers to a sequence of nucleotides that can bind to a specific target sequence, such as the Morpholino used here. It is involved in the therapy.\\n\\nGiven this analysis, the structure that is not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process step-by-step:\\n\\n1. **Understanding the Therapy**: The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n\\n2. **Key Components**:\\n   - **Pre-mRNA**: The initial RNA transcript.\\n   - **Morpholino**: An antisense oligonucleotide that binds to the pre-mRNA.\\n   - **Spliceosome**: An enzyme complex that splices introns from pre-mRNA during RNA processing.\\n   - **Exon Skipping**: The removal of specific exons from the pre-mRNA.\\n   - **In-frame Joining**: Ensuring that the remaining exons are joined in the correct reading frame.\\n\\n3. **Analyzing Each Option**:\\n   - **A) Lariat**: This is a circular RNA structure formed during the splicing process when an intron is being removed. It is directly involved in the splicing mechanism.\\n   - **B) PolyA Tail**: This is added to the 3' end of mature mRNA after splicing. It is not directly involved in the splicing process but rather in the stability and translation of the mRNA.\\n   - **C) R-loops**: These are structures formed when a single strand of DNA is hybridized with its complementary RNA strand, causing a bulge in the DNA. They are not directly involved in the splicing process.\\n   - **D) Antisense**: This refers to the Morpholino used in the therapy, which is designed to bind to the pre-mRNA and prevent splicing.\\n\\nGiven this analysis, the structure that is not directly involved in the proposed therapy, which focuses on preventing spliceosome binding and exon skipping, is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"Let's analyze each option in the context of the proposed therapy:\\n\\n1. **Lariat**: This is a type of RNA structure formed during splicing when the intron is removed from the pre-mRNA. The therapy involves preventing the binding of the spliceosome to create exon skipping, which would affect the formation of lariats. Therefore, the lariat is involved.\\n\\n2. **PolyA tail**: This is added to the 3' end of mRNA after splicing. Since the therapy does not directly involve the 3' end or the addition of a polyA tail, it is not directly involved in this specific therapy.\\n\\n3. **R-loops**: These are structures formed when RNA hybridizes to its corresponding DNA strand, displacing the other DNA strand. The therapy described does not mention anything about DNA or R-loops, so they are not directly involved.\\n\\n4. **Antisense**: Morpholinos used in the therapy are antisense molecules designed to recognize and bind to specific sequences in the pre-mRNA. This means antisense is directly involved in the therapy.\\n\\nGiven this analysis, the structure that is not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the information given:\\n\\n1. **Gene Structure**: The gene has dozens of exons, and central exons code for folded triple alpha helices.\\n2. **Mutation**: Central exon deletions create out-of-frame peptides.\\n3. **Therapy**: Morpholino is used to prevent the spliceosome from binding to the 5' end of the out-of-frame exon, leading to exon skipping and in-frame joining.\\n\\nNow, let's analyze each option:\\n\\nA) **Lariat**: This is a type of RNA structure formed during pre-mRNA splicing when an intron is being removed. It is directly involved in the splicing process and would be affected by the Morpholino therapy.\\n\\nB) **PolyA tail**: This is added to the 3' end of mature mRNA after splicing. While it is part of the mRNA, it is not directly involved in the splicing process itself and would not be affected by the Morpholino targeting the 5' end of the pre-mRNA.\\n\\nC) **R-loops**: These are structures formed when a strand of DNA anneals with its transcribed RNA, displacing the other DNA strand. They are not directly involved in the splicing process and would not be affected by the Morpholino therapy.\\n\\nD) **Antisense**: This refers to a strand of nucleic acid that is complementary to another strand. In this context, the Morpholino acts as an antisense molecule to block the spliceosome. Thus, it is directly involved in the therapy.\\n\\nGiven the analysis, the structure that is not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process:\\n\\n1. **Morpholino Treatment**: The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n\\n2. **Exon Skipping and In-Frame Joining**: This process involves the removal of specific exons from the pre-mRNA, followed by the correct splicing of the remaining exons to form a functional mRNA.\\n\\n3. **Spliceosome Binding**: The spliceosome is a complex of proteins and RNA that is responsible for removing introns and joining exons during RNA splicing. The Morpholino blocks this binding.\\n\\n4. **Pre-mRNA Processing**: Pre-mRNA processing includes adding a polyA tail at the 3' end and splicing out introns. However, the Morpholino specifically targets the 5' end of the out-of-frame exon, not the polyA tail or other structures.\\n\\n5. **Lariat Formation**: During splicing, a lariat structure is formed as part of the spliceosome activity. This structure is involved in the splicing process but is not directly targeted by the Morpholino.\\n\\n6. **R-loops**: R-loops are tripartite nucleic acid structures involving DNA, RNA, and protein. They are not directly involved in the splicing process or the Morpholino treatment.\\n\\n7. **Antisense**: Antisense molecules can be used to target specific sequences in RNA, but in this case, the Morpholino is specifically described as recognizing and blocking spliceosome binding, not acting as an antisense molecule.\\n\\nGiven the above analysis, the structure that is not involved in the proposed therapy is the polyA tail because it is added after the splicing process and is not directly affected by the Morpholino targeting the 5' end of the out-of-frame exon.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process step-by-step:\\n\\n1. **Understanding the Therapy**: The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n\\n2. **Key Components**:\\n   - **Pre-mRNA**: The RNA before splicing.\\n   - **Spliceosome**: The complex that processes RNA during splicing.\\n   - **Exon Skipping and In-frame Joining**: The goal is to skip certain exons and join others to restore the correct reading frame.\\n\\n3. **Analyzing Each Option**:\\n   - **A) Lariat**: During splicing, introns are removed, and the remaining exons are joined. The splicing process forms a lariat structure temporarily as part of the splicing intermediate. This is directly involved in the splicing process.\\n   - **B) PolyA Tail**: This is added to the 3' end of mature mRNA after splicing. It is not directly involved in the splicing process or exon skipping.\\n   - **C) R-loops**: These are structures formed when single-stranded DNA hybridizes with its complementary RNA strand. They are not directly involved in the splicing process or exon skipping.\\n   - **D) Antisense**: Morpholinos are antisense oligomers used to block specific sequences. They are directly involved in the proposed therapy by preventing spliceosome binding.\\n\\n4. **Conclusion**:\\n   - The lariat is formed during the splicing process and is involved.\\n   - The polyA tail is added post-splicing and is not involved.\\n   - R-loops are not related to splicing or exon skipping.\\n   - Antisense molecules like Morpholinos are directly involved in the therapy.\\n\\nTherefore, the structure not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process step by step:\\n\\n1. **Understanding the Therapy**: The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n\\n2. **Components Involved**:\\n   - **Pre-mRNA**: The initial RNA transcript.\\n   - **Morpholino**: The therapeutic agent that binds to the pre-mRNA.\\n   - **Spliceosome**: An enzyme complex that processes pre-mRNA by removing introns and joining exons.\\n   - **Exon Skipping and In-Frame Joining**: The goal of the therapy.\\n\\n3. **Analyzing Each Option**:\\n   - **A) Lariat**: This is a structure formed during the splicing process when an intron is removed, and the 5' end of the intron forms a loop with the 3' end of the intron.\\n   - **B) PolyA Tail**: This is added to the 3' end of mature mRNA after splicing and polyadenylation. It is not directly involved in the splicing process but rather in mRNA stability and translation.\\n   - **C) R-loops**: These are structures formed when a single strand of DNA is displaced by a complementary RNA strand, creating a three-stranded structure. They are not directly involved in the splicing or morpholino-mediated exon skipping.\\n   - **D) Antisense**: This refers to a sequence of nucleotides that can bind to a specific target sequence, often used in gene silencing techniques. The Morpholino used in this therapy acts as an antisense molecule.\\n\\nGiven the context, the structure not directly involved in the proposed therapy (which focuses on preventing spliceosome binding and causing exon skipping) is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the components and process described:\\n\\n1. **Gene Structure**: The gene has dozens of exons, with central exons coding for folded triple helical repeats.\\n2. **Mutation**: Central exon deletions create out-of-frame peptides.\\n3. **Therapy**: Delivery of a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA, preventing spliceosome binding and creating exon skipping and in-frame joining.\\n4. **Outcome**: Several missing exons are well tolerated by the organism.\\n\\nNow, let's analyze each option:\\n\\nA) **Lariat**: This is a structure formed during splicing when the intron is removed and the remaining exons are joined. It is directly involved in the splicing process, which is targeted by the Morpholino.\\n\\nB) **PolyA Tail**: This is added to the 3' end of mature mRNA after transcription and splicing. It is not directly involved in the splicing process or exon recognition by the Morpholino.\\n\\nC) **R-loops**: These are structures formed when an RNA strand hybridizes with its DNA template strand, displacing the other DNA strand. They are not mentioned in the context of the splicing process or the Morpholino therapy.\\n\\nD) **Antisense**: This refers to a strand of nucleic acid that is complementary to another strand and can bind to it, potentially affecting gene expression. The Morpholino used in this therapy acts as an antisense oligonucleotide to prevent binding of the spliceosome.\\n\\nBased on the analysis, the structure that is not directly involved in the proposed therapy is the PolyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process described:\\n\\n1. **Morpholino Recognition**: The Morpholino binds to the 5' end of the out-of-frame exon in pre-mRNA.\\n2. **Prevention of Spliceosome Binding**: This binding prevents the spliceosome from recognizing and splicing the exon.\\n3. **Exon Skipping and In-Frame Joining**: As a result, the exon is skipped, and the remaining exons join in frame, potentially restoring normal protein function.\\n\\nNow, let's analyze each option:\\n\\nA) **Lariat**: Lariats are formed during pre-mRNA processing when introns are spliced out. However, in this case, the spliceosome is prevented from binding, so no lariat would form at the site of the out-of-frame exon. This structure is not directly involved in the therapy.\\n\\nB) **PolyA Tail**: The polyA tail is added to the 3' end of mature mRNA after processing. It is not directly involved in the exon skipping or joining process described here.\\n\\nC) **R-loops**: R-loops are structures formed when RNA hybridizes with its template DNA strand, creating a three-stranded complex. While they can occur in the cell, they are not specifically mentioned in the context of the proposed therapy involving Morpholino and exon skipping.\\n\\nD) **Antisense**: Antisense refers to molecules that are complementary to a specific RNA sequence. In this context, the Morpholino acts as an antisense molecule to prevent the spliceosome from binding. Therefore, it is directly involved in the therapy.\\n\\nGiven the analysis, the structure that is not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process described:\\n\\n1. **Morpholino Recognition**: The Morpholino binds to the 5' end of the out-of-frame exon in pre-mRNA.\\n2. **Preventing Spliceosome Binding**: This binding prevents the spliceosome from recognizing and splicing the exon, leading to exon skipping.\\n3. **In-Frame Joining**: This results in in-frame joining of the remaining exons, which can help restore normal protein function.\\n\\nNow, let's analyze each option:\\n\\nA) **Lariat**: Lariats are formed during the splicing process when introns are removed and the 5' end of one exon forms a lariat structure with the 3' end of another exon. Since the therapy involves preventing splicing, the lariat structure would be affected.\\n\\nB) **PolyA Tail**: The polyA tail is added to the 3' end of mature mRNA after splicing is complete. The therapy does not directly involve the polyA tail; it focuses on pre-mRNA splicing.\\n\\nC) **R-loops**: R-loops are structures formed when RNA hybridizes with its template DNA strand, displacing the other DNA strand. While they can occur in the cell, the therapy described does not specifically mention or involve R-loops.\\n\\nD) **Antisense**: Morpholinos are a type of antisense molecule used to block specific sequences in RNA. The therapy explicitly mentions using a Morpholino, which is an antisense approach.\\n\\nGiven this analysis, the structure that is not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the information provided:\\n\\n1. **Gene Structure**: The gene has dozens of exons, with central exons coding for folded triple helical repeats.\\n2. **Mutations**: Central exon deletions create out-of-frame peptides, leading to progressive degenerative organ waste.\\n3. **Therapy**: A Morpholino is used to recognize the 5' end of the out-of-frame exon in pre-mRNA, preventing the spliceosome from binding and causing exon skipping and in-frame joining.\\n4. **Tolerance**: Several missing exons are well-tolerated by the organism.\\n\\nNow, let's analyze each option:\\n\\nA) **Lariat**: Lariats are formed during splicing when an intron is removed, but this process is not directly mentioned in the therapy described. The Morpholino does not involve the formation or degradation of lariats; it prevents splicing.\\n\\nB) **PolyA Tail**: The polyA tail is added to the 3' end of mature mRNA after splicing is complete. Since the therapy involves pre-mRNA and does not mention the addition of a polyA tail, this is not directly involved.\\n\\nC) **R-loops**: R-loops are structures formed when RNA hybridizes with its template DNA strand, displacing the nontemplate DNA strand. While R-loops can affect gene expression, they are not directly mentioned in the context of the therapy described.\\n\\nD) **Antisense**: Morpholinos are a type of antisense oligonucleotide that can bind to specific sequences on pre-mRNA, which fits the description given in the therapy.\\n\\nGiven the context of the therapy, the structure that is not directly involved is the polyA tail, as it is added post-splicing and not part of the pre-mRNA manipulation described.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process step by step:\\n\\n1. **Understanding the Therapy**: The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n\\n2. **Key Components**:\\n   - **Pre-mRNA**: The initial RNA transcript.\\n   - **Spliceosome**: An enzyme complex that removes introns from pre-mRNA and joins exons.\\n   - **Morpholino**: A synthetic DNA analog used to block the binding of the spliceosome.\\n\\n3. **Exon Skipping and In-Frame Joining**: By preventing the spliceosome from binding, the Morpholino allows for the removal of certain exons (skipping) and ensures that the remaining exons join in frame, producing a functional protein.\\n\\n4. **Options Analysis**:\\n   - **A) Lariat**: This is a type of RNA structure formed during the splicing process when an intron is removed and the 5' end of the intron forms a loop with the 3' end of the intron.\\n   - **B) PolyA Tail**: This is added to the 3' end of mature mRNA after splicing is complete.\\n   - **C) R-loops**: These are structures formed when a single strand of DNA hybridizes with its complementary RNA strand, causing a third strand of DNA to remain unpaired.\\n   - **D) Antisense**: This refers to molecules that can bind to specific RNA sequences, often used in gene silencing techniques.\\n\\nGiven that the therapy involves preventing the spliceosome from binding to the pre-mRNA, the key components are related to the splicing process itself. The lariat is directly involved as it is part of the splicing process. The polyA tail is added after splicing is complete and is not directly involved in the splicing or exon skipping process. R-loops and antisense molecules are not specifically mentioned in the context of this particular therapy.\\n\\nTherefore, the structure not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the information provided:\\n\\n1. **Gene Structure**: The gene has dozens of exons, with central ones coding for specific protein segments.\\n2. **Mutation**: Central exon deletions result in out-of-frame peptides.\\n3. **Therapy**: Morpholino is used to recognize the 5' end of the out-of-frame exon in pre-mRNA, preventing spliceosome binding and creating exon skipping and in-frame joining.\\n4. **Outcome**: Several missing exons are well tolerated by the organism.\\n\\nNow, let's analyze each option:\\n\\n- **A) Lariat**: In pre-mRNA processing, the spliceosome removes introns and joins exons. After splicing, the intron is converted into a lariat structure. This process is directly involved in the therapy as it involves the spliceosome.\\n  \\n- **B) PolyA Tail**: This is added to the 3' end of mature mRNA after transcription and splicing. It is not directly involved in the initial steps of pre-mRNA processing or the therapy described.\\n\\n- **C) R-loops**: These are structures formed when a single strand of DNA anneals with its complementary RNA strand, displacing the other DNA strand. They are not directly involved in the pre-mRNA splicing or the therapy described.\\n\\n- **D) Antisense**: Morpholinos are antisense molecules designed to bind to specific sequences in the pre-mRNA. They prevent the spliceosome from binding, thus affecting the splicing process. This is directly involved in the therapy.\\n\\nGiven this analysis, the structure not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process described:\\n\\n1. **Gene Structure**: The gene has dozens of exons, with central exons coding for specific sequences.\\n2. **Mutation**: Central exon deletions result in out-of-frame peptides.\\n3. **Therapy**: Morpholino oligonucleotides are used to prevent spliceosome binding at the 5' end of the out-of-frame exon, leading to exon skipping and in-frame joining.\\n\\nNow, let's analyze each option:\\n\\nA) **Lariat**: Lariats are formed during pre-mRNA splicing when introns are removed. The spliceosome catalyzes the formation of these structures. Since the therapy involves preventing spliceosome binding, it would indirectly affect lariat formation.\\n\\nB) **PolyA Tail**: This is added to the 3' end of mature mRNA after splicing is complete. It is not directly involved in the initial splicing process or exon skipping as described in the therapy.\\n\\nC) **R-loops**: These are DNA-RNA hybrids that can form when RNA polymerase synthesizes RNA in the same direction as the DNA template strand. They are not directly related to the splicing process or exon skipping described in the therapy.\\n\\nD) **Antisense**: Morpholinos are antisense oligonucleotides designed to bind to specific sequences. In this case, they are used to block the spliceosome from binding to the 5' end of the out-of-frame exon.\\n\\nGiven the description, the structure that is not directly involved in the proposed therapy is the polyA tail, as it is not part of the initial splicing process.\\n\\nAnswer: B<|im_end|>\", \"Let's analyze each option to determine which structure is not involved in the proposed therapy:\\n\\nA) Lariat - This is a structure formed during RNA splicing when introns are removed from pre-mRNA. The therapy involves preventing the spliceosome from binding to the pre-mRNA, but it does not directly involve the formation of a lariat.\\n\\nB) PolyA tail - This is added to the 3' end of mature mRNA after splicing. The therapy described does not mention anything about the polyA tail, so it is not directly involved.\\n\\nC) R-loops - These are structures formed when RNA hybridizes with its corresponding DNA template strand, displacing the other DNA strand. There is no mention of R-loops in the context of the therapy.\\n\\nD) Antisense - This refers to molecules that bind to complementary sequences on RNA, often used to inhibit gene expression. The Morpholino used in the therapy is an example of antisense technology.\\n\\nGiven the description of the therapy, the structure that is not directly involved is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the information given:\\n\\n1. **Gene Structure**: The gene has dozens of exons, with central exons coding for folded triple helical repeats.\\n2. **Mutations**: Central exon deletions create out-of-frame peptides.\\n3. **Therapy**: Morpholino recognizes the 5' end of the out-of-frame exon in pre-mRNA, preventing spliceosome binding, leading to exon skipping and in-frame joining.\\n4. **Tolerance**: Several missing exons are well-tolerated by the organism.\\n\\nNow, let's analyze each option:\\n\\n- **A) Lariat**: This is a structure formed during RNA splicing when an intron is removed and the two exons are joined. It is directly involved in the splicing process.\\n- **B) PolyA Tail**: This is added to the 3' end of mature mRNA after splicing. It is not directly involved in the splicing or skipping process but in the processing of the mRNA.\\n- **C) R-loops**: These are structures formed when an RNA strand anneals to its DNA template strand, displacing the complementary DNA strand. They are not directly involved in RNA splicing or exon skipping.\\n- **D) Antisense**: Morpholinos used here are antisense oligomers designed to bind to specific sequences on pre-mRNA, thus preventing the spliceosome from binding. This is directly involved in the therapy.\\n\\nGiven this analysis, the structure not involved in the proposed therapy is the **polyA tail**.\\n\\nAnswer: B<|im_end|>\", \"Let's break down the information given:\\n\\n1. **Gene Structure**: The gene has dozens of exons, with central exons coding for specific protein segments.\\n2. **Mutation**: Central exon deletions create out-of-frame peptides.\\n3. **Therapy**: Using a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA to prevent spliceosome binding, leading to exon skipping and in-frame joining.\\n4. **Tolerance**: Several missing exons can be well-tolerated by the organism.\\n\\nNow, let's analyze each option:\\n\\nA) **Lariat**: This is a structure formed during RNA splicing when introns are removed. It involves the spliceosome and is directly related to the process described.\\n\\nB) **PolyA tail**: This is added to the 3' end of mature mRNA after splicing but is not involved in the initial recognition or prevention of spliceosome binding as described by the Morpholino.\\n\\nC) **R-loops**: These are structures formed when single-stranded DNA hybridizes with its template strand in the presence of a complementary RNA strand. They are not directly involved in the RNA splicing process described.\\n\\nD) **Antisense**: Morpholinos are antisense molecules used to block specific sequences. They are part of the therapy described.\\n\\nGiven this analysis, the structure not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the components and their roles:\\n\\n1. **Lariat**: This is formed during the splicing process when introns are removed from the pre-mRNA, leaving behind a lariat structure.\\n2. **PolyA Tail**: This is added to the 3' end of the mRNA after processing and is not directly involved in the splicing process or exon skipping.\\n3. **R-loops**: These are structures formed when RNA hybridizes to its DNA template strand, displacing the other DNA strand. They are not directly related to the splicing process or the use of Morpholinos.\\n4. **Antisense**: Morpholinos used in this therapy act as antisense molecules, preventing the spliceosome from binding to the 5' end of the out-of-frame exon, thus causing exon skipping.\\n\\nGiven the context of the therapy involving Morpholinos and the splicing process, the structures directly involved are the lariat (formed during splicing), and the antisense mechanism (Morpholino action).\\n\\nThe polyA tail and R-loops are not directly involved in the splicing process or the Morpholino therapy described.\\n\\nTherefore, the correct answer is:\\n\\nAnswer: C<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the components and their roles:\\n\\n1. **lariat**: This is formed during splicing when the intron is removed and the 3' end of the intron forms a loop with the 5' splice site of the next exon. The spliceosome is involved in this process, and the proposed therapy involves preventing the spliceosome from binding to the 5' end of the out-of-frame exon.\\n\\n2. **polyA tail**: This is added to the 3' end of a pre-mRNA after splicing. It is not directly involved in the splicing process but helps in the stability and translation of the mRNA. The therapy does not mention anything about the polyA tail.\\n\\n3. **R-loops**: These are structures formed when RNA hybridizes with its corresponding DNA strand, displacing the other DNA strand. They are not directly related to splicing or the spliceosome, so they are not involved in the proposed therapy.\\n\\n4. **antisense**: Morpholinos are described as antisense molecules that recognize the 5' end of the out-of-frame exon in pre-mRNA and prevent the spliceosome from binding. This is a key part of the therapy.\\n\\nGiven the context, the structure that is not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the information provided:\\n\\n1. **Gene Structure and Exons**: The gene has dozens of exons, with central exons coding for specific structures.\\n2. **Mutations**: Central exon deletions create out-of-frame peptides.\\n3. **Therapy**: Morpholino is used to recognize the 5' end of the out-of-frame exon in pre-mRNA, preventing spliceosome binding and causing exon skipping and in-frame joining.\\n4. **Tolerance**: Several missing exons can be well-tolerated by the organism.\\n\\nNow, let's analyze each option:\\n\\n- **A) Lariat**: This is a structure formed during pre-mRNA processing when an intron is spliced out. It is involved in the splicing process but not directly mentioned in the context of the therapy.\\n- **B) PolyA Tail**: This is added to the 3' end of mature mRNA after splicing. It is not directly involved in the therapy as described.\\n- **C) R-loops**: These are structures formed when a single strand of DNA hybridizes with a complementary RNA strand, displacing the other DNA strand. They are not mentioned in the context of the therapy.\\n- **D) Antisense**: This refers to a strand of nucleic acid that is complementary to another strand and can bind to it. In this context, the Morpholino is acting as an antisense molecule to prevent spliceosome binding.\\n\\nGiven the description, the structures involved in the therapy are related to splicing and the prevention of spliceosome binding. The structures not directly involved in this process would be the polyA tail, R-loops, and lariat (which is part of the splicing process but not specifically mentioned in the therapy).\\n\\nHowever, since lariat is a direct product of the splicing process, it is more closely related to the therapy than R-loops or the polyA tail.\\n\\nAnswer: C<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the components and their roles:\\n\\n1. **Morpholino**: This is a synthetic molecule that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n2. **Spliceosome**: This is a complex of proteins and RNA that is involved in the splicing process of pre-mRNA.\\n3. **Exon Skipping and In-Frame Joining**: This refers to the process where the morpholino prevents the spliceosome from binding, leading to the removal of the out-of-frame exon and proper joining of the remaining exons.\\n4. **Lariat**: This is a temporary structure formed during pre-mRNA splicing, consisting of an intron looped around a branch point.\\n5. **PolyA Tail**: This is added to the 3' end of mature mRNA after splicing.\\n6. **R-loops**: These are structures formed when an RNA strand hybridizes with a DNA template strand, displacing the other DNA strand.\\n7. **Antisense**: This typically refers to a strand of nucleic acid that is complementary to a specific target sequence and can bind to it, often used in gene silencing techniques.\\n\\nThe therapy involves preventing the spliceosome from binding to the out-of-frame exon, leading to its removal and correct joining of the remaining exons. This process does not directly involve the polyA tail, R-loops, or antisense molecules in the way described. The lariat is involved as a temporary structure during splicing but is not specifically targeted by the morpholino in this context.\\n\\nTherefore, the structure not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"Let's analyze each option step by step:\\n\\nA) Lariat: This is a type of RNA structure formed during pre-mRNA splicing. It is part of the spliceosome complex, which is targeted by the Morpholino to prevent binding and cause exon skipping. So, it is involved in the proposed therapy.\\n\\nB) PolyA tail: This is added to the 3' end of mature mRNA after splicing. The Morpholino targets the 5' end of the out-of-frame exon in pre-mRNA, so the polyA tail is not directly involved in this process. It is not mentioned as being part of the therapy mechanism.\\n\\nC) R-loops: These are structures formed when RNA hybridizes to one strand of DNA, displacing the other DNA strand. They are not mentioned in the context of the proposed therapy involving Morpholino and pre-mRNA processing. Therefore, they are not involved.\\n\\nD) Antisense: Morpholinos are antisense oligonucleotides used in the therapy. They recognize and bind to specific sequences in the pre-mRNA, preventing the spliceosome from binding. Thus, antisense is involved in the therapy.\\n\\nGiven this analysis, the structure that is not involved in the proposed therapy is:\\n\\nAnswer: C<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the components and their roles:\\n\\n1. **Morpholino**: This is a synthetic DNA mimic that binds to the pre-mRNA at the 5' end of the out-of-frame exon.\\n2. **Spliceosome**: This is an enzyme complex that processes RNA during splicing.\\n3. **Exon skipping and in-frame joining**: This involves removing the out-of-frame exon and joining the remaining exons in a way that maintains the reading frame.\\n4. **Lariat**: This is a type of RNA structure formed during splicing when introns are removed.\\n5. **PolyA tail**: This is added to the 3' end of mRNA after processing.\\n6. **R-loops**: These are structures formed when single-stranded RNA hybridizes with double-stranded DNA.\\n7. **Antisense**: This refers to molecules that bind to specific sequences of RNA or DNA to inhibit their function.\\n\\nThe therapy involves preventing the spliceosome from binding to the out-of-frame exon, thus causing exon skipping and in-frame joining. This process does not directly involve the polyA tail, as it is added post-splicing and is not part of the initial splicing process. \\n\\n- **Lariat**: Involved in the splicing process.\\n- **PolyA tail**: Not directly involved in the splicing process.\\n- **R-loops**: Not directly involved in the splicing process.\\n- **Antisense**: Used in the therapy to prevent spliceosome binding.\\n\\nGiven the options, the structure not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process:\\n\\n1. **Morpholino Action**: The Morpholino binds to the 5' end of the out-of-frame exon in pre-mRNA, preventing the spliceosome from binding. This leads to exon skipping and in-frame joining.\\n\\n2. **Spliceosome Binding**: The spliceosome is responsible for removing introns and joining exons during RNA splicing. It is crucial for the process described.\\n\\n3. **Lariat Formation**: During RNA splicing, the spliceosome forms a lariat structure as part of its mechanism. This structure is directly involved in the splicing process.\\n\\n4. **PolyA Tail**: The polyA tail is added to the 3' end of mature mRNA after splicing. It is not directly involved in the initial splicing process but is important for mRNA stability and translation.\\n\\n5. **R-loops**: R-loops are structures formed when an RNA strand anneals to its template DNA strand, displacing the nontemplate DNA strand. They are not directly involved in the splicing process described.\\n\\n6. **Antisense**: Antisense refers to the complementary strand of DNA or RNA. While it can be used in therapeutic applications, it is not specifically mentioned in the context of the proposed therapy involving Morpholino.\\n\\nGiven this analysis, the structure not directly involved in the proposed therapy is the R-loop, as it does not play a role in the splicing process described.\\n\\nAnswer: C<|im_end|>\", \"Let's analyze each option step by step:\\n\\nA) **Lariat**: This is a type of RNA structure formed during splicing when an intron is being removed from the pre-mRNA. It is not directly involved in the proposed therapy of preventing spliceosome binding and creating exon skipping.\\n\\nB) **PolyA tail**: This is added to the 3' end of mRNA after transcription and processing. While it plays a role in mRNA stability and translation, it is not directly involved in the mechanism of preventing spliceosome binding or exon skipping.\\n\\nC) **R-loops**: These are structures formed when RNA hybridizes with its DNA template strand, displacing the other DNA strand. They are involved in various cellular processes but are not directly related to the proposed therapy of exon skipping through Morpholino action.\\n\\nD) **Antisense**: This refers to molecules that are complementary to a specific sequence of RNA and can bind to it, often used in gene silencing techniques. In this context, the Morpholino is described as recognizing the 5' end of the out-of-frame exon, which aligns with the concept of antisense technology.\\n\\nGiven the description of the therapy involving Morpholino preventing spliceosome binding and creating exon skipping, the structure not directly involved in this process is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"Let's analyze each option to determine which structure is not involved in the proposed therapy:\\n\\nA) Lariat - This is a structure formed during splicing when an intron is spliced out. It is part of the splicing process, but not directly involved in the therapy described, which focuses on preventing spliceosome binding and creating exon skipping.\\n\\nB) PolyA tail - This is added to the 3' end of mRNA after transcription and processing. It is not directly involved in the splicing or the therapy described.\\n\\nC) R-loops - These are structures formed when RNA hybridizes with its DNA template strand, displacing the other DNA strand. They are not mentioned in the context of the therapy and do not seem to be directly involved in the proposed treatment.\\n\\nD) Antisense - Morpholinos used in this therapy are antisense oligonucleotides designed to bind to specific sequences in the pre-mRNA. They are a key component of the therapy.\\n\\nGiven the context, the structure not directly involved in the proposed therapy is the R-loop.\\n\\nAnswer: C<|im_end|>\", \"Let's analyze each option step by step:\\n\\nA) Lariat - This is a structure formed during splicing when the intron is covalently linked to the acceptor site of the downstream exon. The Morpholino prevents spliceosome binding, which would affect this process. So, it is involved.\\n\\nB) PolyA tail - This is added to the 3' end of the mRNA after splicing. Since the Morpholino affects the pre-mRNA, it does not directly interact with the polyA tail. Thus, it is not directly involved in the proposed therapy.\\n\\nC) R-loops - These are structures formed when RNA hybridizes with its DNA template strand, displacing the other DNA strand. The therapy does not involve RNA-DNA interactions directly, so R-loops are not involved.\\n\\nD) Antisense - The Morpholino used in the therapy is an antisense oligomer designed to recognize the 5' end of the out-of-frame exon. Therefore, it is involved.\\n\\nBased on this analysis, the structure not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process described:\\n\\n1. **Central Exon Deletions**: The gene has central exons that are deleted, creating out-of-frame peptides.\\n2. **Morpholino Treatment**: A Morpholino is used to recognize the 5' end of the out-of-frame exon in pre-mRNA. This prevents the spliceosome from binding and causes exon skipping and in-frame joining.\\n3. **Exon Skipping and In-Frame Joining**: The goal is to skip over the missing exons and join the remaining parts in frame, allowing for proper protein synthesis.\\n\\nNow, let's analyze each option:\\n\\nA) **Lariat**: Lariats are formed during pre-mRNA splicing as a byproduct when introns are removed. They are not directly involved in the Morpholino treatment or exon skipping process described.\\n\\nB) **PolyA Tail**: The polyA tail is added to the 3' end of mature mRNA after splicing. It is not directly involved in the Morpholino treatment or exon skipping process.\\n\\nC) **R-loops**: R-loops are structures formed when RNA hybridizes to its template DNA strand, displacing the nontemplate DNA strand. While they can affect gene expression, they are not directly involved in the Morpholino treatment or exon skipping process.\\n\\nD) **Antisense**: Morpholinos act as antisense molecules, which means they are designed to bind to specific sequences in the pre-mRNA. This aligns with the described treatment method.\\n\\nGiven the description, the structure that is not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the information provided:\\n\\n1. **Gene Structure**: The gene has dozens of exons, with central ones coding for specific peptides.\\n2. **Mutations**: Central exon deletions create out-of-frame peptides.\\n3. **Therapy**: Morpholino prevents binding of the spliceosome, leading to exon skipping and in-frame joining.\\n4. **Outcome**: Missing exons are well tolerated.\\n\\nNow, let's analyze each option:\\n\\n- **A) Lariat**: This is a structure formed during RNA splicing when introns are removed from pre-mRNA. The spliceosome catalyzes the ligation of exons, and the lariat is part of this process. Since the therapy involves preventing spliceosome binding, the lariat would be involved.\\n\\n- **B) PolyA tail**: This is added to the 3' end of mRNA after splicing. It is not directly involved in the initial splicing process or the therapy described, which focuses on preventing spliceosome binding and exon skipping.\\n\\n- **C) R-loops**: These are structures formed when RNA hybridizes to its DNA template strand, displacing the complementary DNA strand. They are not directly related to the RNA splicing process or the therapy involving Morpholino.\\n\\n- **D) Antisense**: Morpholino is an antisense oligonucleotide that binds to the pre-mRNA to prevent splicing. This is directly involved in the therapy.\\n\\nBased on the analysis, the structure not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process described:\\n\\n1. **Gene Structure**: The gene has dozens of exons, with central ones coding for specific peptide sequences.\\n2. **Mutations**: Central exon deletions create out-of-frame peptides leading to degenerative effects.\\n3. **Therapy**: A Morpholino is used to recognize the 5' end of the out-of-frame exon in pre-mRNA, preventing spliceosome binding, and resulting in exon skipping and in-frame joining.\\n4. **Outcome**: Several missing exons can be tolerated by the organism.\\n\\nNow, let's analyze each option:\\n\\n- **A) Lariat**: This is a circular RNA structure formed during splicing when introns are removed from pre-mRNA. It is directly involved in the splicing process but is not mentioned in the context of the therapy.\\n- **B) PolyA tail**: This is added to the 3' end of mature mRNA after splicing. It is not directly involved in the splicing or the Morpholino therapy.\\n- **C) R-loops**: These are structures formed when single-stranded DNA hybridizes with its complementary RNA strand. They are not part of the splicing or the Morpholino therapy described.\\n- **D) Antisense**: Morpholinos are a type of antisense oligonucleotide that binds to the target sequence to prevent splicing. This is directly involved in the therapy.\\n\\nGiven this analysis, the structure not involved in the proposed therapy is:\\n\\nAnswer: C<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process described:\\n\\n1. **Central Exon Deletions**: The gene has central exons that are deleted, creating out-of-frame peptides.\\n2. **Morpholino Therapy**: A Morpholino is used to recognize the 5' end of the out-of-frame exon in pre-mRNA, preventing the spliceosome from binding and causing exon skipping and in-frame joining.\\n3. **Exon Skipping and In-Frame Joining**: This results in the removal of the deleted exons and restoration of the reading frame.\\n\\nNow, let's analyze each option:\\n\\nA) **Lariat**: This is a structure formed during splicing when the intron is ligated into a circular structure. Since the Morpholino therapy involves preventing the spliceosome from binding, it would affect this process. Therefore, the lariat is involved.\\n\\nB) **PolyA Tail**: This is added to the 3' end of the mature mRNA after splicing. The Morpholino therapy does not directly involve the polyA tail, as it focuses on pre-mRNA and splicing. Therefore, the polyA tail is not directly involved.\\n\\nC) **R-loops**: These are structures formed when single-stranded RNA hybridizes with double-stranded DNA. There is no mention of R-loops in the context of the Morpholino therapy or splicing process. Therefore, R-loops are not involved.\\n\\nD) **Antisense**: The Morpholino used in the therapy is an antisense molecule, designed to bind to the 5' end of the out-of-frame exon. Therefore, antisense is involved.\\n\\nGiven the analysis, the structure that is not involved in the proposed therapy is:\\n\\nAnswer: C<|im_end|>\", \"Let's analyze each option to determine which structure is not involved in the proposed therapy:\\n\\nA) Lariat: This is a structure formed during splicing when an intron is being removed. It involves the 5' splice site of the exon being joined to the 3' splice site of the previous exon. Since the therapy involves preventing the spliceosome from binding to the 5' end of the out-of-frame exon, this would affect the formation of the lariat structure.\\n\\nB) PolyA tail: This is added to the 3' end of a mature mRNA after splicing. While it plays a role in mRNA stability and translation, it is not directly involved in the process of splicing or preventing the spliceosome from binding.\\n\\nC) R-loops: These are structures formed when RNA hybridizes with its template DNA strand, displacing the non-template DNA strand. They are not directly related to the splicing process or the therapy involving Morpholino.\\n\\nD) Antisense: This refers to a strand of nucleic acid that is complementary to another strand, often used in gene silencing techniques like Morpholino. In this context, the Morpholino binds to the 5' end of the out-of-frame exon, acting as an antisense molecule.\\n\\nGiven the above analysis, the structure that is not involved in the proposed therapy is:\\n\\nAnswer: C<|im_end|>\", \"Let's analyze each option to determine which structure is not involved in the proposed therapy:\\n\\nA) Lariat - This is formed during the splicing process when an intron is removed, and the 5' end of the intron forms a lariat structure. The therapy involves preventing the spliceosome from binding, which would affect this structure.\\n\\nB) PolyA tail - This is added to the 3' end of mature mRNA after splicing. Since the therapy focuses on pre-mRNA and involves skipping exons, it does not directly involve the polyA tail.\\n\\nC) R-loops - These are structures formed when an RNA strand anneals to its DNA template strand, displacing the complementary DNA strand. The therapy described does not mention or involve R-loops.\\n\\nD) Antisense - Morpholinos used in the therapy act as antisense molecules, which bind to specific sequences in the pre-mRNA to prevent splicing. This is a key part of the therapy.\\n\\nGiven the analysis, the structure not involved in the proposed therapy is:\\n\\nAnswer: C<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process step by step:\\n\\n1. **Understanding the Therapy**: The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n\\n2. **Role of Each Option**:\\n   - **Lariat (A)**: This is a structure formed during splicing when introns are removed from the pre-mRNA. It is involved in the splicing process but not directly in the Morpholino therapy.\\n   - **PolyA Tail (B)**: This is added to the 3' end of mature mRNA after splicing. It is not directly involved in the splicing or the Morpholino therapy.\\n   - **R-loops (C)**: These are structures formed when RNA hybridizes with its template DNA strand, displacing the non-template DNA strand. They are not directly related to the splicing process or the Morpholino therapy.\\n   - **Antisense (D)**: This refers to molecules that can bind to specific sequences on RNA, such as the Morpholino used in this therapy. Antisense molecules are directly involved in the therapy by preventing spliceosome binding.\\n\\nGiven the above analysis, the structure not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process described:\\n\\n1. **Gene Structure**: The gene has dozens of exons, with central ones coding for specific structures.\\n2. **Mutation**: Central exon deletions cause out-of-frame peptides.\\n3. **Therapy**: Morpholino prevents spliceosome binding, leading to exon skipping and in-frame joining.\\n\\nNow, let's analyze each option:\\n\\nA) **Lariat**: This is a type of RNA structure formed during splicing when the intron is removed. It is involved in the splicing process and could be affected by the therapy as it involves preventing spliceosome binding.\\n\\nB) **PolyA tail**: This is added to the 3' end of mature mRNA after splicing. While it is crucial for mRNA stability and translation, it is not directly involved in the splicing process or the prevention of spliceosome binding.\\n\\nC) **R-loops**: These are tripartite nucleic acid structures consisting of a DNA:RNA hybrid with a third strand of DNA. They are not directly involved in the splicing process or the proposed therapy involving Morpholino.\\n\\nD) **Antisense**: Morpholinos are antisense oligomers designed to bind to specific sequences, which aligns with the described therapy.\\n\\nGiven this analysis, the structure not directly involved in the proposed therapy is the PolyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process described:\\n\\n1. **Gene Structure**: The gene has dozens of exons, and the central ones code for specific sequences.\\n2. **Mutations**: Central exon deletions create out-of-frame peptides.\\n3. **Therapy**: Morpholino is used to prevent the spliceosome from binding to the 5' end of the out-of-frame exon, leading to exon skipping and in-frame joining.\\n\\nNow, let's analyze each option:\\n\\n- **A) Lariat**: This is a structure formed during RNA splicing when introns are removed. It is involved in the splicing process but is not directly targeted or affected by the Morpholino therapy.\\n  \\n- **B) PolyA Tail**: This is added to the 3' end of mature mRNA after splicing. It is not directly involved in the splicing process itself but in post-transcriptional regulation. The Morpholino does not affect this structure.\\n\\n- **C) R-loops**: These are structures formed when single-stranded RNA hybridizes with its corresponding DNA template strand, displacing the other DNA strand. They are not part of the splicing process and are not mentioned in the context of the therapy.\\n\\n- **D) Antisense**: This refers to the Morpholino itself, which is designed to bind to the 5' end of the out-of-frame exon in pre-mRNA and prevent spliceosome binding. It is directly involved in the therapy.\\n\\nBased on the analysis, the structure not involved in the proposed therapy is:\\n\\nAnswer: C<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process described:\\n\\n1. **Gene Structure**: The gene has dozens of exons, with central exons coding for specific regions.\\n2. **Mutation**: Central exon deletions create out-of-frame peptides.\\n3. **Therapy**: Morpholino is used to recognize the 5' end of the out-of-frame exon in pre-mRNA, preventing spliceosome binding and creating exon skipping and in-frame joining.\\n4. **Outcome**: Several missing exons are well-tolerated by the organism.\\n\\nNow, let's analyze each option:\\n\\n- **A) lariat**: During splicing, introns are removed and the remaining exons are joined together. The lariat is a structure formed during this process as the intron is spliced out. Since the therapy involves preventing the spliceosome from binding, it would affect the formation of the lariat.\\n- **B) polyA tail**: This is added to the 3' end of mature mRNA after transcription and processing. The therapy does not directly involve the polyA tail; it focuses on pre-mRNA and splicing.\\n- **C) R-loops**: These are structures formed when single-stranded RNA hybridizes with double-stranded DNA. They are not directly mentioned or involved in the described splicing mechanism or therapy.\\n- **D) antisense**: Morpholino is an antisense oligonucleotide used in the therapy. It binds to the target sequence to prevent splicing.\\n\\nGiven this analysis, the structure not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process step by step:\\n\\n1. **Understanding the Therapy**: The therapy involves delivering a Morpholino that binds to the 5' end of the out-of-frame exon in pre-mRNA. This binding prevents the spliceosome from binding, leading to exon skipping and in-frame joining.\\n\\n2. **Key Components**:\\n   - **Morpholino**: This is the therapeutic agent.\\n   - **Pre-mRNA**: The RNA before splicing.\\n   - **Spliceosome**: An enzyme complex that removes introns and joins exons during splicing.\\n   - **Exon Skipping and In-Frame Joining**: These are the desired outcomes of the therapy.\\n\\n3. **Analyzing Each Option**:\\n   - **A) Lariat**: During splicing, the spliceosome forms a lariat structure as part of the intron processing. This is directly involved in the splicing process.\\n   - **B) PolyA Tail**: This is added to the 3' end of the mRNA after splicing and translation initiation. It is not directly involved in the splicing or the therapy described.\\n   - **C) R-loops**: These are structures formed when RNA hybridizes with its DNA template strand, displacing the complementary DNA strand. They are not directly involved in splicing.\\n   - **D) Antisense**: This term can refer to various mechanisms, but in this context, it likely refers to the Morpholino, which is used in the therapy.\\n\\nGiven the analysis, the structure that is not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"Let's break down the information given and analyze each option:\\n\\n1. **Exon Structure**: The gene has many exons, with central exons coding for specific parts of the protein.\\n2. **Mutation**: Central exon deletions create out-of-frame peptides, leading to degenerative effects.\\n3. **Therapy**: Using Morpholino to recognize the 5' end of the out-of-frame exon in pre-mRNA, preventing spliceosome binding, and creating exon skipping and in-frame joining.\\n\\nNow, let's consider each option:\\n\\nA) **Lariat**: This is a structure formed during RNA splicing when an intron is removed and the flanking exons are joined. The therapy described involves preventing spliceosome binding and thus would not involve the formation of a lariat.\\n\\nB) **PolyA tail**: This is added to the 3' end of mRNA after splicing. The therapy described does not directly involve the polyA tail, as it focuses on pre-mRNA and splicing events.\\n\\nC) **R-loops**: These are structures formed when a newly synthesized RNA strand anneals to its DNA template strand, displacing the complementary DNA strand. There's no mention or implication of R-loops in the therapy described.\\n\\nD) **Antisense**: Morpholinos are often described as antisense oligonucleotides used to block gene expression. They do play a role in the described therapy by recognizing the 5' end of the out-of-frame exon.\\n\\nGiven the context, the structure not involved in the proposed therapy is the R-loop.\\n\\nAnswer: C<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process:\\n\\n1. **Morpholino Delivery**: The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n2. **Prevention of Spliceosome Binding**: This Morpholino prevents the spliceosome from binding, leading to exon skipping and in-frame joining.\\n3. **Exon Skipping and In-Frame Joining**: This results in the creation of a new, in-frame transcript that can be translated into a functional protein.\\n\\nNow, let's analyze each option:\\n\\nA) **Lariat**: Lariats are formed during the splicing process when introns are removed, and they play a role in the splicing reaction. Since the Morpholino prevents the spliceosome from binding, it would affect the formation of lariats as part of the splicing process.\\n\\nB) **PolyA Tail**: The polyA tail is added to the 3' end of mature mRNA after splicing. While the Morpholino affects the splicing process, it does not directly involve the addition or maintenance of the polyA tail.\\n\\nC) **R-loops**: R-loops are structures formed when RNA hybridizes to one strand of DNA, displacing the other DNA strand. They are not directly involved in the splicing process or the Morpholino therapy described here.\\n\\nD) **Antisense**: Antisense molecules can bind to specific sequences on RNA and prevent translation or splicing. While this is related to RNA, the Morpholino specifically targets the 5' end of the out-of-frame exon to prevent spliceosome binding, which is a form of antisense action.\\n\\nGiven the analysis, the structure that is not directly involved in the proposed therapy is the R-loop.\\n\\nAnswer: C<|im_end|>\", \"Let's analyze each option step by step:\\n\\nA) Lariat: This is a structure formed during splicing when an intron is removed and the 5' end of the intron forms a loop with the 3' end of the intron. It is involved in the splicing process but is not directly mentioned or involved in the proposed therapy of using Morpholino to prevent spliceosome binding and create exon skipping.\\n\\nB) PolyA tail: This is added to the 3' end of a pre-mRNA after splicing and is crucial for mRNA stability and translation. However, it is not directly involved in the splicing process or the Morpholino therapy described.\\n\\nC) R-loops: These are structures formed when RNA hybridizes with one strand of its DNA template, displacing the other DNA strand. While they can occur in cells, they are not directly involved in the splicing process or the Morpholino therapy described.\\n\\nD) Antisense: This refers to molecules that bind to specific sequences of RNA to block their function, such as in the case of the Morpholino used in the therapy. This is directly involved in the proposed therapy.\\n\\nGiven the context of the question, the structure not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"Let's analyze each option step by step:\\n\\nA) Lariat: This is a structure formed during splicing when an intron is being removed. The spliceosome catalyzes the formation of a lariat structure, which is then cleaved. Since the therapy involves preventing the spliceosome from binding to the 5' end of the out-of-frame exon, the lariat structure would be affected.\\n\\nB) PolyA tail: This is added to the 3' end of a mature mRNA after splicing. The therapy described does not involve the 3' end or the addition of a polyA tail, so this structure is not directly involved in the proposed therapy.\\n\\nC) R-loops: These are structures formed when a strand of RNA anneals to its template DNA strand, displacing the other DNA strand. While R-loops can form in the context of gene expression, they are not directly involved in the process of splicing or the therapy described, which focuses on preventing spliceosome binding and exon skipping.\\n\\nD) Antisense: Morpholinos used in the therapy act as antisense molecules, binding to the pre-mRNA to prevent the spliceosome from binding and causing exon skipping. Therefore, antisense is directly involved in the therapy.\\n\\nBased on the analysis, the structure not involved in the proposed therapy is:\\n\\nAnswer: C<|im_end|>\", \"Let's analyze each option in the context of the proposed therapy:\\n\\nA) Lariat - This is a structure formed during pre-mRNA splicing when an intron is being excised. The therapy involves preventing the spliceosome from binding, which would indeed affect the formation of lariats.\\n\\nB) PolyA tail - This is added to the 3' end of mature mRNA after splicing. The therapy described does not directly involve the 3' end or the polyA tail, so this structure is not directly affected by the therapy.\\n\\nC) R-loops - These are structures formed when single-stranded RNA hybridizes with its corresponding DNA template strand, displacing the complementary DNA strand. The therapy focuses on pre-mRNA and splicing, so it is unlikely to directly involve R-loops.\\n\\nD) Antisense - Morpholinos used in the therapy are antisense oligomers designed to bind to specific sequences. This means they are involved in the therapy.\\n\\nGiven the analysis, the structure that is not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the components and their roles:\\n\\n1. **Morpholino**: This is a synthetic molecule that binds to the 5' end of the out-of-frame exon in pre-mRNA.\\n2. **Spliceosome**: This is a complex of proteins and RNA that recognizes specific sequences in pre-mRNA and splices out introns.\\n3. **Exon Skipping and In-Frame Joining**: By preventing the spliceosome from binding, the Morpholino causes the skipped exon to be joined in-frame with the remaining exons.\\n\\nNow, let's analyze each option:\\n\\nA) **Lariat**: This is a structure formed during pre-mRNA processing when an intron is being spliced out. It involves the spliceosome and is directly related to the splicing process.\\n\\nB) **PolyA Tail**: This is added to the 3' end of mature mRNA after transcription and processing. It is not directly involved in the splicing process or the mechanism of exon skipping.\\n\\nC) **R-loops**: These are structures formed when RNA hybridizes with its DNA template strand, displacing the complementary DNA strand. While they can affect gene expression, they are not directly involved in the splicing process or the Morpholino mechanism.\\n\\nD) **Antisense**: This refers to a sequence of nucleotides that is complementary to a target sequence. In this context, the Morpholino acts as an antisense molecule to prevent binding of the spliceosome.\\n\\nGiven the context, the structure that is not directly involved in the proposed therapy of exon skipping and in-frame joining through Morpholino action is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the information given:\\n\\n1. **Gene Structure**: The gene has dozens of exons, with central exons coding for folded triple helical repeats.\\n2. **Mutation**: Central exon deletions create out-of-frame peptides.\\n3. **Therapy**: Morpholino is used to recognize the 5' end of the out-of-frame exon in pre-mRNA, preventing spliceosome binding and creating exon skipping and in-frame joining.\\n\\nNow, let's analyze each option:\\n\\nA) **Lariat**: This is a type of RNA structure formed during pre-mRNA splicing when an intron is being removed. It is directly involved in the splicing process.\\n\\nB) **PolyA Tail**: This is added to the 3' end of mature mRNA after splicing. It is not directly involved in the splicing process but in the stability and translation of the mRNA.\\n\\nC) **R-loops**: These are structures formed when RNA hybridizes with one strand of its DNA template. They are not directly involved in the splicing process.\\n\\nD) **Antisense**: Morpholinos act as antisense molecules to prevent binding of the spliceosome. This is directly involved in the therapy described.\\n\\nGiven this analysis, the structure that is not directly involved in the proposed therapy (which focuses on splicing and exon skipping) is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process described:\\n\\n1. **Gene Structure and Exons**: The gene has dozens of exons, with central ones coding for specific sequences.\\n2. **Mutation**: Central exon deletions create out-of-frame peptides, leading to degenerative effects.\\n3. **Therapy**: Morpholino oligonucleotides recognize the 5' end of the deleted exon in pre-mRNA, preventing spliceosome binding and causing exon skipping and in-frame joining.\\n4. **Outcome**: Several missing exons are well-tolerated by the organism.\\n\\nNow, let's analyze each option:\\n\\nA) **Lariat**: Lariats are formed during splicing when an intron is excised and its 5' end forms a lariat structure. In this therapy, the Morpholino prevents the spliceosome from binding to the 5' end of the deleted exon, thus preventing the formation of a lariat. Therefore, lariat formation is involved.\\n\\nB) **PolyA Tail**: The polyA tail is added to the 3' end of the mature mRNA after splicing. It is not directly involved in the initial splicing process or the Morpholino therapy described. Thus, it is not directly involved in the proposed therapy.\\n\\nC) **R-loops**: R-loops are structures formed when RNA hybridizes with one strand of DNA, creating a three-stranded structure. They are not mentioned in the context of the therapy and do not play a role in the splicing process or exon skipping described.\\n\\nD) **Antisense**: Morpholinos are antisense molecules that bind to the target sequence to prevent splicing. This fits within the description of the therapy.\\n\\nGiven the analysis, the structure not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process described:\\n\\n1. **Gene Structure**: The gene has dozens of exons, and the central ones code for folded triple helical repeats.\\n2. **Mutation**: Central exon deletions create out-of-frame peptides.\\n3. **Therapy**: Morpholino oligonucleotides are used to recognize the 5' end of the out-of-frame exon in pre-mRNA, preventing spliceosome binding and causing exon skipping and in-frame joining.\\n4. **Outcome**: Several missing exons are well-tolerated by the organism.\\n\\nNow, let's analyze each option:\\n\\nA) **Lariat**: This is a circular RNA structure formed during pre-mRNA splicing. It is involved in the splicing process but is not directly mentioned in the therapy mechanism described.\\n\\nB) **PolyA Tail**: This is added to the 3' end of mature mRNA after splicing. While it is important for mRNA stability and translation, it is not directly involved in the therapy described.\\n\\nC) **R-loops**: These are structures formed when RNA hybridizes with its DNA template strand, displacing the other DNA strand. They are not mentioned in the context of the therapy and do not play a direct role in the described mechanism.\\n\\nD) **Antisense**: Morpholinos act as antisense molecules, which means they bind to the target sequence to prevent binding of the spliceosome. This is a key part of the therapy described.\\n\\nGiven the context of the therapy involving Morpholinos preventing spliceosome binding, the structure that is not directly involved in this mechanism is the R-loop.\\n\\nAnswer: C<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the components and their roles:\\n\\n1. **Morpholino**: This is a synthetic molecule that specifically targets the 5' end of the out-of-frame exon in pre-mRNA. It prevents the binding of the spliceosome.\\n2. **Spliceosome**: This is a complex of RNA and proteins that is responsible for splicing pre-mRNA to remove introns and join exons.\\n3. **Exon Skipping and In-Frame Joining**: By preventing the spliceosome from binding, the Morpholino allows for the removal of the deleted exon and the joining of the remaining exons in frame, thereby restoring the correct reading frame.\\n\\nNow, let's analyze each option:\\n\\nA) **Lariat**: This is a structure formed during the splicing process when an intron is removed. The spliceosome catalyzes the formation of a lariat structure, which is then cleaved. Since the therapy involves preventing the spliceosome from binding, it would not form a lariat structure.\\n\\nB) **PolyA Tail**: This is added to the 3' end of mature mRNA after transcription and splicing. The therapy does not involve the polyA tail directly, as it pertains to the pre-mRNA and spliceosome activity.\\n\\nC) **R-loops**: These are structures formed when single-stranded DNA hybridizes with its complementary RNA strand. They are not directly involved in the splicing process or the action of the Morpholino.\\n\\nD) **Antisense**: This refers to molecules that can bind to specific RNA sequences, often used in gene silencing techniques. The Morpholino used in this therapy acts as an antisense molecule to prevent spliceosome binding.\\n\\nGiven the context, the structure not involved in the proposed therapy is the **polyA tail**.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process:\\n\\n1. **Understanding the Therapy**: The therapy involves delivering a Morpholino that binds to the 5' end of the out-of-frame exon in pre-mRNA. This binding prevents the spliceosome from recognizing the exon, leading to exon skipping and in-frame joining.\\n\\n2. **Key Components**:\\n   - **Pre-mRNA**: The mRNA before splicing.\\n   - **Spliceosome**: An enzyme complex that removes introns and joins exons.\\n   - **Exon Skipping**: Removal of specific exons.\\n   - **In-frame Joining**: Ensuring the remaining exons are joined correctly.\\n\\n3. **Structures Involved**:\\n   - **Lariat**: A structure formed during splicing when an intron is spliced out, leaving a looped structure.\\n   - **PolyA Tail**: Added to the 3' end of mature mRNA.\\n   - **R-loops**: Structures formed when RNA hybridizes with one strand of DNA, displacing the other strand.\\n   - **Antisense**: Molecules that bind to specific sequences of RNA or DNA.\\n\\n4. **Analysis**:\\n   - **Lariat**: Formed during splicing but not directly involved in the Morpholino binding.\\n   - **PolyA Tail**: Added after splicing and not directly involved in the Morpholino's action.\\n   - **R-loops**: Not mentioned in the context of the therapy.\\n   - **Antisense**: The Morpholino acts as an antisense molecule to prevent spliceosome binding.\\n\\nGiven this analysis, the structures not directly involved in the Morpholino's action are the PolyA tail and R-loops. However, since we need to choose only one option, and R-loops are specifically not mentioned in the context of the therapy, the best answer is:\\n\\nAnswer: C<|im_end|>\", \"Let's analyze each option to determine which structure is not involved in the proposed therapy:\\n\\nA) Lariat - This is a type of RNA structure formed during splicing when introns are removed from pre-mRNA. It is involved in the splicing process but not directly in the therapy described, which involves preventing spliceosome binding.\\n\\nB) PolyA tail - This is added to the 3' end of mature mRNA after splicing. It is not directly involved in the splicing process or the therapy described.\\n\\nC) R-loops - These are structures formed when a strand of DNA hybridizes with its transcribed RNA, displacing the other DNA strand. They are not directly involved in the splicing process or the therapy described.\\n\\nD) Antisense - Morpholinos used in the therapy are antisense molecules designed to bind to specific sequences on the pre-mRNA. They prevent the spliceosome from binding and thus are directly involved in the therapy.\\n\\nBased on the analysis, the structures involved in the therapy are the spliceosome, pre-mRNA, and antisense molecules. The structures not directly involved are the lariat, polyA tail, and R-loops.\\n\\nAnswer: C<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process described:\\n\\n1. **Central Exon Deletions**: The gene has central exons that are deleted, creating out-of-frame peptides.\\n2. **Morpholino Therapy**: The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n3. **Spliceosome Binding**: The spliceosome is responsible for splicing introns out of the pre-mRNA and joining exons together.\\n4. **Exon Skipping and In-Frame Joining**: This results in the creation of in-frame peptides, which can be tolerated by the organism.\\n\\nNow, let's analyze each option:\\n\\nA) **Lariat**: Lariats are formed during the splicing process when an intron is removed, and the 5' and 3' ends of the intron form a lariat structure. Since the therapy involves preventing spliceosome binding, it indirectly affects the formation of lariats.\\n\\nB) **PolyA Tail**: The polyA tail is added to the 3' end of the mature mRNA after transcription and processing. It is not directly involved in the splicing or exon recognition process. Therefore, it is not directly affected by the Morpholino therapy.\\n\\nC) **R-loops**: R-loops are structures formed when RNA hybridizes with its corresponding DNA strand, displacing the other DNA strand. They are not directly involved in the splicing or exon recognition process and are not mentioned in the context of the therapy.\\n\\nD) **Antisense**: Antisense molecules are used in the therapy to recognize the 5' end of the out-of-frame exon and prevent spliceosome binding. Thus, they are directly involved in the therapy.\\n\\nGiven this analysis, the structure that is not involved in the proposed therapy is:\\n\\nAnswer: C<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process step by step:\\n\\n1. **Understanding the Therapy**: The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n\\n2. **Key Components**:\\n   - **Pre-mRNA**: The initial RNA transcript before splicing.\\n   - **Spliceosome**: An enzyme complex that removes introns from pre-mRNA and joins exons.\\n   - **Morpholino**: A synthetic DNA mimic that binds to the pre-mRNA and blocks the spliceosome.\\n   - **Exon Skipping and In-Frame Joining**: This results in the creation of a functional protein despite some exons being skipped.\\n\\n3. **Analysis of Options**:\\n   - **A) Lariat**: This is a circular RNA structure formed during the splicing process when an intron is removed. It is involved in the splicing process but not directly in the Morpholino therapy.\\n   - **B) PolyA Tail**: This is added to the 3' end of mature mRNA after splicing. It is not directly involved in the pre-mRNA processing or the Morpholino therapy.\\n   - **C) R-loops**: These are structures formed when a single strand of DNA hybridizes with its complementary RNA strand, creating a three-stranded structure. They are not directly involved in the splicing process or the Morpholino therapy.\\n   - **D) Antisense**: This refers to a strand of nucleic acid that is complementary to another strand. In this context, the Morpholino acts as an antisense molecule to block the spliceosome. Thus, it is involved in the therapy.\\n\\nGiven the analysis, the structure not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process described:\\n\\n1. **Gene Structure**: The gene has dozens of exons, and central exons code for folded triple helical repeats.\\n2. **Mutation**: Central exon deletions create out-of-frame peptides.\\n3. **Therapy**: Morpholino oligonucleotides are used to recognize the 5' end of the out-of-frame exon in pre-mRNA, preventing spliceosome binding, leading to exon skipping and in-frame joining.\\n4. **Outcome**: Several missing exons are well tolerated by the organism.\\n\\nNow, let's analyze each option:\\n\\n- **A) Lariat**: This is a structure formed during pre-mRNA splicing when introns are removed. It involves the spliceosome and is directly involved in the splicing process. Since the therapy involves preventing spliceosome binding, this structure is relevant.\\n  \\n- **B) PolyA tail**: This is added to the 3' end of mature mRNA after splicing. It is not directly involved in the splicing process but rather in mRNA stability and translation. The therapy does not mention any interaction with the polyA tail.\\n  \\n- **C) R-loops**: These are structures formed when single-stranded DNA hybridizes with its complementary RNA strand, creating a three-stranded structure. They are not directly related to the splicing process or the therapy described.\\n  \\n- **D) Antisense**: Morpholinos are a type of antisense oligonucleotide used in the therapy. They bind to the target sequence to prevent splicing.\\n\\nBased on the analysis, the structure not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process step by step:\\n\\n1. **Understanding the Therapy**: The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n\\n2. **Role of Structures**:\\n   - **Lariat**: Lariats are formed during the splicing process when introns are removed from pre-mRNA. They are not directly involved in the Morpholino's action.\\n   - **PolyA Tail**: This is added to the 3' end of mature mRNA after splicing. It is not directly involved in the Morpholino's action either.\\n   - **R-loops**: These are structures formed when RNA hybridizes to one strand of DNA, displacing the other DNA strand. While they can influence gene expression, they are not directly involved in the Morpholino's mechanism.\\n   - **Antisense**: Antisense molecules can bind to complementary sequences, but in this case, the Morpholino is specifically targeting the 5' end of the out-of-frame exon, which aligns with antisense functionality.\\n\\nGiven the above analysis, the structure that is not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"Let's analyze each option in the context of the proposed therapy:\\n\\n1. **Lariat**: This is a structure formed during pre-mRNA splicing when introns are removed and exons are joined. The therapy involves preventing the binding of the spliceosome, which would prevent the formation of lariats. Therefore, lariat is involved in the process.\\n\\n2. **PolyA tail**: This is added to the 3' end of the mature mRNA after splicing. The therapy does not directly involve the polyA tail, as it focuses on pre-mRNA and the spliceosome. The polyA tail is not mentioned or involved in the described mechanism.\\n\\n3. **R-loops**: These are structures formed when RNA hybridizes to its corresponding DNA strand, displacing the other DNA strand. They are not directly mentioned in the context of the therapy involving Morpholinos and pre-mRNA.\\n\\n4. **Antisense**: Morpholinos used in this therapy work as antisense molecules, meaning they bind to the pre-mRNA and block the spliceosome from binding. Therefore, antisense is involved in the therapy.\\n\\nGiven this analysis, the structure that is not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the components and their roles:\\n\\n1. **Lariat**: This is a temporary structure formed during pre-mRNA processing when the spliceosome removes introns and joins exons. It is part of the splicing process.\\n2. **PolyA tail**: This is added to the 3' end of the mature mRNA after splicing. It is not directly involved in the splicing process but helps in the stability and translation of the mRNA.\\n3. **R-loops**: These are three-stranded DNA-RNA hybrids that can form during transcription. They are not directly related to the splicing or the therapy described.\\n4. **Antisense**: This refers to a type of nucleic acid that can bind to complementary RNA sequences. In this context, the Morpholino is described as an antisense molecule that binds to the 5' end of the out-of-frame exon to prevent spliceosome binding.\\n\\nGiven the description, the Morpholino works by preventing the spliceosome from binding, leading to exon skipping and in-frame joining. This process involves the spliceosome, which uses pre-mRNA and exons to remove introns and join exons together. \\n\\n- The lariat is part of the splicing process.\\n- The polyA tail is added after splicing is complete.\\n- R-loops are not directly involved in the splicing process.\\n- Antisense molecules (like the Morpholino) are used to prevent spliceosome binding.\\n\\nTherefore, the structure that is not involved in the proposed therapy is R-loops.\\n\\nAnswer: C<|im_end|>\", \"Let's analyze each option step by step:\\n\\nA) Lariat: This is a type of RNA structure formed during splicing when introns are removed from pre-mRNA. The Morpholino prevents the spliceosome from binding and thus prevents the formation of lariats. So, it is involved in the therapy.\\n\\nB) PolyA tail: This is added to the 3' end of mature mRNA after splicing. The Morpholino does not affect the addition or presence of the polyA tail as it targets the 5' end of the out-of-frame exon in pre-mRNA. Therefore, this structure is not directly involved in the proposed therapy.\\n\\nC) R-loops: These are structures formed when RNA hybridizes to its template DNA strand, displacing the nontemplate DNA strand. The Morpholino does not directly interact with R-loops as it targets specific sequences in pre-mRNA. Thus, R-loops are not directly involved in the therapy.\\n\\nD) Antisense: Morpholinos are antisense molecules designed to bind to specific RNA sequences, preventing their function. In this case, the Morpholino binds to the 5' end of the out-of-frame exon in pre-mRNA, so it is involved in the therapy.\\n\\nBased on the analysis, the structure that is not directly involved in the proposed therapy is:\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process described:\\n\\n1. **Gene Structure**: The gene has dozens of exons, with central exons coding for specific functional units.\\n2. **Mutation**: Central exon deletions create out-of-frame peptides, leading to progressive degenerative organ waste.\\n3. **Therapy**: Morpholino is used to recognize the 5' end of the out-of-frame exon in pre-mRNA. This prevents the spliceosome from binding, leading to exon skipping and in-frame joining.\\n4. **Outcome**: Several missing exons are well tolerated by the organism.\\n\\nNow, let's analyze each option:\\n\\nA) **Lariat**: Lariats are formed during RNA splicing when introns are removed and the remaining exons are joined. The spliceosome catalyzes this process. In the context of the therapy, preventing spliceosome binding would prevent the formation of lariats. Therefore, lariat formation is involved.\\n\\nB) **PolyA tail**: The polyA tail is added to the 3' end of mature mRNA after splicing. It is not directly involved in the initial recognition or splicing process but rather in the stability and translation of the mRNA. Since the therapy focuses on pre-mRNA and preventing splicing, the polyA tail is not directly involved.\\n\\nC) **R-loops**: R-loops are structures formed when RNA hybridizes with its DNA template strand, displacing the complementary DNA strand. They are not directly related to the splicing process or the use of Morpholinos in this context. Thus, they are not involved in the therapy.\\n\\nD) **Antisense**: Antisense molecules can bind to specific sequences in RNA, potentially inhibiting splicing or other processes. The Morpholino used in the therapy is an example of an antisense molecule. Therefore, antisense is involved in the therapy.\\n\\nGiven this analysis, the structure that is not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the components and their roles:\\n\\n1. **Lariat**: This is formed during the splicing process when an intron is removed and the remaining exons are joined together. The lariat structure is crucial for the splicing process but is not directly mentioned in the context of the therapy described.\\n\\n2. **PolyA Tail**: This is added to the 3' end of the mRNA after processing and is important for mRNA stability and translation efficiency. However, it is not directly involved in the splicing or skipping of exons as described in the therapy.\\n\\n3. **R-loops**: These are structures formed when RNA hybridizes with its DNA template strand, displacing the other DNA strand. They are not directly related to the splicing process or exon skipping therapy described.\\n\\n4. **Antisense**: In this context, Morpholino is used as an antisense oligomer to bind to the 5' end of the out-of-frame exon, preventing the spliceosome from binding and thus allowing for exon skipping. This is directly involved in the therapy.\\n\\nGiven the description, the structures involved in the therapy are primarily related to splicing and exon skipping. The polyA tail is not directly involved in the mechanism of exon skipping and spliceosome inhibition.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process described:\\n\\n1. **Gene Structure**: The gene has dozens of exons, with central exons coding for specific structures.\\n2. **Mutation**: Central exon deletions result in out-of-frame peptides.\\n3. **Therapy**: A Morpholino targets the 5' end of the out-of-frame exon in pre-mRNA, preventing spliceosome binding, leading to exon skipping and in-frame joining.\\n\\nNow, let's analyze each option:\\n\\n- **A) Lariat**: This is a structure formed during splicing when introns are removed from pre-mRNA. Since the therapy involves preventing spliceosome binding, this structure would be affected.\\n- **B) PolyA tail**: This is added to the 3' end of mature mRNA after processing. It is not directly involved in the splicing or the therapy described.\\n- **C) R-loops**: These are structures formed when single-stranded DNA hybridizes with its template strand in RNA-DNA hybrids. They are not directly involved in the splicing or the therapy described.\\n- **D) Antisense**: This refers to a strand of RNA that can bind to and interfere with the function of another RNA molecule. In this context, the Morpholino acts as an antisense molecule to prevent exon recognition.\\n\\nGiven the therapy involves preventing the spliceosome from binding to the 5' end of the exon, the structures directly involved are the lariat (formed during splicing), and the antisense mechanism (used in the Morpholino). The polyA tail and R-loops are not directly involved in this splicing process or the therapy described.\\n\\nTherefore, the structure not involved in the proposed therapy is:\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process described:\\n\\n1. **Central Exon Deletions**: The gene has central exons that are deleted, creating out-of-frame peptides.\\n2. **Morpholino Treatment**: A Morpholino is used to recognize the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome.\\n3. **Exon Skipping and In-Frame Joining**: By preventing spliceosome binding, the Morpholino causes exon skipping and in-frame joining, leading to a functional protein.\\n\\nNow, let's analyze each option:\\n\\nA) **Lariat**: During RNA splicing, a lariat structure is formed as part of the intron processing. However, this is not directly mentioned or involved in the Morpholino therapy described.\\n\\nB) **PolyA Tail**: This is added to the 3' end of mature mRNA but is not directly involved in the splicing process or exon skipping described.\\n\\nC) **R-loops**: These are structures formed when a single strand of DNA hybridizes with a complementary RNA strand, often leading to transcriptional repression. They are not mentioned in the context of the therapy described.\\n\\nD) **Antisense**: Morpholinos are a type of antisense oligonucleotide, meaning they are designed to bind to specific sequences in the RNA. This is directly involved in the therapy.\\n\\nGiven the description, the structure that is not involved in the proposed therapy is the R-loop.\\n\\nAnswer: C<|im_end|>\", \"Let's analyze each option in the context of the proposed therapy:\\n\\n1. **Lariat**: This is a type of RNA structure formed during splicing when introns are removed from pre-mRNA. It is not directly involved in the therapy described, which focuses on preventing the spliceosome from binding to the out-of-frame exon.\\n\\n2. **PolyA tail**: This is added to the 3' end of most mRNAs after transcription. It is not directly involved in the therapy described, as the therapy focuses on the 5' end of the out-of-frame exon and the process of splicing.\\n\\n3. **R-loops**: These are structures formed when RNA hybridizes to its DNA template strand, displacing the other DNA strand. While they can occur in cells, they are not specifically mentioned or relevant to the therapy described.\\n\\n4. **Antisense**: In this context, Morpholino is described as an antisense molecule that recognizes the 5' end of the out-of-frame exon. Antisense molecules are indeed involved in the therapy to prevent the spliceosome from binding.\\n\\nGiven the description of the therapy, the structure that is not directly involved is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process:\\n\\n1. **Understanding the Therapy**: The therapy involves using a Morpholino to recognize the 5' end of the out-of-frame exon in pre-mRNA. This prevents the spliceosome from binding, leading to exon skipping and in-frame joining.\\n\\n2. **Process Involved**:\\n   - **Pre-mRNA**: The mRNA before splicing.\\n   - **Spliceosome**: An enzyme complex that removes introns and joins exons during splicing.\\n   - **Exon Skipping and In-Frame Joining**: The goal is to skip certain exons and ensure the remaining exons join correctly to restore the reading frame.\\n\\n3. **Components of the Process**:\\n   - **Morpholino**: An antisense oligonucleotide that binds to the pre-mRNA.\\n   - **5' End Recognition**: The Morpholino binds to the 5' end of the out-of-frame exon.\\n   - **Prevention of Spliceosome Binding**: This prevents the normal splicing process.\\n\\n4. **Options Analysis**:\\n   - **A) Lariat**: This is a structure formed during RNA splicing when an intron is spliced out, leaving a lariat structure behind. It is directly involved in the splicing process.\\n   - **B) PolyA Tail**: This is added to the 3' end of the mature mRNA after splicing. It is not directly involved in the initial splicing or exon skipping process.\\n   - **C) R-loops**: These are structures formed when a single strand of DNA hybridizes with its complementary RNA strand. They are not directly involved in the splicing process but can affect transcription.\\n   - **D) Antisense**: This refers to the Morpholino used in the therapy, which is directly involved in preventing spliceosome binding.\\n\\nGiven this analysis, the structure that is not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process step by step:\\n\\n1. **Understanding the Therapy**: The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n\\n2. **Key Components**:\\n   - **Pre-mRNA**: The RNA before splicing.\\n   - **Spliceosome**: The complex that performs RNA splicing.\\n   - **Exon Skipping and In-Frame Joining**: The process of removing problematic exons and ensuring that the remaining exons join correctly.\\n\\n3. **Analyzing Each Option**:\\n   - **A) Lariat**: This is a circular RNA structure formed during the splicing process when an intron is excised. It is directly involved in the splicing process.\\n   - **B) PolyA Tail**: This is added to the 3' end of mature mRNA after splicing. It is not directly involved in the splicing or exon skipping process but rather in the stability and translation of the mRNA.\\n   - **C) R-loops**: These are structures formed when RNA hybridizes with one strand of its DNA template, creating a triplex structure. They are not directly involved in the splicing or exon skipping process described.\\n   - **D) Antisense**: This refers to molecules that can bind to specific RNA sequences, often used in gene silencing techniques. In this context, the Morpholino acts as an antisense molecule targeting the 5' end of the out-of-frame exon.\\n\\nGiven the context of the therapy, the structure that is not directly involved in the process of exon skipping and in-frame joining is the polyA tail, as it is added post-splicing and does not participate in the splicing process itself.\\n\\nAnswer: B<|im_end|>\", \"Let's break down the information provided:\\n\\n1. **Gene Structure**: The gene has dozens of exons, with central exons coding for folded triple alpha helices.\\n2. **Mutations**: Central exon deletions cause out-of-frame peptides.\\n3. **Therapy**: A Morpholino is used to recognize the 5' end of the out-of-frame exon in pre-mRNA, preventing spliceosome binding and causing exon skipping and in-frame joining.\\n4. **Tolerance**: Missing several exons can be well-tolerated by the organism.\\n\\nNow, let's analyze each option:\\n\\n- **A) lariat**: This is a structure formed during splicing when an intron is excised from the pre-mRNA. Since the therapy involves preventing spliceosome binding and causing exon skipping, the formation of a lariat would be affected.\\n  \\n- **B) polyA tail**: This is added to the 3' end of mature mRNA after splicing. The therapy does not directly involve the 3' end or the polyA tail; it focuses on the pre-mRNA and splicing events.\\n  \\n- **C) R-loops**: These are structures formed when single-stranded DNA hybridizes with its complementary RNA strand, creating a three-stranded structure. The therapy does not mention anything about R-loops or their involvement.\\n  \\n- **D) antisense**: Morpholinos are antisense oligomers that bind to the target RNA sequence to prevent translation or splicing. The therapy uses Morpholinos, which are antisense molecules.\\n\\nGiven this analysis, the structure not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"Let's analyze each option to determine which structure is not involved in the proposed therapy:\\n\\nA) Lariat: This is a structure formed during splicing when introns are removed from pre-mRNA. It is involved in the process of RNA splicing but is not directly mentioned or involved in the therapy described.\\n\\nB) PolyA tail: This is added to the 3' end of mature mRNA after transcription and processing. While it is part of the mRNA, it is not directly involved in the splicing process or the therapy described.\\n\\nC) R-loops: These are structures formed when a strand of DNA anneals with its corresponding RNA transcript, creating a three-stranded structure. They are not directly involved in RNA splicing or the therapy described.\\n\\nD) Antisense: Morpholinos used in this therapy are antisense molecules designed to bind to specific sequences in the pre-mRNA, preventing the spliceosome from binding and causing exon skipping. This is directly involved in the therapy.\\n\\nGiven the context, the structures involved in the therapy are related to RNA splicing and antisense mechanisms. R-loops (option C) are not directly involved in the splicing process or the mechanism of the therapy described.\\n\\nAnswer: C<|im_end|>\", \"Let's break down the information given and analyze each option:\\n\\n1. **Gene Structure**: The gene has dozens of exons, with central exons coding for folded triple alpha helices.\\n2. **Mutations**: Central exon deletions create out-of-frame peptides leading to degeneration.\\n3. **Therapy**: Morpholino is used to recognize the 5' end of the out-of-frame exon in pre-mRNA, preventing spliceosome binding, thus causing exon skipping and in-frame joining.\\n4. **Tolerance**: Several missing exons can be tolerated by the organism.\\n\\nNow, let's evaluate each option:\\n\\nA) **Lariat**: This is a type of RNA structure formed during splicing when an intron is excised from the pre-mRNA. Since the therapy involves preventing spliceosome binding to create exon skipping, it directly relates to this process.\\n\\nB) **PolyA tail**: This is added to the 3' end of mature mRNA but is not involved in the splicing or exon recognition process described in the therapy. It is not directly related to the mechanism of exon skipping or in-frame joining.\\n\\nC) **R-loops**: These are structures formed when a single strand of DNA anneals to the complementary RNA transcript, displacing the other DNA strand. While they can form in cells, they are not specifically mentioned in the context of the proposed therapy involving pre-mRNA and spliceosome binding.\\n\\nD) **Antisense**: Morpholino is an example of antisense technology, as it is designed to bind to the target sequence (5' end of the out-of-frame exon) and prevent binding of the spliceosome. Thus, it is directly involved in the therapy.\\n\\nBased on this analysis, the structure not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the components of the therapy:\\n\\n1. **Morpholino**: This is an antisense oligonucleotide that binds to the pre-mRNA.\\n2. **5' end of the out-of-frame exon**: The Morpholino recognizes this specific sequence.\\n3. **Spliceosome**: The Morpholino prevents the spliceosome from binding, leading to exon skipping and in-frame joining.\\n4. **Pre-mRNA**: The target RNA where the Morpholino acts.\\n\\nNow, let's analyze each option:\\n\\nA) **Lariat**: This is formed during splicing when an intron is removed, but it is not directly involved in the Morpholino therapy described here, as the focus is on preventing spliceosome binding.\\n\\nB) **PolyA tail**: This is added to the 3' end of the mature mRNA after splicing. It is not directly involved in the Morpholino therapy since the therapy focuses on the pre-mRNA and its interaction with the spliceosome.\\n\\nC) **R-loops**: These are structures formed when RNA hybridizes with its DNA template strand, displacing the complementary DNA strand. They are not mentioned in the context of the Morpholino therapy and do not play a role in this process.\\n\\nD) **Antisense**: This refers to the Morpholino itself, which is used in the therapy to prevent the spliceosome from binding.\\n\\nGiven the description, the structures involved in the therapy are the pre-mRNA, spliceosome, and Morpholino. The structures not directly involved in the Morpholino therapy are the lariat, polyA tail, and R-loops.\\n\\nAnswer: C<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process:\\n\\n1. **Understanding the Therapy**: The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n\\n2. **Components of RNA Processing**:\\n   - **Lariat**: This is a structure formed during splicing when an intron is being removed.\\n   - **PolyA Tail**: Added to the 3' end of mature mRNA after splicing.\\n   - **R-loops**: These are structures formed when single-stranded DNA hybridizes with its complementary RNA strand, often involving transcription.\\n   - **Antisense**: Refers to a strand of nucleic acid that is complementary to another strand.\\n\\n3. **Role in the Therapy**:\\n   - **Lariat**: Formed during splicing but not directly involved in the Morpholino's action.\\n   - **PolyA Tail**: Not directly involved in the Morpholino's mechanism.\\n   - **R-loops**: Not directly involved in the Morpholino's mechanism.\\n   - **Antisense**: The Morpholino itself is an antisense molecule, used to prevent spliceosome binding.\\n\\nGiven the description, the Morpholino works by preventing spliceosome binding, which does not involve the formation of a lariat, polyA tail, or R-loops directly.\\n\\nTherefore, the structure not involved in the proposed therapy is:\\n\\nAnswer: C<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process step-by-step:\\n\\n1. **Understanding the Therapy**:\\n   - The therapy involves delivering a Morpholino that targets the 5' end of the out-of-frame exon in pre-mRNA.\\n   - This Morpholino prevents the binding of the spliceosome.\\n   - As a result, exon skipping and in-frame joining occur.\\n\\n2. **Role of Each Option**:\\n   - **A) Lariat**: In pre-mRNA splicing, the spliceosome catalyzes the formation of an lariat structure during the splicing process. However, the Morpholino prevents this by blocking the spliceosome, so the lariat structure would not form.\\n   - **B) PolyA Tail**: This is added to the 3' end of mature mRNA after splicing. It is not directly involved in the splicing process or exon skipping.\\n   - **C) R-loops**: These are structures formed when a single strand of DNA hybridizes with its transcribed RNA, displacing the other DNA strand. They are not directly related to the splicing process or exon skipping.\\n   - **D) Antisense**: Morpholinos are a type of antisense oligonucleotide, meaning they can base-pair with specific sequences in the RNA to block certain processes. Here, the Morpholino is used to prevent spliceosome binding, making it relevant to the therapy.\\n\\nGiven the explanation, the structures involved in the therapy are the lariat (formed during splicing), and the antisense mechanism (used by the Morpholino). The polyA tail and R-loops are not directly involved in the splicing process or exon skipping.\\n\\nAnswer: C<|im_end|>\", \"Let's analyze each option in the context of the proposed therapy:\\n\\n1. **Lariat**: This is a structure formed during splicing when an intron is being removed. It involves the 5' splice site of the intron forming a loop with the 3' splice site, creating a lariat-like structure. The Morpholino mentioned in the therapy targets the 5' end of the out-of-frame exon to prevent spliceosome binding, thus preventing the formation of a lariat.\\n\\n2. **PolyA tail**: This is added to the 3' end of a mature mRNA after transcription and processing. It is not directly involved in the splicing process or the formation of lariats. The Morpholino does not interact with the polyA tail as it targets the 5' end of the exon.\\n\\n3. **R-loops**: These are structures formed when RNA hybridizes with its template DNA strand, displacing the nontemplate DNA strand. They are not directly involved in the splicing process or the formation of lariats. The Morpholino does not interact with R-loops as it targets the 5' end of the exon.\\n\\n4. **Antisense**: This refers to molecules that bind to complementary sequences of RNA to block their function. In this case, the Morpholino is described as an antisense molecule that binds to the 5' end of the out-of-frame exon to prevent splicing.\\n\\nGiven the description, the structure that is not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"Let's analyze each option step by step:\\n\\nA) Lariat - This is a structure formed during pre-mRNA processing when introns are spliced out. It is involved in the process of RNA splicing.\\n\\nB) PolyA tail - This is added to the 3' end of mature mRNA after splicing. It is not directly involved in the splicing process but rather in the stability and translation of the mRNA.\\n\\nC) R-loops - These are structures formed when a strand of DNA hybridizes with its corresponding RNA transcript, causing the other DNA strand to become single-stranded. They are not directly involved in the splicing or modification of pre-mRNA.\\n\\nD) Antisense - This refers to molecules that are complementary to a specific sequence of RNA, often used to block the function of a specific RNA molecule. In this context, the Morpholino is described as recognizing the 5' end of the out-of-frame exon, which is an antisense mechanism.\\n\\nGiven the context of the question, the structure that is not involved in the proposed therapy of preventing binding of the spliceosome and creating exon skipping and in-frame joining is:\\n\\nC) R-loops\\n\\nAnswer: C<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the components and processes involved:\\n\\n1. **Gene Structure**: The gene has dozens of exons, and central exons code for specific parts of the protein.\\n2. **Mutation**: Central exon deletions create out-of-frame peptides.\\n3. **Therapy**: Morpholino is used to recognize the 5' end of the out-of-frame exon in pre-mRNA, preventing spliceosome binding and causing exon skipping and in-frame joining.\\n4. **Outcome**: Several missing exons can be tolerated by the organism.\\n\\nNow, let's analyze each option:\\n\\nA) **Lariat**: This is a temporary structure formed during RNA splicing when an intron is being removed. It involves the spliceosome and is directly related to the splicing process.\\n\\nB) **PolyA Tail**: This is added to the 3' end of mRNA after splicing is complete. It is not directly involved in the splicing process but in the processing of mature mRNA.\\n\\nC) **R-loops**: These are structures formed when a strand of DNA anneals with a complementary RNA strand, displacing the other DNA strand. They are not directly involved in RNA splicing or the proposed therapy.\\n\\nD) **Antisense**: Morpholinos are antisense molecules that bind to the target sequence, preventing binding of the spliceosome. This is part of the therapy mechanism.\\n\\nGiven the context, the structure that is not directly involved in the proposed therapy is the PolyA tail, as it is added post-splicing and does not affect the splicing process itself.\\n\\nAnswer: B<|im_end|>\", \"Let's break down the information provided:\\n\\n1. **Gene Structure**: The gene has dozens of exons, with central exons coding for folded triple helical repeats.\\n2. **Mutations**: Central exon deletions create out-of-frame peptides.\\n3. **Therapy**: Morpholino is used to recognize the 5' end of the out-of-frame exon in pre-mRNA, preventing spliceosome binding, and creating exon skipping and in-frame joining.\\n4. **Tolerance**: Several missing exons are well tolerated by the organism.\\n\\nNow, let's analyze each option:\\n\\nA) **Lariat**: This is a temporary structure formed during splicing when the intron is ligated to itself, creating a looped structure. Since the therapy involves preventing spliceosome binding and creating exon skipping, this structure would be directly involved.\\n\\nB) **PolyA tail**: This is added to the 3' end of the mRNA after processing. It is not directly involved in the splicing process or exon skipping, so it is not directly related to the therapy described.\\n\\nC) **R-loops**: These are structures formed when RNA hybridizes with one strand of DNA, displacing the other DNA strand. They are not directly involved in the splicing process or exon skipping, so they are not directly related to the therapy described.\\n\\nD) **Antisense**: Morpholino is an antisense oligonucleotide, meaning it is designed to bind to the target sequence and prevent binding of the spliceosome. Therefore, it is directly involved in the therapy.\\n\\nGiven the analysis, the structure not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the information given:\\n\\n1. **Gene Structure and Function**: The gene contains dozens of exons, with central exons coding for folded triple helical repeats.\\n2. **Mutations**: Central exon deletions create out-of-frame peptides, leading to degenerative effects.\\n3. **Therapy**: Morpholino oligonucleotides recognize the 5' end of the out-of-frame exon in pre-mRNA, preventing spliceosome binding and causing exon skipping and in-frame joining.\\n4. **Tolerance**: Several missing exons can be well-tolerated by the organism.\\n\\nNow, let's analyze each option:\\n\\n- **A) Lariat**: This is a type of RNA structure formed during splicing when the 5' end of one intron joins with the 3' end of another intron. It is involved in the splicing process but not directly in the Morpholino-mediated exon skipping therapy described here.\\n  \\n- **B) PolyA tail**: This is added to the 3' end of mature mRNA after transcription and processing. It is not directly involved in the splicing or exon skipping process.\\n\\n- **C) R-loops**: These are structures formed when a single-stranded RNA molecule hybridizes with its corresponding DNA template strand, displacing the other DNA strand. They are not mentioned in the context of the therapy described.\\n\\n- **D) Antisense**: Morpholinos are antisense oligonucleotides designed to bind to specific RNA sequences. They are a key component of the therapy described.\\n\\nGiven this analysis, the structure not directly involved in the proposed therapy is the R-loop.\\n\\nAnswer: C<|im_end|>\", \"Let's break down the information given:\\n\\n1. **Gene Structure**: The gene has dozens of exons, and the central ones code for specific sequences.\\n2. **Mutation**: Central exon deletions create out-of-frame peptides.\\n3. **Therapy**: Morpholino oligonucleotides are used to prevent spliceosome binding and create exon skipping and in-frame joining.\\n4. **Tolerance**: Several missing exons are well tolerated.\\n\\nNow, let's analyze each option:\\n\\nA) **Lariat**: This is a structure formed during pre-mRNA processing when a branch point forms a loop and joins back to the main strand, creating a lariat structure. It is involved in splicing and is relevant to the therapy as it involves spliceosome activity.\\n\\nB) **PolyA tail**: This is added to the 3' end of mature mRNA after transcription. It is not directly involved in the splicing process or the therapy described.\\n\\nC) **R-loops**: These are structures formed when RNA hybridizes with one strand of DNA, displacing the other strand. While they can affect gene expression, they are not directly involved in the splicing process or the therapy described.\\n\\nD) **Antisense**: This refers to molecules that bind to the RNA to inhibit its function. In this context, the Morpholino is acting as an antisense molecule to block the spliceosome binding site.\\n\\nGiven the context, the structure that is not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process step by step:\\n\\n1. **Understanding the Therapy**: The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n\\n2. **Role of Each Option**:\\n   - **A) Lariat**: This is a structure formed during RNA splicing when the intron is removed, and the remaining exons are joined together. The lariat is part of the splicing process.\\n   - **B) PolyA Tail**: This is added to the 3' end of mature mRNA after splicing. It is not directly involved in the splicing process or the therapy described.\\n   - **C) R-loops**: These are structures formed when a single strand of DNA hybridizes with a complementary RNA strand, creating a tripartite structure. They are not directly involved in the splicing process or the therapy described.\\n   - **D) Antisense**: This refers to a sequence of nucleotides that is complementary to another sequence of nucleotides, often used in therapeutic applications like Morpholinos. In this context, it is used to prevent spliceosome binding.\\n\\nGiven that the therapy involves preventing the spliceosome from binding to the 5' end of the out-of-frame exon, the structures involved are primarily related to the splicing process (lariat and spliceosome). The polyA tail and R-loops are not directly involved in the splicing process or the therapy described.\\n\\nTherefore, the correct answer is:\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process described:\\n\\n1. **Morpholino Recognition**: The Morpholino binds to the 5' end of the out-of-frame exon in pre-mRNA.\\n2. **Prevention of Spliceosome Binding**: This action prevents the spliceosome from binding to the pre-mRNA.\\n3. **Exon Skipping and In-Frame Joining**: As a result, the skipped exons are in frame, allowing for correct protein synthesis.\\n\\nNow, let's analyze each option:\\n\\nA) **Lariat**: Lariats are formed during the splicing process when introns are removed and the 5' end of one exon forms a loop with the 3' end of another exon. Since the Morpholino prevents the spliceosome from binding, it would prevent the formation of lariats.\\n\\nB) **PolyA Tail**: The polyA tail is added to the 3' end of mature mRNA after splicing. It is not directly involved in the splicing process or the prevention of exon binding by the spliceosome.\\n\\nC) **R-loops**: R-loops are structures formed when RNA hybridizes with its template DNA strand, displacing the nontemplate DNA strand. They are not directly related to the splicing process or the Morpholino's function in preventing exon binding.\\n\\nD) **Antisense**: Antisense refers to molecules that bind to complementary sequences on RNA, often used to block gene expression. In this context, the Morpholino acts as an antisense molecule by binding to the 5' end of the out-of-frame exon.\\n\\nGiven the analysis, the structure not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the information provided:\\n\\n1. **Gene Structure and Exons**: The gene has dozens of exons, with central exons coding for folded triple alpha helices.\\n2. **Mutation**: Central exon deletions create out-of-frame peptides.\\n3. **Therapy**: Morpholino is used to recognize the 5' end of the out-of-frame exon in pre-mRNA, preventing spliceosome binding, leading to exon skipping and in-frame joining.\\n4. **Tolerance**: Missing several exons is well-tolerated by the organism.\\n\\nNow, let's analyze each option:\\n\\n- **A) Lariat**: This is a structure formed during RNA splicing when an intron is excised from the pre-mRNA. The therapy involves preventing the spliceosome from binding, but it does not directly involve the formation of a lariat.\\n- **B) PolyA tail**: This is added to the 3' end of mature mRNA after splicing. The therapy focuses on pre-mRNA and does not directly involve the addition or maintenance of a polyA tail.\\n- **C) R-loops**: These are structures formed when RNA hybridizes with its DNA template strand, displacing the complementary DNA strand. There is no mention of R-loops in the context of the therapy described.\\n- **D) Antisense**: Morpholinos are antisense oligonucleotides that bind to specific sequences to block splicing. This is directly involved in the therapy.\\n\\nGiven the description, the structure that is not directly involved in the proposed therapy is R-loops.\\n\\nAnswer: C<|im_end|>\", \"Let's analyze each option in the context of the proposed therapy:\\n\\n1. **Lariat**: This is a structure formed during splicing when the intron is joined to itself, creating a looped structure. The therapy involves preventing the binding of the spliceosome to skip exons and join them in frame. This process does not involve the formation of a lariat directly; however, the lariat is a byproduct of splicing that would not be formed if the spliceosome is prevented from binding.\\n\\n2. **PolyA tail**: This is added to the 3' end of mRNA after splicing. The therapy focuses on pre-mRNA and the prevention of exon binding by the spliceosome. The polyA tail is not directly involved in this process.\\n\\n3. **R-loops**: These are structures formed when RNA hybridizes with its template DNA strand, displacing the nontemplate DNA strand. While R-loops can affect gene expression, they are not directly involved in the mechanism of exon skipping and in-frame joining described in the therapy.\\n\\n4. **Antisense**: This refers to molecules that can bind to specific sequences of RNA or DNA. In the therapy, a Morpholino is used to recognize the 5' end of the out-of-frame exon in pre-mRNA, preventing the spliceosome from binding. This is an example of antisense technology.\\n\\nGiven the above analysis, the structure that is not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"Let's analyze each option in the context of the proposed therapy:\\n\\n1. **Lariat**: This is a type of RNA structure formed during splicing when an intron is excised from pre-mRNA. The described therapy involves preventing the spliceosome from binding to the 5' end of the out-of-frame exon, which would prevent the formation of a lariat. Therefore, the lariat is involved in the proposed therapy.\\n\\n2. **PolyA tail**: This is added to the 3' end of most mRNAs after splicing and does not directly affect the splicing process or the binding of the spliceosome. It is not involved in the proposed therapy of exon skipping and in-frame joining.\\n\\n3. **R-loops**: These are structures formed when RNA hybridizes with its DNA template strand, displacing the complementary DNA strand. They are not directly related to the splicing process or the binding of the spliceosome, so they are not involved in the proposed therapy.\\n\\n4. **Antisense**: Morpholinos used in the therapy are antisense oligonucleotides designed to bind to specific sequences on the mRNA. They help in preventing the spliceosome from binding, thus affecting the splicing process. Therefore, antisense is involved in the proposed therapy.\\n\\nBased on this analysis, the structure that is not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process described:\\n\\n1. **Central Exon Deletions**: The gene has central exons that are deleted, creating out-of-frame peptides.\\n2. **Morpholino Treatment**: A Morpholino is used to recognize the 5' end of the out-of-frame exon in pre-mRNA and prevent the binding of the spliceosome.\\n3. **Exon Skipping and In-Frame Joining**: This results in exon skipping and in-frame joining, allowing the remaining in-frame exons to be joined together correctly.\\n\\nNow, let's analyze each option:\\n\\nA) **Lariat**: Lariats are formed during splicing when an intron is excised, leaving a loop structure. They are involved in the splicing process but not directly in the therapy described.\\n\\nB) **PolyA Tail**: The polyA tail is added to the 3' end of mature mRNA after splicing. It is not directly involved in the splicing process or the therapy described.\\n\\nC) **R-loops**: R-loops are structures formed when RNA hybridizes with its template DNA strand, displacing the nontemplate DNA strand. They are not directly involved in the splicing process or the therapy described.\\n\\nD) **Antisense**: Antisense molecules can bind to complementary RNA sequences and inhibit their function. In this case, the Morpholino acts as an antisense molecule to prevent the spliceosome from binding to the 5' end of the out-of-frame exon.\\n\\nGiven the context of the therapy involving the prevention of spliceosome binding and exon skipping, the structures directly involved are related to the splicing process and antisense mechanisms. However, the polyA tail, lariat formation, and R-loops are not directly involved in the specific therapy described.\\n\\nTherefore, the correct answer is:\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process step by step:\\n\\n1. **Understanding the Therapy**: The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n\\n2. **Key Components**:\\n   - **Morpholino**: An antisense oligonucleotide that targets the pre-mRNA.\\n   - **Pre-mRNA**: The RNA precursor that will undergo splicing.\\n   - **Spliceosome**: The complex that recognizes and removes introns from pre-mRNA.\\n   - **Exon Skipping**: The process of removing certain exons.\\n   - **In-frame Joining**: Ensuring that the remaining exons are joined in the correct reading frame.\\n\\n3. **Structures Involved**:\\n   - **Lariat**: This is formed during the splicing process when an intron is being removed.\\n   - **PolyA Tail**: Added to the 3' end of mature mRNA but not directly involved in the splicing process.\\n   - **R-loops**: Structures formed when RNA hybridizes to one strand of DNA, but they are not directly involved in the splicing or exon skipping process.\\n   - **Antisense**: Refers to the Morpholino itself, which is part of the therapy.\\n\\n4. **Analysis**:\\n   - **Lariat**: Formed during splicing, so it is involved.\\n   - **PolyA Tail**: Not involved in the splicing or exon skipping process.\\n   - **R-loops**: Not directly involved in the splicing or exon skipping process.\\n   - **Antisense**: The Morpholino used in the therapy, so it is involved.\\n\\nGiven this analysis, the structure that is not involved in the proposed therapy is the PolyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the information given:\\n\\n1. **Gene Structure**: The gene has dozens of exons, with central ones coding for folded triple helical repeats.\\n2. **Mutation**: Central exon deletions create out-of-frame peptides.\\n3. **Therapy**: Morpholino is used to recognize the 5' end of the out-of-frame exon in pre-mRNA, preventing spliceosome binding, and creating exon skipping and in-frame joining.\\n4. **Tolerance**: Several missing exons are well tolerated by the organism.\\n\\nNow, let's analyze each option:\\n\\nA) **Lariat**: This is a structure formed during pre-mRNA processing when an intron is spliced out. It involves the spliceosome, which is directly targeted by the Morpholino in this therapy. Therefore, it is involved.\\n\\nB) **PolyA Tail**: This is added to the 3' end of mature mRNA after splicing. The therapy does not involve the 3' end or the addition of the polyA tail, so it is not directly involved.\\n\\nC) **R-loops**: These are structures formed when RNA hybridizes with one strand of DNA, causing a triplex structure. The therapy does not mention anything about DNA or R-loops, so they are not involved.\\n\\nD) **Antisense**: Morpholinos are antisense oligonucleotides that bind to the target sequence. They are directly involved in the therapy.\\n\\nGiven the analysis, the structure not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"Let's analyze each option to determine which structure is not involved in the proposed therapy:\\n\\nA) Lariat: This is a type of RNA structure formed during splicing when an intron is removed. The spliceosome catalyzes the formation of a lariat intermediate. In the context of the therapy, the Morpholino prevents the spliceosome from binding to the 5' end of the out-of-frame exon, which would prevent the formation of a lariat. Therefore, the lariat is involved in the therapy.\\n\\nB) PolyA tail: This is added to the 3' end of mature mRNA after splicing. It is not directly involved in the process of splicing or exon recognition by the spliceosome. Therefore, the polyA tail is not directly involved in the proposed therapy.\\n\\nC) R-loops: These are structures formed when a newly transcribed RNA strand anneals with its template DNA strand, displacing the nontemplate DNA strand. While they can affect gene expression, they are not directly involved in the splicing process or the therapy described.\\n\\nD) Antisense: Morpholinos used in this therapy are antisense molecules designed to bind to specific sequences on the pre-mRNA, preventing the spliceosome from binding and causing exon skipping. Therefore, antisense is involved in the therapy.\\n\\nGiven this analysis, the structure that is not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process step by step:\\n\\n1. **Understanding the Therapy**: The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n\\n2. **Key Components**:\\n   - **Pre-mRNA**: The initial RNA transcript before splicing.\\n   - **Spliceosome**: An enzyme complex that removes introns and joins exons during splicing.\\n   - **Exon Skipping and In-Frame Joining**: This is achieved by preventing the spliceosome from recognizing the out-of-frame exon.\\n\\n3. **Analyzing Each Option**:\\n   - **A) Lariat**: During pre-mRNA processing, the spliceosome forms a lariat structure after removing an intron. This is directly involved in the splicing process.\\n   - **B) PolyA Tail**: Added to the 3' end of mature mRNA, it is not directly involved in the splicing or recognition of exons by the spliceosome.\\n   - **C) R-loops**: These are structures formed when single-stranded DNA hybridizes with its complementary RNA strand. They are not directly involved in the splicing process but can affect gene expression.\\n   - **D) Antisense**: Morpholinos used in this therapy are antisense molecules designed to bind to specific sequences, thus preventing the spliceosome from binding. This is directly involved in the therapy.\\n\\n4. **Conclusion**: Among these options, the polyA tail (B) is not directly involved in the splicing process or the proposed therapy mechanism.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the components and their roles:\\n\\n1. **Morpholino**: This is a synthetic molecule designed to recognize the 5' end of the out-of-frame exon in pre-mRNA. It prevents the binding of the spliceosome.\\n2. **Spliceosome**: This is a complex of proteins and RNA that splices introns out of pre-mRNA and joins exons together.\\n3. **Exon Skipping and In-Frame Joining**: By preventing the spliceosome from binding, the Morpholino allows the remaining exons to be joined in frame, potentially creating a functional protein.\\n4. **Lariat**: This is a circular RNA structure formed during the splicing process when an intron is being removed. It is not directly involved in the Morpholino's mechanism of action.\\n5. **PolyA Tail**: This is added to the 3' end of mature mRNA after splicing. It is not directly involved in the initial splicing process but is crucial for mRNA stability and translation.\\n6. **R-loops**: These are structures formed when single-stranded DNA hybridizes with its transcribed RNA strand, displacing the other DNA strand. They are not directly involved in the splicing process or the Morpholino's mechanism of action.\\n7. **Antisense**: This refers to the complementary strand of RNA that can bind to the target mRNA. While Morpholinos can act as antisense molecules, they specifically target the 5' end of the out-of-frame exon in this context.\\n\\nGiven the described mechanism, the structures involved are primarily related to splicing and the initial binding of the spliceosome. The lariat and R-loops are not directly involved in the initial splicing process or the Morpholino's mechanism of action.\\n\\nTherefore, the correct answer is:\\n\\nAnswer: C<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the information provided:\\n\\n1. **Gene Structure and Function**: The gene has dozens of exons, with central exons coding for folded triple helical repeats.\\n2. **Mutation**: Central exon deletions create out-of-frame peptides.\\n3. **Therapy**: Morpholino is used to recognize the 5' end of the out-of-frame exon in pre-mRNA, preventing spliceosome binding, and causing exon skipping and in-frame joining.\\n4. **Tolerance**: Several missing exons are well-tolerated by the organism.\\n\\nNow, let's analyze each option:\\n\\n- **A) Lariat**: In RNA splicing, the intron is removed, and the remaining exons are joined. This process forms a lariat structure temporarily. The Morpholino therapy would affect this process by preventing the spliceosome from recognizing the exon, thus affecting the formation of the lariat.\\n  \\n- **B) PolyA tail**: This is added to the 3' end of mature mRNA after splicing. The therapy described does not directly involve the 3' end or the polyA tail. Therefore, it is unlikely to be involved in this specific therapy.\\n  \\n- **C) R-loops**: These are structures formed when a single strand of DNA anneals to its transcribed RNA, displacing the other DNA strand. The therapy does not mention anything about DNA or R-loops, so this is not involved.\\n  \\n- **D) Antisense**: Morpholinos are antisense oligonucleotides that can bind to specific sequences in RNA and prevent their function. This is directly involved in the therapy described.\\n\\nGiven the analysis, the structure not involved in the proposed therapy is:\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process step-by-step:\\n\\n1. **Understanding the Therapy**: The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n\\n2. **Key Components**:\\n   - **Morpholino**: This is an antisense oligonucleotide used to block splicing.\\n   - **Pre-mRNA**: The RNA before it undergoes splicing.\\n   - **Spliceosome**: An enzyme complex that removes introns and joins exons during RNA splicing.\\n\\n3. **Components Involved in the Process**:\\n   - **Lariat**: This is formed during the splicing process when an intron is being removed. It is part of the splicing process.\\n   - **PolyA Tail**: Added to the 3' end of mature mRNA after splicing. It is not directly involved in the splicing process but in the maturation of the mRNA.\\n   - **R-loops**: These are structures formed when RNA hybridizes to its complementary DNA strand, displacing the other DNA strand. They are not directly involved in the splicing process.\\n   - **Antisense**: This term refers to the Morpholino itself, which is used to block splicing. It is a key component of the therapy.\\n\\n4. **Analysis**:\\n   - **Lariat**: Involved in the splicing process.\\n   - **PolyA Tail**: Not directly involved in the splicing process.\\n   - **R-loops**: Not directly involved in the splicing process.\\n   - **Antisense**: Used in the therapy to block splicing.\\n\\nGiven this analysis, the structure that is not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process described:\\n\\n1. **Central Exon Deletions**: These create out-of-frame peptides.\\n2. **Morpholino Delivery**: The Morpholino binds to the 5' end of the out-of-frame exon in pre-mRNA.\\n3. **Spliceosome Binding Prevention**: The Morpholino prevents the spliceosome from binding.\\n4. **Exon Skipping and In-Frame Joining**: This results in the creation of in-frame peptides.\\n\\nNow, let's analyze each option:\\n\\nA) **Lariat**: This is a structure formed during pre-mRNA splicing when an intron is excised. It is part of the splicing process, so it is involved in the therapy as the spliceosome interacts with it.\\n\\nB) **PolyA Tail**: This is added to the 3' end of mature mRNA after splicing. It is not directly involved in the splicing process or the prevention of spliceosome binding by the Morpholino.\\n\\nC) **R-loops**: These are structures formed when RNA hybridizes with one strand of its DNA template, causing the other strand to become single-stranded. While they can occur in the cell, there is no mention of them being involved in the splicing process or the Morpholino's action.\\n\\nD) **Antisense**: This refers to molecules that are complementary to a specific sequence of RNA, often used to block the function of that RNA. The Morpholino acts as an antisense molecule in this context.\\n\\nGiven the description, the structure that is not involved in the proposed therapy is the PolyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the information provided:\\n\\n1. **Gene Structure**: The gene has dozens of exons, with central exons coding for folded triple alpha helices.\\n2. **Mutation**: Central exon deletions create out-of-frame peptides.\\n3. **Therapy**: Morpholino oligonucleotides are used to prevent the spliceosome from binding to the 5' end of the out-of-frame exon, leading to exon skipping and in-frame joining.\\n4. **Outcome**: Several missing exons are well tolerated.\\n\\nNow, let's analyze each option:\\n\\nA) **Lariat**: This is a type of RNA structure formed during splicing when the intron is removed. It is directly involved in the splicing process and could be affected by the therapy as it involves preventing spliceosome binding.\\n\\nB) **PolyA tail**: This is added to the 3' end of mature mRNA after processing. It is not directly involved in the splicing or exon skipping process described.\\n\\nC) **R-loops**: These are structures formed when single-stranded DNA hybridizes with its complementary RNA strand, displacing the template DNA strand. They are not mentioned in the context of the therapy and are not directly involved in the splicing process.\\n\\nD) **Antisense**: This term can refer to oligonucleotides that bind to specific sequences to block gene expression. In this case, the Morpholino is described as recognizing the 5' end of the out-of-frame exon, which aligns with the concept of antisense technology.\\n\\nBased on the analysis, the structure that is not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process described:\\n\\n1. **Gene Structure**: The gene contains dozens of exons, with central exons coding for folded triple helical repeats.\\n2. **Mutation**: Central exon deletions create out-of-frame peptides.\\n3. **Therapy**: Morpholino oligonucleotides recognize the 5' end of the out-of-frame exon in pre-mRNA, preventing spliceosome binding and causing exon skipping and in-frame joining.\\n4. **Outcome**: Several missing exons can be tolerated by the organism.\\n\\nNow, let's analyze each option:\\n\\nA) **Lariat**: Lariats are formed during RNA splicing as part of the spliceosome complex. They are involved in the processing of introns and are necessary for the splicing process. Since the therapy involves preventing spliceosome binding, lariats would be affected.\\n\\nB) **PolyA Tail**: The polyA tail is added to the 3' end of mature mRNA after splicing. It is not directly involved in the splicing process or exon recognition. Therefore, it is not directly affected by the Morpholino treatment.\\n\\nC) **R-loops**: R-loops are structures formed when an RNA strand anneals to its corresponding DNA template strand, displacing the other DNA strand. They are not involved in the splicing process or exon recognition, so they are not directly affected by the Morpholino treatment.\\n\\nD) **Antisense**: Antisense refers to a complementary strand of RNA that can bind to a target RNA sequence. In this context, the Morpholino oligonucleotide acts as an antisense molecule to prevent exon recognition and binding of the spliceosome.\\n\\nGiven the analysis, the structure that is not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process described:\\n\\n1. **Gene Structure**: The gene contains dozens of exons, with central exons coding for specific functional units.\\n2. **Mutation**: Central exon deletions create out-of-frame peptides.\\n3. **Therapy**: Morpholino oligonucleotides are used to prevent spliceosome binding, leading to exon skipping and in-frame joining.\\n\\nNow, let's analyze each option:\\n\\nA) **Lariat**: This is a type of RNA structure formed during splicing when the intron is excised and the two exons are joined. It is directly involved in the splicing process and would be affected by the Morpholino preventing spliceosome binding.\\n\\nB) **PolyA tail**: This is added to the 3' end of mature mRNA after splicing. It is not directly involved in the splicing process but is part of the mRNA structure. Since the therapy does not mention any involvement with the 3' end, this could be a candidate.\\n\\nC) **R-loops**: These are structures formed when single-stranded RNA hybridizes with its template DNA strand, displacing the other DNA strand. While they can occur in cells, they are not directly involved in the splicing or the morpholino-mediated exon skipping mechanism.\\n\\nD) **Antisense**: Morpholinos are antisense molecules designed to bind to specific RNA sequences, preventing their function. This is directly involved in the therapy.\\n\\nGiven the analysis, the structure not involved in the proposed therapy is:\\n\\nAnswer: C<|im_end|>\", \"Let's break down the information provided and analyze each option:\\n\\n1. **Central Exons and Alpha Helices**: The gene has dozens of exons, with central ones coding for folded triple helical repeats. These are important for connecting the cytoskeleton with the sarcolemma and extracellular space.\\n\\n2. **Mutations**: Common mutations involve central exon deletions, leading to out-of-frame peptides and progressive degenerative organ waste.\\n\\n3. **Therapy**: The proposed solution involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n\\n4. **Exon Skipping and In-Frame Joining**: By skipping certain exons, the resulting mRNA can still produce functional proteins if several missing exons are well-tolerated.\\n\\nNow, let's consider each option:\\n\\n- **A) Lariat**: This is a structure formed during RNA splicing when introns are removed from pre-mRNA. It is involved in the process of splicing but not directly in the Morpholino's mechanism of action.\\n\\n- **B) PolyA Tail**: This is added to the 3' end of mature mRNA after splicing. It is not directly involved in the splicing or exon skipping process described.\\n\\n- **C) R-loops**: These are structures formed when RNA hybridizes with its corresponding DNA strand, displacing the other DNA strand. They are not mentioned in the context of the therapy described.\\n\\n- **D) Antisense**: Morpholinos are a type of antisense oligonucleotide, meaning they are designed to bind to specific sequences on the RNA to prevent splicing. Therefore, this is directly involved in the therapy.\\n\\nGiven the description, the structure that is not involved in the proposed therapy is:\\n\\nAnswer: C<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process described:\\n\\n1. **Gene Structure**: The gene contains dozens of exons, with central exons coding for specific sequences.\\n2. **Mutations**: Central exon deletions create out-of-frame peptides leading to degenerative effects.\\n3. **Therapy**: Morpholino oligonucleotides recognize the 5' end of the out-of-frame exon in pre-mRNA, preventing spliceosome binding, which results in exon skipping and in-frame joining.\\n4. **Outcome**: Several missing exons are well-tolerated by the organism.\\n\\nNow, let's analyze each option:\\n\\nA) **Lariat**: This is a structure formed during pre-mRNA processing when a branch point is made by RNA splicing. It is involved in the splicing process but not directly mentioned in the therapy mechanism.\\n\\nB) **PolyA Tail**: This is added to the 3' end of mature mRNA after splicing. While it is part of the mRNA, it is not directly involved in the exon skipping or joining process described.\\n\\nC) **R-loops**: These are structures formed when RNA hybridizes with its corresponding DNA strand, displacing the other DNA strand. They are not mentioned in the context of the therapy and do not play a role in the described process.\\n\\nD) **Antisense**: This refers to molecules that can bind to specific RNA sequences. In this case, the Morpholino is described as an antisense molecule that binds to the 5' end of the out-of-frame exon, preventing splicing. This is directly involved in the therapy.\\n\\nGiven the context, the structure not involved in the proposed therapy is:\\n\\nAnswer: C<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process step by step:\\n\\n1. **Understanding the Therapy**: The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n\\n2. **Key Components**:\\n   - **Pre-mRNA**: The RNA before splicing.\\n   - **Spliceosome**: An enzyme complex that removes introns and joins exons during RNA splicing.\\n   - **Exon Skipping**: Removing specific exons from the pre-mRNA.\\n   - **In-frame Joining**: Ensuring that the remaining exons are joined in the correct reading frame.\\n\\n3. **Components Involved**:\\n   - **Lariat (A)**: This is a structure formed during RNA splicing when the branch point adenine of the intron is linked to the 3' end of the intron. It is involved in the splicing process.\\n   - **PolyA Tail (B)**: This is added to the 3' end of mature mRNA but is not directly involved in the splicing process.\\n   - **R-loops (C)**: These are three-stranded DNA-RNA hybrids that can form during transcription. They are not directly involved in splicing or the therapy described.\\n   - **Antisense (D)**: Morpholinos are antisense oligonucleotides used to block the binding of the spliceosome. They are involved in the therapy.\\n\\n4. **Conclusion**:\\n   - Lariat (A) and Antisense (D) are involved in the splicing process and the therapy.\\n   - PolyA tail (B) is not directly involved in splicing or the therapy.\\n   - R-loops (C) are not directly involved in splicing or the therapy.\\n\\nTherefore, the structure not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process:\\n\\n1. **Morpholino Delivery**: The Morpholino binds to the 5' end of the out-of-frame exon in pre-mRNA.\\n2. **Prevention of Spliceosome Binding**: This action prevents the spliceosome from recognizing and splicing the exon.\\n3. **Exon Skipping and In-Frame Joining**: As a result, the exon is skipped during RNA processing, leading to in-frame joining of the remaining exons.\\n\\nNow, let's analyze each option:\\n\\nA) **Lariat**: Lariats are formed during pre-mRNA splicing when an intron is removed. However, the proposed therapy involves preventing the spliceosome from recognizing the exon, so the formation of lariats is not directly involved.\\n\\nB) **PolyA Tail**: The polyA tail is added to the 3' end of mature mRNA after splicing. Since the therapy focuses on modifying pre-mRNA and does not involve the addition or removal of the polyA tail, this structure is not directly involved.\\n\\nC) **R-loops**: R-loops are structures formed when an RNA strand anneals to its DNA template strand, displacing the other DNA strand. While R-loops can form during transcription, they are not directly related to the splicing process or the Morpholino therapy described.\\n\\nD) **Antisense**: Antisense molecules can bind to specific sequences in RNA, similar to how the Morpholino is designed to work. Therefore, this is relevant to the therapy as it involves binding to a specific sequence.\\n\\nGiven the analysis, the structure that is not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the components involved:\\n\\n1. **Morpholino**: This is an antisense oligonucleotide that binds to the 5' end of the out-of-frame exon in pre-mRNA.\\n2. **Spliceosome**: This is a complex of proteins and RNA that is responsible for splicing introns out of pre-mRNA.\\n3. **Exon skipping and in-frame joining**: This refers to the process where the morpholino causes the spliceosome to skip the out-of-frame exon and join the remaining exons in frame.\\n\\nNow, let's analyze each option:\\n\\nA) **Lariat**: This is a circular RNA structure formed during the splicing process when an intron is being removed. It is directly involved in the splicing mechanism.\\nB) **PolyA tail**: This is added to the 3' end of mature mRNA after transcription and processing. It is not directly involved in the splicing or the morpholino-mediated exon skipping.\\nC) **R-loops**: These are structures formed when single-stranded DNA anneals to its complementary RNA transcript, creating a triplex structure. They are not directly involved in the splicing process or the morpholino mechanism.\\nD) **Antisense**: This term describes the morpholino itself, which is used to prevent binding of the spliceosome.\\n\\nGiven this analysis, the structure that is not involved in the proposed therapy is the polyA tail, as it is not part of the splicing process or the morpholino-mediated exon skipping mechanism.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the information given:\\n\\n1. **Gene Structure**: The gene has dozens of exons, with central ones coding for specific protein segments.\\n2. **Mutations**: Central exon deletions create out-of-frame peptides leading to degenerative effects.\\n3. **Therapy**: Morpholino oligonucleotides are used to prevent spliceosome binding at the 5' end of the out-of-frame exon, leading to exon skipping and in-frame joining.\\n4. **Outcome**: This therapy allows for several missing exons to be tolerated by the organism.\\n\\nNow, let's analyze each option:\\n\\n- **A) Lariat**: Lariats are formed during splicing as part of the intron ligation process. They are involved in the splicing machinery and could be indirectly affected by the therapy, but they are not directly targeted by the Morpholino.\\n  \\n- **B) PolyA tail**: The polyA tail is added to the 3' end of the mRNA after processing. It is not directly involved in the splicing or the therapy described.\\n\\n- **C) R-loops**: R-loops are structures formed when RNA hybridizes to one strand of DNA, displacing the other DNA strand. They are not mentioned in the context of the therapy and do not play a role in the splicing process described.\\n\\n- **D) Antisense**: Morpholinos are antisense molecules designed to bind to specific sequences on the RNA, preventing splicing. This is directly involved in the therapy.\\n\\nGiven this analysis, the structure that is not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the components and their roles:\\n\\n1. **Morpholino**: This is a synthetic molecule designed to recognize specific sequences in RNA.\\n2. **Pre-mRNA**: The RNA before splicing occurs.\\n3. **Spliceosome**: An enzyme complex that removes introns and joins exons during RNA splicing.\\n4. **Exon skipping and in-frame joining**: This involves preventing the spliceosome from recognizing certain exons, leading to the creation of in-frame peptides.\\n\\nNow, let's analyze each option:\\n\\nA) **Lariat**: This is a type of RNA structure formed during the splicing process when an intron is being removed. It is involved in the splicing mechanism, so it is relevant to the therapy.\\n\\nB) **PolyA tail**: This is added to the 3' end of mRNA after splicing and polyadenylation. It is not directly involved in the splicing process but rather in mRNA stability and translation. Therefore, it is not directly relevant to the proposed therapy.\\n\\nC) **R-loops**: These are three-stranded RNA-DNA hybrids that can form during transcription. They are not directly involved in the splicing or the therapy described.\\n\\nD) **Antisense**: This refers to RNA molecules that can bind to complementary sequences, potentially inhibiting gene expression. In this context, the Morpholino acts as an antisense molecule to prevent the spliceosome from recognizing certain exons.\\n\\nGiven the context, the structure that is not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"Let's analyze each option step by step:\\n\\nA) **Lariat**: This is a structure formed during splicing when an intron is being removed from pre-mRNA. The lariat is not directly involved in the proposed therapy, which focuses on preventing spliceosome binding and creating exon skipping.\\n\\nB) **PolyA tail**: This is added to the 3' end of mature mRNA after splicing. It is not directly involved in the process of exon skipping or spliceosome binding prevention.\\n\\nC) **R-loops**: These are structures formed when RNA hybridizes with its parent DNA strand, displacing the other DNA strand. They are not directly related to the mechanism of exon skipping or spliceosome binding prevention described.\\n\\nD) **Antisense**: Morpholinos used in the therapy are antisense molecules designed to bind to specific sequences. This is directly involved in the therapy as it prevents the spliceosome from binding.\\n\\nGiven the context of the therapy involving Morpholino and exon skipping, the structure not directly involved is the lariat, as it is part of the splicing process but not specifically targeted by the Morpholino treatment.\\n\\nAnswer: A<|im_end|>\", \"Let's analyze each option to determine which structure is not involved in the proposed therapy:\\n\\nA) Lariat: This is a structure formed during splicing when introns are removed from pre-mRNA. The spliceosome catalyzes the formation of a lariat structure as it excises introns. In the context of the therapy described, the Morpholino prevents spliceosome binding, which would prevent the formation of a lariat.\\n\\nB) PolyA tail: This is added to the 3' end of mature mRNA after splicing. It is not directly involved in the process of splicing or the prevention of spliceosome binding by the Morpholino.\\n\\nC) R-loops: These are structures formed when RNA hybridizes with one strand of its DNA template. They are not directly related to the splicing process or the function of the Morpholino in this context.\\n\\nD) Antisense: This refers to molecules that can bind to specific RNA sequences, such as the Morpholino used in the therapy. The Morpholino is designed to recognize the 5' end of the out-of-frame exon and prevent spliceosome binding.\\n\\nGiven the description, the structure that is not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"Let's analyze each option to determine which structure is not involved in the proposed therapy:\\n\\nA) Lariat: This is a structure formed during pre-mRNA splicing when introns are removed and exons are joined. The described therapy involves preventing the spliceosome from binding to the out-of-frame exon, which would prevent the formation of a lariat.\\n\\nB) PolyA tail: This is added to the 3' end of the mature mRNA after splicing. The therapy described does not involve the polyA tail; it focuses on pre-mRNA and splicing.\\n\\nC) R-loops: These are structures formed when RNA hybridizes with its corresponding DNA strand, displacing the other DNA strand. There is no mention of R-loops in the context of the therapy described.\\n\\nD) Antisense: Morpholinos used in the therapy act as antisense molecules, which means they bind to the target sequence to prevent binding of the spliceosome. This is directly involved in the therapy.\\n\\nGiven this analysis, the structure not involved in the proposed therapy is:\\n\\nAnswer: C<|im_end|>\", \"Let's break down the information given:\\n\\n1. The gene has dozens of exons, with central ones coding for specific functional units.\\n2. Mutations involve deletions of central exons, creating out-of-frame peptides.\\n3. The therapy involves delivering a Morpholino that targets the 5' end of the out-of-frame exon in pre-mRNA to prevent spliceosome binding.\\n4. This results in exon skipping and in-frame joining.\\n\\nNow, let's analyze each option:\\n\\nA) Lariat - This is a structure formed during splicing when an intron is removed, and the 5' end of the intron forms a lariat structure. Since the therapy involves preventing the spliceosome from binding, it would be directly involved in the process.\\n\\nB) PolyA tail - This is added to the 3' end of mRNA after splicing is complete. It is not directly involved in the initial splicing or exon recognition processes targeted by the Morpholino.\\n\\nC) R-loops - These are structures formed when RNA hybridizes to its template DNA strand, displacing the nontemplate DNA strand. They are not directly mentioned in the context of the proposed therapy.\\n\\nD) Antisense - Morpholinos are antisense molecules used to block the function of specific RNA sequences. They are directly involved in the proposed therapy.\\n\\nBased on this analysis, the structure not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"Let's analyze each option to determine which structure is not involved in the proposed therapy:\\n\\nA) Lariat - This is a type of RNA structure formed during splicing when introns are removed from pre-mRNA. It is part of the splicing process and would be involved if the therapy involves altering splicing.\\n\\nB) PolyA tail - This is added to the 3' end of mature mRNA after splicing. It is not directly involved in the splicing process or exon recognition, so it might not be directly involved in the therapy described.\\n\\nC) R-loops - These are structures formed when a strand of RNA hybridizes with its corresponding DNA template strand, displacing the other DNA strand. They are not directly related to splicing or exon recognition in pre-mRNA.\\n\\nD) Antisense - This refers to a strand of nucleic acid that is complementary to another strand, often used in molecular biology techniques to block gene expression. In this context, the Morpholino is an antisense molecule that targets specific sequences to prevent splicing.\\n\\nGiven the description of the therapy, it primarily involves preventing the spliceosome from binding to the 5' end of the out-of-frame exon, which affects the splicing process. Therefore, the structures directly involved are the spliceosome and pre-mRNA, but not specifically the lariat, polyA tail, R-loops, or antisense in the way described.\\n\\nThe correct answer is C) R-loops, as they are not directly involved in the proposed therapy.\\n\\nAnswer: C<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process:\\n\\n1. **Understanding the Therapy**: The therapy involves delivering a Morpholino that binds to the 5' end of the out-of-frame exon in pre-mRNA. This binding prevents the spliceosome from recognizing and splicing this exon, leading to exon skipping and in-frame joining.\\n\\n2. **Key Components**:\\n   - **Pre-mRNA**: The mRNA before it is fully processed.\\n   - **Spliceosome**: The complex responsible for RNA splicing.\\n   - **Exon Skipping**: The process of omitting an exon during splicing.\\n   - **In-frame Joining**: Ensuring that the remaining exons join in the correct reading frame.\\n\\n3. **Components Mentioned in the Options**:\\n   - **Lariat**: This is a type of RNA structure formed during the splicing process when introns are removed.\\n   - **PolyA Tail**: Added to the 3' end of mature mRNA after splicing.\\n   - **R-loops**: Structures formed when single-stranded DNA hybridizes with its corresponding RNA strand.\\n   - **Antisense**: A strand of nucleic acid that is complementary to another strand.\\n\\n4. **Analysis**:\\n   - **Lariat**: Involved in the splicing process, but not directly mentioned in the therapy.\\n   - **PolyA Tail**: Not involved in the splicing or exon skipping process; added later.\\n   - **R-loops**: Not part of the splicing machinery or the therapy described.\\n   - **Antisense**: The Morpholino used in the therapy is an example of antisense technology.\\n\\nGiven the description of the therapy and the options provided, the structure that is not involved in the proposed therapy is the **polyA tail**.\\n\\nAnswer: B<|im_end|>\", \"Let's analyze each option step by step:\\n\\nA) **Lariat**: Lariats are formed during splicing as a branch point RNA ligates to itself. They are involved in the splicing process but not directly in preventing the spliceosome from binding or creating exon skipping.\\n\\nB) **PolyA tail**: The polyA tail is added to the 3' end of the mRNA after splicing and does not play a role in the initial splicing process or in preventing the spliceosome from binding. It is not directly involved in the proposed therapy.\\n\\nC) **R-loops**: R-loops are formed when RNA hybridizes with its template DNA strand, displacing the nontemplate DNA strand. They are not directly involved in the splicing process or in preventing the spliceosome from binding.\\n\\nD) **Antisense**: Morpholinos used in the therapy are antisense molecules that recognize and bind to specific sequences in the pre-mRNA, preventing the spliceosome from binding and causing exon skipping. This is directly involved in the proposed therapy.\\n\\nGiven the context of the therapy involving Morpholino preventing the spliceosome from binding, the structure not directly involved in this process would be the polyA tail, as it is added post-splicing.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the information provided:\\n\\n1. **Gene Structure**: The gene has dozens of exons, with central ones coding for folded triple helical repeats.\\n2. **Mutation**: Central exon deletions create out-of-frame peptides.\\n3. **Therapy**: Morpholino is used to recognize the 5' end of the out-of-frame exon in pre-mRNA, preventing spliceosome binding and creating exon skipping and in-frame joining.\\n4. **Tolerance**: Several missing exons are well-tolerated by the organism.\\n\\nNow, let's analyze each option:\\n\\n- **A) Lariat**: This is a structure formed during splicing when an intron is removed, leaving a lariat-shaped loop. It is directly involved in the splicing process, which is what the Morpholino targets to prevent.\\n\\n- **B) PolyA tail**: This is added to the 3' end of mRNA after splicing. It is not directly involved in the splicing process or the exon recognition by Morpholino.\\n\\n- **C) R-loops**: These are structures formed when RNA hybridizes with its DNA template strand, displacing the complementary DNA strand. They are not directly involved in the splicing process or the exon skipping mechanism described.\\n\\n- **D) Antisense**: Morpholinos are antisense oligonucleotides designed to bind to specific sequences. In this context, the Morpholino is antisense to the 5' end of the out-of-frame exon, making it directly involved in the therapy.\\n\\nGiven the analysis, the structure not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process step by step:\\n\\n1. **Understanding the Therapy**: The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n\\n2. **Key Components**:\\n   - **Morpholino**: An antisense oligonucleotide that targets the 5' end of the out-of-frame exon.\\n   - **Pre-mRNA**: The mRNA before it undergoes splicing.\\n   - **Spliceosome**: A complex of proteins and RNA that processes pre-mRNA by removing introns and joining exons.\\n   - **Exon Skipping and In-Frame Joining**: This results from preventing the spliceosome from recognizing and processing the out-of-frame exon.\\n\\n3. **Analyzing the Options**:\\n   - **A) Lariat**: During pre-mRNA processing, a lariat structure is formed when the spliceosome removes an intron, leaving a lariat-shaped RNA structure. This is part of the splicing process but not directly involved in the Morpholino therapy.\\n   - **B) PolyA Tail**: This is added to the 3' end of the mature mRNA after splicing. It is not directly involved in the Morpholino therapy since the therapy focuses on the 5' end and the splicing process.\\n   - **C) R-loops**: These are structures formed when single-stranded DNA hybridizes with its complementary RNA strand, creating a three-stranded structure. They are not directly involved in the Morpholino therapy as described.\\n   - **D) Antisense**: This refers to the Morpholino itself, which is a key component of the therapy.\\n\\n4. **Conclusion**: Among the options provided, the structure that is not directly involved in the proposed Morpholino therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the components and their roles:\\n\\n1. **Morpholino**: This is a synthetic molecule used to prevent the binding of the spliceosome to the 5' end of the out-of-frame exon. It causes exon skipping and in-frame joining.\\n2. **Spliceosome**: This is a complex of proteins and RNA that splices introns out of pre-mRNA during RNA processing.\\n3. **Pre-mRNA**: This is the precursor mRNA that undergoes processing before becoming mature mRNA.\\n4. **Lariat**: This is a structure formed during pre-mRNA processing when the spliceosome joins two exons together, creating a lariat structure as part of the splicing process.\\n5. **PolyA tail**: This is added to the 3' end of the mature mRNA after transcription and splicing.\\n6. **R-loops**: These are structures formed when a single strand of DNA hybridizes with a complementary RNA strand, displacing the other DNA strand.\\n7. **Antisense**: This refers to a sequence of nucleotides that can bind to a specific target sequence, often used to inhibit gene expression.\\n\\nGiven the therapy involves preventing the spliceosome from binding to the 5' end of the out-of-frame exon using a Morpholino, the key processes involve pre-mRNA splicing, specifically the prevention of spliceosome binding.\\n\\n- **Lariat**: Formed during splicing, so it is involved.\\n- **PolyA tail**: Added after splicing and processing, so it is not directly involved in the proposed therapy.\\n- **R-loops**: Not directly involved in splicing or the Morpholino mechanism.\\n- **Antisense**: Used in some gene silencing mechanisms but not directly relevant here.\\n\\nThe structure that is not involved in the proposed therapy is the PolyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the information given:\\n\\n1. **Gene Structure**: The gene has dozens of exons, with central exons coding for folded triple helical repeats.\\n2. **Mutation**: Central exon deletions create out-of-frame peptides.\\n3. **Therapy**: Morpholino is used to prevent binding of the spliceosome, leading to exon skipping and in-frame joining.\\n4. **Tolerance**: Several missing exons are well-tolerated by the organism.\\n\\nNow, let's analyze each option:\\n\\nA) **Lariat**: Lariats are formed during splicing when introns are removed and the remaining exons are joined. They are involved in the splicing process, which is directly targeted by the Morpholino to prevent exon inclusion and promote exon skipping.\\n\\nB) **PolyA tail**: This is added to the 3' end of the mature mRNA after splicing. It is not directly involved in the splicing process or the exon skipping mechanism described.\\n\\nC) **R-loops**: These are structures formed when RNA hybridizes with its DNA template strand, displacing the other DNA strand. While they can occur in the cell, they are not specifically mentioned in the context of the splicing process or the Morpholino therapy.\\n\\nD) **Antisense**: Morpholinos are antisense oligonucleotides that bind to specific sequences on the pre-mRNA to prevent splicing. This is directly part of the proposed therapy.\\n\\nGiven this analysis, the structure not directly involved in the proposed therapy is the polyA tail, as it is added post-splicing and not part of the splicing or exon skipping mechanism.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the information given:\\n\\n1. **Gene Structure**: The gene has dozens of exons, with central exons coding for folded triple helical repeats.\\n2. **Mutation**: Central exon deletions create out-of-frame peptides.\\n3. **Therapy**: Morpholino prevents spliceosome binding, leading to exon skipping and in-frame joining.\\n4. **Tolerance**: Several missing exons can be tolerated by the organism.\\n\\nNow, let's analyze each option:\\n\\n- **A) Lariat**: This is a type of RNA structure formed during splicing when an intron is removed. It is involved in the splicing process but is not directly targeted or affected by the Morpholino treatment.\\n- **B) PolyA Tail**: This is added to the 3' end of mRNA after transcription. It is not involved in the splicing process or the Morpholino treatment.\\n- **C) R-loops**: These are structures formed when a single strand of DNA is transcribed into RNA, and the RNA strand anneals to the opposite DNA strand, displacing the other DNA strand. While they can affect gene expression, they are not directly involved in the splicing process or the Morpholino treatment.\\n- **D) Antisense**: Morpholinos are antisense oligomers designed to bind to specific RNA sequences and prevent their function. They are central to the proposed therapy.\\n\\nGiven this analysis, the structure not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"Let's analyze each option to determine which structure is not involved in the proposed therapy:\\n\\nA) Lariat - This is a type of RNA structure formed during splicing when an intron is excised from the pre-mRNA. It is involved in the process of splicing but not directly in the proposed therapy involving Morpholino.\\n\\nB) PolyA tail - This is added to the 3' end of pre-mRNA after splicing. It is not directly involved in the splicing process or the therapy described.\\n\\nC) R-loops - These are structures formed when the DNA template strand hybridizes with the transcribed RNA strand, causing a separation of the other DNA strand. They are not directly involved in splicing or the therapy described.\\n\\nD) Antisense - Morpholinos are antisense molecules designed to bind to specific sequences on the pre-mRNA, preventing the spliceosome from binding. This is directly involved in the therapy.\\n\\nGiven the context, the structure not involved in the proposed therapy is:\\n\\nAnswer: C<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the process described:\\n\\n1. **Gene Structure and Exons**: The gene has dozens of exons, with central exons coding for specific sequences.\\n2. **Mutation**: Central exon deletions create out-of-frame peptides.\\n3. **Therapy**: Morpholino oligonucleotides recognize the 5' end of the out-of-frame exon in pre-mRNA, preventing spliceosome binding, leading to exon skipping and in-frame joining.\\n4. **Outcome**: Several missing exons can be tolerated by the organism.\\n\\nNow, let's analyze each option:\\n\\nA) **Lariat**: Lariats are formed during splicing when introns are removed and the 3' end of the intron forms a loop with a 5' splice site. This is directly involved in the splicing process, so it is relevant to the therapy.\\n\\nB) **PolyA Tail**: The polyA tail is added to the 3' end of the mature mRNA after splicing. It is not directly involved in the splicing process or the recognition by the Morpholino. Therefore, this is not directly involved in the proposed therapy.\\n\\nC) **R-loops**: R-loops form when RNA hybridizes with its DNA template strand, displacing the other DNA strand. They are not directly involved in the splicing process or the Morpholino therapy.\\n\\nD) **Antisense**: Morpholinos are antisense oligonucleotides designed to bind to specific regions of pre-mRNA. This is directly involved in the therapy.\\n\\nGiven this analysis, the structure that is not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the information provided:\\n\\n1. **Gene Structure**: The gene has dozens of exons, with central exons coding for specific parts.\\n2. **Mutation**: Central exon deletions create out-of-frame peptides.\\n3. **Therapy**: Morpholino is used to prevent spliceosome binding, leading to exon skipping and in-frame joining.\\n4. **Outcome**: Missing exons are well-tolerated by the organism.\\n\\nNow, let's analyze each option:\\n\\n- **A) Lariat**: This is a structure formed during splicing when an intron is removed and the two exons are joined. The Morpholino therapy involves preventing the spliceosome from binding, thus affecting splicing. Therefore, the lariat formation would be involved.\\n  \\n- **B) PolyA Tail**: This is added to the 3' end of mature mRNA after splicing. Since the therapy focuses on pre-mRNA and does not mention anything about the 3' end processing, this structure is not directly involved in the proposed therapy.\\n  \\n- **C) R-loops**: These are structures formed when a single-stranded DNA strand hybridizes with its complementary RNA transcript. The therapy described does not involve any mechanism related to R-loop formation or resolution.\\n  \\n- **D) Antisense**: Morpholinos are antisense oligonucleotides that bind to the target sequence to inhibit gene expression. Therefore, this is involved in the therapy.\\n\\nBased on the analysis, the structure not involved in the proposed therapy is:\\n\\nAnswer: C<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the information provided:\\n\\n1. **Gene Structure**: The gene has dozens of exons, with central exons coding for folded triple alpha helices.\\n2. **Mutation**: Central exon deletions create out-of-frame peptides.\\n3. **Therapy**: Morpholino oligonucleotides recognize the 5' end of the out-of-frame exon in pre-mRNA, preventing spliceosome binding and causing exon skipping and in-frame joining.\\n4. **Outcome**: Several missing exons are well tolerated by the organism.\\n\\nNow, let's analyze each option:\\n\\n- **A) lariat**: This is a structure formed during splicing when the intron is excised and ligated to the remaining exons. Since the therapy involves preventing the spliceosome from binding, it would affect the formation of lariats.\\n- **B) polyA tail**: This is added to the 3' end of mature mRNAs after splicing. The therapy does not involve the 3' end or the polyA tail, so this structure is not directly involved.\\n- **C) R-loops**: These are structures formed when single-stranded DNA anneals to its complementary RNA transcript, displacing the other strand of DNA. The therapy focuses on pre-mRNA and splicing, so R-loops are not directly involved.\\n- **D) antisense**: Morpholinos used in the therapy are antisense molecules, meaning they bind to the pre-mRNA to prevent splicing. This is directly involved in the therapy.\\n\\nGiven the analysis, the structure that is not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"Let's analyze each option to determine which structure is not involved in the proposed therapy:\\n\\nA) Lariat: This is a structure formed during splicing when an intron is being removed. It is involved in the splicing process, but not directly in the therapy described.\\n\\nB) PolyA tail: This is added to the 3' end of mRNA after splicing. It is not directly involved in the splicing process or the therapy described.\\n\\nC) R-loops: These are structures formed when RNA hybridizes with one strand of DNA, displacing the other DNA strand. They are not directly involved in the splicing process or the therapy described.\\n\\nD) Antisense: This refers to a type of molecule that can bind to specific sequences of RNA, such as Morpholinos used in the therapy. It is directly involved in the therapy described.\\n\\nGiven the context of the therapy involving Morpholinos preventing spliceosome binding and creating exon skipping, the structures involved are primarily related to splicing and RNA processing.\\n\\nThe structure not involved in the proposed therapy is C) R-loops.\\n\\nAnswer: C<|im_end|>\", 'To determine which structure is not involved in the proposed therapy, let\\'s break down the information provided:\\n\\n1. **Gene Structure and Function**: The gene has dozens of exons, with central ones coding for folded triple helical repeats.\\n2. **Mutation**: Central exon deletions create out-of-frame peptides.\\n3. **Therapy**: Morpholino recognizes the 5\\' end of the out-of-frame exon in pre-mRNA, preventing spliceosome binding, leading to exon skipping and in-frame joining.\\n4. **Tolerance**: Several missing exons are well tolerated by the organism.\\n\\nNow, let\\'s analyze each option:\\n\\n- **A) Lariat**: This is a structure formed during RNA splicing when an intron is removed, leaving a loop or \"lariat\" structure. It is directly involved in the splicing process.\\n- **B) PolyA tail**: This is added to the 3\\' end of mature mRNA after splicing. It is not directly involved in the splicing process but rather in mRNA stability and translation.\\n- **C) R-loops**: These are structures formed when RNA hybridizes with its DNA template strand, displacing the nontemplate DNA strand. They are not directly involved in RNA splicing.\\n- **D) Antisense**: Morpholinos are antisense oligomers used to block specific RNA sequences. In this context, it is used to prevent spliceosome binding.\\n\\nGiven the therapy involves preventing spliceosome binding and creating exon skipping and in-frame joining, the structures directly involved are the lariat and possibly the antisense mechanism. The polyA tail and R-loops are not directly involved in the splicing process targeted by this therapy.\\n\\nTherefore, the structure not involved in the proposed therapy is:\\n\\nAnswer: C<|im_end|>', \"Let's analyze each option in the context of the proposed therapy:\\n\\n1. **Lariat**: Lariats are formed during splicing when introns are removed from the pre-mRNA. They are part of the spliceosome complex. The Morpholino prevents the spliceosome from binding, which would prevent the formation of lariats. So, the lariat is involved in this process.\\n\\n2. **PolyA tail**: The polyA tail is added to the 3' end of the mRNA after splicing is complete. It is not directly involved in the initial recognition or binding of the spliceosome. Therefore, it is not directly affected by the Morpholino preventing spliceosome binding.\\n\\n3. **R-loops**: R-loops are structures formed when RNA hybridizes with its DNA template strand, displacing the other DNA strand. They are not directly related to the splicing process or the binding of the spliceosome. Thus, they are not involved in the proposed therapy.\\n\\n4. **Antisense**: Antisense refers to a complementary strand of RNA that can bind to another RNA molecule, often used in gene silencing techniques. In this case, the Morpholino acts as an antisense molecule, recognizing and binding to the 5' end of the out-of-frame exon to prevent spliceosome binding. Hence, antisense is involved in the therapy.\\n\\nBased on this analysis, the structure that is not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's break down the information given:\\n\\n1. **Gene Structure**: The gene has dozens of exons, with central exons coding for folded triple helical repeats.\\n2. **Mutations**: Central exon deletions create out-of-frame peptides.\\n3. **Therapy**: Morpholino is used to recognize the 5' end of the out-of-frame exon in pre-mRNA, preventing spliceosome binding and creating exon skipping and in-frame joining.\\n4. **Outcome**: Several missing exons are well tolerated by the organism.\\n\\nNow, let's analyze each option:\\n\\nA) **Lariat**: This is a type of RNA structure formed during splicing when an intron is removed from the pre-mRNA. Since the therapy involves preventing the spliceosome from binding, it would affect the formation of lariats.\\n\\nB) **PolyA Tail**: This is added to the 3' end of mature mRNA but is not directly involved in the splicing process. It is not mentioned in the context of the therapy.\\n\\nC) **R-loops**: These are structures formed when single-stranded RNA hybridizes with double-stranded DNA, often causing transcriptional pausing or termination. They are not mentioned in the context of the therapy.\\n\\nD) **Antisense**: Morpholinos are antisense oligomers that bind to the target sequence, thus this is directly involved in the therapy.\\n\\nBased on the analysis, the structure not involved in the proposed therapy is the PolyA tail.\\n\\nAnswer: B<|im_end|>\"], 'correct': [False, False, False, False, False, False, True, True, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, True, False, True, False, True, False, True, False, True, False, False, False, True, True, True, True, False, False, True, False, False, True, True, False, True, False, False, False, False, True, False, True, True, True, False, False, False, False, True, False, False, False, False, True, False, False, False, False, True, False, True, True, True, False, True, False, False, True, False, False, False, True, False, False, False, False, False, False, False, True, False, False, False, False, False, True, True, True, False, False, False, False, False, False, False, True, False, True, False, False, False, False, False, False, False, True, False, True, False, True, True, False, False], 'explanations': [\"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\"], 'num_tokens': [403, 337, 290, 356, 327, 240, 385, 311, 349, 396, 244, 352, 415, 410, 400, 355, 361, 344, 386, 454, 349, 348, 219, 327, 293, 257, 280, 406, 353, 259, 338, 312, 268, 219, 228, 347, 329, 320, 365, 280, 217, 296, 289, 330, 335, 343, 324, 378, 264, 273, 222, 349, 294, 380, 343, 382, 392, 241, 408, 399, 353, 283, 252, 332, 279, 415, 273, 362, 321, 247, 413, 391, 340, 249, 369, 351, 321, 358, 319, 243, 334, 340, 352, 310, 345, 361, 339, 304, 285, 387, 399, 329, 291, 355, 385, 366, 393, 345, 353, 380, 325, 386, 354, 415, 358, 330, 346, 331, 234, 256, 219, 296, 312, 376, 257, 349, 411, 389, 352, 320, 209, 353, 327, 349, 225, 360, 303, 318], 'rewards': [0.0927734375, 0.09326171875, 0.09521484375, 0.09716796875, 0.09228515625, 0.099609375, 0.07666015625, 0.0810546875, 0.09716796875, 0.09033203125, 0.09765625, 0.09228515625, 0.08740234375, 0.09765625, 0.09130859375, 0.09423828125, 0.09423828125, 0.0888671875, 0.09228515625, 0.087890625, 0.10009765625, 0.0966796875, 0.0908203125, 0.09228515625, 0.09130859375, 0.0791015625, 0.0908203125, 0.0712890625, 0.08740234375, 0.08837890625, 0.0869140625, 0.0859375, 0.09423828125, 0.09033203125, 0.09375, 0.08935546875, 0.095703125, 0.0859375, 0.0771484375, 0.0810546875, 0.08935546875, 0.09375, 0.0947265625, 0.0859375, 0.09375, 0.09521484375, 0.0869140625, 0.08642578125, 0.087890625, 0.08251953125, 0.0947265625, 0.091796875, 0.08642578125, 0.09423828125, 0.08984375, 0.08740234375, 0.08349609375, 0.072265625, 0.07421875, 0.09765625, 0.09765625, 0.0947265625, 0.09716796875, 0.0830078125, 0.0927734375, 0.0947265625, 0.0888671875, 0.09423828125, 0.091796875, 0.09033203125, 0.09423828125, 0.095703125, 0.0927734375, 0.0869140625, 0.09521484375, 0.07861328125, 0.08154296875, 0.0732421875, 0.09326171875, 0.0791015625, 0.09033203125, 0.09375, 0.08544921875, 0.0908203125, 0.08837890625, 0.08984375, 0.09228515625, 0.09716796875, 0.09765625, 0.083984375, 0.0947265625, 0.0947265625, 0.08984375, 0.0966796875, 0.07373046875, 0.09326171875, 0.09033203125, 0.09130859375, 0.09130859375, 0.0908203125, 0.07568359375, 0.07861328125, 0.08154296875, 0.0888671875, 0.08935546875, 0.09228515625, 0.09619140625, 0.09130859375, 0.0849609375, 0.09130859375, 0.08935546875, 0.087890625, 0.07275390625, 0.0966796875, 0.09228515625, 0.09814453125, 0.09912109375, 0.09228515625, 0.0986328125, 0.09521484375, 0.0859375, 0.09423828125, 0.07568359375, 0.09228515625, 0.083984375, 0.08056640625, 0.0947265625, 0.09326171875], 'ground_truths': ['C'], 'question_meta': None, 'model_name': 'hf_chat:Qwen/Qwen2.5-7B-Instruct', 'reward_model_name': 'armo_rm:RLHFlow/ArmoRM-Llama3-8B-v0.1'}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 67%|â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–‹   | 8/12 [00:22<00:10,  2.59s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Skipping corrupt file ../final_runs/GPQA_el2/Llama-3.2-1B--temp-0.6--samples-128--max-512.jsonl: Expecting value: line 1 column 1 (char 0)\n",
      "{'qid': 'gpqa-1', 'prompt': \"Answer the following multiple choice question. The last line of your response should be of the following format: 'Answer: $LETTER' (without quotes) where LETTER is one of ABCD. Think step by step before answering.\\n\\nA large gene has dozens of exons, of which the central ones code for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space. Each exon usually codes for one folded triple alpha helix. The most common mutations of the gene are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste. A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. The molecule prevents binding of the spliceosome and creates exon skipping and in-frame joining. Several missing exons are well tolerated by an organism. Which structure below is not involved in the proposed therapy?\\n\\nA) lariat\\nB) polyA tail\\nC) R-loops\\nD) antisense\", 'answers': [\"The answer is B) polyA tail. \\n\\nExplanation:\\nPolyA tails are involved in the process of mRNA splicing, which is crucial for the proper assembly of ribosomes into the correct structures. In this case, the mutation is likely caused by a deletion or insertion of a sequence of nucleotides on the 3' end of the gene, which disrupts the proper functioning of the polyA tail. Therefore, the polyA tail is not involved in the proposed therapy.<|im_end|>\", 'Answer: D) antisense\\n\\nExplanation:\\nThe question is asking about a therapeutic approach to a gene mutation. The answer choices provided do not directly relate to the question or provide any information about the structures involved in a treatment for gene mutations. Therefore, it cannot be determined whether these options are correct or incorrect based on the given information.<|im_end|>', \"Answer: B) polyA tail\\n\\nExplanation:\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This molecule prevents binding of the spliceosome and creates exon skipping and in-frame joining. Therefore, it does not involve any of the structures mentioned in the answer choices - lariat, polyA tail, R-loops, or antisense.<|im_end|>\", 'The answer would be B) polyA tail. \\n\\nExplanation:\\nThe question asks about the structure that is not involved in the proposed therapy. The options given are:\\nA) lariat\\nB) polyA tail\\nC) R-loops\\nD) antisense\\n\\nThe correct answer is B) polyA tail because it is not part of the proposed therapy and does not have any known function in the cell.<|im_end|>', \"Answer: B) polyA tail\\n\\nExplanation: The proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This results in the formation of a poly(A) tail, which can be used as a delivery vector or a therapeutic target. Therefore, option B, polyA tail, is not involved in the proposed therapy.<|im_end|>\", 'Answer: D) antisense<|im_end|>', 'The answer is B) polyA tail. \\n\\nExplanation:\\nPolyA tails are known as \"molecular chaperones\" because they help proteins fold properly during protein synthesis. They are composed of two strands of DNA, each containing a specific number of nucleotides. When these strands combine at a specific site on the mRNA, it becomes more stable and ready to fold into its proper shape. PolyA tails can also bind to other molecules, such as ribosomes, to help them fold correctly during protein synthesis.<|im_end|>', 'The answer is D) antisense. \\n\\nExplanation: Antisense oligonucleotides are small molecules that mimic the function of their complementary sequence in the mRNA transcript. They can interfere with the translation process, preventing the synthesis of a protein from its mRNA template. In the case of a gene encoding a protein, they can cause the protein to be misfolded or degraded, leading to reduced production of the protein.<|im_end|>', \"The answer is B) polyA tail. This is because the proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA, which results in the inhibition of the spliceosome and creation of exon skipping and in-frame joining. This is different from the other options such as lariat, polyA tail, R-loop, or antisense.<|im_end|>\", 'Answer: D) antisense\\n\\nThe correct answer is D) antisense because it does not involve any of the structures mentioned in the question - lariat, polyA tail, R-loop, or antisense.<|im_end|>', \"Answer: D) antisense\\n\\nExplanation:\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This means that the therapy targets the mRNA sequence that contains the out-of-frame exon. Therefore, the correct answer is D) antisense.<|im_end|>\", \"The answer would be C) R-loops. \\n\\nExplanation:\\nIn the context of mRNA splicing, r-loops are known as ribosomal RNA loops or rRNAs. They play a crucial role in mRNA splicing by facilitating the addition of introns to the ends of mature mRNA molecules. However, there are some proteins that can interact with rRNAs and inhibit their function. One such protein is the rRNA ligase, which helps to remove introns from rRNAs. Therefore, it's likely that r-loops might have been involved in the proposed therapy mentioned in the question.<|im_end|>\", 'The answer is C) R-loops. R-loop molecules are small molecules that bind to DNA and prevent replication from continuing, allowing the cell to divide properly. They are commonly used as therapeutic agents in cancer treatment.<|im_end|>', 'The answer is C) R-loops. \\n\\nR-loop molecules can bind to the RNA polymerase enzyme and prevent it from synthesizing new mRNA strands. This results in a decrease in the number of newly synthesized mRNA strands, leading to reduced protein synthesis. Therefore, the proposed therapy involves using a R-loop molecule to disrupt the ribosomes and prevent the production of new mRNA strands. However, it is important to note that this therapy may not work for all types of genetic disorders or diseases.<|im_end|>', \"Answer: C) R-loops\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This molecule prevents binding of the spliceosome and creates exon skipping and in-frame joining. However, the answer does not directly relate to any of the options provided.<|im_end|>\", \"Answer: B) polyA tail\\n\\nExplanation: The proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This is different from the structures mentioned in the options, such as lariat, polyA tail, or R-loop.<|im_end|>\", \"The answer would be D) antisense. This is because the sentence states that the proposed therapy involves delivering a morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA, which means it targets the antisense RNA strand.<|im_end|>\", \"The proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. The molecule prevents binding of the spliceosome and creates exon skipping and in-frame joining. Therefore, none of the options listed (lariat, polyA tail, R-loops, or antisense) is involved in the proposed therapy.\\nAnswer: D<|im_end|>\", 'Answer: D) antisense<|im_end|>', 'Answer: D) antisense<|im_end|>', 'The answer would be C) R-loops. R-loop proteins are involved in the regulation of mRNA splicing and can prevent splicing from occurring at specific sites. However, the question does not specify which type of protein is being referred to as \"the\" structure. It could refer to any of the options listed. Therefore, the correct answer is C) R-loops.<|im_end|>', \"The answer is C) R-loops. \\n\\nR-loop molecules are small loops that can be used as scaffolds or as targets for protein synthesis. They are typically formed during the early stages of protein synthesis and are often used in therapeutic applications due to their ability to form stable structures. However, it's important to note that r-loops are not involved in the proposed therapy mentioned in the question.<|im_end|>\", \"The answer is B) polyA tail. This is because the proposed therapy involves delivering a morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA, preventing binding of the spliceosome and creating exon skipping and in-frame joining. However, this does not involve any of the other structures listed - lariat, polyA tails, R-loops, or antisense.<|im_end|>\", 'The answer is D) antisense. Antisense molecules are not involved in the proposed therapy.<|im_end|>', 'Answer: C) R-loops\\n\\nExplanation: The given statement mentions that the most common mutations of the gene are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste. This suggests that the R-loop structure is not involved in this process. The other options, such as lariat, polyA tail, or antisense, are all structures that can be involved in the treatment of genetic disorders.<|im_end|>', 'Answer: D) antisense<|im_end|>', 'Answer: C) R-loops\\n\\nExplanation:\\nThe passage mentions that the most common mutations of the gene are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste. This suggests that the proposed therapy involves removing the out-of-frame peptide from the mRNA transcript. Therefore, the correct answer is C) R-loops.<|im_end|>', 'Answer: D) antisense<|im_end|>', \"Answer: C) R-loops\\n\\nExplanation: In the context of the given information, the correct answer would be C) R-loops because it is mentioned that the proposed therapy involves delivery of a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This is likely referring to the use of rRNA (ribonucleic acid) as a target for a novel therapeutic approach. The other options do not directly relate to this scenario or provide any relevant information about the proposed therapy.<|im_end|>\", 'Answer: C) R-loops\\n\\nExplanation:\\nThe passage mentions that the most common mutations of the gene are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste. Therefore, none of the options listed (lariat, polyA tail, R-loops, or antisense) directly relate to the proposed therapy mentioned in the passage.<|im_end|>', 'The answer is C) R-loops. \\n\\nExplanation: The question is asking about a potential treatment for a disease or condition. The provided information does not mention any specific structures or molecules being used for this treatment. Instead, it focuses on understanding the genetic changes that can lead to the development of certain diseases and the ways in which these changes can be addressed using specific treatments. Therefore, the best answer would be a combination of letters that do not fit into any of the given options.<|im_end|>', \"The answer is B) polyA tail. \\n\\nExplanation:\\nPolyA tails are involved in mRNA splicing and can help prevent DNA damage from occurring during protein synthesis. They also play a role in mRNA stability and can bind to ribosomes to help them navigate through the ribosome's outer membrane.<|im_end|>\", 'The answer would be D) antisense. This is because the question does not mention any other structures involved in the proposed therapy, such as lariat or polyA tails.<|im_end|>', 'The answer would be B) polyA tail. \\n\\nExplanation:\\nThe article mentions that the most common mutations of the gene are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste. This suggests that the protein produced by the gene is likely involved in the process of generating proteins from mRNA, rather than directly affecting them.\\nThe article also mentions that some organisms can tolerate the absence of certain exons, which could suggest that these exons may play a role in the proposed therapy.\\nTherefore, the correct answer is B) polyA tail.<|im_end|>', \"The answer is D) antisense. \\n\\nAntisense molecules can bind to mRNA transcripts and prevent them from being translated into proteins, thus preventing the formation of the out-of-frame peptide and progressive degenerative organ waste. However, it's important to note that this treatment involves delivery of a specific molecule to the target site, and there may be other factors that contribute to the effectiveness of the therapy as well.<|im_end|>\", \"The answer is D) antisense. Antisense RNA molecules can bind to specific DNA sequences and stop transcribed mRNA from being translated into proteins. In this case, the proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.<|im_end|>\", 'Answer: C) R-loops\\n\\nThe correct answer is C because r-loop is not involved in the proposed therapy.<|im_end|>', \"The proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. The molecule prevents binding of the spliceosome and creates exon skipping and in-frame joining. However, it does not include any structures like lariat, polyA tails, R-loops, or antisense. Therefore, the correct answer is:\\n\\nB) polyA tail<|im_end|>\", \"The proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This does not involve any of the structures mentioned in the options provided. Therefore, the correct answer is B) polyA tail.<|im_end|>\", \"Answer: D) antisense\\n\\nExplanation: Antisense RNA molecules can interfere with mRNA translation and inhibit protein synthesis, leading to diseases such as Alzheimer's disease. Therefore, none of the structures listed (lariat, polyA tail, R-loops, or antisense) is involved in the proposed therapy of gene deletion and replacement.<|im_end|>\", 'Answer: B) polyA tail\\n\\nExplanation:\\nThe question asks about the structure not involved in the proposed therapy. Among the options given, only \"polyA tail\" does not involve any structure mentioned in the answer choices. Therefore, the correct answer is B) polyA tail.<|im_end|>', 'The answer would be D) antisense. \\n\\nExplanation:\\nAntisense molecules are small RNA molecules that can bind to specific mRNA regions and prevent their translation into proteins. They are typically used as therapeutic agents because they target the mRNA transcript directly, rather than interfering with the ribosomal protein or other proteins involved in translation.<|im_end|>', \"Answer: B) polyA tail\\n\\nExplanation: The proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. The molecule prevents binding of the spliceosome and creates exon skipping and in-frame joining. Therefore, none of the options listed (lariat, polyA tail, R-loops, and antisense) are involved in this process.<|im_end|>\", \"Answer: B) polyA tail\\n\\nExplanation: The proposed therapy involves delivering a morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. The molecule prevents binding of the spliceosome and creates exon skipping and in-frame joining. This process involves the assembly of polyA tails on the mRNA strand, which can lead to the elimination of these non-coding sequences from the transcriptome. Therefore, none of the options listed ($lariat$, $polyA tail$, $R-loops$, and $antisense$) involve this process or feature of the gene being studied.<|im_end|>\", \"The proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This molecule prevents binding of the spliceosome and creates exon skipping and in-frame joining. Therefore, none of the structures listed above are involved in this proposed therapy. The correct answer is D) antisense.<|im_end|>\", 'The answer is C) R-loops. R-loops are involved in the proposed therapy because they prevent the formation of out-of-frame peptides and progressive degenerative organ waste.<|im_end|>', \"Answer: C) R-loops\\n\\nExplanation:\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This allows the mRNA to skip this exon and join the rest of the coding sequence without affecting its function or stability. Therefore, the correct answer is C) R-loops, which is not part of the proposed therapy.<|im_end|>\", 'The answer is D) antisense. \\n\\nExplanation:\\nAntisense RNA is a type of messenger RNA (mRNA) that targets and silences a specific gene or protein. It does this by binding to its target mRNA and preventing it from translating into proteins. Antisense RNA can be used as a therapeutic tool because it can interfere with the translation process and disrupt the function of the targeted gene. However, it is important to note that antisense RNA may also interact with other molecules in the body, such as enzymes and receptors, which could potentially cause side effects. Therefore, the use of antisense RNA in cancer treatment would require careful consideration of potential risks and benefits.<|im_end|>', \"The answer is B) polyA tail. This is because the proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA, which is then removed from the mRNA sequence through a process called exon skipping. This results in the removal of the out-of-frame exon from the mRNA, allowing it to join with other exons and form a complete transcript. Therefore, the proposed therapy does not involve any of the structures mentioned in the question, such as a lariat, polyA tail, or R-loops.<|im_end|>\", \"The proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This can prevent binding of the spliceosome and create exon skipping and in-frame joining. Therefore, the answer is C) R-loops.<|im_end|>\", 'The answer is D) antisense. Antisense molecules can be used to prevent mRNA splicing, which can lead to the production of missense or nonsense variants.<|im_end|>', \"The answer is D) antisense. Antisense is not involved in the proposed therapy because it does not alter the mRNA sequence but instead targets the mRNA transcript to prevent its translation into protein. \\n\\nAntisense molecules can target specific regions within the mRNA to disrupt the translation process, which could potentially lead to the treatment of diseases such as cancer or neurological disorders. However, the proposed therapy involves delivering a morpholino molecule, which specifically targets the 5' end of the out-of-frame exon in pre-mRNA, and preventing binding of the spliceosome and creating exon skipping and in-frame joining. This approach may offer a potential therapeutic option for certain diseases.<|im_end|>\", \"The answer is D) antisense. Antisense molecules can be used to target specific regions of DNA or RNA and disrupt protein synthesis, potentially reducing the risk of cancer and other diseases. However, it's important to note that this treatment does not work as currently known and may not be effective for all types of cancers.<|im_end|>\", 'The answer is C) R-loops. \\n\\nR-loop molecules are known for their ability to prevent protein synthesis and can be used as therapeutic agents to inhibit the formation of ribosomes from mRNA. However, they do not have any direct involvement in the proposed therapy of mRNA splicing or DNA repair.<|im_end|>', 'The answer is C) R-loops. \\n\\nExplanation:\\nR-loop molecules are known to have a role in regulating the expression of certain genes. They can be used as therapeutic targets for genetic disorders or diseases. However, they are not typically used in the treatment of cancer. Therefore, option C) R-loop is not involved in the proposed therapy.<|im_end|>', 'The answer is D) antisense. \\n\\nThis is because the problem statement mentions that the proposed therapy involves delivery of a \"Morpholino\" that recognizes the 5\\' end of the out-of-frame exon in pre-mRNA. This means that the target protein would be a sequence of DNA that encodes for the out-of-frame exon. Therefore, it is not possible to identify any other structures mentioned in the problem statement as being involved in the proposed therapy.<|im_end|>', \"The proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This enzyme is responsible for removing the splicing factor Splicease I from the mRNA transcript, resulting in the removal of the out-of-frame exon. Therefore, the answer is B) polyA tail.<|im_end|>\", 'Answer: D) antisense<|im_end|>', 'The answer is D) antisense. Antisense RNA molecules can interfere with mRNA translation, preventing the proper folding of proteins and potentially causing diseases such as cancer.<|im_end|>', \"The answer is D) antisense. \\n\\nAntisense RNA molecules can inhibit protein synthesis by interfering with the translation of mRNA. In this case, the proposed therapy involves delivering a morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA, which would interfere with protein synthesis. Therefore, the correct answer is D) antisense.<|im_end|>\", \"The answer is C) R-loops. \\n\\nExplanation:\\nR-loop structures are a type of RNA secondary structure that can be used as a target for RNA interference (RNAi). In this case, the proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This would prevent binding of the spliceosome and create exon skipping and in-frame joining. However, it is not mentioned whether the R-loop is involved in the proposed therapy or not.<|im_end|>\", \"Answer: B) polyA tail\\n\\nExplanation:\\nThe proposed therapy involves delivering a morpholino molecule that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This molecule prevents binding of the spliceosome and creates exon skipping and in-frame joining. However, it does not directly involve any of the structures listed - lariat, polyA tail, R-loop, or antisense. Therefore, option B) polyA tail is not involved in the proposed therapy.<|im_end|>\", \"Answer: D) antisense\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This treatment prevents binding of the spliceosome and creates exon skipping and in-frame joining, but does not involve any of the other structures listed - lariat, polyA tail, R-loops, or antisense.<|im_end|>\", \"The answer is C) R-loops. This is because the proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA, which results in the removal of this exon from the mRNA. This results in the formation of a novel transcript, allowing for the incorporation of the deleted exon into the genome without disrupting the normal function of the gene.<|im_end|>\", 'Answer: C) R-loops\\n\\nExplanation:\\nThe passage states that the most common mutations of the gene are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste. This suggests that the proposed therapy involves targeting the central exon deletion, which is not directly related to the structure mentioned in the answer choices - r-loop, polyA tail, or antisense.<|im_end|>', 'The answer is D) antisense. Antisense is not involved in the proposed therapy because it does not change the amino acid sequence of the mRNA transcript but instead modifies the protein-protein interactions between the mRNA and the ribosomes.<|im_end|>', 'Answer: D) antisense<|im_end|>', \"The answer is D) antisense. \\n\\nAntisense RNA is a type of messenger RNA that targets specific genes or proteins and inhibits their translation. It can be used as a therapeutic approach to treat diseases such as cancer and Alzheimer's disease. However, it is important to note that the use of antisense RNA requires careful monitoring and regulation to avoid unintended consequences such as toxicity or resistance to treatment.<|im_end|>\", \"Answer: D) antisense\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This would disrupt the function of the spliceosome and create exon skipping and in-frame joining. Therefore, the correct answer is D) antisense.<|im_end|>\", 'Answer: C) R-loops\\n\\nExplanation:\\nThe question asks about a structure that is not involved in the proposed therapy. Among the options provided, only R-loops are known to be involved in the proposed therapy. Therefore, the correct answer is C) R-loops.<|im_end|>', \"Answer: C) R-loops\\n\\nExplanation:\\nThe passage mentions that a solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This suggests that the R-loop is not involved in the proposed therapy. The other options are either related to the structure of RNA or DNA, but they do not directly address the problem described in the passage.<|im_end|>\", 'Answer: D) antisense<|im_end|>', \"The proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. The molecule prevents binding of the spliceosome and creates exon skipping and in-frame joining. \\n\\nTherefore, the answer is C) R-loops.<|im_end|>\", \"The proposed therapy involves delivering a morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This molecule prevents binding of the spliceosome and creates exon skipping and in-frame joining. \\n\\nTherefore, the correct answer is B) polyA tail.<|im_end|>\", \"Answer: B) polyA tail\\n\\nExplanation:\\nThe proposed therapy involves delivering a morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This is similar to the process used to deliver a polyadenylation signal to regulate mRNA stability and function in other organisms.\\nTherefore, the answer is B) polyA tail.<|im_end|>\", \"Answer: D) antisense\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This is because it prevents binding of the spliceosome and creates exon skipping and in-frame joining. However, this is not involved in the proposed therapy. Therefore, the correct answer is D) antisense.<|im_end|>\", \"The answer is C, R-loops. R-loop molecules are proteins that can bind to mRNA and prevent its proper translation into protein. They are often used in genetic therapies as they allow for the modification of RNA sequences to target specific genes or diseases. However, it's important to note that r-loops can also cause problems if not used correctly, such as causing splicing errors or disrupting protein synthesis.<|im_end|>\", 'Answer: C) R-loops\\n\\nExplanation:\\nThe passage states that the most common mutations of the gene are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste. This suggests that the R-loop structure is involved in this process. The R-loop is a type of RNA loop found in rRNA genes that allows them to fold into a compact ring shape. However, it is important to note that the passage does not provide information on how the R-loop structure is involved in the proposed therapy or any other structures mentioned. Therefore, the correct answer is C) R-loop.<|im_end|>', 'Answer: D) antisense<|im_end|>', \"The answer is B) polyA tail. \\n\\nExplanation: The passage states that the most common mutations of the gene are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste. Therefore, the proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This would likely involve the polyA tail of mRNA as it is often involved in mRNA stability and splicing. However, there is no mention of any other structures mentioned in the passage, so the polyA tail is not involved in the proposed therapy.<|im_end|>\", 'The answer is D) antisense. Antisense RNA molecules can bind to specific mRNA regions and prevent their translation into proteins, which can lead to the desired therapeutic effect of delivering a Morpholino to the gene.<|im_end|>', 'Answer: D) antisense<|im_end|>', \"The proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This molecule prevents binding of the spliceosome and creates exon skipping and in-frame joining. However, it does not involve any structures mentioned in the answer choices:\\n\\n- A) lariat - This is not related to the proposed therapy.\\n- B) polyA tail - This is not related to the proposed therapy.\\n- C) R-loops - These are not involved in the proposed therapy.\\n- D) antisense - This is not related to the proposed therapy.\\n\\nTherefore, the correct answer is B) polyA tail.<|im_end|>\", \"The answer is B) polyA tail. The polyA tail is a component of the mRNA that is necessary for translation and is often used as a therapeutic target for diseases such as Alzheimer's disease. It is not involved in the proposed therapy.<|im_end|>\", \"The answer is C) R-loops. This is because the proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. However, the structure B) polyA tail or D) antisense is not involved in the proposed therapy.<|im_end|>\", 'The answer is B) polyA tail. \\n\\nExplanation:\\nPolyA tails are known to be involved in the process of mRNA splicing, specifically in the regulation of introns and non-coding sequences. They play a crucial role in maintaining the integrity of the mRNA transcript and preventing splicing errors. However, they do not directly contribute to the proposed therapy of removing the out-of-frame exon from the gene.<|im_end|>', \"Answer: B) polyA tail\\n\\nExplanation:\\nThe proposed therapy involves delivering a morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. The molecule prevents binding of the spliceosome and creates exon skipping and in-frame joining. This process results in the elimination of the out-of-frame exon from the gene's sequence. Therefore, none of the structures listed (lariat, polyA tail, R-loops, or antisense) are involved in this process.<|im_end|>\", \"Answer: D) antisense\\n\\nExplanation:\\nThe proposed therapy involves delivering a morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This allows the mRNA to skip the exon and form a loop, which can then be joined by the ribosome. However, this process does not involve any of the structures listed above - lariat, polyA tail, or R-loops. Therefore, the correct answer is D) antisense.<|im_end|>\", 'The answer is D) antisense. \\n\\nAntisense RNA molecules can bind to mRNA and prevent its translation into protein. This is different from other structures mentioned in the options such as lariat, polyA tails, and R-loops.<|im_end|>', \"Answer: B) polyA tail\\n\\nExplanation: The proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This allows the molecule to prevent binding of the spliceosome and create exon skipping and in-frame joining. However, the correct answer is not provided in the options given.<|im_end|>\", \"Answer: C) R-loops\\n\\nExplanation:\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This enzyme cleaves the intron, allowing the mRNA to enter the ribosome and initiate translation. However, this process can lead to the degradation or mistranslation of the protein, which can result in disease symptoms. \\n\\nOption B (polyA tails) does not directly address the issue of protein degradation and mistranslation, while option D (antisense) could potentially interfere with protein synthesis but does not directly prevent the degradation of the protein.\\n\\nOption A (lariat) is related to the structure of ribosomes, but it is not directly involved in the proposed therapy. Option C (R-loops) do not directly address the issue of protein degradation and mistranslation, while option E (antisense) could potentially interfere with protein synthesis but does not directly prevent the degradation of the protein.<|im_end|>\", 'The answer would be D) antisense. This is because it does not involve any specific structures mentioned in the options.<|im_end|>', \"The answer is B) polyA tail. \\n\\nExplanation: The article states that the proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This is not related to any of the other options listed.<|im_end|>\", 'The answer is D) antisense.<|im_end|>', 'The answer would be C) R-loops. R-loop structures are known to be involved in the process of exon skipping and in-frame joining. However, there is no information provided about whether these structures are involved in the proposed therapy. Therefore, the correct answer is C).<|im_end|>', 'Answer: D) antisense<|im_end|>', 'The answer is B) polyA tail. \\n\\nExplanation:\\nPolyA tails are found on the ends of messenger RNA molecules and are essential for mRNA translation. They help to anchor the mRNA to the ribosomes and prevent premature termination during protein synthesis. In this case, the polyA tail is being used as part of a therapeutic approach to repair the damaged DNA sequence and prevent further mutations.<|im_end|>', \"Answer: B) polyA tail\\n\\nExplanation:\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This allows for the removal of the out-of-frame peptide and the insertion of the desired intron into the gene's coding sequence. \\n\\nPolyA tails, on the other hand, do not involve in the proposed therapy. They are used to package proteins for transport or delivery. Therefore, they cannot be involved in the treatment of a gene mutation caused by the deletion of an exon. \\n\\nR-loops are also not involved in the proposed therapy as they are used to wrap DNA around RNA molecules during transcription.<|im_end|>\", 'The answer is D) antisense. Antisense RNA molecules can interfere with the splicing of mRNA into DNA, preventing the formation of mature proteins. This is why some organisms have developed therapies that use antisense RNA to treat genetic diseases or disorders.<|im_end|>', \"Answer: C) R-loops\\n\\nExplanation:\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This molecule prevents binding of the spliceosome and creates exon skipping and in-frame joining. However, the answer provided does not mention any specific structures related to this therapy or its mechanism of action. Therefore, it cannot be determined whether any of these structures is not involved in the proposed therapy.<|im_end|>\", 'Answer: D) antisense\\n\\nExplanation: Antisense RNA molecules can inhibit the translation process of mRNA by blocking the ability of ribosomes to bind to the mRNA. This can lead to reduced production of protein products, including those involved in gene expression. Therefore, it is not involved in the proposed therapy.<|im_end|>', 'The answer would be D) antisense. \\n\\nExplanation:\\nThe question is asking about a treatment for a gene mutation that affects the folding of proteins. One possible treatment is to use a molecule called a \"Morpholino\" that recognizes the 5\\' end of the out-of-frame exon in pre-mRNA and prevents binding of the spliceosome. This prevents the splicing process from cutting the mRNA, resulting in the creation of an exon skipping and in-frame joining mechanism. However, it is important to note that this treatment is not involved in the proposed therapy because it does not involve any of the other options provided in the answer choices.<|im_end|>', 'The answer is C) R-loops. R-loop structures are involved in the process of exon skipping and in-frame joining.<|im_end|>', 'Answer: B) polyA tail\\n\\nExplanation:\\nThe answer is not among the options provided as it does not match the information given about the proposed therapy. The option \"lariat\" is related to the concept of the Lariat, which is a type of muscle fiber, but it does not address the proposed therapy or any specific structure mentioned in the passage. Therefore, none of the other options, including \"polyA tail,\" \"R-loops,\" \"antisense,\" or \"Lariat,\" can be considered correct answers based on the information provided.<|im_end|>', 'The answer is C) R-loops. \\n\\nR- loops are involved in the assembly of mRNA into ribosomes, but they do not play a role in the proposed therapy described in the question. Therefore, option C is not correct.<|im_end|>', 'The answer is B) polyA tail. \\n\\nExplanation:\\nThe first sentence mentions that the last line of the response talks about the last exon in the gene being coded for by a folded triple helix. The second sentence then goes on to say that this last exon is typically coded for by one folded triple alpha helix, but it also states that the most common mutations of the gene involve deletion of the last exon. This means that the last exon in the gene is not part of the structure described in the answer choices. Therefore, the correct answer is B) polyA tail.<|im_end|>', \"Answer: B) polyA tail\\n\\nExplanation: The proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This is similar to the polyA tail found in mRNA. However, the treatment does not involve any specific structure mentioned in the options provided.<|im_end|>\", 'The answer is D) antisense. Antisense RNA molecules can bind to the mRNA and prevent translation from occurring. This can help to correct errors or misfolded proteins in the cell.<|im_end|>', 'The answer is D) antisense. Antisense molecules are designed to bind to specific DNA sequences and inhibit their translation into proteins, preventing them from being translated into mRNA. They do this by blocking the interaction between the RNA polymerase enzyme and the complementary sequence on the mRNA.<|im_end|>', 'The answer is B) polyA tail. \\n\\nExplanation: The answer is not among the options provided because none of them directly addresses the problem or solution being discussed in the passage. The passage discusses about the treatment of the gene mutation and its effects on the organism\\'s cells, but does not mention anything about a \"polyA tail\" or any other structure involved in the proposed therapy. Therefore, the correct answer is not listed as one of the given options.<|im_end|>', 'The answer is D) antisense.<|im_end|>', 'The answer is B) polyA tail. \\n\\nExplanation:\\nPolyA tails are small molecules that bind to RNA polymerase III and prevent it from translating the mRNA into proteins. They can also act as a scaffold for other proteins to bind to, such as ribosomes and transporters. However, they are not directly involved in the proposed therapy of removing out-of-frame exons.<|im_end|>', 'The answer would be B) polyA tail. \\n\\nExplanation:\\nPolyA tails are known to be involved in the treatment of diseases such as cancer by inhibiting the expression of oncogenes. They are also found in many viral infections and other pathogenic organisms. However, they do not play a role in the proposed therapy for the gene mutation mentioned in the question. Therefore, the correct answer is B).<|im_end|>', \"Answer: D) antisense\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This allows the mRNA to skip the out-of-frame region, creating exon skipping and in-frame joining. Therefore, the correct answer is D) antisense.<|im_end|>\", 'Answer: D) antisense\\n\\nThe structure below is not involved in the proposed therapy: Antisense RNA molecules, which are designed to target specific sequences within a gene or DNA sequence, but do not have any direct involvement in the process of gene regulation or protein synthesis.<|im_end|>', \"The answer is C, r-loops. \\n\\nR-loops are a type of RNA structure that can help repair damaged DNA. They are typically found in eukaryotic cells and have been used as a tool for repairing damaged DNA in cancer treatments. However, they are not directly involved in the proposed therapy of delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. Instead, these structures are involved in the repair process of damaged DNA and are not directly related to the proposed therapy.<|im_end|>\", 'Answer: B) polyA tail\\n\\nExplanation:\\nThe passage mentions that the most common mutations of the gene are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste. This suggests that the gene may contain a polyA tail. Therefore, option B, \"polyA tail\", is not involved in the proposed therapy.<|im_end|>', 'The answer is C) R-loops. \\n\\nExplanation:\\nThe question asks about the structure involved in the proposed therapy. Among the options given, only option B (polyA tail) does not contain any structures related to r-loop or RNA loops. Therefore, it cannot be the correct answer. Option A (lariat) contains a lariat structure but does not have any specific properties associated with r-loop or RNA loops. Option D (antisense) also contains a r-loop structure but does not have any specific properties associated with r-loop or RNA loops.<|im_end|>', 'The answer is C) R-loops. \\n\\nExplanation:\\nR-loop structures are known to be involved in the process of gene silencing or deletion. In the case of a gene mutation, the protein that normally binds to the mutated gene may become inactive because it no longer recognizes the mutated sequence. This can lead to a loss of function or even death of the cell if there is no way for the protein to bind to the mutated sequence. However, if the protein does bind to the mutated sequence, it may form a stable complex with the rest of the DNA, preventing further changes to the gene and potentially leading to the restoration of normal functions. Therefore, R-loops are often used as a therapeutic target in cancer treatment.<|im_end|>', \"Answer: B) polyA tail\\n\\nExplanation:\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. The molecule prevents binding of the spliceosome and creates exon skipping and in-frame joining. This process involves the interaction between the mRNA and the RNA polymerase, which can lead to errors or mutations if the mRNA is not properly processed. Therefore, the polyA tail is not involved in this process. The other options listed, such as lariat, polyA tails, R-loops, and antisense, are all related to the processing and assembly of mRNA molecules.<|im_end|>\", \"The answer is C) R-loops. This is because the proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA, which is similar to a ribosomal RNA (rRNA) loop. However, this is different from the rRNA loops found in prokaryotic ribosomes, which are more complex structures.<|im_end|>\", \"Answer: D) antisense\\n\\nExplanation:\\nThe proposed therapy involves delivering a morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This is similar to the mechanism used in the development of antisense oligonucleotides to target specific genes or regions of DNA. However, the use of antisense oligonucleotides as a therapeutic approach would require the delivery of the antisense oligonucleotide within the coding region of the gene being targeted, rather than between the exon and intronic regions. Therefore, the correct answer is D) antisense.<|im_end|>\", \"The proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This enzyme prevents binding of the spliceosome and creates exon skipping and in-frame joining. Therefore, the answer would be D) antisense.<|im_end|>\", \"The answer is B) polyA tail. This is because the proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA, preventing binding of the spliceosome and creating exon skipping and in-frame joining.<|im_end|>\", \"Answer: C) R-loops\\n\\nExplanation: The proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This is not directly related to any structures mentioned in the options. The other structures listed are involved in the process of mRNA splicing, including lariat, polyA tails, and antisense RNA molecules.<|im_end|>\", 'Answer: B) polyA tail\\n\\nExplanation:\\nThe passage mentions that the most common mutations of the gene are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste. However, there is no mention of any other structures involved in this process, such as the lariat, polyA tail, or R-loops. Therefore, none of these options are correct answers.<|im_end|>', \"Answer: C) R-loops\\n\\nThe proposed therapy involves delivering a morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. The molecule prevents binding of the spliceosome and creates exon skipping and in-frame joining. However, it does not include any of the structures listed - lariat, polyA tails, R-loops, or antisense.<|im_end|>\", \"Answer: B) polyA tail\\n\\nExplanation:\\nThe passage mentions that the most common mutations of the gene are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste. This suggests that the proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. The passage does not mention any specific structures like the lariat, polyA tail, or R-loops.<|im_end|>\"], 'correct': [False, False, False, False, False, False, False, False, False, False, False, False, False, False, True, False, False, False, False, False, False, False, False, False, True, False, True, False, True, True, False, False, False, False, False, False, True, False, False, False, False, False, False, False, False, False, True, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, True, False, False, False, False, True, True, False, False, False, False, False, False, True, False, False, False, False, False, False, False, False, False, False, False, False, True, False, False, False, False, False, False, False, False, True, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, True, False, True, False], 'explanations': [\"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='B'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='D'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='B'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='C'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='C'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='B'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='C'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='D'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='D'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='C'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='D'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='D'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='D'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='D'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='D'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='D'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='C'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='D'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='B'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='D'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='B'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='B'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='D'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='B'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='B'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='D'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='B'; truth='C'\"], 'num_tokens': [98, 68, 86, 85, 80, 7, 104, 86, 82, 44, 65, 122, 44, 99, 68, 62, 54, 78, 7, 7, 77, 81, 83, 21, 86, 7, 70, 7, 108, 74, 98, 60, 36, 114, 83, 62, 25, 81, 54, 69, 58, 65, 84, 124, 69, 36, 82, 137, 116, 56, 35, 134, 66, 61, 71, 95, 69, 7, 34, 76, 104, 99, 78, 82, 78, 48, 7, 82, 64, 57, 83, 7, 57, 58, 73, 76, 82, 121, 7, 121, 45, 7, 133, 50, 62, 83, 102, 97, 50, 71, 196, 25, 56, 9, 56, 7, 78, 139, 52, 95, 63, 130, 26, 112, 49, 118, 66, 40, 57, 93, 9, 77, 83, 66, 56, 110, 70, 113, 146, 131, 79, 123, 56, 55, 79, 80, 80, 92], 'rewards': [0.056884765625, 0.04541015625, 0.0654296875, 0.06689453125, 0.044189453125, 0.06689453125, 0.044677734375, 0.04345703125, 0.06884765625, 0.0537109375, 0.06494140625, 0.049072265625, 0.053955078125, 0.040283203125, 0.06298828125, 0.07666015625, 0.050537109375, 0.056640625, 0.06689453125, 0.06689453125, 0.04736328125, 0.04931640625, 0.06640625, 0.054443359375, 0.061767578125, 0.06689453125, 0.07177734375, 0.06689453125, 0.061767578125, 0.062255859375, 0.04931640625, 0.06787109375, 0.049560546875, 0.05322265625, 0.041748046875, 0.048095703125, 0.07568359375, 0.051513671875, 0.058349609375, 0.03955078125, 0.07763671875, 0.0458984375, 0.0625, 0.037353515625, 0.033935546875, 0.060791015625, 0.07861328125, 0.030029296875, 0.057861328125, 0.06884765625, 0.048583984375, 0.034423828125, 0.033935546875, 0.06298828125, 0.0673828125, 0.041015625, 0.0478515625, 0.06689453125, 0.047119140625, 0.04345703125, 0.0693359375, 0.07275390625, 0.052978515625, 0.0654296875, 0.0634765625, 0.04443359375, 0.06689453125, 0.032470703125, 0.0654296875, 0.0556640625, 0.0693359375, 0.06689453125, 0.07373046875, 0.0771484375, 0.06884765625, 0.058837890625, 0.04052734375, 0.0380859375, 0.06689453125, 0.04833984375, 0.046875, 0.06689453125, 0.053466796875, 0.0693359375, 0.060546875, 0.068359375, 0.06494140625, 0.04150390625, 0.0498046875, 0.06640625, 0.03955078125, 0.0556640625, 0.07666015625, 0.0615234375, 0.0625, 0.06689453125, 0.060302734375, 0.062255859375, 0.035400390625, 0.06298828125, 0.050537109375, 0.0380859375, 0.07421875, 0.042724609375, 0.06298828125, 0.033935546875, 0.06005859375, 0.048095703125, 0.034423828125, 0.05078125, 0.0615234375, 0.0654296875, 0.0634765625, 0.0654296875, 0.05322265625, 0.05078125, 0.062255859375, 0.044921875, 0.049072265625, 0.05419921875, 0.052001953125, 0.0478515625, 0.0498046875, 0.07958984375, 0.06787109375, 0.050537109375, 0.060546875, 0.06689453125], 'ground_truths': ['C'], 'question_meta': None, 'model_name': 'hf_chat:Qwen/Qwen2-0.5B-Instruct', 'reward_model_name': 'armo_rm:RLHFlow/ArmoRM-Llama3-8B-v0.1'}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 75%|â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–Œ  | 9/12 [00:23<00:06,  2.26s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'qid': 'gpqa-1', 'prompt': \"Answer the following multiple choice question. The last line of your response should be of the following format: 'Answer: $LETTER' (without quotes) where LETTER is one of ABCD. Think step by step before answering.\\n\\nA large gene has dozens of exons, of which the central ones code for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space. Each exon usually codes for one folded triple alpha helix. The most common mutations of the gene are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste. A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. The molecule prevents binding of the spliceosome and creates exon skipping and in-frame joining. Several missing exons are well tolerated by an organism. Which structure below is not involved in the proposed therapy?\\n\\nA) lariat\\nB) polyA tail\\nC) R-loops\\nD) antisense\", 'answers': [\"To solve this question, let's break down the process and the structures involved in the proposed therapy:\\n\\n- The Morpholino is delivering to the pre-mRNA, targeting the 5' end of the out-of-frame exon.\\n- This Morpholino prevents the binding of the spliceosome, which is a complex that usually recognizes and cuts out exons to join the remaining exons in frame.\\n- By preventing spliceosome binding, the Morpholino causes exon skipping, but allows in-frame joining of the remaining exons.\\n\\nNow, let's look at the options:\\n\\nA) Lariat: A lariat is a structure formed by the RNA during splicing, where the exon is removed and a loop is left behind. This is indeed involved in the splicing process.\\n\\nB) PolyA tail: The polyA tail is added to the 3' end of the mRNA after splicing is complete. This is not directly involved in the proposed therapy, as the Morpholino is targeting the 5' end of the exon and preventing spliceosome binding before splicing occurs.\\n\\nC) R-loops: R-loops are a structure formed during RNA splicing, where a single-stranded RNA is bound to the double-stranded RNA. This is involved in the splicing process.\\n\\nD) Antisense: Antisense molecules can bind to specific RNA sequences, and in this case, the Morpholino is an antisense molecule that binds to the 5' end of the out-of-frame exon.\\n\\nConsidering the above information, the structure not involved in the proposed therapy is the polyA tail, as it is added after splicing is complete.\\n\\nAnswer: B<|eot_id|>\", \"To answer this question, we need to understand the proposed therapy and the structures involved.\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA, preventing the binding of the spliceosome and creating exon skipping and in-frame joining. This is a form of antisense therapy, where a molecule is designed to bind to a specific sequence of RNA to prevent the normal splicing process.\\n\\nNow, let's evaluate the options:\\n\\nA) Lariat: A lariat is a type of RNA structure that forms during the splicing process, specifically during the 2' to 5' phosphodiester bond formation. It is indeed involved in the splicing process and can be affected by the Morpholino therapy.\\n\\nB) PolyA tail: The polyA tail is a feature of mature messenger RNA (mRNA) that helps stabilize the mRNA and facilitate its translation. While it is not directly involved in the splicing process, it is a feature of the mature mRNA that can be affected by the splicing process.\\n\\nC) R-loops: R-loops are a type of RNA structure that forms during the splicing process, specifically during the 5' to 3' exon junction. They are indeed involved in the splicing process and can be affected by the Morpholino therapy.\\n\\nD) Antisense: Antisense is the mechanism of action of the proposed therapy, where a molecule is designed to bind to a specific sequence of RNA to prevent the normal splicing process. Therefore, antisense is the correct answer, as it is not a structure involved in the proposed therapy.\\n\\nAnswer: D<|eot_id|>\", \"To approach this question, let's break down the key elements of the proposed therapy:\\n\\n1. The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n2. The Morpholino prevents the binding of the spliceosome, which is a complex that assembles on the pre-mRNA to facilitate splicing.\\n3. As a result of this action, exon skipping occurs, and in-frame joining happens, allowing the creation of a functional protein.\\n\\nGiven these details, let's examine the options:\\n\\nA) Lariat: This structure is involved in the splicing process, particularly in the recognition of introns and the formation of the lariat-shaped structure that holds the intron in place during splicing. The Morpholino could potentially interfere with this process.\\n\\nB) PolyA tail: This is a feature of eukaryotic mRNA that is involved in mRNA stability and translation initiation. It is not directly involved in the splicing process.\\n\\nC) R-loops: These are formed during the splicing process, particularly during the recognition of introns. The Morpholino could interfere with this process.\\n\\nD) Antisense: This is a type of oligonucleotide that can bind to specific mRNA sequences, preventing splicing or translation. The Morpholino is an antisense oligonucleotide designed to bind to the 5' end of the out-of-frame exon.\\n\\nConsidering the roles of these structures in the splicing process, the one that is not directly involved in the proposed therapy is the polyA tail, which is involved in mRNA stability and translation rather than splicing.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's analyze the information given and the options provided.\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, which leads to exon skipping and in-frame joining. The Morpholino is designed to target the out-of-frame exon, and its recognition is specific to the 5' end of the exon.\\n\\nA) Lariat: The lariat is a structure formed by the spliceosome during the splicing process. It is involved in the recognition and removal of introns, and it is not directly involved in the proposed therapy.\\n\\nB) PolyA tail: The polyA tail is a structure that is added to the 3' end of mRNA after splicing. It is not directly involved in the proposed therapy, but it is a normal part of the mRNA processing.\\n\\nC) R-loops: R-loops are a type of RNA-DNA hybrid structure that can form during the splicing process. They are involved in the recognition of the splice site and the removal of introns, and they are relevant to the proposed therapy.\\n\\nD) Antisense: Antisense oligonucleotides, like the Morpholino in the proposed therapy, are designed to recognize specific sequences of RNA and can prevent the binding of proteins or other molecules to those sequences.\\n\\nGiven the information provided and the analysis of each option, the structure not involved in the proposed therapy is the lariat.\\n\\nAnswer: A<|eot_id|>\", \"To solve this question, let's analyze the mechanism of the proposed therapy:\\n\\n- The Morpholino delivers a molecule that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n- This recognition prevents the binding of the spliceosome, which is a complex that assembles at the splice site and catalyzes the removal of the intron and joining of the exons.\\n- As a result of this prevention, the spliceosome creates exon skipping and in-frame joining, effectively bypassing the problematic exon.\\n\\nNow, let's examine the options:\\n\\nA) Lariat: The lariat structure is a type of intron that is removed during splicing. In this context, it's not directly involved in the proposed therapy, but rather a byproduct of normal splicing. However, it's not the correct answer because the Morpholino's action is aimed at preventing splicing, not creating a lariat.\\n\\nB) PolyA tail: The polyA tail is a feature of mature mRNA, not directly involved in the splicing process. However, it's worth noting that the Morpholino's action could affect mRNA stability, but it's not directly involved in the splicing process.\\n\\nC) R-loops: R-loops are involved in the splicing process. They are a structure that forms during the splicing process, and the Morpholino's action prevents the formation of the spliceosome, which in turn affects the formation of R-loops.\\n\\nD) Antisense: Antisense molecules like Morpholino work by binding to the target mRNA, in this case, the 5' end of the out-of-frame exon. This binding prevents the recognition of the splice site by the spliceosome, leading to exon skipping and in-frame joining.\\n\\nConsidering the mechanism of the proposed therapy, the structure not directly involved in the proposed therapy is the lariat. However, this is a bit of a tricky question because the lariat is indeed a byproduct of normal splicing, but the Morpholino's action is aimed at preventing splicing. Given the options provided, it seems the question is looking for a structure not directly involved in the proposed therapy, which would be the polyA tail.\\n\\nAnswer: B<|eot_id|>\", 'To solve this question, we need to understand the context of the proposed therapy and the structures involved.\\n\\nThe therapy involves delivering a Morpholino that recognizes the 5\\' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining. The spliceosome is a complex of proteins that assembles at the splice site to catalyze the splicing of pre-mRNA into mature mRNA.\\n\\nThe key structures involved in this process are:\\n\\n- Lariat: A lariat structure is a type of RNA structure that forms during the splicing process. It is a looped structure that holds the exon-intron boundary together.\\n- PolyA tail: A polyA tail is a feature of mature mRNA that helps stabilize it and facilitate its translation. However, it is not directly involved in the splicing process.\\n- R-loops: R-loops are a type of RNA structure that can form during the splicing process, but they are not directly involved in the proposed therapy.\\n\\nAntisense RNA is a type of RNA that is complementary to the target mRNA, and it can bind to the target mRNA to prevent its splicing. However, the question asks which structure is \"not involved in the proposed therapy\", and antisense RNA is actually the mechanism of action of the Morpholino.\\n\\nTherefore, the correct answer is the structure that is not involved in the proposed therapy.\\n\\nAnswer: B<|eot_id|>', \"To solve this question, let's analyze the information step by step:\\n\\n1. The question describes a therapy that uses a Morpholino to prevent the binding of the spliceosome, leading to exon skipping and in-frame joining. This is a type of antisense therapy, where a single-stranded nucleic acid (in this case, the Morpholino) is designed to bind to a specific sequence of RNA, preventing its normal processing.\\n\\n2. The Morpholino binds to the 5' end of the out-of-frame exon in pre-mRNA, which is a characteristic of antisense therapy.\\n\\n3. The spliceosome is a complex that catalyzes the splicing of pre-mRNA. By preventing its binding, the Morpholino is interfering with the normal splicing process, leading to exon skipping.\\n\\n4. A lariat is a type of RNA secondary structure that can form during the splicing process. It is not directly involved in the proposed therapy, which aims to prevent splicing.\\n\\n5. The polyA tail is a feature of mature mRNA, not directly involved in the proposed therapy.\\n\\n6. R-loops are RNA-DNA hybrids that form during the splicing process. While they are involved in splicing, they are not directly involved in the proposed therapy.\\n\\n7. Antisense therapy is the mechanism described in the question.\\n\\nConsidering these points, the structure that is not involved in the proposed therapy is the lariat.\\n\\nAnswer: A<|eot_id|>\", \"To solve this question, let's break down the key elements of the proposed therapy:\\n\\n1. The therapy involves delivering a Morpholino that recognizes the 5' end of an out-of-frame exon in pre-mRNA.\\n2. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n3. The goal is to create a functional protein by joining the skipped exon.\\n\\nNow, let's examine the options:\\n\\nA) Lariat: This is a type of RNA structure that forms during the splicing process, but it is not directly involved in the proposed therapy.\\n\\nB) PolyA tail: This is a polyadenylate tract added to the 3' end of mRNA, which is not directly involved in the proposed therapy.\\n\\nC) R-loops: These are RNA-DNA or RNA-RNA structures formed during the splicing process, which is relevant to the proposed therapy.\\n\\nD) Antisense: This is a type of RNA molecule that can bind to specific sequences of mRNA, including the 5' end of the out-of-frame exon targeted by the Morpholino, which is directly involved in the proposed therapy.\\n\\nGiven the information above, the structure that is not involved in the proposed therapy is the lariat.\\n\\nAnswer: A<|eot_id|>\", \"To solve this question, let's analyze the information given and the options provided.\\n\\nThe Morpholino is a type of antisense oligonucleotide that binds to the pre-mRNA, preventing the spliceosome from binding to the out-of-frame exon. This results in exon skipping and in-frame joining of the remaining exons. \\n\\nNow, let's examine the options:\\n\\nA) Lariat: A lariat is a structure formed by the splicing of the pre-mRNA after the spliceosome binds to the out-of-frame exon. However, the Morpholino prevents the spliceosome from binding, so this is not directly involved in the proposed therapy.\\n\\nB) PolyA tail: The polyA tail is a feature of mature mRNA, not directly involved in the proposed therapy.\\n\\nC) R-loops: R-loops are involved in the splicing process, specifically in the recognition of the splice sites.\\n\\nD) Antisense: As mentioned, the Morpholino is an antisense oligonucleotide, which is directly involved in the proposed therapy.\\n\\nGiven the information and analysis, the correct answer is the structure not directly involved in the proposed therapy.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's break down the key components involved in the proposed therapy:\\n\\n1. The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n2. The Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n\\nNow, let's examine the options:\\n\\nA) Lariat: Lariat structures are involved in RNA splicing, specifically in the recognition and removal of introns. They are part of the spliceosome complex. Therefore, the lariat is involved in the splicing process and could be affected by the Morpholino.\\n\\nB) PolyA tail: The polyA tail is a feature of mature messenger RNA (mRNA) that helps stabilize it and facilitate its translation. It is not directly involved in the splicing process.\\n\\nC) R-loops: R-loops are a type of RNA secondary structure that forms during the splicing process. They are involved in the recognition of splice sites. Therefore, the R-loops are also involved in the splicing process and could be affected by the Morpholino.\\n\\nD) Antisense: Antisense oligonucleotides, like Morpholinos, work by binding to the target RNA, in this case, the out-of-frame exon, to prevent the splicing process. Therefore, antisense is directly involved in the proposed therapy.\\n\\nGiven the information, the structure that is not involved in the proposed therapy is the polyA tail, as it is not directly involved in the splicing process.\\n\\nAnswer: B<|eot_id|>\", \"To approach this question, let's break down the key elements of the proposed therapy:\\n\\n1. **Morpholino delivery**: Morpholinos are antisense oligonucleotides that bind to specific sequences of pre-mRNA, typically to prevent splicing.\\n2. **Prevents binding of the spliceosome**: The spliceosome is a complex that assembles on the pre-mRNA to catalyze the splicing reaction. By preventing its binding, the Morpholino effectively blocks splicing.\\n3. **Creates exon skipping and in-frame joining**: This indicates that the Morpholino is inducing an alternative splicing event, where instead of including the skipped exon, the splicing machinery joins the remaining exons in an in-frame manner.\\n\\nNow, let's examine the options:\\n\\nA) **Lariat**: A lariat is a type of RNA secondary structure formed during splicing, where the branch point of the intron is connected to the exon. While lariat structures are involved in splicing, they are not directly involved in the proposed therapy.\\n\\nB) **PolyA tail**: The polyA tail is a long sequence of adenine nucleotides added to the 3' end of mature mRNA, which helps in mRNA stability and translation. While not directly involved in splicing, it's not relevant to the proposed therapy.\\n\\nC) **R-loops**: R-loops are RNA-DNA hybrids that form during transcription and are involved in the regulation of gene expression. They are not directly involved in the splicing process, but they are relevant to the process of transcription, which is the precursor to splicing.\\n\\nD) **Antisense**: Antisense oligonucleotides, like Morpholinos, are directly involved in the proposed therapy by binding to specific sequences of pre-mRNA, preventing splicing.\\n\\nConsidering the above explanations, the structure not involved in the proposed therapy is:\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's analyze the information step by step:\\n\\n1. The question is about a therapy that involves delivering a Morpholino that recognizes the 5' end of an out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n\\n2. The spliceosome is a complex that forms during splicing, where it cuts out the intron and joins the exons together. The Morpholino binds to the pre-mRNA at the 5' end of the out-of-frame exon, preventing the spliceosome from binding and cutting out the exon.\\n\\n3. The question mentions that the solution involves exon skipping, which means the spliceosome's normal function is being disrupted.\\n\\n4. Let's analyze the options given:\\n\\n   A) Lariat: A lariat is a type of RNA secondary structure that can form during splicing. The spliceosome uses the lariat to bind to the pre-mRNA and cut out the intron. Since the Morpholino prevents the spliceosome from binding, it disrupts the formation of the lariat, making it less likely to be involved in the proposed therapy.\\n\\n   B) PolyA tail: The polyA tail is a feature of mature mRNA, not directly involved in splicing. It's a long sequence of adenine nucleotides added to the 3' end of the mRNA during post-transcriptional processing. The Morpholino's action is focused on splicing, not on the polyA tail.\\n\\n   C) R-loops: R-loops are a type of RNA-DNA hybrid structure that can form during splicing. They are involved in the recognition of the splice site by the spliceosome. The Morpholino's action could potentially affect R-loops, but this is not explicitly ruled out.\\n\\n   D) Antisense: Antisense oligonucleotides can bind to specific RNA sequences, including pre-mRNA, and prevent their splicing. This mechanism is similar to the Morpholino's action, so it's plausible that antisense oligonucleotides could be involved in the proposed therapy.\\n\\nConsidering the information and the analysis, the structure that is not involved in the proposed therapy is the polyA tail, as it is not directly related to splicing.\\n\\nAnswer: B<|eot_id|>\", \"To approach this question, let's break down the key components and the proposed therapy.\\n\\n1. **Gene and its structure**: The gene has dozens of exons, with some coding for folded triple alpha helices that connect the cytoskeleton with the sarcolemma and extracellular space. Mutations, specifically central exon deletions, lead to out-of-frame peptides and progressive degeneration.\\n\\n2. **Proposed therapy**: The solution involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n\\n3. **Exon skipping and the role of the structures**:\\n   - **Antisense**: This refers to a type of RNA that is complementary to the target mRNA sequence. In the context of the Morpholino therapy, the Morpholino acts as an antisense molecule, recognizing and binding to the out-of-frame exon.\\n   - **Lariat**: Lariat-shaped structures are involved in RNA splicing, particularly in the recognition of pre-mRNA splicing sites. They are part of the spliceosome complex, which assembles to facilitate the splicing process.\\n   - **PolyA tail**: The polyA tail is a polyadenylate tract at the 3' end of most eukaryotic mRNAs, involved in mRNA stability and transport. It's not directly involved in the splicing process.\\n   - **R-loops**: R-loops are structures that form during the processing of pre-mRNA, particularly in the splicing process. They are part of the spliceosome complex.\\n\\nConsidering the information, the **polyA tail (B)** is not directly involved in the splicing process, which is the focus of the proposed therapy involving exon skipping and in-frame joining.\\n\\nAnswer: B<|eot_id|>\", \"To answer this question, let's break down the process described:\\n\\n1. The problem: A gene with dozens of exons is mutated, leading to out-of-frame peptides and degenerative effects. The proposed solution involves delivering a Morpholino that targets the 5' end of the out-of-frame exon to prevent the spliceosome from binding and induce exon skipping and in-frame joining.\\n\\n2. The Morpholino works by recognizing the 5' end of the out-of-frame exon. This means it's targeting the RNA, specifically the pre-mRNA.\\n\\n3. Now, let's look at the options:\\n   - A) Lariat: This is a structure formed during splicing, specifically when the spliceosome binds to the pre-mRNA. Since the Morpholino prevents spliceosome binding, lariat structures are not directly involved in the proposed therapy.\\n   - B) PolyA tail: This is a feature of mRNA after splicing, not directly involved in the proposed therapy.\\n   - C) R-loops: These are involved in splicing, particularly in the process of removing introns. The Morpholino's action could indirectly affect R-loops, as preventing spliceosome binding could impact the formation of these structures.\\n   - D) Antisense: This is the type of RNA that the Morpholino is, designed to recognize the 5' end of the out-of-frame exon and prevent spliceosome binding.\\n\\nGiven the information, the structure not directly involved in the proposed therapy is the lariat, as the Morpholino's action is focused on preventing spliceosome binding, which is not directly related to the formation of lariat structures.\\n\\nAnswer: A<|eot_id|>\", \"To solve this question, let's analyze the given information step by step:\\n\\n1. The problem mentions a gene with dozens of exons, and the goal is to deliver a Morpholino to prevent the spliceosome from binding to an out-of-frame exon in pre-mRNA, leading to exon skipping and in-frame joining.\\n\\n2. The Morpholino binds to the 5' end of the out-of-frame exon, preventing the spliceosome from joining the out-of-frame exon to the rest of the pre-mRNA. This process involves the lariat structure, which is a characteristic feature of splicing reactions.\\n\\n3. The polyA tail is a feature of mature mRNA, not directly involved in splicing.\\n\\n4. R-loops are involved in RNA processing, including splicing, but they are not directly related to the mechanism of the Morpholino therapy.\\n\\n5. Antisense oligonucleotides, like Morpholinos, work by binding to specific sequences of pre-mRNA, preventing splicing or other RNA processing events.\\n\\nConsidering these points, the structure not involved in the proposed therapy is the polyA tail, which is a feature of mature mRNA, not pre-mRNA.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's analyze the given information and the options provided:\\n\\n1. The question describes a therapy using Morpholino molecules to prevent exon skipping by binding to the 5' end of out-of-frame exons in pre-mRNA. This is a method to correct the genetic defect by skipping the problematic exon and joining the remaining exons in an in-frame manner.\\n\\n2. The Morpholino molecules work by recognizing the 5' end of the out-of-frame exon, which means they are targeting a specific sequence in the pre-mRNA.\\n\\n3. The options provided are all structures related to RNA processing or modification, but we need to identify which one is NOT involved in the proposed therapy.\\n\\n- A) Lariat: This is a structure formed during RNA splicing, where a lariat-shaped RNA structure is created to remove introns from the pre-mRNA. This is not directly related to the proposed therapy, but it is involved in the broader context of RNA processing.\\n\\n- B) PolyA tail: This is a structure added to the 3' end of mRNA during post-transcriptional processing, which is not directly involved in the proposed therapy.\\n\\n- C) R-loops: These are formed during RNA processing and are involved in the regulation of gene expression, but they are not directly related to the proposed therapy.\\n\\n- D) Antisense: This is a type of RNA molecule that is complementary to the target mRNA sequence. The Morpholino molecules in the proposed therapy work by binding to the antisense strand, preventing the spliceosome from binding to the out-of-frame exon.\\n\\nGiven the information provided, the structure that is NOT involved in the proposed therapy is the polyA tail, as it is added to the 3' end of mRNA and is not directly involved in the recognition of the out-of-frame exon by the Morpholino molecules.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's analyze the mechanism of the proposed therapy and the structures involved:\\n\\n- The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n- This Morpholino prevents the binding of the spliceosome, which is a complex that assembles on the pre-mRNA and catalyzes the splicing process.\\n- As a result, the spliceosome skips the out-of-frame exon and joins the remaining exons in an in-frame manner.\\n\\nNow, let's examine the options:\\n\\nA) Lariat: A lariat is a type of RNA structure that can be formed during the splicing process. It is a characteristic structure of the intron that is removed during splicing. The Morpholino is targeting the 5' end of the out-of-frame exon, but this doesn't directly relate to lariat formation.\\n\\nB) PolyA tail: The polyA tail is a long sequence of adenine nucleotides added to the 3' end of the mRNA after transcription and before translation. It is not directly involved in the splicing process.\\n\\nC) R-loops: R-loops are a type of RNA-DNA hybrid structure that can form during the splicing process. They are involved in the recognition of the splice sites and the assembly of the spliceosome.\\n\\nD) Antisense: Antisense oligonucleotides, like Morpholino, are single-stranded RNA molecules that are complementary to the target RNA. They can bind to the target RNA and prevent the binding of other molecules, in this case, the spliceosome.\\n\\nGiven the context of the proposed therapy, the structure not involved is the polyA tail, as it is not directly related to the splicing process.\\n\\nAnswer: B<|eot_id|>\", \"To answer this question, let's break down the process described:\\n\\n1. The Morpholino binds to the 5' end of the out-of-frame exon in pre-mRNA.\\n2. This binding prevents the spliceosome from binding and attaching to the pre-mRNA.\\n3. As a result, the spliceosome skips the exon, creating an in-frame joining of the remaining exons.\\n\\nNow, let's examine the options given:\\n\\nA) Lariat: A lariat is a type of RNA structure that can be involved in RNA splicing. In the context of splicing, a lariat can form when the spliceosome creates a loop that can bind to the pre-mRNA, but this is not directly involved in the proposed therapy described.\\n\\nB) PolyA tail: The polyA tail is a structure that can be added to the 3' end of mRNA after splicing is complete. It's not directly involved in the proposed therapy.\\n\\nC) R-loops: R-loops are involved in RNA splicing, specifically in the process of exon skipping, as they can help to stabilize the RNA structure during the splicing process.\\n\\nD) Antisense: Antisense oligonucleotides, like Morpholinos, can bind to specific sequences on the pre-mRNA, preventing the splicing process. This is directly involved in the proposed therapy.\\n\\nGiven the context, the structure that is not involved in the proposed therapy is the polyA tail, as it is added after splicing is complete, not during the splicing process.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's break down the key elements of the proposed therapy and the structures involved:\\n\\n1. **Morpholino:** A synthetic oligonucleotide that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n2. **Spliceosome:** The complex that catalyzes the splicing of pre-mRNA to remove introns and join exons together.\\n3. **Exon skipping:** The process of skipping one or more exons during splicing, resulting in a shorter mRNA and protein product.\\n4. **In-frame joining:** The process of joining the remaining exons together to form a continuous coding sequence.\\n\\nNow, let's examine the structures mentioned in the options:\\n\\nA) **Lariat:** A hairpin-shaped structure that forms during the splicing process when a 5' splice site is missed. The lariat is involved in the recognition and removal of the skipped exon.\\n\\nB) **PolyA tail:** A polyadenylate tract added to the 3' end of mRNA after splicing. It's not directly involved in the splicing process or the recognition of the Morpholino.\\n\\nC) **R-loops:** A structure formed during the splicing process when a 5' splice site is missed. The R-loop can be involved in the recognition of the skipped exon.\\n\\nD) **Antisense:** A type of oligonucleotide that binds to the target mRNA, preventing the recognition of the spliceosome and promoting exon skipping. This is relevant to the proposed therapy.\\n\\nBased on the above analysis, the structure not involved in the proposed therapy is the polyA tail, as it's not directly related to the recognition of the skipped exon or the splicing process.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's break down the key elements of the proposed therapy and the structures involved.\\n\\n1. **Morpholino delivery**: Morpholinos are antisense oligonucleotides, which are short, synthetic strands of nucleotides that are designed to bind to the messenger RNA (mRNA) of a specific gene. They are used to treat genetic diseases by preventing the translation of the mRNA into a protein.\\n\\n2. **Recognition of the 5' end of the out-of-frame exon**: In the context of this therapy, the Morpholino binds to the 5' end of the out-of-frame exon in pre-mRNA. This binding prevents the spliceosome from adding the exon to the mRNA, effectively creating exon skipping and in-frame joining.\\n\\n3. **Spliceosome**: The spliceosome is a complex of proteins that recognizes the splice sites on the pre-mRNA and facilitates the splicing process, which involves removing introns and joining exons together.\\n\\nGiven these points, let's evaluate the options:\\n\\nA) **Lariat**: A lariat is a type of RNA structure that can form during the splicing process, but it's not directly involved in the proposed therapy. However, it's not the correct answer because lariat structures can form due to the splicing process being prevented by the Morpholino.\\n\\nB) **PolyA tail**: The polyA tail is a structure that can form on the 3' end of mRNA after splicing is complete. It's not directly involved in the proposed therapy.\\n\\nC) **R-loops**: R-loops are RNA-DNA hybrids that can form during the splicing process. They are involved in the recognition of splice sites and the splicing process itself, but the Morpholino's action is specifically targeting the pre-mRNA, not directly interacting with the spliceosome or R-loops.\\n\\nD) **Antisense**: Antisense oligonucleotides like Morpholinos are the correct mechanism of action for the proposed therapy, as they bind to the mRNA to prevent splicing.\\n\\nConsidering the specific mechanism of action of the Morpholino and the structures involved in splicing, the structure that is not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's analyze the information given and the options provided.\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA, preventing the binding of the spliceosome and creating exon skipping and in-frame joining. This process is known as antisense therapy.\\n\\nNow, let's examine the options:\\n\\nA) Lariat: Lariat structures are involved in the splicing process, specifically in the recognition of the 5' splice site by the spliceosome. The Morpholino binds to the 5' end of the out-of-frame exon, preventing the spliceosome from binding, which is consistent with the lariat structure being involved.\\n\\nB) PolyA tail: The polyA tail is added to the 3' end of the mRNA after splicing, not directly involved in the proposed therapy.\\n\\nC) R-loops: R-loops are involved in the splicing process, specifically in the recognition of the 3' splice site by the spliceosome. The Morpholino binds to the 5' end of the out-of-frame exon, which is consistent with the R-loop being involved.\\n\\nD) Antisense: Antisense therapy involves the delivery of a molecule that binds to the target RNA, in this case, the 5' end of the out-of-frame exon, preventing the spliceosome from binding and creating exon skipping and in-frame joining. This is the mechanism described in the question.\\n\\nGiven the above analysis, the structure not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|eot_id|>\", \"To answer this question, let's break down the information provided and analyze the options one by one.\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining. The Morpholino works by binding to the pre-mRNA, preventing the normal splicing process.\\n\\nA) Lariat: Lariat structures are involved in RNA splicing, specifically in the recognition of introns and the ligation of exons. They are a key part of the splicing process. However, in the context of this therapy, the Morpholino is preventing the spliceosome from binding, so lariat structures are not directly involved.\\n\\nB) PolyA tail: The polyA tail is a feature of eukaryotic mRNA that is added after splicing and is involved in mRNA stability and translation. However, it is not directly involved in the splicing process.\\n\\nC) R-loops: R-loops are structures formed during RNA splicing, where the RNA-DNA hybrid is unwound and the RNA strand is removed. They play a role in the recognition of introns and the splicing process.\\n\\nD) Antisense: Antisense oligonucleotides are used to bind to specific RNA sequences, in this case, the 5' end of the out-of-frame exon. They can prevent the binding of the spliceosome and induce exon skipping, which is the desired outcome of the proposed therapy.\\n\\nGiven the information provided, the structure not involved in the proposed therapy is the polyA tail, as it is not directly involved in the splicing process.\\n\\nAnswer: B<|eot_id|>\", 'To solve this question, let\\'s break down the process described:\\n\\n1. The Morpholino binds to the 5\\' end of the out-of-frame exon in pre-mRNA.\\n2. This binding prevents the spliceosome from proceeding.\\n3. As a result, the exon is skipped, and the spliceosome joins the remaining exons in an in-frame manner.\\n\\nNow, let\\'s analyze the options given in the context of the described mechanism:\\n\\nA) Lariat: Lariat structures are involved in RNA splicing. They are formed during the splicing process, when a part of the intron is left behind, creating a \"loop\" or \"lariat\" shape. However, this is a natural part of the splicing process, not the Morpholino\\'s mechanism.\\n\\nB) PolyA tail: The polyA tail is a feature of eukaryotic mRNA that helps in its stability and translation. It is not directly involved in the splicing process or the mechanism of the Morpholino.\\n\\nC) R-loops: R-loops are a type of RNA-DNA hybrid structure that can form during transcription and splicing. They are indeed involved in the splicing process and can be affected by the Morpholino\\'s action.\\n\\nD) Antisense: Antisense oligonucleotides, like Morpholino, work by binding to complementary RNA sequences. In this case, the Morpholino binds to the 5\\' end of the out-of-frame exon, preventing the spliceosome from binding and skipping the exon.\\n\\nConsidering the information provided and the role of each structure in the splicing process, the correct answer is:\\n\\nAnswer: B<|eot_id|>', \"To solve this question, let's break down the key points:\\n\\n1. The proposed therapy involves delivering a Morpholino that recognizes the 5' end of an out-of-frame exon in pre-mRNA.\\n2. The Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n3. The goal is to restore the normal gene expression by skipping the mutated exon.\\n\\nNow, let's analyze the options in relation to the proposed therapy:\\n\\nA) Lariat: A lariat is a type of RNA structure that can be involved in RNA splicing. In the context of this therapy, a lariat could potentially be involved in the recognition of the out-of-frame exon by the Morpholino.\\n\\nB) PolyA tail: A polyA tail is a feature of mature mRNA that helps in its stability and translation. While it's related to mRNA processing, it's not directly involved in the proposed therapy.\\n\\nC) R-loops: R-loops are RNA-DNA hybrids that can be involved in RNA splicing. They could potentially be involved in the recognition of the out-of-frame exon by the Morpholino.\\n\\nD) Antisense: Antisense oligonucleotides can be used to recognize specific RNA sequences, including the 5' end of the out-of-frame exon in pre-mRNA, and prevent splicing by binding to the spliceosome.\\n\\nConsidering the above points, the structure that is not involved in the proposed therapy is the polyA tail, as it's more related to mRNA stability and translation rather than splicing.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, we need to understand the mechanism of the proposed therapy. The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA, preventing the spliceosome from binding and creating exon skipping and in-frame joining. This process involves the recognition of the pre-mRNA by the Morpholino, which is an antisense oligonucleotide.\\n\\nA) lariat: A lariat is a structure involved in the splicing process, where the spliceosome forms a loop to hold the pre-mRNA in place, allowing the splicing to occur. The Morpholino's action does not directly involve lariat structures.\\n\\nB) polyA tail: The polyA tail is a feature of eukaryotic mRNA, which is involved in mRNA stability and translation. The Morpholino's action does not directly involve the polyA tail.\\n\\nC) R-loops: R-loops are a type of RNA-DNA hybrid structure that can form during the splicing process. The Morpholino's action can indirectly involve R-loops, as the recognition of the pre-mRNA by the Morpholino can lead to the formation of R-loops.\\n\\nD) antisense: The Morpholino is an antisense oligonucleotide, which is designed to recognize and bind to the pre-mRNA, preventing the spliceosome from binding and creating exon skipping and in-frame joining.\\n\\nConsidering the above information, the structure not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|eot_id|>\", \"To approach this question, let's break down the information provided and analyze the options given.\\n\\n1. The question describes a therapeutic approach using a Morpholino, which is a type of antisense oligonucleotide designed to bind to a specific sequence of RNA and prevent splicing. In this context, it targets the 5' end of an out-of-frame exon in pre-mRNA.\\n\\n2. The Morpholino works by preventing the binding of the spliceosome, which is a complex that assembles on the pre-mRNA to catalyze the splicing process. This results in exon skipping and in-frame joining, effectively creating a functional protein.\\n\\n3. Now, let's analyze the options given:\\n   - A) Lariat: Lariat structures are indeed involved in RNA splicing, where they form during the splicing process to hold the RNA together while the exons are joined. However, the Morpholino's action is to prevent spliceosome binding, not directly interacting with the lariat structure.\\n   - B) PolyA tail: The polyA tail is involved in mRNA stability and translation, but not directly involved in the splicing process.\\n   - C) R-loops: R-loops are indeed involved in RNA splicing, particularly in the removal of introns. They are a critical component of the splicing process and are indeed relevant to the mechanism of action of the Morpholino.\\n   - D) Antisense: Antisense oligonucleotides like Morpholino are directly involved in the proposed therapy, as they bind to the target RNA to prevent splicing.\\n\\nConsidering the information provided and the roles of each structure in the splicing process, the structure not directly involved in the proposed therapy is the polyA tail, as it is not directly involved in the splicing process.\\n\\nAnswer: B<|eot_id|>\", \"To answer this question, let's break down the information given and analyze each option in relation to the proposed therapy.\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining. This process is a form of RNA interference (RNAi) or antisense technology, where an antisense oligonucleotide (in this case, the Morpholino) binds to the target RNA (the out-of-frame exon) and prevents its inclusion in the mature mRNA, thus skipping it during splicing.\\n\\nA) Lariat: Lariat structures are involved in RNA splicing. They are formed by the RNA-binding proteins that recognize and bind to the 5' splice site of an intron, creating a loop-like structure. This structure is indeed involved in the splicing process, which is the opposite of what the Morpholino aims to prevent.\\n\\nB) PolyA tail: The polyA tail is a feature of the 3' untranslated region (UTR) of many eukaryotic mRNAs, not directly involved in the splicing process.\\n\\nC) R-loops: R-loops are a type of RNA structure that can form during the splicing process, particularly at the 5' splice site. They are indeed involved in the splicing process and can be targeted by splicing factors.\\n\\nD) Antisense: Antisense technology, as mentioned, is the mechanism by which the Morpholino works, recognizing and binding to the target RNA to prevent splicing.\\n\\nGiven the context of the question, the structure not involved in the proposed therapy is the polyA tail, as it is not directly involved in the splicing process.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's break down the key elements of the proposed therapy and the structures involved.\\n\\nThe proposed therapy involves using a Morpholino that recognizes the 5' end of an out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining. The goal is to create a functional protein by skipping the non-functional exons.\\n\\nNow, let's analyze the options:\\n\\nA) Lariat: Lariat structures are involved in RNA splicing. They are formed during the splicing process when a part of the pre-mRNA is removed, and the remaining parts are joined together. In this context, the Morpholino prevents the formation of a lariat by blocking the spliceosome's binding at the 5' end of the out-of-frame exon.\\n\\nB) PolyA tail: The polyA tail is a feature of eukaryotic mRNA that is added to the 3' end of the mRNA after splicing. It is not directly involved in the proposed therapy, which targets the 5' end of the out-of-frame exon.\\n\\nC) R-loops: R-loops are a type of RNA secondary structure that can form during the splicing process. They are involved in the recognition of splice sites and the formation of the lariat structure. The Morpholino could potentially interfere with R-loop formation, but this is not the most direct structure not involved in the proposed therapy.\\n\\nD) Antisense: Antisense oligonucleotides can bind to specific sequences of RNA, including pre-mRNA. In this case, the Morpholino acts as an antisense molecule that recognizes the 5' end of the out-of-frame exon, preventing the spliceosome's binding.\\n\\nConsidering the details of the proposed therapy, the structure not directly involved is the polyA tail, which is a feature of the mRNA after splicing, not a structure involved in the splicing process itself.\\n\\nAnswer: B<|eot_id|>\", \"To answer this question, let's analyze the proposed therapy and the structures involved.\\n\\nThe therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino binds to the pre-mRNA, preventing the binding of the spliceosome and creating exon skipping and in-frame joining. This process is a form of antisense therapy.\\n\\nNow, let's examine the structures involved in the process:\\n\\nA) Lariat: A lariat is a structure involved in the splicing process, where the spliceosome forms a loop to recognize and remove the intron. In this context, it's not directly involved in the proposed therapy.\\n\\nB) PolyA tail: The polyA tail is a feature of mature mRNA, not directly involved in the proposed therapy.\\n\\nC) R-loops: R-loops are a type of secondary structure formed during RNA splicing, and they are involved in the process.\\n\\nD) Antisense: Antisense therapy is the proposed method used in this scenario, where a Morpholino binds to the pre-mRNA to prevent the spliceosome from binding.\\n\\nConsidering the options, the structure not involved in the proposed therapy is the polyA tail, as it is a feature of mature mRNA, not directly involved in the splicing process.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's analyze the mechanism of the proposed therapy and the structures involved in RNA splicing and the delivery of Morpholino oligomers.\\n\\nThe Morpholino oligomer is designed to recognize the 5' end of the out-of-frame exon in pre-mRNA. This is an antisense approach, as it binds to the complementary sequence on the mRNA, preventing the spliceosome from binding and creating exon skipping and in-frame joining. This is a classic example of antisense therapy.\\n\\nNow, let's examine the options:\\n\\nA) Lariat: Lariat structures are involved in RNA splicing, specifically in the recognition and binding of the spliceosome to the pre-mRNA. They are not directly involved in the proposed therapy.\\n\\nB) PolyA tail: The polyA tail is a feature of eukaryotic mRNA, involved in mRNA stability and transport. It is not directly involved in the proposed therapy.\\n\\nC) R-loops: R-loops are formed during RNA splicing, where a loop of RNA forms a secondary structure that helps to stabilize the splice site. They are involved in the RNA splicing process, but not directly involved in the proposed therapy.\\n\\nD) Antisense: As mentioned earlier, antisense therapy is the mechanism used in the proposed treatment, where the Morpholino oligomer binds to the complementary sequence on the mRNA.\\n\\nConsidering the mechanism of the proposed therapy and the structures involved in RNA splicing, the structure not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's analyze the given information and the options one by one:\\n\\n1. The Morpholino molecule recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n2. It prevents the binding of the spliceosome, which is a complex that assembles on the pre-mRNA to facilitate splicing.\\n3. As a result, the Morpholino creates exon skipping and in-frame joining.\\n\\nGiven these points, we can evaluate the options:\\n\\nA) Lariat: A lariat is a structure formed by the spliceosome during the splicing process, which is indeed involved in the splicing process. However, the Morpholino's action is more related to preventing the spliceosome's binding, not directly forming a lariat.\\n\\nB) PolyA tail: The polyA tail is involved in mRNA stability and translation, not directly related to the splicing process.\\n\\nC) R-loops: R-loops are a structure that can be involved in the splicing process, particularly during the removal of introns.\\n\\nD) Antisense: Antisense molecules can bind to specific mRNA sequences, which can prevent the translation of that mRNA or the splicing process.\\n\\nConsidering the above points, the structure that is not involved in the proposed therapy is the polyA tail, as it is not directly involved in the splicing process.\\n\\nAnswer: B<|eot_id|>\", \"To approach this question, let's break down the key elements of the proposed therapy:\\n\\n1. **Target**: The Morpholino binds to the 5' end of the out-of-frame exon in pre-mRNA.\\n2. **Action**: The Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n\\nNow, let's analyze the options given:\\n\\nA) **Lariat**: A lariat is a structure involved in the splicing process, specifically in the recognition of introns and the removal of the intron. However, the Morpholino binds to the 5' end of the out-of-frame exon, not to an intron, so the lariat is not directly involved in this specific action.\\n\\nB) **PolyA tail**: The polyA tail is involved in the processing of pre-mRNA, particularly in the addition of a polyadenylate tail to the 3' end of the mature mRNA. This is not directly related to the proposed therapy.\\n\\nC) **R-loops**: R-loops are formed during the splicing process, specifically in the recognition of introns. Although not directly involved in the action of the Morpholino, they are part of the splicing machinery, which is affected by the Morpholino's action.\\n\\nD) **Antisense**: Antisense oligonucleotides, like Morpholinos, work by binding to the target RNA, in this case, the out-of-frame exon. This binding prevents the spliceosome from recognizing and processing the exon, leading to exon skipping and in-frame joining.\\n\\nConsidering the details of the proposed therapy, the structure that is not involved is the polyA tail, as it is not directly related to the action of the Morpholino on the pre-mRNA.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, we need to understand the mechanism of the proposed therapy and the structures involved.\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino molecule prevents the binding of the spliceosome, leading to exon skipping and in-frame joining. The spliceosome is a complex of proteins that catalyzes the splicing of pre-mRNA.\\n\\nNow, let's examine the options:\\n\\nA) Lariat: A lariat is a type of RNA structure that can be formed during splicing. It is a characteristic structure of the pre-mRNA after the removal of the intron. The Morpholino is binding to the 5' end of the out-of-frame exon, which is likely to be a lariat structure. Therefore, lariat is involved in the proposed therapy.\\n\\nB) PolyA tail: The polyA tail is a feature of mature mRNA, not directly involved in splicing. However, it is worth noting that the polyA tail can be added to the mRNA after splicing has occurred. This option is less directly related to the proposed therapy.\\n\\nC) R-loops: R-loops are RNA structures that are formed during splicing, particularly during the processing of pre-mRNA. They are involved in the recognition of splice sites and the formation of the lariat structure. R-loops are involved in the proposed therapy.\\n\\nD) Antisense: Antisense oligonucleotides, like Morpholinos, work by binding to the target RNA, in this case, the pre-mRNA. They can prevent the binding of proteins involved in splicing, leading to exon skipping and in-frame joining. Antisense is directly involved in the proposed therapy.\\n\\nConsidering the options, the structure that is not directly involved in the proposed therapy is the polyA tail. While it is related to mRNA processing, it is not directly involved in the recognition of the out-of-frame exon or the prevention of splicing.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's analyze the given information and the options one by one:\\n\\n- The Morpholino is designed to target the 5' end of the out-of-frame exon in pre-mRNA, preventing the spliceosome from binding and causing exon skipping.\\n- The spliceosome is a complex that assembles to remove introns from pre-mRNA and join exons together.\\n- Lariat structures are involved in the splicing process, specifically in the removal of introns.\\n- R-loops are involved in the recognition of the splice site by the spliceosome.\\n- Antisense oligonucleotides, like Morpholino, work by binding to the target mRNA, preventing the recognition of the spliceosome.\\n- The polyA tail is involved in mRNA stability and translation, not directly involved in the splicing process.\\n\\nGiven this information, the structure not involved in the proposed therapy is the polyA tail, as it is not directly related to the splicing process.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's break down the information given and analyze the options one by one:\\n\\n1. The question describes a scenario where a Morpholino is used to prevent the splicing of a pre-mRNA by recognizing the 5' end of an out-of-frame exon, thus skipping it and joining the remaining exons in an in-frame manner.\\n\\n2. The Morpholino works by preventing the binding of the spliceosome to the pre-mRNA, effectively blocking the splicing process.\\n\\n3. Now, let's look at the options provided in the context of RNA splicing and the mechanism of the Morpholino:\\n\\n   A) Lariat: In RNA splicing, lariat-shaped structures (also known as lariat intermediates) are indeed involved. They are formed during the splicing process when the pre-mRNA is processed. The Morpholino could interfere with the formation of these lariat structures, preventing splicing.\\n\\n   B) PolyA tail: The polyA tail is added to the mRNA after splicing has occurred. The Morpholino does not directly affect the polyA tail, as it acts before splicing.\\n\\n   C) R-loops: R-loops are a type of RNA structure that can form during the splicing process. The Morpholino could interfere with R-loop formation, preventing splicing.\\n\\n   D) Antisense: Antisense oligonucleotides can bind to specific sequences of RNA, including pre-mRNA, and can prevent splicing by blocking the recognition of the splice site by the spliceosome.\\n\\nGiven this information, the structure not directly involved in the proposed therapy is the polyA tail, as the Morpholino acts before the addition of the polyA tail.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, we need to understand the mechanism of the proposed therapy and the structures involved in RNA processing.\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA, preventing the binding of the spliceosome and creating exon skipping and in-frame joining. This is a form of antisense therapy, where an antisense oligonucleotide (the Morpholino) is designed to bind to a specific sequence of RNA, thereby preventing the splicing of the gene.\\n\\nNow, let's examine the options:\\n\\nA) Lariat: A lariat is a type of RNA structure that forms during the splicing process, specifically during the 5' splice site recognition. It is not directly involved in the proposed therapy.\\n\\nB) PolyA tail: The polyA tail is a feature of mature mRNA, which is added by the addition of RNA polymerase. While it's not directly involved in the proposed therapy, it's a feature of mature mRNA.\\n\\nC) R-loops: R-loops are formed during the splicing process, specifically during the 3' splice site recognition. They are involved in the proposed therapy, as the Morpholino binds to the 5' end of the out-of-frame exon, preventing the formation of the R-loop.\\n\\nD) Antisense: As mentioned earlier, the proposed therapy involves antisense oligonucleotides (Morpholinos), which bind to specific sequences of RNA to prevent splicing.\\n\\nBased on this analysis, the structure not involved in the proposed therapy is the lariat.\\n\\nAnswer: A<|eot_id|>\", \"To solve this question, let's break down the information provided and analyze the options given:\\n\\n- The question describes a therapy involving Morpholino molecules that target pre-mRNA to prevent exon skipping by blocking the spliceosome. This implies that the Morpholino is acting as an antisense oligonucleotide, which binds to the mRNA to prevent splicing.\\n\\n- The Morpholino binds to the 5' end of the out-of-frame exon, preventing the spliceosome from joining it to the rest of the mRNA. This is a characteristic of antisense technology, where an antisense oligonucleotide is designed to bind to a complementary sequence on the mRNA, preventing splicing or translation.\\n\\n- The lariat structure is involved in RNA splicing, where it forms a loop structure that holds the intron out of the way of the spliceosome. This is a crucial step in the splicing process, so it's involved in the proposed therapy.\\n\\n- The polyA tail is involved in mRNA stability and translation, but it's not directly involved in the splicing process. It's a feature of mature mRNA that protects it from degradation and enhances its translation efficiency.\\n\\n- R-loops are a type of RNA structure that can form during splicing, but the question is asking about the structure involved in the proposed therapy. The Morpholino's action is to prevent splicing, and R-loops are a product of splicing, not a factor in the proposed therapy.\\n\\nGiven this analysis, the structure not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|eot_id|>\", \"To answer this question, let's break down the process and the structures involved in the proposed therapy:\\n\\n1. **Spliceosome**: The spliceosome is a complex that assembles on the pre-mRNA and is responsible for removing introns and joining exons together to form a mature mRNA molecule. The Morpholino works by recognizing the 5' end of the out-of-frame exon in pre-mRNA and preventing the spliceosome from binding.\\n\\n2. **Lariat structure**: A lariat is a type of RNA secondary structure that can be formed by a spliced intron. In the context of the spliceosome, the lariat structure is involved in the recognition of the 5' splice site of an intron. The Morpholino, by binding to the 5' end of the out-of-frame exon, effectively blocks the formation of the lariat structure at that site, preventing the spliceosome from assembling.\\n\\n3. **PolyA tail**: The polyA tail is a long sequence of adenine nucleotides that is added to the 3' end of most eukaryotic mRNAs. It is involved in mRNA stability and translation. The polyA tail is not directly involved in the spliceosome's function or the proposed therapy.\\n\\n4. **R-loops**: R-loops are a type of RNA secondary structure that can form during the processing of pre-mRNA. They are involved in the recognition of the 5' splice site of an intron by the spliceosome. The Morpholino, by binding to the 5' end of the out-of-frame exon, could potentially interfere with the formation of R-loops at that site.\\n\\nGiven the information, the structure that is **not** involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's break down the process and the components involved in the proposed therapy.\\n\\nThe therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino molecule prevents the binding of the spliceosome, leading to exon skipping and in-frame joining. This process is aimed at correcting the genetic defect caused by central exon deletions.\\n\\nNow, let's examine the options provided:\\n\\nA) Lariat: A lariat is a type of RNA structure that can be involved in the splicing process, especially during the early stages of splicing. However, in the context of the proposed therapy, the Morpholino molecule is targeting the 5' end of the out-of-frame exon, not directly interacting with the lariat.\\n\\nB) PolyA tail: The polyA tail is a polyadenylation signal involved in the process of mRNA stabilization and nuclear export. While it's not directly involved in the splicing process, the polyA tail can be involved in mRNA processing and is often found at the 3' end of mature mRNA.\\n\\nC) R-loops: R-loops (RNA-DNA hybrids) are indeed involved in the splicing process, particularly in the recognition of the 5' splice site by the spliceosome. They can interact with the spliceosome and are crucial for the splicing process.\\n\\nD) Antisense: Antisense oligonucleotides are short RNA or DNA molecules that are complementary to the target mRNA sequence. In this context, the Morpholino molecule acts similarly, recognizing the 5' end of the out-of-frame exon and preventing the spliceosome from binding, which is a form of antisense action.\\n\\nConsidering the above information, the structure not involved in the proposed therapy is the polyA tail, as it's not directly involved in the recognition of the 5' end of the out-of-frame exon or the splicing process itself.\\n\\nAnswer: B<|eot_id|>\", \"To answer this question, let's analyze the information provided and the options given.\\n\\nThe Morpholino molecule is designed to recognize the 5' end of the out-of-frame exon in pre-mRNA, prevent the binding of the spliceosome, and create exon skipping and in-frame joining. This is a type of RNA interference (RNAi) therapy, where the Morpholino binds to the target RNA, preventing its splicing and allowing for the skipping of the exon.\\n\\nLet's examine the options:\\n\\nA) Lariat: This is a structure formed during splicing, where the lariat arm of the spliceosome binds to the branch point of the intron. This is indeed involved in the splicing process.\\n\\nB) PolyA tail: This is a polyadenylate tail added to the 3' end of the mature mRNA, which is not directly involved in the proposed therapy.\\n\\nC) R-loops: These are RNA-DNA hybrids that form during the splicing process, where the RNA strand is complementary to the DNA template. This is indeed involved in the splicing process.\\n\\nD) Antisense: This is a type of RNA molecule that is complementary to the target mRNA and can bind to it, preventing its translation or splicing. This is indeed involved in the proposed therapy.\\n\\nConsidering the information provided, the structure not involved in the proposed therapy is the polyA tail, which is a feature of mature mRNA, not directly related to the splicing process.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's break down the key elements of the proposed therapy and analyze each option:\\n\\n1. The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n2. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n3. The goal is to create a functional protein by joining the skipped exons in an in-frame manner.\\n\\nNow, let's examine each option in relation to the proposed therapy:\\n\\nA) Lariat: Lariat structures are involved in RNA splicing, particularly in the recognition of the 5' splice site. The Morpholino could potentially interact with the lariat structure to prevent the spliceosome from binding and to facilitate exon skipping.\\n\\nB) PolyA tail: The polyA tail is involved in the regulation of mRNA stability and translation, but it is not directly involved in the splicing process.\\n\\nC) R-loops: R-loops are a type of RNA structure that can form during splicing, particularly at the 5' splice site. The Morpholino could potentially interact with the R-loop to prevent the spliceosome from binding.\\n\\nD) Antisense: Antisense oligonucleotides are a class of molecules that can recognize specific sequences of RNA and prevent their splicing or translation.\\n\\nConsidering the mechanism of the proposed therapy, all options A, C, and D are involved in RNA splicing or recognition of RNA sequences. However, option B, the polyA tail, is not directly involved in the splicing process and is primarily related to mRNA stability and translation.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, we need to understand the mechanism of the proposed therapy. The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining. The spliceosome is a complex that assembles on the pre-mRNA and catalyzes the splicing process. The Morpholino acts as an antisense oligonucleotide, binding to the pre-mRNA and preventing the spliceosome from interacting with the out-of-frame exon.\\n\\nNow, let's evaluate the options:\\n\\nA) Lariat: The lariat structure is a characteristic of the pre-mRNA splicing process, where the intron is removed and the exons are joined. The Morpholino could potentially interact with the lariat structure.\\n\\nB) PolyA tail: The polyA tail is a feature of mature mRNA, which is not directly involved in the splicing process. However, it is a feature of the mature mRNA that is produced after splicing.\\n\\nC) R-loops: R-loops are a type of RNA secondary structure that forms during the splicing process. The Morpholino could potentially interact with R-loops.\\n\\nD) Antisense: Antisense oligonucleotides, like the Morpholino, bind to complementary RNA sequences, which is consistent with the proposed therapy.\\n\\nGiven the above analysis, the structure that is not involved in the proposed therapy is the polyA tail, as it is a feature of mature mRNA and not directly involved in the splicing process.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, we need to understand the proposed therapy and the structures involved.\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining. This is a form of antisense therapy, where a molecule (antisense oligonucleotide) is used to bind to the pre-mRNA and prevent splicing.\\n\\nNow, let's examine the options:\\n\\nA) Lariat: Lariat structures are involved in the splicing process, where they form a loop that holds the intron in place until the spliceosome can bind and remove it. The Morpholino in the proposed therapy prevents the spliceosome from binding, so the lariat is not involved in the proposed therapy.\\n\\nB) PolyA tail: The polyA tail is a structure that is added to the 3' end of the mRNA after splicing. It is not directly involved in the proposed therapy, which targets the 5' end of the out-of-frame exon.\\n\\nC) R-loops: R-loops are a type of RNA structure that can form during the splicing process. They are not directly involved in the proposed therapy, but they are related to the splicing process.\\n\\nD) Antisense: Antisense therapy is the proposed method of delivering a Morpholino to prevent splicing and create exon skipping.\\n\\nBased on the above analysis, the structure that is not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|eot_id|>\", \"To approach this question, let's break down the key elements of the proposed therapy:\\n\\n1. The therapy involves delivering a Morpholino molecule that recognizes the 5' end of an out-of-frame exon in pre-mRNA.\\n2. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n3. The goal is to create a normal, in-frame protein despite the presence of a large number of exons.\\n\\nGiven these points, let's analyze the options:\\n\\nA) Lariat: A lariat is a type of RNA structure involved in the splicing process. In the context of the spliceosome, a lariat can form when a pre-mRNA molecule is spliced out of frame, and the remaining part of the RNA is retained. The Morpholino, by preventing the spliceosome from binding, could potentially prevent the formation of this lariat structure.\\n\\nB) PolyA tail: The polyA tail is a feature of mature mRNA that helps with mRNA stability and translation. However, it is not directly involved in the splicing process or the proposed therapy.\\n\\nC) R-loops: R-loops are RNA structures that can form during the splicing process. They are involved in the recognition of the splice site and the joining of the exons. The Morpholino could potentially interfere with the formation of R-loops.\\n\\nD) Antisense: Antisense molecules are known to bind to specific RNA sequences, including those involved in splicing. In this case, the Morpholino acts as an antisense molecule, binding to the 5' end of the out-of-frame exon to prevent spliceosome binding.\\n\\nConsidering the options, the structure that is not involved in the proposed therapy is the polyA tail, as it is not directly involved in the splicing process.\\n\\nAnswer: B<|eot_id|>\", \"To approach this question, let's break down the key elements of the proposed therapy:\\n\\n1. The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n2. The Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n3. The goal is to create a therapeutic approach to address progressive degenerative organ waste caused by central exon deletions.\\n\\nNow, let's examine the options provided:\\n\\nA) Lariat: Lariat structures are involved in RNA splicing, specifically in the recognition and binding of the pre-mRNA by the spliceosome. The Morpholino's action of preventing spliceosome binding could be related to lariat structures.\\n\\nB) PolyA tail: The polyA tail is a feature of mature mRNA, not directly involved in the splicing process. It's a polyadenylation signal that protects the mRNA from degradation and helps in its transport out of the nucleus.\\n\\nC) R-loops: R-loops are indeed involved in RNA splicing, particularly in the recognition of pre-mRNA by the spliceosome. They are crucial for the splicing process.\\n\\nD) Antisense: Antisense oligonucleotides, like the Morpholino, can recognize specific sequences of RNA and interfere with their function, in this case, preventing spliceosome binding.\\n\\nGiven the information, the structure not directly involved in the proposed therapy is the polyA tail, as it is not directly related to the recognition or splicing of pre-mRNA by the spliceosome.\\n\\nAnswer: B<|eot_id|>\", \"To answer this question, let's break down the process described:\\n\\n1. The gene has dozens of exons, and a central exon is crucial for coding a folded triple helical repeat. Mutations in this exon lead to out-of-frame peptides and degenerative issues.\\n2. The proposed therapy involves delivering a Morpholino that targets the 5' end of the out-of-frame exon in pre-mRNA.\\n3. The Morpholino prevents the spliceosome from binding, leading to exon skipping and in-frame joining.\\n\\nNow, let's analyze the options:\\n\\nA) Lariat: Lariat structures are involved in RNA splicing, specifically in the recognition of introns and the removal of the intron from the pre-mRNA. The Morpholino, by preventing spliceosome binding, effectively acts as a lariat to skip the out-of-frame exon.\\n\\nB) PolyA tail: The polyA tail is a feature of mature mRNA, involved in mRNA stability and translation. While it is not directly involved in the splicing process, it's not relevant to the proposed therapy.\\n\\nC) R-loops: R-loops are formed during RNA splicing, where a short RNA stem-loop structure is formed on the pre-mRNA. This is indeed involved in the splicing process, and the Morpholino's action could be seen as interfering with an R-loop structure.\\n\\nD) Antisense: Antisense oligonucleotides can bind to specific RNA sequences, including the 5' end of the out-of-frame exon, preventing the spliceosome from binding and leading to exon skipping. This matches the proposed mechanism of the Morpholino.\\n\\nConsidering the options, the structure not involved in the proposed therapy is the polyA tail, as it is not directly involved in the splicing process.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's break down the key elements of the proposed therapy:\\n\\n1. The goal is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n2. The Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n3. The therapy aims to create a continuous, functional gene product despite the presence of missing exons.\\n\\nNow, let's analyze the options in relation to the proposed therapy:\\n\\nA) Lariat: This is a structure formed during splicing, which is relevant to the process the Morpholino aims to disrupt. The spliceosome forms a lariat to remove the intron, and the Morpholino's action affects this process. So, it's involved in the proposed therapy.\\n\\nB) PolyA tail: This is a feature of mature mRNA, not directly involved in splicing or the proposed therapy's mechanism. The Morpholino's action is focused on preventing spliceosome binding, not modifying the mRNA's polyA tail.\\n\\nC) R-loops: These are formed during splicing and can interact with the spliceosome. The Morpholino's action could indirectly affect R-loops, as it prevents spliceosome binding, which is necessary for the formation of R-loops. So, R-loops are involved in the proposed therapy.\\n\\nD) Antisense: This refers to the direction of the Morpholino's action, which is complementary to the mRNA sequence. Antisense molecules can recognize and bind to specific mRNA sequences, including the 5' end of the out-of-frame exon, making them involved in the proposed therapy.\\n\\nGiven the above analysis, the structure not involved in the proposed therapy is the polyA tail, as it's not directly related to the splicing process affected by the Morpholino.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's analyze the given information step by step:\\n\\n1. The question describes a gene with dozens of exons, where mutations lead to progressive degenerative organ waste. The proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n\\n2. The Morpholino prevents the binding of the spliceosome and creates exon skipping and in-frame joining. This implies that the Morpholino is acting as an antisense oligonucleotide, which is a type of RNA molecule that is complementary to the target mRNA.\\n\\n3. Now, let's evaluate the options:\\n   - A) Lariat: A lariat is a type of RNA structure that is involved in the splicing process, where a branch point is created in the intron and a loop is formed. It is not directly involved in the proposed therapy.\\n   - B) PolyA tail: The polyA tail is a polyadenylate tract at the 3' end of eukaryotic mRNAs, which is involved in mRNA stability and translation. It is not directly involved in the proposed therapy.\\n   - C) R-loops: R-loops are RNA-DNA hybrids that form during the splicing process. They are involved in the regulation of splicing, but not directly involved in the proposed therapy.\\n   - D) Antisense: Antisense oligonucleotides, like the Morpholino, are complementary to the target mRNA and are involved in the proposed therapy.\\n\\nBased on the analysis, the structure that is not involved in the proposed therapy is the lariat.\\n\\nAnswer: A<|eot_id|>\", \"To solve this question, let's break down the key elements of the proposed therapy and the structures involved:\\n\\n1. The therapy involves delivering a Morpholino molecule that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n2. This Morpholino prevents the binding of the spliceosome, which is a complex that assembles to remove introns from pre-mRNA.\\n3. The Morpholino creates exon skipping, which means that the out-of-frame exon is not included in the final mRNA transcript.\\n4. As a result, the mRNA transcript is joined in-frame, which means that the remaining exons are correctly spliced together.\\n\\nNow, let's consider the structures involved in the proposed therapy:\\n\\nA) Lariat: A lariat is a type of RNA secondary structure that can form during the splicing process. It is a characteristic of the pre-mRNA that is being spliced. Therefore, the Morpholino is likely to interact with the lariat structure.\\n\\nB) PolyA tail: The polyA tail is a feature of mature mRNA, not pre-mRNA. It is a long sequence of adenine nucleotides that is added to the 3' end of the mRNA after splicing. The Morpholino is targeting the 5' end of the out-of-frame exon, not the 3' end, so it is not likely to interact with the polyA tail.\\n\\nC) R-loops: R-loops are a type of RNA secondary structure that can form during the splicing process. They are involved in the recognition of splice sites and the assembly of the spliceosome. The Morpholino is likely to interact with the R-loop structure.\\n\\nD) Antisense: Antisense RNA is a type of RNA that is complementary to a specific mRNA sequence. The Morpholino is an antisense molecule that recognizes the 5' end of the out-of-frame exon, so it is likely to interact with an antisense structure.\\n\\nBased on this analysis, the structure that is not involved in the proposed therapy is the polyA tail, which is a feature of mature mRNA.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, we need to understand the mechanism of the proposed therapy and the structures involved.\\n\\nThe therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, which is a complex that assembles to remove the out-of-frame exon and join the remaining exons in an in-frame manner. The goal is to create exon skipping and in-frame joining.\\n\\nNow, let's examine the options:\\n\\nA) Lariat: The spliceosome forms a lariat-like structure during the splicing process, which is not relevant to the proposed therapy.\\n\\nB) PolyA tail: The polyA tail is involved in mRNA stabilization and is not directly related to the proposed therapy.\\n\\nC) R-loops: R-loops are formed during the splicing process and are involved in the recognition of the pre-mRNA by the spliceosome, which is relevant to the proposed therapy.\\n\\nD) Antisense: Antisense oligonucleotides like Morpholinos are used to recognize and bind to specific sequences in pre-mRNA, preventing the binding of the spliceosome and promoting exon skipping, which is the basis of the proposed therapy.\\n\\nConsidering the mechanism of the proposed therapy, the structure not involved in this process is the polyA tail.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, we need to understand the mechanism of the proposed therapy. The therapy involves delivering a Morpholino oligonucleotide that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino binds to the pre-mRNA, preventing the binding of the spliceosome, which is a complex that assembles on the pre-mRNA to catalyze splicing. By preventing spliceosome binding, the Morpholino causes exon skipping, and in-frame joining of the remaining exons. This results in the creation of a normal-length protein.\\n\\nNow, let's examine the options:\\n\\nA) Lariat: A lariat is a type of RNA structure that is formed during splicing. It is a characteristic feature of the splicing process. Therefore, it is involved in the proposed therapy.\\n\\nB) PolyA tail: A polyA tail is a feature of mature mRNA, not directly involved in the splicing process. It is added to the 3' end of the mRNA after splicing is complete. This option is not directly involved in the proposed therapy.\\n\\nC) R-loops: R-loops are RNA-DNA hybrids that form during the splicing process. They are involved in the recognition of the splice site by the spliceosome. Therefore, they are involved in the proposed therapy.\\n\\nD) Antisense: Antisense oligonucleotides like Morpholino work by binding to specific sequences of RNA, typically on the 5' or 3' untranslated region, to regulate gene expression. In this case, the Morpholino binds to the 5' end of the out-of-frame exon, preventing spliceosome binding. Therefore, antisense is involved in the proposed therapy.\\n\\nBased on the analysis, the correct answer is:\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's break it down step by step:\\n\\n1. The question is about a therapy that involves a Morpholino molecule to treat a genetic disorder caused by mutations in a large gene. The Morpholino molecule recognizes the 5' end of an out-of-frame exon in pre-mRNA and prevents the spliceosome from binding, resulting in exon skipping and in-frame joining.\\n\\n2. The key concept here is that the Morpholino molecule is binding to the pre-mRNA, which means it is interacting with the RNA molecule before it is spliced.\\n\\n3. Now, let's look at the options:\\n   - A) Lariat: This is a structure involved in the splicing process, specifically in the recognition of the branch point of the pre-mRNA. It is involved in the spliceosome's activity.\\n   - B) PolyA tail: This is a feature of the 3' end of the mRNA, not directly involved in the splicing process.\\n   - C) R-loops: These are involved in the splicing process, specifically in the recognition of the branch point of the pre-mRNA.\\n   - D) Antisense: This refers to a type of RNA that is complementary to the target RNA, which in this case is the pre-mRNA. Antisense RNA molecules can bind to specific regions of the target RNA, including the 5' end of the out-of-frame exon.\\n\\nConsidering the information above, the structure that is NOT involved in the proposed therapy is the polyA tail, as it is not directly involved in the splicing process.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's break down the key elements:\\n\\n1. The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n2. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n3. The goal is to create a functional protein by skipping certain exons and joining the remaining ones in a way that produces a complete, functional protein.\\n\\nGiven these points, let's analyze the options:\\n\\nA) Lariat: A lariat is a type of RNA structure that can form during the splicing process. In the context of this therapy, the Morpholino binds to the 5' end of the out-of-frame exon, preventing the lariat structure from forming, which is necessary for the normal splicing process. Therefore, the lariat is involved in the proposed therapy.\\n\\nB) PolyA tail: A polyA tail is a feature of mature mRNA that helps in its export from the nucleus and stability in the cytoplasm. While it is not directly involved in the splicing process, it is a feature of mature mRNA. However, the question is focused on the splicing process, not the post-splicing features of mRNA.\\n\\nC) R-loops: R-loops are a type of RNA structure that can form during the splicing process, particularly during the 5' splice site recognition. They are involved in the recognition of the splice sites and the initiation of the splicing process. Therefore, R-loops are involved in the proposed therapy.\\n\\nD) Antisense: Antisense oligonucleotides are a class of molecules that can bind to specific RNA sequences, including the target mRNA. In this case, the Morpholino is an antisense oligonucleotide that binds to the 5' end of the out-of-frame exon, preventing the spliceosome from binding and leading to exon skipping. Therefore, antisense is involved in the proposed therapy.\\n\\nBased on the analysis, the structure that is not directly involved in the proposed therapy is the polyA tail, as it is a feature of mature mRNA and not directly involved in the splicing process.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, we need to understand the concept of Morpholino therapy and the structures involved in RNA processing.\\n\\nMorpholino therapy involves delivering a molecule that recognizes the 5' end of an out-of-frame exon in pre-mRNA, preventing the binding of the spliceosome and creating exon skipping and in-frame joining. This is a type of antisense therapy, where the Morpholino oligonucleotide is complementary to the target RNA sequence.\\n\\nThe correct structures involved in the proposed therapy are:\\n\\n- Antisense (D): the Morpholino oligonucleotide is an antisense molecule that binds to the target RNA sequence.\\n- R-loops (C): R-loops are involved in the RNA splicing process, and the Morpholino therapy disrupts this process by preventing the spliceosome from binding to the target exon.\\n- PolyA tail (B): the polyA tail is a feature of mature mRNA, and while it's not directly involved in the RNA splicing process, it's a feature of the mature mRNA that the Morpholino therapy aims to affect by creating in-frame joining.\\n\\nThe lariat (A) is a structure involved in the RNA splicing process, specifically in the 2' splice site recognition by the spliceosome. However, it's not the structure that is disrupted by the Morpholino therapy, as the Morpholino binds to the 5' end of the out-of-frame exon, preventing the spliceosome from binding to the target exon.\\n\\nAnswer: A<|eot_id|>\", \"To approach this question, let's break down the information provided and analyze the options given.\\n\\n1. **Gene structure and function**: The gene in question codes for a protein with folded triple helical repeats that connect the cytoskeleton with the sarcolemma and extracellular space. The central exons are crucial for this function.\\n\\n2. **Effect of mutations**: Mutations, specifically central exon deletions, lead to out-of-frame peptides, which results in progressive degenerative organ waste.\\n\\n3. **Therapeutic approach**: The proposed solution involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n\\n4. **Analysis of options**:\\n   - A) Lariat: Lariat structures are involved in RNA splicing, particularly in the recognition of introns and the joining of exons. The Morpholino could potentially interact with lariat structures to prevent exon skipping.\\n   - B) PolyA tail: The polyA tail is involved in mRNA stability and transport but is not directly involved in the splicing process. It's not directly related to the proposed therapeutic approach.\\n   - C) R-loops: R-loops are crucial in the splicing process, as they are involved in the recognition of introns and the joining of exons. The Morpholino could interact with R-loops to prevent exon skipping.\\n   - D) Antisense: Antisense oligonucleotides are used to bind to specific sequences in mRNA and can prevent gene expression. In this context, antisense could potentially interfere with the binding of the Morpholino to its target sequence.\\n\\nConsidering the information provided, the structure not directly involved in the proposed therapy is the polyA tail, as it is involved in mRNA stability and transport rather than the splicing process.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's break down the key elements of the proposed therapy:\\n\\n1. **Morpholino**: A synthetic oligonucleotide that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n2. **Prevents binding of the spliceosome**: The Morpholino binds to the pre-mRNA, blocking the spliceosome from accessing the out-of-frame exon.\\n3. **Creates exon skipping and in-frame joining**: By blocking the spliceosome, the out-of-frame exon is skipped, and the remaining exons are joined in an in-frame manner.\\n\\nNow, let's examine the options in the context of RNA splicing and the proposed therapy:\\n\\nA) **Lariat**: A lariat structure is involved in the splicing process, where the lariat structure is formed by the spliceosome to recognize and remove the intron. However, the Morpholino does not directly interact with the lariat structure.\\n\\nB) **PolyA tail**: The polyA tail is a feature of mature mRNA, not directly involved in the splicing process. However, it's worth noting that the Morpholino binds to the pre-mRNA before splicing occurs, so it's not directly interacting with the polyA tail.\\n\\nC) **R-loops**: R-loops are formed during the splicing process, where a RNA-DNA hybrid is formed. The Morpholino could potentially interact with the pre-mRNA before the R-loop is formed, affecting the splicing process.\\n\\nD) **Antisense**: Antisense oligonucleotides like Morpholino work by binding to the complementary sequence on the pre-mRNA, preventing the splicing process. Therefore, the Morpholino is an antisense oligonucleotide.\\n\\nGiven the context, the structure not directly involved in the proposed therapy is the **polyA tail** (B), as it's a feature of mature mRNA and not directly affected by the Morpholino.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's break down the information provided and analyze each option step by step:\\n\\n1. The question describes a therapy involving a Morpholino that recognizes the 5' end of an out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n\\n2. The spliceosome is a complex that assembles at the splice site to catalyze the splicing of pre-mRNA. The Morpholino blocks its binding, which is a key step in the splicing process.\\n\\n3. The question asks which structure is NOT involved in the proposed therapy.\\n\\nNow, let's analyze the options:\\n\\nA) Lariat: Lariat structures are indeed involved in the splicing process. They form during the splicing process when the pre-mRNA is cleaved and joined. The Morpholino could potentially interfere with the formation of lariat structures by preventing the spliceosome from binding.\\n\\nB) PolyA tail: The polyA tail is added to the 3' end of pre-mRNA after splicing. The Morpholino's action is focused on preventing splicing, not on the polyA tail.\\n\\nC) R-loops: R-loops are formed during the splicing process, specifically during the removal of the intron. The Morpholino's action could potentially interfere with R-loop formation.\\n\\nD) Antisense: Antisense oligonucleotides like Morpholinos are used to target specific sequences of pre-mRNA, preventing the binding of the spliceosome. This matches the described mechanism of action.\\n\\nGiven the above analysis, the structure that is NOT involved in the proposed therapy is the polyA tail, as the Morpholino's action is focused on preventing splicing, not on the addition of the polyA tail.\\n\\nAnswer: B<|eot_id|>\", \"To answer this question, let's analyze the information provided and the options given.\\n\\nThe Morpholino oligonucleotide is designed to recognize the 5' end of the out-of-frame exon in pre-mRNA and prevent the binding of the spliceosome, resulting in exon skipping and in-frame joining. This process is a form of RNA interference (RNAi) therapy.\\n\\nNow, let's examine each option:\\n\\nA) Lariat: Lariat structures are involved in the splicing process, specifically in the recognition of the 5' splice site by the spliceosome. The Morpholino oligonucleotide is designed to recognize the 5' end of the out-of-frame exon, which is the lariat structure.\\n\\nB) PolyA tail: The polyA tail is a polyadenylate tract at the 3' end of the mature mRNA, involved in mRNA stability and translation. It is not directly involved in the splicing process.\\n\\nC) R-loops: R-loops are formed during the splicing process, specifically during the removal of introns from the pre-mRNA. The Morpholino oligonucleotide is designed to interfere with the splicing process by preventing the binding of the spliceosome.\\n\\nD) Antisense: Antisense oligonucleotides are a type of RNAi therapy that works by binding to specific sequences of RNA, including pre-mRNA. The Morpholino oligonucleotide is a type of antisense oligonucleotide designed to recognize the 5' end of the out-of-frame exon.\\n\\nConsidering the mechanisms involved in the proposed therapy, the structure not involved in the process is the polyA tail.\\n\\nAnswer: B<|eot_id|>\", \"To approach this question, let's break down the key elements of the proposed therapy:\\n\\n1. **Morpholino**: A type of antisense oligonucleotide that recognizes the 5' end of the out-of-frame exon in pre-mRNA. Antisense oligonucleotides work by binding to the target mRNA, preventing its splicing and thus skipping the exon that causes the disease.\\n\\n2. **Prevents binding of the spliceosome**: The spliceosome is a complex that assembles on the pre-mRNA to catalyze the splicing process. By preventing the spliceosome from binding, the Morpholino effectively prevents the splicing of the out-of-frame exon.\\n\\n3. **Creates exon skipping and in-frame joining**: This is the therapeutic effect of the Morpholino, leading to a normal protein being produced instead of the aberrant, out-of-frame peptide.\\n\\n4. **Several missing exons are well tolerated by an organism**: This indicates that the organism can still produce functional proteins even if some exons are missing, as long as the remaining exons are in frame.\\n\\nGiven these points, let's analyze the options:\\n\\nA) **Lariat**: A lariat is a type of RNA secondary structure that can be involved in RNA splicing. It's a plausible structure involved in the spliceosome's activity.\\n\\nB) **PolyA tail**: A polyA tail is a feature of eukaryotic mRNA that helps stabilize the mRNA and facilitate its translation. It's not directly involved in the splicing process but is related to mRNA processing.\\n\\nC) **R-loops**: R-loops are a type of RNA secondary structure that can be involved in various RNA processing events, including splicing.\\n\\nD) **Antisense**: This is the type of oligonucleotide mentioned in the question as the therapeutic agent. It's directly involved in the proposed therapy.\\n\\nConsidering these points, the structure not directly involved in the proposed therapy is the **polyA tail**. The polyA tail is related to mRNA stability and translation but is not directly involved in the splicing process.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's break down the key elements of the proposed therapy and the structures listed in the options:\\n\\n1. **Proposed Therapy**: The therapy involves using a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining. This is a form of antisense therapy, where a molecule (the Morpholino) binds to the target mRNA to prevent splicing.\\n\\n2. **Exon Skipping**: Exon skipping is a process where a spliceosome skips over a particular exon during RNA splicing. This is achieved by the Morpholino in the proposed therapy, which binds to the 5' end of the out-of-frame exon, preventing the spliceosome from attaching and skipping the exon.\\n\\nNow, let's examine the options:\\n\\nA) **Lariat**: A lariat is a type of RNA structure that can be formed by the spliceosome during the splicing process. It's a characteristic structure that results from the removal of an intron. In the context of this therapy, the Morpholino prevents the formation of the lariat by blocking the spliceosome's attachment to the out-of-frame exon.\\n\\nB) **PolyA tail**: A polyA tail is a polyadenylate tail added to the 3' end of a mature mRNA molecule. This is a normal part of eukaryotic mRNA processing and is not directly involved in the proposed therapy.\\n\\nC) **R-loops**: R-loops are RNA-DNA hybrid structures that can form during the splicing process. They are involved in the recognition of the splice site by the spliceosome. The Morpholino in the proposed therapy might indirectly affect R-loops by preventing the spliceosome's attachment, but it is not a direct participant in the proposed mechanism.\\n\\nD) **Antisense**: Antisense therapy, as described in the proposed solution, involves using a molecule (Morpholino) that binds to the target mRNA to prevent splicing. This is a correct description of the proposed therapy.\\n\\nConsidering the above explanations, the structure that is **not involved in the proposed therapy** is the polyA tail, as it is a feature of mature mRNA and not directly involved in the splicing process affected by the Morpholino.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's break down the key elements of the proposed therapy and the structures mentioned:\\n\\n1. The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n2. This Morpholino prevents the binding of the spliceosome, which is a complex that assembles at the 5' splice site to initiate splicing.\\n3. The goal is to create exon skipping and in-frame joining, allowing the inclusion of the skipped exon in the final mRNA.\\n\\nNow, let's examine the structures mentioned in the options:\\n\\nA) Lariat: This is a structure formed by the 5' exon during splicing, when the pre-mRNA is cleaved at the 5' splice site and the 3' exon is joined to the 5' exon, creating a loop. This structure is involved in the splicing process and is targeted by the Morpholino.\\n\\nB) PolyA tail: This is a polyadenylate tract added to the 3' end of mRNA after splicing. It's not directly involved in the splicing process or the proposed therapy.\\n\\nC) R-loops: These are RNA-DNA hybrids formed during the splicing process when the spliceosome forms a complex with the pre-mRNA and the template DNA. R-loops are involved in the splicing process and can be affected by the Morpholino.\\n\\nD) Antisense: This refers to a type of RNA that is complementary to the target mRNA sequence. Antisense oligonucleotides, like the Morpholino, can bind to specific sequences in pre-mRNA, preventing the splicing process.\\n\\nConsidering the above explanations, the structure not involved in the proposed therapy is the polyA tail, as it is not directly involved in the splicing process or the mechanism of action of the Morpholino.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's analyze the mechanism of the proposed therapy:\\n\\nThe Morpholino molecule recognizes the 5' end of the out-of-frame exon in pre-mRNA and prevents the binding of the spliceosome, leading to exon skipping and in-frame joining. This means that the Morpholino is binding to the pre-mRNA before splicing occurs.\\n\\nNow, let's analyze the options:\\n\\nA) Lariat: A lariat is a structure involved in the splicing process, specifically in the recognition of the branch point of the intron. It is not directly involved in the proposed therapy.\\n\\nB) PolyA tail: The polyA tail is a feature of mature mRNA that helps in its stability and translation. It is not directly involved in the splicing process.\\n\\nC) R-loops: R-loops are a structure formed during the splicing process, specifically in the recognition of the branch point of the intron. They are involved in the proposed therapy.\\n\\nD) Antisense: Antisense oligonucleotides like Morpholino bind to the pre-mRNA, preventing the recognition of the spliceosome, which is involved in the proposed therapy.\\n\\nBased on this analysis, the structure that is not involved in the proposed therapy is:\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's analyze the information provided and the options given.\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining. The Morpholino works by binding to the pre-mRNA, preventing the normal splicing process.\\n\\nNow, let's examine the options given:\\n\\nA) Lariat: Lariat structures are involved in the splicing process. They are formed by the removal of the intron and the joining of the exons. In this context, the Morpholino would interfere with the lariat structure by preventing the spliceosome from forming.\\n\\nB) PolyA tail: The polyA tail is a feature of mature mRNA, not directly involved in the splicing process. It's a polyadenylation signal that helps in the export of mRNA from the nucleus to the cytoplasm.\\n\\nC) R-loops: R-loops are a structure that forms during the splicing process. They are involved in the recognition of the splice site and the recruitment of the spliceosome.\\n\\nD) Antisense: Antisense oligonucleotides, like the Morpholino in this case, work by binding to complementary sequences on the pre-mRNA, preventing the splicing process.\\n\\nConsidering the information, the structure not involved in the proposed therapy is the polyA tail, as it is a feature of mature mRNA and not directly involved in the splicing process.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's break down the process described and analyze the options given.\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of an out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining. The key aspect here is the recognition of the 5' end of the out-of-frame exon. This is a characteristic of an antisense approach.\\n\\nA) Lariat: This structure is involved in the splicing process, specifically in the recognition of the branch point and the exon junction. However, it is not directly involved in the recognition of the 5' end of an out-of-frame exon by the Morpholino.\\n\\nB) PolyA tail: This is a feature of eukaryotic mRNA, involved in mRNA stability and export. It's not directly related to the proposed therapy.\\n\\nC) R-loops: These are involved in the splicing process, specifically in the recognition of the 5' end of an exon. They play a role in the splicing of introns from the pre-mRNA.\\n\\nD) Antisense: This is the correct approach in the proposed therapy, as it involves delivering a molecule that recognizes the 5' end of the out-of-frame exon, preventing the spliceosome from binding and leading to exon skipping.\\n\\nConsidering the details of the proposed therapy and the functions of the structures listed, the correct answer is the one that is not involved in the recognition of the 5' end of the out-of-frame exon.\\n\\nAnswer: A<|eot_id|>\", \"To solve this question, let's break down the process described:\\n\\n1. The gene has dozens of exons, and a mutation creates an out-of-frame peptide due to a central exon deletion.\\n2. The Morpholino oligonucleotide targets the 5' end of the out-of-frame exon in pre-mRNA.\\n3. The Morpholino prevents the spliceosome from binding, leading to exon skipping and in-frame joining.\\n\\nNow, let's analyze the options in relation to the proposed therapy:\\n\\nA) Lariat: This is a type of RNA structure formed during splicing, but it's not directly involved in the proposed therapy, which targets the spliceosome's binding to the pre-mRNA.\\n\\nB) PolyA tail: This is a feature of mature mRNA, but it's not directly involved in the proposed therapy, which aims to prevent spliceosome binding.\\n\\nC) R-loops: These are RNA-DNA or RNA-RNA structures involved in splicing, but they are not directly involved in the proposed therapy.\\n\\nD) Antisense: This is a type of oligonucleotide that can bind to specific RNA sequences, including pre-mRNA, which is exactly how the Morpholino oligonucleotide works in the proposed therapy.\\n\\nConsidering the mechanism of the proposed therapy, the structure not involved is the polyA tail, as it's not directly related to the splicing process targeted by the Morpholino oligonucleotide.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, we need to understand the mechanism of the proposed therapy and the structures involved in RNA processing and splicing.\\n\\nThe therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining. The spliceosome is a complex that assembles on the pre-mRNA and catalyzes the splicing reaction, which involves the removal of introns and joining of exons.\\n\\nThe structure that is NOT involved in the proposed therapy is the polyA tail. The polyA tail is a feature of mature mRNA that helps stabilize it, but it is not directly involved in the splicing process.\\n\\nThe lariat structure is involved in the splicing reaction, as it forms during the removal of the intron. The R-loop is also involved in the splicing reaction, as it forms during the recognition of the splice site by the spliceosome. Antisense oligonucleotides, like the Morpholino, can be used to recognize and block the splicing process by binding to specific sequences in the pre-mRNA.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's analyze the given information and the options provided:\\n\\n- The Morpholino molecule is designed to recognize the 5' end of the out-of-frame exon in pre-mRNA and prevent the spliceosome from binding, leading to exon skipping and in-frame joining. This is a form of RNA interference (RNAi) therapy.\\n\\n- A lariat (A) is a structure that can form during splicing, where a piece of the RNA is looped back to rejoin with the rest of the RNA. It is involved in the splicing process.\\n\\n- A polyA tail (B) is a feature of mature mRNA, adding a polyadenylate tail to the 3' end to facilitate mRNA export. It is not directly involved in the splicing process.\\n\\n- R-loops (C) are involved in RNA processing, particularly during the splicing process, where they can form during the process of splicing.\\n\\n- Antisense (D) oligonucleotides are used in RNA interference (RNAi) therapy, similar to the Morpholino molecule, by recognizing and binding to specific RNA sequences to prevent the expression of genes.\\n\\nGiven the context of the Morpholino molecule's action, the structure not involved in the proposed therapy is the polyA tail (B), as it is a feature of mature mRNA, not directly involved in the splicing process.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's analyze the information provided:\\n\\n- The Morpholino is designed to recognize the 5' end of the out-of-frame exon in pre-mRNA.\\n- It prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n- The goal is to bypass the problematic exons and restore the normal gene function.\\n\\nNow, let's examine the options:\\n\\nA) Lariat: Lariat structures are involved in the splicing process, specifically in the recognition of introns. They are not directly related to the proposed therapy, which aims to prevent spliceosome binding and promote exon skipping.\\n\\nB) PolyA tail: The polyA tail is involved in mRNA stabilization and export. While it's not directly involved in the splicing process, it's not the correct answer because the Morpholino is designed to interact with pre-mRNA before it's processed.\\n\\nC) R-loops: R-loops are involved in the splicing process, specifically in the recognition of introns. They are relevant to the proposed therapy, as the Morpholino prevents spliceosome binding, which can be affected by R-loops.\\n\\nD) Antisense: Antisense oligonucleotides, like the Morpholino, work by binding to the target mRNA, preventing the splicing process. This option is directly related to the proposed therapy.\\n\\nConsidering the information, the structure not involved in the proposed therapy is the lariat, as it's not directly affected by the Morpholino's mechanism of action.\\n\\nAnswer: A<|eot_id|>\", \"To answer this question, let's break down the process described:\\n\\n1. The gene has dozens of exons, and the central ones are crucial for coding folded triple helical repeats that connect the cytoskeleton with the sarcolemma and extracellular space.\\n2. A mutation creates an out-of-frame peptide due to a central exon deletion.\\n3. A Morpholino is used to recognize the 5' end of the out-of-frame exon in pre-mRNA, preventing the spliceosome from binding and creating exon skipping and in-frame joining.\\n4. The goal is to avoid creating a non-functional protein due to the mutation.\\n\\nGiven these details, let's analyze the options:\\n\\nA) Lariat: This is a structure involved in the splicing process, where a lariat-shaped RNA structure is formed to hold the intron during splicing. The Morpholino could potentially interact with the lariat structure during this process.\\n\\nB) PolyA tail: This is a feature of eukaryotic mRNA that protects the 3' end from degradation. It is not directly involved in the splicing process or the proposed therapy.\\n\\nC) R-loops: These are RNA structures that form during the splicing process, helping to stabilize the pre-mRNA. They could be involved in the splicing process, potentially interacting with the Morpholino.\\n\\nD) Antisense: This is a type of RNA that is complementary to the target mRNA and can bind to it, potentially interfering with its function. In this context, the Morpholino acts similarly to an antisense oligonucleotide, recognizing the target mRNA and preventing splicing.\\n\\nConsidering the above points, the structure that is not involved in the proposed therapy is the polyA tail, as it is not directly involved in the splicing process.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's break down the information provided:\\n\\n1. The gene in question codes for folded triple alpha helices that connect the cytoskeleton with the sarcolemma and extracellular space.\\n2. The most common mutations are central exon deletions that create out-of-frame peptides, leading to progressive degenerative organ waste.\\n3. The proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA, preventing the spliceosome from binding and creating exon skipping and in-frame joining.\\n\\nGiven these points, we're looking for a structure that is not involved in the proposed therapy:\\n\\n- A) Lariat: This is a structure involved in RNA splicing, where the lariat structure is formed by a single-stranded RNA that loops back to itself, creating a hairpin-like structure. This is relevant to the process of splicing and could be involved in the proposed therapy.\\n- B) PolyA tail: This is a polyadenylate tail added to the 3' end of RNA to stabilize it and facilitate its export from the nucleus. It is not directly involved in the splicing process but is a feature of the mRNA after splicing has occurred.\\n- C) R-loops: These are RNA-DNA hybrid structures formed during the splicing process, where the RNA forms a loop that base pairs with the DNA template. They are indeed involved in the splicing process.\\n- D) Antisense: This refers to a type of RNA that is complementary to a specific mRNA sequence and can be used to prevent the translation of that mRNA. It is not directly involved in the splicing process but can be used as a therapeutic approach.\\n\\nConsidering the options, the structure not involved in the proposed therapy is the polyA tail, as it is a feature of the mRNA after splicing has occurred and is not directly involved in the splicing process.\\n\\nAnswer: B<|eot_id|>\", \"To answer this question, let's analyze the proposed therapy and the structures involved:\\n\\n- The Morpholino is designed to bind to the 5' end of the out-of-frame exon in pre-mRNA, preventing the spliceosome from binding and creating exon skipping and in-frame joining. This is a classic antisense oligonucleotide mechanism, where the Morpholino is complementary to the target mRNA sequence.\\n\\n- A lariat (A) is a type of RNA structure involved in the splicing process, where a branch of the RNA molecule forms a loop that connects to the rest of the RNA. It's not directly involved in the proposed therapy.\\n\\n- The polyA tail (B) is a poly(A) tail that is added to the 3' end of mRNA after splicing. While it's involved in mRNA processing, it's not directly involved in the proposed therapy.\\n\\n- R-loops (C) are a type of RNA structure that forms during the splicing process, where a portion of the RNA molecule folds back on itself. They can be involved in the splicing process, but not directly in the proposed therapy.\\n\\n- Antisense (D) refers to the type of molecule used in the proposed therapy, which is designed to bind to the target mRNA sequence.\\n\\nConsidering the above, the structure that is not involved in the proposed therapy is the lariat (A).\\n\\nAnswer: A<|eot_id|>\", \"To approach this question, let's break down the key elements of the proposed therapy:\\n\\n1. The goal is to prevent the binding of the spliceosome to the out-of-frame exon, thereby skipping it and joining the remaining in-frame exons.\\n2. A Morpholino is used, which recognizes the 5' end of the out-of-frame exon.\\n3. This Morpholino prevents the spliceosome from performing its normal function, leading to exon skipping.\\n\\nNow, let's analyze the options:\\n\\nA) Lariat: This is a structure formed during splicing, where a piece of the intron is removed and a lariat-shaped structure is left behind. This is indeed involved in the splicing process, and the Morpholino's action could potentially disrupt this process.\\n\\nB) PolyA tail: This is a tail of adenine nucleotides added to the 3' end of the mRNA, which is not directly involved in the splicing process. It's more related to mRNA stability and transport.\\n\\nC) R-loops: These are a type of RNA structure that can form during splicing, where a piece of the intron is removed and a loop is left behind. This is also involved in the splicing process.\\n\\nD) Antisense: This refers to a type of RNA that is complementary to the target mRNA. In this case, the Morpholino acts as an antisense molecule, binding to the 5' end of the out-of-frame exon to prevent the spliceosome from binding.\\n\\nConsidering these points, the structure that is not involved in the proposed therapy is the polyA tail, as it's not directly related to the splicing process.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's break down the process and components involved in the proposed therapy:\\n\\n1. The therapy aims to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n2. This Morpholino prevents the binding of the spliceosome, which is a complex that assembles on the pre-mRNA and catalyzes the splicing process.\\n3. As a result, the therapy creates exon skipping and in-frame joining.\\n\\nNow, let's analyze the options given:\\n\\nA) Lariat: The lariat structure is involved in RNA splicing. It is a loop formed by the spliceosome that binds to the pre-mRNA, which is not part of the proposed therapy, as the Morpholino prevents the spliceosome's binding.\\n\\nB) PolyA tail: The polyA tail is a polyadenylate tract added to the 3' end of the mRNA, which is not directly involved in the proposed therapy.\\n\\nC) R-loops: R-loops are a type of RNA secondary structure that can form during RNA processing. They are not directly involved in the proposed therapy.\\n\\nD) Antisense: Antisense oligonucleotides are a type of molecule that can bind to specific RNA sequences, which is relevant to the proposed therapy, as the Morpholino acts as an antisense oligonucleotide to the pre-mRNA.\\n\\nGiven the information, the structure not involved in the proposed therapy is the lariat, as it is part of the normal RNA splicing process that the Morpholino is trying to prevent.\\n\\nAnswer: A<|eot_id|>\", \"To solve this question, we need to understand the mechanism of the proposed therapy. The Morpholino is designed to recognize the 5' end of the out-of-frame exon in pre-mRNA and prevent the spliceosome from binding, resulting in exon skipping and in-frame joining. This is a form of antisense therapy, where an oligonucleotide (in this case, a Morpholino) is designed to bind to the target RNA and prevent splicing.\\n\\nA) Lariat structures are involved in the splicing process, where the spliceosome forms a lariat-shaped complex to remove the intron. This is relevant to the proposed therapy.\\n\\nB) The polyA tail is involved in mRNA stability and translation, but not directly involved in the splicing process.\\n\\nC) R-loops are involved in the splicing process, where the spliceosome forms an R-loop to remove the intron.\\n\\nD) Antisense oligonucleotides, like the Morpholino, are designed to bind to the target RNA and prevent splicing, making it relevant to the proposed therapy.\\n\\nBased on this analysis, the structure not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's break down the key components involved in the proposed therapy and analyze each option:\\n\\n1. The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n2. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n3. The goal is to create a functional protein by joining the skipped exons.\\n\\nNow, let's examine each option in the context of the proposed therapy:\\n\\nA) Lariat: Lariat structures are involved in the splicing process, specifically in the recognition of pre-mRNA and the formation of the splicing complex. However, in the context of the proposed therapy, the Morpholino's action is to prevent the spliceosome from binding, which is more closely related to the function of antisense molecules or other splicing inhibitors, not lariat structures directly.\\n\\nB) PolyA tail: The polyA tail is involved in mRNA stabilization and translation, not directly involved in the splicing process.\\n\\nC) R-loops: R-loops are involved in the recognition of pre-mRNA and the initiation of splicing. They can be involved in the splicing process, but the proposed therapy's mechanism (using a Morpholino to prevent spliceosome binding) is more closely related to the function of antisense molecules.\\n\\nD) Antisense: Antisense molecules can bind to specific sequences of RNA, including pre-mRNA, and can interfere with the splicing process by preventing the binding of the spliceosome. This is the mechanism by which the Morpholino works in the proposed therapy.\\n\\nConsidering the above explanations, the structure that is not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's break down the information and analyze each option step by step.\\n\\n1. The question is about a proposed therapy that uses a Morpholino to prevent the binding of the spliceosome to an out-of-frame exon in pre-mRNA, allowing for exon skipping and in-frame joining. This implies that the Morpholino is designed to interact with the pre-mRNA molecule.\\n\\n2. A lariat (A) is a type of RNA structure that can be formed by a splicing complex during the splicing process. It is indeed involved in the splicing process, so this is not the correct answer.\\n\\n3. A polyA tail (B) is a poly(A) tail that is added to the 3' end of mRNA after splicing. While it's not directly involved in the proposed therapy, it's not entirely unrelated to the splicing process, so we'll keep this in mind.\\n\\n4. R-loops (C) are a type of RNA structure that can form during the splicing process, particularly when a splice site is not recognized correctly. However, they are not typically involved in the proposed therapy, which aims to prevent spliceosome binding at a specific exon.\\n\\n5. Antisense (D) RNA is a type of RNA that is complementary to a specific mRNA sequence. The Morpholino in the proposed therapy is designed to recognize the 5' end of the out-of-frame exon, which implies that it acts as an antisense molecule to prevent spliceosome binding.\\n\\nGiven the information, the structure not involved in the proposed therapy is the R-loop, as it is not directly involved in the interaction between the Morpholino and the pre-mRNA.\\n\\nAnswer: C<|eot_id|>\", \"To answer this question, let's break down the key components of the proposed therapy and the structures listed in the options:\\n\\n1. **Morpholino:** This is a synthetic oligonucleotide that is designed to bind to the 5' end of the out-of-frame exon in pre-mRNA. This binding prevents the spliceosome from forming, leading to exon skipping and in-frame joining.\\n\\n2. **Spliceosome:** This is a complex that assembles on the pre-mRNA and catalyzes the splicing process. By preventing the spliceosome from binding, the Morpholino effectively prevents splicing of the out-of-frame exon.\\n\\n3. The question mentions that the goal is to create exon skipping and in-frame joining. This suggests that the goal is to bypass the out-of-frame exon and join the remaining exons in a way that results in a normally functioning protein.\\n\\nNow, let's evaluate the options:\\n\\nA) **Lariat:** This is a structure that forms during splicing, particularly when a splice site is not properly recognized. It's not directly involved in the proposed therapy, which aims to prevent splicing by blocking the spliceosome, not to create or stabilize a lariat structure.\\n\\nB) **PolyA tail:** This is a feature of eukaryotic mRNA that protects it from degradation. While not directly involved in the proposed therapy, the presence of a polyA tail can affect mRNA stability and translation efficiency, which might indirectly influence the effectiveness of the therapy.\\n\\nC) **R-loops:** These are structures formed during RNA processing, particularly during splicing. They can interact with the spliceosome and influence the splicing process. The Morpholino's action of preventing the spliceosome binding could indirectly affect R-loop formation, but it's not a structure that is directly involved in the proposed therapy.\\n\\nD) **Antisense:** This refers to a type of oligonucleotide that binds to the complementary sequence on the mRNA, preventing the translation of the mRNA into protein. The Morpholino used in the proposed therapy is an antisense oligonucleotide that binds to the 5' end of the out-of-frame exon, preventing splicing.\\n\\nConsidering the above explanations, the structure that is **not involved in the proposed therapy** is the lariat (A), as the therapy aims to prevent splicing and does not involve creating or stabilizing lariat structures.\\n\\nAnswer: A<|eot_id|>\", \"To solve this question, let's analyze the given information and the options:\\n\\n1. The question describes a therapy involving a Morpholino that targets the 5' end of an out-of-frame exon in pre-mRNA to prevent the spliceosome from binding and create exon skipping and in-frame joining. This process is known as antisense therapy.\\n\\n2. Antisense therapy involves the use of a single-stranded RNA molecule that is complementary to the target mRNA sequence. This molecule binds to the target mRNA, preventing the spliceosome from recognizing the out-of-frame exon and causing exon skipping.\\n\\n3. Now, let's examine the options:\\n\\n   A) Lariat: Lariat structures are involved in RNA splicing, specifically in the recognition of the branch point of the intron. They are not directly involved in the proposed therapy.\\n   \\n   B) PolyA tail: The polyA tail is a polyadenylate tract at the 3' end of the mRNA, which is involved in mRNA stability and translation. It is not directly involved in the proposed therapy.\\n   \\n   C) R-loops: R-loops are a structure formed during RNA processing, where a short RNA strand is looped back to the main RNA strand. They are involved in the recognition of the splice site. They are not directly involved in the proposed therapy.\\n   \\n   D) Antisense: Antisense is the therapy described in the question, which involves the use of a Morpholino that recognizes the 5' end of the out-of-frame exon.\\n\\nBased on the analysis, the structure not involved in the proposed therapy is the lariat.\\n\\nAnswer: A<|eot_id|>\", \"To solve this question, let's break it down step by step:\\n\\n1. The question describes a scenario where a Morpholino is used to deliver a solution to a gene with dozens of exons. The Morpholino recognizes the 5' end of an out-of-frame exon in pre-mRNA, preventing the spliceosome from binding and creating exon skipping and in-frame joining.\\n\\n2. The question asks us to identify the structure not involved in the proposed therapy.\\n\\n3. The Morpholino binds to the pre-mRNA, preventing the spliceosome from binding. This suggests that the spliceosome is involved in the proposed therapy.\\n\\n4. The spliceosome is a complex that is involved in splicing pre-mRNA. It consists of various components, including the lariat structure, which is a characteristic feature of the spliceosome.\\n\\n5. The polyA tail is a feature of mature mRNA, not directly involved in splicing.\\n\\n6. R-loops are involved in RNA processing, but they are not directly involved in the proposed therapy.\\n\\n7. Antisense molecules can bind to specific RNA sequences, including pre-mRNA, and can prevent the splicing process. However, the question asks us to identify a structure not involved in the proposed therapy, and the Morpholino is the one doing the binding, not an antisense molecule.\\n\\nConsidering these points, the structure not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's analyze the information provided step by step:\\n\\n1. The question describes a scenario where a Morpholino is used to treat a genetic disorder caused by the deletion of central exons in a gene. This deletion results in out-of-frame peptides and progressive degeneration of organs.\\n\\n2. The Morpholino works by recognizing the 5' end of the out-of-frame exon in pre-mRNA and prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n\\n3. The question asks which structure is not involved in the proposed therapy.\\n\\nLet's examine the options given:\\n\\nA) Lariat: Lariat structures are involved in RNA splicing. They are formed when a pre-mRNA is processed and a part of the RNA is removed, and a new 5' end is added. The Morpholino in the question prevents the binding of the spliceosome, which could potentially involve lariat structures in the splicing process. Therefore, lariat structures are involved in the proposed therapy.\\n\\nB) PolyA tail: The polyA tail is a feature of eukaryotic mRNA that is added after splicing. While it is involved in mRNA processing, it is not directly involved in the splicing process that the Morpholino is trying to prevent. However, it is still a part of the mRNA after splicing.\\n\\nC) R-loops: R-loops are a type of RNA structure that can form during the splicing process. They are involved in the process of removing introns from pre-mRNA. Therefore, R-loops are involved in the proposed therapy.\\n\\nD) Antisense: Antisense RNA molecules are complementary to the mRNA and can bind to specific sequences of the mRNA, including the 5' end of the out-of-frame exon. This binding prevents the spliceosome from adding the missing exon, leading to exon skipping and in-frame joining. Therefore, antisense molecules are directly involved in the proposed therapy.\\n\\nConsidering the information, the structure that is not directly involved in the proposed therapy is the polyA tail, as it is a feature of the mRNA after splicing, not during the splicing process itself.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's analyze the information provided and the options given.\\n\\nThe Morpholino mentioned in the question is used to prevent the binding of the spliceosome to the out-of-frame exon, resulting in exon skipping and in-frame joining. This is achieved by recognizing the 5' end of the out-of-frame exon. The Morpholino works by binding to the pre-mRNA, preventing the normal splicing process.\\n\\nNow, let's examine the options:\\n\\nA) Lariat: Lariat structures are involved in RNA splicing, specifically in the recognition of introns. They are part of the spliceosome complex. Since the Morpholino prevents the spliceosome from binding, lariat structures could be indirectly involved in the process, as they are part of the machinery that is being disrupted.\\n\\nB) PolyA tail: The polyA tail is a feature of eukaryotic mRNA that is added to the 3' end of the mRNA after splicing. It is not directly involved in the splicing process, but rather in the processing of the mRNA after it has been spliced. The Morpholino's action is aimed at preventing splicing, not affecting the polyA tail.\\n\\nC) R-loops: R-loops are involved in the regulation of RNA splicing. They form between the pre-mRNA and the introns, helping to protect them from premature splicing. The Morpholino's action of preventing spliceosome binding could indirectly affect R-loops, as they are part of the splicing machinery.\\n\\nD) Antisense: Antisense oligonucleotides like Morpholino work by binding to complementary RNA sequences, preventing the splicing process from occurring. They are directly involved in the proposed therapy.\\n\\nConsidering the information provided and the role of each structure in RNA splicing, the structure not involved in the proposed therapy is the polyA tail, as it is not directly affected by the Morpholino's action.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's break down the information given and analyze each option step by step:\\n\\n1. The question describes a therapy involving a Morpholino that recognizes the 5' end of an out-of-frame exon in pre-mRNA, preventing the spliceosome from binding and causing exon skipping and in-frame joining. This is a method to correct a genetic defect by skipping the problematic exon and restoring the in-frame reading frame.\\n\\n2. Now, let's examine each option in relation to this context:\\n\\n   A) Lariat: Lariat structures are formed during splicing, where a piece of RNA (in this case, an intron) is cleaved off from the pre-mRNA and then re-annealed to the remaining part of the pre-mRNA. The Morpholino is preventing the spliceosome from binding, which could prevent the formation of lariat structures, as the spliceosome is necessary for their formation.\\n\\n   B) PolyA tail: The polyA tail is added to the 3' end of the mRNA after splicing is complete. The Morpholino is targeting the 5' end of the exon, so it wouldn't affect the polyA tail.\\n\\n   C) R-loops: R-loops are a type of RNA structure that can form during splicing. The Morpholino could potentially interact with RNA structures that form during splicing, but it's not directly stated that it's targeting R-loops specifically.\\n\\n   D) Antisense: Antisense oligonucleotides, like Morpholinos, work by binding to complementary sequences on the target RNA, preventing splicing or other RNA processing events. The Morpholino in the question is acting similarly to an antisense oligonucleotide by binding to the 5' end of the out-of-frame exon.\\n\\n3. Given the information, the structure not involved in the proposed therapy is the polyA tail because the Morpholino is targeting the 5' end of the exon, which is not where the polyA tail is added.\\n\\nAnswer: B<|eot_id|>\", \"To approach this question, let's break down the key elements of the proposed therapy and the structures mentioned in the options.\\n\\nThe therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining. The spliceosome is a complex of proteins that assembles on the pre-mRNA and is responsible for splicing out the introns and joining the exons together.\\n\\nThe key structures involved in the proposed therapy are:\\n- Morpholino (an antisense oligonucleotide that recognizes the 5' end of the out-of-frame exon)\\n- The spliceosome (complex that assembles on the pre-mRNA and is responsible for splicing out the introns and joining the exons together)\\n\\nNow, let's evaluate the options:\\n\\nA) Lariat: A lariat is a type of RNA structure that can be involved in the splicing process, particularly in the formation of the lariat structure during the splicing of the pre-mRNA. However, it is not directly involved in the proposed therapy.\\n\\nB) PolyA tail: The polyA tail is a feature of mature messenger RNA (mRNA) that helps stabilize it. It is not directly involved in the proposed therapy.\\n\\nC) R-loops: R-loops are RNA-DNA hybrid structures that can form during the splicing process. They are involved in the recognition of the splice site and are relevant to the splicing process.\\n\\nD) Antisense: Antisense oligonucleotides, like the Morpholino mentioned in the question, can recognize complementary sequences on the mRNA and interfere with the splicing process. This is directly involved in the proposed therapy.\\n\\nConsidering the above information, the structure that is not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's analyze the information provided and the options given.\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA, preventing the binding of the spliceosome and creating exon skipping and in-frame joining. This process is essentially antisense therapy, where the Morpholino acts as an antisense oligonucleotide that binds to the pre-mRNA and alters the splicing process.\\n\\nNow, let's examine the options:\\n\\nA) Lariat: The lariat structure is involved in RNA splicing, specifically in the recognition of the 5' end of the intron by the spliceosome. This is consistent with the proposed therapy.\\n\\nB) PolyA tail: The polyA tail is involved in mRNA stabilization and export, but it is not directly involved in the splicing process.\\n\\nC) R-loops: R-loops are a type of RNA secondary structure involved in the splicing process, particularly in the recognition of the 5' end of the intron.\\n\\nD) Antisense: As explained, this is the mechanism of action of the Morpholino used in the proposed therapy.\\n\\nGiven this analysis, the structure not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|eot_id|>\", \"To approach this question, let's break down the key components involved in the proposed therapy and the structures listed as options.\\n\\n1. **Gene structure and function**: The question describes a gene with dozens of exons that code for folded triple alpha helices. These exons are crucial for the gene's function, and mutations, particularly central exon deletions, can lead to degenerative conditions.\\n\\n2. **Morpholino therapy**: The proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the spliceosome from binding, leading to exon skipping and in-frame joining. This process essentially bypasses the problematic exon.\\n\\n3. **Spliceosome and its role**: The spliceosome is a complex that assembles to remove introns from pre-mRNA and join exons together. In the context of the Morpholino therapy, it is the target of the Morpholino, which prevents the spliceosome from binding to the out-of-frame exon.\\n\\n4. **Structures involved in the proposed therapy**:\\n   - **A) Lariat**: This is a structure formed by the removal of an intron from pre-mRNA, which is indeed a part of the splicing process. The Morpholino therapy indirectly affects this process by preventing the spliceosome from binding.\\n   - **B) PolyA tail**: The polyA tail is added to the 3' end of mRNA after splicing. It is not directly involved in the proposed therapy, which targets the spliceosome's binding to the pre-mRNA.\\n   - **C) R-loops**: R-loops are structures that can form during the splicing process, particularly at the 5' end of introns. They can be a site for the recognition of the Morpholino.\\n   - **D) Antisense**: Antisense oligonucleotides are complementary to the target mRNA sequence and can bind to the pre-mRNA, preventing the recognition of the spliceosome and thereby preventing splicing.\\n\\nGiven the above explanations, the structure not directly involved in the proposed therapy is the polyA tail, as it is added after splicing and not a part of the splicing process targeted by the Morpholino.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's break down the key components involved in the proposed therapy:\\n\\n- The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n- This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n- The goal is to create a functional protein by skipping the non-coding exons that are causing the degenerative effects.\\n\\nNow, let's examine the options provided:\\n\\nA) Lariat: A lariat is a structure formed during splicing, where a piece of the RNA is removed and joined to another piece. This is indeed related to the process of splicing and could be involved in the proposed therapy, as the Morpholino is preventing the normal splicing process.\\n\\nB) PolyA tail: A polyA tail is a sequence of adenine nucleotides added to the 3' end of a mRNA transcript after splicing. It serves as a signal for mRNA export and is not directly involved in the splicing process itself.\\n\\nC) R-loops: R-loops are a type of RNA-DNA hybrid structure that forms during the splicing process. They are indeed involved in the splicing process.\\n\\nD) Antisense: Antisense oligonucleotides are used in therapies to bind to specific RNA sequences, often involved in disease-causing processes. The Morpholino in the proposed therapy is an antisense molecule that binds to the 5' end of the out-of-frame exon.\\n\\nConsidering the information above, the structure that is not directly involved in the proposed therapy is the polyA tail, as it is not a part of the splicing process itself.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's analyze the proposed therapy step by step:\\n\\n1. The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n2. The Morpholino prevents the binding of the spliceosome, which is a complex that assembles to remove introns from pre-mRNA.\\n3. The Morpholino creates exon skipping and in-frame joining, meaning that the spliceosome is unable to properly process the mRNA and instead joins the remaining exons in the correct reading frame.\\n\\nGiven this, let's look at the options:\\n\\nA) Lariat: A lariat is a type of RNA structure that can be formed during splicing, where a part of the intron is removed and the remaining part is joined to the remaining exons. This is indeed involved in the splicing process.\\n\\nB) PolyA tail: A polyA tail is a feature of mature mRNA that helps stabilize it, but it's not directly involved in the splicing process.\\n\\nC) R-loops: R-loops are a type of RNA structure that can form during splicing, where a part of the pre-mRNA is looped back to the splice site. This is also involved in the splicing process.\\n\\nD) Antisense: Antisense oligonucleotides (like the Morpholino) can bind to specific RNA sequences, including those involved in splicing. This is the mechanism by which the Morpholino works in the proposed therapy.\\n\\nConsidering the information, the structure not directly involved in the proposed therapy is the polyA tail, which is a feature of mature mRNA and not directly involved in the splicing process.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's break down the information provided:\\n\\n1. The gene has dozens of exons, and a common mutation is the deletion of a central exon, leading to out-of-frame peptides and degenerative effects.\\n2. The proposed therapy involves delivering a Morpholino that targets the 5' end of the out-of-frame exon, preventing the spliceosome from binding and causing exon skipping and in-frame joining.\\n3. The question asks which structure is NOT involved in the proposed therapy.\\n\\nNow, let's analyze the options:\\n\\nA) Lariat: A lariat is a type of RNA structure involved in RNA splicing, where a loop of RNA is formed to stabilize the splice site. This could be involved in the proposed therapy as it is related to RNA splicing.\\n\\nB) PolyA tail: The polyA tail is a feature of eukaryotic mRNA, but it is not directly involved in the splicing process. However, it is a feature of mRNA that can be targeted by certain types of RNA-binding proteins.\\n\\nC) R-loops: R-loops are RNA-DNA hybrid structures formed during RNA processing, particularly during the splicing process. They are involved in the recognition of splice sites.\\n\\nD) Antisense: Antisense oligonucleotides are short, single-stranded DNA or RNA molecules that can bind to specific mRNA sequences, typically to prevent splicing or translation.\\n\\nConsidering the options, the polyA tail (B) is the structure that is NOT directly involved in the proposed therapy, as it is not directly involved in the splicing process.\\n\\nAnswer: B<|eot_id|>\", \"To answer this question, let's break down the information provided and analyze each option step by step:\\n\\n1. The question is about a therapy involving a Morpholino that recognizes the 5' end of an out-of-frame exon in pre-mRNA and prevents the spliceosome from binding, leading to exon skipping and in-frame joining.\\n\\n2. The Morpholino works by binding to the 5' end of the out-of-frame exon, which is a common mechanism used in antisense oligonucleotide therapies. \\n\\n3. Now, let's analyze the options given:\\n\\n   A) lariat: A lariat structure is involved in the splicing process. It is a hairpin-like structure that can form during the splicing process, especially when there is an out-of-frame exon. This is relevant to the proposed therapy, so it is not the answer.\\n\\n   B) polyA tail: The polyA tail is added to the 3' end of the mRNA after splicing. It is not directly involved in the splicing process itself but is a feature of mature mRNA. The Morpholino's action is upstream of this process, making this option less directly relevant to the mechanism of action.\\n\\n   C) R-loops: R-loops are structures that form during the splicing process, particularly when a 5' splice site is not recognized. However, the Morpholino binds to the 5' end of the out-of-frame exon, which is the opposite scenario of an R-loop formation. This option might seem less directly relevant, but it's still involved in splicing, so it could be considered in the broader context.\\n\\n   D) antisense: The Morpholino works by binding to the 5' end of the out-of-frame exon, which is an antisense mechanism. This is directly relevant to the proposed therapy.\\n\\nGiven the information, the structure that is not directly involved in the proposed therapy is the polyA tail, as it is a feature of mature mRNA and not a part of the splicing process that the Morpholino is targeting.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's break it down step by step:\\n\\n1. The question describes a therapy involving a Morpholino that recognizes the 5' end of an out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome and creates exon skipping and in-frame joining.\\n\\n2. The spliceosome is a complex that assembles at the 5' splice site of an intron and catalyzes the removal of the intron and joining of the exons. In this context, the Morpholino's action prevents the spliceosome from binding at the 5' end of the out-of-frame exon.\\n\\n3. The question asks us to identify a structure not involved in the proposed therapy. We know that the Morpholino binds at the 5' end of the out-of-frame exon, preventing the spliceosome from binding. This implies that the structure involved in the spliceosome's binding is not the Morpholino, but rather the structure that forms the spliceosome itself.\\n\\n4. The spliceosome is a complex that assembles at the 5' splice site, but it does not directly involve a structure like a lariat or R-loop in its primary function.\\n\\n5. The polyA tail is a structure that is involved in mRNA processing, but it is not directly involved in the spliceosome's binding at the 5' end of the exon.\\n\\n6. The R-loop is a structure that can form during the splicing process, but it is not directly involved in the spliceosome's binding at the 5' end of the exon.\\n\\n7. The lariat is a structure that forms during the splicing process, and it is indeed involved in the spliceosome's binding at the 5' end of the exon.\\n\\n8. The antisense strand is a single-stranded RNA that is complementary to the target mRNA. The Morpholino is an antisense oligonucleotide that binds to the 5' end of the out-of-frame exon, preventing the spliceosome from binding.\\n\\nConsidering these points, the structure not involved in the proposed therapy is the polyA tail, which is not directly involved in the spliceosome's binding at the 5' end of the exon.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's analyze the proposed therapy and the structures listed in the options:\\n\\nThe therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining. This is a form of antisense therapy, where an antisense oligonucleotide is designed to bind to the target mRNA, preventing the normal splicing process.\\n\\nNow, let's examine the structures listed in the options:\\n\\nA) Lariat: A lariat is a type of RNA structure that can form during the splicing process, particularly during the 2'-5' splice site recognition by the snRNP complex. It is not directly involved in the proposed therapy.\\n\\nB) PolyA tail: The polyA tail is a long sequence of adenine nucleotides added to the 3' end of the mRNA during post-transcriptional processing. While it's involved in mRNA stability and transport, it's not directly involved in the proposed therapy.\\n\\nC) R-loops: R-loops are a type of RNA secondary structure that can form during the splicing process, particularly during the 5' splice site recognition by the U2AF65 protein. They are involved in the proposed therapy, as the Morpholino binds to the 5' end of the out-of-frame exon, which may disrupt the formation of an R-loop.\\n\\nD) Antisense: Antisense oligonucleotides, like the Morpholino, are involved in the proposed therapy, as they bind to the target mRNA to prevent splicing.\\n\\nConsidering the options, the structure that is not involved in the proposed therapy is the lariat (A). The Morpholino binds to the 5' end of the out-of-frame exon, preventing the binding of the spliceosome and leading to exon skipping, but it does not form a lariat.\\n\\nAnswer: A<|eot_id|>\", \"To solve this question, let's analyze the information given and the options provided:\\n\\n- The question is about a Morpholino that recognizes the 5' end of an out-of-frame exon in pre-mRNA, preventing the spliceosome from binding and creating exon skipping and in-frame joining.\\n- The Morpholino works by recognizing the 5' end of the out-of-frame exon, which is a specific sequence on the pre-mRNA.\\n- This is a classic description of antisense technology, where an antisense oligonucleotide binds to the target mRNA to prevent its splicing.\\n- Let's evaluate the options:\\n  A) lariat: This is a structure formed during the splicing process, not a component of the Morpholino therapy.\\n  B) polyA tail: This is a feature of mature mRNA, not directly involved in the proposed therapy.\\n  C) R-loops: These are a part of the splicing process, but not a structure involved in the Morpholino therapy.\\n  D) antisense: This is the mechanism of action of the Morpholino, making it the correct choice.\\n\\nAnswer: A<|eot_id|>\", \"To solve this question, let's analyze the information step by step:\\n\\n1. The question is about a therapy that involves delivering a Morpholino to prevent exon skipping and create in-frame joining in a gene with out-of-frame peptides due to central exon deletions. This Morpholino recognizes the 5' end of the out-of-frame exon.\\n\\n2. The Morpholino works by preventing the binding of the spliceosome, which is a complex that assembles on the pre-mRNA to perform splicing. By preventing spliceosome binding, the Morpholino causes exon skipping.\\n\\n3. Exon skipping is a process where a normal exon is skipped during splicing, resulting in an out-of-frame peptide. The Morpholino creates in-frame joining, meaning the remaining exons are joined together to form a continuous coding sequence.\\n\\n4. The options provided involve structures related to RNA processing:\\n   - A) Lariat: a structure formed during splicing, specifically during the 2'-hydroxyl attack on the 5' splice site.\\n   - B) PolyA tail: a poly(A) tail added to the 3' end of the mature mRNA, not directly involved in splicing.\\n   - C) R-loops: a structure involved in the recognition of the 5' splice site by the spliceosome.\\n   - D) Antisense: a type of RNA that is complementary to the target mRNA and can bind to it, potentially interfering with splicing.\\n\\nGiven the context of the Morpholino's action, which involves preventing spliceosome binding and causing exon skipping, the structure not directly involved in the proposed therapy is the polyA tail. The polyA tail is added to the mature mRNA and is not directly involved in splicing or the mechanism of the Morpholino.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's break down the key points and analyze the options:\\n\\n1. The question describes a therapy that involves delivering a Morpholino, which recognizes the 5' end of an out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n\\n2. The Morpholino works by binding to the pre-mRNA and preventing the normal splicing process, which involves the spliceosome. The spliceosome is a complex of RNA and proteins that recognizes the splice sites in the pre-mRNA and catalyzes the removal of the introns and joining of the exons.\\n\\n3. The question asks for a structure not involved in the proposed therapy. Let's analyze the options:\\n\\n   A) Lariat: A lariat is a structure involved in the splicing process, specifically in the recognition of the 5' splice site. The Morpholino binds to the 5' end of the out-of-frame exon, which is a critical step in the splicing process. Therefore, lariat structures are involved in the proposed therapy.\\n\\n   B) PolyA tail: The polyA tail is a feature of mature mRNA, not directly involved in the splicing process. It's a sequence of adenine nucleotides that is added to the 3' end of the mRNA after splicing. The Morpholino does not interact with the polyA tail.\\n\\n   C) R-loops: R-loops are involved in the splicing process, specifically in the recognition of the 3' splice site. They are a type of RNA secondary structure that forms during the splicing process. Therefore, R-loops are involved in the proposed therapy.\\n\\n   D) Antisense: Antisense oligonucleotides can bind to specific sequences of RNA, including pre-mRNA. In this context, the Morpholino is an antisense oligonucleotide that binds to the 5' end of the out-of-frame exon, preventing the spliceosome from binding. Therefore, antisense is involved in the proposed therapy.\\n\\nBased on the analysis, the structure not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, we need to understand the mechanism of the proposed therapy. The Morpholino oligonucleotide binds to the 5' end of the out-of-frame exon in pre-mRNA, preventing the spliceosome from binding and causing exon skipping and in-frame joining. This process involves the formation of a lariat structure, which is a characteristic feature of splicing reactions. The lariat is a hairpin-like structure that forms during the splicing process.\\n\\nA) lariat - This structure is involved in the proposed therapy.\\n\\nB) polyA tail - This is a feature of mature mRNA, not directly involved in the proposed therapy.\\n\\nC) R-loops - These are involved in splicing reactions and are a type of RNA secondary structure.\\n\\nD) antisense - This is the type of oligonucleotide used in the proposed therapy.\\n\\nConsidering the options, the structure not involved in the proposed therapy is the polyA tail, which is a feature of mature mRNA, not directly involved in the proposed therapy.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's break down the key components and the proposed therapy:\\n\\n1. The question describes a scenario where a Morpholino is used to treat a genetic disorder by skipping certain exons in a gene, which leads to a progressive degenerative condition. The Morpholino works by binding to the pre-mRNA, preventing the spliceosome from joining the out-of-frame exons.\\n\\n2. The spliceosome is a complex that assembles to catalyze the splicing of pre-mRNA. The Morpholino binds to the 5' end of the out-of-frame exon, preventing the spliceosome from binding and thus skipping the exon.\\n\\n3. The question mentions lariat, polyA tail, R-loops, and antisense in the context of RNA processing.\\n\\n- A lariat is a type of RNA secondary structure that can form during the splicing process, where a piece of RNA is removed from the pre-mRNA and re-annealed to the rest of the molecule. This is relevant to the process the Morpholino is trying to interfere with.\\n\\n- A polyA tail is a feature of mature mRNA, where a poly(A) sequence is added to the 3' end of the mRNA. It is not directly involved in the splicing process.\\n\\n- R-loops are RNA structures that form during the splicing process, where the RNA is held together by a short RNA-DNA hybrid. This is relevant to the process the Morpholino is trying to interfere with.\\n\\n- Antisense RNA is a type of RNA that is complementary to a specific mRNA sequence. The Morpholino works by binding to the pre-mRNA, preventing the spliceosome from binding and thus skipping the exon. This is relevant to the process the Morpholino is trying to interfere with.\\n\\nConsidering the information, the structure that is not involved in the proposed therapy is the polyA tail, as it is a feature of mature mRNA, not directly involved in the splicing process.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's break down the key elements of the proposed therapy:\\n\\n1. The therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n2. The Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n3. The goal is to bypass the problematic exons and restore the normal gene expression.\\n\\nNow, let's analyze the options:\\n\\nA) Lariat: Lariat structures are involved in the splicing process, specifically in the recognition of introns and the formation of the lariat-shaped complex that binds to the pre-mRNA. The Morpholino's action on the spliceosome would likely involve lariat structures, as it prevents the spliceosome from binding to the out-of-frame exon.\\n\\nB) PolyA tail: The polyA tail is a feature of mature mRNA, not directly involved in the splicing process. The Morpholino's action is focused on preventing spliceosome binding, not affecting the polyA tail.\\n\\nC) R-loops: R-loops are a type of RNA structure that can form during the splicing process, particularly during the 3' processing of pre-mRNA. The Morpholino's action on the spliceosome might indirectly affect R-loops, as the spliceosome's function is compromised.\\n\\nD) Antisense: Antisense oligonucleotides, like Morpholinos, work by binding to specific RNA sequences, in this case, the 5' end of the out-of-frame exon. This binding prevents the spliceosome from recognizing and processing the exon, leading to exon skipping.\\n\\nConsidering the mechanism of action of the Morpholino, the structure not directly involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's analyze the information step by step:\\n\\n1. The question is about a therapy that involves delivering a Morpholino to prevent the splicing of an out-of-frame exon in a gene. This Morpholino binds to the 5' end of the out-of-frame exon in pre-mRNA.\\n\\n2. The Morpholino prevents the binding of the spliceosome, which is a complex involved in splicing. This prevents the normal splicing process, leading to exon skipping and in-frame joining.\\n\\n3. The spliceosome is composed of various components, including the lariat, R-loops, and the catalytic component of the spliceosome (also known as U2AF(65) or U2AF65). The polyA tail is a feature of eukaryotic mRNA that is involved in mRNA stability and translation, but it is not directly involved in the splicing process.\\n\\n4. Given the information about the Morpholino and the spliceosome, we can eliminate options A (lariat) and C (R-loops) as they are components of the spliceosome. Option D (antisense) is not directly related to the splicing process, but it is a type of RNA molecule that can be involved in the regulation of gene expression.\\n\\n5. This leaves us with option B (polyA tail), which is not directly involved in the splicing process.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's analyze the information provided step by step:\\n\\n1. The question describes a scenario where a Morpholino is used to treat a genetic disorder caused by a large gene with dozens of exons, many of which code for folded triple alpha helices. The Morpholino works by recognizing the 5' end of an out-of-frame exon in pre-mRNA and prevents the spliceosome from binding, leading to exon skipping and in-frame joining.\\n\\n2. The Morpholino's mechanism involves the recognition of the 5' end of the out-of-frame exon. This is typically achieved through an antisense oligonucleotide, which is complementary to the mRNA sequence.\\n\\n3. The options provided are:\\n   - A) Lariat: A lariat is a type of RNA secondary structure, but it is not directly involved in the proposed therapy.\\n   - B) PolyA tail: A polyA tail is a feature of eukaryotic mRNA, but it is not involved in the proposed therapy.\\n   - C) R-loops: R-loops are RNA-DNA hybrids that form during the processing of pre-mRNA, but they are not directly involved in the proposed therapy.\\n   - D) Antisense: Antisense oligonucleotides are used to recognize and bind to specific mRNA sequences, which is consistent with the mechanism of the Morpholino.\\n\\nConsidering the information provided, the structure not involved in the proposed therapy is the lariat.\\n\\nAnswer: A<|eot_id|>\", \"To answer this question, we need to understand the proposed therapy and the structures involved.\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining. This process is a form of RNA interference (RNAi) or antisense therapy.\\n\\nLet's analyze the options:\\n\\nA) Lariat: A lariat is a type of RNA structure that can be involved in the splicing process. It is formed by the removal of an intron and the ligation of the remaining exons. In the context of this therapy, the Morpholino prevents the lariat structure from forming, which is a key step in the splicing process.\\n\\nB) PolyA tail: A polyA tail is a feature of eukaryotic messenger RNA (mRNA) that helps stabilize the mRNA and facilitate its translation. It is not directly involved in the splicing process.\\n\\nC) R-loops: R-loops are a type of RNA structure that can form during the splicing process. They are involved in the recognition of the splice site and the recruitment of the spliceosome.\\n\\nD) Antisense: Antisense therapy involves the delivery of a molecule that is complementary to the target mRNA. In this case, the Morpholino is an antisense molecule that recognizes the 5' end of the out-of-frame exon.\\n\\nConsidering the above explanations, the structure that is not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's break it down step by step:\\n\\n1. The question describes a therapy that involves delivering a Morpholino, which recognizes the 5' end of an out-of-frame exon in pre-mRNA.\\n2. The Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n3. The goal is to create a normal in-frame peptide by skipping the out-of-frame exon.\\n\\nNow, let's analyze the options:\\n\\nA) Lariat: A lariat is a type of RNA structure that forms during splicing, specifically during the 2' to 5' phosphodiester bond formation step. It is involved in the splicing process, so it is relevant to the proposed therapy.\\n\\nB) PolyA tail: A polyA tail is a sequence of adenine nucleotides added to the 3' end of mRNA during post-transcriptional processing. While it is not directly involved in the splicing process, it is a feature of mature mRNA, which is the product of splicing.\\n\\nC) R-loops: R-loops are RNA-DNA hybrid structures that form during the splicing process, specifically during the 5' to 3' phosphodiester bond formation step. They are involved in the splicing process, so they are relevant to the proposed therapy.\\n\\nD) Antisense: Antisense RNA is a single-stranded RNA that is complementary to a specific mRNA sequence. In the context of this therapy, the Morpholino acts as an antisense oligonucleotide, binding to the 5' end of the out-of-frame exon to prevent splicing.\\n\\nConsidering the above analysis, the structure that is not involved in the proposed therapy is the polyA tail, which is a feature of mature mRNA, not directly involved in the splicing process.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's break down the information and analyze each option given:\\n\\n1. The question describes a therapy involving Morpholino molecules that target the 5' end of an out-of-frame exon in pre-mRNA. This is a mechanism to prevent the spliceosome from binding and induce exon skipping and in-frame joining.\\n\\n2. The spliceosome is the complex that assembles to remove introns from pre-mRNA and join exons together to form a mature mRNA molecule. \\n\\n3. The question asks for a structure not involved in the proposed therapy. Let's analyze the options:\\n\\n   A) Lariat: Lariat-shaped structures are indeed involved in RNA splicing. They are the result of the exon lariat, which is a temporary structure formed during the splicing process when the spliceosome binds to the intron.\\n\\n   B) PolyA tail: The polyA tail is involved in mRNA stability and translation initiation but is not directly involved in the splicing process.\\n\\n   C) R-loops: R-loops are involved in RNA splicing, particularly in the removal of introns from pre-mRNA.\\n\\n   D) Antisense: Antisense oligonucleotides are indeed involved in RNA interference (RNAi) and can target specific mRNA sequences, preventing translation or degradation.\\n\\nConsidering the information, the polyA tail is not directly involved in the splicing process, making it the correct answer.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's break down the information provided and analyze each option given:\\n\\n1. The question mentions a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA, preventing the spliceosome from binding and creating exon skipping and in-frame joining. This is a method to address the issue of out-of-frame peptides caused by central exon deletions.\\n\\n2. Let's analyze the options given:\\n\\n   A) Lariat: A lariat is a structure involved in the splicing process, particularly in the recognition of pre-mRNA by the spliceosome. It is involved in the proposed therapy as the Morpholino recognizes the 5' end of the out-of-frame exon, preventing the spliceosome from binding, which could be interpreted as a lariat-like structure in the context of preventing splicing.\\n\\n   B) PolyA tail: The polyA tail is a feature of eukaryotic mRNA that helps in the stabilization of the mRNA. It is not directly involved in the splicing process or the proposed therapy.\\n\\n   C) R-loops: R-loops are formed during the splicing process, particularly during the removal of introns. They could be involved in the splicing process, and their formation is related to the splicing process.\\n\\n   D) Antisense: Antisense oligonucleotides (like Morpholinos) are used to recognize and bind to specific sequences on the pre-mRNA, preventing the splicing process or the translation of out-of-frame peptides. This is directly involved in the proposed therapy.\\n\\nConsidering the information provided and the analysis above, the structure not involved in the proposed therapy is the polyA tail, as it is not directly related to the splicing process or the recognition of the out-of-frame exon by the Morpholino.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's break down the information provided and analyze the options given.\\n\\nThe proposed therapy involves using a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA, preventing the binding of the spliceosome and creating exon skipping and in-frame joining. This is a technique known as antisense oligonucleotide therapy, which is a method used to treat genetic disorders by targeting specific regions of RNA.\\n\\nNow, let's examine the options given:\\n\\nA) Lariat: A lariat is a type of RNA structure that can be involved in RNA splicing, but it is not directly involved in the proposed therapy.\\n\\nB) PolyA tail: The polyA tail is a polyadenylate tract added to the 3' end of mRNA, which is not directly involved in the proposed therapy.\\n\\nC) R-loops: R-loops are RNA structures that can be involved in RNA splicing, particularly in the process of exon skipping.\\n\\nD) Antisense: Antisense oligonucleotides are used in the proposed therapy to recognize and bind to specific regions of RNA, preventing the normal splicing process.\\n\\nConsidering the information above, the structure not involved in the proposed therapy is the polyA tail, which is not directly involved in the process of exon skipping and splicing.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's break down the key elements:\\n\\n1. The gene has dozens of exons, and the central ones code for folded triple helical repeats. This suggests that the gene is involved in structural or cytoskeletal functions.\\n2. The most common mutations are central exon deletions that create out-of-frame peptides, leading to progressive degenerative organ waste. This indicates that the gene plays a critical role in maintaining proper protein function and that its dysregulation can lead to severe consequences.\\n3. The proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon, preventing the spliceosome from binding and creating exon skipping and in-frame joining. This is a form of antisense therapy, where a molecule binds to the pre-mRNA to modify its splicing.\\n4. The question asks which structure is not involved in the proposed therapy.\\n\\nGiven these points, let's examine the options:\\n\\nA) Lariat: Lariat structures are involved in RNA splicing, particularly in the recognition of introns and the removal of exons. This is relevant to the proposed therapy.\\nB) PolyA tail: The polyA tail is involved in mRNA stability and translation, but it's not directly involved in the splicing process or the proposed therapy.\\nC) R-loops: R-loops are formed during RNA splicing and can interact with other RNA molecules, including the spliceosome. They are involved in the splicing process.\\nD) Antisense: As mentioned, the proposed therapy involves delivering an antisense molecule to recognize and bind to the pre-mRNA, preventing spliceosome binding and promoting exon skipping.\\n\\nConsidering these points, the structure not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's analyze the given information and the options provided.\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining. The spliceosome is a complex of proteins that assembles at the 5' splice site of the pre-mRNA and facilitates the removal of the intron and joining of the exons.\\n\\nA) Lariat: The lariat structure is formed by the interaction between the 5' splice site and the branch point of the intron. This structure is involved in the splicing process, as it allows the spliceosome to recognize and bind to the pre-mRNA. Therefore, the lariat is involved in the proposed therapy.\\n\\nB) PolyA tail: The polyA tail is a feature of mature mRNA, which is added after splicing. It is not directly involved in the splicing process and is not relevant to the proposed therapy.\\n\\nC) R-loops: R-loops are a type of RNA structure that can form during the splicing process, particularly at the branch point of the intron. They can be involved in the recognition of the pre-mRNA by the spliceosome. Therefore, R-loops are involved in the proposed therapy.\\n\\nD) Antisense: Antisense oligonucleotides are single-stranded DNA or RNA molecules that are complementary to a specific sequence of mRNA. In this case, the Morpholino is an antisense oligonucleotide that recognizes the 5' end of the out-of-frame exon in pre-mRNA. Therefore, antisense is involved in the proposed therapy.\\n\\nConsidering the information above, the structure that is not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|eot_id|>\", \"To approach this question, let's break down the key elements of the proposed therapy and the structures listed in the options:\\n\\n1. **Morpholino therapy**: This is a method used to treat genetic diseases caused by premature termination of protein synthesis due to mutations in RNA splicing. Morpholinos bind to the pre-mRNA, specifically targeting the 5' end of the out-of-frame exon, preventing the spliceosome from binding and allowing for exon skipping and in-frame joining.\\n\\n2. **Exon skipping**: This is a process where the cell splices out a particular exon from the mRNA transcript, skipping over the mutation and continuing to translate the rest of the protein. This is the desired outcome in the proposed therapy.\\n\\n3. **Structures involved in the proposed therapy**:\\n   - **Lariat**: This is a type of RNA structure that can form during the splicing process. The Morpholino binds to the 5' end of the out-of-frame exon, which could potentially interact with or be part of a lariat structure as part of the splicing process. So, it's plausible that a lariat could be involved.\\n   - **PolyA tail**: This is a polyadenylate tract added to the 3' end of the mRNA after splicing. While it's not directly involved in the splicing process, it's a feature of the mature mRNA and could be affected by the Morpholino binding. However, its primary role is not in the splicing process itself.\\n   - **R-loops**: These are RNA-DNA hybrids that form during the splicing process. They are indeed involved in the splicing process and could interact with the Morpholino. So, it's plausible that an R-loop could be involved.\\n   - **Antisense**: This refers to a type of RNA that is complementary to a specific mRNA sequence. In the context of the Morpholino therapy, an antisense RNA could potentially be used to guide the Morpholino to the correct location on the pre-mRNA. So, it's plausible that an antisense RNA could be involved.\\n\\nConsidering the above points, the structure that is **not directly involved in the proposed therapy** is the **polyA tail**, as it's more related to the post-splicing modification of the mRNA rather than the splicing process itself.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's break it down step by step.\\n\\n1. The question describes a therapeutic approach to treat a genetic disorder by using a Morpholino that recognizes the 5' end of an out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n\\n2. The spliceosome is a complex that assembles on the pre-mRNA to facilitate splicing. It includes the lariat structure, which forms a covalent bond with the 5' splice site.\\n\\n3. The polyA tail is a feature of mature mRNA that protects it from degradation and helps in its translation. It is not directly involved in the splicing process.\\n\\n4. R-loops are formed during the splicing process as a result of the lariat structure.\\n\\n5. Antisense molecules can bind to specific RNA sequences and interfere with splicing by preventing the assembly of the spliceosome.\\n\\nConsidering the above points, the structure that is not involved in the proposed therapy is the polyA tail, as it is not directly related to the splicing process.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's analyze the information provided and the options given.\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA, preventing the binding of the spliceosome and creating exon skipping and in-frame joining. This is a form of antisense therapy, where the Morpholino acts as an antisense oligonucleotide to bind to the pre-mRNA and prevent the normal splicing process.\\n\\nNow, let's examine the options:\\n\\nA) Lariat: A lariat is a structure involved in the splicing process, specifically in the recognition of the 5' splice site by the spliceosome. The Morpholino in the proposed therapy binds to the 5' end of the out-of-frame exon, which is similar to the role of a lariat in the normal splicing process.\\n\\nB) PolyA tail: The polyA tail is a feature of mature mRNA, not directly involved in the splicing process. However, it's worth noting that the Morpholino's action on pre-mRNA does not involve the polyA tail, but rather the recognition of the out-of-frame exon.\\n\\nC) R-loops: R-loops are formed during the splicing process, specifically in the recognition of the 3' splice site by the spliceosome. The Morpholino's action does not involve R-loops.\\n\\nD) Antisense: As explained, the Morpholino is an antisense oligonucleotide, which is the correct mechanism of action.\\n\\nConsidering the information provided and the options, the structure not involved in the proposed therapy is the R-loop.\\n\\nAnswer: C<|eot_id|>\", \"To solve this question, we need to understand the mechanism of the proposed therapy. The Morpholino oligonucleotide binds to the 5' end of the out-of-frame exon in pre-mRNA, preventing the spliceosome from binding and creating exon skipping and in-frame joining. This is a form of antisense therapy, where an oligonucleotide (in this case, a Morpholino) is designed to bind to a specific sequence of RNA and prevent its splicing.\\n\\nA) Lariat: A lariat is a type of RNA structure that forms during splicing, where a loop of RNA is formed from the intron. This structure is involved in the splicing process, and the Morpholino is targeting it. So, this is involved in the proposed therapy.\\n\\nB) PolyA tail: The polyA tail is a polyadenylate tail that is added to the 3' end of mRNA after splicing. It is not directly involved in the proposed therapy, which targets the splicing process before the polyA tail is added.\\n\\nC) R-loops: R-loops are RNA-DNA hybrids that form during the splicing process. They are involved in the splicing process, and the Morpholino is targeting the 5' end of the out-of-frame exon, which is likely to form an R-loop. So, this is involved in the proposed therapy.\\n\\nD) Antisense: As mentioned earlier, this is the type of therapy being proposed, where an oligonucleotide (Morpholino) binds to the target RNA to prevent splicing.\\n\\nAnswer: B<|eot_id|>\", 'To solve this question, let\\'s break it down step by step:\\n\\n1. The question is about a gene therapy approach that uses a Morpholino to prevent exon skipping and create in-frame joining in a gene with out-of-frame peptides due to central exon deletions.\\n\\n2. The Morpholino binds to the 5\\' end of the out-of-frame exon in pre-mRNA, preventing the spliceosome from binding and creating exon skipping.\\n\\n3. The goal is to prevent exon skipping and create in-frame joining, which means the spliceosome\\'s role is to join the exons together in the correct order.\\n\\n4. The spliceosome is a complex that forms during splicing, which is the process of removing introns (non-coding regions) and joining exons (coding regions) together. The spliceosome\\'s structure involves several components, but the key one relevant to this context is the lariat.\\n\\n5. The lariat is a structure formed by the spliceosome during the splicing process, which \"grasps\" the intron and holds it in place while the exons are joined together.\\n\\n6. Now, let\\'s evaluate the options:\\n\\n   A) lariat: Involved in the spliceosome and relevant to the process of splicing.\\n   \\n   B) polyA tail: This is a feature of mature mRNA, not directly involved in the spliceosome or splicing process.\\n   \\n   C) R-loops: Involved in the splicing process, specifically in the formation of the lariat.\\n   \\n   D) antisense: Refers to a type of RNA that is complementary to the mRNA, which can bind to specific sequences and regulate gene expression, but is not directly involved in the spliceosome\\'s structure or function.\\n\\nGiven the above analysis, the correct answer is the one that is not involved in the spliceosome\\'s structure or function:\\n\\nAnswer: B<|eot_id|>', \"To answer this question, let's analyze the information provided and the options given.\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA, preventing the binding of the spliceosome and creating exon skipping and in-frame joining. This process is similar to the mechanism of antisense oligonucleotides, which are designed to bind to complementary sequences on target RNA molecules, preventing their normal processing.\\n\\nA) Lariat: Lariat structures are involved in the splicing process, specifically in the recognition of introns. They are indeed involved in the proposed therapy, as the Morpholino is binding to the 5' end of the out-of-frame exon.\\n\\nB) PolyA tail: The polyA tail is a feature of mature mRNA that helps in its export from the nucleus. It is not directly involved in the proposed therapy, which aims to prevent splicing.\\n\\nC) R-loops: R-loops are formed during the splicing process, where a strand of RNA is formed that is complementary to the 5' splice site of the intron. They are involved in the proposed therapy.\\n\\nD) Antisense: Antisense oligonucleotides are the type of molecules used in the proposed therapy, which bind to complementary sequences on target RNA molecules to prevent splicing.\\n\\nConsidering the options, the structure not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's analyze the given information step by step:\\n\\n1. The question describes a gene with dozens of exons that code for folded triple helical repeats, which connect the cytoskeleton with the sarcolemma and extracellular space. This information sets the context for the gene's function and the nature of the mutations.\\n\\n2. The mutations involve central exon deletions that result in out-of-frame peptides and progressive degenerative organ waste. This indicates the impact of the mutations on the gene's function and the potential for a therapeutic approach to mitigate this effect.\\n\\n3. The proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n\\n4. The question asks us to identify the structure not involved in the proposed therapy. Let's examine the options:\\n\\n   A) Lariat: Lariat structures are involved in RNA splicing, specifically in the recognition and removal of introns. They are indeed involved in the splicing process and could be relevant to the proposed therapy.\\n\\n   B) PolyA tail: The polyA tail is involved in the processing of pre-mRNA, specifically in the addition of a poly(A) tail at the 3' end. This is not directly involved in the proposed therapy, which focuses on preventing spliceosome binding and exon skipping.\\n\\n   C) R-loops: R-loops are involved in RNA splicing, particularly in the recognition of introns and the protection of exons. They are relevant to the splicing process and could be involved in the proposed therapy.\\n\\n   D) Antisense: Antisense oligonucleotides are used to recognize specific sequences in RNA and can prevent their translation or splicing. The Morpholino mentioned in the question is an antisense oligonucleotide that recognizes the 5' end of the out-of-frame exon.\\n\\nConsidering the information provided, the structure not involved in the proposed therapy is the polyA tail, as it is not directly involved in the recognition or prevention of spliceosome binding.\\n\\nAnswer: B<|eot_id|>\", \"To approach this question, let's break down the key components and the proposed therapy:\\n\\n1. **Gene and Mutation**: The gene in question has dozens of exons, with central ones coding for folded triple helical repeats. A common mutation is the deletion of central exons, leading to out-of-frame peptides and progressive degeneration.\\n\\n2. **Proposed Therapy**: The solution involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n\\n3. **Components of the proposed therapy**:\\n   - **Morpholino**: A synthetic oligonucleotide that recognizes the target sequence and prevents the spliceosome from binding.\\n   - **Spliceosome**: The complex that assembles on the pre-mRNA to facilitate splicing.\\n   - **Exon skipping**: The process of skipping over the mutated exon and joining the remaining exons together in an in-frame manner.\\n\\nNow, let's analyze the options given:\\n\\nA) **Lariat**: This is a structure involved in RNA splicing, where a lariat-shaped structure is formed to hold the intron during the splicing process.\\n\\nB) **PolyA tail**: This is a poly(A) tail added to the 3' end of pre-mRNA for stability and export from the nucleus. It is not directly involved in the splicing process.\\n\\nC) **R-loops**: These are crucial in the splicing process as they help in the recognition of the splice sites by the spliceosome.\\n\\nD) **Antisense**: This refers to a type of RNA that is complementary to the target mRNA and can bind to it, potentially preventing its translation or affecting its splicing.\\n\\nGiven the context of the proposed therapy, which involves preventing the spliceosome from binding to the pre-mRNA, the structure that is **not involved** in this process is the **polyA tail**. The polyA tail is involved in mRNA stability and export but not directly in the splicing process.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's analyze the mechanism of the proposed therapy step by step:\\n\\n1. The Morpholino is delivering to pre-mRNA.\\n2. It recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n3. It prevents the binding of the spliceosome.\\n4. This results in exon skipping and in-frame joining.\\n\\nThe Morpholino is essentially acting as an antisense oligonucleotide, binding to the pre-mRNA and preventing the normal splicing process from occurring.\\n\\nNow, let's examine the options:\\n\\nA) Lariat: A lariat is a structure formed by the spliceosome during the splicing process. It is involved in the recognition and removal of the intron. The Morpholino is preventing the spliceosome from binding, so the lariat is not involved in the proposed therapy.\\n\\nB) PolyA tail: The polyA tail is a feature of mature mRNA, not directly involved in the splicing process. However, it's not the correct answer because the Morpholino is targeting pre-mRNA, and the polyA tail is added after splicing.\\n\\nC) R-loops: R-loops are involved in the splicing process, specifically in the recognition of the branch point site. They are not directly involved in the proposed therapy, but they are not the correct answer either.\\n\\nD) Antisense: This is the correct answer. The Morpholino is acting as an antisense oligonucleotide, binding to the pre-mRNA and preventing the spliceosome from binding. Antisense oligonucleotides are not involved in the splicing process and are not the structure in question.\\n\\nAnswer: D<|eot_id|>\", \"To solve this question, let's analyze the information step by step:\\n\\n1. The question describes a scenario where a Morpholino is used to treat a genetic disorder caused by a large gene with dozens of exons. The Morpholino recognizes the 5' end of an out-of-frame exon in pre-mRNA and prevents the spliceosome from binding, leading to exon skipping and in-frame joining.\\n\\n2. The question asks us to identify a structure not involved in the proposed therapy.\\n\\n3. Let's examine the options:\\n   - A) Lariat: This is a structure formed during splicing, where an intron is temporarily joined to the 5' end of an exon, which can be recognized and skipped by the Morpholino. So, lariat is involved in the proposed therapy.\\n   - B) PolyA tail: This is a poly(A) tail added to the 3' end of mRNA after splicing. It's not directly involved in the proposed therapy.\\n   - C) R-loops: These are involved in splicing, where the 5' splice site of an intron is recognized and joined to the 3' splice site of an exon. So, R-loops are involved in the proposed therapy.\\n   - D) Antisense: This is a type of RNA that is complementary to the target mRNA, which can bind to the Morpholino in this scenario. So, antisense is involved in the proposed therapy.\\n\\n4. Based on this analysis, the structure not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, we need to understand the context of the proposed therapy and the structures involved.\\n\\nThe therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining. The spliceosome is a complex that assembles on the pre-mRNA to catalyze the splicing process.\\n\\nThe spliceosome is composed of five main components: U2, U4, U5, U6, and U2AF (U2- associated factor). The U2AF is further composed of two subunits: U2AF35 and U2AF65. The U2AF65 is a lariat structure.\\n\\nNow, let's analyze the options:\\n\\nA) lariat: This is a component of the U2AF65 subunit of the spliceosome, which is involved in the proposed therapy.\\n\\nB) polyA tail: This is a polyadenylate tail that is added to the 3' end of the mRNA after splicing. It is not directly involved in the spliceosome or the proposed therapy.\\n\\nC) R-loops: These are RNA structures that form during the splicing process, but they are not directly involved in the proposed therapy.\\n\\nD) antisense: This is a type of RNA that is complementary to the target mRNA. In this case, the Morpholino is an antisense molecule that recognizes the 5' end of the out-of-frame exon.\\n\\nConsidering the above analysis, the structure that is not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's analyze the information given and the options provided.\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, which leads to exon skipping and in-frame joining. This process is known as antisense therapy, where the Morpholino acts as an antisense oligonucleotide that binds to the pre-mRNA, preventing the normal splicing process.\\n\\nNow, let's analyze the options:\\n\\nA) Lariat: A lariat is a structure formed by the spliceosome during the splicing process, so it is involved in the normal splicing process, which the Morpholino is trying to prevent.\\n\\nB) PolyA tail: The polyA tail is a structure added to the 3' end of the mRNA after splicing, so it is not directly involved in the proposed therapy.\\n\\nC) R-loops: R-loops are structures formed during the splicing process, so they are involved in the normal splicing process, which the Morpholino is trying to prevent.\\n\\nD) Antisense: Antisense therapy is the mechanism of action of the Morpholino, so it is involved in the proposed therapy.\\n\\nConsidering the above analysis, the correct answer is the structure that is not involved in the proposed therapy:\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's break down the process and the components involved in the proposed therapy.\\n\\nThe Morpholino molecule recognizes the 5' end of the out-of-frame exon in pre-mRNA, preventing the spliceosome from binding and creating exon skipping and in-frame joining. This process involves several steps and structures:\\n\\n- The Morpholino binds to the pre-mRNA.\\n- This binding prevents the spliceosome from recognizing the exon, leading to exon skipping.\\n- The skipping of the exon results in an in-frame joining of the remaining exons.\\n\\nNow, let's analyze the options in relation to the proposed therapy:\\n\\nA) Lariat: Lariat structures are involved in RNA splicing, particularly in the recognition of introns and the removal of the intron. They are not directly involved in the proposed therapy.\\n\\nB) PolyA tail: The polyA tail is a feature of mature mRNA, not directly involved in the proposed therapy.\\n\\nC) R-loops: R-loops are involved in the recognition of pre-mRNA and the splicing process.\\n\\nD) Antisense: Antisense oligonucleotides, like Morpholinos, are used to bind to specific sequences on target RNA, in this case, preventing the spliceosome from binding and creating exon skipping.\\n\\nGiven the above information, the structure not involved in the proposed therapy is:\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, we need to understand the mechanism of the proposed therapy and the structures involved in RNA splicing.\\n\\nThe therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, which is a complex that assembles on the pre-mRNA to catalyze the splicing reaction. The spliceosome is composed of multiple components, including the lariat structure, which forms a loop in the pre-mRNA during the splicing process.\\n\\nThe polyA tail is a feature of mature mRNA, not involved in the splicing process. It is a polyadenylate tract added to the 3' end of the mRNA by the poly(A) polymerase after splicing has occurred.\\n\\nR-loops are a type of RNA structure that can form during the splicing process, but they are not a component of the spliceosome itself.\\n\\nAntisense RNA is a type of RNA that can bind to specific mRNA sequences, including the target mRNA in this case, to prevent splicing.\\n\\nGiven this information, the structure not involved in the proposed therapy is the polyA tail, as it is a feature of mature mRNA and not directly involved in the splicing process.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's analyze the given information step by step:\\n\\n1. The question describes a therapeutic approach using a Morpholino that recognizes the 5' end of an out-of-frame exon in pre-mRNA. This Morpholino prevents the binding of the spliceosome, leading to exon skipping and in-frame joining.\\n\\n2. The spliceosome is a complex of proteins that catalyzes the splicing of pre-mRNA to remove introns and join exons together.\\n\\n3. The Morpholino works by recognizing the 5' end of the out-of-frame exon, which is a critical step in the splicing process.\\n\\n4. The question asks which structure is NOT involved in the proposed therapy. \\n\\nNow, let's evaluate the options:\\n\\nA) Lariat: A lariat structure is involved in the splicing process, as it is the structure that forms when the spliceosome binds to the 5' end of the intron. The Morpholino in the question works by preventing this binding, so the lariat is involved in the proposed therapy.\\n\\nB) PolyA tail: The polyA tail is a feature of mature mRNA, not directly involved in the splicing process. However, it's worth noting that the polyA tail can be added to the mRNA after splicing has occurred.\\n\\nC) R-loops: R-loops are a type of RNA structure that forms during the splicing process, specifically during the ligation step. They are indeed involved in the splicing process.\\n\\nD) Antisense: Antisense oligonucleotides, like the Morpholino mentioned in the question, work by binding to the target RNA and preventing the splicing process. Therefore, antisense oligonucleotides are directly involved in the proposed therapy.\\n\\nConsidering the options, B) polyA tail is the structure that is NOT directly involved in the proposed therapy, as the Morpholino works by preventing the splicing process, and the polyA tail is added after splicing has occurred.\\n\\nAnswer: B<|eot_id|>\", \"To approach this question, let's break down the key elements of the proposed therapy and the structures mentioned in the options:\\n\\n1. **Morpholino therapy**: This is a type of antisense therapy where a synthetic molecule (Morpholino) is designed to bind to the pre-mRNA of a specific gene, in this case, to prevent the splicing of the gene. The Morpholino binds to the 5' end of the out-of-frame exon, preventing the spliceosome from joining it to the rest of the mRNA, effectively skipping the exon and creating an in-frame reading frame.\\n\\n2. **Lariat**: A lariat is a type of RNA secondary structure that can form during splicing. It is a characteristic structure of introns, which are the non-coding regions of pre-mRNA that are removed during splicing. The lariat structure is formed when a piece of intron is removed from the pre-mRNA, and the remaining 3' end of the intron becomes a 3' splice site, which is recognized by the spliceosome.\\n\\n3. **PolyA tail**: A poly(A) tail is a long sequence of adenine nucleotides added to the 3' end of mRNA after splicing. It serves as a binding site for proteins involved in mRNA export and stability. The presence of a poly(A) tail is not directly involved in the process of splicing.\\n\\n4. **R-loops**: R-loops are a type of RNA secondary structure that forms during the process of splicing. They are formed when a piece of intron is removed from the pre-mRNA, and the remaining 5' end of the intron forms a loop that interacts with the spliceosome.\\n\\nConsidering the above explanations, the structure not involved in the proposed Morpholino therapy is the polyA tail. The Morpholino binds to the pre-mRNA to prevent splicing, and the polyA tail is added after splicing has occurred.\\n\\nAnswer: B<|eot_id|>\", 'To approach this question, let\\'s break down the key elements of the proposed therapy:\\n\\n1. **Morpholino delivery**: Morpholinos are a class of oligonucleotides that can bind to specific sequences in RNA, in this case, the 5\\' end of the out-of-frame exon. This binding prevents the spliceosome from forming, leading to exon skipping and in-frame joining.\\n\\n2. **Spliceosome**: This is a complex that assembles to catalyze the splicing of pre-mRNA. By preventing the spliceosome from binding, the Morpholino effectively prevents splicing.\\n\\n3. **Exon skipping and in-frame joining**: This is the desired outcome where the missing exons are \"skipped\" and the remaining exons are joined together in an in-frame manner to produce a functional protein.\\n\\nNow, let\\'s look at the options provided:\\n\\nA) **Lariat**: Lariat structures are involved in the splicing process, specifically in the recognition and removal of introns. They are part of the spliceosome. The Morpholino\\'s action prevents the spliceosome\\'s formation, which indirectly affects lariat structures.\\n\\nB) **PolyA tail**: The polyA tail is a feature of mature messenger RNA (mRNA) that helps in mRNA stability and export. While it\\'s not directly involved in the splicing process, it is a feature of the mature mRNA that can be affected by the therapy. However, it\\'s not directly involved in the proposed mechanism of action.\\n\\nC) **R-loops**: R-loops are indeed part of the splicing process. They form between the intron and exon sequences during the splicing process. The Morpholino\\'s action prevents the spliceosome\\'s formation, which could indirectly affect R-loop formation.\\n\\nD) **Antisense**: Antisense oligonucleotides, like Morpholinos, work by binding to the target RNA sequence. In this case, the Morpholino binds to the 5\\' end of the out-of-frame exon, preventing the spliceosome from binding and causing exon skipping. This is an example of an antisense mechanism.\\n\\nConsidering the information provided, the structure that is **not involved in the proposed therapy** is the **polyA tail**. While it\\'s a feature of mature mRNA, the Morpholino\\'s action is focused on preventing the spliceosome\\'s formation and causing exon skipping, rather than directly affecting the polyA tail.\\n\\nAnswer: B<|eot_id|>', \"To solve this question, let's break down the process described:\\n\\n1. The Morpholino binds to the 5' end of the out-of-frame exon in pre-mRNA, preventing the spliceosome from binding.\\n2. This prevents the normal splicing process, which would result in the creation of an out-of-frame peptide.\\n3. Instead, the spliceosome is prevented from joining the out-of-frame exon to the rest of the mRNA, effectively creating exon skipping.\\n4. This results in an in-frame joining of the remaining exons, which should produce a functional protein.\\n\\nNow, let's look at the options:\\n\\nA) Lariat: This is a structure formed during the splicing process when a lariat-shaped RNA structure is created during the removal of an intron. It is not directly involved in the proposed therapy.\\n\\nB) PolyA tail: This is a polyadenylate tail added to the 3' end of the mRNA after splicing is complete. It is not directly involved in the proposed therapy.\\n\\nC) R-loops: These are RNA-DNA hybrids that can form during the splicing process. They can be involved in the recognition of the pre-mRNA by the Morpholino.\\n\\nD) Antisense: This is a type of RNA that is complementary to the target mRNA and can bind to it, preventing its translation. The Morpholino is an antisense molecule that binds to the 5' end of the out-of-frame exon.\\n\\nGiven the description of the Morpholino's mechanism of action, we can see that it is an antisense molecule (D) that prevents the spliceosome from binding to the out-of-frame exon. The other options are not directly involved in the proposed therapy.\\n\\nAnswer: D<|eot_id|>\", \"To solve this question, let's analyze the information provided and the options given.\\n\\nThe Morpholino molecule is used to recognize the 5' end of the out-of-frame exon in pre-mRNA and prevents the binding of the spliceosome, leading to exon skipping and in-frame joining. This is a type of antisense therapy, where an antisense oligonucleotide (in this case, a Morpholino) binds to the target RNA (pre-mRNA) to regulate its processing.\\n\\nA) Lariat structures are involved in RNA splicing, particularly in the recognition and binding of the spliceosome. They are not directly involved in the proposed therapy.\\n\\nB) Poly(A) tails are added to the 3' end of mRNA after splicing, which is not relevant to the proposed therapy.\\n\\nC) R-loops are involved in the splicing process, where they help to stabilize the pre-mRNA.\\n\\nD) Antisense molecules, like the Morpholino in the proposed therapy, are indeed involved in the process.\\n\\nGiven the information, the structure not involved in the proposed therapy is the lariat.\\n\\nAnswer: A<|eot_id|>\", \"To solve this question, we need to understand the proposed therapy and the structures involved.\\n\\nThe proposed therapy involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA, preventing the binding of the spliceosome and creating exon skipping and in-frame joining. This process is known as antisense therapy.\\n\\nLet's examine the options:\\n\\nA) Lariat: Lariat structures are involved in the splicing process, where they help to remove introns from pre-mRNA. The Morpholino is binding to the 5' end of the out-of-frame exon, which is preventing the spliceosome from binding, so lariat structures are not involved in this process.\\n\\nB) PolyA tail: The polyA tail is involved in the processing of pre-mRNA, where it is added to the 3' end of the mature mRNA. This is not directly related to the proposed therapy.\\n\\nC) R-loops: R-loops are formed during the splicing process, where the spliceosome forms a loop with the intron to remove it from the pre-mRNA. Although not directly involved in the proposed therapy, R-loops are related to the splicing process.\\n\\nD) Antisense: Antisense therapy is the proposed method of delivering the Morpholino to prevent the spliceosome from binding, so it is involved in the proposed therapy.\\n\\nConsidering the above information, the structure not involved in the proposed therapy is:\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's break down the information given and analyze the options:\\n\\n- The question describes a scenario where a Morpholino is used to treat a genetic disorder by skipping an out-of-frame exon in a gene, thereby preventing the creation of a non-functional protein.\\n- The Morpholino works by recognizing the 5' end of the out-of-frame exon in pre-mRNA, preventing the spliceosome from binding and allowing in-frame joining of the remaining exons.\\n- The key structures involved in the proposed therapy are:\\n  - Morpholino (an antisense oligonucleotide)\\n  - The 5' end of the out-of-frame exon (which is recognized by the Morpholino)\\n  - The spliceosome (involved in the splicing process)\\n  - R-loops (involved in the splicing process, specifically in the removal of introns)\\n  - PolyA tail (not directly involved in the splicing process or the proposed therapy)\\n\\nGiven the information, we can conclude that the polyA tail, which is a feature of mature mRNA, is not involved in the proposed therapy.\\n\\nAnswer: B<|eot_id|>\", \"To solve this question, let's analyze the information provided and the options given.\\n\\nThe Morpholino mentioned in the question is used to recognize the 5' end of the out-of-frame exon in pre-mRNA and prevent the binding of the spliceosome, which leads to exon skipping and in-frame joining. This is a form of antisense therapy, where a molecule is designed to bind to the pre-mRNA and alter the splicing process.\\n\\nA) Lariat: This is a structure formed during the splicing process, where a lariat-shaped structure is formed by the spliceosome to hold the intron out of the way. It is involved in the proposed therapy.\\n\\nB) PolyA tail: This is a polyadenylate tail that is added to the 3' end of mRNA after splicing. It is not directly involved in the proposed therapy.\\n\\nC) R-loops: These are short, single-stranded loops of RNA that form during the splicing process. They are involved in the proposed therapy.\\n\\nD) Antisense: This is the type of therapy used in the question, where a molecule is designed to bind to the pre-mRNA.\\n\\nBased on the analysis, the structure not involved in the proposed therapy is the polyA tail.\\n\\nAnswer: B<|eot_id|>\"], 'correct': [False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, True, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, True, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False], 'explanations': [\"parsed='B'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\"], 'num_tokens': [339, 338, 339, 316, 454, 298, 296, 262, 238, 325, 389, 478, 380, 340, 245, 383, 366, 318, 358, 462, 324, 353, 338, 324, 314, 374, 372, 406, 270, 311, 281, 369, 414, 203, 357, 329, 319, 365, 403, 303, 338, 334, 324, 375, 325, 368, 381, 338, 437, 276, 368, 329, 451, 309, 394, 404, 377, 343, 430, 484, 387, 259, 319, 325, 298, 243, 288, 315, 368, 393, 284, 344, 330, 243, 360, 348, 490, 334, 292, 446, 401, 419, 387, 262, 466, 353, 348, 328, 426, 457, 403, 233, 368, 453, 211, 407, 367, 288, 306, 325, 380, 293, 374, 275, 358, 378, 480, 233, 341, 329, 382, 296, 441, 428, 344, 323, 338, 285, 280, 263, 415, 406, 501, 356, 230, 300, 233, 260], 'rewards': [0.10400390625, 0.10791015625, 0.1083984375, 0.11181640625, 0.1044921875, 0.1123046875, 0.1201171875, 0.11962890625, 0.11328125, 0.1171875, 0.11474609375, 0.1142578125, 0.10888671875, 0.11767578125, 0.12060546875, 0.10595703125, 0.11279296875, 0.11474609375, 0.1064453125, 0.1083984375, 0.1083984375, 0.115234375, 0.11328125, 0.10595703125, 0.1162109375, 0.11669921875, 0.11865234375, 0.10498046875, 0.11669921875, 0.107421875, 0.115234375, 0.11328125, 0.107421875, 0.115234375, 0.1142578125, 0.11572265625, 0.11083984375, 0.1220703125, 0.10888671875, 0.111328125, 0.10400390625, 0.11279296875, 0.10546875, 0.1103515625, 0.11083984375, 0.10986328125, 0.109375, 0.12060546875, 0.1064453125, 0.10986328125, 0.1142578125, 0.11181640625, 0.1064453125, 0.10986328125, 0.10888671875, 0.10546875, 0.10791015625, 0.11474609375, 0.10546875, 0.11181640625, 0.1103515625, 0.10400390625, 0.1162109375, 0.10595703125, 0.115234375, 0.11376953125, 0.1123046875, 0.11083984375, 0.11279296875, 0.109375, 0.1103515625, 0.10400390625, 0.11279296875, 0.1103515625, 0.10986328125, 0.11279296875, 0.1064453125, 0.119140625, 0.1171875, 0.109375, 0.109375, 0.12060546875, 0.1171875, 0.12255859375, 0.115234375, 0.10498046875, 0.12109375, 0.10888671875, 0.1025390625, 0.11572265625, 0.11083984375, 0.10009765625, 0.12109375, 0.109375, 0.10986328125, 0.11083984375, 0.1142578125, 0.10546875, 0.10791015625, 0.11572265625, 0.111328125, 0.11279296875, 0.11767578125, 0.115234375, 0.10986328125, 0.111328125, 0.115234375, 0.10986328125, 0.1083984375, 0.1044921875, 0.10888671875, 0.1142578125, 0.11279296875, 0.1044921875, 0.10791015625, 0.1103515625, 0.109375, 0.12255859375, 0.11572265625, 0.12109375, 0.1005859375, 0.10693359375, 0.10888671875, 0.11328125, 0.1171875, 0.11572265625, 0.11474609375, 0.11279296875], 'ground_truths': ['C'], 'question_meta': None, 'model_name': 'hf_chat:meta-llama/Llama-3.2-3B-Instruct', 'reward_model_name': 'armo_rm:RLHFlow/ArmoRM-Llama3-8B-v0.1'}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 83%|â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–Ž | 10/12 [00:26<00:05,  2.54s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'qid': 'gpqa-1', 'prompt': \"Answer the following multiple choice question. The last line of your response should be of the following format: 'Answer: $LETTER' (without quotes) where LETTER is one of ABCD. Think step by step before answering.\\n\\nA large gene has dozens of exons, of which the central ones code for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space. Each exon usually codes for one folded triple alpha helix. The most common mutations of the gene are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste. A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. The molecule prevents binding of the spliceosome and creates exon skipping and in-frame joining. Several missing exons are well tolerated by an organism. Which structure below is not involved in the proposed therapy?\\n\\nA) lariat\\nB) polyA tail\\nC) R-loops\\nD) antisense\", 'answers': ['<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>://Hmm, okay, so I\\'ve got this biology question here about gene therapy and exon skipping. Let me try to wrap my head around it. I\\'m a bit rusty on this, but I\\'ll think it through.\\n\\nSo, the question is about a gene that has a lot of exons, like maybe a big gene with several exons. The central ones code for these triple helical repeats that connect the cytoskeleton with the sarcolemma and the extracellular space. Each exon usually codes for one of these triple helices. So, the structure of the protein must be made up of these repeats, which are probably alpha-helices because triple helical repeats are common in such structures.\\n\\nThe problem says that the most common mutations are central exon deletions causing out-of-frame peptides leading to progressive degenerative organ failure. So, out-of-frame mutations, which typically result in a truncated protein. Those are usually not good because the reading frame is shifted, leading to incorrect amino acids and probably nonfunctional proteins.\\n\\nThe solution given is using a Morpholino that recognizes the 5\\' end of the out-of-frame exon in the pre-mRNA. Morpholinos are antisense oligonucleotides, right? They bind to specific DNA or RNA sequences. If it\\'s the 5\\' end of an exon, they probably bind to the pre-mRNA to prevent it from being recognized by the spliceosome.\\n\\nWait, the idea is that the spliceosome recognizes the splice sites. The spliceosome recognizes the splice donor and acceptor sites on the pre-mRNA. If the Morpholino binds to the 5\\' end of the exon, maybe it\\'s blocking the splice site so that the exon is skipped. So when the spliceosome comes along, it might skip that exon. Skipping the exon would mean that the reading frame is restored, making the protein in-frame again. So, in-frame exons are those where the number of nucleotides is a multiple of three, so the reading frame isn\\'t messed up.\\n\\nThe question is asking which structure is not involved in the therapy. The options are lariat, polyA tail, R-loops, or antisense.\\n\\nSo, what do I know about each of these? Let\\'s think.\\n\\nOption A: Lariat. The lariat structure is part of the splicing process. When introns are removed, they form a lariat structure with the branch site adenosine. So, the spliceosome uses the branch site, which is usually a conserved sequence in the intron. So lariat is involved in splicing.\\n\\nOption B: PolyA tail. The polyA tail is added to the 3\\' end of mRNA. It\\'s involved in stability and export from the nucleus. But does the Morpholino affect this? The therapy here is about splicing, so maybe the polyA tail is not directly involved. Unless the process of splicing somehow relates to polyA addition.\\n\\nOption C: R-loops. R-loops are three-stranded structures with RNA:DNA hybrids. They\\'re usually formed during transcription and can cause DNA damage or other issues. I\\'m not sure how this relates to the therapy. The Morpholino is binding to RNA, so maybe R-loops are not involved here.\\n\\nOption D: Antisense. Morpholino is an antisense molecule, so it\\'s involved. The question is about what is not involved.\\n\\nWait, the therapy is using an antisense molecule, so D is involved. So the question is which one is not involved.\\n\\nWait, the therapy uses Morpholino, which is antisense, so option D is part of the process. So the structures not involved would be one of the others.\\n\\nLooking back: the process involves splicing. The spliceosome uses the branch site (lariat), the splice sites, and the polyA tail is added later. The Morpholino blocks the splice site, so the spliceosome can\\'t recognize the exon. So, the spliceosome\\'s recognition is affected, leading to exon skipping. The polyA tail is added after splicing, so maybe it\\'s not involved in the splicing process itself. Or is it? Because sometimes the polyA tail signals for the mRNA to be exported and help with stability.\\n\\nWait, but in splicing, the polyA tail is added after the intron is removed. So the polyA tail is part of the mRNA processing, but not directly part of the splicing mechanism. So in this therapy, the polyA tail might not be directly involved in the splicing process that\\'s being targeted by the Morpholino. So the structures involved in the therapy are the spliceosome, the lariat (because the splice sites form lariat introns), and the antisense Morpholino. So the structures not involved would be the polyA tail and R-loops.\\n\\nWait, but the question is which structure is not involved. So the structures involved in the therapy are the splice sites, the branch site (lariat), the spliceosome, and the antisense molecule. The polyA tail is added after splicing, so maybe it\\'s not involved in the splicing process itself. R-loops are not part of splicing.\\n\\nSo the options are A, B, C, D. The therapy uses antisense (D), which is involved. The structures involved in splicing are the lariat (A) and the splice sites. The polyA tail (B) is added after, so not part of the splicing here. R-loops (C) aren\\'t part of the process.\\n\\nWait, but wait. Let me think again. The question is about what\\'s not involved in the therapy. The therapy is about preventing the binding of the spliceosome, leading to exon skipping.\\n\\nSo in the therapy, the Morpholino binds to the 5\\' end of the out-of-frame exon. The spliceosome normally recognizes the 5\\' splice site, so if the Morpholino is blocking that, the spliceosome can\\'t recognize it, so the exon is skipped. So the spliceosome is involved.\\n\\nThe lariat is part of the splicing process, so it\\'s involved. The polyA tail is added later. So the polyA tail is not directly involved in the splicing here. R-loops are not involved in splicing. So the structures not involved are the polyA tail and R-loops.\\n\\nWait, but the question is about which one is not involved. The options are:\\n\\nA) lariat â†’ involved.\\n\\nB) polyA â†’ not involved.\\n\\nC) R-loops â†’ not involved.\\n\\nD) antisense â†’ involved.\\n\\nThe question is which is not involved. The correct answer is either B or C.\\n\\nWait, the question asks which structure is not involved. So, the structures used in the therapy are the spliceosome, which uses the lariat. The antisense Morpholino is used, so D is involved.\\n\\nSo the structures involved are A and D. Structures not involved would be B and C.\\n\\nBut the question is which one is not involved. The options are A, B, C, D. The question says \"which structure is not involved in the proposed therapy\".\\n\\nWait, the therapy is about splicing. The polyA tail is added after splicing. So during splicing, the polyA isn\\'t involved. So the polyA tail (B) isn\\'t involved in the splicing process that the therapy targets. R-loops are structures formed during DNA transcription, but not part of splicing. So neither B nor C are involved.\\n\\nWait, but the question is about which structure is not involved. So the answer would be either B or C.\\n\\nWait, the therapy is using a Morpholino, which is antisense, so D is involved.\\n\\nThe structures not involved are B and C. But the options are A, B, C, D.\\n\\nWait, the question says the therapy prevents the spliceosome from binding, leading to exon skipping. The spliceosome is involved, so lariat is involved (A), so A is involved.\\n\\nSo the structures not involved are polyA tail (B) and R-loops (C). The question is which one is not involved. So the answer would be either B or C.\\n\\nWait, the question says the possible options are A, B, C, D. The question is which is not involved in the therapy.\\n\\nThe process involves the spliceosome (so lariat is involved), antisense (D is involved). So which is not involved: either B or C.\\n\\nThe polyA tail is added after splicing, so it\\'s part of mRNA processing but not directly part of the splicing that the therapy is affecting. R-loops are not part of the splicing process.\\n\\nSo the structures not involved would be B and C.\\n\\nWait, but the question is about the therapy mechanism. The therapy uses an antisense molecule (so D is involved), so the structure not involved must be either B or C.\\n\\nThe question is about what is not involved. The process of splicing involves the splice sites (donor and acceptor), the branch site (lariat), and the spliceosome. The polyA tail is added after splicing, so it\\'s not part of the splicing process. R-loops are not part of splicing.\\n\\nSo the structures not involved would be B and C. But the options are single answer.\\n\\nWait, perhaps the polyA tail is not involved in the splicing process. So in the therapy, the polyA tail isn\\'t a factor. R-loops are not involved in splicing.\\n\\nSo the question is, which structure is not involved in the proposed therapy.\\n\\nThe possible options are A (lariat), B (polyA), C (R-loops), D (antisense). The therapy uses antisense (D), so D is involved. So not involved is either B or C.\\n\\nBut the question is which structure is not involved. Let\\'s read the question again: the therapy uses', \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>://\\nOkay, so I have this biology question here about a gene therapy scenario. Hmm, let me try to break it down. So the question is about a large gene with many exons, and the central ones code for these triple helical repeats that connect the cytoskeleton with the sarcolemma and extracellular space. Each exon usually codes for one of these triple helical structures. \\n\\nThe mutations causing problems are central exon deletions leading to out-of-frame peptides and progressive degenerative issues. The solution is using a Morpholino that targets the 5' end of the out-of-frame exon in pre-mRNA. The Morpholino prevents the spliceosome from binding, causing exon skipping and in-frame joining. This helps because several missing exons are tolerated by the organism.\\n\\nThe question is asking which structure isn't involved in this therapy. The options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nWait, let me think about each option. \\n\\nFirst, what do I know about the spliceosome? The spliceosome is involved in splicing pre-mRNA. It recognizes intron-exon boundaries. The splice sites are usually at the ends of introns, with the 5' splice site and 3' splice site. The spliceosome recognizes these sites and cuts the intron, joining the exons. The process forms a lariat structure where the intron is removed.\\n\\nWhen a Morpholino is used, it binds to a specific region of the pre-mRNA. If it's targeting the 5' end of an exon, it would prevent the spliceosome from recognizing the splice site. So the spliceosome can't recognize the intron-exon boundary, and the exon gets skipped. Skipping the exon leads to the exons being joined in a way that's in-frame, so the reading frame is maintained.\\n\\nSo the process of splicing is involved, which uses the spliceosome and creates a lariat as part of the intron removal. So the lariat structure is definitely part of the normal splicing process. So option A is part of the process, so it's involved. So the question is which structure is not involved.\\n\\nOption B is polyA tail. The polyA tail is added to the 3' end of mRNA. I'm not sure how that ties into splicing. Wait, the spliceosome does interact with the polyA tail indirectly. Like, during splicing, the polyA tail binding proteins might help in the process. But in this therapy, the Morpholino is acting at the splice site. So the polyA tail might not be directly involved here. Or wait, when the mRNA is being processed, the polyA tail is added after splicing, so during splicing, the polyA tail isn't part of the spliceosome's action. So the polyA tail is added later, perhaps by other factors, not directly involved in the splicing process when the Morpholino is acting.\\n\\nOption C is R-loops. R-loops are structures in DNA where RNA is bound to DNA, causing the DNA to loop. They can form during transcription and are thought to be involved in certain genetic disorders. I don't think R-loops are part of the splicing process. The spliceosome works on RNA, not DNA, so maybe R-loops aren't involved here.\\n\\nOption D is antisense. Morpholinos are antisense oligonucleotides, which bind to RNA in an antisense manner. So antisense is definitely involved in the therapy. So option D is involved, so the answer isn't D.\\n\\nSo the structures involved are lariat (A), antisense (D), and the polyA tail (B) is maybe not. Or wait, wait, during splicing, the polyA tail is added after splicing. So the spliceosome's process doesn't involve the polyA tail. The polyA tail is more of a post-splicing event, like in the cytoplasm. So in the therapy, the Morpholino is working at the pre-mRNA stage, which is during splicing. So the polyA tail isn't part of this process.\\n\\nWait, but when the spliceosome binds, does it affect the polyA tail? No, the polyA tail is added by other enzymes after splicing. So in this therapy, the polyA tail isn't directly involved. So the structure not involved would be the polyA tail.\\n\\nWait, but what about the polyA tail in splicing? I thought that some splicing factors are associated with the polyA tail. Like the cleavage and polyadenylation occur after the spliceosome does its work. So the polyA tail is added after the splicing is done. So in the splicing process, the polyA tail is not directly involved. So in this therapy, the polyA tail isn't a part of the mechanism.\\n\\nSo the question is which structure is not involved. The structures involved are:\\n\\n- Lariat (A) because the intron is removed to form a lariat.\\n- Antisense (D) because the Morpholino is an antisense molecule.\\nSo the structures involved in the therapy are lariat and antisense. \\n\\nWhich leaves polyA tail (B) and R-loops (C) as options.\\n\\nWait, the question is about what's not involved. So the structures involved are lariat, antisense. The structures not involved would be R-loops and polyA. Because R-loops are DNA-RNA structures, not part of splicing. The polyA is added later.\\n\\nWait, but the polyA tail is part of the mRNA after splicing. So during the splicing process, the polyA tail isn't involved. So in the therapy, the polyA tail isn't being acted upon. So the structures not involved in the therapy are R-loops (C) and polyA (B). Wait, the question asks which is not involved. So the structures used are lariat (part of splicing), antisense (Morpholino), and possibly polyA is not involved because the spliceosome doesn't use it. R-loops are not involved.\\n\\nWait, but what about the polyA tail? The polyA tail is part of the mRNA, but in this therapy, the Morpholino is acting on the pre-mRNA, before it's exported from the nucleus. So polyA tail is added after splicing, so maybe not directly involved in the splicing process where the Morpholino works. So the polyA tail is not part of the splicing process, so it's not involved in the therapy.\\n\\nSo the options are:\\n\\nA) lariat - involved\\n\\nB) polyA tail - not involved\\n\\nC) R-loops - not involved\\n\\nD) antisense - involved.\\n\\nWait, the question is which structure is not involved. So the correct answer is either B or C.\\n\\nWait, the question asks which structure is not involved. So among the options, the therapy process uses lariat (A), antisense (D), and the polyA tail (B) isn't involved because it's added later. R-loops (C) are DNA structures, not RNA, so not involved.\\n\\nSo the structures not involved are R-loops (C) and polyA (B). But the options are only four, and the question says which is not involved.\\n\\nWait, the therapy uses the Morpholino, which is an antisense molecule (D is involved). The spliceosome uses lariat (A is involved). The polyA tail is not part of the spliceosome action, so it's not involved in this therapy. R-loops are not part of the process.\\n\\nSo the structures involved are A and D. So the structures not involved would be B and C.\\n\\nWait the question is which structure is not involved. So the structures not involved would be either B or C.\\n\\nWait, the question is which is not involved in the proposed therapy. The therapy involves the spliceosome, which forms a lariat. The Morpholino is an antisense molecule (so D is involved). So the structures not involved would be polyA tail and R-loops.\\n\\nBut the options are A, B, C, D, and the question is which is not involved.\\n\\nWait, the polyA tail is part of mRNA, but the therapy is about splicing. The polyA tail is added after splicing, so it's not involved in this particular therapy. R-loops are DNA structures, so they are not involved.\\n\\nSo the structures not involved in the therapy would be B (polyA tail) and C (R-loops). But the question asks for which is not involved, so which of the four options is not involved.\\n\\nWait, the options are A, B, C, D. The correct answer is either B or C.\\n\\nAlternatively, perhaps the polyA tail is part of the splicing process. Wait, I thought that the polyA tail is added after the intron is removed. The polyA is added at the 3' end of the mRNA, which is after splicing. So the polyA tail is not directly involved in the splicing process. So in this therapy, the polyA tail isn't involved. So the structures not involved would be B and C.\\n\\nWait, but the question is which structure is not involved. So the correct answer is either B or C.\\n\\nWait, the question is about the structures involved in the therapy. The therapy uses the spliceosome (which uses lariat, A) and the antisense Morpholino (D). The polyA tail is not part of the splicing, so B is not involved. R-loops are DNA structures, not involved.\\n\\nSo the structures not involved are B and C.\\n\\nBut the question says which structure is not involved. So the answer is either B or C. How to choose between them.\\n\\nWait, the spliceosome process involves the\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>:// What's the question again? Oh right, I need to figure out which structure isn't involved in the described gene therapy.\\n\\nSo, the gene in question has many exons, and the central ones are involved in making these triple helical structures that connect the cytoskeleton to the sarcolemma and the extracellular space. The most common mutations are deletions of central exons, which cause the peptide to be out-of-frame. This leads to the production of faulty proteins that result in progressive organ degeneration.\\n\\nThe therapy mentioned uses a Morpholino that recognizes the 5' end of an out-of-frame exon in the pre-mRNA. Morpholinos are antisense molecules, which probably bind to the RNA and prevent the spliceosome from recognizing the exon, leading to its skipping. This way, the exon is skipped, and the remaining exons are joined in an in-frame manner, so the protein is correct.\\n\\nThe question is asking which structure is not involved in this therapy.\\n\\nThe options are:\\nA) lariat\\nB) polyA tail\\nC) R-loops\\nD) antisense\\n\\nHmm, so what do I know about these structures?\\n\\nAntisense molecules are involved. Morpholino is an antisense oligo, so option D is involved. So D is used in the therapy, so the question is which one is not involved.\\n\\nPoly-A tail is added during mRNA processing. The spliceosome is involved in splicing, which is part of the process. R-loops are RNA-DNA structures that form during transcription. The lariat structure is part of the splicing mechanismâ€”during splicing, the branch site is a lariat structure.\\n\\nWait, the therapy uses a Morpholino that blocks the spliceosome from binding. So the spliceosome is involved. The spliceosome recognizes the splice sites and creates the lariat structure. So the lariat is part of the splicing process, so it's involved.\\n\\nThe polyA tail is added after splicing, as part of mRNA processing. The Morpholino is affecting the splicing, so the polyA tail is part of the process. So all except one are involved.\\n\\nWait, the question is which is NOT involved. So the correct answer would be the structure that's not involved in the therapy.\\n\\nSo, which option isn't part of this process.\\n\\nMorpholino is antisense (D is involved), so D is part of the therapy. So the options are A, B, C.\\n\\nPolyA tail is part of mRNA processing. But in this therapy, the Morpholino is about splicing. So when the spliceosome is prevented from recognizing the exon, the mRNA is spliced without that exon. The polyA tail is added after splicing. So the polyA tail is involved, so B is involved. So the structures involved are spliceosome (lariat), polyA tail, antisense (Morpholino), but not sure about R-loops.\\n\\nWhat is an R-loop? R-loops are three-stranded structures where RNA is hybridized to DNA, displacing the other DNA strand. They can form during transcription, but do they have anything to do with splicing? I don't think so. So the therapy doesn't involve R-loops. So the structure not involved is C, R-loops.\\n</think>\\n\\nTo determine which structure is not involved in the described gene therapy, let's analyze the process:\\n\\nThe gene in question has multiple exons, and the central ones code for triple helical repeats that connect the cytoskeleton to the sarcolemma and extracellular space. Mutations causing deletions of central exons lead to out-of-frame peptides, resulting in progressive organ degeneration. The therapy uses a Morpholino, which is an antisense molecule that binds to the 5' end of the out-of-frame exon in pre-mRNA. This binding prevents the spliceosome from recognizing the exon, leading to exon skipping and in-frame joining of the remaining exons, producing a functional protein.\\n\\n### Analysis of the options:\\n1. **Lariat (A):** The lariat structure is part of the splicing process. During splicing, the branch site of the intron forms a lariat structure. Since the spliceosome is involved in this therapy, the lariat is relevant and thus involved.\\n\\n2. **PolyA tail (B):** The polyA tail is added to the 3' end of the mRNA after splicing. While it is part of mRNA processing, it is not directly involved in the splicing mechanism targeted by the Morpholino. However, it is indirectly involved as part of the mRNA maturation process.\\n\\n3. **R-loops (C):** R-loops are RNA-DNA structures that form during transcription, where RNA hybridizes with the DNA template strand, displacing the non-template strand. These structures are not involved in the splicing process or the mechanism of the Morpholino. Therefore, R-loops are not involved in this therapy.\\n\\n4. **Antisense (D):** Morpholinos are antisense molecules that bind to the target RNA to block splicing. This is the primary mechanism of the therapy, so antisense molecules are directly involved.\\n\\n### Conclusion:\\nThe structure not involved in the proposed therapy is **R-loops**, as they are unrelated to the splicing process or the use of Morpholinos.\\n\\n**Answer: C**<ï½œendâ–ofâ–sentenceï½œ>\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>://\\n\\n</think>\\n\\nTo determine which structure is not involved in the proposed therapy, let's analyze the scenario and the options provided.\\n\\nThe question describes a gene with multiple exons, where the central exons code for triple helical repeats that connect the cytoskeleton with the sarcolemma and the extracellular space. Mutations in this gene often involve central exon deletions, leading to out-of-frame peptides and progressive degenerative conditions. The proposed therapy uses a Morpholino molecule that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the spliceosome from binding, causing exon skipping and allowing the remaining exons to join in an in-frame manner. This approach is well-tolerated when multiple exons are missing.\\n\\n### Key Analysis of the Options:\\n\\n1. **Option A: lariat**  \\n   The spliceosome is involved in splicing pre-mRNA, where introns are removed and joined to form a lariat structure. Since the therapy involves spliceosome activity (splicing), the lariat is definitely involved.  \\n\\n2. **Option B: polyA tail**  \\n   The polyA tail is added to the 3' end of mRNA during processing. While the therapy focuses on splicing, the polyA tail is a normal part of mRNA processing and is not directly relevant to the described mechanism of the therapy.  \\n\\n3. **Option C: R-loops**  \\n   R-loops are three-stranded structures involving RNA:DNA hybrids. They are not directly mentioned in the description of the therapy or the splicing process. This structure is unrelated to the described mechanism.  \\n\\n4. **Option D: antisense**  \\n   The therapy uses a Morpholino, which is an antisense molecule that binds to complementary RNA sequences. Antisense molecules are central to the therapy's mechanism, so this is involved.  \\n\\n### Conclusion:  \\nThe structure not involved in the proposed therapy is **C) R-loops**.\\n</think>\\n\\nThe structure not involved in the proposed therapy is **C) R-loops**. \\n\\nAnswer: C<ï½œendâ–ofâ–sentenceï½œ>\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>://\\nOkay, so I've got this question about gene therapy and molecular biology, and I need to figure out the answer. Let me read through the question carefully.\\n\\nThe question is about a large gene that has many exons. The central exons code for triple helical repeats that connect the cytoskeleton with the sarcolemma and the extracellular space. Each exon usually codes for one folded alpha helix. The common mutations are central exon deletions leading to out-of-frame peptides and progressive organ degeneration. The solution is to use a Morpholino that targets the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the spliceosome from binding, causing exon skipping and in-frame joining. Some missing exons are well-tolerated by the organism.\\n\\nThe question asks which structure is not involved in this therapy. The options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nHmm, I need to figure out which of these is not part of this process.\\n\\nLet me break it down. The gene in question has exons that code for these triple helical structures. So, this gene is probably related to something structural, maybe a cytoskeleton protein, perhaps like the dystrophin gene in muscular dystrophy. Mutations here lead to exon skipping, causing a frameshift, which causes the protein to be nonfunctional and leads to degeneration.\\n\\nThe therapy uses a Morpholino, which I remember is an antisense oligonucleotide. Antisense molecules bind to specific RNA sequences. Morpholinos are synthetic molecules that can block certain structures.\\n\\nThe Morpholino targets the 5' end of an out-of-frame exon in the pre-mRNA. Wait, the 5' end of the exon. So the spliceosome recognizes certain sequences when it assembles. The spliceosome recognizes intron-exon boundaries. The 5' splice site is usually at the donor site of the intron. So, when a Morpholino binds to the 5' end of the exon, maybe it's overlapping with the splice site or near it, preventing the spliceosome from recognizing the splice sites.\\n\\nWhen the spliceosome can't bind, the exon is skipped. So, the pre-mRNA is spliced in a way that skips that exon. This leads to the mRNA missing that exon, which would be an in-frame deletion. So, the mRNA is in frame, so the resulting protein is still functional, or at least less harmful than the out-of-frame version.\\n\\nThe therapy is called exon skipping, which is a type of exon skipping gene therapy. So the Morpholino is acting as an antisense molecule, which is option D. So D is involved, so that's not the answer.\\n\\nThe process involves the spliceosome. The spliceosome involves small nuclear ribonucleoproteins and snRNA. When the spliceosome recognizes the splice sites, it removes the introns. The introns are joined, and the exons are joined. The lariat structure is formed when the intron is spliced. So the lariat (A) is involved in splicing. So A is involved, not the answer.\\n\\nThe polyA tail is added to the 3' end of mRNA. In this scenario, the Morpholino is acting on the pre-mRNA. So the polyA tail is part of mRNA processing, but I'm not sure if it's involved in this therapy. Let me think. The spliceosome is involved in splicing, which occurs during mRNA processing before the polyA tail is added. The polyA tail is added by polyA polymerase after the mRNA is cleaved and during the final steps of processing. So the polyA tail isn't directly involved in the splicing process. But wait, does the polyA tail influence splicing? I thought some factors can influence splicing, but in this case, the Morpholino is directly affecting the splice sites. So the polyA tail may not be part of the process here. But I'm not entirely sure yet.\\n\\nR-loops are structures where RNA is bound to DNA, forming a three-stranded structure with the DNA strands. R-loops can influence gene expression, but I don't think they're directly involved in the splicing process. The spliceosome doesn't involve R-loops, as far as I remember. So R-loops are probably not involved in this therapy. So option C is the structure not involved.\\n\\nWait, but wait. The question is about what's not involved. Let me recap:\\n\\n- Morpholino is antisense (D is involved)\\n- Splicing involves lariat (A is involved)\\n- The process is about splicing, so the polyA tail is added after, but is it part of the splice process? Or is it unrelated?\\n\\nI think the polyA tail is added after splicing. So in this therapy, the polyA tail is not directly involved. But the question is, which structure is not involved. The therapy is about splicing, so the polyA tail is part of mRNA, but is it part of the splicing mechanism? The spliceosome doesn't directly interact with the polyA tail. So the polyA tail isn't involved in the process of splicing here.\\n\\nWait, but the question is about which structure is not involved. The options are A, B, C, D.\\n\\nWait, the process involves the spliceosome, so the lariat is involved. The polyA tail isn't involved in the splicing step. So the structures involved are the spliceosome's components, including the lariat, and the antisense Morpholino (D). So the structures involved are A, D. Structures not involved are B (polyA tail) and C (R-loops). But the question is which is not involved in the therapy.\\n\\nWait, the question is about what's not involved. So which of the options is not part of this therapy.\\n\\nSo, the therapy is about splicing. The polyA tail is part of mRNA processing, but in this case, the splicing is done before the polyA tail is added. So the polyA tail isn't part of this process.\\n\\nWait, but the question is about the structures involved in the therapy. The therapy's mechanism is the Morpholino binding to the pre-mRNA, which is before the polyA tail is added. So the polyA tail isn't involved here.\\n\\nSo the structures involved are: antisense (D), lariat (A), and the splicing machinery. The structures not involved are polyA tail (B) and R-loops (C). But the question asks which one is not involved. So which of the options is not involved.\\n\\nWait, the question says: Which structure is not involved in the proposed therapy.\\n\\nSo which of the options is not involved. So the correct answer is either B or C.\\n\\nBut I need to think about what the therapy does. The Morpholino binds to the pre-mRNA, which is before the polyA tail is added. The polyA tail is added later. So the polyA tail isn't part of the splicing process that the therapy is influencing. So B (polyA tail) isn't involved.\\n\\nR-loops are DNA-RNA structures. Since the therapy is acting on RNA, maybe R-loops are not involved. So the structures involved are lariat (splicing), antisense (Morpholino), and possibly the splice sites. The polyA tail isn't directly involved, and R-loops are not.\\n\\nSo the structures not involved would be B and C. The question asks which is not involved, so the answer is either B or C.\\n\\nWait, the question asks which structure is not involved in the therapy. So the correct answer is either B (polyA) or C (R-loops). \\n\\nWhat's R-loops got to do with this? I don't think R-loops are part of splicing. So C is not involved.\\n\\nSo the structures involved in the therapy are A (lariat), D (antisense), and the spliceosome components. The polyA is part of mRNA but not directly involved in this splicing process. R-loops are not part of the splicing process.\\n\\nWait, the question is about the therapy. So the therapy uses an antisense molecule (D is involved), which is part of the process. The spliceosome and the lariat are involved in the splicing process. The polyA tail is part of mRNA, but the splicing occurs before the polyA tail is added. So the polyA tail isn't involved in the splicing process that this therapy affects. R-loops are not involved.\\n\\nSo the structures not involved would be either B or C.\\n\\nBut the options are four options, and I have to choose one that's not involved.\\n\\nThe question is about the structures involved in the therapy. The therapy uses an antisense molecule, so D is involved. The process of splicing uses the splice sites and the lariat (A). The polyA tail is not part of the splicing process in this context. R-loops are not part of the splicing process.\\n\\nSo the structures not involved are B and C. The question is which one is not involved. The options are A, B, C, D.\\n\\nThe question is about which structure is not involved. So the correct answer is either B or C.\\n\\nWait, the process is about splice site recognition. The 5' splice site is recognized by the spliceosome, and the Morpholino binds here, so the spliceosome's components are involved, including the lariat (A). The polyA tail is added after splicing, so it's not involved in the splicing process. R-loops are not part of the splicing mechanism.\\n\\nSo the structures not involved are polyA (B) and R-loops (C). The question is which one is not involved in\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>://\\n\\n</think>\\n\\nTo determine which structure is not involved in the proposed therapy, let's analyze the scenario and the options provided:\\n\\nThe question describes a gene with multiple exons, where central exons code for triple helical repeats that connect the cytoskeleton, sarcolemma, and extracellular space. Mutations causing out-of-frame deletions in these exons lead to degenerative conditions. The therapy involves delivering a Morpholino, which targets the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the spliceosome from binding, leading to exon skipping and in-frame joining of the remaining exons, which are well tolerated.\\n\\nNow, let's evaluate each option:\\n\\n- **Option A: Lariat**  \\n  The spliceosome forms a lariat structure during splicing, where the branch site adenine attacks the 3' splice site, creating a looped lariat structure. This process is essential for splicing, but the therapy described here involves preventing the spliceosome from binding, not directly interacting with the lariat structure. So, while lariats are involved in splicing, they are not directly relevant to the therapy described.\\n\\n- **Option B: PolyA tail**  \\n  The polyA tail is added to the 3' end of pre-mRNA and is important for mRNA stability and export from the nucleus. The therapy focuses on the 5' end of the exon, so the polyA tail is not directly involved in this process.\\n\\n- **Option C: R-loops**  \\n  R-loops are structures formed when RNA binds to DNA, causing the DNA strand to unwind and form a three-stranded structure with the non-template strand. This is not relevant to the described therapy, which involves splicing mechanisms rather than DNA-RNA interactions.\\n\\n- **Option D: Antisense**  \\n  Morpholinos are antisense oligonucleotides designed to bind to specific RNA sequences. This is a key part of the therapy described, as the Morpholino binds to the 5' end of the exon to prevent spliceosome binding. Thus, antisense molecules are directly involved in the therapy.\\n\\nBased on this analysis, the structure not involved in the therapy is **A) lariat**.\\n</think>\\n\\nThe therapy involves the use of Morpholino antisense oligonucleotides to target the 5' end of an out-of-frame exon in pre-mRNA, preventing spliceosome binding and leading to exon skipping. This process does not directly involve lariat structures, which are formed during splicing but are not relevant to the described mechanism. The polyA tail, R-loops, and antisense molecules are either unrelated or directly involved in the therapy.\\n\\nAnswer: A<ï½œendâ–ofâ–sentenceï½œ>\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>://\\nOkay, so I have this question about gene therapy and splice variants. Let me try to think through it step by step. \\n\\nThe question is about a gene that has many exons, and the central ones are important because they code for triple helical repeats that connect the cytoskeleton to the sarcolemma and the extracellular space. So, each exon usually codes for one of these helical structures. \\n\\nThe problem arises when there are mutations that cause central exon deletions, leading to out-of-frame peptides and progressive degenerative issues. Out-of-frame mutations usually mean that the reading frame is shifted, so the protein is messed up, leading to a nonfunctional protein, which is bad. \\n\\nThe solution proposed is to use a Morpholino that targets the 5' end of the out-of-frame exon in the pre-mRNA. Morpholinos are antisense oligonucleotides, right? They bind to specific RNA sequences. If the Morpholino recognizes the 5' end of the out-of-frame exon, it probably binds there and prevents the spliceosome from recognizing the exon, causing it to be skipped. So the exon is skipped, and the remaining exons are joined in frame, making an in-frame mRNA which might produce a functional protein.\\n\\nThe question is asking which structure is not involved in this therapy. The options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nWait, what do I remember about splicing and the spliceosome? The spliceosome is involved in removing introns, and in the splicing process, a lariat structure is formed. The spliceosome recognizes intron-exon boundaries. The 3' splice site has a branch site, and the intron forms a loop (the lariat) attached to the branch site adenine. So the lariat is involved in the splicing process.\\n\\nPolyA tail is added to the 3' end of mRNA, but that's more about mRNA processing, not directly about splicing. However, the splicing machinery is part of mRNA processing.\\n\\nAntisense refers to RNA sequences that are complementary to the target mRNA. Morpholinos are antisense molecules, so option D is part of the therapy.\\n\\nR-loops are structures formed when RNA is hybridized with DNA, causing the DNA to unwind. I'm not sure how this plays into splicing. R-loops are more about transcription or DNA repair, maybe.\\n\\nSo the therapy uses antisense (Morpholino) to block the splice site. The spliceosome binds the 5' splice site, so if the Morpholino is blocking that, the spliceosome can't recognize it. So the exon is skipped. \\n\\nIn the splicing process, the spliceosome recognizes the 5' splice site, which is usually at the beginning of the intron. If the Morpholino is antisense to the exon's 5' end, maybe it's binding to the RNA and blocking the recognition of that site, leading to the exon being excluded.\\n\\nSo what structures are involved in this therapy? The antisense (the Morpholino) is used, so D is involved. The lariat is part of the splicing process, so A is involved. The polyA tail is part of mRNA processing, so B is involved. R-loops, I think, are not directly involved in splicing. So the structure not involved is C) R-loops.\\n\\nWait, but do R-loops have any role in splicing? I'm trying to remember. R-loops are more about DNA-RNA hybrids forming structures that can affect gene expression, maybe during transcription. So they might form during DNA replication or transcription, but not directly involved in splicing. So the process described doesn't involve R-loops, so the correct answer would be C.\\n</think>\\n\\nTo address the question, we need to determine which structure is not involved in the described gene therapy using a Morpholino to treat exon deletions. Here's the analysis:\\n\\nThe gene in question has central exons that code for triple helical repeats important for cytoskeletal structure. Mutations causing central exon deletions lead to out-of-frame peptides, resulting in degenerative conditions. The therapy involves using a Morpholino, an antisense oligonucleotide, to bind to the 5' end of the out-of-frame exon in pre-mRNA. This binding prevents the spliceosome from recognizing the exon, leading to exon skipping and in-frame joining of the remaining exons, potentially restoring protein function.\\n\\n### Analysis of the Options:\\n1. **Lariat (A):** The lariat structure is a key part of the splicing process. During splicing, the branch site adenine forms a lariat structure with the intron. Since the spliceosome is involved in recognizing and processing the mRNA, the lariat is integral to this process. Therefore, the lariat is involved in the therapy.\\n\\n2. **PolyA tail (B):** The polyA tail is added to the 3' end of mRNA and is part of mRNA processing. While it is not directly involved in the splicing process, it is a component of mRNA, which is relevant to the overall gene expression. Thus, the polyA tail is involved in the therapy.\\n\\n3. **R-loops (C):** R-loops are structures formed when RNA binds to DNA, causing the DNA to unwind. These structures are more associated with transcription or other DNA-related processes, not with the splicing mechanism. The therapy described does not involve R-loops, so this structure is not involved.\\n\\n4. **Antisense (D):** Morpholinos are antisense oligonucleotides that bind to complementary RNA sequences. The therapy explicitly uses antisense molecules (the Morpholino) to block the spliceosome's recognition of the exon, making this structure directly involved in the therapy.\\n\\n### Conclusion:\\nThe structure not involved in the proposed therapy is **R-loops**, as they are unrelated to the splicing process or the use of Morpholinos. \\n\\nAnswer: C<ï½œendâ–ofâ–sentenceï½œ>\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>://\\nOkay, so I've got this question about genetics and gene therapy, and I'm a bit rusty, but I'll try to work through it. Let's see what the question is about.\\n\\nThe question talks about a gene with many exons, specifically central ones that code for these triple helical repeats. These repeats help connect the cytoskeleton with the sarcolemma and the extracellular space. So, the gene's structure is such that each exon codes for one of these alpha helices. The problem arises when there are central exon deletions, leading to out-of-frame peptides, which cause progressive organ degeneration. \\n\\nThe solution given is using a Morpholino that targets the 5' end of an out-of-frame exon in pre-mRNA. This Morpholino prevents the spliceosome from binding, leading to exon skipping and in-frame joining. The idea is that several missing exons are tolerable by the organism. The question is about which structure isn't involved in this therapy.\\n\\nThe options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nHmm. Let's break it down.\\n\\nFirst, I remember that exons are coding regions in DNA, and introns are non-coding, spliced out. The spliceosome recognizes intron-exon boundaries. When a mutation causes a deletion in a central exon, the reading frame shifts, leading to a truncated protein, which is probably nonfunctional, causing problems.\\n\\nMorpholino oligos are antisense oligonucleotides. They bind to specific RNA sequences to block certain processes. In this case, the Morpholino targets the 5' end of the out-of-frame exon. Wait, the 5' endâ€”so the beginning of the exon. So if the spliceosome binds to the intron-exon boundary, and the Morpholino is blocking the 5' splice site or the splice site recognition?\\n\\nWait, the 5' splice site is the donor site, where the intron starts. So, the spliceosome recognizes the intron's 5' end. If the Morpholino is binding to the 5' end of the exon, maybe it's actually binding to the region near the intron-exon boundary.\\n\\nWait, maybe the Morpholino is designed to bind the intron's 5' splice site, so that the spliceosome can't recognize it. Because the spliceosome binds to the intron's 5' end to initiate splicing. So if the Morpholino is an antisense molecule that prevents the spliceosome from binding, it would cause the intron to be skipped. Because the spliceosome can't recognize the splice site, so the intron isn't removed, but wait, wait, no, if the spliceosome can't bind, then the intron might be retained, but the question says exon skipping. Oh, wait, maybe the Morpholino is binding to the exon, so the spliceosome skips the exon. Hmm.\\n\\nWait, the spliceosome recognizes the intron's 5' splice site. If the Morpholino is antisense to the exon's 5' end, perhaps it's binding to the exon, causing the spliceosome to skip that exon. So the intron is retained, but the exon is not included. Or perhaps the splice site is in the intron. Let me think about the structure.\\n\\nIntron structure: the intron has a 5' end (GU at the beginning) and a 3' end (AG at the end). The spliceosome recognizes the 5' splice site (GU) and the branch site (branch point) for the lariat formation. So, during splicing, the intron is removed, and the exons are joined. \\n\\nIf the Morpholino is binding to the 5' end of the exon, perhaps it's binding to a region in the intron? Or maybe the exon's 5' end. Wait, the question says the Morpholino recognizes the 5' end of the out-of-frame exon. So the exon's 5' end is in the pre-mRNA, which is the part that's being spliced. The exon's 5' end is at the end of the intron. Hmm, no, wait. The exon is the coding sequence, so the intron is between exons. So the 5' end of the exon is the beginning of the exon. Wait, perhaps the Morpholino is binding to the 5' end of the exon, which is the beginning of the exon. So it's the region where the exon starts.\\n\\nWait, maybe I should think about how splicing works. The spliceosome recognizes the 5' splice site at the beginning of the intron. So, the intron starts with GU, and the spliceosome binds there. The first step in splicing is the recognition of the 5' splice site. The branch site is a little downstream.\\n\\nIf the Morpholino is designed to prevent the spliceosome from binding to the 5' splice site of the intron, then the spliceosome can't recognize the intron, so the intron isn't spliced out. But the question says the result is exon skipping, not intron retention. So maybe the spliceosome recognizes the exon instead.\\n\\nWait, I'm getting confused. Alternatively, the Morpholino could be binding to the exon, making the spliceosome skip it. For example, in alternative splicing, certain sequences can be recognized by the spliceosome to include or exclude exons. So if the Morpholino binds to the exon, it might mask the splice sites flanking the exon, leading to the exon being skipped. So, the spliceosome can't recognize the 3' splice site if the exon is skipped. Wait, but the question says the Morpholino prevents the spliceosome from binding. So perhaps it's blocking the recognition of the 5' splice site of the intron.\\n\\nWait, perhaps the Morpholino is an antisense to the intron's 5' end. So it binds to the intron's 5' end, preventing the spliceosome from binding. Without the spliceosome binding, the intron isn't recognized, so the spliceosome doesn't process it. But the question states that the result is exon skipping. Hmm, that doesn't align. Alternatively, maybe the Morpholino is binding to the exon, which causes the spliceosome to skip the exon.\\n\\nWait, another approach: When the spliceosome binds to the 5' splice site of the intron, it recruits components to remove the intron and join the exons. If the Morpholino blocks the 5' splice site, the intron isn't spliced out, but that's intron retention, which isn't what the question says. The question says the result is exon skipping, so the exon is excluded.\\n\\nSo maybe the Morpholino is binding to the exon's 5' end, making the spliceosome not recognize the exon. So the spliceosome can't recognize the exon, so it's skipped. But how does the spliceosome recognize exons? Wait, exons are part of the mRNA, and the spliceosome recognizes introns. The exons are the parts that remain. So perhaps the Morpholino is binding to the intron-exon boundary, preventing the spliceosome from recognizing the intron's 5' site. So the intron is not removed, but the exon is retained. Wait, but the question says the exon is skipped. Hmm.\\n\\nAlternatively, perhaps the Morpholino is binding to the 5' end of the exon, which is actually the beginning of the intron. No, the exon is the coding sequence. Let me think differently.\\n\\nWhen the spliceosome skips an exon, it's because the splice sites are not recognized. So for an exon to be skipped, the 5' splice site of the upstream intron and the 3' splice site of the downstream intron must not be recognized. Alternatively, perhaps the splice sites are blocked.\\n\\nWait, the question says the Morpholino prevents the spliceosome from binding. So maybe the spliceosome cannot recognize the intron's 5' splice site, so the intron is not spliced, but then the exon is retained. But the question says the result is exon skipping. So perhaps the spliceosome is not recognizing the intron, so the exon is not spliced in, but I'm not sure. Alternatively, perhaps the spliceosome is prevented from binding to the intron's 5' site, so the intron is retained. Hmm.\\n\\nAlternatively, perhaps the Morpholino is an antisense oligo that binds to the exon's 5' end, causing the exon to be skipped. Wait, how would that work? The splice sites are in the introns. So if the spliceosome can't recognize the intron's 5' site because the Morpholino is blocking, the intron isn't spliced, so the exon is retained. But the question says exon skipping, so perhaps the exon is excluded. Maybe I'm getting this wrong.\\n\\nAlternatively, the Morpholino could be binding to the exon's 5' end, which is the same as the intron's 5' end. So the spliceosome can't recognize the intron, leading to the intron being retained. But the question says the result is exon skipping. So perhaps the correct mechanism is that the spliceosome can't bind because the Morpholino is blocking the intron's 5' end, so the intron is not removed. So the exon is retained. But that would lead to a longer mRNA, but the question says it's in-frame.\\n\\nWait, the question says that the solution is that the exon is skipped. So the mRNA skips the exon, making the reading frame correct again. So the Morpholino must be\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>://\\n\\n</think>\\n\\nTo determine which structure is not involved in the proposed therapy, let's analyze the scenario and the options provided.\\n\\nThe question describes a gene with multiple exons, where the central exons code for triple helical repeats that connect the cytoskeleton, sarcolemma, and extracellular space. Mutations causing central exon deletions lead to out-of-frame peptides and degenerative conditions. The proposed therapy involves delivering a Morpholino that targets the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the spliceosome from binding, leading to exon skipping and in-frame joining of the remaining exons, which are well-tolerated.\\n\\n### Key Points:\\n1. **Morpholino Function**: Morpholinos are antisense oligonucleotides designed to bind to specific RNA sequences. In this case, the Morpholino targets the 5' splice site of the mutated exon, preventing the spliceosome from recognizing and splicing it out. This results in exon skipping, where the defective exon is excluded from the final mRNA, allowing the remaining exons to remain in-frame.\\n\\n2. **Exon Skipping**: Skipping an exon typically involves the spliceosome recognizing and removing the exon. This process is facilitated by the splicing machinery recognizing splice sites at the boundaries of exons. In this therapy, the Morpholino blocks the 5' splice site, preventing the exon from being recognized and spliced out.\\n\\n3. **In-Frame Joining**: By skipping the defective exon, the remaining exons remain in their original reading frame, preserving the protein structure. This is crucial for the proper function of the protein.\\n\\n4. **Tolerance of Missing Exons**: The organism can tolerate multiple missing exons, indicating that the exons are not essential for the protein's function.\\n\\n### Analysis of Options:\\n- **A) Lariat**: The lariat structure is a feature of the spliceosome's mechanism during splicing. However, in this therapy, the spliceosome is being blocked by the Morpholino, not the lariat itself being involved in the process. So, the lariat is not directly relevant here.\\n- **B) PolyA tail**: The polyA tail is added to the 3' end of the mRNA during processing. While splicing occurs before the polyA tail is added, the polyA tail itself is not directly involved in the exon skipping mechanism in this therapy.\\n- **C) R-loops**: R-loops are three-stranded structures involving RNA-DNA hybrids. There is no mention of R-loops being involved in this therapy, as the Morpholino acts by binding to RNA, not DNA or forming R-loops.\\n- **D) Antisense**: Morpholinos are antisense oligonucleotides, so this structure is directly involved in the therapy.\\n\\n### Conclusion:\\nThe structure not involved in the proposed therapy is the **lariat**. The lariat is part of the splicing mechanism, but it is not directly relevant to the exon-skipping process facilitated by the Morpholino in this context.\\n</think>\\n\\nThe structure not involved in the proposed therapy is the lariat. \\n\\nAnswer: A<ï½œendâ–ofâ–sentenceï½œ>\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>://\\n\\n</think>\\n\\nTo determine which structure is not involved in the proposed therapy, let's analyze the scenario and the options provided.\\n\\nThe question describes a gene with multiple exons, where the central exons code for triple helical repeats that connect the cytoskeleton with the sarcolemma and the extracellular space. Mutations in this gene often involve deletions of central exons, leading to out-of-frame peptides and progressive degenerative conditions. The proposed therapy uses a Morpholino molecule that targets the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the spliceosome from binding, causing exon skipping and allowing the remaining exons to join in an in-frame manner, which is well-tolerated by the organism.\\n\\n### Key Analysis of the Structures:\\n1. **Lariat**: The spliceosome forms a lariat structure during splicing, where the intron is removed and joined to form a looped structure. This process is essential for exon skipping, so the lariat is involved in the therapy.\\n\\n2. **PolyA tail**: The polyA tail is added to the 3' end of mRNA during processing and is a feature of mature mRNA. While it plays a role in RNA stability and export from the nucleus, the therapy described here focuses on splicing, so the polyA tail is not directly involved in the splice skipping mechanism.\\n\\n3. **R-loops**: R-loops are RNA:DNA hybrids formed during transcription and are associated with various genomic processes, including splicing. However, the therapy described does not mention R-loops being directly involved in the spliceosome-mediated exon skipping.\\n\\n4. **Antisense**: Morpholino molecules are antisense oligonucleotides that bind to specific RNA sequences to modulate splicing. The Morpholino used in this therapy is an antisense molecule that prevents spliceosome binding, so antisense is directly involved.\\n\\n### Conclusion:\\nThe structure not involved in the proposed therapy is the polyA tail.\\n</think>\\n\\nThe structure not involved in the proposed therapy is the polyA tail.\\n\\n**Answer: B**<ï½œendâ–ofâ–sentenceï½œ>\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>://mRNA splicing occurs during the processing of pre-mRNA, which is guided by spliceosomes. The spliceosome is a complex structure that recognizes specific sequences in the pre-mRNA to determine which exons are retained or removed. When the spliceosome binds, it removes introns and joins the exons. The introns are removed in a process that forms a lariat structure. The polyA tail is added after the mRNA is fully processed and is essential for stability and export of the mRNA from the nucleus to the cytoplasm.\\n\\nIn this scenario, a Morpholino is used to prevent the spliceosome from binding to the 5' splice site of an out-of-frame exon. This leads to the skipping of that exon, effectively creating an in-frame mRNA, which is a more stable and functional protein. The Morpholino acts as an antisense molecule that binds to the mRNA to block the spliceosome from recognizing the splice site.\\n\\nThe question asks which structure is not involved in this therapy. The options are lariat, polyA tail, R-loops, and antisense.\\n\\nThe lariat structure is formed during splicing when the intron is removed. Since the Morpholino prevents the spliceosome from recognizing the splice site, it doesn't directly involve the lariat structure. The polyA tail is added after splicing and is part of mRNA processing. Antisense molecules are used in this therapy to block the splice site, so antisense is involved. R-loops are structures formed when RNA binds to DNA, which doesn't seem to be part of this process.\\n\\nSo, the structure not involved is R-loops.\\n</think>\\n\\nTo address the question, let's analyze the process and the structures involved in the therapy described:\\n\\n1. **Understanding the Therapy**: The therapy involves using a Morpholino, which is an antisense molecule that binds to the 5' splice site of an out-of-frame exon in pre-mRNA. This prevents the spliceosome from recognizing the splice site, leading to exon skipping. This results in an in-frame mRNA, which is more stable and produces a functional protein.\\n\\n2. **Key Structures and Their Roles**:\\n   - **Lariat**: During mRNA splicing, introns are removed, and a lariat structure is formed. However, in this therapy, the spliceosome is prevented from binding, so the lariat is not directly involved in the splicing process that occurs due to the Morpholino.\\n   - **PolyA Tail**: The polyA tail is added after splicing and is essential for mRNA stability and export. While it is part of mRNA processing, it is not directly involved in the splicing mechanism altered by the Morpholino.\\n   - **R-loops**: R-loops are structures formed when RNA binds to DNA, typically in processes like transcription or other RNA-related functions. This structure is not relevant to the splicing process or the action of the Morpholino in this therapy.\\n   - **Antisense**: The Morpholino itself is an antisense molecule that binds to the pre-mRNA to block spliceosome recognition, making antisense a key component of the therapy.\\n\\n3. **Conclusion**: Among the options, R-loops are not involved in this therapeutic mechanism, as they are unrelated to the splicing process or the action of the Morpholino.\\n\\nANSWER: C<ï½œendâ–ofâ–sentenceï½œ>\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>:// I've got this genetics question here, and I'm a bit confused. Let me think through it step by step. Okay, so the question is about a gene with multiple exons, right? It's a large gene with many exons, specifically the central ones code for these triple helical repeats that connect the cytoskeleton with the sarcolemma and the extracellular space. Hmm, okay, so these exons are important for the structure of some kind of protein that links the cytoskeleton to the cell membrane, I think.\\n\\nEach exon usually codes for one of these folded triple alpha helices. So each exon is coding for a part of this triple helix. Now, the question says that the most common mutations are central exon deletions that create out-of-frame peptides. Wait, out-of-frame mutations are frameshifts, right? So if you delete a central exon, the reading frame shifts, leading to a messed up protein product. These are probably causing some kind of degenerative diseases, like maybe muscular dystrophy or something similar, where the protein doesn't function properly and the tissues waste away, hence 'organ waste' as the question says.\\n\\nThe solution proposed is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. Morpholinos are antisense oligos, right? They are synthetic RNA analogs that can bind to specific RNA sequences. So this Morpholino would bind to the pre-mRNA to prevent the spliceosome from binding.\\n\\nWait, the spliceosome recognizes intron-exon boundaries. Oh, but wait, the question says the Morpholino prevents the binding of the spliceosome. So if the spliceosome can't bind, maybe the exon is skipped. Because the spliceosome usually binds to the splice sites, and if something blocks that, the cell might skip that exon. So exon skipping would mean that the mRNA is processed without that exon. But since it's an out-of-frame exon, skipping it would lead to a frameshift being corrected, making the protein in-frame again. So the peptide would be correct, and the disease would be treated.\\n\\nThe question asks which structure is not involved in the therapy. The options are lariat, polyA tail, R-loops, antisense.\\n\\nWait, let's think about each option.\\n\\nOption A) lariat. The spliceosome creates a lariat structure during splicing. The intron is removed, and a branch site adenine attacks the 5' splice site, creating a loop. So lariat is definitely involved in splicing. Since the therapy is about splicing, lariat would be used.\\n\\nOption B) polyA tail. The polyA tail is added during mRNA processing. The polyA tail is added by the polyA polymerase, which is part of the mRNA processing steps. So if the spliceosome is involved, the polyA tail would be present. So polyA tail is involved.\\n\\nOption C) R-loops. R-loops are structures in DNA where RNA is hybridized to DNA, displacing the other DNA strand. They are more associated with certain genetic disorders, like some immunodeficiencies or maybe some diseases involving RNA-DNA interactions. I'm not sure how this ties in here. The Morpholino is an RNA analog, but the spliceosome is about splicing. Maybe R-loops aren't involved in splicing. So perhaps this is the correct answer.\\n\\nOption D) antisense. Antisense is exactly what the Morpholino is. The Morpholino is an antisense oligo that binds to the mRNA. So antisense is definitely involved.\\n\\nSo the question is asking which structure is not involved. So the options are lariat (involved), polyA tail (involved), R-loops (probably not), antisense (involved). So the structure not involved is R-loops. So the answer would be C.\\n</think>\\n\\nThe question describes a gene with multiple exons, where central exons code for triple helical repeats that connect the cytoskeleton with the sarcolemma and extracellular space. Mutations causing central exon deletions lead to out-of-frame peptides, resulting in degenerative effects. A Morpholino, an antisense oligonucleotide, is used to bind to the 5' end of the out-of-frame exon in pre-mRNA, preventing spliceosome binding and inducing exon skipping. This correction restores the reading frame, addressing the mutation.\\n\\nThe therapy involves several structures and processes:\\n\\n- **Option A: Lariat**  \\nThe spliceosome forms a lariat structure during splicing, where the intron is removed and joined to a branch site adenine. Since the therapy involves splicing, the lariat is directly involved.\\n\\n- **Option B: PolyA tail**  \\nThe polyA tail is added to the 3' end of mRNA during processing. Since the spliceosome is involved in mRNA processing, the polyA tail is also involved in this therapy.\\n\\n- **Option C: R-loops**  \\nR-loops are RNA-DNA hybrids that form during certain genetic processes, but they are not directly involved in splicing or the mechanism of Morpholino therapy. This is likely the correct answer as it is not part of the described therapy.\\n\\n- **Option D: Antisense**  \\nMorpholinos are antisense oligonucleotides that bind to RNA. This is the central mechanism of the therapy, making antisense directly involved.\\n\\nThe structure not involved in the therapy is **R-loops**.\\n\\nAnswer: C<ï½œendâ–ofâ–sentenceï½œ>\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>://\\n\\n</think>\\n\\nTo address the question, let's break down the scenario and the options provided:\\n\\nThe question is about a gene with multiple exons, where the central exons code for triple helical repeats that connect the cytoskeleton, sarcolemma, and extracellular space. The most common mutations are deletions in central exons, leading to out-of-frame peptides and progressive degenerative conditions. The proposed therapy involves delivering a Morpholino that targets the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the spliceosome from binding, causing exon skipping and in-frame joining, which is well-tolerated in the organism.\\n\\nNow, let's analyze the options to determine which structure is not involved in this therapy:\\n\\n1. **Option A: lariat**  \\n   The spliceosome forms a lariat structure during splicing. During splicing, the branch site adenine is transferred to the 3' end of the intron, forming a lariat structure. This process is essential for removing introns. Since the therapy involves spliceosome activity, the lariat is involved in splicing and is likely part of the process.\\n\\n2. **Option B: polyA tail**  \\n   The polyA tail is added to the 3' end of the mRNA during processing. This tail is added by the enzyme polyA polymerase and is important for mRNA stability and export from the nucleus. While the therapy targets the spliceosome, the polyA tail is not directly involved in the splicing process. However, its presence in the mRNA is a natural part of gene expression.\\n\\n3. **Option C: R-loops**  \\n   R-loops are structures formed when RNA binds to DNA, displacing the other DNA strand. They are typically associated with transcription and genome instability. There is no mention of R-loops in the context of spliceosome function or the proposed therapy. This option is unlikely to be involved.\\n\\n4. **Option D: antisense**  \\n   Morpholinos are antisense oligonucleotides designed to bind to specific RNA sequences. They are used in this therapy to block spliceosome binding, which is central to the mechanism of the therapy. Therefore, antisense molecules are directly involved.\\n\\nBased on this analysis, the structure not involved in the therapy is **R-loops**.\\n</think>\\n\\nThe therapy involves the use of Morpholinos, which are antisense molecules that bind to the 5' end of the out-of-frame exon in pre-mRNA to prevent spliceosome binding. This process facilitates exon skipping and in-frame joining. The spliceosome's role in splicing involves the formation of a lariat structure during intron removal. While the polyA tail is a natural part of mRNA processing, it is not directly involved in the splicing mechanism targeted by this therapy. R-loops, which are RNA-DNA structures linked to transcription and genome instability, are not relevant to the spliceosome or the therapy mechanism. Therefore, the structure not involved in the therapy is **R-loops**.\\n\\nAnswer: C<ï½œendâ–ofâ–sentenceï½œ>\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>://\\n\\n</think>\\n\\nTo address this question, let's break down the information provided and analyze the structures involved in the proposed therapy.\\n\\nThe question discusses a gene with multiple exons, where the central exons code for triple helical repeats that connect the cytoskeleton with the sarcolemma and extracellular space. Mutations in this gene often involve central exon deletions, leading to out-of-frame peptides and progressive degenerative conditions. The proposed therapy uses a Morpholino molecule that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the spliceosome from binding, causing exon skipping and allowing the remaining exons to join in an in-frame manner. The organism can tolerate the missing exons.\\n\\nNow, let's evaluate each option to identify which structure is not involved in this therapy:\\n\\n1. **A) Lariat**: The spliceosome is involved in splicing, where introns are removed and joined to form a lariat structure. Since the therapy involves spliceosome activity (splicing), the lariat is relevant and involved.\\n\\n2. **B) PolyA tail**: The polyA tail is added to the 3' end of mRNA during processing. While it's part of mRNA processing, the therapy described focuses on spliceosome activity and exon skipping, not polyA tail modification. The polyA tail is not directly involved in this specific mechanism.\\n\\n3. **C) R-loops**: R-loops are three-stranded structures formed by RNA:DNA hybrids. They are typically associated with genome instability and DNA repair mechanisms. There is no mention of R-loops in the described therapy, so this is unlikely to be involved.\\n\\n4. **D) Antisense**: Morpholino molecules are antisense oligonucleotides designed to bind to specific RNA sequences. This is a key part of the therapy, as the Morpholino recognizes and binds to the pre-mRNA.\\n\\nBased on this analysis, the structure not involved in the therapy is the polyA tail.\\n</think>\\n\\nTo address the question, let's analyze the structures involved in the proposed therapy:\\n\\n1. **A) Lariat**: The spliceosome facilitates splicing by removing introns and joining exons, forming a lariat structure. Since the therapy involves spliceosome activity (splicing), the lariat is relevant and involved.\\n\\n2. **B) PolyA tail**: The polyA tail is added to the 3' end of mRNA during processing. While it is part of mRNA processing, the therapy focuses on spliceosome activity and exon skipping, not polyA tail modification. Thus, the polyA tail is not directly involved in this specific mechanism.\\n\\n3. **C) R-loops**: These are three-stranded RNA:DNA hybrids typically associated with genome instability and repair mechanisms. There is no mention of R-loops in the described therapy, so this is unlikely to be involved.\\n\\n4. **D) Antisense**: Morpholino molecules are antisense oligonucleotides that bind to RNA sequences, which is a key part of the therapy. Therefore, antisense molecules are directly involved.\\n\\nThe structure not involved in the therapy is the polyA tail.\\n\\n**Answer: B**<ï½œendâ–ofâ–sentenceï½œ>\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>:// I need to figure out which structure is not involved in the spliceosome-mediated mRNA splicing process. The question is about a therapy using Morpholino, which is an antisense oligonucleotide. \\n\\nHmm, okay, let me think. So the question is about an alternative splicing mechanism. The scenario is that a large gene has many exons, and the central ones code for these triple helical structures. The most common mutations are deletions in the central exons causing out-of-frame changes, leading to a peptide that's not functional. The solution is using a Morpholino that targets the 5' end of the out-of-frame exon in pre-mRNA. The Morpholino prevents the spliceosome from binding, causing exon skipping and in-frame joining. So the therapy corrects the reading frame by skipping some exons without disrupting the rest. \\n\\nThe question asks which structure is not involved in the proposed therapy. The options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nWait, I'm a bit fuzzy on the spliceosome structure. I remember that the spliceosome is involved in splicing pre-mRNA. The spliceosome is a complex of snRNPs (small nuclear ribonucleoproteins). The process involves intron removal. The spliceosome recognizes splice sites: the donor site (GU at the beginning) and acceptor site (AG at the end). The intron is cut, and the exons are joined. During this process, an intron lariat is formed. So lariat structures are involved in the splicing mechanism. So the lariat is definitely involved. So option A is involved, so it's not the correct answer.\\n\\nPolyA tail: mRNA is processed after splicing. The polyA tail is added during mRNA maturation. I'm not sure if the spliceosome is involved in adding the polyA tail. Wait, the polyA tail is added by a different enzyme called the polyA polymerase, right? The polyA tail is added after splicing. So the spliceosome (which is involved in splicing) and the polyA addition is a separate process. So the polyA tail is not directly involved in the splicing process itself, but in mRNA processing. So if the therapy is about splicing, polyA is processed, but not involved in the splicing mechanism. Or wait, the question is about what's not involved in the therapy. The therapy uses an antisense molecule (Morpholino), which is an antisense oligonucleotide. So antisense is part of the therapy. So option D, antisense, is involved. So what's not involved.\\n\\nSo the structures involved in the spliceosome-mediated process: lariat (A) is involved, polyA is part of mRNA but not part of the splicing process. R-loops: R-loops are structures in DNA-RNA hybrids, but I don't recall their role in splicing. Wait, in RNA splicing, maybe R-loops are not involved. Alternatively, maybe they're formed during replication but not splicing. So R-loops might not be involved in the spliceosome process.\\n\\nSo the structures involved in the process: lariat (A is involved), polyA is part of mRNA (B is part of the mRNA, but not part of the splicing mechanism), antisense (D is part of the therapy, so involved). So the structures not involved would be C) R-loops.\\n\\nWait, let me think again. The question is which structure is not involved in the proposed therapy. The therapy uses a Morpholino, which is an antisense oligonucleotide. So antisense is part of the therapy (so D is involved). The spliceosome (so lariat is part of the splicing, so A is involved). The polyA tail is added after splicing, so it's not part of the splicing process. So the polyA tail isn't involved in the splicing process. So B) polyA tail is not involved. Or is the polyA part of the process?\\n\\nWait, the therapy is about splicing. The spliceosome is part of the splicing process. The polyA tail is added after splicing. So in the therapy, when the spliceosome acts, it doesn't involve the polyA tail. So structures not involved in the therapy would be polyA. So the question is, which is not involved. The options are:\\n\\nA) lariat â€” involved.\\n\\nB) polyA â€” not involved.\\n\\nC) R-loops â€” not involved.\\n\\nD) antisense â€” involved.\\n\\nWait, the question is about the therapy. The therapy uses antisense (so D is involved). The spliceosome is involved. So what's not involved? So the options are A, B, C, D.\\n\\nThe question is asking which structure is not involved. So the structures involved in the therapy are antisense (D) and the spliceosome (lariat A). The polyA tail (B) and R-loops (C) are not involved in the therapy.\\n\\nWait, but the therapy is about the splicing process. The polyA tail is part of mRNA processing, but not splicing. So in the therapy, the polyA tail is present, but it's not directly involved in the splicing mechanism. So which structure is not involved in the therapy?\\n\\nSo the question is about what is not involved in the therapy. The therapy uses the antisense molecule (so D is involved). The polyA tail is not part of the splicing, so it's not involved. So the structures not involved are B) polyA and C) R-loops. But the options are A, B, C, D.\\n\\nWait, the question is which structure is not involved in the proposed therapy. So the therapy is about the spliceosome-mediated exon skipping. The structures involved in the spliceosome are the lariat (A), and the antisense oligonucleotide (D). The polyA tail (B) is added after splicing, so it's part of mRNA but not directly part of the splicing. So, the structures not involved in the therapy would be polyA (B) and R-loops (C). But the options are A, B, C, D, and only one is not involved.\\n\\nWait, let me think again. The therapy is about splicing. The spliceosome is involved, which uses the lariat structure. The antisense is part of the therapy (so D is involved). So which structures are not involved in the therapy.\\n\\nThe polyA tail is not part of the splicing process. So the polyA tail is not involved in the therapy. R-loops are structures in DNA-RNA interactions, perhaps during transcription, but not in splicing. So in the therapy, which is about splicing, R-loops would not be involved. So the structures not involved in the therapy are polyA and R-loops.\\n\\nWait, but the question says, which structure is not involved in the proposed therapy. So the structures that are part of the process are the lariat (A) and antisense (D). So the structures not involved are B and C.\\n\\nWait, but the question is which structure is not involved. So the options are B and C, but the options are A, B, C, D. The question is about the therapy, so which is not involved. So the options are B) polyA tail, C) R-loops.\\n\\nBut the question is which structure is not involved in the therapy. So the therapy process is the splicing process, which includes the spliceosome, which includes lariat (A). The therapy uses antisense (D), so that's involved. The polyA is added after splicing, so it's not part of the splicing process. R-loops are not part of splicing. So which is not involved in the therapy: polyA (B) and R-loops (C). But the options are A, B, C, D. So the correct answer is either B or C.\\n\\nWait, the question asks which structure is not involved. So the correct answer is either B or C.\\n\\nWait, the therapy is about the spliceosome-mediated process. The spliceosome is a complex of snRNP particles. The polyA tail is added by a different mechanism. So polyA is not part of the spliceosome or the splicing process. R-loops are structures formed when RNA binds to DNA, but not directly involved in splicing.\\n\\nSo the structures involved in the therapy (splicing) are A (lariat) and D (antisense). So the structures not involved are B and C. But the options are each of the four structures.\\n\\nSo the question is which one is not involved. So the correct answer would be either B or C.\\n\\nWait, the question is about the therapy. The therapy uses the antisense molecule, which is D. So D is involved. So the structures not involved are B and C.\\n\\nBut the options are:\\n\\nA) lariat (involved)\\n\\nB) polyA tail (not involved)\\n\\nC) R-loops (not involved)\\n\\nD) antisense (involved)\\n\\nThe question is, which is not involved. So the answer must be either B or C.\\n\\nBut the question is about the process of the therapy. The therapy is about the spliceosome-mediated splicing, which involves the lariat (A). The antisense molecule is part of the therapy (D), so it's involved.\\n\\nSo the structures not involved in the therapy (splicing) are polyA (B) and R-loops (C).\\n\\nBut the options are A, B, C, D. The question is which is not involved in the therapy.\\n\\nWait, the polyA tail is part of mRNA, but it's added after splicing. So during splicing, the polyA is not present. So\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>://mRNA processing steps are involved in the splicing of pre-mRNA. The spliceosome is a complex structure composed of snRNPs (small nuclear ribonucleoproteins) that recognize splice sites. The spliceosome recognizes consensus sequences in the pre-mRNA, such as the donor and acceptor sites, and facilitates the removal of introns. The process includes the first step, where the 5' splice site is recognized and cleaved, followed by the second step, where the 3' splice site is recognized and cleaved, leading to the joining of the exons. During this process, a branch site adenosine is added to the intron, forming a lariat structure. The polyA tail is added after splicing and is important for mRNA stability and export from the nucleus.\\n\\nThe question asks which structure is not involved in the therapy described. The therapy involves using a Morpholino that recognizes the 5' end of an out-of-frame exon in the pre-mRNA. This Morpholino prevents the spliceosome from binding to the 5' splice site, leading to exon skipping. When the spliceosome cannot recognize the 5' splice site due to the Morpholino, the splicing mechanism adjusts by using a nearby downstream splice site, resulting in the skipping of the exon. This leads to an in-frame (correct reading frame) mRNA that is translated correctly.\\n\\nLooking at the options:\\n\\nA) lariat: involved in spliceosome function.\\nB) polyA tail: added after splicing and important for mRNA stability.\\nC) R-loops: structures formed during transcription and are involved in the regulation of gene expression.\\nD) antisense: Morpholino is an antisense oligonucleotide.\\n\\nWhich structure is not involved in the therapy? The therapy involves the spliceosome, so the lariat and polyA tail are directly involved. R-loops are not part of the splicing process, and antisense is a description of the Morpholino.\\n\\nWait, wait. So the question is which structure is NOT involved in the proposed therapy. So the therapy is about splicing, so structures involved in splicing would be involved. The options are A, B, C, D.\\n\\nThe therapy uses a Morpholino, which is antisense (D). So D is involved.\\n\\nOption C is R-loops. The therapy does not involve R-loops. R-loops are more about transcription (as they form during DNA transcription), maybe involved in gene expression regulation. So the therapy process doesn't use R-loops.\\n\\nSo the structures involved are lariat (A), polyA tail (B), antisense (D). So which is not involved? The one that is not used. So the structure not involved is C) R-loops.\\n</think>\\n\\nThe therapy described involves the use of a Morpholino, which is an antisense oligonucleotide designed to bind to the 5' end of an out-of-frame exon in pre-mRNA. This binding prevents the spliceosome from recognizing the 5' splice site, leading to exon skipping and the joining of the remaining exons in an in-frame manner. This process ensures the mRNA is correctly translated.\\n\\nAnalyzing the options:\\n\\n- **A) Lariat**: The lariat structure is a key part of the splicing process. During splicing, the branch site adenosine forms a lariat structure, which is essential for the removal of introns. Since the therapy involves splicing, the lariat is directly involved.\\n\\n- **B) PolyA tail**: The polyA tail is added after splicing and is crucial for mRNA stability and export from the nucleus. While it is not directly involved in the splicing process itself, it plays a supporting role in the overall mRNA processing.\\n\\n- **C) R-loops**: R-loops are structures formed during transcription and are associated with transcription regulation. They are not part of the splicing machinery or the mechanism of the therapy described. The therapy does not involve R-loops.\\n\\n- **D) Antisense**: The Morpholino used in the therapy is an antisense oligonucleotide, which is directly involved in the splicing process by binding to the pre-mRNA. Thus, antisense is part of the therapy.\\n\\nThe structure not involved in the therapy is **R-loops**, as they are unrelated to the splicing process or the Morpholino-based therapy described.\\n\\nAnswer: C<ï½œendâ–ofâ–sentenceï½œ>\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>://\\n\\n</think>\\n\\nTo determine which structure is not involved in the proposed therapy, let's analyze the question and the options provided.\\n\\nThe question describes a gene with multiple exons, where the central exons code for triple helical repeats involved in connecting the cytoskeleton with the sarcolemma and the extracellular space. Mutations causing central exon deletions lead to out-of-frame peptides and degenerative effects. The therapy involves delivering a Morpholino that binds to the 5' end of the out-of-frame exon in pre-mRNA. This prevents the spliceosome from recognizing the exon, leading to exon skipping and in-frame joining of the remaining exons. The therapy is well-tolerated when multiple exons are missing.\\n\\n### Key Analysis of the Options:\\n1. **Option A: lariat**  \\n   The spliceosome forms a lariat structure during splicing. This process is involved in the normal splicing of mRNA, but the therapy described here is about preventing the inclusion of a specific exon. While the spliceosome is involved, the lariat structure itself is not directly targeted by the Morpholino. Thus, it is not involved in the therapy.\\n\\n2. **Option B: polyA tail**  \\n   The polyA tail is added to the 3' end of mRNA during processing. This is a standard feature of mRNA, but the therapy described does not involve the polyA tail. The Morpholino targets the 5' end of an exon, not the polyA tail.\\n\\n3. **Option C: R-loops**  \\n   R-loops are RNA-DNA hybrids that form during transcription. They are not directly relevant to the splicing process or the mechanism of the Morpholino therapy described in the question. This option is unrelated.\\n\\n4. **Option D: antisense**  \\n   Morpholinos are antisense oligonucleotides that bind to complementary RNA sequences. This is a key part of the therapy described, as the Morpholino binds to the pre-mRNA to prevent splicing.\\n\\n### Conclusion:\\nThe therapy involves antisense molecules (Morpholinos) binding to the pre-mRNA, preventing the spliceosome from recognizing the exon. The lariat, polyA tail, and R-loops are not directly involved in this process. Therefore, the structure not involved is **A) lariat**.\\n</think>\\n\\nThe therapy uses antisense molecules (Morpholinos) to bind to the pre-mRNA and prevent the spliceosome from recognizing an out-of-frame exon, leading to exon skipping. This process does not involve the lariat structure, polyA tail, or R-loops. \\n\\nAnswer: A<ï½œendâ–ofâ–sentenceï½œ>\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>://\\n\\n</think>\\n\\nTo determine which structure is not involved in the proposed therapy, let's analyze the scenario:\\n\\nThe question describes a gene with multiple exons, where the central exons code for triple helical repeats involved in connecting the cytoskeleton, sarcolemma, and extracellular space. Mutations causing central exon deletions lead to out-of-frame peptides and degenerative conditions. The proposed therapy involves delivering a Morpholino that recognizes the 5' end of an out-of-frame exon in pre-mRNA. This Morpholino prevents the spliceosome from binding, leading to exon skipping and in-frame joining of the remaining exons. The therapy is well-tolerated when multiple exons are missing.\\n\\n### Key Analysis of the Options:\\n1. **Option A: lariat**  \\n   The spliceosome is involved in removing introns during splicing, forming a lariat structure as part of the splicing mechanism. Since the therapy involves spliceosome activity (splicing), the lariat is relevant and involved in this process.\\n\\n2. **Option B: polyA tail**  \\n   The polyA tail is added to the 3' end of mRNA during processing. While it's important for mRNA stability and export from the nucleus, the therapy described focuses on spliceosome function and exon skipping. The polyA tail is not directly involved in this specific mechanism.\\n\\n3. **Option C: R-loops**  \\n   R-loops are structures formed when RNA hybridizes with DNA, leading to the transcription process. There is no mention of DNA or transcription in the therapy described. The therapy acts on pre-mRNA and the spliceosome, so R-loops are not involved.\\n\\n4. **Option D: antisense**  \\n   Morpholinos are antisense oligonucleotides designed to bind to specific RNA sequences. The therapy uses antisense technology to target the 5' end of the exon, so antisense molecules are directly involved.\\n\\n### Conclusion:  \\nThe polyA tail and R-loops are not directly involved in the described therapy. However, based on the options provided, the question asks for the structure **not** involved. Between B and C, the polyA tail (B) is not directly part of the spliceosome or the splicing process being targeted by the therapy. Therefore, the structure not involved is the polyA tail.\\n\\nAnswer: B<ï½œendâ–ofâ–sentenceï½œ>\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>://\\nAlright, I'm trying to tackle this genetics question, but I'm a bit confused. Let me read through the problem again.\\n\\nSo, the question is about a gene with many exons, specifically central ones that code for triple helical repeats. These repeats connect the cytoskeleton with the sarcolemma and the extracellular space. Each exon usually codes for one of these triple helices. The common mutations are deletions in the central exons, causing out-of-frame peptides leading to degenerative diseases. The proposed solution is using a Morpholino that targets the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the spliceosome from binding and causes exon skipping, leading to in-frame joining. The question is about which structure is NOT involved in this therapy.\\n\\nThe options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nHmm, let me think about what each of these terms means and how they relate to the situation.\\n\\nFirst, the gene's structure: multiple exons, central exons are coding for triple helical structures. So, each exon probably forms a part of the protein. If a central exon is deleted, the reading frame shifts, leading to a peptide that's out-of-frame. This causes issues like the protein not folding correctly, leading to degenerative diseases.\\n\\nThe Morpholino is an antisense oligo. Antisense refers to RNA molecules that are complementary to a specific DNA or RNA sequence. Morpholinos are synthetic molecules that bind to RNA, often used to block certain sequences. So, the Morpholino here is binding to the pre-mRNA, the precursor mRNA.\\n\\nThe Morpholino targets the 5' end of the out-of-frame exon. Wait, the 5' end of the exon? Wait, but exons are parts of the mRNA. So, the pre-mRNA has introns and exons. The spliceosome recognizes the splice sites at the boundaries of exons. If an exon is missing, the spliceosome might skip it, but if it's in the middle, it can cause a frameshift.\\n\\nWait, but in this case, the Morpholino is binding to the pre-mRNA and preventing the spliceosome from binding. So, when the spliceosome can't recognize the splice sites, it skips the exon. Skipping the exon would mean that the mRNA doesn't include that exon. So, the mRNA would be shorter by that exon, which might restore the reading frame, making the peptide in-frame.\\n\\nNow, the question is about which structure is not involved in this therapy.\\n\\nThe options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nLet me go through each option:\\n\\nA) Lariat: The lariat structure is a structure formed during splicing. When introns are spliced out, the spliceosome removes the intron and forms a lariat structure. So during splicing, the intron forms a loop with the 3' OH group attaching to the branch site adenosine. So, lariat is part of the splicing process. But in this therapy, the spliceosome is prevented from binding, so the intron would not be spliced, but maybe the lariat isn't formed. Or perhaps the lariat is part of the process that's being altered.\\n\\nWait, but in the therapy, the spliceosome is prevented from recognizing the splice sites, so the intron wouldn't be removed, right? Or wait, the spliceosome is prevented from binding to the splice sites. So, the exons might not be joined correctly.\\n\\nWait, the therapy is causing exon skipping. So, the spliceosome is supposed to recognize the exon's splice sites. If the Morpholino blocks the recognition, the spliceosome can't recognize the site, so the exon is skipped. So, the intron remains attached, but without being spliced out. Wait, but that can't be right. Normally, the spliceosome recognizes the splice sites and removes the intron. If the splice sites are blocked, perhaps the intron is not spliced, so the mRNA would have the exon without the intron, but wait, no. Alternatively, the exon is removed. Let me think.\\n\\nWait, when a splice site is blocked, the spliceosome might skip the exon. So, the exon is excluded from the mRNA. So, the intron remains, but without being processed. Or does the intron just stay attached? Or does the spliceosome skip the exon, leading to a longer intron? Hmm, I'm a bit fuzzy on that.\\n\\nBut in any case, the lariat is part of the splicing process. So, if the spliceosome is prevented from binding, the lariat would not form because the intron isn't removed. So the lariat is involved in normal splicing but perhaps not in this therapy. Wait, but the therapy is using the spliceosome's inability to bind, so maybe the lariat isn't formed because the intron isn't spliced. But the question is about which structure is NOT involved.\\n\\nWait, the therapy uses the Morpholino to prevent the spliceosome from binding. So the spliceosome is involved, so the lariat is part of the normal splicing process, which is now not happening here. So the lariat is involved in the normal process but not in the therapy mechanism. Or perhaps the lariat isn't involved at all in this therapy.\\n\\nAlternatively, maybe the lariat is a structure that's formed, but since the spliceosome isn't working, it's not formed. So the lariat isn't part of the process here because the splicing isn't happening. So, perhaps the lariat is not involved in this therapy. Or maybe the lariat is part of the process, but the therapy is blocking it.\\n\\nAlternatively, if the spliceosome is prevented, the lariat is not formed, so the lariat isn't part of the therapy. Hmm, but the question is about which structure is NOT involved in the therapy.\\n\\nMoving on. Option B is polyA tail. The polyA tail is added during mRNA processing. The pre-mRNA is processed by adding a polyA tail at the 3' end. The spliceosome is involved in the initial steps of splicing, but the polyA tail is a separate process. The therapy is about splicing, so perhaps the polyA tail is involved in the pre-mRNA processing but not in this particular therapy's mechanism. Or maybe it's not involved at all. Hmm, but the question is about structures involved in the therapy. Since the therapy is about splicing, the polyA tail is part of mRNA processing but perhaps not directly involved in the splicing process that the Morpholino affects. So, if the spliceosome is prevented, the polyA tail is still added. So, polyA is present.\\n\\nOption C is R-loops. R-loops are structures formed during transcription when RNA binds to DNA, causing the DNA strand to loop. They can form during transcription when the RNA transcript is being made and anneals to the DNA. R-loops can interfere with transcription. I'm not sure how this applies here. The therapy is about splicing, so R-loops may not be directly involved. Unless the Morpholino somehow forms R-loops, but I don't think that's the case. Or maybe the Morpholino binding to RNA leads to some R-loop formation, but I don't think so. So perhaps R-loops are not involved in this therapy.\\n\\nOption D is antisense. The Morpholino is an antisense molecule, so antisense is definitely involved. So the therapy uses antisense technology.\\n\\nSo, the question is which structure is not involved. The options are A) lariat, B) polyA, C) R-loops, D) antisense.\\n\\nWait, the therapy uses antisense (D), so D is involved. So the structures not involved are either A, B, or C.\\n\\nThe therapy prevents the spliceosome from binding, which would prevent the formation of the lariat. Because in normal splicing, the spliceosome recognizes the splice sites, removes the intron, and the intron forms a lariat. If the spliceosome can't recognize the sites, the intron isn't removed, so the lariat isn't formed. So, the lariat is not part of this therapy; the lariat structure isn't present because the intron is not removed. So, the lariat is not involved. Alternatively, is it the other way around?\\n\\nWait, the question is about what's not involved in the therapy. The therapy uses the spliceosome binding. The lariat is a structure formed during normal splicing, but in this therapy, since the spliceosome isn't working, the lariat isn't formed. So the lariat is part of the normal process but not in the therapy.\\n\\nSo the structures involved in the therapy would be the spliceosome, antisense (Morpholino), the mRNA, and the splice sites. The structures involved in the therapy are the splice sites, the spliceosome, the pre-mRNA, and the antisense (Morpholino). The lariat is part of the process when the intron is normally spliced, but in this therapy, the intron isn't being spliced, so the lariat isn't formed. So the lariat isn't involved in the therapy.\\n\\nWait, the question is asking which is not involved. So the lariat is part of the normal splicing process, but in this therapy, it's not involved because the spliceosome isn't binding. So the lariat is not part of the therapy.\\n\\nAlternatively, the lariat is not part of the therapy's mechanism. So, the correct answer is either A or C.\\n\\nWhat about R-loops? R-loops are more about DNA-RNA hybrids,\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>://\\n\\n</think>\\n\\nTo determine which structure is not involved in the proposed therapy, let's analyze the scenario and the options provided:\\n\\nThe question describes a gene with multiple exons, where the central exons code for triple helical repeats that connect the cytoskeleton with the sarcolemma and the extracellular space. Mutations in this gene often involve central exon deletions, leading to out-of-frame peptides and progressive degenerative conditions. The proposed therapy uses a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the spliceosome from binding, causing exon skipping and in-frame joining of the remaining exons, which is well-tolerated by the organism.\\n\\n### Key Analysis of the Therapy:\\n1. **Morpholino Function**: Morpholinos are antisense oligonucleotides designed to bind to specific RNA sequences. In this case, the Morpholino targets the 5' end of the out-of-frame exon, leading to exon skipping. Skipping the exon restores the reading frame, as the remaining exons are joined in-frame.\\n   \\n2. **Spliceosome and Exon Skipping**: The spliceosome recognizes splice sites in pre-mRNA and removes introns. If the Morpholino blocks spliceosome binding, it disrupts the recognition of the exon, leading to its skipping. This process involves spliceosome machinery and splice sites.\\n\\n3. **In-Frame Joining**: Skipping an exon results in the remaining exons being joined in-frame, which is generally well-tolerated by the organism since the protein product remains functional.\\n\\n### Evaluation of the Options:\\n- **A) Lariat**: The lariat structure is a feature of splicing. During splicing, the intron is removed and joined to form a lariat structure. However, in this therapy, the spliceosome is prevented from binding, so the lariat structure is not directly involved in this specific process.\\n  \\n- **B) PolyA tail**: The polyA tail is added to the 3' end of mRNA during processing. While splicing is involved in mRNA maturation, the polyA tail is not directly related to the mechanism of exon skipping caused by the Morpholino.\\n\\n- **C) R-loops**: R-loops are structures formed when RNA hybridizes with DNA, typically leading to transcriptional silencing. This mechanism is not relevant to the spliceosome-mediated exon skipping in this context.\\n\\n- **D) Antisense**: Morpholinos are antisense molecules, as they bind to complementary RNA sequences. This is directly involved in the therapy described.\\n\\n### Conclusion:\\nThe therapy involves the use of antisense molecules (Morpholino) to block spliceosome binding and cause exon skipping. Structures like the lariat and polyA tail are not directly involved in this mechanism. R-loops are unrelated to the process. Therefore, the structure not involved is **A) lariat**.\\n</think>\\n\\nThe therapy involves the use of antisense molecules (Morpholino) to block spliceosome binding and cause exon skipping. The lariat structure, which forms during splicing, is not directly involved in this process. \\n\\nAnswer: A<ï½œendâ–ofâ–sentenceï½œ>\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>://start\\nOkay, so I've got this biology question here about gene therapy and exon skipping. Hmm, let me try to break it down. I'm a bit rusty, but I'll think through it.\\n\\nAlright, the question is about a gene that has many exons, and the central ones form triple helical structures connecting the cytoskeleton with the sarcolemma and extracellular space. Each exon codes for one of these triple helices. So I think this gene is probably involved in some structural protein, maybe something like the dystrophin gene, which is related to muscle function. Those triple helical repeats are common in certain proteins that form structures like the sarcospanin or dystrophin, which help link the cytoskeleton to the membrane.\\n\\nThe problem is that the most common mutations are deletions in the central exons, causing out-of-frame changes, leading to a truncated peptide. These mutations cause a wasting disease, probably muscular dystrophy or something similar. The solution proposed is using a Morpholino that targets the 5' end of the out-of-frame exon in the pre-mRNA. Morpholinos are antisense oligonucleotides, right? They bind to specific RNA sequences and can block certain interactions, like preventing the spliceosome from recognizing certain splice sites.\\n\\nSo the idea is that the Morpholino would bind to the 5' end of the mutated exon. Wait, the pre-mRNA is the precursor mRNA before splicing. The spliceosome recognizes intron-exon boundaries. If the exon is out-of-frame, maybe the spliceosome is trying to splice in a way that skips that exon, but the Morpholino is preventing that. Or wait, no. Wait, the question says the Morpholino recognizes the 5' end of the out-of-frame exon and prevents the spliceosome from binding. So I think the spliceosome usually recognizes the splice sites, which are at the intron ends. So if the exon is deleted, maybe the spliceosome is trying to skip the exon, but the Morpholino is blocking that.\\n\\nWait, the question says the Morpholino prevents the spliceosome from binding, leading to exon skipping. Oh, so the spliceosome would normally recognize the exon's ends, but the Morpholino is blocking that recognition, causing the exon to be skipped. So, when the spliceosome can't recognize the exon, it gets excluded from the mRNA. So the mRNA that's made would have some exons missing, but since the exons are in the middle, the reading frame is restored because the number of missing exons is manageable. The organism can tolerate that. So the peptide becomes in-frame again, thus functional.\\n\\nThe question is about which structure isn't involved in this therapy. The options are lariat, polyA tail, R-loops, antisense.\\n\\nI think about the process. The spliceosome is involved, which creates the lariat structures as part of splicing. The polyA tail is added after splicing, so it's probably involved. Antisense molecules like Morpholinos bind to RNA, so antisense is involved. R-loops are RNA:DNA hybrids. Wait, but in this therapy, the Morpholino is binding to RNA. So do R-loops form here? I don't think so. R-loops are usually when RNA binds to DNA, displacing the DNA strand. But the Morpholino is binding RNA, so R-loops shouldn't be involved.\\n\\nWait, but wait. Morpholino is an antisense molecule, so it's an RNA analog. It's a DNA analog that binds to RNA. So the structure would be RNA:DNA, but in this case, the Morpholino is binding to RNA. So R-loops involve RNA pairing with DNA. If the Morpholino is just binding RNA, then R-loops might not be part of this process.\\n\\nSo which structures are involved? The process includes spliceosomes, which form the lariat during splicing. The polyA tail is added later. The Morpholino is antisense, so that's involved. So the structures involved are lariat (A), polyA (B), antisense (D), so the structure not involved would be R-loops (C).\\n\\nWait, but the question asks which structure is NOT involved. So the correct answer would be C, R-loops.\\n\\nLet me double-check. The therapy uses a Morpholino that binds the 5' end of the out-of-frame exon. The spliceosome is trying to splice around that exon. The Morpholino blocks the splice site, causing the exon to be skipped. So the splicing process happens, but the exon is skipped, so the mRNA is shorter but the reading frame is maintained because the number of exons is a multiple of three, I guess.\\n\\nSo the structures involved in splicing include the spliceosome, which forms the lariat. The polyA tail is added after splicing. The Morpholino is antisense, so D is involved. R-loops aren't involved here because the Morpholino binds RNA, not DNA.\\n</think>\\n\\nThe question describes a gene therapy approach using a Morpholino to address a genetic disorder caused by central exon deletions. These deletions lead to out-of-frame mutations, resulting in truncated, non-functional proteins. The Morpholino, an antisense oligonucleotide, binds to the 5' end of the out-of-frame exon, preventing the spliceosome from recognizing the exon and leading to its skipping. This results in an in-frame mRNA, which is well-tolerated by the organism.\\n\\nTo determine which structure is not involved in this therapy:\\n\\n1. **Lariat (Option A):** The spliceosome forms lariat structures during splicing, which is a key step in the process of removing introns. Since splicing occurs in this therapy, the lariat is involved.\\n\\n2. **PolyA tail (Option B):** The polyA tail is added to the 3' end of the mRNA after splicing. While it is not directly involved in the splicing process itself, it is part of the mRNA maturation and stability, which could be relevant to the therapy.\\n\\n3. **R-loops (Option C):** R-loops are RNA:DNA hybrids that form when RNA binds to DNA, displacing one DNA strand. In this therapy, the Morpholino binds to RNA, not DNA, so R-loops are not involved.\\n\\n4. **Antisense (Option D):** Morpholinos are antisense molecules that bind to RNA, and this is the mechanism of action in the therapy. Therefore, antisense is directly involved.\\n\\nSince the therapy does not involve RNA:DNA hybrids (R-loops), the structure not involved is **C) R-loops**.\\n\\nAnswer: C<ï½œendâ–ofâ–sentenceï½œ>\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>://start\\n\\nOkay, so I've got this biology question here about gene therapy using something called Morpholino. Hmm, I'm a bit rusty on this, but I'll try to think it through.\\n\\nThe question is about a gene with multiple exons, specifically central ones that code for triple helical repeats connecting the cytoskeleton with the sarcolemma and extracellular space. So, each exon usually codes for a part of this structure. The problem is that the most common mutations are central exon deletions leading to out-of-frame peptides, causing progressive organ degeneration. \\n\\nThe solution uses a Morpholino that targets the 5' end of the out-of-frame exon in pre-mRNA. Morpholino, if I remember correctly, is an antisense oligonucleotide. Antisense molecules bind to RNA, right? So the Morpholino probably binds to the mRNA, preventing the spliceosome from recognizing the exon. This skipping of the exon leads to in-frame joining, which might help the protein structure.\\n\\nThe question asks which structure is NOT involved in the therapy. The options are lariat, polyA tail, R-loops, or antisense.\\n\\nWait, what do I know about each of these structures? Let's break them down.\\n\\nFirst, the lariat. I remember that during splicing, the spliceosome forms a lariat structure when introns are removed. The spliceosome's mechanism involves the branch site adenine, which forms a lariat structure. So when an exon is skipped, that process might not form, but I'm not sure how that ties in here.\\n\\nPolyA tail is the tail at the 3' end of mRNA. I don't think the polyA tail is directly involved in splicing decisions. The polyA tail is more about stability and export from the nucleus, maybe.\\n\\nR-loops are structures in DNA where RNA is bound to DNA, causing the DNA to form a loop. I'm not exactly sure how this fits in with the therapy. Wait, Morpholino binds to RNA, so maybe R-loops are involved in that process somehow. Or maybe not.\\n\\nAntisense is the key here. Morpholino is an antisense molecule, so the therapy uses antisense. So option D, antisense, is involved. So the question is about which is NOT involved. So if the options are A to D, and the therapy uses antisense, then the structure not involved would be one of the others.\\n\\nWait, the therapy uses antisense (so D is involved, so it's not the correct answer), so the question is which is not involved. Let me think about each option.\\n\\nThe therapy works by binding to the 5' end of the out-of-frame exon. So the Morpholino binds to the pre-mRNA. When the spliceosome comes along, it normally recognizes the exon-exon junctions. If the Morpholino blocks the 5' splice site, the spliceosome might skip that exon. So during splicing, the exon is excluded, and the remaining exons are joined in frame, making a normal protein.\\n\\nWhat structures are involved in splicing? The spliceosome is involved, which includes small nuclear RNA (snRNA) and various proteins. The splice sites are the donor (GU at the intron start) and acceptor (AG at intron end). The branch site is where the lariat forms.\\n\\nIn the therapy, the Morpholino acts as a decoy. So the spliceosome's recognition of the exon is blocked. So the process would prevent the exon from being included, hence skipping it. So the lariat is formed from the branch site, but if an exon is skipped, maybe the lariat is part of the process whether or not the exon is included. Or perhaps the lariat is still formed, but the exon is skipped.\\n\\nWait, if an exon is skipped, the intron is usually processed. So during normal splicing, the intron is removed as a lariat. If an exon is skipped, maybe the intron is processed normally. So the lariat would still be involved because the intron is removed as usual.\\n\\nSo in this therapy, the lariat (A) is involved. So A is involved, so not the correct answer.\\n\\nPolyA tail: the polyA tail is added to the 3' end of mRNA. The splicing process occurs before the polyA tail is added. So the polyA tail isn't directly involved in the splicing process. So in the therapy, the polyA tail is not directly involved. But wait, is it part of the pre-mRNA? The Morpholino binds to the pre-mRNA, which is before the polyA tail is added. So polyA tail is part of the mRNA after splicing. So the polyA tail isn't involved in this splicing process. So the polyA tail is not involved in the therapy process. But wait, the question is which structure is not involved in the therapy. The therapy uses the pre-mRNA, so the polyA tail is not part of that process. So the polyA tail (option B) is not involved in the therapy, meaning it's not involved in the proposed therapy. But wait, the therapy doesn't involve the polyA tail. So the question is, which structure is not involved in the therapy. So the therapy involves the spliceosome, antisense (Morpholino), lariat (splicing process), but not the polyA tail.\\n\\nAlternatively, the polyA tail is part of mRNA, but the splicing occurs before the tail is added. So the polyA tail is not part of the splicing process. So in the therapy, the polyA tail isn't directly involved. So the question is, which structure is not involved in the therapy? The options are the structures related to the process. So the therapy uses splice sites, spliceosome, lariat, and the antisense (Morpholino). The polyA tail is not part of the splicing process, so it's not involved. So the structure not involved is the polyA tail.\\n\\nWait, but the question is about the therapy's structures involved. So which structure is not involved? The therapy uses the antisense (so D is involved), the lariat (A is involved), and the polyA tail (B) is not involved. So the answer is B) polyA tail.\\n</think>\\n\\nThe question involves a gene therapy approach using Morpholino, an antisense oligonucleotide, to address central exon deletions in a gene. These deletions cause out-of-frame mutations, leading to misfolded proteins and degenerative conditions. The Morpholino binds to the 5' end of the out-of-frame exon in pre-mRNA, preventing the spliceosome from recognizing the exon and causing it to be skipped. This results in in-frame joining of the remaining exons, potentially restoring protein function.\\n\\nTo determine which structure is NOT involved in this therapy, let us analyze the options:\\n\\n1. **Lariat (Option A):** During splicing, the spliceosome removes introns by forming a lariat structure at the branch site. Even when an exon is skipped, the intron is still processed into a lariat. Therefore, the lariat is involved in the splicing process and is part of the therapy.\\n\\n2. **PolyA tail (Option B):** The polyA tail is added to the 3' end of mRNA after splicing. It is not directly involved in the splicing process itself or in the recognition of splice sites. Since the therapy focuses on splicing machinery and antisense binding, the polyA tail is not directly involved in this therapy.\\n\\n3. **R-loops (Option C):** R-loops are structures where RNA binds to DNA, forming a loop. While R-loops can influence gene expression in other contexts, they are not relevant to the spliceosome or the mechanism of Morpholino action in this therapy.\\n\\n4. **Antisense (Option D):** Morpholino is an antisense oligonucleotide that binds to the pre-mRNA to block splice site recognition. This is the key mechanism of the therapy, so antisense is directly involved.\\n\\nIn summary, the therapy involves the spliceosome, lariat formation, and antisense binding, but the polyA tail is not directly involved in the splicing process or the therapy mechanism. Therefore, the structure not involved is the polyA tail.\\n\\nAnswer: B<ï½œendâ–ofâ–sentenceï½œ>\", '<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>://\\nOkay, so I\\'ve got this genetics question in front of me, and I\\'m trying to figure it out. Let me read through it carefully.\\n\\nThe question is about a gene with many exons, and the central ones code for these triple helical repeats that connect the cytoskeleton with the sarcolemma and extracellular space. Each exon usually codes for one of these triple helices. The most common mutations are deletions in the central exons, causing out-of-frame peptides leading to degenerative issues. So the solution is to use a Morpholino that targets the 5\\' end of the out-of-frame exon in the pre-mRNA. This Morpholino prevents the spliceosome from binding, causing exon skipping, which allows the mRNA to join in an in-frame way. The question asks which structure isn\\'t involved in this therapy.\\n\\nThe options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nHmm, I need to remember what each of these structures does. \\n\\nFirst, the scenario: using a Morpholino to skip an exon. Morpholino oligos are antisense oligonucleotides, right? They bind to specific RNA sequences. Since it\\'s targeting the 5\\' end of the exon, the Morpholino probably binds to the pre-mRNA and stops the spliceosome from recognizing that exon, so the exon is skipped. Skipping the exon would mean that the mRNA is joined without that exon, making it in-frame again. So the exon is spliced out, but since the deletion was out-of-frame, skipping it corrects the reading frame.\\n\\nNow, the options: \\n\\nOption A is lariat. Wait, the lariat is part of the splicing process. When introns are spliced out, the intron forms a lariat structure with the branch site adenine. So the lariat is involved in the splicing process. Since the Morpholino is affecting splicing, the lariat is involved. So A is involved, so it\\'s not the correct answer.\\n\\nOption B: polyA tail. The polyA tail is added to the 3\\' end of mRNA. The process of splicing occurs before the polyadenylation. The spliceosome\\'s machinery includes the polyA polymerase. So if an exon is skipped, would the polyA tail be affected? The polyA addition is part of the mRNA processing, but the question is about splicing, so the polyA tail is involved in mRNA stability and export, but not directly in the splicing decision. Wait, but during splicing, the polyA tail is added after splicing. So if exons are skipped, does the polyA tail come after that? So polyA is part of mRNA processing but not directly involved in the splicing process itself. Hmm, not sure yet.\\n\\nOption C: R-loops. R-loops are RNA:DNA hybrids. They form when the RNA is bound to DNA, displacing the other DNA strand. R-loops can cause genome instability and are involved in things like gene expression and DNA repair. I don\\'t see how this relates to splicing. Morpholino binds to RNA, so R-loops don\\'t seem relevant here. So maybe C is the correct answer because R-loops aren\\'t involved in this therapy.\\n\\nOption D: antisense. Morpholino is an antisense molecule, meaning it\\'s complementary to the target RNA. So antisense is definitely involved in the therapy. So D is part of the process, so not the correct answer.\\n\\nSo the question is which structure is NOT involved. So the options are B and C.\\n\\nWait, the therapy is using an antisense molecule (D is involved). So the structures involved in the therapy would be the spliceosome (A, involved), the pre-mRNA (so polyA is part of mRNA, but is it involved in the splicing process?), and antisense (D is involved). R-loops are not part of splicing, so the answer is C.\\n\\nWait, the polyA tail is added after splicing, so it\\'s part of mRNA processing but not part of the splicing mechanism. But the question is which structure is not involved in the therapy. So the therapy is about splicing. The structures involved in splicing include splice sites, the spliceosome, branch sites (lariat), and the exons being spliced. The polyA tail is added after splicing, so it\\'s not directly involved in the splicing process. So option B, the polyA tail, is not involved. Hmm, but wait, does the polyA tail affect splicing? I don\\'t think so. PolyA is added after splicing, so it\\'s not directly involved.\\n\\nWait, but the question is about what\\'s not involved in the therapy. The therapy involves the spliceosome (A is involved), the antisense molecule (D is involved), the polyA tail is part of mRNA but not part of splicing. So the polyA tail isn\\'t involved in the splicing process. So B is not involved, so the correct answer would be B.\\n\\nWait, but earlier I thought the answer was C. Let me think again. The therapy is about splicing. The polyA tail is added after splicing. So during splicing, the polyA is not present. So the polyA tail is not part of the splicing mechanism. So which structure is not involved in the therapy? The therapy uses antisense (D), lariat (A) is part of splicing, so the structures involved are A and D. So the structures not involved are B (polyA) and C (R-loops). Wait, but R-loops are not part of the process.\\n\\nWait, the question is about which is not involved. So the options are A, B, C, D.\\n\\nWhich of these is not involved in the therapy. So the therapy involves the spliceosome, antisense, and exons. So the polyA tail is part of mRNA but not involved in splicing. So the structures involved in the therapy are A, D, and the pre-mRNA, but not B and C.\\n\\nWait, the polyA tail is added by the polyA polymerase, which is part of the mRNA processing. The question is about which is not involved in the therapy. So the therapy is about splicing. So polyA is not involved in splicing, so the structure not involved is B. So the correct answer is B.\\n\\nWait, but I thought the answer was C earlier because I thought R-loops aren\\'t involved. But the options are about the structures involved in the therapy.\\n\\nWait, what\\'s R-loops? They\\'re involved in gene expression but not in splicing. So in the therapy, the process is about splicing, so R-loops aren\\'t involved. So the structures not involved are C and B.\\n\\nWait, but the question is which one is not involved. So which of the options is not involved. So the correct answer is either B or C.\\n\\nWait, the therapy uses antisense (D is involved), so D is not the answer. The lariat (A) is part of splicing, so A is involved, not the answer. So the structures not involved are B and C. So the question is, which one is not involved.\\n\\nIf the therapy is about splicing, then the polyA tail is not part of splicing. So the polyA tail (B) is not involved. R-loops (C) are not involved in splicing. So both B and C are not involved. But the question says \"which structure is not involved\".\\n\\nWait, but looking back: the therapy is about splicing. The polyA tail is part of mRNA processing, but not of splicing. So B is not involved. R-loops are about DNA-RNA interactions, which are not part of splicing. So both B and C are not involved. But the question asks for which one is not involved.\\n\\nWait, perhaps I made a mistake. The polyA tail is added after splicing. So during splicing, the polyA is not present. So in the splicing process, the polyA is not involved. So when the spliceosome skips an exon, the polyA tail is added afterward, but it\\'s not part of the splicing process. So the polyA is not involved in the splicing process itself.\\n\\nSo the structures involved in the therapy are: spliceosome (A is involved), antisense (D is involved), and the pre-mRNA. So the structures not involved are polyA (B) and R-loops (C). But the options are single choice.\\n\\nWait, the question says \"which structure is not involved in the proposed therapy.\" So perhaps the polyA tail is not involved. So the correct answer is B.\\n\\nWait, but in the therapy, the polyA tail is part of mRNA, but it\\'s not part of the splicing mechanism. So the structure not involved is C) R-loops because R-loops are about DNA-RNA binding, which isn\\'t part of the splicing process.\\n\\nWait, the therapy is about the splicing of the pre-mRNA. So the structures involved are splice sites, the spliceosome, the branch site (lariat), and the antisense molecule. The polyA is added after splicing, so it\\'s not involved in the splicing process. R-loops are not involved in splicing. So the options are B and C. But the question is about which is not involved.\\n\\nWait, the question asks which is not involved in the therapy. So the therapy process includes the spliceosome (so A is involved, not the answer). The polyA is part of mRNA but not in splicing (so B is not involved). R-loops (C) are not involved. Antisense (D) is involved.\\n\\nSo, the question is which structure is not', \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>://question about exons and mRNA splicing\\n\\nOkay, so I have this question about gene therapy and mRNA splicing. Hmm, I remember that exons are the coding parts of a gene, right? So the question says that a large gene has many exons, and the central ones are important because they code for these triple helical repeats that connect the cytoskeleton with the sarcolemma and the extracellular space. Oh wait, I think the sarcolemma is the cell membrane, but wait, no, the sarcolemma is the sarcoplasmic reticulum, or maybe it's the cell membrane? Wait, no, I'm getting confused. Oh right, the sarcolemma is actually the cell membrane, but wait, no, wait, I think I'm mixing things up. The sarcolemma is a term I'm not too familiar with. Oh wait, I think it's the sarcoplasmic reticulum's membrane, which is a part of the cell's structure, but I'm not entirely sure. Maybe it's not super relevant right now.\\n\\nEach exon codes for one of these triple helical repeats, so the gene has a lot of exons that code for these structures. The most common mutations are deletions in the central exons, which cause the protein to be out-of-frame. Out-of-frame mutations usually lead to frameshifts, which can cause all sorts of issues because the reading frame is messed up. So the protein doesn't fold correctly, leading to some degenerative disease or organ failure.\\n\\nThe solution proposed is to use a Morpholino that targets the 5' end of the out-of-frame exon in the pre-mRNA. Morpholinos are antisense oligonucleotides, right? They bind to specific sequences on the RNA and can block certain interactions. So if the spliceosome is about to recognize that exon, the Morpholino would prevent it from being included, leading to exon skipping. So the exon is skipped, and when the mRNA is spliced, the remaining exons are joined in frame, making the protein in-frame. This way, the protein might be functional again because it doesn't have the faulty exons.\\n\\nThe question is about which structure isn't involved in this therapy. The options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nWait, so I need to think about what each of these structures is involved in.\\n\\nFirst, lariat. I remember that in splicing, the spliceosome creates a lariat structure. The intron is removed, and a branch site adenine is used to form a loop, so the lariat is part of the spliceosome's process. So the spliceosome is involved, so lariat is involved in the splicing process. So A is involved.\\n\\nPolyA tail is added to the 3' end of mRNA. I think the polyA tail is involved in mRNA stability and export from the nucleus. But in this therapy, the spliceosome is acting on the pre-mRNA, so the polyA tail is probably not directly involved here. But wait, the polyA tail is added after splicing, so perhaps it's not involved in the splicing process itself. Or maybe it is? I'm a bit fuzzy on that. Alternatively, the polyA tail is added after the mRNA is processed, so the spliceosome's action doesn't directly involve the polyA tail. So maybe B is not involved.\\n\\nR-loops. I'm a bit unsure about R-loops. R-loops are structures in DNA where RNA is bound to DNA, causing the DNA to form a loop. I think they can form during transcription, maybe leading to certain genomic regions being read or not. But how does that relate to splicing? I'm not too sure. Alternatively, maybe during splicing, some RNA structures form, but I don't recall R-loops being part of the splicing process. So perhaps R-loops are not involved in this therapy. So C might be the answer.\\n\\nAntisense is involved because the Morpholino is an antisense oligonucleotide. Antisense molecules bind to complementary sequences on the RNA. So option D is involved, so not the correct answer.\\n\\nSo the question is which is not involved. The correct answer would be the structure not involved. The structures involved are lariat, antisense (Morpholino), and polyA. Wait, no: wait, the polyA tail is added after splicing, so perhaps it's not part of the splicing process itself. So the therapy doesn't directly involve the polyA tail. So the structures involved are lariat (A), antisense (D), and maybe polyA is not involved.\\n\\nWait, but wait: the therapy is about the spliceosome. The spliceosome recognizes certain signals in the pre-mRNA. The Morpholino binds the 5' splice site of the exon. The spliceosome is involved in splicing, which uses the branch site adenine to form the lariat. So the lariat is definitely involved.\\n\\nSo the options are:\\n\\nA) lariat - involved\\nB) polyA - maybe not\\nC) R-loops - not involved\\nD) antisense - yes, because the Morpholino is antisense\\n\\nThe question is which structure is NOT involved. So the structures not involved are C) R-loops.\\n\\nSo the correct answer is C.\\n</think>\\n\\nTo address the question, we need to determine which structure is not involved in the proposed gene therapy. The therapy involves using a Morpholino, an antisense oligonucleotide, to bind to the 5' end of an out-of-frame exon in pre-mRNA, thereby preventing the spliceosome from recognizing it and causing exon skipping. This results in an in-frame mRNA, which is more likely to produce a functional protein.\\n\\n### Analysis of the options:\\n\\n1. **Lariat (A)**: The spliceosome forms a lariat structure during splicing when the intron is removed. This process is integral to the splicing mechanism, and since the therapy involves spliceosome action, the lariat is directly involved.\\n\\n2. **PolyA tail (B)**: The polyA tail is added to the 3' end of mRNA after splicing and is involved in mRNA stability and export from the nucleus. However, the splicing process itself does not directly involve the polyA tail, so it is not directly relevant to this therapy.\\n\\n3. **R-loops (C)**: R-loops are RNA-DNA structures that form during transcription and are not part of the splicing process. They are not involved in the spliceosome's function or the mechanism of exon skipping in this therapy.\\n\\n4. **Antisense (D)**: The Morpholino is an antisense oligonucleotide that binds to the pre-mRNA, making antisense mechanisms central to the therapy.\\n\\n### Conclusion:\\nThe structure not involved in the therapy is **R-loops**, as they are unrelated to the spliceosome or the splicing process.\\n\\nAnswer: C<ï½œendâ–ofâ–sentenceï½œ>\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>://start\\nOkay, so I've got this genetics question here, and I need to figure it out. Let me read through it carefully.\\n\\nThe question is about a gene with many exons. The central exons code for triple helical repeats that connect the cytoskeleton with the sarcolemma and extracellular space. Each exon makes a folded triple helix. The common mutations are deletions in the central exons, causing out-of-frame peptides and leading to progressive organ degeneration. The solution is using a Morpholino that targets the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the spliceosome from binding, causing exon skipping and in-frame joining. The organism can tolerate missing exons. The question is which structure isn't involved in this therapy.\\n\\nThe options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nHmm. So the therapy uses a Morpholino, which is an antisense molecule. I remember that Morpholino oligos are synthetic antisense oligonucleotides. Antisense technology is used to block gene expression by binding to specific DNA sequences. But wait, here it's about pre-mRNA. Oh, so the Morpholino is binding to the pre-mRNA.\\n\\nIn this scenario, the Morpholino recognizes the 5' end of the out-of-frame exon. So it's acting on the pre-mRNA. The idea is that the spliceosome normally recognizes the splice sites. The spliceosome recognizes the donor site (GU at the intron's end) and the acceptor site (AG at the intron's end). But if an exon is out of frame due to a deletion, the spliceosome might skip that exon.\\n\\nWait, but the question says that the Morpholino prevents the spliceosome from binding. How does that work? Oh, I think Morpholinos can bind to RNA and block certain regions. So if the Morpholino binds to the 5' splice site of the exon, maybe it prevents the spliceosome from recognizing the normal splice sites. So the spliceosome might skip that exon, leading to a smaller exon or a deletion, but in a way that the reading frame is maintained. Because when exons are skipped, the mRNA is joined in frame, so the resulting protein is correct.\\n\\nSo, in this process, the splice sites are in the introns. Wait, the donor site is at the end of the intron, so the spliceosome binds to that. If the Morpholino is binding to the exon's 5' end, maybe it's preventing the recognition of the donor site, so the intron isn't spliced, and the exon is skipped.\\n\\nWait, but the question says that the Morpholino prevents binding of the spliceosome. So, what structures are involved in splicing?\\n\\nThe spliceosome is a complex of proteins and snRNPs (small nuclear ribonucleoproteins). The spliceosome recognizes the splice sites in the pre-mRNA. The 5' splice site is usually the GU at the intron's end. The 3' splice site is the AG. The splicing process involves the spliceosome recognizing these sites, then the intron is cut, and the exons are joined.\\n\\nIf a Morpholino binds to the 5' end of an exon, perhaps it's binding to the 5' splice site? Or maybe the intron's donor site? Or perhaps the Morpholino is binding to the exon's sequence, making the spliceosome not recognize the site, leading the intron to not be spliced out, so the exon is skipped. Or wait, no, because the question says it's causing exon skipping.\\n\\nWait, when a splice site is skipped, the exon is excluded. So the spliceosome must have been supposed to recognize the 5' site of the exon. If the Morpholino blocks that, the spliceosome can't recognize it, so the intron is not spliced, and the exon is excluded. So the pre-mRNA would have a longer intron, and the exon is skipped.\\n\\nWait, but the question says the Morpholino prevents the spliceosome from binding. So the spliceosome's binding is prevented, meaning that the spliceosome doesn't recognize that site. So the spliceosome can't bind, so the intron is not spliced, and the exon is skipped.\\n\\nNow, the options: Which structure isn't involved. Let's see each option.\\n\\nA) lariat. During splicing, the intron is removed and forms a lariat structure. So lariat is involved in the process. So A is involved.\\n\\nB) polyA tail. The polyA tail is added to the 3' end of the mRNA after splicing. So if the spliceosome is involved, the polyA tail would be added later. But in this therapy, the splicing is altered, but the polyA tail is added as usual. So does this process affect the polyA? Not sure. Or perhaps the polyA tail is part of the mRNA after splicing, so it's not involved in the splicing process. So maybe it's not involved in the therapy. Or perhaps the polyA tail is added during processing, so it's involved.\\n\\nWait, the polyA tail is added after the mRNA is processed. So the splicing occurs before the polyA is added. So the polyA tail is not directly involved in splicing. So if the therapy is about splicing, then polyA might not be involved in this particular mechanism. So B) polyA tail may not be involved.\\n\\nC) R-loops. R-loops are three-stranded structures with RNA:DNA hybrids. Do they form during splicing? Not sure. I don't remember R-loops being part of splicing. Maybe they're more involved in DNA replication or other processes. So perhaps C is not involved.\\n\\nD) antisense. Morpholino is an antisense molecule, so this is involved. The therapy uses antisense, so D is involved.\\n\\nSo the question is asking which is NOT involved. So the correct answer is C) R-loops.\\n\\nWait, but let me double-check.\\n\\nAnother way: the process is about splicing. The spliceosome is involved. Structures involved in splicing include snRNPs (U1, U2, etc.), the lariat, and the splice sites. The polyA tail is added after splicing, so it's part of the mRNA, but not part of the splicing process itself. R-loops are more about DNA-RNA interactions, like in transcription or DNA repair, maybe not in splicing. So the structures involved in the therapy are the spliceosome (so polyA is not directly involved), and the antisense Morpholino, and the lariat.\\n\\nSo the structure not involved would be R-loops. So the answer is C) R-loops.\\n</think>\\n\\nThe question involves a gene with multiple exons, where the central exons code for triple helical repeats involved in connecting the cytoskeleton with the sarcolemma and extracellular space. Mutations causing central exon deletions lead to out-of-frame peptides and progressive degeneration. A Morpholino is used to target the 5' end of the out-of-frame exon in pre-mRNA, preventing spliceosome binding, resulting in exon skipping and in-frame joining. The organism tolerates missing exons, and the question asks which structure is not involved in this therapy.\\n\\n### Analysis of the Options:\\n\\n- **A) Lariat**: During splicing, the intron is removed and forms a lariat structure. Since splicing is a key part of the therapy, the lariat is involved.\\n- **B) PolyA tail**: The polyA tail is added to the mRNA after splicing. While it is part of mRNA processing, it is not directly involved in the splicing process itself, which is the focus of this therapy.\\n- **C) R-loops**: R-loops are three-stranded structures involving RNA:DNA hybrids and are more commonly associated with transcription or DNA repair, not splicing. They are not directly involved in the splicing process.\\n- **D) Antisense**: Morpholinos are antisense molecules designed to bind to RNA and block specific sequences. This is central to the therapy, as the Morpholino prevents spliceosome binding by targeting the exon.\\n\\nThe therapy primarily involves splicing mechanisms (spliceosome, lariat) and the use of antisense molecules. The polyA tail is part of mRNA processing but not directly involved in splicing. R-loops are unrelated to this process. Therefore, the structure not involved is **C) R-loops**.\\n\\nAnswer: C<ï½œendâ–ofâ–sentenceï½œ>\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>://Question: A large gene has dozens of exons, of which the central ones code for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space. Each exon usually codes for one folded triple alpha helix. The most common mutations of the gene are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste. A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. The molecule prevents binding of the spliceosome and creates exon skipping and in-frame joining. Several missing exons are well tolerated by an organism. Which structure is not involved in the therapy?\\n\\nOptions:\\nA) lariat\\nB) polyA tail\\nC) R-loops\\nD) antisense\\n</think>\\n\\nOkay, so I'm trying to figure out this genetics question. Let me read through it again and break it down. The question is about a gene with many exons, specifically central ones that code for triple helical repeats. These repeats connect the cytoskeleton with the sarcolemma and extracellular space. Each exon usually codes for a triple alpha helix. The common mutations are central exon deletions, leading to out-of-frame peptides and causing progressive organ degeneration. The solution is to use a Morpholino that targets the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the spliceosome from binding, leading to exon skipping and in-frame joining. The organism can tolerate several missing exons.\\n\\nThe question is asking which structure isn't involved in this therapy. The options are lariat, polyA tail, R-loops, and antisense.\\n\\nHmm, I remember that during splicing, the spliceosome recognizes certain signals in the pre-mRNA. Exon skipping occurs when a splice site is skipped, so the introns are retained or excluded. Morpholinos are antisense oligonucleotides that bind to the RNA and block certain regions. They can prevent the spliceosome from recognizing a splice site, so the exon is excluded.\\n\\nIn this case, the Morpholino targets the 5' end of the out-of-frame exon. Wait, 5' splice sites are usually at the beginning of exons, right? So if the Morpholino is binding to the 5' end of the exon, it's probably preventing the spliceosome from recognizing the donor site at the beginning of the exon. So the exon is skipped, which would remove it from the mRNA, making the reading frame correct again (in-frame).\\n\\nBut the question is about what structure isn't involved. So each step of the splicing process involves certain structures. Let me think about the spliceosome and the process.\\n\\nSplicing involves introns being removed, and the exons joined. The spliceosome is a complex of proteins and snRNPs (small nuclear ribonucleoproteins). The process starts with the U1 snRNP binding to the 5' splice site (GU at the intron's donor site), and U2 binds the branch site, which is usually a branch site with an adenine. The 3' splice site is at the end of the intron, usually an AG. The intron is cut, the branch site's adenine is attacked by the 2'OH of the branch site, forming a lariat structure. Then the exons are ligated.\\n\\nSo the lariat structure is definitely involved in splicing. So option A is involved, so it's not the answer.\\n\\nThe polyA tail is added to the 3' end of mRNA. I don't think the spliceosome directly involves the polyA tail in splicing. The polyA tail is added by polyA polymerase after splicing. So the polyA tail isn't directly involved in the splicing process. Wait, but waitâ€”do some mechanisms during splicing involve the polyA tail? I don't recall. The splicing machinery mainly uses the splice sites and the branch site. So the polyA tail is more about mRNA stability and export from the nucleus. So perhaps the polyA tail isn't directly involved in the splicing process. So option B, polyA tail, might not be involved in the therapy, but I'm not sure yet.\\n\\nR-loops are RNA:DNA structures, like when the RNA is hybridized with DNA. I'm trying to think if the spliceosome forms R-loops. The spliceosome is RNA-based. Wait, no, the spliceosome is a complex of snRNPs, which are proteins and RNA. So the spliceosome doesn't form R-loops. R-loops are more of a transcription thing, perhaps during DNA replication or transcription, but not in splicing. So option C, R-loops, isn't involved in splicing. Or maybe during some other process like RNA editing or transcription, but not in the spliceosome's action. So if the therapy is about splicing, R-loops aren't involved. But I'm not 100% sure.\\n\\nAntisense molecules are RNA or DNA oligonucleotides that bind to complementary sequences. Morpholinos are antisense oligonucleotides that bind to RNA, preventing certain structures. So the therapy uses antisense (option D), which is definitely involved. So D is not the answer.\\n\\nSo the structures involved are lariat (A, involved), antisense (D, involved). So the structures not involved are polyA tail (B) and R-loops (C). Wait, but what about the splice sites and the process? The splice sites are involved, but the polyA tail isn't. The R-loops are not part of the spliceosome.\\n\\nWait, the therapy involves preventing the spliceosome from binding. So the spliceosome's binding is inhibited. The Morpholino is an antisense molecule, so that's involved. The spliceosome's recognition of the 5' splice site is prevented, leading to exon skipping. The lariat is formed when the intron is removed (in normal splicing), so the lariat is part of the process. So, in the therapy, the lariat is formed as usual because the intron is still being spliced out, but a part of the exon is skipped.\\n\\nWait, but wait. If the Morpholino causes the spliceosome to skip the exon, the intron is then spliced in a way that skips the exon. So the lariat is still formed from the intron. So the lariat is involved in the splicing process and is part of the therapy.\\n\\nSo which structure is not involved in the therapy? The polyA tail is added after splicing, so it's not part of the splicing process. So the polyA tail isn't involved in the therapy. Similarly, R-loops aren't part of the splicing process. So the options are B and C.\\n\\nBut the question is about which structure is not involved in the therapy. The therapy's process is about splicing, so structures involved are spliceosome components like lariat, and the antisense (Morpholino).\\n\\nSo the structures not involved are polyA tail and R-loops. But the question is which is not involved in the therapy. So the options are B and C.\\n\\nWait, the question says which structure is NOT involved in the therapy. The therapy is about splicing, so the polyA tail is not directly involved. R-loops are more about DNA-RNA interactions, not splicing. So both B and C are not involved. But the options are A, B, C, D.\\n\\nWait, the question is about which is not involved. So the structures involved in the therapy are lariat (A, involved), antisense (D, involved). So the structures not involved are B and C.\\n\\nWait, the therapy is about the spliceosome. The polyA tail is added after splicing, so not involved. R-loops are not part of the splicing process. So the structures not involved are B and C. But the question is which one is not involved, so the options are four, and I have to choose one.\\n\\nWait, perhaps I need to think about the process again. The question says that the Morpholino prevents the spliceosome from binding. So the spliceosome binds to the 5' splice site, but the Morpholino stops that. So the 5' splice site is in the intron. Wait, no, the 5' splice site is at the beginning of the intron, right? So the exon is the coding region. The Morpholino is targeting the 5' end of the out-of-frame exon, which is the beginning of the exon, which is followed by the intron.\\n\\nWait, wait, I'm getting confused. The 5' end of the exon is the beginning of the exon, which is followed by the intron. So the spliceosome recognizes the 5' splice site, which is at the end of the exon and the beginning of the intron. So if the Morpholino is binding to the 5' end of the exon, maybe it's at the end of the exon. No, wait. The 5' splice site is the donor site, which is at the end of the intron. Wait, no, the 5' splice site is the donor site, which is at the intron's beginning. So the 5' splice site is part of the intron.\\n\\nWait, I think I'm getting the intron-exon structure wrong. Let me think. Exon 1 - Intron 1 - Exon 2 - Intron 2 - Exon 3, etc. The intron starts with a 5' splice site (GU) and ends with a 3' splice site (AG). So the spliceosome recognizes the 5' end of the intron for the donor site and the 3'\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>:// I'm trying to figure out this question about gene therapy using Morpholinos. Okay, so the question is about a gene that has many exons, with central ones making triple helical repeats. These exons code for parts that connect the cytoskeleton with the sarcolemma and the extracellular space. The mutations causing this gene are deletions in the central exons, leading to out-of-frame peptides and causing organ degeneration. \\n\\nThe therapy involves using a Morpholino that targets the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the spliceosome from binding, leading to exon skipping and in-frame joining. The question asks which structure isn't involved in this therapy.\\n\\nThe options are lariat, polyA tail, R-loops, antisense. Hmm.\\n\\nSo, let me think. Morpholinos are antisense oligonucleotides. They're used to bind to RNA and prevent certain interactions. In this case, they're binding to the pre-mRNA, the unprocessed mRNA before splicing. So the spliceosome normally recognizes the splice sites, and during splicing, introns are removed, and exons are joined.\\n\\nWhen a Morpholino binds to the pre-mRNA, it can block the spliceosome from recognizing the exon-exon junction. So if the Morpholino is at the 5' end of the exon, it might prevent the recognition of the donor site. So when the spliceosome tries to recognize the exon, the Morpholino blocks it, leading the spliceosome to skip that exon. Skipping it would mean that the next exon is joined in frame, making the protein in-frame, which could correct the frameshift caused by the deletion.\\n\\nNow, the question is about which structure is not involved in this therapy.\\n\\nThe options are lariat, polyA tail, R-loops, antisense.\\n\\nWait, what structures are involved in splicing? The spliceosome uses small nuclear RNA (snRNA) and various proteins. The splice sites are the donor (GU at the intron start) and acceptor (AG at the intron end). The spliceosome recognizes these sites, and during the splicing process, the intron is removed, with the 5' splice site's phosphate attacking the branch site adenine to form a lariat structure. The lariat is a structure formed during splicing, with the intron forming a loop.\\n\\nPolyA tail is added during mRNA processing after splicing. So if the Morpholino is affecting splicing, the polyA tail would not be involved in the splicing process itself. Wait, but the polyA tail is part of mRNA processing, but in this scenario, the Morpholino is affecting splicing, not polyadenylation.\\n\\nR-loops are RNA:DNA hybrids, like when RNA binds to DNA, causing the DNA to unwind, and the RNA is hybridized to the DNA. But in this case, the Morpholino is binding to RNA, so R-loops probably aren't involved here.\\n\\nAntisense refers to RNA molecules that are complementary to the target. Morpholino is an antisense oligo, so antisense is definitely involved.\\n\\nWait, but the options are structures. So the process of splicing involves the lariat (intron removal), the polyA tail is part of mRNA processing, which happens after splicing. So the polyA tail is involved in the process of mRNA maturation, but the therapy is about splicing.\\n\\nWait, the question is about the structures involved in the therapy. So the therapy uses Morpholinos which bind to RNA. The spliceosome uses the branch site (lariat) to remove the intron. So lariat is involved in the splicing process. The polyA tail is not part of splicing but is added later. R-loops are not part of this process. Antisense is the type of molecule used (the Morpholino), so antisense is involved.\\n\\nSo the structures not involved are R-loops and polyA tail. The question asks which is not involved. So the options are A) lariat (involved), B) polyA (involved?), C) R-loops (not involved), D) antisense (involved).\\n\\nWait, wait, polyA is part of mRNA processing, but the therapy is about splicing. So does the polyA tail influence splicing? I think polyadenylation (adding the polyA tail) is a separate step, occurs after splicing. So in this therapy, the polyA tail is not directly involved in the splicing process. So the structures used in the therapy (splicing) are lariat and antisense. The polyA is part of mRNA processing, not the splicing. So the therapy is about the splicing process, which involves the lariat. The antisense (the Morpholino) is the tool used. So the structures not involved are R-loops and polyA tail. But the options are:\\n\\nThe question is, which structure is not involved in the therapy. So the structures involved are lariat (A), antisense (D). Structures not involved: polyA (B) and R-loops (C). The question says, which is not involved.\\n\\nSo the options are B and C. But the question asks which is not involved.\\n\\nLooking back, the therapy uses antisense (Morpholino) which is option D. So D is involved. So the structures not involved are B and C.\\n\\nWait, the options are:\\n\\nA) lariat\\n\\nB) polyA tail\\n\\nC) R-loops\\n\\nD) antisense\\n\\nThe therapy uses antisense (so D is involved), so the structures not involved would be B and C.\\n\\nThe question is which is not involved, so the answer is either B or C.\\n\\nWait, R-loops are structures where RNA:DNA hybrid forms, which is not part of splicing. So in the therapy, the Morpholino binds to RNA, not DNA or any R-loops. So R-loops are not involved.\\n\\nPolyA is added to the mRNA after splicing, so it's part of mRNA processing, but not part of the splicing itself.\\n\\nSo, in the therapy, the structures involved are lariat (A) and antisense (D). The structures not involved are B and C. The question is which one of the options is not involved, so the options are either B or C.\\n\\nThe question asks which is not involved. So the correct answer is either B or C.\\n\\nWait, the question is about which structure is not involved in the therapy. So the therapy uses the antisense (D is involved), and the spliceosome uses the lariat (A is involved). So the structures not involved are polyA and R-loops.\\n\\nThe options are B and C.\\n\\nBut the question asks which one is not involved.\\n\\nWait, the therapy is about splicing. The lariat is part of splicing. The polyA is part of mRNA processing, not splicing. R-loops are not part of splicing.\\n\\nSo the therapy's process involves the lariat (A is involved), antisense (D is involved). The structures not involved are polyA (B) and R-loops (C).\\n\\nSo the question is which is not involved. So the correct answer is either B or C.\\n\\nThe options are:\\n\\nA) lariat - involved\\n\\nB) polyA - not involved\\n\\nC) R-loops - not involved\\n\\nD) antisense - involved\\n\\nThe question is, which is not involved. So the correct answer is either B or C.\\n\\nLooking back at the question, the options are four, and the question is which one is not involved.\\n\\nThe question says, the therapy is about binding to the 5' end of the exon, causing the spliceosome to skip the exon. So the spliceosome is involved, which uses the lariat (A is involved). The Morpholino is antisense (D is involved). The polyA is added after splicing, so it's part of mRNA processing, not splicing. R-loops are not part of splicing.\\n\\nSo the structures not involved are B and C. The question is, which is not involved. So the correct answer is either B or C.\\n\\nWait, the question is which structure is not involved. So if all four structures are given, and the correct answer is the one that's not part of the process.\\n\\nSo, the structures used are antisense (the Morpholino, D is involved), lariat (A is involved). The polyA (B) and R-loops (C) are not involved.\\n\\nSo the question asks which structure is not involved, and the options are A, B, C, D.\\n\\nThe answer must be either B or C.\\n\\nLooking at the options, the correct answer is either B or C.\\n\\nWait, the question says that the therapy involves creating exon skipping. So the process is splicing. The spliceosome uses the branch site (lariat) and the splice sites. The polyA is added after splicing. So polyA is not involved in the splicing process. R-loops are not part of splicing. So the structures not involved are B and C.\\n\\nThe question is asking which is not involved in the therapy. So the answer is either B or C.\\n\\nWait, I'm a bit confused. Let me think again.\\n\\nIn the process of splicing, the intron is removed and forms a lariat. The polyA is added after splicing, so it's not part of the splicing process. So the polyA is not involved in the splicing step that the therapy is affecting. So the structure not involved is polyA (B) or R-loops.\\n\\nSo the correct answer is B) polyA tail or C) R-loops.\\n\\nWait, the therapy is using an antisense molecule (D is involved). So the structures not involved\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>://\\nOkay, so I'm trying to tackle this question about gene therapy using Morpholino oligos. Hmm, I remember that Morpholinos are used in RNA therapy, but I'm a bit fuzzy on the details. Let me think through this.\\n\\nThe question is about a gene that has many exons, and the central ones are involved in connecting the cytoskeleton with the sarcolemma and the extracellular space. These exons code for triple helical repeats, which I think are like these structures that form a triple helix, maybe something like in alpha-actin or another structural protein. Each exon typically codes for one of these triple helices. \\n\\nThe mutations mentioned are central exon deletions, leading to out-of-frame peptides causing degenerative issues. Out-of-frame mutations usually result in frameshifts, which can cause proteins to be shorter or have incorrect amino acids, leading to problems. So, the solution is to use a Morpholino that targets the 5' end of the out-of-frame exon in pre-mRNA. When the Morpholino binds, it stops the spliceosome from binding, so the exon is skipped. Skipping the exon means that the remaining exons are joined in frame, so the protein would be correctly formed, right? That would prevent the degenerative effects.\\n\\nThe question is about which structure is NOT involved in this therapy. The options are lariat, polyA tail, R-loops, and antisense.\\n\\nWait, let me think about what each option refers to. \\n\\nA) Lariat: The spliceosome creates a lariat structure during splicing. The branch site is where the intron is joined to form this loop. So when exons are skipped, the spliceosome would still form a lariat because the splicing machinery is involved. So lariat is involved.\\n\\nB) PolyA tail: The polyA tail is added to the 3' end of mRNA. Morpholino binding occurs on the pre-mRNA, which is before the polyA tail is added. But I'm not sure how the polyA tail is involved in this therapy. The Morpholino affects splicing, not the polyA addition. So maybe the polyA tail isn't involved here.\\n\\nC) R-loops: R-loops are structures where RNA is hybridized with DNA, forming a three-stranded structure. I don't recall spliceosomes or splicing being directly involved with R-loops. Maybe in some other process, like transcription, but not in splicing. So R-loops might not be involved here.\\n\\nD) Antisense: Morpholinos are antisense molecules, meaning they bind to complementary RNA sequences. So antisense is definitely involved in the therapy. So the answer shouldn't be D.\\n\\nSo the question is which structure is not involved. So the options are A, B, C, D.\\n\\nIf the therapy is about splicing, then structures involved are splice sites (lariat) and the spliceosome. The polyA tail is part of the mRNA, but maybe not directly involved in this therapy's mechanism. R-loops don't play a role in splicing, I think. So the structure not involved would be either B or C.\\n\\nWait, the question says the Morpholino recognizes the 5' end of the out-of-frame exon. So the Morpholino binds to the pre-mRNA, which is before the polyA tail is added. The polyA tail is added after splicing. So the polyA tail isn't part of the splicing process. So the polyA tail isn't involved in the therapy process of splicing here.\\n\\nSo the options are B and C. Let me think again. R-loops form during transcription, when RNA is being made. Since the therapy is about splicing, maybe R-loops are not involved.\\n\\nSo which structures are involved: lariat (A), antisense (D), so the answer is either B or C.\\n\\nWait, the question is about which structure is not involved. So the therapy uses antisense (D is involved), so not the answer. So options left: A, B, C.\\n\\nLariat is part of splicing. So the therapy is about splicing, so lariat is involved.\\n\\nSo the structures involved are lariat (A), antisense (D), and polyA tail (B) is not involved. Or is it?\\n\\nWait, the polyA tail is added after splicing. The spliceosome removes introns and joins exons, and then the polyA tail is added. So the polyA tail is not involved in splicing. So the polyA tail (B) is not involved in the therapy's mechanism.\\n\\nSo the options are: the structures involved are lariat, antisense. The structures not involved would be polyA tail and R-loops. So the question is, which of these is not involved.\\n\\nThe question says which structure is not involved in the therapy.\\n\\nThe therapy uses antisense ( Morpholino), which is option D. So D is involved. So which is not involved? The options are A, B, C.\\n\\nWait, the question is about which is not involved. The therapy uses antisense (so D is involved), so that's not the answer. The other options are A, B, C.\\n\\nThe therapy process involves the spliceosome, which forms a lariat, so A is involved. So the structures not involved would be polyA (B) and R-loops (C). Which of these is not involved in the therapy.\\n\\nThe therapy is about splicing, so the polyA tail is not involved. R-loops are about transcription. So in this therapy, polyA is not involved, R-loops are not involved.\\n\\nSo the question is, which is not involved. So the structures not involved are B and C.\\n\\nThe question is, which one of the options is not involved. The options are B and C.\\n\\nWait, the question says which structure is not involved. So from the options, the correct answer is either B or C.\\n\\nIn the therapy, the Morpholino is part of antisense (D is involved). So the structures not involved are B and C.\\n\\nThe therapy process: the spliceosome binds, skips the exon, forms a lariat. The polyA tail is added after splicing. So polyA is not involved in this process. R-loops are not involved in splicing. So both B and C are not involved.\\n\\nBut the options are A, B, C, D. The question is which structure is not involved.\\n\\nThe options are:\\n\\nA) lariat (involved)\\nB) polyA (not involved)\\nC) R-loops (not involved)\\nD) antisense (involved)\\n\\nSo the options not involved are B and C.\\n\\nThe question is asking which is NOT involved. So the answer is either B or C.\\n\\nWait, the question says which structure is not involved. So which of these is not involved. So in the therapy, the lariat is involved, antisense is involved. So the structures not involved are polyA (B) and R-loops (C).\\n\\nBut the options are A, B, C, D.\\n\\nThe question is, which of the structures is not involved in the proposed therapy.\\n\\nSo, the answer would be either B or C.\\n\\nWait, the question is about the structures involved in the therapy. The therapy uses a Morpholino that is an antisense molecule (D is involved), which affects splicing. So the spliceosome and lariat are involved (A is involved). The polyA tail is added after splicing, so it's not involved in the splicing process. R-loops are not part of splicing, so they are not involved.\\n\\nSo the structures not involved are B and C.\\n\\nBut the options are A, B, C, D. The correct answer is B or C.\\n\\nWait, the question asks which is not involved. So the correct answer is either B or C.\\n\\nWhich of the options is not involved: the polyA tail and R-loops.\\n\\nSo in the therapy, the process is about splicing, so polyA is added after, so not involved. R-loops are about DNA-RNA hybrid structures, so not involved in splicing.\\n\\nSo the structures not involved are B and C. The question is, which one is not involved. So the answer is either B or C.\\n\\nWait, the question is a multiple-choice question, and the options are A, B, C, D. So the correct answer is either B or C.\\n\\nI think the correct answer is B) polyA tail because the polyA tail is added after splicing. So during the splicing process, the polyA tail isn't involved. Therefore, the polyA tail isn't involved in the therapy. So the correct answer is B.\\n\\nAlternatively, R-loops aren't involved in splicing, so if the question is about which is not involved, then both B and C are not involved. But the options don't have an option for both. Hmm.\\n\\nWait, the question is about the therapy's structures. The therapy uses antisense (D), so D is involved. The therapy involves the spliceosome (lariat A is involved). The polyA tail is not involved in the splicing, so B is not involved. R-loops are not involved in splicing, so C is not involved. So both B and C are not involved. But the options don't allow choosing two. So perhaps I'm missing something.\\n\\nWait, perhaps the polyA tail is involved in the mRNA processing, but not in the splicing. So the question is about the structures involved in the therapy, which is about splicing. So polyA is not involved in splicing, so it's not involved. R-loops are not involved in splicing. So the structures not involved are B and C.\\n\\nBut the question asks which is not involved. So the correct answer would\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>://www.thoughtmaybe.com\\nOkay, so I've got this question about a gene therapy concept, and I'm a bit new to this stuff, but I'll try to think it through. Let's see what the question says.\\n\\nSo the gene in question has a lot of exons, like dozens, and the middle ones code for these triple helical repeats. These repeats help connect the cytoskeleton to the sarcolemma and the extracellular space. Each exon typically codes for one of these triple helices. The problem is that the most common mutations are deletions in the central exons, which cause out-of-frame peptides leading to degenerative diseases. The solution proposed is using a Morpholino that targets the 5' end of the out-of-frame exon in the pre-mRNA. This Morpholino prevents the spliceosome from binding, causing exon skipping and allowing the mRNA to join in an in-frame way. The question is asking which structure isn't involved in this therapy.\\n\\nThe options are A) lariat, B) polyA tail, C) R-loops, D) antisense.\\n\\nHmm. Let's break this down. So, the gene has exons, and the central ones are important for these triple helices. Mutations here cause the exons to be deleted, leading to messed-up proteins. The therapy uses a Morpholino, which is an antisense oligonucleotide, I think. Morpholinos are synthetic molecules that can bind to specific RNA sequences. They can block certain regions, like preventing the spliceosome from binding, which is involved in splicing.\\n\\nSo when the spliceosome binds, it removes introns and joins exons. If the Morpholino binds to the 5' end of an out-of-frame exon, it might prevent the spliceosome from recognizing that exon, so it gets skipped. Skipping this exon would mean the reading frame remains correct because the exons are joined in a way that doesn't shift the frame, which was out-of-frame before. So the mRNA ends up being in frame, which is better.\\n\\nNow, the question is about which structure isn't involved in this therapy. Let's think about each option.\\n\\nOption A: Lariat. The spliceosome forms a lariat structure during splicing. The spliceosome recognizes the splice sites (donor and acceptor sites), and the intron is looped into a lariat structure. So if the spliceosome is prevented from binding, maybe the lariat isn't formed. But wait, the Morpholino is blocking the splice site. If the spliceosome can't bind, then the exon is skipped, and the intron is still spliced out. Or does the lariat form when the intron is spliced? So if the exon is skipped, the intron is still processed as usual. So the lariat is involved in the splicing process. So the lariat would be involved. So A is involved, so the answer can't be A.\\n\\nOption B: polyA tail. The polyA tail is added to the 3' end of mRNA. I don't see how the therapy directly relates to the polyA tail. The therapy is about splicing, so the polyA tail is added during mRNA processing. But the therapy targets splicing by blocking the spliceosome. So the polyA tail is part of the mRNA, but is it involved in the therapy? Hmm. I think the polyA tail is added after splicing. So the therapy doesn't directly affect it. So maybe the polyA tail isn't involved in this process.\\n\\nOption C: R-loops. R-loops are structures where RNA is bound to DNA, causing the DNA to loop around. I'm not sure how this relates. The therapy uses Morpholinos, which bind to RNA, not DNA. So maybe R-loops are not involved. Alternatively, during splicing, are there any R-loops? I'm not certain. I think R-loops are more about DNA-RNA interactions in DNA repair or transcription. So perhaps R-loops aren't involved here.\\n\\nOption D: antisense. Morpholinos are antisense molecules. They bind to complementary RNA sequences in an antisense manner. So the therapy is using antisense technology, so antisense is definitely involved. So D is involved, so the answer can't be D.\\n\\nSo the options are B and C. The therapy doesn't involve the polyA tail. The polyA tail is added by the enzyme polyA polymerase after splicing. Since the therapy is about splicing, the polyA tail isn't directly involved. So the structure not involved is the polyA tail.\\n\\nWait, but wait. What if the polyA tail is part of the mRNA processing. The splicing machinery processes the introns, and then the polyA tail is added. So the therapy affects the splicing, not the polyA tail. So the polyA tail isn't involved in the therapy's mechanism. So the structure not involved would be the polyA tail, which is option B.\\n</think>\\n\\nThe question revolves around a gene therapy approach using Morpholinos to address a genetic disorder caused by central exon deletions. These deletions lead to out-of-frame peptides, resulting in degenerative conditions. The Morpholino binds to the 5' end of the out-of-frame exon, preventing the spliceosome from recognizing it, thereby causing exon skipping and allowing the mRNA to join in an in-frame manner, which is well-tolerated by the organism.\\n\\nTo determine which structure is not involved in this therapy, let's analyze the options:\\n\\n- **Option A: Lariat**  \\n  The spliceosome forms a lariat structure during splicing when introns are removed. Even if an exon is skipped, the intron is still spliced out, and the lariat structure is formed. Therefore, the lariat is involved in the splicing process and is part of the therapy's mechanism.  \\n\\n- **Option B: PolyA tail**  \\n  The polyA tail is added to the 3' end of mRNA after splicing and is part of mRNA processing. The therapy targets the splicing process by preventing the spliceosome from recognizing the exon, but it does not directly involve the polyA tail. Thus, the polyA tail is not directly related to this therapy.  \\n\\n- **Option C: R-loops**  \\n  R-loops are structures involving RNA bound to DNA, typically associated with transcription or DNA repair. The therapy involves RNA-binding Morpholinos and splicing, not DNA-RNA interactions. Therefore, R-loops are not involved.  \\n\\n- **Option D: Antisense**  \\n  Morpholinos are antisense molecules that bind to RNA in an antisense manner. Since the therapy explicitly uses Morpholinos, antisense is directly involved in the process.  \\n\\nThe structure not involved in the therapy is the polyA tail.  \\n\\nAnswer: B<ï½œendâ–ofâ–sentenceï½œ>\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>://\\n\\n</think>\\n\\nTo determine which structure is not involved in the proposed therapy, let's analyze the scenario:\\n\\nThe question describes a gene with multiple exons, where the central exons code for triple helical repeats involved in connecting the cytoskeleton with the sarcolemma and extracellular space. Mutations causing central exon deletions lead to out-of-frame peptides and progressive degenerative issues. The therapy involves delivering a Morpholino that targets the 5' end of an out-of-frame exon in pre-mRNA. This Morpholino prevents the spliceosome from binding, leading to exon skipping and in-frame joining of the remaining exons. The organism tolerates the missing exons well.\\n\\nKey structures involved in this process include:\\n- **Lariat**: During splicing, the spliceosome forms a lariat structure where the intron is joined to the branch site adenosine. This is a critical step in mRNA processing.\\n- **PolyA tail**: The polyA tail is added to the 3' end of the mRNA, enhancing stability and export from the nucleus.\\n- **R-loops**: These are structures formed when RNA binds to DNA, causing the DNA strand to unwind. They are involved in various regulatory processes, including splicing.\\n- **Antisense**: Morpholinos are antisense oligonucleotides that bind to specific RNA sequences to modulate gene expression.\\n\\nThe structure **not involved** is **C) R-loops**, as the therapy described focuses on preventing spliceosome binding and exon skipping, without directly involving R-loops in the described mechanism. \\n\\nAnswer: C<ï½œendâ–ofâ–sentenceï½œ>\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>://\\n\\n</think>\\n\\nTo determine which structure is not involved in the proposed therapy, let's analyze the scenario and the options provided:\\n\\nThe question describes a gene with multiple exons, where the central exons code for triple helical repeats that connect the cytoskeleton with the sarcolemma and extracellular space. Mutations causing central exon deletions lead to out-of-frame peptides and progressive degenerative conditions. The proposed therapy involves delivering a Morpholino that targets the 5' end of the out-of-frame exon in pre-mRNA. This Morpholino prevents the spliceosome from binding, leading to exon skipping and in-frame joining of exons, which is well-tolerated by the organism.\\n\\n### Key Analysis of the Structures:\\n1. **Lariat**: The spliceosome is involved in removing introns during splicing, and the lariat structure is a hallmark of this process. Since the spliceosome is mentioned, the lariat is likely involved.\\n2. **PolyA tail**: The polyA tail is added to the 3' end of mRNA during processing and is a common feature of mRNA. However, the therapy focuses on the 5' end of the exon, not the polyA tail.\\n3. **R-loops**: R-loops are structures formed when RNA hybridizes with DNA, displacing the other DNA strand. There is no mention of R-loops being relevant to the described therapy.\\n4. **Antisense**: Morpholinos are antisense oligonucleotides that bind to specific RNA sequences. This matches the description of the therapy, so antisense is involved.\\n\\n### Conclusion:\\nThe therapy involves the spliceosome and antisense molecules but does not directly involve R-loops. Therefore, the structure not involved in the therapy is **R-loops**.\\n</think>\\n\\nThe therapy described involves the spliceosome, antisense molecules (Morpholinos), and the splicing process to correct exon skipping. R-loops, which involve RNA-DNA interactions, are not part of this mechanism.\\n\\nAnswer: C<ï½œendâ–ofâ–sentenceï½œ>\", \"<think>\\n<ï½œbeginâ–ofâ–sentenceï½œ>://\\nOkay, so I've got this question about gene therapy using Morpholinos, and I'm trying to figure it out. Let me think through this step by step. \\n\\nThe question is asking which structure isn't involved in the therapy described. The scenario is about a large gene with many exons, and the central ones code for these triple helical repeats that connect the cytoskeleton with the sarcolemma and extracellular space. The common mutations are deletions in the central exons, causing out-of-frame peptides leading to organ degeneration. \\n\\nSo the solution is using Morpholinos. I remember Morpholinos are antisense oligonucleotides, right? They're used in splicing therapy. They bind to specific RNA sequences and affect splicing by preventing certain exons from being included or included. \\n\\nIn this case, the Morpholino recognizes the 5' end of an out-of-frame exon in the pre-mRNA. By binding there, the spliceosome can't recognize that exon, so it gets skipped. This leads to the exons being excluded, which means the mRNA is in-frame, so the protein produced is less likely to be faulty. Skipping some exons can correct the reading frame, so the peptide is correct.\\n\\nThe question is about which structure is not involved in this therapy. The options are lariat, polyA tail, R-loops, antisense. Wait, the options are A) lariat, B) polyA, C) R-loops, D) antisense.\\n\\nLet me recall what each of these terms means. \\n\\nA lariat is a structure involved in splicing. During splicing, the intron is removed, and the spliceosome creates a lariat structure where the branch site adenosine attacks the intron's splice site, forming a loop. So the lariat is part of the splicing process. Since the Morpholino affects splicing, the lariat is used here. So option A is involved, so it's not the answer.\\n\\nThe polyA tail is added to the 3' end of mRNA. Morpholinos bind to the pre-mRNA, which is before the polyA tail is added. So the polyA tail is added after splicing, so when the Morpholino is binding, the polyA isn't involved in that process. But wait, the polyA tail is part of mRNA, but in the context of splicing, is the polyA tail involved in the splicing mechanism? Or is it just added after? I think polyA is added during processing, but the splicing machinery doesn't directly use it. So maybe the polyA tail isn't involved in this therapy. But wait, do Morpholinos interact with polyA? I don't think so. So B might be the correct answer, but I'm not sure.\\n\\nR-loops are structures formed when RNA is bound to DNA, causing the DNA to unwind. R-loops can form during transcription, perhaps in splicing? Or is that more about DNA replication or transcription. Wait, during splicing, I don't think R-loops are a part of the process. So option C, R-loops, is not involved. But wait, the therapy is about splicing, so maybe R-loops aren't part of that. So if the therapy is about splicing, R-loops wouldn't be involved. So C might be the answer.\\n\\nWait, the question is which structure is NOT involved. The therapy uses antisense molecules (Morpholinos), which are antisense. So option D is antisense, which is definitely involved, so D is not the answer.\\n\\nSo the options are A, B, C, D. The therapy is about splicing, so the lariat (A) is involved. The polyA tail is added after splicing, so the polyA is not involved in the splicing process, but the Morpholino is binding to the pre-mRNA before polyA is added. So polyA isn't part of the splicing mechanism here. So the structures involved are lariat (A), antisense (D). The structures not involved would be polyA (B) and R-loops (C). The question is which is not involved. So the question is, which of these is not involved in the therapy.\\n\\nWait, let me think again. The therapy is about splicing. The spliceosome recognizes splice sites and exons. Morpholino blocks the 5' splice site of an exon, so the spliceosome can't use it, leading to exon skipping. So during splicing, the spliceosome uses the branch site, which forms the lariat. So lariat is involved, so A is not the answer. \\n\\nPolyA tail is added after splicing, so the presence of the polyA tail isn't directly involved in the splicing process itself. So when the Morpholino binds, it's during the splicing when the exons are being joined. So the polyA tail isn't part of that process. So the polyA tail (B) isn't involved in the therapy. But wait, does the presence of the polyA affect splicing? I thought that the polyA is added after the splicing is done. So in the process of splicing, polyA is not involved. So the therapy doesn't involve the polyA tail. So the polyA tail isn't involved, making option B the correct answer.\\n\\nWait, but what about R-loops? R-loops are structures formed when RNA binds to DNA. I don't think they're involved in splicing. So the therapy doesn't involve R-loops. So the structures not involved would be both B and C. But the question says which structure is not involved. So which one is not involved.\\n\\nWait, the options are A, B, C, D. The correct answer is either B or C.\\n\\nWait, the therapy's mechanism is about the splice sites. So the spliceosome uses the branch site to create the lariat, so A is involved. Antisense (D) is involved because the Morpholino is an antisense oligo. So the structures not involved are polyA (B) and R-loops (C). The question is which is not involved.\\n\\nIn the question, which structure is not involved in the therapy. So the therapy doesn't involve the polyA tail or R-loops.\\n\\nWait, the process of splicing doesn't involve R-loops. So the structures used in splicing are the splice sites, branch sites, lariat, etc. So R-loops are not part of that. So the correct answer is either B or C. \\n\\nThe question is about which structure is NOT involved. So if the therapy uses antisense, which is D, which is involved, so D is not the answer. So the structures involved are lariat (A), antisense (D), and not B and C.\\n\\nWait, but the polyA tail is part of mRNA. The question is about structures involved in the therapy. The Morpholino binds to the pre-mRNA, which is before the polyA is added. So the polyA isn't part of the process. So the structures involved are lariat and antisense (so A and D are involved, so they are not the correct answer). So the structures not involved are B (polyA) and C (R-loops). The question is, which one is not involved. So which structure is not part of the therapy. \\n\\nThe therapy's mechanism is about splicing. So R-loops are structures that form during transcription but not splicing. So R-loops are not involved in splicing. So the structures not involved would be B and C.\\n\\nBut the options are B and C, and the question is which is not involved. So the correct answer would be either B or C.\\n\\nWait, the question asks which is not involved. So the correct answer is either B) polyA tail or C) R-loops.\\n\\nNow, what do I know about R-loops and their involvement in splicing? I'm not certain. Do splicing factors form R-loops? Or is that more about DNA/RNA interaction during replication or transcription? I think R-loops are more about DNA-RNA binding, perhaps in transcription. So during splicing, the spliceosome doesn't form R-loops. Therefore, the therapy doesn't involve R-loops. So the structure not involved is C) R-loops.\\n\\nWait, but the polyA tail is part of mRNA. The therapy is about the pre-mRNA before it's processed. So the polyA tail is added after splicing. So the presence of polyA isn't part of the splicing process. So polyA is not involved in this therapy.\\n\\nSo the structures involved in the therapy are lariat (A), antisense (D), so the structures not involved are B and C. The question is which of the four options is not involved. The question is which structure is not involved. So the options are B and C.\\n\\nWait, the question says which is not involved. So which of the four is not involved. So the correct answer is either B or C.\\n\\nWait, the therapy uses antisense (D is involved). So the structures involved are A, D. So the ones not involved are B and C.\\n\\nThe question is which structure is not involved. So the correct answer is either B or C.\\n\\nWait, the polyA tail is part of the mRNA, but it's added after splicing. So the splicing process doesn't involve the polyA. So the polyA isn't part of the splicing process, so the therapy doesn't involve the polyA. So B) polyA is not involved.\\n\\nSimilarly, R-loops are not part of the splicing process, so C) R-loops are not involved.\\n\\nBut the question is which one is not involved. So the options are B\"], 'correct': [False, False, True, True, False, False, True, False, False, False, True, True, True, False, False, True, False, False, False, False, True, False, False, True, True, False, False, False, False, True, True, False], 'explanations': [\"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='C'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='C'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='B'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='B'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='C'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='C'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\"], 'num_tokens': [[0, 2048], [0, 2048], [683, 1111], [5, 431], [0, 2048], [5, 561], [792, 1252], [0, 2048], [5, 655], [5, 431], [336, 686], [806, 1141], [5, 629], [5, 656], [0, 2048], [570, 908], [5, 544], [5, 484], [0, 2048], [5, 653], [1052, 1404], [1319, 1744], [0, 2048], [1123, 1459], [1436, 1806], [167, 2048], [0, 2048], [0, 2048], [1039, 1422], [5, 327], [5, 417], [0, 2048]], 'rewards': [0.01953125, 0.0169677734375, 0.0771484375, 0.0693359375, 0.0140380859375, 0.0732421875, 0.0751953125, -0.0019073486328125, 0.0771484375, 0.0830078125, 0.07080078125, 0.07421875, 0.06591796875, 0.083984375, 0.0184326171875, 0.0771484375, 0.07177734375, 0.0830078125, 0.01336669921875, 0.0712890625, 0.06591796875, 0.057861328125, 0.00946044921875, 0.05908203125, 0.05908203125, 0.0184326171875, 0.00897216796875, 0.0079345703125, 0.07275390625, 0.07666015625, 0.06884765625, 0.015625], 'ground_truths': ['C'], 'question_meta': None, 'model_name': 'hf_chat:deepseek-ai/DeepSeek-R1-Distill-Llama-8B', 'reward_model_name': 'armo_rm:RLHFlow/ArmoRM-Llama3-8B-v0.1'}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 92%|â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–| 11/12 [00:29<00:02,  2.60s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'qid': 'gpqa-1', 'prompt': \"Answer the following multiple choice question. The last line of your response should be of the following format: 'Answer: $LETTER' (without quotes) where LETTER is one of ABCD. Think step by step before answering.\\n\\nA large gene has dozens of exons, of which the central ones code for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space. Each exon usually codes for one folded triple alpha helix. The most common mutations of the gene are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste. A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. The molecule prevents binding of the spliceosome and creates exon skipping and in-frame joining. Several missing exons are well tolerated by an organism. Which structure below is not involved in the proposed therapy?\\n\\nA) lariat\\nB) polyA tail\\nC) R-loops\\nD) antisense\", 'answers': [\"To answer this question correctly, let's analyze each option:\\n\\nA) lariat - Lariat structures are formed during RNA splicing when a branch point is created, leading to a loop of RNA. They do not seem directly involved in the described therapy of skipping an out-of-frame exon through Morpholino action.\\n\\nB) polyA tail - This is an extension of the 3' end of eukaryotic mRNA. It does not play a direct role in the splicing process or the Morpholino therapy described.\\n\\nC) R-loops - These are triplex structures consisting of DNA, RNA, and DNA. They can form due to mismatches between the DNA template and the newly synthesized RNA. They are not directly mentioned as being part of the Morpholino therapy process.\\n\\nD) antisense - Morpholino molecules function as antisense oligonucleotides, targeting specific mRNA sequences. They are used in the therapy to prevent the binding of the spliceosome and thus enable exon skipping.\\n\\nGiven the information provided and the context of the therapy, the structure not directly involved in the proposed therapy seems to be:\\n\\nAnswer: A<|im_end|>\", 'The proposed therapy involves using a Morpholino to prevent binding of the spliceosome and create exon skipping. This process does not involve the creation of a lariat structure, which is formed during alternative splicing but is not directly related to the Morpholino-mediated exon skipping technique described. Therefore, the structure not involved in the proposed therapy is:\\n\\nA) lariat<|im_end|>', 'The structure that is not directly involved in the proposed therapy of exon skipping using a Morpholino molecule is:\\n\\nC) R-loops<|im_end|>', 'The proposed therapy involves using a Morpholino molecule to prevent binding of the spliceosome and create exon skipping. This process does not involve any of the structures listed as options directly. However, among the given choices, the structure that is not directly involved in the proposed therapy is:\\n\\nA) lariat\\n\\nLariats are covalently closed RNA structures formed during the processing of pre-mRNA but are not directly involved in the Morpholino-mediated exon skipping therapy described.<|im_end|>', 'Answer: C<|im_end|>', \"To answer this question, let's analyze each option:\\n\\nA) Lariat - Lariat structures are formed during RNA splicing and involve the formation of a covalent bond between the 3' end of an intron and the 5' end of its corresponding exon. They are not directly related to the proposed therapy.\\n\\nB) PolyA tail - This is a sequence of adenine nucleotides at the 3' end of an mRNA molecule. It is involved in stabilizing the mRNA and aiding in its export from the nucleus. It is not directly related to the proposed therapy of exon skipping.\\n\\nC) R-loops - These are triplex structures consisting of DNA and two complementary RNA strands. They can form during transcription and are not directly involved in the proposed therapy.\\n\\nD) Antisense - Morpholinos are antisense molecules used in the therapy to prevent binding of the spliceosome, leading to exon skipping.\\n\\nGiven the context, the structure not involved in the proposed therapy is A) lariat. \\n\\nAnswer: A<|im_end|>\", \"To answer this question correctly, let's break down the information provided:\\n\\n1. The gene in question has dozens of exons, and mutations often involve central exon deletions, creating out-of-frame peptides.\\n2. The proposed solution involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA, preventing binding of the spliceosome and creating exon skipping and in-frame joining.\\n3. The goal is to tolerate several missing exons by the organism.\\n\\nNow, let's evaluate each option:\\n\\nA) Lariat - Lariats are covalently closed RNA structures formed during splicing. They are not directly involved in the proposed therapy of exon skipping.\\n\\nB) PolyA tail - This is the polyadenylation tail at the 3' end of eukaryotic mRNA molecules. It is involved in mRNA stability and transport, but not specifically in the mechanism of exon skipping as described.\\n\\nC) R-loops - These are DNA-RNA hybrid structures formed when transcription occurs and RNA polymerase reads the template strand, while the non-template strand is transcribed into RNA. R-loops can cause genomic instability, but they are not directly related to the process of exon skipping.\\n\\nD) Antisense - Antisense molecules can bind to complementary sequences of mRNA, potentially affecting its function. In the context of exon skipping, antisense molecules might be used to block the splicing of certain exons, aligning with the therapy's purpose.\\n\\nGiven the description, it seems the question aims to identify which structure is not directly involved in the proposed therapy of exon skipping through Morpholino delivery. Among the options:\\n\\nA) lariat\\nB) polyA tail\\nC) R-loops\\nD) antisense\\n\\nOption B) polyA tail is not directly involved in the mechanism of exon skipping described in the therapy, making it the correct answer.\\n\\nAnswer: B<|im_end|>\", \"To answer this question, let's break down the information provided and understand the context of the therapy:\\n\\n1. The gene has dozens of exons, with central ones coding for folded triple helical repeats connecting the cytoskeleton with sarcolemma and extracellular space.\\n2. Common mutations involve deletions of these central exons, creating out-of-frame peptides and leading to progressive degenerative organ waste.\\n3. The proposed solution involves delivering a Morpholino, an antisense oligonucleotide, to recognize the 5' end of the out-of-frame exon in pre-mRNA.\\n4. This Morpholino prevents binding of the spliceosome, causing exon skipping, and enabling in-frame joining of the remaining exons.\\n5. The goal is to tolerate several missing exons by ensuring the remaining exons are joined in-frame.\\n\\nNow, let's examine each option:\\n\\nA) Lariat - This refers to a covalently closed circular RNA structure formed during RNA splicing. It's not directly mentioned in the context of the therapy described, but it's not part of the therapy itself either, as the focus is on exon skipping using a Morpholino.\\n\\nB) PolyA tail - This is the sequence of adenine nucleotides at the 3' end of many eukaryotic mRNAs, essential for mRNA stability and transport. It's not directly involved in the exon skipping process described, making it a candidate for being the answer.\\n\\nC) R-loops - These are structures formed by DNA-RNA hybrids when transcription occurs, involving a single-stranded DNA strand and a complementary RNA transcript. They're not directly relevant to the therapy or its mechanism of action, so they could potentially be the answer.\\n\\nD) Antisense - As mentioned, the Morpholino is an antisense oligonucleotide used in the therapy. It's directly involved in the proposed treatment.\\n\\nGiven the context and the options, the structure not directly involved in the proposed therapy is:\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze each option:\\n\\nA) Lariat - This refers to the covalently closed circular RNA formed during RNA splicing. It is directly related to the process described in the therapy as it involves splicing.\\n\\nB) PolyA tail - This is the addition of adenine nucleotides to the 3' end of an mRNA transcript. It is not directly related to the process of exon skipping or the proposed therapy, which focuses on the 5' end of the out-of-frame exon.\\n\\nC) R-loops - These are structures composed of DNA-RNA hybrids and single-stranded DNA. They can form during transcription and are related to the regulation of gene expression, which could influence the therapy but is not directly involved in the process of exon skipping.\\n\\nD) Antisense - This refers to the use of synthetic molecules that bind to complementary sequences of mRNA, preventing translation. It is directly related to the proposed therapy as Morpholinos are used to prevent the binding of the spliceosome.\\n\\nBased on this analysis, the structure that is not directly involved in the proposed therapy is:\\n\\nAnswer: B<|im_end|>\", 'The proposed therapy involves using a Morpholino to prevent binding of the spliceosome and create exon skipping. This process does not involve the creation of a lariat structure, which is formed during splicing but is not directly related to the Morpholino therapy described. Therefore, the structure not involved in the proposed therapy is:\\n\\nA) lariat<|im_end|>', 'The structure that is not directly involved in the proposed therapy of exon skipping using a Morpholino molecule is:\\n\\nC) R-loops<|im_end|>', 'Answer: C<|im_end|>', 'Answer: C<|im_end|>', 'The structure that is not directly involved in the proposed therapy of exon skipping using a Morpholino is:\\n\\nC) R-loops<|im_end|>', 'The structure not involved in the proposed therapy is C) R-loops. Answer: C<|im_end|>', 'The proposed therapy involves using a Morpholino molecule to prevent binding of the spliceosome and create exon skipping. This process does not involve the creation of a lariat structure, which is formed during alternative splicing but is not directly related to the Morpholino-mediated exon skipping mechanism described. Therefore, the structure not involved in the proposed therapy is:\\n\\nA) lariat<|im_end|>', \"To answer this question, let's break down the information provided and understand the components mentioned:\\n\\n1. The gene in question has dozens of exons.\\n2. Central exons code for folded triple helical repeats connecting the cytoskeleton with sarcolemma and extracellular space.\\n3. Mutations often involve central exon deletions leading to out-of-frame peptides and progressive degenerative organ waste.\\n4. A solution involves delivering a Morpholino, an antisense molecule, that recognizes the 5' end of the out-of-frame exon in pre-mRNA.\\n5. The Morpholino prevents binding of the spliceosome, creating exon skipping and in-frame joining.\\n6. The goal is to tolerate several missing exons.\\n\\nNow, let's examine each option:\\n\\nA) Lariat - This refers to a circular RNA structure formed after the splicing process. It is not directly involved in the described therapy of exon skipping or the creation of in-frame joining.\\n\\nB) PolyA tail - This is a sequence of adenine nucleotides at the 3' end of many messenger RNAs. It is important for stability and translation but not directly involved in the described therapy mechanism.\\n\\nC) R-loops - These are structures formed when DNA transcription leads to a hairpin loop between the transcribed RNA and the complementary strand of DNA. They can affect gene expression but are not mentioned as part of the therapy process described.\\n\\nD) Antisense - This refers to the Morpholino molecule used in the therapy, which binds to the target mRNA, preventing binding of the spliceosome and enabling exon skipping.\\n\\nBased on this analysis, the structure that is not involved in the proposed therapy is:\\n\\nAnswer: A<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze each option:\\n\\nA) Lariat - Lariats are formed during RNA splicing when the 3' end of one intron joins the 5' end of another, creating a loop. This structure is related to RNA splicing and could potentially influence the therapy as it relates to splicing mechanisms.\\n\\nB) PolyA tail - The polyA tail is added to the 3' end of eukaryotic mRNAs and plays a role in mRNA stability and export from the nucleus. It does not directly influence splicing but affects mRNA processing. Its presence might not be directly relevant to the therapy described.\\n\\nC) R-loops - R-loops are structures that form when a DNA strand is transcribed into an RNA molecule, creating a ternary complex involving DNA-RNA-DNA. They can affect gene expression and regulation. R-loops might indirectly impact the therapy if they interfere with splicing or RNA processing.\\n\\nD) Antisense - Antisense molecules are used to inhibit gene expression by complementary base pairing. In this case, a Morpholino molecule acts as an antisense agent to prevent binding of the spliceosome.\\n\\nGiven the context of the therapy involving Morpholino preventing spliceosome binding and creating exon skipping, the structure that is not directly involved in this process is likely B) polyA tail, as it does not directly relate to splicing mechanisms or the specific therapy described.\\n\\nAnswer: B<|im_end|>\", 'The structure not involved in the proposed therapy is:\\n\\nC) R-loops<|im_end|>', \"To answer this question, let's analyze each option:\\n\\nA) Lariat - In RNA processing, a lariat is formed when a 3' end of a pre-mRNA becomes ligated to the 5' end after splicing. This process is not directly mentioned in the context of the therapy described, but it is part of normal pre-mRNA processing. \\n\\nB) PolyA tail - The polyA tail is an addition to the 3' end of eukaryotic pre-mRNAs, influencing mRNA stability and translation. It's not directly related to the therapy of exon skipping, but it is part of pre-mRNA processing.\\n\\nC) R-loops - R-loops are transient triplex structures formed by the hybridization of the coding strand of DNA with its complementary strand, creating a structure with a single-stranded DNA template strand. They are not directly involved in the therapy described, as it focuses on exon skipping through Morpholino molecules.\\n\\nD) Antisense - Antisense molecules can bind to complementary sequences in mRNA or DNA, affecting gene expression. In the context of the therapy, they are used to prevent binding of the spliceosome and facilitate exon skipping.\\n\\nGiven the context of the therapy, the structure not directly involved is C) R-loops.\\n\\nAnswer: C<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze each option:\\n\\nA) Lariat - This refers to a covalently closed circular RNA generated during the processing of certain types of pre-mRNA. It is not directly related to the therapy described as it does not involve Morpholinos or exon skipping.\\n\\nB) PolyA tail - This is an extension of adenine nucleotides added to the 3' end of mature eukaryotic mRNA. It plays a role in mRNA stability and translation but is not directly involved in the proposed therapy mechanism.\\n\\nC) R-loops - These are structures formed when DNA-RNA hybrids are present due to transcriptional pausing. They can affect splicing and are known to be involved in RNA interference and regulation of gene expression. In the context of the therapy, R-loops could potentially influence the efficiency of exon skipping.\\n\\nD) Antisense - Morpholino molecules are considered antisense because they bind to complementary sequences on the target RNA, preventing its function. They are used in the therapy to prevent binding of the spliceosome to the out-of-frame exon.\\n\\nBased on this analysis, the structure that is not directly involved in the proposed therapy is:\\n\\nA) lariat<|im_end|>\", 'The structure that is not involved in the proposed therapy is:\\n\\nC) R-loops<|im_end|>', 'The proposed therapy involves using a Morpholino molecule to prevent binding of the spliceosome and create exon skipping. This process does not involve the creation of a lariat structure, which typically results from the processing of pre-mRNA in eukaryotes. Therefore, the structure that is not involved in the proposed therapy is:\\n\\nA) lariat<|im_end|>', \"To answer this question correctly, let's break down the information given:\\n\\n- The gene has dozens of exons.\\n- Central exons code for folded triple helical repeats.\\n- Mutations often involve deletions of these central exons, leading to out-of-frame peptides and progressive degenerative organ waste.\\n- A solution involves using a Morpholino, which is an antisense molecule.\\n- This molecule recognizes the 5' end of the out-of-frame exon in pre-mRNA, preventing binding of the spliceosome and creating exon skipping, which leads to in-frame joining.\\n- The goal is to tolerate several missing exons.\\n\\nGiven this context, we can analyze each option:\\n\\nA) Lariat - This refers to a circular RNA structure formed when a 3' end of an RNA strand joins its 5' end after a splicing event. It's not directly mentioned in the proposed therapy, but it could potentially be involved in the splicing process or the regulation of RNA stability. However, it's not specifically mentioned as being part of the Morpholino therapy described.\\n\\nB) PolyA tail - This is the sequence of adenine nucleotides at the 3' end of many eukaryotic messenger RNAs. It plays a role in stabilizing mRNA and aiding in its export from the nucleus. It's not directly related to the Morpholino therapy described, which focuses on exon skipping rather than mRNA stabilization or export.\\n\\nC) R-loops - These are structures composed of DNA-RNA hybrids that form when a nascent RNA strand anneals to a template DNA strand while still extending into the unwound region. They can cause transcriptional silencing and have been implicated in various diseases. While they're not directly mentioned in the therapy, their presence or absence might influence the effectiveness of the therapy indirectly.\\n\\nD) Antisense - This term refers to molecules that bind to complementary RNA or DNA sequences, effectively inhibiting their function. The Morpholino molecule described in the therapy is an example of an antisense approach.\\n\\nBased on this analysis, option B (polyA tail) seems to be the least directly involved in the Morpholino therapy described, which primarily focuses on exon skipping and in-frame joining.\\n\\nAnswer: B<|im_end|>\", 'The structure that is not involved in the proposed therapy is:\\n\\nC) R-loops<|im_end|>', 'To answer this question correctly, let\\'s break down the information provided:\\n\\n- The gene has exons coding for folded triple helical repeats.\\n- Mutations involve deletions of central exons, creating out-of-frame peptides.\\n- The proposed therapy involves delivering a Morpholino to prevent binding of the spliceosome and create exon skipping.\\n- The Morpholino targets the 5\\' end of the out-of-frame exon in pre-mRNA.\\n\\nNow, let\\'s analyze each option:\\n\\nA) Lariat - This is not directly mentioned in the context of the therapy described. However, it could be indirectly involved as part of the splicing process, but the question asks about what is \"not\" involved in the therapy.\\n\\nB) PolyA tail - This is also not directly mentioned in the context of the therapy. The therapy focuses on exon skipping and does not specifically mention any involvement of the polyA tail.\\n\\nC) R-loops - These are structures formed when DNA-RNA hybrids are present, typically due to transcription. They are not directly mentioned in the context of the therapy, making them a potential answer.\\n\\nD) Antisense - This term is mentioned in the context of the therapy as the Morpholino acts as an antisense molecule.\\n\\nGiven the options and the context of the therapy, the structure that is not directly involved in the proposed therapy is:\\n\\nAnswer: C<|im_end|>', 'To answer this question, let\\'s break down the context provided:\\n\\n- A gene has dozens of exons.\\n- Central exons code for folded triple helical repeats connecting the cytoskeleton, sarcolemma, and extracellular space.\\n- Mutations often involve deletions of these central exons creating out-of-frame peptides.\\n- A Morpholino molecule is used as a solution to recognize the 5\\' end of the out-of-frame exon in pre-mRNA.\\n- The Morpholino prevents binding of the spliceosome and facilitates exon skipping and in-frame joining.\\n\\nNow, let\\'s consider the options:\\n\\nA) lariat - This refers to a type of RNA structure formed during splicing, but it\\'s not directly mentioned in the therapy described, so it could be potentially involved or not involved depending on specifics.\\n\\nB) polyA tail - This is the polyadenylation tail at the 3\\' end of an mRNA molecule, important for stability and transport, but not directly related to the therapy described involving exon skipping.\\n\\nC) R-loops - These are structures formed when DNA transcription outpaces replication, leading to a complex of DNA-DNA-RNA triplex. They are not directly mentioned in the context of the therapy described.\\n\\nD) Antisense - This term refers to molecules complementary to a specific RNA sequence, used to inhibit its function. It is directly relevant to the therapy described as it involves an antisense molecule (the Morpholino).\\n\\nConsidering the context and options, \"lariat\" seems to be the least directly involved in the described therapy, although the exact involvement would depend on additional details not provided here. However, since the question asks for what is not involved in the therapy, and given the information provided, \"lariat\" fits best as the answer based on the context that it\\'s not specifically mentioned as part of the therapy.\\n\\nAnswer: A<|im_end|>', 'Answer: C<|im_end|>', \"To answer this question correctly, let's break down the components mentioned:\\n\\n1. **Central exon deletions** - These cause out-of-frame peptides.\\n2. **Morpholino** - It targets the 5' end of the out-of-frame exon in pre-mRNA.\\n3. **Exon skipping** - The Morpholino prevents binding of the spliceosome, creating exon skipping.\\n4. **In-frame joining** - This allows the creation of functional proteins despite missing exons.\\n5. **Structure not involved** - The question asks which structure is not part of this therapy.\\n\\nLet's analyze each option:\\n\\nA) **Lariat** - This refers to a structure formed during RNA splicing, but it's not directly mentioned in the context of the therapy described. The therapy focuses on exon skipping and doesn't involve lariats specifically.\\n\\nB) **PolyA tail** - This is the addition of adenine nucleotides at the 3' end of mRNA. It's not directly involved in the described therapy, which centers around exon skipping and the use of Morpholinos.\\n\\nC) **R-loops** - These are structures formed when DNA transcription leads to a region where the DNA strand is displaced by the newly synthesized RNA strand, forming a loop with the third strand. They are not typically part of the direct mechanisms involved in splicing or exon skipping therapies.\\n\\nD) **Antisense** - This refers to the use of molecules complementary to a specific sequence of RNA, like the Morpholino used in the therapy. It's directly related to the therapy described.\\n\\nGiven this analysis, the structure that is not directly involved in the proposed therapy is **A) lariat**, as it does not play a role in the mechanism of exon skipping or the use of Morpholinos described in the question.\\n\\nAnswer: A<|im_end|>\", \"To answer this question, let's analyze the context provided:\\n\\n1. The gene has dozens of exons, some of which code for folded triple helical repeats.\\n2. Mutations often involve central exon deletions creating out-of-frame peptides.\\n3. The proposed solution involves delivering a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA to prevent binding of the spliceosome, causing exon skipping and in-frame joining.\\n\\nGiven this context, we need to identify which of the options (A) lariat, (B) polyA tail, (C) R-loops, and (D) antisense is not involved in the proposed therapy.\\n\\nA) Lariat - This is typically formed during RNA splicing but does not seem directly related to the Morpholino's function in preventing spliceosome binding and causing exon skipping.\\n\\nB) PolyA tail - This is part of mRNA and influences its stability and translation but is not mentioned as a factor in the Morpholino therapy.\\n\\nC) R-loops - These are structures formed by DNA-RNA hybrids, but they do not seem to be directly relevant to the Morpholino's mechanism of action.\\n\\nD) Antisense - This term is used in the context of the Morpholino, which acts as an antisense molecule to prevent binding of the spliceosome.\\n\\nConsidering the context and the roles of these components, it appears that lariat formation is not directly involved in the Morpholino therapy described. Therefore, the correct answer is:\\n\\nA) lariat<|im_end|>\", 'The structure that is not directly involved in the proposed therapy of exon skipping using a Morpholino is B) polyA tail. Answer: B<|im_end|>', 'Answer: C<|im_end|>', 'The structure not involved in the proposed therapy is C) R-loops. Answer: C<|im_end|>', \"To answer this question correctly, let's break down the components mentioned:\\n\\n- The gene has dozens of exons.\\n- Central exons code for folded triple helical repeats.\\n- Mutations involve central exon deletions creating out-of-frame peptides.\\n- A Morpholino molecule is used to prevent binding of the spliceosome, creating exon skipping.\\n- The goal is to join exons in-frame.\\n\\nNow, let's evaluate each option in relation to the proposed therapy:\\n\\nA) Lariat - Lariats are covalently closed circular RNA structures formed during splicing. They do not seem directly involved in the Morpholino-induced exon skipping described here.\\n\\nB) PolyA tail - This is the polyadenylation signal at the 3' end of a eukaryotic mRNA. It's not part of the process described, which focuses on the 5' end of the out-of-frame exon and exon skipping.\\n\\nC) R-loops - These are transient triplex structures involving DNA-RNA hybrids and DNA single strands. They can form due to transcription or replication processes and might be indirectly related to the therapy, but they are not directly mentioned in the context of the therapy mechanism.\\n\\nD) Antisense - Morpholinos are a type of antisense oligonucleotides that can bind to complementary sequences on the target RNA, thus interfering with its function. This fits within the context of the proposed therapy.\\n\\nGiven the information provided and the context of the therapy, the structure not directly involved in the Morpholino-induced exon skipping therapy would likely be:\\n\\nAnswer: A) lariat<|im_end|>\", 'Answer: C<|im_end|>', 'The structure not involved in the proposed therapy is:\\n\\nC) R-loops<|im_end|>', 'The structure not involved in the proposed therapy is C) R-loops. Answer: C<|im_end|>', \"To answer this question, let's break down the information given and identify which structure is not involved in the proposed therapy:\\n\\n1. A large gene with dozens of exons.\\n2. Central exons code for folded triple helical repeats.\\n3. Mutations involve central exon deletions creating out-of-frame peptides.\\n4. Therapy uses a Morpholino to recognize the 5' end of the out-of-frame exon in pre-mRNA.\\n5. Morpholino prevents binding of the spliceosome, creating exon skipping and in-frame joining.\\n6. Several missing exons are well tolerated by an organism.\\n\\nNow, let's examine each option:\\nA) Lariat - This refers to a circularized RNA structure formed during RNA splicing. It is not mentioned in the context of the therapy described, so it seems to be an irrelevant structure here.\\nB) PolyA tail - This is the addition of adenine nucleotides to the 3' end of mRNA. It is related to mRNA stability but not directly involved in the therapy described.\\nC) R-loops - These are structures formed when DNA transcription occurs, resulting in a DNA-RNA hybrid and a single-stranded DNA overhang. They can be involved in gene regulation, but not specifically in the described therapy.\\nD) Antisense - This refers to molecules that bind to complementary sequences of RNA, effectively blocking its function. It is part of the therapy described as the Morpholino binds to the 5' end of the out-of-frame exon.\\n\\nBased on the analysis, the structure that is not involved in the proposed therapy is:\\n\\nA) lariat<|im_end|>\", 'The structure that is not directly involved in the proposed therapy of exon skipping using a Morpholino molecule is:\\n\\nC) R-loops<|im_end|>', \"To answer this question correctly, let's analyze the components mentioned:\\n\\n1. Exons: Pieces of DNA that code for proteins.\\n2. Triple helical repeats: Structures formed by the gene's coding sequence.\\n3. Cytoskeleton: A network of protein fibers within cells.\\n4. Sarcolemma: The plasma membrane of muscle cells.\\n5. Exon skipping: A genetic correction technique involving RNA splicing.\\n6. Morpholino: An antisense molecule used in gene therapy.\\n7. Pre-mRNA: Unprocessed RNA transcripts from genes.\\n\\nThe proposed therapy involves using a Morpholino antisense molecule to prevent the binding of the spliceosome at the 5' end of an out-of-frame exon, leading to exon skipping and in-frame joining.\\n\\nLet's evaluate each option:\\n\\nA) Lariat: This refers to a covalently closed circular RNA that forms when a single-stranded RNA loop is created by the action of a ribozyme or an RNA ligase. It is not directly involved in the described therapy process.\\n\\nB) PolyA tail: This is an addition of adenine nucleotides to the 3' end of mRNA, important for its stability and export from the nucleus. It's not directly involved in the exon skipping process described.\\n\\nC) R-loops: These are triplex structures formed between a DNA strand and a complementary RNA strand, with the third strand being the non-complementary DNA strand. They can interfere with transcription and replication. R-loops might indirectly influence the therapy by affecting gene expression or transcription.\\n\\nD) Antisense: Morpholinos are considered antisense molecules as they bind to specific RNA sequences, preventing their translation into proteins. They are directly involved in the therapy.\\n\\nGiven the analysis, the structure that is not directly involved in the proposed therapy is:\\n\\nAnswer: A<|im_end|>\", \"To answer this question correctly, let's break down the information given:\\n\\n1. The gene has dozens of exons.\\n2. Central exons code for folded triple helical repeats connecting the cytoskeleton with sarcolemma and extracellular space.\\n3. Mutations often involve deletions of these central exons creating out-of-frame peptides.\\n4. A Morpholino molecule is used to prevent binding of the spliceosome and create exon skipping, resulting in in-frame joining.\\n5. The goal is to tolerate several missing exons.\\n\\nNow, let's evaluate each option:\\n\\nA) Lariat - This refers to a circularized RNA structure that can occur during mRNA processing, but it's not directly related to the Morpholino therapy described here. It's more about the RNA processing itself, not the specific mechanism of exon skipping.\\n\\nB) PolyA tail - This is a sequence of adenine nucleotides added to the 3' end of eukaryotic mRNAs. It's important for stability and transport of the mRNA, but not directly involved in the exon skipping process.\\n\\nC) R-loops - These are structures formed when DNA-RNA hybrids are created, often due to transcriptional pausing or RNA processing. They are not directly mentioned as part of the Morpholino therapy or exon skipping process.\\n\\nD) Antisense - Morpholinos are a type of antisense molecule used in gene therapy to block gene expression by preventing specific RNA sequences from being translated into proteins. They are directly involved in the therapy described.\\n\\nGiven this analysis, the structure not directly involved in the proposed therapy is:\\n\\nAnswer: A) lariat<|im_end|>\", 'Answer: C<|im_end|>', 'The structure that is not involved in the proposed therapy is:\\n\\nC) R-loops<|im_end|>', \"To answer this question, let's break down the information provided:\\n\\n1. The gene has dozens of exons, with central ones coding for folded triple helical repeats.\\n2. Mutations often involve deletions of these central exons, leading to out-of-frame peptides and degenerative effects.\\n3. A solution involves delivering a Morpholino that targets the 5' end of the out-of-frame exon in pre-mRNA, preventing spliceosome binding and enabling exon skipping and in-frame joining.\\n\\nNow, let's analyze each option:\\n\\nA) Lariat - This term refers to a structure formed when a pre-mRNA undergoes splicing, where the 5' end of the intron ligates to the 3' end of the same intron, forming a loop. It is involved in splicing but not directly in the Morpholino therapy described.\\n\\nB) PolyA tail - This is an addition of adenine nucleotides at the 3' end of a eukaryotic mRNA molecule. It is crucial for stability and translation of mRNAs, but it does not seem directly related to the Morpholino therapy or exon skipping.\\n\\nC) R-loops - These are structures formed by DNA-RNA hybrids and single-stranded DNA that can form during transcription. They are not directly involved in the Morpholino therapy or exon skipping mechanism described.\\n\\nD) Antisense - This refers to molecules complementary to a specific RNA sequence, which can bind to it and prevent its function. In the context of the therapy described, the Morpholino molecule acts as an antisense agent by targeting the 5' end of the out-of-frame exon.\\n\\nGiven the information provided, the structure that is not directly involved in the proposed therapy is:\\n\\nAnswer: A) lariat<|im_end|>\", 'The structure that is not involved in the proposed therapy is:\\n\\nC) R-loops<|im_end|>', 'To determine which structure is not involved in the proposed therapy, let\\'s break down the components:\\n\\n1. **Morpholino**: This is an antisense oligonucleotide designed to bind to the target RNA sequence, preventing it from being translated into a protein. It\\'s part of the proposed therapy.\\n2. **5\\' end of the out-of-frame exon**: This refers to the specific location on the pre-mRNA where the Morpholino binds.\\n3. **Pre-mRNA**: This is the initial form of mRNA before splicing.\\n4. **Spliceosome**: This is a large ribonucleoprotein that catalyzes the process of splicing in eukaryotes.\\n5. **Exon skipping**: This is the process where certain exons are not included in the final mRNA transcript, leading to a different protein sequence.\\n6. **In-frame joining**: This ensures that the resulting protein sequence can still be translated without causing issues due to the deletion of exons.\\n\\nGiven these components, let\\'s evaluate each option:\\n\\n- **A) Lariat**: This is not directly mentioned in the context of the therapy. However, lariats are a type of covalently closed circular RNA produced during splicing when an intron is removed. They are not directly involved in the Morpholino\\'s mechanism of action, but they are part of the splicing process itself. So, it could be seen as indirectly related, but the question seems to ask about structures \"not\" involved in the therapy, making this option less likely to be correct based on the information provided.\\n\\n- **B) PolyA tail**: This is a sequence of adenine nucleotides added at the 3\\' end of the mature mRNA. It\\'s crucial for mRNA stability and export from the nucleus. It\\'s not directly involved in the Morpholino\\'s mechanism of action or the process of exon skipping. Therefore, this is a strong candidate for the answer.\\n\\n- **C) R-loops**: These are DNA-RNA hybrids formed when transcription occurs in a direction opposite to that of DNA replication. They are not typically mentioned in the context of splicing or mRNA processing, and their role in the proposed therapy is not clear from the information provided.\\n\\n- **D) Antisense**: As mentioned earlier, the Morpholino is an antisense oligonucleotide used in the therapy. This is directly involved in the therapy.\\n\\nBased on the above analysis, the structure that is not directly involved in the proposed therapy is:\\n\\nAnswer', 'Answer: C<|im_end|>', \"To answer this question, let's break down the components mentioned:\\n\\n1. Central exon deletions create out-of-frame peptides.\\n2. Morpholino molecule is used to prevent binding of the spliceosome.\\n3. This results in exon skipping and in-frame joining.\\n4. The structure that's not involved in the proposed therapy is asked.\\n\\nNow, let's analyze each option:\\n- A) Lariat: Not directly mentioned in the context of the therapy but typically associated with RNA splicing. It could be indirectly involved since it relates to RNA processing.\\n- B) PolyA tail: Also not directly mentioned as part of the therapy process. Its role is mainly in mRNA stability and translation, not specifically related to the exon skipping mechanism described.\\n- C) R-loops: These are structures formed by DNA-RNA hybrids and can potentially affect splicing. However, their direct involvement in the described therapy is not specified.\\n- D) Antisense: This term is directly mentioned in the context of the Morpholino molecule, which is an antisense oligonucleotide designed to target specific RNA sequences.\\n\\nGiven the information provided, the structure not directly involved in the proposed therapy seems to be:\\n\\nAnswer: B<|im_end|>\", 'Answer: C<|im_end|>', \"To answer this question correctly, let's break down the components mentioned:\\n\\n1. **Exon Deletions**: These cause out-of-frame peptides due to the loss of coding sequence.\\n2. **Morpholino**: An antisense molecule that targets the 5' end of the out-of-frame exon in pre-mRNA, preventing binding of the spliceosome.\\n3. **Exon Skipping**: The therapy involves creating in-frame joining by skipping the problematic exon.\\n4. **Organism Tolerance**: Several missing exons can be tolerated.\\n\\nNow, let's analyze the options:\\n\\n- **A) Lariat**: Not directly involved in the therapy described, as it refers to a covalently closed circular RNA intermediate during splicing, not related to exon skipping or Morpholino use.\\n- **B) PolyA Tail**: Involved in mRNA stability and translation, but not specifically in the described exon skipping mechanism.\\n- **C) R-loops**: Structures formed by DNA-RNA hybrids, not directly relevant to the Morpholino therapy or exon skipping process.\\n- **D) Antisense**: Directly involved in the therapy, as the Morpholino acts as an antisense molecule to prevent the spliceosome from binding.\\n\\nGiven the context and definitions provided, the structure not directly involved in the proposed therapy would be:\\n\\nAnswer: A) lariat<|im_end|>\", 'The structure that is not involved in the proposed therapy is:\\n\\nC) R-loops<|im_end|>', \"To answer this question, let's analyze each option:\\n\\nA) Lariat - This refers to the covalently closed loop formed during RNA splicing. It's involved in the process but not directly related to the therapy described.\\n\\nB) PolyA tail - This is the string of adenine nucleotides at the 3' end of an mRNA molecule. It's not involved in the mechanism of exon skipping or the Morpholino therapy.\\n\\nC) R-loops - These are structures formed when DNA transcription occurs, leading to a DNA-RNA-DNA triplex. They're not directly involved in the Morpholino therapy either.\\n\\nD) Antisense - Morpholinos are a type of antisense molecule used to inhibit gene expression by blocking the translation of mRNA. They're directly involved in the therapy described.\\n\\nGiven the context of the therapy involving Morpholinos preventing spliceosome binding and creating exon skipping, the structure that is not directly involved in this process would be:\\n\\nAnswer: B<|im_end|>\", 'Answer: C<|im_end|>', \"To determine which structure is not involved in the proposed therapy, let's analyze each option:\\n\\nA) Lariat - This refers to a circular RNA structure formed after splicing, which is part of the mRNA processing pathway but not directly involved in the Morpholino therapy described. \\n\\nB) PolyA tail - This is a sequence of adenine nucleotides added to the 3' end of mature eukaryotic mRNA. It is essential for mRNA stability and export from the nucleus, but it does not directly participate in the Morpholino therapy mechanism.\\n\\nC) R-loops - These are transient structures that form when DNA is transcribed into RNA, resulting in a single-stranded DNA-DNA-RNA triplex. They can disrupt gene expression and are implicated in various diseases, but they do not directly interact with the Morpholino therapy.\\n\\nD) Antisense - Morpholino molecules are a type of antisense oligonucleotide used in this therapy. They bind to complementary sequences in the target mRNA, leading to exon skipping and in-frame joining. Thus, antisense is directly involved in the therapy.\\n\\nGiven the analysis, none of the options A, B, C, or D are directly involved in the Morpholino therapy described, as all of them can play roles in mRNA processing and regulation. However, the question seems to ask which structure is not directly involved in the mechanism of the Morpholino therapy. Based on the context provided, the Morpholino therapy specifically targets the pre-mRNA and involves exon skipping, so the focus is on the direct interaction with the mRNA rather than on the general mRNA processing components listed.\\n\\nAnswer: $B<|im_end|>\", 'To answer this question, let\\'s analyze the components mentioned:\\n\\n- \"Morpholino\" is an antisense molecule that can bind to RNA.\\n- It targets the 5\\' end of the out-of-frame exon in pre-mRNA.\\n- It prevents binding of the spliceosome, leading to exon skipping.\\n- This process results in in-frame joining of exons, correcting the mutation.\\n\\nNow, let\\'s evaluate each option:\\n\\nA) Lariat - This refers to a structure formed during RNA splicing, but it\\'s not directly involved in the Morpholino\\'s action described.\\n\\nB) PolyA tail - This is part of the mature mRNA and involved in stability and export, but it\\'s not directly related to the Morpholino\\'s function in preventing spliceosome binding or exon skipping.\\n\\nC) R-loops - These are DNA-RNA hybrid structures that can form when transcription occurs, potentially interfering with processes like replication and recombination. They\\'re not directly mentioned as being involved in the Morpholino\\'s mechanism.\\n\\nD) Antisense - This term describes the Morpholino molecule used in the therapy.\\n\\nGiven this analysis, all options A, B, and C are structures or processes that are not directly involved in the Morpholino\\'s mechanism of action, as described. However, since the question asks for a single correct answer and considering the context provided, the best fit among these options would be:\\n\\nAnswer: $C<|im_end|>', 'The structure that is not directly involved in the proposed therapy of exon skipping using a Morpholino is B) polyA tail. Answer: B<|im_end|>', 'The structure not involved in the proposed therapy is:\\n\\nC) R-loops<|im_end|>', 'The structure not involved in the proposed therapy is:\\n\\nC) R-loops<|im_end|>', 'The proposed therapy involves the use of a Morpholino molecule to prevent binding of the spliceosome and create exon skipping, resulting in in-frame joining of the pre-mRNA. This process does not involve the creation of a lariat structure, which is formed during RNA splicing but is not directly related to the Morpholino-mediated exon skipping technique described. Therefore, the structure not involved in the proposed therapy is:\\n\\nA) lariat<|im_end|>', 'Answer: C<|im_end|>', 'The structure not involved in the proposed therapy is:\\n\\nC) R-loops<|im_end|>', \"To answer this question, let's analyze each option:\\n\\nA) lariat - Lariats are covalently closed RNA structures that can form when a splice site is skipped during splicing. They are not directly mentioned in the context of the therapy described.\\n\\nB) polyA tail - The polyA tail is a sequence of adenine nucleotides added at the 3' end of a eukaryotic mRNA transcript. It plays a role in stabilizing the mRNA and promoting its export from the nucleus. It is not directly involved in the exon skipping therapy described.\\n\\nC) R-loops - R-loops are transient triplex structures formed by DNA-RNA hybrids and single-stranded DNA. They can affect splicing by interfering with spliceosome function. They are relevant to the therapy as they might prevent binding of the spliceosome, leading to exon skipping.\\n\\nD) antisense - Antisense molecules can bind to complementary sequences on the target RNA, preventing its translation or affecting its stability. In the context of the therapy, antisense molecules are used to recognize and prevent the binding of the spliceosome to the out-of-frame exon.\\n\\nGiven the context of the therapy described, the structure that is not directly involved is the lariat, as it does not play a role in the mechanism of exon skipping through antisense or R-loop formation.\\n\\nAnswer: A<|im_end|>\", 'Answer: C<|im_end|>', \"To determine which structure is not involved in the proposed therapy, let's analyze each option:\\n\\nA) Lariat - This refers to a structure formed when an intron is removed from pre-mRNA, leaving behind a loop. It is involved in splicing but not directly related to the Morpholino therapy described.\\n\\nB) PolyA tail - This is an addition of adenine nucleotides at the 3' end of pre-mRNA. It is important for stability and translation of mRNA but does not play a role in the Morpholino therapy mentioned.\\n\\nC) R-loops - These are structures that occur when DNA transcription creates a stable complex between DNA, RNA, and RNA polymerase. They can interfere with DNA replication and transcription, but they are not directly involved in the Morpholino therapy process described.\\n\\nD) Antisense - Morpholinos are a type of antisense molecule used in gene therapy to block gene expression. They bind to complementary sequences on pre-mRNA, preventing it from being translated into protein. This fits within the context of the therapy described.\\n\\nGiven the context and definitions provided, the structure that is not directly involved in the proposed Morpholino therapy is:\\n\\nAnswer: A) lariat<|im_end|>\", 'Answer: C<|im_end|>', 'The proposed therapy involves the use of a Morpholino to prevent binding of the spliceosome and create exon skipping. This process does not involve the creation of a lariat structure, which is formed during alternative splicing but is not directly related to the Morpholino-mediated exon skipping technique described. Therefore, the structure that is not involved in the proposed therapy is:\\n\\nA) lariat<|im_end|>', 'The structure that is not involved in the proposed therapy is:\\n\\nC) R-loops<|im_end|>', \"The structure that is not directly involved in the proposed therapy of using a Morpholino to recognize the 5' end of an out-of-frame exon in pre-mRNA and prevent binding of the spliceosome is:\\n\\nA) lariat\\n\\nAnswer: A<|im_end|>\", \"The structure that is not directly involved in the proposed therapy of using a Morpholino to recognize the 5' end of an out-of-frame exon in pre-mRNA and prevent binding of the spliceosome is:\\n\\nC) R-loops<|im_end|>\", 'The proposed therapy involves using a Morpholino to prevent binding of the spliceosome and create exon skipping. This process does not involve the creation of a lariat structure, which is formed during alternative splicing. Therefore, the structure that is not involved in the proposed therapy is:\\n\\nA) lariat<|im_end|>', 'Answer: C<|im_end|>', 'The structure that is not directly involved in the proposed therapy of exon skipping using a Morpholino molecule is:\\n\\nC) R-loops<|im_end|>', 'Answer: C<|im_end|>', \"The structure that is not directly involved in the proposed therapy of using a Morpholino to recognize the 5' end of the out-of-frame exon in pre-mRNA is:\\n\\nB) polyA tail<|im_end|>\", 'Answer: C<|im_end|>', 'The structure that is not directly involved in the proposed therapy of exon skipping using a Morpholino is:\\n\\nC) R-loops<|im_end|>', 'The structure that is not involved in the proposed therapy is:\\n\\nC) R-loops<|im_end|>', 'To answer this question, let\\'s analyze each option:\\n\\nA) Lariat - This refers to a structure formed during RNA splicing, where a loop of RNA is created after a 3\\' end of an intron is spliced out. It\\'s not directly related to the therapy described.\\n\\nB) PolyA tail - This is a sequence of adenine nucleotides added to the 3\\' end of an mRNA molecule during the maturation process. It\\'s not directly involved in the mechanism of exon skipping or antisense therapy.\\n\\nC) R-loops - These are structures formed when DNA-RNA hybrids are generated, typically at transcriptional start sites. They can interfere with DNA replication and transcription, but they\\'re not directly related to the antisense therapy described.\\n\\nD) Antisense - This refers to the use of synthetic oligonucleotides that bind to complementary mRNA sequences, preventing their translation into proteins. It\\'s a key component of the therapy described.\\n\\nGiven this analysis, it seems that all options except for A) lariat could potentially be involved in the therapy. However, since the question asks which structure is \"not\" involved, and given the context of the therapy, the lariat is indeed not directly involved in the mechanism of exon skipping and antisense therapy as described. Therefore, the correct answer is:\\n\\nA) lariat<|im_end|>', 'The proposed therapy involves using a Morpholino to prevent binding of the spliceosome and create exon skipping, resulting in in-frame joining. This process does not involve creating a lariat structure, as typically seen in alternative splicing mechanisms. Therefore, the structure not involved in the proposed therapy is:\\n\\nA) lariat<|im_end|>', 'Answer: C<|im_end|>', \"To answer this question, let's break down the information provided:\\n\\n1. The gene has dozens of exons, some of which code for folded triple helical repeats.\\n2. Central exon deletions cause out-of-frame peptides and degenerative organ waste.\\n3. A Morpholino molecule is used to recognize the 5' end of the out-of-frame exon in pre-mRNA.\\n4. This molecule prevents binding of the spliceosome and allows for exon skipping, creating in-frame joining.\\n5. The therapy tolerates several missing exons.\\n\\nNow, let's evaluate each option:\\n\\nA) Lariat - This refers to the covalent loop structure formed during RNA splicing. It could potentially be involved in the therapy process.\\n\\nB) PolyA tail - This is the polyadenylation tail at the 3' end of eukaryotic mRNAs. It's not directly mentioned as being involved in the therapy described.\\n\\nC) R-loops - These are structures that form when DNA is transcribed into RNA, creating a DNA-RNA-DNA triplex. They are not typically involved in the splicing process or exon skipping therapies.\\n\\nD) Antisense - Morpholino molecules are a type of antisense oligonucleotides, which can bind to specific mRNA sequences to prevent translation or promote exon skipping. This is clearly part of the therapy described.\\n\\nGiven the context, the structure that is not directly involved in the proposed therapy is likely:\\n\\nAnswer: B<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze each option:\\n\\nA) Lariat - This structure is formed during the process of splicing when a branch point within an intron causes the RNA to loop back on itself. It is directly related to the splicing process, which is part of the mechanism of the proposed therapy.\\n\\nB) PolyA tail - This is a sequence of adenine nucleotides at the 3' end of an mRNA molecule. It plays a role in stabilizing the mRNA, but it does not directly impact the splicing process or the creation of exon skipping. Therefore, it might not be directly involved in the proposed therapy.\\n\\nC) R-loops - These are transient structures formed by the interaction between DNA, RNA, and proteins that occur during transcription. They can disrupt gene expression, but their direct involvement in the splicing process or exon skipping is not clear from the context provided.\\n\\nD) Antisense - This refers to molecules that are complementary to the target mRNA. In the context of the therapy described, antisense molecules like Morpholinos are used to prevent binding of the spliceosome, which is crucial for the therapy.\\n\\nGiven the information provided and the context of the therapy involving exon skipping, it seems that option B (polyA tail) is the least directly involved in the process of exon skipping and creating in-frame joining, making it the correct answer.\\n\\nAnswer: B<|im_end|>\", 'The structure that is not directly involved in the proposed therapy of exon skipping using a Morpholino is:\\n\\nC) R-loops\\n\\nAnswer: C<|im_end|>', 'The structure not involved in the proposed therapy is:\\n\\nC) R-loops<|im_end|>', \"To answer this question correctly, let's review the information provided:\\n\\n1. The gene contains dozens of exons, and the central ones are responsible for folding triple helical repeats connecting the cytoskeleton with sarcolemma and extracellular space.\\n2. Common mutations involve deletions in central exons, creating out-of-frame peptides and leading to degenerative organ waste.\\n3. A Morpholino is used to recognize the 5' end of the out-of-frame exon in pre-mRNA, preventing binding of the spliceosome and enabling exon skipping and in-frame joining.\\n\\nGiven these details, we're looking for a structure that is not involved in the proposed therapy. Let's examine each option:\\n\\nA) Lariat - This is a covalently closed circular RNA formed during splicing, typically after an intron is removed. It's not directly related to the Morpholino therapy described here.\\n\\nB) PolyA tail - This is an extension of adenine nucleotides at the 3' end of eukaryotic mRNA, important for stability and translation. It doesn't seem to play a direct role in the Morpholino therapy described.\\n\\nC) R-loops - These are structures involving DNA-RNA hybrids and single-stranded DNA, formed when transcription occurs in the direction opposite to the replication fork. They could potentially interfere with the splicing process but are not specifically mentioned in the context of the therapy.\\n\\nD) Antisense - Morpholinos are a type of antisense oligonucleotide, designed to bind to complementary mRNA sequences, preventing their translation or promoting exon skipping. This is directly relevant to the therapy described.\\n\\nGiven this analysis, the structure that is not directly involved in the proposed therapy is:\\n\\nAnswer: A) lariat<|im_end|>\", 'The structure that is not directly involved in the proposed therapy of exon skipping using a Morpholino molecule is:\\n\\nC) R-loops<|im_end|>', \"To answer this question, let's break down the components mentioned:\\n\\n1. **Central exon deletions** - This refers to the removal of specific exons from the gene.\\n2. **Out-of-frame peptides** - These are proteins produced due to the deletion, causing the reading frame to shift and leading to incorrect protein synthesis.\\n3. **Progressive degenerative organ waste** - This is the consequence of producing faulty proteins.\\n4. **Morpholino** - An antisense oligonucleotide that can bind to the target RNA, preventing the binding of other molecules like the spliceosome.\\n5. **Exon skipping** - This is the process of skipping the deleted exon during splicing, resulting in a functional mRNA.\\n6. **In-frame joining** - Ensuring that the protein coding sequence remains in the correct reading frame.\\n7. **lariat**, **polyA tail**, and **R-loops** - These are all features or structures related to RNA processing and stability.\\n8. **Antisense** - This term refers to the Morpholino used in the therapy.\\n\\nGiven the context of the therapy, we need to identify which of these structures is not directly involved in the process described:\\n\\n- **A) lariat** - Lariats are involved in RNA processing, specifically in the formation of introns during splicing. They could potentially play a role in the process if there's an alteration in the splicing mechanism due to the deletion of exons.\\n- **B) polyA tail** - The polyA tail is involved in stabilizing the mRNA and aiding in its export from the nucleus. It doesn't seem directly involved in the exon skipping process unless there's a specific interaction that isn't mentioned.\\n- **C) R-loops** - R-loops are structures formed when DNA transcription occurs, and they consist of a DNA-RNA hybrid and an unwound DNA strand. They aren't typically involved in mRNA processing but could potentially influence it under certain conditions.\\n- **D) antisense** - As mentioned, the Morpholino used in the therapy is an antisense molecule, designed to prevent the binding of the spliceosome and facilitate exon skipping.\\n\\nBased on the information provided and considering the options, **B) polyA tail** seems to be the least directly involved in the described therapy of exon skipping through exon recognition and skipping, especially since the focus is on correcting the splicing issue rather than affecting mRNA stability or processing.\\n\\nAnswer: B<|im_end|>\", 'Answer: C<|im_end|>', 'The structure that is not directly involved in the proposed therapy of exon skipping using a Morpholino is:\\n\\nC) R-loops<|im_end|>', \"To determine which structure is not involved in the proposed therapy, let's analyze each option:\\n\\nA) Lariat - This refers to a covalently closed circular RNA formed by the removal of an intron from a pre-mRNA. It is not directly mentioned in the context of the therapy described.\\n\\nB) PolyA tail - This is a sequence of adenine nucleotides added to the 3' end of a eukaryotic pre-mRNA. It is involved in mRNA stability and translation initiation, but not directly related to the exon skipping process described.\\n\\nC) R-loops - These are structures formed when DNA transcription generates a single-stranded DNA template that hybridizes to the complementary mRNA transcript. They can affect gene expression but are not part of the described exon skipping mechanism.\\n\\nD) Antisense - This refers to molecules that bind to complementary RNA sequences, preventing the binding of the spliceosome or other cellular machinery. It is part of the described therapy.\\n\\nBased on this analysis, the structure that is not directly involved in the proposed therapy is:\\n\\nA) lariat<|im_end|>\", 'The structure not involved in the proposed therapy is:\\n\\nC) R-loops<|im_end|>', \"To answer this question correctly, let's review each option:\\n\\nA) lariat - This is a covalently closed RNA loop formed during RNA splicing, but it's not directly involved in the Morpholino therapy described.\\nB) polyA tail - This is the addition of a string of adenine nucleotides at the 3' end of an mRNA molecule, important for stability and export from the nucleus, but not part of the Morpholino therapy mechanism.\\nC) R-loops - These are structures that form when DNA-RNA hybrids are present, typically during transcription, but they are not directly involved in the Morpholino therapy described.\\nD) antisense - This refers to molecules that can bind to complementary sequences on the target RNA, thus blocking its function. This is indeed part of the Morpholino therapy mechanism.\\n\\nGiven the description of the Morpholino therapy, the structure not directly involved in this process would be:\\nA) lariat<|im_end|>\", 'The structure that is not directly involved in the proposed therapy of exon skipping using a Morpholino is B) polyA tail. Answer: B<|im_end|>', \"To answer this question, let's analyze each option:\\n\\nA) lariat - This refers to the covalently linked intron after splicing. It could be involved in the process but is not directly related to the therapy described.\\n\\nB) polyA tail - This is the addition of adenine nucleotides at the 3' end of a mature mRNA. It's not directly related to the therapy described involving exon skipping.\\n\\nC) R-loops - These are structures formed by DNA-RNA hybrids when RNA transcription outpaces DNA replication. They can be involved in various cellular processes but are not specifically mentioned in the context of the therapy.\\n\\nD) antisense - Morpholinos are antisense molecules designed to target specific sequences in pre-mRNA, facilitating the proposed therapy.\\n\\nGiven the description of the therapy and the options provided, it appears that all options except for one are not directly involved in the therapy of exon skipping described. The question asks which structure is not involved in the proposed therapy. \\n\\nTherefore, the answer would be:\\nAnswer: A<|im_end|>\", \"To answer this question correctly, let's break down the process of the proposed therapy:\\n\\n1. The therapy involves using a Morpholino molecule to target specific exons in the gene.\\n2. The Morpholino prevents the spliceosome from binding to the targeted exon.\\n3. This leads to exon skipping, creating an in-frame sequence for the protein.\\n4. Several missing exons can be tolerated by the organism.\\n\\nNow, let's analyze each option:\\n\\nA) Lariat - This refers to the formation of a loop in the RNA strand after splicing. The proposed therapy does not involve lariat formation or removal, so it is not directly involved in the process.\\n\\nB) PolyA tail - This is the addition of a string of adenine nucleotides at the 3' end of a messenger RNA (mRNA). It is important for mRNA stability and export from the nucleus but is not directly involved in the proposed exon skipping process.\\n\\nC) R-loops - These are structures formed by the hybridization of DNA and complementary mRNA strands, with the non-complementary DNA strand remaining unpaired. They can affect gene expression, but they are not directly involved in the mechanism of the proposed therapy.\\n\\nD) Antisense - This refers to the use of molecules complementary to the target RNA strand. The Morpholino molecule used in the therapy acts as an antisense agent, preventing the spliceosome from binding to the targeted exon.\\n\\nGiven the analysis above, the structure that is not directly involved in the proposed therapy is:\\n\\nAnswer: A) lariat<|im_end|>\", 'The structure that is not involved in the proposed therapy is:\\n\\nC) R-loops<|im_end|>', 'The structure that is not directly involved in the proposed therapy is B) polyA tail. Answer: B<|im_end|>', \"To answer this question, let's first understand the context. The proposed therapy involves using a Morpholino molecule to prevent binding of the spliceosome and create exon skipping. This means that certain exons are not spliced in, resulting in in-frame joining of the pre-mRNA. The goal is to tolerate the absence of several missing exons.\\n\\nNow, let's evaluate each option:\\n\\nA) Lariat - Lariats are covalently closed circular structures formed during RNA splicing. They are not directly involved in the proposed therapy of exon skipping.\\n\\nB) PolyA tail - The polyA tail is part of the mature mRNA and plays a role in stabilizing the mRNA and facilitating its export from the nucleus. It is not directly involved in the process of exon skipping or the Morpholino therapy.\\n\\nC) R-loops - R-loops are transient triplex structures formed when a single-stranded DNA template strand is flanked by two complementary RNA strands. They can cause transcriptional interference and may play a role in gene regulation. However, they are not typically associated with the direct mechanism of exon skipping or Morpholino therapy.\\n\\nD) Antisense - Antisense molecules are often used in gene therapy to block the expression of a gene by binding to the target RNA sequence. In this context, the Morpholino molecule acts as an antisense agent to prevent the binding of the spliceosome to the out-of-frame exon.\\n\\nBased on the information provided, the structure that is not directly involved in the proposed therapy of exon skipping via Morpholino treatment is:\\n\\nAnswer: A) lariat<|im_end|>\", 'The structure not involved in the proposed therapy is:\\n\\nC) R-loops<|im_end|>', \"To determine which structure is not involved in the proposed therapy, let's analyze each option:\\n\\nA) Lariat - This refers to a covalently closed circular RNA formed during RNA splicing. It is part of the mRNA processing machinery but does not directly influence the described therapy mechanism.\\n\\nB) PolyA tail - This is a sequence of adenine nucleotides added to the 3' end of an mRNA transcript during its maturation. It plays a role in mRNA stability and transport, but it is not directly involved in the described exon skipping mechanism.\\n\\nC) R-loops - These are transient structures composed of DNA-RNA hybrids that form when an RNA transcript unwinds from a template strand, creating a loop of RNA-DNA. They can affect gene expression but do not directly impact the therapy described.\\n\\nD) Antisense - This refers to the use of antisense molecules, such as Morpholinos, which bind to complementary sequences on the target mRNA, preventing specific interactions or functions. This is exactly how the therapy works in the context provided.\\n\\nGiven this analysis, the structure that is not directly involved in the proposed therapy is:\\n\\nAnswer: A<|im_end|>\", 'To answer this question, let\\'s break down the components mentioned:\\n\\n- **Central exon deletions**: This refers to deletions within the gene\\'s coding sequence.\\n- **Out-of-frame peptides**: These are proteins produced due to the deletion, leading to altered function or toxicity.\\n- **Morpholino**: An antisense oligonucleotide used to prevent binding of the spliceosome, aiding in exon skipping.\\n- **Exon skipping**: This technique removes specific exons from the mRNA transcript, creating a functional protein.\\n- **In-frame joining**: Ensures the remaining parts of the gene can still code for a functional protein.\\n\\nNow, let\\'s identify which structure is not directly involved in the described therapy:\\n\\n- **A) lariat**: Lariats are RNA structures formed during the processing of pre-mRNA, but they\\'re not directly related to the Morpholino therapy or exon skipping process described. \\n- **B) polyA tail**: This is a crucial part of mRNA that helps stabilize the molecule, but it doesn\\'t play a role in the mechanism of exon skipping or the Morpholino therapy.\\n- **C) R-loops**: These are DNA-RNA hybrids that form during transcription and can interfere with gene expression. They might be indirectly related as they could affect splicing, but the question specifically asks about structures \"not\" involved in the therapy, and the therapy focuses on direct interactions with pre-mRNA using a Morpholino.\\n- **D) antisense**: Morpholino oligonucleotides are considered antisense molecules, playing a direct role in the therapy by interfering with splicing.\\n\\nGiven the context provided and the options listed, **lariat** and **polyA tail** are not directly involved in the Morpholino therapy for exon skipping. However, since the question asks for a single correct answer and considering the broader scope of the options given, the most appropriate choice based on the information provided would be:\\n\\nAnswer: **A) lariat**<|im_end|>', \"To answer this question, let's break down the components mentioned:\\n\\n1. Morpholino: This is an antisense molecule that binds to pre-mRNA.\\n2. 5' end of the out-of-frame exon: This is the target site on the pre-mRNA.\\n3. Spliceosome: This is a complex of proteins that performs splicing, removing introns from pre-mRNA.\\n4. Exon skipping: This is a process where the spliceosome skips over a mutated exon.\\n5. In-frame joining: This refers to the correct alignment of exons after skipping.\\n6. lariat, polyA tail, R-loops, and antisense: These are all components related to mRNA processing or regulation.\\n\\nGiven the context of the therapy, it seems to involve antisense molecules targeting specific mRNA sequences to prevent the spliceosome from acting on them. This suggests that the therapy is designed to manipulate mRNA processing rather than directly affecting the polyA tail, which is involved in mRNA stability but not in the described mechanism.\\n\\nTherefore, the structure that is not directly involved in the proposed therapy is:\\n\\nAnswer: B) polyA tail<|im_end|>\", \"To answer this question, let's break down the components mentioned:\\n\\n1. **Central exon deletions** - These refer to deletions within the middle part of the gene.\\n2. **Out-of-frame peptides** - This occurs when there is a shift in the reading frame due to the deletion, leading to incorrect protein synthesis.\\n3. **Progressive degenerative organ waste** - This suggests that the gene mutation leads to the degradation of organs over time.\\n4. **Morpholino** - This is a synthetic antisense molecule used to inhibit gene expression by preventing the binding of specific mRNA sequences.\\n5. **Exon skipping** - This technique involves the removal of specific exons during mRNA processing, leading to a different mRNA sequence and potentially a functional protein.\\n6. **In-frame joining** - This refers to the process of connecting the remaining exons in a way that maintains the reading frame.\\n\\nThe question asks which structure is NOT involved in the proposed therapy. Let's analyze each option:\\n\\nA) **lariat** - This refers to the formation of a circular RNA structure after splicing, which is not directly related to the therapy described (exon skipping).\\n\\nB) **polyA tail** - This is the addition of a string of adenine nucleotides at the 3' end of the mRNA. It is crucial for stability and translation but does not seem directly involved in the described exon skipping therapy.\\n\\nC) **R-loops** - These are structures formed by DNA-RNA hybrids and single-stranded DNA. They are not typically associated with the processes described in the therapy.\\n\\nD) **antisense** - This refers to the use of morpholinos, which are indeed part of the therapy described.\\n\\nGiven the options, all except A) lariat could potentially be indirectly involved in the process as it is a feature of mRNA post-splicing. However, since the question asks for what is NOT involved, and based on the information provided, the lariat formation is the least directly related to the therapy described (exon skipping via Morpholino).\\n\\nAnswer: A<|im_end|>\", 'Answer: C<|im_end|>', 'The structure that is not directly involved in the proposed therapy is B) polyA tail. Answer: B<|im_end|>', 'Answer: C<|im_end|>', 'The structure that is not directly involved in the proposed therapy is the polyA tail. Therefore, the answer is:\\n\\nB) polyA tail<|im_end|>', \"To determine which structure is not involved in the proposed therapy, let's break down the process:\\n\\n1. The Morpholino molecule targets the 5' end of the out-of-frame exon in pre-mRNA.\\n2. This prevents binding of the spliceosome.\\n3. Exon skipping occurs, leading to in-frame joining of exons.\\n4. The result is the creation of a functional protein despite some missing exons.\\n\\nNow, let's analyze each option:\\n\\nA) Lariat - Lariat structures are formed during RNA splicing, but they are not directly involved in the Morpholino-mediated exon skipping process described.\\n\\nB) PolyA tail - The polyA tail is part of mRNA and can influence stability and translation, but it is not directly involved in the Morpholino-mediated exon skipping mechanism.\\n\\nC) R-loops - R-loops involve the formation of a complex between DNA and RNA, typically during transcription, but they are not directly related to the Morpholino's role in exon skipping.\\n\\nD) Antisense - Antisense molecules can target specific sequences, including those involved in splicing, potentially affecting the spliceosome's activity as described in the therapy.\\n\\nGiven this analysis, the structure that is not directly involved in the proposed therapy is:\\n\\nAnswer: A) lariat<|im_end|>\", 'The structure that is not directly involved in the proposed therapy of exon skipping using a Morpholino is:\\n\\nC) R-loops<|im_end|>', \"To determine which structure is not involved in the proposed therapy, let's analyze each option:\\n\\nA) Lariat - Lariat structures can form during mRNA processing, but they are not directly involved in the mechanism described for exon skipping using Morpholinos.\\n\\nB) PolyA tail - This is part of the mRNA molecule and plays a role in its stability and transport, but it does not directly participate in the exon skipping process described.\\n\\nC) R-loops - These are structures formed by DNA-RNA hybrids that can occur during transcription, but they are not directly mentioned as being involved in the Morpholino-mediated exon skipping.\\n\\nD) Antisense - Morpholinos are a type of antisense molecule used for gene regulation. They specifically target the RNA sequence complementary to the DNA template, facilitating exon skipping.\\n\\nBased on this analysis, it appears that none of the options A, B, C, or D are directly involved in the mechanism of the proposed therapy. However, given the instruction to choose the structure that is not involved, we must consider the context of the question more closely. In the context of the proposed therapy involving Morpholinos for exon skipping, the direct mechanism focuses on preventing spliceosome binding and creating in-frame joining, rather than on any specific structural elements like lariat, polyA tail, R-loops, or antisense itself.\\n\\nAnswer: $D<|im_end|>\", \"To answer this question, let's break down the information provided:\\n\\n- The gene in question has dozens of exons.\\n- Central exons code for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space.\\n- Mutations often involve deletions of these central exons, leading to out-of-frame peptides and degenerative conditions.\\n- The proposed therapy involves using a Morpholino, an antisense molecule, to recognize the 5' end of the out-of-frame exon in pre-mRNA, preventing binding of the spliceosome, and creating exon skipping, thus in-frame joining.\\n- The goal is to tolerate several missing exons without causing issues.\\n\\nNow, let's consider each option in relation to the proposed therapy:\\n\\nA) Lariat - This refers to a structure formed when a single-stranded loop is created from a pre-mRNA after splicing. It's not directly involved in the Morpholino's function or the exon skipping process described.\\n\\nB) PolyA tail - This is a sequence of adenine nucleotides added to the 3' end of a mature mRNA. It's crucial for stability and translation but not directly related to the Morpholino's mechanism of action or the exon skipping process.\\n\\nC) R-loops - These are structures composed of DNA-RNA hybrids and a displaced single-stranded DNA strand. They can interfere with gene expression and replication, but they're not directly mentioned as being involved in the Morpholino therapy.\\n\\nD) Antisense - This term describes the Morpholino molecule used in the therapy, recognizing the 5' end of the out-of-frame exon to prevent binding of the spliceosome.\\n\\nGiven the information and the context of the therapy, the structure that is not directly involved in the proposed Morpholino therapy is:\\n\\nAnswer: A) lariat<|im_end|>\", \"To answer this question, let's analyze the components mentioned:\\n\\nA) Lariat - This refers to a covalently closed circular RNA formed during splicing. It is not directly involved in the proposed therapy.\\n\\nB) PolyA tail - This is a sequence of adenine nucleotides at the 3' end of an mRNA molecule. It is important for mRNA stability and translation but is not directly involved in the proposed therapy mechanism.\\n\\nC) R-loops - These are structures formed when a single-stranded DNA molecule is displaced from its double helix due to the presence of complementary RNA. They can be involved in gene regulation and are not directly related to the therapy described.\\n\\nD) Antisense - This refers to molecules that bind to complementary RNA or DNA sequences. In the context of the therapy, an antisense molecule is used to prevent binding of the spliceosome and enable exon skipping.\\n\\nThe question asks which structure is not involved in the proposed therapy. Based on this analysis:\\n\\nAnswer: A) lariat<|im_end|>\", \"To answer this question, let's break down the components mentioned:\\n\\n1. **Exon Deletions**: The issue starts with central exon deletions, leading to out-of-frame peptides.\\n2. **Morpholino**: A type of antisense oligonucleotide (ANSO) used in the therapy to prevent binding of the spliceosome.\\n3. **Exon Skipping**: The Morpholino enables exon skipping, creating in-frame joining.\\n4. **Lariat Structure**: This refers to a form of RNA secondary structure created during splicing.\\n5. **PolyA Tail**: An important part of mRNA that aids in stability and translation.\\n6. **R-loops**: Structures formed when DNA is transcribed but not replicated, involving three strands of nucleic acid.\\n\\nThe therapy involves using a Morpholino to prevent exon deletion-induced frame-shifts by creating exon skipping. Key components are the Morpholino itself as an antisense molecule and the concept of exon skipping, which doesn't directly involve:\\n\\n**Lariat structure**, **PolyA tail**, or **R-loops** in the context of the therapy described. These are not the primary focus or components directly impacted by the Morpholino therapy. \\n\\n**Antisense** is indeed relevant to the Morpholino therapy, as it's the type of molecule used in the treatment.\\n\\nTherefore, the correct answer is:\\n\\n**C) R-loops**<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze each option:\\n\\nA) Lariat - This refers to a covalently closed circular RNA structure formed during splicing. It's related to the splicing process but not directly involved in the Morpholino therapy described, which focuses on preventing spliceosome binding and creating exon skipping.\\n\\nB) PolyA tail - This is an addition of adenine nucleotides to the 3' end of pre-mRNA. It's crucial for mRNA stability and translation but not directly relevant to the Morpholino therapy mechanism.\\n\\nC) R-loops - These are structures formed when DNA is transcribed into RNA, leading to a triplex of DNA-RNA-DNA. They can affect gene expression but are not specifically mentioned as part of the therapy mechanism described.\\n\\nD) Antisense - Morpholinos are a type of antisense molecule used in this therapy. They bind to specific sequences of RNA and prevent it from being translated or spliced.\\n\\nBased on this analysis, option A) lariat is the structure that is not directly involved in the proposed therapy mechanism described.\\n\\nAnswer: A<|im_end|>\", 'The structure that is not involved in the proposed therapy is C) R-loops. Answer: C<|im_end|>', \"To determine which structure is not involved in the proposed therapy, let's analyze each option:\\n\\nA) Lariat - This refers to a circularized RNA molecule formed during RNA splicing. It's not directly mentioned in the context of the therapy described, so it might not be involved.\\n\\nB) PolyA tail - This is an adenine-rich sequence at the 3' end of a eukaryotic mRNA. It's not part of the therapy described, which focuses on exon skipping and in-frame joining.\\n\\nC) R-loops - These are structures consisting of DNA-RNA hybrids that can form when a gene is transcribed. They are not directly related to the therapy described, which involves Morpholino molecules recognizing specific pre-mRNA sequences.\\n\\nD) Antisense - This refers to the use of synthetic molecules that bind to complementary mRNA sequences, preventing their translation or degradation. It's a key component of the therapy described.\\n\\nGiven this analysis, all options except for B (polyA tail) seem to have some connection to the proposed therapy, albeit indirectly. However, the direct involvement in the mechanism of action described is more clearly associated with options A, C, and D. \\n\\nAnswer: B<|im_end|>\", 'The proposed therapy involves the use of a Morpholino to prevent binding of the spliceosome and create exon skipping. This process does not involve the creation of a lariat structure, which is formed during splicing but is not directly related to the exon skipping mechanism described. Therefore, the structure not involved in the proposed therapy is:\\n\\nA) lariat<|im_end|>', 'To answer this question correctly, let\\'s analyze the given information and the options provided:\\n\\n1. The gene has dozens of exons, with central ones coding for triple helical repeats connecting the cytoskeleton with sarcolemma and extracellular space.\\n2. Common mutations involve central exon deletions, leading to out-of-frame peptides and progressive degenerative organ waste.\\n3. The proposed solution involves delivering a Morpholino that recognizes the 5\\' end of the out-of-frame exon in pre-mRNA. This molecule prevents binding of the spliceosome and enables exon skipping, creating in-frame joining.\\n4. The goal is to tolerate several missing exons.\\n\\nNow, let\\'s examine the options:\\n\\nA) Lariat - This refers to a covalently closed circular RNA structure formed during RNA splicing. It\\'s not directly related to the Morpholino therapy described.\\n\\nB) PolyA tail - This is the sequence of adenine nucleotides at the 3\\' end of many eukaryotic mRNAs. It\\'s involved in mRNA stability but not directly relevant to the Morpholino therapy mechanism.\\n\\nC) R-loops - These are structures composed of DNA-RNA hybrids formed when transcription outcompetes replication or repair processes. They\\'re not directly related to the Morpholino therapy mechanism either.\\n\\nD) Antisense - Morpholinos are considered antisense molecules because they bind to complementary sequences on the target RNA, preventing specific interactions such as splicing. This is directly related to the therapy mechanism.\\n\\nGiven the analysis, it appears that all options except for A) lariat are indirectly related to the process described in the therapy. However, since the question asks which structure is \"not\" involved in the proposed therapy, the correct answer should focus on what is not part of the therapy mechanism itself rather than its relevance to the gene or RNA processing.\\n\\nAnswer: A<|im_end|>', \"To determine which structure is not involved in the proposed therapy, let's analyze each option:\\n\\nA) Lariat - This refers to the covalently closed circular RNA formed when a branch point acceptor site in an intron is spliced out, which is not directly related to the therapy described.\\n\\nB) PolyA tail - This is the sequence of adenine nucleotides at the 3' end of many eukaryotic mRNA molecules, which aids in mRNA stability and export from the nucleus. It is not directly mentioned in the context of the therapy described.\\n\\nC) R-loops - These are DNA-RNA hybrid structures that form when transcription occurs and RNA is synthesized but not immediately degraded. They can disrupt gene function and are implicated in genome instability. They could potentially be involved in the therapy by interfering with normal splicing processes.\\n\\nD) Antisense - This refers to the use of synthetic oligonucleotides that can bind to complementary RNA sequences, preventing their translation into proteins or promoting their degradation. This is a key component of the therapy described.\\n\\nBased on this analysis, the structure that is not directly involved in the proposed therapy is:\\n\\nAnswer: A<|im_end|>\", \"To determine which structure is not involved in the proposed therapy, let's analyze each option:\\n\\nA) Lariat - Lariats are formed during RNA splicing as a result of a 3' to 5' splice site. They play a role in the splicing process but are not directly involved in the Morpholino therapy described. \\n\\nB) PolyA tail - This is a sequence of adenine nucleotides added to the 3' end of messenger RNA. It's important for stability and export of mRNA from the nucleus but does not directly participate in the Morpholino-mediated exon skipping.\\n\\nC) R-loops - These are structures composed of DNA-RNA hybrids formed during transcription, where a segment of RNA complementary to a DNA template strand forms a double-stranded complex with it. R-loops can interfere with DNA replication and transcription, but they are not mentioned as part of the Morpholino therapy.\\n\\nD) Antisense - This refers to the use of molecules that are complementary to a specific RNA sequence. In the context of the proposed therapy, Morpholinos are used as antisense molecules to prevent the binding of the spliceosome and facilitate exon skipping.\\n\\nBased on this analysis, the structure not involved in the proposed therapy is:\\n\\nAnswer: B<|im_end|>\", 'To answer this question, let\\'s break down the components mentioned:\\n\\n1. **Central exon deletions** - This refers to mutations involving the deletion of central exons.\\n2. **Out-of-frame peptides** - These are proteins resulting from mutations that cause frameshifts.\\n3. **Progressive degenerative organ waste** - This indicates the detrimental effects of such mutations on the organism.\\n4. **Morpholino** - A type of antisense oligonucleotide used in the therapy.\\n5. **Exon skipping** - The process where a mutated exon is excluded during mRNA processing.\\n6. **In-frame joining** - Ensuring the remaining exons are joined in a way that does not disrupt the reading frame.\\n\\nGiven these components, let\\'s evaluate the options:\\n\\n- **A) Lariat** - Typically associated with RNA splicing, specifically the formation of a covalent bond between the 3\\' end of one exon and the 5\\' end of the next, forming a loop or \"lariat\". This structure could potentially influence the process of exon skipping but is not directly involved in the therapy described.\\n- **B) PolyA tail** - An adenine-rich sequence at the 3\\' end of an mRNA, involved in mRNA stability and translation initiation. It doesn\\'t play a direct role in the exon skipping mechanism described.\\n- **C) R-loops** - Structures formed by DNA-RNA hybrids that can interfere with transcription and replication. They are not directly mentioned as part of the therapy mechanism.\\n- **D) Antisense** - The Morpholino molecule used in the therapy is an example of antisense technology, which is directly involved in the therapy.\\n\\nThe structure not directly involved in the proposed therapy would likely be either **A) lariat**, **B) polyA tail**, or **C) R-loops**, depending on how they are interpreted within the context of the therapy mechanism. However, since the question asks for a single incorrect structure and given the context, the most direct answer considering the role in the therapy process would be **A) lariat**, as it is not a component used to prevent binding of the spliceosome or create exon skipping.\\n\\nAnswer: A<|im_end|>', 'The structure that is not involved in the proposed therapy is:\\n\\nC) R-loops<|im_end|>', 'Answer: C<|im_end|>', 'To answer this question, let\\'s analyze each option:\\n\\nA) lariat - This refers to a structure formed during RNA splicing, where a branch point is created, and the rest of the RNA forms a loop. It\\'s not directly related to the Morpholino therapy described.\\n\\nB) polyA tail - This is the addition of adenine nucleotides at the 3\\' end of an mRNA molecule, crucial for stability and export from the nucleus. It doesn\\'t play a direct role in the Morpholino therapy described.\\n\\nC) R-loops - These are structures composed of DNA-RNA hybrids formed during transcription. They can interfere with DNA replication and transcription, but they\\'re not directly mentioned as being involved in the Morpholino therapy.\\n\\nD) antisense - Morpholinos are antisense molecules designed to bind to specific RNA sequences, preventing their translation or leading to exon skipping. This mechanism is part of the therapy described.\\n\\nThe question asks which structure is not involved in the proposed therapy. Based on this analysis, all options A, B, C, and D are indirectly related to the therapy, except for one. However, since the question specifies \"Which structure below is not involved,\" and given the context of the therapy, the focus is on the components that directly contribute to the therapy mechanism rather than being a product of it. The Morpholino therapy does not involve the creation of lariat structures directly, so:\\n\\nAnswer: A<|im_end|>', 'To answer this question, let\\'s analyze the information given:\\n\\n- The gene has dozens of exons, and mutations involve central exon deletions creating out-of-frame peptides.\\n- The proposed solution involves delivering a Morpholino that prevents binding of the spliceosome, leading to exon skipping and in-frame joining.\\n- This process tolerates several missing exons.\\n\\nNow, let\\'s evaluate each option:\\n\\nA) Lariat: Lariats are covalently closed circular RNA structures formed during RNA splicing. They are not directly mentioned as part of the proposed therapy.\\n\\nB) PolyA tail: The polyA tail is a crucial part of mRNA that helps stabilize the molecule and promote its export from the nucleus. It\\'s not directly related to the exon skipping process described.\\n\\nC) R-loops: R-loops are transient triplex structures consisting of DNA, RNA, and RNA polymerase. They can form during transcription and might interfere with processes like splicing. However, they are not specifically mentioned in the context of the therapy.\\n\\nD) Antisense: Antisense molecules can bind to complementary sequences on the target RNA, preventing it from being translated into protein or interfering with its function. In the context of the therapy, Morpholino molecules act as antisense agents to prevent exon binding and enable skipping.\\n\\nGiven the analysis above, it seems that all options except for A) lariat are either directly or indirectly involved in the proposed therapy. However, since the question asks for the structure that is \"not\" involved, and considering the information provided doesn\\'t explicitly mention lariats as part of the therapy, the correct answer based on the given context is:\\n\\nAnswer: A<|im_end|>', 'The structure that is not involved in the proposed therapy is C) R-loops. \\n\\nAnswer: C<|im_end|>', 'The structure that is not directly involved in the proposed therapy of exon skipping using a Morpholino is:\\n\\nC) R-loops\\n\\nAnswer: C<|im_end|>', 'The structure that is not directly involved in the proposed therapy is B) polyA tail. Answer: B<|im_end|>'], 'correct': [False, False, False, False, True, False, False, False, False, False, False, True, True, False, True, False, False, False, False, True, False, False, False, False, False, True, False, True, False, False, False, True, True, False, True, False, True, False, False, False, False, True, False, False, False, False, True, False, True, False, False, False, True, False, True, False, False, False, False, True, False, False, True, False, True, False, False, False, False, False, True, False, True, False, True, False, False, False, False, True, False, False, True, False, False, False, False, True, False, False, False, False, False, False, False, False, False, False, False, False, False, False, False, True, False, True, False, False, False, False, False, False, False, False, True, False, False, False, False, False, False, False, True, False, False, True, True, False], 'explanations': [\"parsed='A'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='C'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='C'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='C'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='B'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='A'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='C'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='C'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='C'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='A'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='A'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='B'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='C'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='C'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='A'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='C'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='C'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='C'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='C'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='A'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='C'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='C'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='A'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='D'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='B'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='B'; truth='C'\", \"parsed='A'; truth='C'\", \"no 'Answer: [A-D]' pattern found; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='A'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='C'; truth='C'\", \"parsed='B'; truth='C'\"], 'num_tokens': [231, 74, 28, 96, 4, 211, 388, 407, 237, 70, 28, 4, 4, 27, 19, 75, 344, 304, 16, 265, 252, 18, 70, 455, 18, 279, 380, 4, 374, 315, 30, 4, 19, 323, 4, 16, 19, 329, 28, 373, 334, 4, 18, 363, 18, 512, 4, 245, 4, 276, 18, 202, 4, 338, 290, 30, 16, 16, 88, 4, 16, 276, 4, 248, 4, 78, 18, 52, 49, 61, 4, 28, 4, 42, 4, 27, 18, 274, 64, 4, 301, 291, 31, 16, 356, 28, 504, 4, 27, 219, 16, 196, 30, 213, 315, 18, 22, 325, 16, 234, 403, 231, 424, 4, 22, 4, 29, 263, 27, 277, 375, 206, 288, 233, 21, 244, 71, 381, 238, 258, 451, 18, 4, 294, 339, 22, 31, 22], 'rewards': [0.07568359375, 0.076171875, 0.083984375, 0.06884765625, 0.0615234375, 0.078125, 0.08203125, 0.08447265625, 0.091796875, 0.08056640625, 0.083984375, 0.0615234375, 0.0615234375, 0.0859375, 0.08544921875, 0.07666015625, 0.078125, 0.0869140625, 0.078125, 0.08544921875, 0.07568359375, 0.0791015625, 0.08203125, 0.083984375, 0.0791015625, 0.07666015625, 0.0625, 0.0615234375, 0.07568359375, 0.06982421875, 0.095703125, 0.0615234375, 0.08544921875, 0.08251953125, 0.0615234375, 0.078125, 0.08544921875, 0.06298828125, 0.083984375, 0.0771484375, 0.07763671875, 0.0615234375, 0.0791015625, 0.07373046875, 0.0791015625, 0.06982421875, 0.0615234375, 0.09375, 0.0615234375, 0.08837890625, 0.0791015625, 0.0888671875, 0.0615234375, 0.0625, 0.07080078125, 0.095703125, 0.078125, 0.078125, 0.0732421875, 0.0615234375, 0.078125, 0.0712890625, 0.0615234375, 0.076171875, 0.0615234375, 0.07421875, 0.0791015625, 0.07763671875, 0.08251953125, 0.078125, 0.0615234375, 0.083984375, 0.0615234375, 0.0810546875, 0.0615234375, 0.0859375, 0.0791015625, 0.050048828125, 0.078125, 0.0615234375, 0.08740234375, 0.083984375, 0.0927734375, 0.078125, 0.078125, 0.083984375, 0.07958984375, 0.0615234375, 0.0859375, 0.07568359375, 0.078125, 0.06494140625, 0.095703125, 0.0693359375, 0.08056640625, 0.0791015625, 0.0947265625, 0.07470703125, 0.078125, 0.078125, 0.0634765625, 0.07373046875, 0.06591796875, 0.0615234375, 0.0947265625, 0.0615234375, 0.08154296875, 0.07958984375, 0.0859375, 0.060302734375, 0.078125, 0.0625, 0.06298828125, 0.07421875, 0.0869140625, 0.07470703125, 0.08056640625, 0.068359375, 0.0751953125, 0.0927734375, 0.07470703125, 0.0791015625, 0.0615234375, 0.0703125, 0.07470703125, 0.09033203125, 0.0927734375, 0.0947265625], 'ground_truths': ['C'], 'question_meta': None, 'model_name': 'hf_chat:Qwen/Qwen2-7B-Instruct', 'reward_model_name': 'armo_rm:RLHFlow/ArmoRM-Llama3-8B-v0.1'}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ| 12/12 [00:32<00:00,  2.69s/it]\n"
     ]
    }
   ],
   "source": [
    "import json\n",
    "from pathlib import Path\n",
    "from tqdm import tqdm\n",
    "from strategic_ttc.verifiers.gpqa_per import GPQAPer\n",
    "\n",
    "folder = Path(\"../final_runs/GPQA_el2/\")\n",
    "\n",
    "verifier = GPQAPer()\n",
    "\n",
    "flag = False\n",
    "\n",
    "for file in tqdm(list(folder.iterdir())):\n",
    "    if not file.is_file() or file.suffix not in [\".json\", \".jsonl\"]:\n",
    "        continue\n",
    "        \n",
    "    try:\n",
    "        with open(file, \"r\") as f:\n",
    "            ver_data = [json.loads(line) for line in f if line.strip()]\n",
    "    except json.JSONDecodeError as e:\n",
    "        print(f\"Skipping corrupt file {file}: {e}\")\n",
    "        continue\n",
    "    \n",
    "    new_data = []\n",
    "\n",
    "    for line in ver_data:\n",
    "        answers = line.get(\"answers\", [])\n",
    "        ground_truth = line.get(\"ground_truths\") \n",
    "        \n",
    "        new_explanations = []\n",
    "        new_correct = []\n",
    "\n",
    "        for ans in answers:\n",
    "            result = verifier.verify(\n",
    "                model_answer=ans,\n",
    "                ground_truths=ground_truth,\n",
    "            )\n",
    "            new_explanations.append(result.explanation)\n",
    "            new_correct.append(result.correct)\n",
    "\n",
    "        line[\"explanations\"] = new_explanations\n",
    "        line[\"correct\"] = new_correct\n",
    "        new_data.append(line)\n",
    "        \n",
    "        if flag == False:\n",
    "            print(line)\n",
    "            flag = True\n",
    "    with open(file, \"w\") as f:\n",
    "        for line in new_data:\n",
    "            f.write(json.dumps(line) + \"\\n\")\n",
    "    \n",
    "    flag = False"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "svenv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.2"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
